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Colorectal cancer is a common disease, affecting millions worldwide and represents 
a global health problem. Effective therapeutic solutions and control measures for 
the disease will come from the collective research efforts of clinicians and scientists 
worldwide. This book presents the current status of the strides being made to understand 
the fundamental scientific basis of colorectal cancer. It provides contributions from 
scientists, clinicians and investigators from 20 different countries. The four sections 
of this volume examine the evidence and data in relation to genes and various 
polymorphisms, tumor microenvironment and infections associated with colorectal 
cancer. An increasingly better appreciation of the complex inter-connected basic biology 
of colorectal cancer will translate into effective measures for management and treatment 
of the disease. Research scientists and investigators as well as clinicians searching for a 
good understanding of the disease will find this book useful.
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Preface 
When a patient is diagnosed with colorectal cancer, the options available to that 
patient are determined by the current state of knowledge. That knowledge is 
dependent on a complex balance, between the advances in fundamental cell and tissue 
research in experimental environments on the one hand, and the advances in clinical
management and treatment that result from better knowledge and application of the
fundamental information about the disease.
Colorectal cancer is a major killer - that much is restated in many parts of this book. 
This underlies the drive in research efforts towards finding solutions to important 
questions about how the disease starts, how it progresses, and how it spreads. So what 
do we know? A lot has been discovered, but all of the answers are still not within 
reach. Great steps and strides forward in in vitro studies still defy translation to the 
patient and hospital bedside - more work needs to be done to find out how to safely
and effectively apply what we have discovered to the patient's illness. 
This book about colorectal cancer comes in two volumes - both of which address 
several aspects of the endeavors of the biomedical and clinical community to find
resolutions and solutions to the disease and its complications. The first section of this
volume (Volume 1) deals with genes and genetic background associated with 
colorectal cancer and explores roles of the gene polymorphisms that mediate some of 
the presentations of the disease, as well as the short single strand ribonucleic acid
molecules (microRNA) that help to regulate the expression of these genes. The second
section deals with many cellular and molecular aspects of the biochemical pathways
involved in colorectal carcinogenesis and tumor progression. Section 3 examines the 
tumor microenvironment and the role of intestinal microbes and host-microbial
interactions in colorectal cancer. Section 4 presents a collection of short reports from 
studies that explore aspects such as fluorescent biomarkers and tumor infiltrating
lymphocytes. The chapters in this book represent some of the efforts of the thousands 
of workers involved in finding solutions and cures to colorectal cancer. This book is
directed to clinicians and scientists who want to ask why, learn how and know more. 
Dr Rajunor Ettarh
Professor & Associate Director of Anatomical Teaching, 
Department of Structural and Cellular Biology, 
Tulane University School of Medicine, New Orleans,
USA
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Colorectal Cancer: It Starts and It Runs 
Rajunor Ettarh 
Department of Structural and Cellular Biology,  
Tulane University School of Medicine, New Orleans,  
USA 
1. Introduction  
An automobile starts and runs. In much the same way, colorectal cancer starts and runs but 
our understanding of how this happens is incomplete. The disease affects millions of men 
and women around the world, and is responsible for significant morbidity and mortality in 
patients. Increasing numbers of new cases continue to appear worldwide and there is little 
evidence of a decline in incidence of the disease. The necessity for improved management 
and treatment of colorectal cancer in patients continues to drive studies and investigations 
towards a better understanding of the origins of the disease. Much of the evidence suggests 
that the origins of colorectal cancer are multifactorial: genetic and environmental factors 
intertwine with risk factors. Figure 1 lays out various aspects of colorectal cancer that 
provide broad focal points for studies and research investigations. In vitro studies have 
helped to define the scientific knowledge base regarding initiation of colorectal cancer and 
the mechanisms that sustain progression and encourage spread of the disease. Clinical 
studies and trials have provided insights into disease management and patient care. Animal 
modeling provides an important bridge between in vitro studies and investigations in 
patients. So what is the current state of the evidence regarding the causes and biological 
mechanisms involved in colorectal cancer? While the chapters in this volume of the book 
deliver detailed overviews of various aspects of the basic science involved in our 
understanding of the disease, this introductory chapter offers a summary outline of some of 
the evidence. 
2. Genes and heredity 
Genetic and hereditary mechanisms have a significant influence on colorectal cancer. 
Studies indicate that familial history plays a role in up to 25% of patients who are diagnosed 
with colorectal cancer (Gala & Chung, 2011) and this helps to explain the origins of their 
disease. Several genes have been implicated in the process of colorectal carcinogenesis 
including adenomatous polyposis coli (APC), rat sarcoma oncogene K-ras, tumor 
suppressor TP53, DNA glycosylase gene MUTYH, and murine sarcoma oncogene BRAF. In 
many patients, the most frequently mutated gene is the APC gene (Bettstetter et al, 2007; 
Vasovcak et al, 2011). Some of the methods by which these genes are affected include 
hypermethylation of promoter sequences for tumor suppressor genes as well as the 
induction of microsatellite instability. About 15% of colorectal cancers show microsatellite 
instability from mutated mismatch repair genes (Pino & Chung, 2011). 
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A majority of colorectal cancers are associated with colonic polyposis. Familial adenomatous 
polyposis (FAP) confers a genetic predisposition to developing multiple benign polyps in 
the large intestine, a reflection of the inherited mutation in the APC gene. Polyps eventually 
progress to malignant colorectal cancer. Patients with Lynch Syndrome have a genetic 
predisposition that confers a high risk for developing early onset, right-sided colorectal 
cancer (Bellizzi & Frankel, 2009). More recently recognized syndromes also include 
MUTYH-associated polyposis (MAP), and hyperplastic polyposis syndromes which show 
mutations of K-ras and microsatellite instability – changes similar to those associated with 
colorectal cancer (Hawkins et al, 2000; Jass et al, 2000; Liljegren et al, 2003). 
 
 
Fig. 1. The aspects of colorectal cancer that drive the quest for improved understanding, 
better management, effective therapies, and prevention. Aspects of initiation and 
mechanisms are considered in this volume of the book. Management, diagnosis and 
epidemiological considerations are dealt with in the second volume of the book. 
Animal models of colorectal cancer have contributed to improving understanding of the 
disease. The APC min mouse model develops multiple intestinal polyps and illustrates the 
role of Wnt signaling and beta catenin regulation in the formation of these polyps 
(Kawahara et al, 2000; Senda et al, 2007). The model provides one avenue for testing and 
evaluating pharmacotherapeutic approaches in colorectal cancer. 
3. Nutrition 
The relationship between nutrition and colorectal cancer remains inconsistent and 
debatable. Some studies suggest variable colorectal cancer risk with ingestion of fruit and 
vegetables, other studies indicate a reduction in the risk (Millen et al, 2007; Koushik et al, 
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2007; Anemma et al, 2011). The evidence is just as conflicting even when specific food 
components such as folate are considered (Mason, 2011). Some of the published data 
supports the association between colorectal cancer and processed foods as well as with 
consumption of red meat: the risk of colorectal cancer increases in line with increasing 
intake (Fu et al, 2011; Gingras and Beliveau, 2011). In addition, the risk among heavy alcohol 
drinkers for developing colorectal cancer is considerably higher than the risk for those 
whose alcohol intake is low (Pelluchi et al, 2011). 
4. Mechanisms 
The role of inflammation in colorectal cancer is demonstrated by the increased risk of 
colorectal in patients with chronic inflammatory conditions: the risk in patients with 
ulcerative colitis is 2-fold higher than for the general population and up to 0.8% of patients 
with Crohn's disease develop colorectal cancer (Pohl et al, 2000; Rizzo et al, 2011). These 
inflammatory diseases also demonstrate genetic alterations in some of the same targets 
associated with colorectal cancer. In addition, anti-inflammatory therapy significantly 
reduces the risk of colorectal cancer (Trinchieri, 2011).  
The intestine is colonized by great numbers of microbes in a symbiotic relationship with the 
gut epithelium, a relationship that affects digestion, absorption and nutrition. Nonetheless, 
there is increasing evidence of the association between intestinal streptococcal infection and 
colorectal cancer. However the precise mechanism by which these streptococcal strains are 
involved in the development or propagation of colorectal cancer remains unclear (Boleij et 
al, 2011). Enteric microbes are thought to alter normal regulatory mechanisms in epithelial 
cells to promote disruption and tumor growth (Wu et al, 2003; Sun et al, 2004; Franco et al, 
2005; Ye et al, 2007; Suzuki et al, 2009; Gnad et al, 2010; Liu et al, 2010).  
The idea that colorectal cancer is sustained by stem cells that continually supply new tumor 
cells continues to spur research investigations and generate new data. The idea however 
remains controversial despite several reports presenting data on putative cell surface 
markers for these stem cells. Isolated colorectal cancer stem cells (initiating cells) express a 
variety of cluster of differentiation proteins or markers that suggest a multipotent ability 
(Willis et al, 2008; Kemper et al, 2010; Davies et al, 2011; Zeki et al, 2011) but identification of 
a reliable stem cell biomarker is still elusive. These cells offer a potential target for cure of 
the disease in patients and for the control of metastatic spread that is thought to arise from 
residual stem cells that survive therapy for the primary tumor. 
5. Conclusion 
Our understanding of colorectal cancer in terms of origination, genesis, initiating causes and 
progression continues to improve. While multiple factors contribute to and influence the 
initiation and progression of the disease, the number of potential targets continues to increase. 
This targeting potential will ultimately lead to the development of effective strategies for 
management of the disease and translate into improved treatments for patients. 
6. References  
Annema N, Heyworth JS, McNaughton SA, Iacopetta B, Fritschi L. (2011). Fruit and 
vegetable consumption and the risk of proximal colon, distal colon, and rectal 
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This targeting potential will ultimately lead to the development of effective strategies for 
management of the disease and translate into improved treatments for patients. 
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1. Introduction  
Population-based studies indicate that approximately 35% of an individual’s risk of 
developing colorectal cancer (CRC) is due to inherited genetic factors (Lichtenstein et al. 
2000). Indeed, approximately 50,000 individuals diagnosed with CRC in the United States 
each year will have at least one other family member with CRC (Kaz & Brenthall, 2006). 
Classically, genetic susceptibility to CRC is described as three types: Low, moderate and 
high risk. In reality, the risk of developing colorectal cancer due to genetic factors exists on a 
continuum from very low to very high risk (Figure 1). In addition to colon cancer 
susceptibility, genetic variants are likely to play a role in response to therapy and prognosis 
of colon cancer. This Chapter will provide an overview of the current knowledge in genetic 
susceptibility to hereditary and non-hereditary CRC, the complexities and issues around the 
identification of germline genetic risk factors, and the current and future use of genetic 
information in the clinic.  
High penetrance risk includes inheritance of mutations in genes which segregate in a 
Mendelian fashion in families and confer a high lifetime risk of disease. Hereditary cancer 
syndromes are those in which a mutation confers a high lifetime risk of developing CRC. 
Several syndromes have been described. The two most familiar CRC syndromes are Familial 
Adenomatous Polyposis (FAP) and Lynch Syndrome (LS) (Table 1). Moderately-penetrant 
mutations are mutations or polymorphic variants which can manifest as colon cancer 
clustering in families but without a clear cancer syndrome or inheritance pattern. Low-
penetrance variants are those which are present in a reasonably high frequency in the 
general population, but have small influences on risk and are not themselves sufficient for 
the development of colon cancer.  
2. Hereditary colorectal cancer syndromes  
Hereditary colorectal cancer syndromes are those in which an inherited or de novo germline 
mutation confers a high lifetime risk of developing CRC. Approximately 5% of all CRC 
diagnoses are thought to be due to highly penetrant mutations (Bodmer, 2006; de la 
Chapelle, 2004). These familial mutations were the first germline genetic alterations to be 
discovered to be important for CRC risk. Several syndromes have been described. They can 
be subdivided into syndromes with adenomatous polyps, those with hamartomatous polyps 
and syndromes with polyps of mixed histopathology (Table 1). Syndromes that present with 
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a few or many adenomatous polyps include FAP, LS and MUTYH-associated polyposis 
(MAP) (Table 1). The hamartomatous polyp syndromes include Cowden Syndrome, 
Juvenile Polyposis and Peutz-Jeghers Syndrome. Not all genes contributing to hereditary 
CRC have been identified and characterized. It is likely as genome-wide and exonic 
sequencing become more common that additional rare mutations leading to hereditary 
colorectal cancer will be discovered. 
 
 
Fig. 1. Genes and variants associated with CRC risk. The allele frequency and lifetime risk of 
genes associated with familial colorectal cancer (red) and variants associated with a small 
increase in lifetime risk of CRC (blue) are illustrated. (The Y179C variant is associated with a 
low risk of CRC when individuals only carry one mutated MUTYH allele.) 
One common feature of all of these CRC syndromes is that the age of diagnosis of cancer 
tends to be much earlier than that in the general population. Typically colorectal cancer 
occurs 10-20 years earlier in individuals with these syndromes than in the general 
population. In individuals who carry a mutation in one of these hereditary CRC genes there 
is also considerable increased risk, up to 99%, of developing colon cancer. Individuals with 
most of these syndromes have detectable polyps prior to the onset of colorectal cancer; 
however many probands that were not undergoing regular screening are brought to 
attention following a diagnosis of CRC.  
A clinical diagnosis of a specific cancer syndrome can be made based on an extensive family 
history in combination with histological and pathological information about the number 
and type of polyps. More definitive diagnoses are made by genetic testing coordinated 
through a genetic counsellor or medical geneticist of an affected proband, or, in the case of 
LS, analysis of tumours for loss of one of the LS-related proteins. Even though individually 
these syndrome are rare, proper management and diagnoses can impact the incidence and 
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mortality related to CRC. Because mutations leading to these genes confer a high lifetime 
risk of CRC, knowledge of one’s family history and mutation status influences medical 
management and can significantly reduce the incidence of CRC. 
 
Syndrome CRC Risk Unique characteristics Other features Gene(s) 
HNPCC 20-75%* Microsatellite instability of tumors
Endometrial, gastric, 
ovarian, small bowel, 






FAP 99% Hundreds of polyps
Desmoids, 
hepatoblastoma & 
papillary thyroid ca, 
CHRPE 
APC 
Peutz-Jeghers 39% Hamartomatous polyps 
Gastric, breast, & 










Two common mutations 
in individuals with 
Northern European 







metaplastic polyps  BMPR1A 
Cowden None Hamartomatous polyps 
Macrocephaly, benign & 
malignant thryoid, 
breast & uterine 
neoplasms 
PTEN 
Juvenile Polyposis 39% Hamartomatous polyps GI polyps, gastric ca 
SMAD4, 
BMPR1A, 
Table 1. Hereditary Colon Cancer and Polyposis Syndromes. ca, cancer; CHRPE, congenital 
hypertrophy of the retinal pigment epithelium; ND, not determined; GI, gastrointestinal; 
*CRC risk depends on which gene is mutated. 
2.1 Hereditary non-polyposis colorectal cancer/lynch syndrome 
Hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome (LS), 
is the most common hereditary CRC syndrome associated with a strong family history of 
colon cancer. Approximately 2-4% of all colon cancers are due to LS (Hampel et al., 2008). 
Although individuals with LS frequently have adenomatous polyps, individuals with this 
syndrome do not have polyposis. In addition to a lifetime risk of approximately 50-80% for 
colorectal cancer, there is an increased risk of ovarian, endometrial and gastric cancers 
(Jasperson et al., 2010). Since the genes have been identified, some conditions which were 
once thought to be distinct (e.g. Muir-Torre syndrome which is characterized by familial 
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CRC with sebaceous neoplasms and Turcot syndrome which is characterized by CRC with 
glioblastomas) are variants of LS. LS is inherited in an autosomal dominant fashion and is 
associated with mutations in four genes important in mismatch repair (MMR): MLH1, 
MSH2, PMS2 and MSH6. Tumours arising in individuals with germline mutations in these 
genes, which are important for DNA repair, typically exhibit microsatellite instability which 
is sometimes used clinically to aid in a diagnosis. The most commonly mutated genes in LS 
are MLH1 and MSH2. Recently, deletions of the 3’end of EPCAM, a gene mapping 5’ of the 
MSH2 gene, have been found to give rise to LS by causing methylation of the MSH2 gene in 
about 6% of LS cases (Niessen et al., 2009a).  
Criteria based on family history, Amsterdam I, Amsterdam II and Bethesda criteria, were 
developed in order to identify families for further evaluation of Lynch syndrome. 
Amsterdam I criteria, the first described, includes three first degree relatives with CRC, two 
or more generations affected, one family member with CRC diagnosed under the age of 50 
and FAP must be ruled out (Vasen et al., 1991). Amsterdam II criteria are the same as 
Amsterdam I except that endometrial, small bowel or other LS-related cancers can be 
substituted for CRC (Vasen et al., 1999). Revised Bethesda criteria include one CRC 
diagnosed under the age of 50, one CRC under the age of 60 with evidence of microsatellite 
instability, CRC or LS-related cancer in at least one first degree relative under the age of fifty 
or CRC or LS-related cancers in at least two first or second degree relatives at any age (Umar 
et al., 2004). In addition, three online prediction programs MMRpredict, PREMM, and 
MMRpro have been developed to identify families with LS. Sensitivities of the online 
models and revised Bethesda criteria are about 75% with a range of specificity from 50-60%; 
the Amsterdam II criteria have a lower sensitivity of 37.5%, but a better specificity of 99% 
(Tresallet et al., 2011). Many hospitals have begun to screen all colon cancer cases by 
immunohistochemistry for loss of the four MMR proteins or for microsatellite instability 
regardless of family history which has a higher sensitivity than the family history based 
models (Hampel et al., 2008). Individuals whose tumours show absence of MLH1, MSH2, 
PMS2 and MSH6 and/or microsatellite instability are referred for genetic evaluation of LS 
and, in some cases, additional testing to rule out somatic events specific to the tumours 
which lead to loss of the proteins.   
The risk and spectrum of cancer depends on which LS gene is mutated. The lifetime colon 
cancer risk is 97% for males and 53% for females with germline MLH1 mutations. 
Endometrial cancer risk associated with MLH1 mutations ranges from 25 to 33% (Ramsoekh 
et al., 2009; Stoffel et al., 2009). The lifetime risk of CRC in male MSH2 mutation carriers is 
52% and is 40% for females. There is a 44-49% risk of endometrial cancer for female MSH2 
mutation carriers (Stoffel et al., 2009). About 10% of Lynch syndrome families have a 
mutation in MSH6 (Talseth-Palmer et al., 2010). The estimated risk of colorectal cancer in 
individuals with a MLH6 mutation is lower than some of the other mutations at 30-61% and 
the risk of endometrial cancer is higher with 65-70% of females developing endometrial 
cancer by the age of 70 (Talseth-Palmer et al., 2010; Ramsoekh et al., 2009). PMS2 mutations 
are less frequently the cause of LS accounting for only 2 to 14% of LS cases (Senter et al., 
2008; Niessen et al., 2009b; Talseth-Palmer et al., 2010). The cumulative risk by the age of 70 
of developing a colon cancer in mono-allelic PMS2 mutation carriers is 15-20%, endometrial 
cancer is 15% and other Lynch-related cancers is from 25-32% (Senter et al., 2008). Bi-allelic 
mutations in the MMR genes have been observed and lead to a severe phenotype with 
childhood brain tumours, leukaemia, and LS-associated tumors known as Constitutional 
MMR Deficiency (Senter et al., 2008; Felton et al., 2007; Wimmer & Kratz, 2010). EPCAM 
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deletions show a comparable risk of colon cancer to MLH1 and MSH2 mutation carriers, but 
a decreased risk of endometrial cancer. In families with EPCAM deletions there is a 75% risk 
of developing cancer by the age of 70 and a 12% risk of endometrial cancer (Kempers et al., 
2011). As the risks of colon, endometrial and other cancers are high, regardless of the gene, 
individuals with LS are recommended to follow more intensive cancer screening guidelines.  
2.2 Familial adenomatous polyposis 
Familial adenomatous polyposis (FAP) is an autosomal dominant CRC syndrome that 
accounts for less than 1% of all CRC diagnoses (Burt, 2000). In classic FAP, individuals 
develop hundreds to thousands of adenomatous polyps beginning in the early to mid-teen 
years. By age 35, 95% of individuals with FAP have polyps and the penetrance of colorectal 
cancer associated with this disease is over 90% (Petersen et al., 1991) which is why 
prophylactic colectomy is recommended in individuals who have this syndrome. FAP is 
caused by mutations in the adenomatous polyposis coli (APC) gene, although a high 
percentage (12-20%) of individuals with a clinical diagnosis of classical FAP do not have 
identifiable mutations in APC or another polyposis gene, MUTYH, (de la Chapelle, 2004; 
Filipe et al., 2009). Other features of FAP include small bowel adenomas, gastric polyposis, 
congenital hypertrophy of the retinal pigment epithelium (CHRPE), and desmoids (Allen & 
Terdiman, 2003). Desmoids cause significant mortality in FAP despite their non-malignant 
nature. Attenuated FAP is a milder form of this disease in which there are fewer polyps and 
a later onset of disease. Two other variants of FAP are Turcot syndrome which includes FAP 
and central nervous syndrome tumors, primarily medulloblastomas, and Gardner 
syndrome which includes soft-tissue tumours, osteomas and dental abnormalities. 
2.3 MUTYH-associated polyposis 
MUTYH-associated polyposis (MAP) is an autosomal recessive syndrome conferring a 43 to 
nearly 100% lifetime risk of CRC (Farrington et al., 2005; Lubbe et al., 2009). Penetrance for 
cancer in bi-allelic mutation carriers is estimated to be 20% at 40 years and 43% at 50 years of 
age (Lubbe et al., 2009). Individuals typically present with 10-100 adenomatous polyps, 
although some bi-allelic mutation carriers do not have any polyps on screening (Farrington 
et al, 2005; Nielsen et al., 2007). Polyposis of the duodenum can also be observed. Between 
24 and 56% of FAP and attenuated-FAP families lacking mutations in APC have been found 
to carry bi-allelic mutations in MUTYH, suggesting that mutations in the two genes account 
for a significant proportion of familial polyposis (Nielsen et al., 2007; Gomez-Fernandez et 
al., 2009). Two common MUTYH mutations comprising 80-85% of disease causing mutations 
in Caucasians of Northern European ancestry are Tyr179Cys and Gly396Asp (previously 
known as Y165C and G382D; Al-Tassan et al., 2002). Importantly, 4% of bi-allelic mutation 
carriers will not have either of the two common mutations (Goodenberger et al., 2011). The 
mutation frequency of these mutations varies between populations and other founder and 
relatively frequent mutations have been identified (Gomez-Fernandez et al., 2009).  
2.4 Other adenomatous polyposis syndromes 
A handful of case reports of mutations leading to unique or rare familial presentation of 
CRC exist which may explain a small proportion of polyposis families that do not have APC 
or MUTYH germline mutations. One recent description is of homozygous mutations in 
BUB1B leading to CRC (Rio Frio et al., 2010). This gene has not been extensively tested in 
 
 Colorectal Cancer Biology – From Genes to Tumor 14
CRC with sebaceous neoplasms and Turcot syndrome which is characterized by CRC with 
glioblastomas) are variants of LS. LS is inherited in an autosomal dominant fashion and is 
associated with mutations in four genes important in mismatch repair (MMR): MLH1, 
MSH2, PMS2 and MSH6. Tumours arising in individuals with germline mutations in these 
genes, which are important for DNA repair, typically exhibit microsatellite instability which 
is sometimes used clinically to aid in a diagnosis. The most commonly mutated genes in LS 
are MLH1 and MSH2. Recently, deletions of the 3’end of EPCAM, a gene mapping 5’ of the 
MSH2 gene, have been found to give rise to LS by causing methylation of the MSH2 gene in 
about 6% of LS cases (Niessen et al., 2009a).  
Criteria based on family history, Amsterdam I, Amsterdam II and Bethesda criteria, were 
developed in order to identify families for further evaluation of Lynch syndrome. 
Amsterdam I criteria, the first described, includes three first degree relatives with CRC, two 
or more generations affected, one family member with CRC diagnosed under the age of 50 
and FAP must be ruled out (Vasen et al., 1991). Amsterdam II criteria are the same as 
Amsterdam I except that endometrial, small bowel or other LS-related cancers can be 
substituted for CRC (Vasen et al., 1999). Revised Bethesda criteria include one CRC 
diagnosed under the age of 50, one CRC under the age of 60 with evidence of microsatellite 
instability, CRC or LS-related cancer in at least one first degree relative under the age of fifty 
or CRC or LS-related cancers in at least two first or second degree relatives at any age (Umar 
et al., 2004). In addition, three online prediction programs MMRpredict, PREMM, and 
MMRpro have been developed to identify families with LS. Sensitivities of the online 
models and revised Bethesda criteria are about 75% with a range of specificity from 50-60%; 
the Amsterdam II criteria have a lower sensitivity of 37.5%, but a better specificity of 99% 
(Tresallet et al., 2011). Many hospitals have begun to screen all colon cancer cases by 
immunohistochemistry for loss of the four MMR proteins or for microsatellite instability 
regardless of family history which has a higher sensitivity than the family history based 
models (Hampel et al., 2008). Individuals whose tumours show absence of MLH1, MSH2, 
PMS2 and MSH6 and/or microsatellite instability are referred for genetic evaluation of LS 
and, in some cases, additional testing to rule out somatic events specific to the tumours 
which lead to loss of the proteins.   
The risk and spectrum of cancer depends on which LS gene is mutated. The lifetime colon 
cancer risk is 97% for males and 53% for females with germline MLH1 mutations. 
Endometrial cancer risk associated with MLH1 mutations ranges from 25 to 33% (Ramsoekh 
et al., 2009; Stoffel et al., 2009). The lifetime risk of CRC in male MSH2 mutation carriers is 
52% and is 40% for females. There is a 44-49% risk of endometrial cancer for female MSH2 
mutation carriers (Stoffel et al., 2009). About 10% of Lynch syndrome families have a 
mutation in MSH6 (Talseth-Palmer et al., 2010). The estimated risk of colorectal cancer in 
individuals with a MLH6 mutation is lower than some of the other mutations at 30-61% and 
the risk of endometrial cancer is higher with 65-70% of females developing endometrial 
cancer by the age of 70 (Talseth-Palmer et al., 2010; Ramsoekh et al., 2009). PMS2 mutations 
are less frequently the cause of LS accounting for only 2 to 14% of LS cases (Senter et al., 
2008; Niessen et al., 2009b; Talseth-Palmer et al., 2010). The cumulative risk by the age of 70 
of developing a colon cancer in mono-allelic PMS2 mutation carriers is 15-20%, endometrial 
cancer is 15% and other Lynch-related cancers is from 25-32% (Senter et al., 2008). Bi-allelic 
mutations in the MMR genes have been observed and lead to a severe phenotype with 
childhood brain tumours, leukaemia, and LS-associated tumors known as Constitutional 
MMR Deficiency (Senter et al., 2008; Felton et al., 2007; Wimmer & Kratz, 2010). EPCAM 
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deletions show a comparable risk of colon cancer to MLH1 and MSH2 mutation carriers, but 
a decreased risk of endometrial cancer. In families with EPCAM deletions there is a 75% risk 
of developing cancer by the age of 70 and a 12% risk of endometrial cancer (Kempers et al., 
2011). As the risks of colon, endometrial and other cancers are high, regardless of the gene, 
individuals with LS are recommended to follow more intensive cancer screening guidelines.  
2.2 Familial adenomatous polyposis 
Familial adenomatous polyposis (FAP) is an autosomal dominant CRC syndrome that 
accounts for less than 1% of all CRC diagnoses (Burt, 2000). In classic FAP, individuals 
develop hundreds to thousands of adenomatous polyps beginning in the early to mid-teen 
years. By age 35, 95% of individuals with FAP have polyps and the penetrance of colorectal 
cancer associated with this disease is over 90% (Petersen et al., 1991) which is why 
prophylactic colectomy is recommended in individuals who have this syndrome. FAP is 
caused by mutations in the adenomatous polyposis coli (APC) gene, although a high 
percentage (12-20%) of individuals with a clinical diagnosis of classical FAP do not have 
identifiable mutations in APC or another polyposis gene, MUTYH, (de la Chapelle, 2004; 
Filipe et al., 2009). Other features of FAP include small bowel adenomas, gastric polyposis, 
congenital hypertrophy of the retinal pigment epithelium (CHRPE), and desmoids (Allen & 
Terdiman, 2003). Desmoids cause significant mortality in FAP despite their non-malignant 
nature. Attenuated FAP is a milder form of this disease in which there are fewer polyps and 
a later onset of disease. Two other variants of FAP are Turcot syndrome which includes FAP 
and central nervous syndrome tumors, primarily medulloblastomas, and Gardner 
syndrome which includes soft-tissue tumours, osteomas and dental abnormalities. 
2.3 MUTYH-associated polyposis 
MUTYH-associated polyposis (MAP) is an autosomal recessive syndrome conferring a 43 to 
nearly 100% lifetime risk of CRC (Farrington et al., 2005; Lubbe et al., 2009). Penetrance for 
cancer in bi-allelic mutation carriers is estimated to be 20% at 40 years and 43% at 50 years of 
age (Lubbe et al., 2009). Individuals typically present with 10-100 adenomatous polyps, 
although some bi-allelic mutation carriers do not have any polyps on screening (Farrington 
et al, 2005; Nielsen et al., 2007). Polyposis of the duodenum can also be observed. Between 
24 and 56% of FAP and attenuated-FAP families lacking mutations in APC have been found 
to carry bi-allelic mutations in MUTYH, suggesting that mutations in the two genes account 
for a significant proportion of familial polyposis (Nielsen et al., 2007; Gomez-Fernandez et 
al., 2009). Two common MUTYH mutations comprising 80-85% of disease causing mutations 
in Caucasians of Northern European ancestry are Tyr179Cys and Gly396Asp (previously 
known as Y165C and G382D; Al-Tassan et al., 2002). Importantly, 4% of bi-allelic mutation 
carriers will not have either of the two common mutations (Goodenberger et al., 2011). The 
mutation frequency of these mutations varies between populations and other founder and 
relatively frequent mutations have been identified (Gomez-Fernandez et al., 2009).  
2.4 Other adenomatous polyposis syndromes 
A handful of case reports of mutations leading to unique or rare familial presentation of 
CRC exist which may explain a small proportion of polyposis families that do not have APC 
or MUTYH germline mutations. One recent description is of homozygous mutations in 
BUB1B leading to CRC (Rio Frio et al., 2010). This gene has not been extensively tested in 
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polyposis families so it is unknown if it will contribute much to the overall risk of familial 
adenomatous polyposis. Mutations in the AXIN2 gene are associated with tooth agenesis-
colorectal cancer syndrome in a large Finnish family (Lammi et al., 2004), but mutations in 
this gene do not appear to account for a large proportion of hereditary CRC. 
2.5 Familial Colorectal Cancer Type X 
About half of the families that have a strong-family history of colorectal cancer suggestive of 
LS by Amsterdam or Bethesda criteria have no evidence of mismatch repair deficiency or 
loss of any of the HNPCC related proteins in tumours (de la Chapelle & Lynch, 2003). To be 
classified as Familial Colorectal Cancer Type X, families must meet Amsterdam I criteria 
and have no evidence of MMR deficiency. A closer look at these pedigrees shows that they 
tend to have fewer individuals diagnosed with cancer, their cancers are less likely to look 
like those in LS and their average age of diagnosis is older than those in families with MMR 
mutations (Jass et al., 1995; Lindor et al. 2005). The genes contributing to Familial Colorectal 
Cancer Type X are as yet unknown.  
2.6 Peutz-Jeghers syndrome 
Peutz-Jeghers syndrome is a rare autosomal dominant condition with an estimated 
incidence of 1 in 200,000 births first described by Peutz in 1921. It is characterized by 
childhood onset of hamartomatous polyps in the gastrointestinal tract and by 
mucocutaneous pigmentation of the lips and buccal mucosa. Mutations in LKB1 (STK11) are 
the only known cause of Peutz-Jeghers syndrome. LKB1 mutations have been found in 50-
94% of individuals with classic features of this disorder indicating that there may be locus 
heterogeneity (Boardman et al. 2000; Volikos et al., 2006; Aretz et al., 2005). The penetrance 
for GI polyps in this syndrome is 100%. There is also a 76-85% lifetime risk of cancer which 
includes lifetime risks of 40% for colon cancer, 30-60% for gastric cancer, 15-30% for small 
intestinal cancer and 11-35% for pancreatic cancer (Hearle et al., 2006, van Lier et al., 2010; 
van Lier et al., 2011). Breast and gynaecological cancers can be seen at high frequencies. 
There is a high mortality associated with this syndrome with a median age of death at 45 
years of life, mostly due to cancer or bowel intussusceptions (van Lier et al., 2011). 
2.7 Cowden syndrome 
Cowden syndrome is an autosomal dominant syndrome with features of skin lesions, 
macrocephaly, thyroid manifestations and hamartomatous polyps of the GI tract. It is 
caused by mutations in the PTEN gene. Although this disorder and an allelic disorder 
Bannayan-Ruvalcaba-Riley Syndrome are both characterized by many hamartomatous 
polyps, there is no clear increased risk of colon cancer associated with Cowden syndrome. 
2.8 Juvenile Polyposis 
Hereditary juvenile polyposis (JP) is defined as the presence of 10 or more juvenile polyps. 
These polyps are primarily hamartomatous. The typical age of diagnosis is between the ages 
of 5 and 15 years (Merg & Howe, 2004). Most children are brought to medical attention 
because of colorectal bleeding. The risk of CRC associated with JP varies from 20-50% 
depending on the study and the gene which is mutated. (Handra-Luca et al., 2005). In 
addition to CRC, there is a significant risk of upper GI cancers. JP is inherited as an 
autosomal dominant syndrome. Multiple genes have been implicated in this disorder. The 
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majority of mutations in individuals with JP have been found in SMAD4 and BMPR1A. 
Individuals with BMPR1A mutations have a higher risk of cancers including those of the 
stomach, pancreas and small bowel. Mutations have also been found in PTEN, but these 
may be misdiagnosed cases of Cowden syndrome. There have been reports of SMAD4 
mutations in families with features of both juvenile polyposis and hereditary hemorrhagic 
telangiectasia (Gallione et al., 2004). Not all individuals with features of JP have identifiable 
mutations implicating additional as yet unidentified genes (Handra-Luca et al., 2005).  
2.9 Hereditary mixed polyposis 
Hereditary mixed polyposis (HMP) is an autosomal dominant condition characterized by 
polyps of mixed histology including adenomatous, hyperplastic and atypical juvenile types. 
Mutations in BMPR1A have been found in a proportion of families presenting with polyps 
of mixed type (Cheah et al., 2009). Despite the observation that families with both juvenile 
polyps and hereditary mixed polyposis can have mutations in BMPR1A, families with HMP 
are less likely to have juvenile type polyps and have an older age of diagnosis in adulthood 
(Merg & Howe, 2004). A locus for HMP, called CRAC1 or HMPS, has been mapped to 
chromosome 15q13-q14 in multiple in several Ashkenazi Jewish families, but the gene has 
not yet been identified (Jaeger et al., 2008). 
2.10 Hyperplastic polyposis (HPP) 
Hyperplastic polyposis syndrome (HPP) is not yet well defined, but is characterized by 
multiple or large hyperplastic or serrated polyps and an association with an increased risk 
of CRC. The range of polyps has been described from 5 to over 100 and the pathology of the 
polyps can be diverse. HPP is often diagnosed in the fifth through seventh decade of life. 
The frequency of CRC in individuals with HPP ranges from 25-50% (Lage et al., 2004; 
Kalady et al., 2011). About 30% of individuals with HPP have a family history of CRC. The 
inheritance pattern of HPP is not well defined, but a few characterized families show 
possible recessive inheritance (Young & Jass, 2006). A germline mutation in EPHB2 was 
identified in an individual who had more than 100 hyperplastic polyps, but EPHB2 
mutations have not been observed in other HPP cases (Kokko et al., 2006). Thus, the causal 
genes for most individuals with HPP have yet to be identified. 
2.11 Rare cancer predisposition syndromes and risk of colon cancer 
Whereas many hereditary cancer syndromes have specific cancers which occur at greater 
frequency than the general population, a few syndromes have elevated risks of many 
different types of cancer. Li-Fraumeni syndrome (LFS) is a rare autosomal dominant 
inherited condition caused by germline mutations in TP53. The classical types of cancer seen 
in individuals with LFS include breast cancer, sarcomas, brain tumors, leukemia and 
adrenal cortical tumours; however, there is also an increased risk of colon cancer of 2.8-fold 
over the general population (Ruijs et al., 2010).  
3. Moderate risk alleles 
Familial clusters of colon cancer account for approximately 20% of all CRC cases, however, 
most of these cases will not be due to the known CRC syndromes (Burt et al., 1990). A 
familial cluster is multiple individuals within families who have a similar presentation, but 
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polyposis families so it is unknown if it will contribute much to the overall risk of familial 
adenomatous polyposis. Mutations in the AXIN2 gene are associated with tooth agenesis-
colorectal cancer syndrome in a large Finnish family (Lammi et al., 2004), but mutations in 
this gene do not appear to account for a large proportion of hereditary CRC. 
2.5 Familial Colorectal Cancer Type X 
About half of the families that have a strong-family history of colorectal cancer suggestive of 
LS by Amsterdam or Bethesda criteria have no evidence of mismatch repair deficiency or 
loss of any of the HNPCC related proteins in tumours (de la Chapelle & Lynch, 2003). To be 
classified as Familial Colorectal Cancer Type X, families must meet Amsterdam I criteria 
and have no evidence of MMR deficiency. A closer look at these pedigrees shows that they 
tend to have fewer individuals diagnosed with cancer, their cancers are less likely to look 
like those in LS and their average age of diagnosis is older than those in families with MMR 
mutations (Jass et al., 1995; Lindor et al. 2005). The genes contributing to Familial Colorectal 
Cancer Type X are as yet unknown.  
2.6 Peutz-Jeghers syndrome 
Peutz-Jeghers syndrome is a rare autosomal dominant condition with an estimated 
incidence of 1 in 200,000 births first described by Peutz in 1921. It is characterized by 
childhood onset of hamartomatous polyps in the gastrointestinal tract and by 
mucocutaneous pigmentation of the lips and buccal mucosa. Mutations in LKB1 (STK11) are 
the only known cause of Peutz-Jeghers syndrome. LKB1 mutations have been found in 50-
94% of individuals with classic features of this disorder indicating that there may be locus 
heterogeneity (Boardman et al. 2000; Volikos et al., 2006; Aretz et al., 2005). The penetrance 
for GI polyps in this syndrome is 100%. There is also a 76-85% lifetime risk of cancer which 
includes lifetime risks of 40% for colon cancer, 30-60% for gastric cancer, 15-30% for small 
intestinal cancer and 11-35% for pancreatic cancer (Hearle et al., 2006, van Lier et al., 2010; 
van Lier et al., 2011). Breast and gynaecological cancers can be seen at high frequencies. 
There is a high mortality associated with this syndrome with a median age of death at 45 
years of life, mostly due to cancer or bowel intussusceptions (van Lier et al., 2011). 
2.7 Cowden syndrome 
Cowden syndrome is an autosomal dominant syndrome with features of skin lesions, 
macrocephaly, thyroid manifestations and hamartomatous polyps of the GI tract. It is 
caused by mutations in the PTEN gene. Although this disorder and an allelic disorder 
Bannayan-Ruvalcaba-Riley Syndrome are both characterized by many hamartomatous 
polyps, there is no clear increased risk of colon cancer associated with Cowden syndrome. 
2.8 Juvenile Polyposis 
Hereditary juvenile polyposis (JP) is defined as the presence of 10 or more juvenile polyps. 
These polyps are primarily hamartomatous. The typical age of diagnosis is between the ages 
of 5 and 15 years (Merg & Howe, 2004). Most children are brought to medical attention 
because of colorectal bleeding. The risk of CRC associated with JP varies from 20-50% 
depending on the study and the gene which is mutated. (Handra-Luca et al., 2005). In 
addition to CRC, there is a significant risk of upper GI cancers. JP is inherited as an 
autosomal dominant syndrome. Multiple genes have been implicated in this disorder. The 
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majority of mutations in individuals with JP have been found in SMAD4 and BMPR1A. 
Individuals with BMPR1A mutations have a higher risk of cancers including those of the 
stomach, pancreas and small bowel. Mutations have also been found in PTEN, but these 
may be misdiagnosed cases of Cowden syndrome. There have been reports of SMAD4 
mutations in families with features of both juvenile polyposis and hereditary hemorrhagic 
telangiectasia (Gallione et al., 2004). Not all individuals with features of JP have identifiable 
mutations implicating additional as yet unidentified genes (Handra-Luca et al., 2005).  
2.9 Hereditary mixed polyposis 
Hereditary mixed polyposis (HMP) is an autosomal dominant condition characterized by 
polyps of mixed histology including adenomatous, hyperplastic and atypical juvenile types. 
Mutations in BMPR1A have been found in a proportion of families presenting with polyps 
of mixed type (Cheah et al., 2009). Despite the observation that families with both juvenile 
polyps and hereditary mixed polyposis can have mutations in BMPR1A, families with HMP 
are less likely to have juvenile type polyps and have an older age of diagnosis in adulthood 
(Merg & Howe, 2004). A locus for HMP, called CRAC1 or HMPS, has been mapped to 
chromosome 15q13-q14 in multiple in several Ashkenazi Jewish families, but the gene has 
not yet been identified (Jaeger et al., 2008). 
2.10 Hyperplastic polyposis (HPP) 
Hyperplastic polyposis syndrome (HPP) is not yet well defined, but is characterized by 
multiple or large hyperplastic or serrated polyps and an association with an increased risk 
of CRC. The range of polyps has been described from 5 to over 100 and the pathology of the 
polyps can be diverse. HPP is often diagnosed in the fifth through seventh decade of life. 
The frequency of CRC in individuals with HPP ranges from 25-50% (Lage et al., 2004; 
Kalady et al., 2011). About 30% of individuals with HPP have a family history of CRC. The 
inheritance pattern of HPP is not well defined, but a few characterized families show 
possible recessive inheritance (Young & Jass, 2006). A germline mutation in EPHB2 was 
identified in an individual who had more than 100 hyperplastic polyps, but EPHB2 
mutations have not been observed in other HPP cases (Kokko et al., 2006). Thus, the causal 
genes for most individuals with HPP have yet to be identified. 
2.11 Rare cancer predisposition syndromes and risk of colon cancer 
Whereas many hereditary cancer syndromes have specific cancers which occur at greater 
frequency than the general population, a few syndromes have elevated risks of many 
different types of cancer. Li-Fraumeni syndrome (LFS) is a rare autosomal dominant 
inherited condition caused by germline mutations in TP53. The classical types of cancer seen 
in individuals with LFS include breast cancer, sarcomas, brain tumors, leukemia and 
adrenal cortical tumours; however, there is also an increased risk of colon cancer of 2.8-fold 
over the general population (Ruijs et al., 2010).  
3. Moderate risk alleles 
Familial clusters of colon cancer account for approximately 20% of all CRC cases, however, 
most of these cases will not be due to the known CRC syndromes (Burt et al., 1990). A 
familial cluster is multiple individuals within families who have a similar presentation, but 
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no clear inheritance pattern of disease transmission. The risk of colon cancer is increased to 
individuals who have a relative with CRC or adenomas; first-degree relatives of affected 
individuals have a two- to three-fold increase in risk and when more than one first-degree 
relative is affected the risk increases to nearly four-fold (Butterworth et al., 2006; Taylor et al. 
2010). To date, moderate-risk alleles (ORs of 3-5) have not been identified. It is possible that 
some families exhibiting clustering of CRC may have multiple low-penetrance alleles which 
work synergistically to increase risk.  
4. Low-penetrance risk alleles 
The majority of genetic risk for CRC in the population is likely to be due to low-penetrance 
susceptibility alleles which act with other low-pentrance variants and the environment. A 
debate in the field is whether most of the genetic risk will be due to common variants with 
low effects and allele frequencies greater than 1% or rare or unique variants with low to 
moderate effects (Bodmer, 2006). Historically, variants conferring an increased risk of CRC 
in the general population have been identified through cohort or population-based 
case/control studies looking at candidate genes, but recent genome-wide association studies 
(GWAS) have been quite successful in identifying well-replicated variants conferring risk. 
Whereas a great many studies have identified positive associations with some of these 
genes, the vast majority have not been consistently replicated. Lack of replication does not 
mean in all cases that the initial association is faulty, but could be due to differences in 
populations leading to differences in allele frequencies or linkage disquilibrium, 
environmental exposures, study design or underpowered replicate studies. 
Whereas the low-penetrance variants identified to date are not particularly predictive for 
CRC risk on their own, several direct-to-consumer genetic testing companies include some 
of these variants in their analysis of genomic risks of common disease. We will highlight 
some of the different types of variants which have been identified through multiple types of 
studies as showing evidence of contribution to CRC risk. 
4.1 Candidate-gene studies 
The studies to assess the risk of DNA variants, mainly single nucleotide polymorphisms 
(SNPs), have been association case/control studies or cohort studies testing SNPs in genes 
with relevant biological function for CRC. Many such candidate gene studies for CRC risk 
have been completed. Some of these have been replicated in one or two studies, but few 
have stood up to repeated replication studies or meta-analyses. A meta-analysis of 50 
published CRC association studies for common alleles in 13 genes found three variants: APC 
I1307K, a HRAS1 repeat variant and MTHFR 677V were convincingly associated with 
modest CRC risk in the general population (Houlston & Tomlinson, 2001). Other genes with 
variants showing CRC risk in multiple studies include NAT1, NAT2 and TGFBRII (Burt, 
2010). It is possible that some of these are real associations, but are population-specific or 
depend upon gene-environment interactions present only in certain individuals.  
Candidate genes for CRC case/control studies have been chosen in a variety of ways. 
Variants and genes studied include common variants in high-risk genes, genes in pathways 
believed to be important in CRC and genes in pathways linked to environmental factors 
associated with CRC. One strategy which has been under-utilized is to map loci for cancer 
susceptibility in the mouse and then test these genes/loci for cancer risk in human 
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populations (Ruivenkamp et al., 2002; Ewart-Toland et al., 2005; Toland et al., 2008). A large 
number of cancer susceptibility and resistance loci for cancers of the lung, colon, skin, liver, 
and the hematopoetic system have been identified using mouse models.  Two putative CRC 
susceptibility genes, PTPRJ and AURKA, were first identified from mouse studies 
(Ruivenkamp et al., 2002; Ewart-Toland et al., 2003). Variants in these genes show evidence 
of modest CRC risk in some human studies (Ewart-Toland et al., 2005; Toland et al., 2008).  
4.2 Variants of high-risk genes 
Once genes for hereditary cancer syndromes began to be identified, researchers 
hypothesized that common variants in these genes contribute to cancer risk in the general 
population. Studies on common variants of almost all hereditary CRC predisposition genes 
have been assessed, but only a handful of variants in these high risk genes have been 
determined to contribute to sporadic CRC risk.  
4.2.1 Carriers of MUTYH mutations 
Bi-allelic mutations in MUTYH lead to MAP as described above. Several studies have looked 
at the cancer risks associated with mono-allelic mutations in MUTYH. The range of cancer 
incidence associated with the Y179C allele is between 1.27 to 2-fold (Table 2, Jones et al., 
2009; Tenesa et al., 2006; Theodoratou et al., 2010). As a result, colon adenomas or cancer 
cancer may be seen in multiple generations in families with MAP. 
4.2.2 APC I1307K 
One frequently described modest-risk allele is the I1307K variant in the APC gene. This 
variant is seen in approximately 6% of individuals of Ashkenazi jewish (AJ) ancestry and 
28% of AJ individuals with a family history of CRC (Laken et al., 1997). Carriers of the 
I1307K allele have 1.5 to 2-fold increased risk of CRC compared to individuals who are non-
carriers (Table 2, Dundar et al., 2007; Gryfe et al., 1999). The variant itself is not thought to 
change function of the APC gene, however, the change results in a stretch of eight 
consecutive adenosines. During replication this polyadenosine track is thought to have 
increased risk of somatic mutation due to polymerase slippage. Addition or loss of a single 
nucleotide then results in a frame-shift and non-functional APC gene (Laken et al., 1997). As 
the age of onset of CRC related to this polymorphism does not appear to differ from 
sporadic CRC, cancer screening beyond general population recommendations is not 
typically done (Petersen et al., 1999).  
4.2.3 Bloom’s syndrome mutation carriers 
Bloom’s syndrome is a rare autosomal recessive condition characterized by abnormal rates 
of sister chromatid exchange, growth deficiency and an increased incidence of multiple 
types of cancer. One in 107 individuals of AJ ancestry carries a founder mutation, 
designated as BlmAsh, in the Bloom’s syndrome gene, BLM (Li et al., 1998). Early studies 
suggested a 2-fold increase in colon cancer risk in BlmAsh carriers, but this has not held up in 
subsequent studies (Gruber et al, 2002; Cleary et al., 2003).  
4.2.4 CHEK2 
CHEK2 is a gene important in response to DNA damage. Studies have demonstrated 
increased risk of breast cancer with an 1100delC polymorphism but have been inconclusive 
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no clear inheritance pattern of disease transmission. The risk of colon cancer is increased to 
individuals who have a relative with CRC or adenomas; first-degree relatives of affected 
individuals have a two- to three-fold increase in risk and when more than one first-degree 
relative is affected the risk increases to nearly four-fold (Butterworth et al., 2006; Taylor et al. 
2010). To date, moderate-risk alleles (ORs of 3-5) have not been identified. It is possible that 
some families exhibiting clustering of CRC may have multiple low-penetrance alleles which 
work synergistically to increase risk.  
4. Low-penetrance risk alleles 
The majority of genetic risk for CRC in the population is likely to be due to low-penetrance 
susceptibility alleles which act with other low-pentrance variants and the environment. A 
debate in the field is whether most of the genetic risk will be due to common variants with 
low effects and allele frequencies greater than 1% or rare or unique variants with low to 
moderate effects (Bodmer, 2006). Historically, variants conferring an increased risk of CRC 
in the general population have been identified through cohort or population-based 
case/control studies looking at candidate genes, but recent genome-wide association studies 
(GWAS) have been quite successful in identifying well-replicated variants conferring risk. 
Whereas a great many studies have identified positive associations with some of these 
genes, the vast majority have not been consistently replicated. Lack of replication does not 
mean in all cases that the initial association is faulty, but could be due to differences in 
populations leading to differences in allele frequencies or linkage disquilibrium, 
environmental exposures, study design or underpowered replicate studies. 
Whereas the low-penetrance variants identified to date are not particularly predictive for 
CRC risk on their own, several direct-to-consumer genetic testing companies include some 
of these variants in their analysis of genomic risks of common disease. We will highlight 
some of the different types of variants which have been identified through multiple types of 
studies as showing evidence of contribution to CRC risk. 
4.1 Candidate-gene studies 
The studies to assess the risk of DNA variants, mainly single nucleotide polymorphisms 
(SNPs), have been association case/control studies or cohort studies testing SNPs in genes 
with relevant biological function for CRC. Many such candidate gene studies for CRC risk 
have been completed. Some of these have been replicated in one or two studies, but few 
have stood up to repeated replication studies or meta-analyses. A meta-analysis of 50 
published CRC association studies for common alleles in 13 genes found three variants: APC 
I1307K, a HRAS1 repeat variant and MTHFR 677V were convincingly associated with 
modest CRC risk in the general population (Houlston & Tomlinson, 2001). Other genes with 
variants showing CRC risk in multiple studies include NAT1, NAT2 and TGFBRII (Burt, 
2010). It is possible that some of these are real associations, but are population-specific or 
depend upon gene-environment interactions present only in certain individuals.  
Candidate genes for CRC case/control studies have been chosen in a variety of ways. 
Variants and genes studied include common variants in high-risk genes, genes in pathways 
believed to be important in CRC and genes in pathways linked to environmental factors 
associated with CRC. One strategy which has been under-utilized is to map loci for cancer 
susceptibility in the mouse and then test these genes/loci for cancer risk in human 
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populations (Ruivenkamp et al., 2002; Ewart-Toland et al., 2005; Toland et al., 2008). A large 
number of cancer susceptibility and resistance loci for cancers of the lung, colon, skin, liver, 
and the hematopoetic system have been identified using mouse models.  Two putative CRC 
susceptibility genes, PTPRJ and AURKA, were first identified from mouse studies 
(Ruivenkamp et al., 2002; Ewart-Toland et al., 2003). Variants in these genes show evidence 
of modest CRC risk in some human studies (Ewart-Toland et al., 2005; Toland et al., 2008).  
4.2 Variants of high-risk genes 
Once genes for hereditary cancer syndromes began to be identified, researchers 
hypothesized that common variants in these genes contribute to cancer risk in the general 
population. Studies on common variants of almost all hereditary CRC predisposition genes 
have been assessed, but only a handful of variants in these high risk genes have been 
determined to contribute to sporadic CRC risk.  
4.2.1 Carriers of MUTYH mutations 
Bi-allelic mutations in MUTYH lead to MAP as described above. Several studies have looked 
at the cancer risks associated with mono-allelic mutations in MUTYH. The range of cancer 
incidence associated with the Y179C allele is between 1.27 to 2-fold (Table 2, Jones et al., 
2009; Tenesa et al., 2006; Theodoratou et al., 2010). As a result, colon adenomas or cancer 
cancer may be seen in multiple generations in families with MAP. 
4.2.2 APC I1307K 
One frequently described modest-risk allele is the I1307K variant in the APC gene. This 
variant is seen in approximately 6% of individuals of Ashkenazi jewish (AJ) ancestry and 
28% of AJ individuals with a family history of CRC (Laken et al., 1997). Carriers of the 
I1307K allele have 1.5 to 2-fold increased risk of CRC compared to individuals who are non-
carriers (Table 2, Dundar et al., 2007; Gryfe et al., 1999). The variant itself is not thought to 
change function of the APC gene, however, the change results in a stretch of eight 
consecutive adenosines. During replication this polyadenosine track is thought to have 
increased risk of somatic mutation due to polymerase slippage. Addition or loss of a single 
nucleotide then results in a frame-shift and non-functional APC gene (Laken et al., 1997). As 
the age of onset of CRC related to this polymorphism does not appear to differ from 
sporadic CRC, cancer screening beyond general population recommendations is not 
typically done (Petersen et al., 1999).  
4.2.3 Bloom’s syndrome mutation carriers 
Bloom’s syndrome is a rare autosomal recessive condition characterized by abnormal rates 
of sister chromatid exchange, growth deficiency and an increased incidence of multiple 
types of cancer. One in 107 individuals of AJ ancestry carries a founder mutation, 
designated as BlmAsh, in the Bloom’s syndrome gene, BLM (Li et al., 1998). Early studies 
suggested a 2-fold increase in colon cancer risk in BlmAsh carriers, but this has not held up in 
subsequent studies (Gruber et al, 2002; Cleary et al., 2003).  
4.2.4 CHEK2 
CHEK2 is a gene important in response to DNA damage. Studies have demonstrated 
increased risk of breast cancer with an 1100delC polymorphism but have been inconclusive 
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for the role of the 1100del C variant in CRC risk. However, another variant, I157T, has been 
associated with Lynch-syndrome like cancers and confers an increased risk of 1.4 to 2-fold of 
CRC (Kilpivaara et al., 2006).  
4.3 Genome-wide association studies (GWAS) 
With technological advances allowing the genotyping of up to millions of SNPs, the ability 
to interrogate the entire genome without bias has led to the identification of SNPs with 
reproducible, but small associations with cancer risk. The strength of these studies is that 
that very large numbers of samples were used, large independent replication studies have 
been completed and very low p-values were required to meet genome-wide significance. 
About 18 SNPs have been identified to date (Table 2). Interestingly, although many map 
near genes, none of them fall within coding regions of genes suggesting that these SNPs 
may play a role in gene regulation. Despite the confidence that these are “real”, the variants 
identified through GWAS to date explain a very small percentage of the overall risk of CRC 
ascribed to genetics. One computational assessment estimates that there may be as many as 
170 low-penetrance variants which contribute to CRC risk (Tenesa and Dunlop, 2009). 
4.3.1 8q24 and rs6983267 
Two of the first GWAS studies for CRC identified a variant, rs6983267, on chromosome 8q24 
which was significantly associated with CRC risk (Tomlinson et al. 2007; Haiman et al. 
2007). The effects were modest with ORs ranging from of 1.14 to 1.24. Additional variants on 
8q24 including rs7014346, rs783728, and rs10505477 were also identified in subsequent 
screens (Tenesa et al. 2008; Poynter et al. 2007). Several groups have replicated these 
findings and show a consistent effect of the rs6983267 variant. This SNP falls into a gene-
poor region on 8q24 with the closest gene, cMYC, 335 kb away. One study showed that the 
rs6983267 variant falls within an enhancer element and alleles differentially bind a WNT-
related transcription-factor 7-like 2 (TCF7L2). However, correlation with expression of MYC 
has not been detected, and the exact role of this SNP in colon cancer development has yet to 
be definitively determined (Pomerantz et al. 2009; Tuupanen et al. 2009).  
4.3.2 GWAS variants in the Bone Morphogenic Protein (BMP)/Transforming Growth 
Factor Beta (TGF) pathway 
Multiple variants identified by GWAS (rs4444235, rs4939827, rs4779584, rs961253 
rs10411210, rs4925386) are located near genes involved in BMP and/or TGF signalling 
(Tenesa & Dunlop, 2009). BMP proteins are positive regulators of the Wnt pathway which 
have long been known to be important in CRC tumorigenesis. TGF is a master signalling 
molecule controlling many processes important in cancer and cancer suppression. There is 
considerable overlap and interaction between the BMP and TGF pathways. Germline 
mutations in SMAD4, BMPR1A and APC are associated with specific hereditary colon 
cancer syndromes. Whereas the exact effect of these SNPs on the nearby BMP/TGF 
signalling genes is not determined, location and number of these SNPs suggest that 
perturbation of these pathways may be critical for CRC risk in the general population. 
4.4 Population specific risk factors 
One of the caveats to many of the candidate gene and GWAS studies for CRC risk to date is 
that they have been predominantly completed in Caucasian populations. The rs6983267 
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SNP Locus Nearby genes OR Type of Study Reference 
Rs6691170 1q41 DUSP10 1.06 GWAS Houlston et al., 2010 
Rs6687758 1q41 DUSP10 1.09 GWAS Houlston et al., 2010 
Rs10936599 3q26.2 MYNN 0.93 GWAS Houlston et al., 2010 
Rs16892766 8q23.3 EIF3H 1.27 GWAS Tomlinson et al., 2008 
Rs6983267 8q24 Gene desert 1.21-1.23 GWAS 
Tomlinson et al. 
2007; Xiong et al. 
2011 
Rs7014346 8q24 POU5F1P1, DQ515897 1.19 GWAS Tenesa et al., 2008 
Rs719725 9p24 Several 1.46 GWAS Poynter et al. 2007 
Rs10795668 10p14 FLJ3802842 1.23 GWAS 
Tomlinson et al., 
2008; Xiong et al., 
2011 
Rs3802842 11q23 Several 1.11-1.29 GWAS 
Pittman et al., 2008; 
Tenesa et al., 2008; 
Xing et al., 2011 
Rs11169552 12q13.13 LARP4, DIP2B 0.92* GWAS Houlston et al., 2010 
Rs7136702 12q13.13 LARP4, DIP2B 1.06 GWAS Houlston et al., 2010 
Rs4444235 14q22.2 BMP4 1.11 GWAS Houlston et al. 2008 
Rs4779584 15q13.3 CRAC1/ GREM1 1.23 GWAS Jaeger et al., 2008 
Rs9929218 16q22.1 CDH1 0.91* GWAS Houlston et al. 2008 
Rs4939827 18q21 SMAD7 1.17 GWAS Tenesa et al., 2008; Xiong et al., 2011 
Rs10411210 19q13.1 RHPN2 0.87* GWAS Houlston et al. 2008 
Rs961253 20p12.3 BMP2 1.12-1.37 GWAS Xiong et al., 2011 
Rs4925386 20q13.3 LAMA5 0.93 GWAS Houlston et al., 2010 
I1307K 5q21-22 APC 1.5-2.0 Candidate Dundar et al., 2007; Gryfe et al., 1999 
Y179C (mono-
allelic) 1p34.1 MUTYH 1.27-2.0 Candidate 
Tenesa et al., 2006 
Theodoratou et al., 
2010 
Table 2. Low-penetrance variants associated with CRC Risk  
OR, odds ratio; *The common allele is the risk allele. 
variant has been replicated in multiple ethnic groups including African-American and 
Chinese populations with fairly consistent results (Xiong et al., 2011; He et al. 2011). 
However, rs3802842 on chromosome 11q23 is associated with no increased risk in Japanese 
populations. A GWAS performed in Japanese CRC cases identified a novel variant, 
rs7758229 on chromosome 6 which has not been linked with risk in Caucasians (Cui et al., 
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for the role of the 1100del C variant in CRC risk. However, another variant, I157T, has been 
associated with Lynch-syndrome like cancers and confers an increased risk of 1.4 to 2-fold of 
CRC (Kilpivaara et al., 2006).  
4.3 Genome-wide association studies (GWAS) 
With technological advances allowing the genotyping of up to millions of SNPs, the ability 
to interrogate the entire genome without bias has led to the identification of SNPs with 
reproducible, but small associations with cancer risk. The strength of these studies is that 
that very large numbers of samples were used, large independent replication studies have 
been completed and very low p-values were required to meet genome-wide significance. 
About 18 SNPs have been identified to date (Table 2). Interestingly, although many map 
near genes, none of them fall within coding regions of genes suggesting that these SNPs 
may play a role in gene regulation. Despite the confidence that these are “real”, the variants 
identified through GWAS to date explain a very small percentage of the overall risk of CRC 
ascribed to genetics. One computational assessment estimates that there may be as many as 
170 low-penetrance variants which contribute to CRC risk (Tenesa and Dunlop, 2009). 
4.3.1 8q24 and rs6983267 
Two of the first GWAS studies for CRC identified a variant, rs6983267, on chromosome 8q24 
which was significantly associated with CRC risk (Tomlinson et al. 2007; Haiman et al. 
2007). The effects were modest with ORs ranging from of 1.14 to 1.24. Additional variants on 
8q24 including rs7014346, rs783728, and rs10505477 were also identified in subsequent 
screens (Tenesa et al. 2008; Poynter et al. 2007). Several groups have replicated these 
findings and show a consistent effect of the rs6983267 variant. This SNP falls into a gene-
poor region on 8q24 with the closest gene, cMYC, 335 kb away. One study showed that the 
rs6983267 variant falls within an enhancer element and alleles differentially bind a WNT-
related transcription-factor 7-like 2 (TCF7L2). However, correlation with expression of MYC 
has not been detected, and the exact role of this SNP in colon cancer development has yet to 
be definitively determined (Pomerantz et al. 2009; Tuupanen et al. 2009).  
4.3.2 GWAS variants in the Bone Morphogenic Protein (BMP)/Transforming Growth 
Factor Beta (TGF) pathway 
Multiple variants identified by GWAS (rs4444235, rs4939827, rs4779584, rs961253 
rs10411210, rs4925386) are located near genes involved in BMP and/or TGF signalling 
(Tenesa & Dunlop, 2009). BMP proteins are positive regulators of the Wnt pathway which 
have long been known to be important in CRC tumorigenesis. TGF is a master signalling 
molecule controlling many processes important in cancer and cancer suppression. There is 
considerable overlap and interaction between the BMP and TGF pathways. Germline 
mutations in SMAD4, BMPR1A and APC are associated with specific hereditary colon 
cancer syndromes. Whereas the exact effect of these SNPs on the nearby BMP/TGF 
signalling genes is not determined, location and number of these SNPs suggest that 
perturbation of these pathways may be critical for CRC risk in the general population. 
4.4 Population specific risk factors 
One of the caveats to many of the candidate gene and GWAS studies for CRC risk to date is 
that they have been predominantly completed in Caucasian populations. The rs6983267 
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SNP Locus Nearby genes OR Type of Study Reference 
Rs6691170 1q41 DUSP10 1.06 GWAS Houlston et al., 2010 
Rs6687758 1q41 DUSP10 1.09 GWAS Houlston et al., 2010 
Rs10936599 3q26.2 MYNN 0.93 GWAS Houlston et al., 2010 
Rs16892766 8q23.3 EIF3H 1.27 GWAS Tomlinson et al., 2008 
Rs6983267 8q24 Gene desert 1.21-1.23 GWAS 
Tomlinson et al. 
2007; Xiong et al. 
2011 
Rs7014346 8q24 POU5F1P1, DQ515897 1.19 GWAS Tenesa et al., 2008 
Rs719725 9p24 Several 1.46 GWAS Poynter et al. 2007 
Rs10795668 10p14 FLJ3802842 1.23 GWAS 
Tomlinson et al., 
2008; Xiong et al., 
2011 
Rs3802842 11q23 Several 1.11-1.29 GWAS 
Pittman et al., 2008; 
Tenesa et al., 2008; 
Xing et al., 2011 
Rs11169552 12q13.13 LARP4, DIP2B 0.92* GWAS Houlston et al., 2010 
Rs7136702 12q13.13 LARP4, DIP2B 1.06 GWAS Houlston et al., 2010 
Rs4444235 14q22.2 BMP4 1.11 GWAS Houlston et al. 2008 
Rs4779584 15q13.3 CRAC1/ GREM1 1.23 GWAS Jaeger et al., 2008 
Rs9929218 16q22.1 CDH1 0.91* GWAS Houlston et al. 2008 
Rs4939827 18q21 SMAD7 1.17 GWAS Tenesa et al., 2008; Xiong et al., 2011 
Rs10411210 19q13.1 RHPN2 0.87* GWAS Houlston et al. 2008 
Rs961253 20p12.3 BMP2 1.12-1.37 GWAS Xiong et al., 2011 
Rs4925386 20q13.3 LAMA5 0.93 GWAS Houlston et al., 2010 
I1307K 5q21-22 APC 1.5-2.0 Candidate Dundar et al., 2007; Gryfe et al., 1999 
Y179C (mono-
allelic) 1p34.1 MUTYH 1.27-2.0 Candidate 
Tenesa et al., 2006 
Theodoratou et al., 
2010 
Table 2. Low-penetrance variants associated with CRC Risk  
OR, odds ratio; *The common allele is the risk allele. 
variant has been replicated in multiple ethnic groups including African-American and 
Chinese populations with fairly consistent results (Xiong et al., 2011; He et al. 2011). 
However, rs3802842 on chromosome 11q23 is associated with no increased risk in Japanese 
populations. A GWAS performed in Japanese CRC cases identified a novel variant, 
rs7758229 on chromosome 6 which has not been linked with risk in Caucasians (Cui et al., 
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2011). These examples illustrate that specific variants identified by GWAS are often markers 
for the causal, as yet unidentified variant, which may be absent or in different linkage 
disquilibrium patterns with the identified SNP in other populations. Additional possibilities 
for the differential risk effects include different frequencies of important interacting variants 
or population specific gene-environment interactions. When low-penetrance variants 
become a part of determination of cancer risk, care should be taken to ensure that only 
variants which have been validated in the ethnic background of the patient be utilized. 
4.5 Missing heritability: Additive effects, gene-gene and gene-environmental factors 
When GWAS were first utilized they were hailed as the tool by which all low-penetrance 
variants for disease risk would be identified. While these screens have been successful, the 
variants identified to date explain less than 10% of the estimated genetic contributions to 
CRC which makes use of known variants for risk prediction difficult. Several possible 
explanations for the “missing heritability” exist. One is that much of the genetic risk of CRC 
will be due to rare or unique low-penetrance variants which are not detectible by 
population-based GWAS. A second is that synergistic or epistatic gene-gene interactions 
which are only detectible when taking into account interacting loci will account for the 
missing heritability. Gene-environmental interactions in which risk is dependent on both a 
variant and exposure to the environmental risk factor may also play a role. 
Transgenerational epigenetic effects, epigenetic alterations which are inherited through the 
germline and/or observed through multiple generations, may also account for some of the 
missing heritability (Fleming et al., 2008). 
As the effects of single variants identified by candidate gene or genome-wide studies have 
been low, it is important to determine if there are combined effects of carrying multiple risk 
alleles. One study assessed three SNPs identified through GWAS (rs3802842, rs7014346, 
rs4939827) and found that carrying all six risk alleles confers a 2.6-fold increased risk of CRC 
(Tenesa et al., 2008). It is likely that CRC risk could increase if all 18 identified GWAS 
variants were included in the analysis. Animal models have been instrumental for 
demonstrating synergistic and epistatic interactions between genetic risk factors (Nagase et 
al. 2001). Mouse models led to the identification of several CRC susceptibility loci that 
interact synergistically or epistatically (van Wezel et al., 1996; van Wezel et al. 1999). Thus 
far, no synergistic or epistatic interactions for CRC risk have been definitively identified in 
human populations. As computational tools for assessing the data from GWAS studies 
improve, genetic interactions are likely to be identified as important factors for CRC risk in 
humans.  
Several environmental factors including cigarette smoking, body mass index, polycyclic 
aromatic hydrocarbons, N-nitroso compounds, and diets high in red meat which increase 
exposure to heterocyclic amines have been associated with increased risk of CRC (Botteri et 
al. 2008; Norat et al. 2002; Pischon et al. 2006). Although many studies show contradictory 
results, interactions between genetic variations and environmental exposures can modify 
CRC risk. mEH is an enzyme important in xenobiotic activation of tobacco carcinogens. Two 
variants have been identified in the mEH gene which lead to low or high activity. A meta-
analysis of several studies showed that smokers with the mEH3 low metabolizer genotype 
had lower risk of colon cancer compared to smokers with a mEH3 high metabolizer 
genotype suggesting that genetic variants can modify the cancer risk associated with 
smoking (Raimondi et al. 2009). Interactions between dietary factors and genotypes have 
also been observed for CRC. In one study, individuals who consumed browned red meat 
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and had the 751Lys/Lys and 312 Asp/Asp genotypes in the XPD gene were at highest risk 
of developing CRC (Joshi et al., 2009). Much work remains to be done to fully assess gene-
environment interactions for CRC.  
4.6 Modifier genes for penetrance in high-risk syndromes 
The risk of cancer does not reach 100% even for individuals with mutations leading to high-
penetrance CRC syndromes like LS. Thus, it has been proposed that even in the context of a 
mutation, environmental factors and low-penetrance variants may impact cancer risk. To 
this end, modifier genes, alleles that modify the risk of a mutation, have been sought. Most 
of the studies to date have been for LS. A variant in CHEK2, 1100delC, has been established 
as a moderate risk allele for breast cancer. Some families with 1100delC mutations have CRC 
in addition to breast cancer. Several studies have tested this variant for risk in LS families 
and some found modest increases in risk in LS carriers who also have the 1100delC variant 
(Wasielewski et al., 2008) while others have found no increase in risk (Sanchez et al., 2005). 
Genes with variants conferring suggestive effects in some studies for age of diagnosis in 
HNPCC carriers include CCND1, CDKN2A, AURKA, TP53, E2F2, and IGF1 (Talseth et al. 
2008; Jones et al., 2004; Chen et al. 2009). 
5. The use of genetic information for CRC treatment and prognosis 
Currently, the use of germline genetic variants is not used routinely for making clinical 
decisions regarding colorectal cancer therapy. The bulk of research and clinical application 
has been with somatic tumour mutations. Despite this, germline mutations and variants 
have been associated with different tumor histopathology and survival outcomes.  
5.1 Low-penetrance risk alleles and tumor histopathology  
In addition to playing a role in overall CRC risk, studies indicate that SNPs may impact 
morphology and type of colon cancer. Some of the low-penetrance SNPs identified through 
GWAS (rs3802842, rs4939827) have higher risks for rectal cancer than colon cancer (Tanesa 
et al., 2008). Preliminary studies also suggest differences in risk of necrosis (rs719725), mucin 
production (rs96153), desmoplastic reaction (rs10411210), Crohn-like lymphocytic reaction 
(rs6983267, rs4444235) and moderate/well-differentiated histology (rs10795668)(Ghazi et al., 
2010). The SNP rs4779584 is associated with reduced risk of death in a Chinese cohort (Xing 
et al. 2011), but thus far, none of the GWAS-identified variants assessed show an effect on 
overall survival in Caucasian populations (Tenesa et al., 2010). These studies suggest that 
variants may impact the development of certain subtypes of colon cancer which provide 
possible mechanistic insights into colon tumorigenesis and new therapeutic targets. 
5.2 Variants to predict response to and off-target effects of cancer therapy 
Targeted therapies for colorectal cancer have been developed based on somatic mutations 
occurring during tumorigenesis. In addition to targeted therapies to somatic mutations, 
germline variations in enzymes which process more standard chemotherapeutic agents 
impact prognosis and treatment response. Standard therapies for CRC include 5-fluorouracil 
and oxaliplatin (FOLFOX). One study looked at the role of germline variants of DNA repair 
pathways on metastatic CRC patients’ response to FOLFOX (Lamas et al., 2011). One variant 
in XPD, Lys751Gln, was associated with longer survival, but the numbers in this study were 
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2011). These examples illustrate that specific variants identified by GWAS are often markers 
for the causal, as yet unidentified variant, which may be absent or in different linkage 
disquilibrium patterns with the identified SNP in other populations. Additional possibilities 
for the differential risk effects include different frequencies of important interacting variants 
or population specific gene-environment interactions. When low-penetrance variants 
become a part of determination of cancer risk, care should be taken to ensure that only 
variants which have been validated in the ethnic background of the patient be utilized. 
4.5 Missing heritability: Additive effects, gene-gene and gene-environmental factors 
When GWAS were first utilized they were hailed as the tool by which all low-penetrance 
variants for disease risk would be identified. While these screens have been successful, the 
variants identified to date explain less than 10% of the estimated genetic contributions to 
CRC which makes use of known variants for risk prediction difficult. Several possible 
explanations for the “missing heritability” exist. One is that much of the genetic risk of CRC 
will be due to rare or unique low-penetrance variants which are not detectible by 
population-based GWAS. A second is that synergistic or epistatic gene-gene interactions 
which are only detectible when taking into account interacting loci will account for the 
missing heritability. Gene-environmental interactions in which risk is dependent on both a 
variant and exposure to the environmental risk factor may also play a role. 
Transgenerational epigenetic effects, epigenetic alterations which are inherited through the 
germline and/or observed through multiple generations, may also account for some of the 
missing heritability (Fleming et al., 2008). 
As the effects of single variants identified by candidate gene or genome-wide studies have 
been low, it is important to determine if there are combined effects of carrying multiple risk 
alleles. One study assessed three SNPs identified through GWAS (rs3802842, rs7014346, 
rs4939827) and found that carrying all six risk alleles confers a 2.6-fold increased risk of CRC 
(Tenesa et al., 2008). It is likely that CRC risk could increase if all 18 identified GWAS 
variants were included in the analysis. Animal models have been instrumental for 
demonstrating synergistic and epistatic interactions between genetic risk factors (Nagase et 
al. 2001). Mouse models led to the identification of several CRC susceptibility loci that 
interact synergistically or epistatically (van Wezel et al., 1996; van Wezel et al. 1999). Thus 
far, no synergistic or epistatic interactions for CRC risk have been definitively identified in 
human populations. As computational tools for assessing the data from GWAS studies 
improve, genetic interactions are likely to be identified as important factors for CRC risk in 
humans.  
Several environmental factors including cigarette smoking, body mass index, polycyclic 
aromatic hydrocarbons, N-nitroso compounds, and diets high in red meat which increase 
exposure to heterocyclic amines have been associated with increased risk of CRC (Botteri et 
al. 2008; Norat et al. 2002; Pischon et al. 2006). Although many studies show contradictory 
results, interactions between genetic variations and environmental exposures can modify 
CRC risk. mEH is an enzyme important in xenobiotic activation of tobacco carcinogens. Two 
variants have been identified in the mEH gene which lead to low or high activity. A meta-
analysis of several studies showed that smokers with the mEH3 low metabolizer genotype 
had lower risk of colon cancer compared to smokers with a mEH3 high metabolizer 
genotype suggesting that genetic variants can modify the cancer risk associated with 
smoking (Raimondi et al. 2009). Interactions between dietary factors and genotypes have 
also been observed for CRC. In one study, individuals who consumed browned red meat 
 
Germline Genetics in Colorectal Cancer Susceptibility and Prognosis 23 
and had the 751Lys/Lys and 312 Asp/Asp genotypes in the XPD gene were at highest risk 
of developing CRC (Joshi et al., 2009). Much work remains to be done to fully assess gene-
environment interactions for CRC.  
4.6 Modifier genes for penetrance in high-risk syndromes 
The risk of cancer does not reach 100% even for individuals with mutations leading to high-
penetrance CRC syndromes like LS. Thus, it has been proposed that even in the context of a 
mutation, environmental factors and low-penetrance variants may impact cancer risk. To 
this end, modifier genes, alleles that modify the risk of a mutation, have been sought. Most 
of the studies to date have been for LS. A variant in CHEK2, 1100delC, has been established 
as a moderate risk allele for breast cancer. Some families with 1100delC mutations have CRC 
in addition to breast cancer. Several studies have tested this variant for risk in LS families 
and some found modest increases in risk in LS carriers who also have the 1100delC variant 
(Wasielewski et al., 2008) while others have found no increase in risk (Sanchez et al., 2005). 
Genes with variants conferring suggestive effects in some studies for age of diagnosis in 
HNPCC carriers include CCND1, CDKN2A, AURKA, TP53, E2F2, and IGF1 (Talseth et al. 
2008; Jones et al., 2004; Chen et al. 2009). 
5. The use of genetic information for CRC treatment and prognosis 
Currently, the use of germline genetic variants is not used routinely for making clinical 
decisions regarding colorectal cancer therapy. The bulk of research and clinical application 
has been with somatic tumour mutations. Despite this, germline mutations and variants 
have been associated with different tumor histopathology and survival outcomes.  
5.1 Low-penetrance risk alleles and tumor histopathology  
In addition to playing a role in overall CRC risk, studies indicate that SNPs may impact 
morphology and type of colon cancer. Some of the low-penetrance SNPs identified through 
GWAS (rs3802842, rs4939827) have higher risks for rectal cancer than colon cancer (Tanesa 
et al., 2008). Preliminary studies also suggest differences in risk of necrosis (rs719725), mucin 
production (rs96153), desmoplastic reaction (rs10411210), Crohn-like lymphocytic reaction 
(rs6983267, rs4444235) and moderate/well-differentiated histology (rs10795668)(Ghazi et al., 
2010). The SNP rs4779584 is associated with reduced risk of death in a Chinese cohort (Xing 
et al. 2011), but thus far, none of the GWAS-identified variants assessed show an effect on 
overall survival in Caucasian populations (Tenesa et al., 2010). These studies suggest that 
variants may impact the development of certain subtypes of colon cancer which provide 
possible mechanistic insights into colon tumorigenesis and new therapeutic targets. 
5.2 Variants to predict response to and off-target effects of cancer therapy 
Targeted therapies for colorectal cancer have been developed based on somatic mutations 
occurring during tumorigenesis. In addition to targeted therapies to somatic mutations, 
germline variations in enzymes which process more standard chemotherapeutic agents 
impact prognosis and treatment response. Standard therapies for CRC include 5-fluorouracil 
and oxaliplatin (FOLFOX). One study looked at the role of germline variants of DNA repair 
pathways on metastatic CRC patients’ response to FOLFOX (Lamas et al., 2011). One variant 
in XPD, Lys751Gln, was associated with longer survival, but the numbers in this study were 
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small. Variants in TS and GSTT1 have been found to be associated with response to both 
LV5FU2 and FOLFOX (Boige et al. 2010), and two variants in MTHFR (677C>T and 1298 
C>A) were associated with better response to FOLFOX (Etienne-Grimaldi et al. 2010). A 
variant in ERCC2, K751Q was associated with FOLFOX-induced hematologic toxicity (Boige 
et al. 2010), suggesting that germline variations may also predict CRC treatment side-effects. 
Since the field of colon cancer pharmacogenomics is still new, it is likely that other variants 
important in metabolism of CRC therapeutics will be identified. 
5.3 Prognosis in tumors with mismatch instability mutations 
Colorectal cancers can be divided into different subtypes depending on histology and the 
presence or absence of specific molecular markers. Treatment and prognosis of these 
subtypes varies. About 15% of all CRC tumours show evidence of microsatellite instability 
of which a small proportion are germline mutations (Murphy et al., 2006; Salovaara et al., 
2000). A meta-analysis of 32 studies correlating MSI status with clinical outcomes included 
patients with both germline LS mutations and sporadic MMR defects. Individuals with no 
evidence of MSI or with MSI-low tumours showed decreased survival (HR=0.67, 95%CI 
0.53-0.83) compared to individuals with MSI-high tumours. Polymorphisms in MMR genes 
are also associated with specific phenotypes. In one study, individuals who carried one or 
more G alleles of the MLH1 655A>G SNP had a better outcome and less risk of vascular 
invasion, distant metastasis or recurrence (Nejda et al., 2009). Some studies have 
documented better survival in individuals with MUTYH-associated colorectal cancer 
compared to matched controls with colon cancer (Nielsen et al., 2010). Together these data 
suggest that tumours that have deficits in DNA repair capabilities through germline or 
somatic mutations show better survival than tumours competent in DNA repair. 
6. Conclusion  
In summary, just over a third of colorectal cancer risk is thought to be due to inherited 
genetic factors. A number of mutations in genes have been found to increase CRC in 
individuals with hereditary cancer syndromes. These syndromes confer a vastly increased 
risk of CRC over the general population and an earlier age of diagnosis. Individuals with a 
family history of CRC should be referred to genetics for evaluation of a genetic syndrome 
and for guidelines for risk-reducing strategies. In addition to highly-penetrant mutations, 
many variants of small effect sizes have been identified through family-based and genome-
wide association based studies. Whereas many of the variants identified through GWAS 
have been replicated in many studies, the effect size is small, only a small part of the total 
genetic risk has been identified, and the clinical utility is not established. The use of 
germline genetic information may be of clinical utility in the prevention and treatment of 
CRC; yet there is much that remains to be discovered. Technological advances are yielding 
new insights into genetic susceptibility to CRC on the population level, but we have yet to 
find the aetiology of most of the genetic risk contributing to CRC.  
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risk of CRC over the general population and an earlier age of diagnosis. Individuals with a 
family history of CRC should be referred to genetics for evaluation of a genetic syndrome 
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have been replicated in many studies, the effect size is small, only a small part of the total 
genetic risk has been identified, and the clinical utility is not established. The use of 
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1. Introduction  
There are a number of inherited predispositions to colorectal cancer (CRC) which can be 
broadly categorized into two groups; those with associated polyposis, such as familial 
adenomatous polyposis and the hamartomatous polyposis syndromes; and those that are 
linked to the non-polyposis syndromes, such as hereditary non polyposis colorectal cancer 
(HNPCC). The genetic basis of both the polyposis and non-polyposis syndromes are 
reflected in the CRC population who have no apparent family history of disease. 
Approximately 80% of all cases of CRC are associated with chromosomal instability [1] and 
are likely to have mutations in the Adenomatous Polyposis Coli (APC) gene whereas the 
remaining 20% with microsatellite instability appears to be due primarily to epigenetic 
inactivation of the DNA mismatch repair (MMR) gene MLH1 [2]. 
The disease HNPCC accounts for somewhere between 2% and 5% of all CRCs diagnosed 
and is associated with a younger age of disease onset compared to the general population 
[3,4]. HNPCC is a disease by definition based on the Amsterdam Criteria where there need 
to be three cases of CRC, one of which must be diagnosed under the age of 50 years, one 
patient must be a first degree relative of the other two, span two generations and familial 
adenomatous polyposis should be excluded [5]. Modification of the Amsterdam Criteria has 
been ongoing since its original inception due to an increasing awareness of what constitutes 
this disease. HNPCC used to be known as either the Cancer Family Syndrome or Lynch 
Syndrome [6]. It is now accepted that families where a mutation in the DNA mismatch 
repair genes (MMR) MSH2, MLH1, MSH6 or PMS2 has been identified are now termed 
Lynch Syndrome families whereas those with no mutation are termed HNPCC [7].  The 
primary function of MMR genes is to eliminate base-base mismatches and insertion-deletion 
loops which arise as a consequence of DNA polymerase slippage during DNA replication 
[8]. MMR confers several genetic stabilisation functions; it corrects DNA biosynthesis errors, 
ensures the fidelity of genetic recombination and participates in the earliest steps of cell 
cycle checkpoint control and apoptotic responses [9,10]. MMR gene defects increases the risk 
of malignant transformation of cells, which ultimately results in the disruption of one or 
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several genes associated with epithelial integrity. The identification of germline mutations in 
families with Lynch Syndrome accounts for only ~50% of all families that fulfil the clinical 
diagnosis defined by the Amsterdam criteria [11]. The remaining families have no 
identifiable genetic predisposition yet fulfil the diagnostic criteria for the disease and are 
referred to as HNPCC families. 
DNA MMR is a housekeeping function of all nucleated cells and as such any breakdown in 
the fidelity of this process is likely to result in disease irrespective of which gene is affected. 
Unlike other predispositions to colorectal cancer such as familial adenomatous polyposis, 
there are no obvious genotype/phenotype correlations in Lynch syndrome. Mutations that 
result in the loss of MSH2 or MLH1 irrespective of where they occur in the respective gene 
alter the risk of developing malignancy. Furthermore, mutations in DNA MMR genes do not 
predict a phenotype since any breakdown in the fidelity of this process results in a “mutator 
phenotype”.  It has been obvious from the first MSH2 and MLH1 mutation reports that 
differences in the ages of cancer diagnosis in patients harbouring germline mutations in 
DNA MMR genes do occur both within and between families. Furthermore, unrelated 
families harbouring the same mutation present with different disease profiles as do patients 
from within the same family [12-14]. The differences in disease expression both within and 
between families harbouring the same mutation are most likely a result of environmental, 
genetic or a mixture of both influences.  
Identification of environmental factors that could account for differences in the age of 
colorectal cancer diagnosis of Lynch Syndrome is almost intractable when undertaken as a 
retrospective study and is best undertaken prospectively to include as many environmental 
variables as possible. Notwithstanding, knowledge about environmental factors and disease 
risk in Lynch Syndrome is important and studies are required to identify those which 
protect or promote disease. 
Conversely, as genetic factors can be assessed after the fact they lend themselves more 
readily to retrospective interrogation and consequently identification. Identifying genetic 
factors that could explain differential disease expression in Lynch syndrome is now 
achievable due to the development of appropriate technology that allows for the rapid 
screening of large numbers of patients in conjunction with the accumulation of large cohorts 
of patients that allow for robust statistical analysis.  
The search for modifier genes has been ongoing ever since the first groups of Lynch 
syndrome families were identified. Initial studies focused on genes associated with 
xenobiotic metabolism which have been followed by genes involved in the immune 
response, DNA repair, cell cycle control and as yet undefined genomic regions identified as 
a result of large genome wide association studies searching for genetic risk factors for 
colorectal cancer. This review will focus on “modifiable” (those that can be altered by 
manipulation) candidate modifier genes and those that have been chosen as a result of 
biological plausibility (which may or may not be modifiable), as shown in Table 1. 
Biological plausibility and pathways of published “positive” results have been questioned 
[15], indicating that the functional significance of single nucleotide polymorphisms (SNPs) 
should be known before they are linked to disease [16]. A few published reports linking 
SNPs without known functional significance [17,18] or studies have failed to confirm a 
reported associations [19]. Known genetic variation has significantly impacted on the early 
detection and diagnosis of inherited cancer [20, 21], indicating that the search for genetic 
variation in cancer should continue.  
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Modifier Genes and polymorphisms studied in Lynch Syndrome 




association or not 
IGF1 CA-repeat promoter function [22, 23]
MTHFR SNP enzyme activity [24]
HFE SNP protein function [25]
NAT2 SNP enzyme activity [26, 27]
GSTM1 null allele enzyme activity [26, 27]
GSTT1 null allele enzyme activity [26, 27]
ATM SNP protein function [28]
IL6 SNP cytokine activity [29]
IL4 SNP cytokine activity [29]
IL1 SNP receptor binding  
IL10 SNP cytokine activity [29]
IL1Rn SNP null receptor [29]
TNF- SNP cytokine activity  
IFN- SNP cytokine activity  
TP53 SNP protein function [32, 39, 40] 
MDM2 SNP promoter function [42]
Aurora-A SNP protein function [44, 45, 48] 
Cyclin D1 SNP protein function [44, 45, 48] 
Table. 1. Candidate modifier genes and their respective types of polymorphism that have 
been studied in cohorts of Lynch syndrome patients.   
2. Cell cycle control gene polymorphisms: TP53. MDM2, Aurora-A and 
CyclinD1 
The TP53 gene isa tumour suppressor gene that regulates the transcription of genes 
necessary for the maintenance of genomic integrity by blocking cell proliferation after DNA 
damage and initiating apoptosis if it is too extensive [30, 31]. In 2004 the R72P 
polymorphism in TP53 was found to be associated with age of diagnosis of colorectal cancer 
(CRC) in an American Lynch syndrome study [32]. The R72P SNP in TP53 has been shown 
to result in two forms of the protein, which are not functionally equivalent [33, 34], and has 
been widely studied in a variety of malignancies [35 - 38]. Subsequent studies, including one 
Finnish and a collaborative Australian and Polish study, of the TP53 polymorphism and age 
of diagnosis of CRC in Lynch syndrome failed to confirm the reported association [39, 40]. 
The lack of an association was suggested to be related to a polymorphism in MDM2, which 
results in increased levels of MDM2 that culminates in the inability to properly stabilise 
TP53’s response to cellular stress [40]. Evidence supporting this notion in HNPCC however, 
could not be found in other studies [39, 41]. The failure to corroborate the role of TP53 as a 
modifier gene between the different studies could be due to differences in the mutation 
spectrum of the various study populations; number of relatives included, population 
stratification and/or type 1 statistical error. Population stratification is unlikely to account 
for differences between the study populations as it has been shown that for most of the 
common disease associated polymorphisms, ethnicity is likely to be a poor predictor of an 
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individuals’ genotype [43]. Type 1 statistical error seems to be the most likely explanation 
since the population sizes differ significantly in size with a range between 86 cases through 
to a maximum number of 220. In the larger studies reported to date (encompassing 193 and 
220 patients, respectively), no association was observed thereby providing evidence against 
an association. 
Aurora-A and Cyclin D1, genes both involved in cell cycle control, have also been associated 
with the age of onset of CRC in Lynch syndrome patients from North America [44, 45]. After 
the initial studies suggesting Aurora-A polymorphisms were linked to the average age of 
disease diagnosis follow-up reports in larger patient populations consistently failed to 
replicate this finding.  In contrast, studies of Cyclin D1 polymorphisms and their association 
with the age of disease onset in Lynch syndrome resulted in contradictory results when 
studied in populations from North America, Germany, Finland and a combined study of 
Australian and Polish patients [44, 46 – 48]. A potential explanation for the association 
between Cyclin D1 and hMSH2 mutation carriers observed in the Australian and Polish 
Lynch syndrome patients was the relative paucity of MSH2 mutation carriers in the German 
and Finnish populations [47]. With the expansion of the study population from the 
Australian/Polish patient cohort the original report of an association with Cyclin D1 could 
not be replicated (See Fig. 1). In conclusion, the evidence now suggests that there is no 
association between Cyclin D1, MSH2 and disease risk in Lynch syndrome, such that overall 
Cyclin D1 does not appear to be associated with the age of disease diagnosis. 
 
 
Fig. 1. Kaplan-Meier analysis of Cyclin D1 polymorphism and the age of disease onset in 
Australian and Polish Lynch syndrome patients.  276 MSH2 mutation positive patients were 
included in this study of which 107 were diagnosed with colorectal cancer. Log-rank, 
Wilcoxon and Tarone-Ware tests were not significant. 
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3. Xenobiotic clearance gene polymorphisms: NAT1, NAT2, GST, CYP1A1 
Genes involved in xenobiotic metabolism, which include N-acetyl transferase 1 (NAT1), N-
acetyl transferase 2 (NAT2), glutathione-S-transferase (GST) and cytochrome P450, have the 
ability to influence an individual’s susceptibility to environmental and occupational 
carcinogens and predisposition to cancer [49]. The detoxification and elimination of foreign 
chemicals is controlled by complex mechanisms involving phase I enzymes that include 
cytochrome P450, and phase II enzymes such as GSTs and NATs [50]. Because of the 
significance of xenobiotics in the environment, perturbations in the ability to remove them 
are likely to alter disease risk. Polymorphisms in the genes mentioned above have been 
associated with colorectal cancer but the roles that the different SNPs have on cancer risk are 
controversial [26, 27, 51 – 61].  
In 1999 an association between polymorphisms in NAT2 and the age of diagnosis of CRC in 
Lynch syndrome patients was reported, and the association was later replicated in a second 
independent report [26, 54]. Both studies had relatively small sample sizes (78 and 86 cases). 
Re-investigation of the association in a smaller study (69 cases) and a more appropriately 
sized one (220 cases) failed to confirm the association [58, 26]. The failure to confirm the 
association could be due to population stratification, but this is unlikely since if there is a 
functional difference in the gene in question,so its effects should be observed in all subjects, 
although not necessarily statistically significant in all populations. The most likely 
explanation for the failure to replicate initial findings is the small study population sizes that 
were used in assessing the potential association. This is further confirmed in a review by 
Brockton et al. 2000 [62] concluding that in 10 of 11 studies of invasive CRC and NAT2 
acetylator genotype, no association was observed.  
Similar results are reported for the polymorphisms in GST and cytochrome p450 genes 
and Lynch syndrome. Several research groups reported an association, while others failed 
to confirm them [25, 26, 51, 52, 53, 53, 63]. In on study the Msp1 wildtype allele of 
cytochrome P450 1A1 gene (CYP1A1) was associated with a decreased risk of CRC [26] 
which could have been due to it not being in Hardy-Weinberg equilibrium. The 
identification of an allele that is not in Hardy-Weinberg equilibrium suggests that either a 
genotyping error has occurred thereby skewing the results or it can be  
taken as supporting evidence for a correlation with disease [64]. The CYP1A1 gene has 
previously been associated with CRC and two SNPs in the CYP1A1 gene have been 
associated with CRC [65], which taken together with the report of Talseth et al. 2006 [26] 
supports the notion that variation in this gene is involved in the some aspect of CRC 
development.  
Studies examining variation in xenobiotic clearance are likely to be subject to strong 
environmental influence and this is supported by findings from different countries. Studies 
examining patients of European descent for polymorphisms in GST genes seems to find no 
obvious relationship between the SNPs and cancer risk, while a study from Korea reports an 
association [25, 26, 63]. Taken together, these results suggest a complex relationship between 
the environment and individual genotypes that add to other more obvious problems 
associated with searching for modifier genes. Additional studies are required to determine 
the relationship between GST and CYP1A1 polymorphisms and disease risk in Lynch 
syndrome.  
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4. Immune response gene polymorphisms: IL6, IL4, IL1IL10, IL1Rn,  
TNF-IFN- 
Cytokine mediated events may play a role in tumour development within inflammatory 
cells by producing an environment that supports tumour growth by promoting 
angiogenesis and facilitating genomic instability. The quintessential example is that of 
Crohn’s disease where there is an increased risk of developing CRC if left untreated [66]. 
Inflammatory responses can also increase DNA damage, growth stimulation and enhanced 
survival of damaged cells [66, 67]. SNPs in cytokine genes can have an effect on the 
transcription levels of the respective genes and resulting in differences in both pro- and anti-
inflammatory response activity. A series of polymorphisms in a number of cytokines has 
been investigated in relation to CRC risk and other cancer types but not for Lynch syndrome 
[68 – 77]. In addition, genetic variation in pro- and anti-inflammatory cytokine genes has 
been shown to influence individual response to carcinogen exposure [69], but no association 
has been identified in the one report focusing on a series of SNPs in cytokine genes and 
disease expression in Lynch syndrome [28]. Given the complexity of the inflammatory 
response and the limited number of SNPs utilised in that study, it cannot be ruled out that a 
relationship between SNPs influencing the immune response and Lynch syndrome exits.  
5. Insulin like Growth Factor IGF-1 Gene polymorphisms 
The IGF-1 gene was first reported as a potential modifying gene in Lynch syndrome disease 
expression in 2006. The CA-repeat polymorphism located near the IGF-1 promoter region was 
described as having an association with the age of disease onset in a cohort of 121 Lynch 
syndrome patients originating from the United States [22]. Certainly this is not the first time 
that a repeat region has been implicated in disease; with numerous studies reporting a link 
between DNA repeat regions significantly altering risk of prostate cancer [78 – 80] breast 
cancer, squamous cell carcinoma, bladder and lung cancers [81 – 84]. DNA microsatellite 
repeat regions are also strongly associated with Lynch Syndrome by virtue of their instability 
in tumours which is a consequence of the loss in the fidelity of DNA MMR [8].  
IGF-1 is important for cellular proliferation and differentiation however, elevated levels of 
IGF-1 have been reported to have significant links to diseases such as CRC which is thought 
to be a result of the mitogenic and anti-apoptotic effects elicited by this protein [22, 85]. 
Several environmental and physiological reasons have been proposed that influence IGF-1 
expression; however there is now evidence to suggest that a genetic role is significant. Rosen 
et al. was the first to report that the length of the CA repeat region in IGF-1 may be 
associated with circulating IGF-1 levels [86]. In a similar growth factor related gene, 
Epidermal Growth Factor Receptor (EGFR), a CA repeat region is located in intron 1. A 
study of this EGFR polymorphic repeat region revealed lower transcriptional activity with 
increasing numbers of polymorphic CA repeats coinciding with lower levels of gene 
expression [87]. In 2007, a similar result was reported for the IGF-1 gene in swine where the 
length of the CA repeat region was clearly associated with circulating levels of IGF-1 [88]. 
More recently, additional human data has been published which supports the notion that 
this polymorphism is linked to serum levels of IGF-1 [89]. From this data a trend is 
emerging that CA repeat polymorphisms in growth factor related genes, such as IGF-1, are 
related to overall gene expression, which is reflected in the circulating serum levels of the 
respective proteins. Accumulating evidence suggests that serum IGF-1 levels appear to be 
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linked to disease with recent reports indicating that elevated levels of IGF-1 are observed in 
breast, prostate and CRC [90 – 93]. There have been estimates that higher circulating levels 
of IGF-1 result in a 15% increase in the risk of developing disease, insinuating the 
importance of circulating IGF-1 in disease progression [94].  
As CRC involves the accrual of a number of specific molecular alterations [95, 96], 
consistently high IGF-1 serum levels may increase cellular proliferation, thereby enhancing 
the rate by which genetic alterations accumulate. Both normal colonic epithelial and 
transformed cells are IGF-1 responsive; thus, IGF-1 can influence not only the likelihood of 
disease initiation but also disease progression. This overall process provides some insight 
into how intracellular serum levels of IGF-1 may have a significant influence in accelerating 
the accumulation of genetic errors leading to disease, especially in persons who have 
inherited a predisposition to develop malignancy characterized by a mutator phenotype as 
observed in Lynch syndrome.  
An equally important facet to disease risk as a result of increased levels of IGF-1 is its link 
with obesity. Obesity and physical inactivity are strong independent determinants of insulin 
resistance and hyperinsulinaemia [97 – 104] and this is associated with an increased risk of 
CRC [101, 102]. Increased blood insulin lowers IGF-1 binding protein levels, which often 
results in an increase of free IGF-1 [105]. As IGF-1 is associated with both percentage body 
fat and general overall obesity [106], an increased level of IGF-1 expression as a result of 
shorter CA repeat lengths may have an enhanced effect in persons who are obese where 
IGF-1 serum levels are already elevated.  
In addition to the IGF-1 effect, CRC risk is also increased in obese patients through oxidative 
stress in adipose tissue. This is caused by increased lipid peroxidation leading to the 
production of reactive oxygen species. In regards to cancer, reactive oxygen species can 
damage DNA by several methods including DNA base modification, deletions, frame shifts, 
strand breaks, DNA-protein cross-links, and chromosomal rearrangements [107]. Both lipid 
peroxidation and increased DNA damage are likely to promote tumour development by 
generating reactive oxygen species, increasing hormone production/bioavailability of IGF-1 
and providing an energy-rich environment. This combined mechanism is potentially a risk 
factor for all types of CRC, however in Lynch syndrome this may be of greater significance 
in a deficient DNA repair environment where enhanced levels of IGF-1 inhibit cell death 
and encourage cellular proliferation. Together, the relationship between obesity and IGF-1 
CA repeat length may be of particular importance in obese Lynch syndrome cases as these 
may be at greatest risk of developing disease at a younger age.  
The role of inherited factors in circulating IGF1 serum levels is likely to be substantial with 
estimates of the proportion of variance in IGF-1 that is genetically determined varying 
somewhere between 38% to over 80% [108]. A substantial amount of data has been reported 
revealing differences in IGF levels across ethnic groups [109 – 111], however this is 
suggestive of dietary and lifestyle factors having a more modifiable effect on serum levels 
when combined with genetic ancestry. One such study has shown that the impact of several 
nutritional factors such as calcium, dairy products and vegetables on IGF1 levels is quite 
different in racially stratified models as reported between African-American and European 
American males [112]. This is strongly suggestive of there being population differences that 
differentially modify the effect of several nutrients on IGF levels. Together this information 
is suggestive that environmental factors such as calorific intake, lifestyle and demographic 
factors are probably playing a substantial role in ethnic variation in disease risk in regards to 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
42
4. Immune response gene polymorphisms: IL6, IL4, IL1IL10, IL1Rn,  
TNF-IFN- 
Cytokine mediated events may play a role in tumour development within inflammatory 
cells by producing an environment that supports tumour growth by promoting 
angiogenesis and facilitating genomic instability. The quintessential example is that of 
Crohn’s disease where there is an increased risk of developing CRC if left untreated [66]. 
Inflammatory responses can also increase DNA damage, growth stimulation and enhanced 
survival of damaged cells [66, 67]. SNPs in cytokine genes can have an effect on the 
transcription levels of the respective genes and resulting in differences in both pro- and anti-
inflammatory response activity. A series of polymorphisms in a number of cytokines has 
been investigated in relation to CRC risk and other cancer types but not for Lynch syndrome 
[68 – 77]. In addition, genetic variation in pro- and anti-inflammatory cytokine genes has 
been shown to influence individual response to carcinogen exposure [69], but no association 
has been identified in the one report focusing on a series of SNPs in cytokine genes and 
disease expression in Lynch syndrome [28]. Given the complexity of the inflammatory 
response and the limited number of SNPs utilised in that study, it cannot be ruled out that a 
relationship between SNPs influencing the immune response and Lynch syndrome exits.  
5. Insulin like Growth Factor IGF-1 Gene polymorphisms 
The IGF-1 gene was first reported as a potential modifying gene in Lynch syndrome disease 
expression in 2006. The CA-repeat polymorphism located near the IGF-1 promoter region was 
described as having an association with the age of disease onset in a cohort of 121 Lynch 
syndrome patients originating from the United States [22]. Certainly this is not the first time 
that a repeat region has been implicated in disease; with numerous studies reporting a link 
between DNA repeat regions significantly altering risk of prostate cancer [78 – 80] breast 
cancer, squamous cell carcinoma, bladder and lung cancers [81 – 84]. DNA microsatellite 
repeat regions are also strongly associated with Lynch Syndrome by virtue of their instability 
in tumours which is a consequence of the loss in the fidelity of DNA MMR [8].  
IGF-1 is important for cellular proliferation and differentiation however, elevated levels of 
IGF-1 have been reported to have significant links to diseases such as CRC which is thought 
to be a result of the mitogenic and anti-apoptotic effects elicited by this protein [22, 85]. 
Several environmental and physiological reasons have been proposed that influence IGF-1 
expression; however there is now evidence to suggest that a genetic role is significant. Rosen 
et al. was the first to report that the length of the CA repeat region in IGF-1 may be 
associated with circulating IGF-1 levels [86]. In a similar growth factor related gene, 
Epidermal Growth Factor Receptor (EGFR), a CA repeat region is located in intron 1. A 
study of this EGFR polymorphic repeat region revealed lower transcriptional activity with 
increasing numbers of polymorphic CA repeats coinciding with lower levels of gene 
expression [87]. In 2007, a similar result was reported for the IGF-1 gene in swine where the 
length of the CA repeat region was clearly associated with circulating levels of IGF-1 [88]. 
More recently, additional human data has been published which supports the notion that 
this polymorphism is linked to serum levels of IGF-1 [89]. From this data a trend is 
emerging that CA repeat polymorphisms in growth factor related genes, such as IGF-1, are 
related to overall gene expression, which is reflected in the circulating serum levels of the 
respective proteins. Accumulating evidence suggests that serum IGF-1 levels appear to be 
 
The Role of Modifier Genes in Lynch Syndrome 
 
43 
linked to disease with recent reports indicating that elevated levels of IGF-1 are observed in 
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serum IGF levels. This is intriguing as it may also be contributing to the differences in 
relative disease risk observed between the Polish and Australian cohorts as reported [22]. 
The data reported to date [21] indicate a significant interaction between the CA repeat 
polymorphism length and disease expression in Lynch syndrome which is likely to be 
linked to circulating levels of IGF-1. The data suggest a significant correlation for earlier 
onset CRC in participants who carry 17 or less IGF-1 CA repeats in over 400 Lynch 
syndrome patients. An encouraging aspect of the results of this study is that significance is 
retained across two different populations where variance in IGF-1 allele size frequencies 
occur [22]. A limitation however in defining the exact relationship between IGF-1 expression 
and cancer incidence in Lynch syndrome patients is the genotype–phenotype correlation 
between the IGF-1 CA-repeat number and the corresponding serum levels. Assessment of 
serum IGF-1 concentration, however, has the inherent problem of serum IGF-I 
measurement, which is typically assessed at only one time point yet for accurate analysis 
should be performed multiple times from any single patient. Whether it would be feasible to 
monitor IGF-1 serum levels in families with Lynch syndrome is an area which needs further 
investigation. Future work should also include additional candidate polymorphisms located 
within IGF-1 or IGFBP-3 that interact with the IGF-1 pathway and may provide further 
insight into the overall IGF-1 effect. At present, however the IGF-1 pathway remains largely 
under-investigated, and there is now a requirement for further work to develop a more 
thorough understanding of the relationship between IGF-1 genotype, expression and its 
implication in disease risk.  
6. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms 
There have been tantalizing reports in the literature that polymorphisms in the MTHFR gene 
are associated with altered CRC risk. These polymorphisms occur in relatively high 
frequency in the general population and the two that promote special attention are both 
associated with altered enzymatic function. MTHFR is a key folate-metabolizing enzyme 
involved in both DNA methylation and DNA synthesis. The enzyme catalyses the 
irreversible conversion of 5,10-methylenetetrahydrofolate (5,10-MTHF), needed for purine 
and thymidine synthesis, to 5-methyltetrahydrofolate (5-MTHF), which is necessary for 
methionine production. Insufficient thymidine results in uracil misincorporation into DNA, 
leading to single-strand and double-strand breaks. This can increase the incidence of DNA 
damage, thereby increasing the risk of genetic instability. The understanding that folate 
metabolism can both equally influence DNA synthesis and methylation has made the study 
of environmental and genetic variants associated with MTHFR particularly attractive as a 
candidate genetic factor that influences cancer susceptibility. Two common polymorphisms, 
C677T and A1298C are located within the MTHFR gene and have been linked to altering the 
function of the encoded protein. This has lead to these variants being the focus of numerous 
studies into CRC risk outside the context of an inherited predisposition to disease. Both 
polymorphisms result in a substitution of an amino acid and have previously been shown to 
significantly influence MTHFR enzyme activity [113]. C677T is located within the coding 
region for the catalytic domain, resulting in an amino acid substitution from alanine to 
valine that is associated with a reduction of enzyme activity. The A1298C polymorphism, 
located in the regulatory region of MTHFR, substitutes an amino acid change from 
glutamine to alanine. Evidence suggests that A1298C also reduces MTHFR activity, however 
it is reported to be less influential than C677T [114]. This modifying effect incurred by the 
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presence of one or both polymorphisms in a pivotal folate metabolism pathway and its 
association with sporadic disease suggests that these polymorphisms are of particular 
interest with respect to modifying disease risk in Lynch syndrome.   
Both A1298C and C677T are in strong linkage disequilibrium with no evidence of the 
existence of a MTHFR allele that carries both the homozygote (C1298C/T677T) variants of 
these polymorphisms [115 – 117]. Owing to this linkage disequilibrium, no studies have 
been reported where patients have inherited both homozygote variants. Nevertheless, 
heterozygote carriers of 1298C and 677T have been reported. The effect of inheriting both 
alleles in trans (i.e. one allele with the 677T polymorphism and the other with the 1298C 
polymorphism) effectively reduces overall MTHFR activity, thereby significantly altering 
the kinetics of folate metabolism. Data reported from an Australian and Polish study on the 
effects of MTHFR variants and disease expression in Lynch syndrome revealed that 
heterozygote forms of the MTHFR variants were required for a significant protective effect 
to occur [23]. The Kaplan-Meier survival estimates reported in this study predicted a 
median age gap of 10 years later for CRC onset in patients carrying the combined 
heterozygote MTHFR genotype which was supported by multi variable regression 
modelling statistics. The data also suggested this effect was significant in both hMLH1 and 
hMSH2 carriers, where previously only a significant association had been described in 
hMLH1 for C677T only [118]. The most likely cause for this discrepancy between the 
Australian/Polish study and those by reported by Pande et al (2007) [119] is likely to be due 
to a type 1 statistical error as the reported association in hMLH1 carriers were in a 
considerable smaller sample size, although differences in the ethnicity of Lynch syndrome 
cohorts cannot be ruled out as a contributing factor.  
The mechanism by which C677T and A1298C appears to influence disease risk can be 
explained by the functional effects that these polymorphisms have on MTHFR and 
consequently folate metabolism. Previous reports have demonstrated a reduction of up to 
60% in the activity of MTHFR when both C677T and A1298C heterozygote alleles were 
present in the gene. The reduction of MTHFR activity leads to an increased concentration of 
its substrate 5,10-MTHF. The increased pool of 5,10-MTHF pushes folate metabolism 
towards DNA synthesis, in turn reducing the pool of uracil. A reduced quantity of uracil 
potentially reduces the overall risk of uracil misincorporation as a result of its limited 
availability. For individuals with a MMR deficiency, the effect of reduced MTHFR enzyme 
activity may be advantageous since uracil misincorporation could be particularly 
deleterious in conjunction with an impaired DNA repair pathway. The subsequent lower 
levels of 5-MTHF may also be beneficial due to a potential reduction in DNA methylation. 
Hypermethylation of the promoter of tumour suppressor or MMR genes may lead to gene 
silencing, therefore a reduction in methylation through decreased MTHFR activity could 
lead to lower probability of this type of gene silencing occurring.  
Numerous case control and cohort studies have investigated the relationship between folate 
intake and CRC risk with the majority reporting a reduction in CRC incidence with higher 
levels of folate [116]. The outcome of one meta-analysis suggested that CRC risk could be 
reduced by up to 25% with a high level of dietary folate compared to a low level one [117]. 
Further studies are required to clarify to what extent total folate has on disease risk; 
however it is generally accepted that there is an association and that a number of common 
genetic variants alter either the cellular levels or functioning of folate metabolism enzymes 
and are likely to have an important role in determining an individual’s response to changes 
in dietary folate. With this in mind further studies into functional polymorphisms in the 
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availability. For individuals with a MMR deficiency, the effect of reduced MTHFR enzyme 
activity may be advantageous since uracil misincorporation could be particularly 
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levels of 5-MTHF may also be beneficial due to a potential reduction in DNA methylation. 
Hypermethylation of the promoter of tumour suppressor or MMR genes may lead to gene 
silencing, therefore a reduction in methylation through decreased MTHFR activity could 
lead to lower probability of this type of gene silencing occurring.  
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intake and CRC risk with the majority reporting a reduction in CRC incidence with higher 
levels of folate [116]. The outcome of one meta-analysis suggested that CRC risk could be 
reduced by up to 25% with a high level of dietary folate compared to a low level one [117]. 
Further studies are required to clarify to what extent total folate has on disease risk; 
however it is generally accepted that there is an association and that a number of common 
genetic variants alter either the cellular levels or functioning of folate metabolism enzymes 
and are likely to have an important role in determining an individual’s response to changes 
in dietary folate. With this in mind further studies into functional polymorphisms in the 
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folate metabolism pathway would benefit significantly by including total folate levels so 
that a more exact assessment its role could be made. Using this approach a more precise 
view of the relationship between folate intake and disease risk may become apparent where 
Lynch syndrome patients could be stratified by MTHFR genotype. Accurately estimating 
dietary folate intake however may prove difficult and therefore the analysis of plasma folate 
levels may be a more viable alternative. Future studies would benefit by including other 
dietary factors including alcohol, choline, and methionine intake which are known to effect 
folate metabolism besides folate and folic acid [119]. An accurate level of plasma folate 
combined with MTHFR C677T and A1298C genotypes is an interesting prospect and may 
provide an indicator of individual risk of developing a Lynch syndrome related CRC.  
The identification of MTHFR polymorphisms being associated with divergence in disease 
risk in Lynch syndrome provides the basis for targeted intervention measures that could be 
used to reduce the risk of disease development. Dietary supplementation of folate/folic acid 
in Lynch syndrome families may prove to be beneficial in decreasing disease risk or 
prolonging the time before the diagnosis of malignancy. Dietary supplementation and a 
change in disease risk however, are more complex than previously thought. Folic acid 
supplementation has been proven to be beneficial in decreasing neural tube defects (NTD’s), 
[120] and was the catalyst for the United States and Canada introducing the compulsory 
supplementation of folic acid in flour in 1996 with the aim to reduce the incidence of NTD’s. 
Despite proving successful for this purpose an unexpected trend was observed in both 
countries as described by Mason et al. (2007) [121] who investigated the relationship 
between the onset of folic acid fortification and rises in the incidence of CRC. This analysis 
indicated that in the early part of the 1990’s the age-adjusted incidence of CRC had declined 
gradually in both countries. Between 1995 and 1996 however, the incidence rate in the 
United States showed a slight increase followed by more marked increases in 1997 and 1998. 
A similar finding was observed in the Canadian population, which also corresponded to the 
mandatory supplementation of folic acid. In both populations the increase in CRC incidence 
was highly significant when compared to pre-existing trends in both men and women. 
These observations have lead to a hypothesis that mandatory folic acid supplementation 
was responsible for the spike in CRC rates which after peaking approximately 2-3 years 
after its introduction have begun to decline once again [121].  
The association of increased CRC incidence with folate supplementation has been supported 
by the results of two large-scale studies which have recently emerged from both the United 
States and United Kingdom. In both these phase III studies a common trend was observed 
in participants who supplemented their diets for three years with a daily dose of 1000ug and 
500ug folic acid respectively, and an increased risk of developing a colorectal adenoma, with 
the greater risk in those participants consuming the higher 1000ug dose [122, 123]. Studies in 
mismatch repair or tumour suppressor gene deficient mice have demonstrated that the 
timing of folate supplementation is important in the association it may have on disease risk. 
In the first few months of folate supplementation a threefold decrease in colorectal 
adenomas has been observed when compared to mice with a moderate folate deficient diet. 
Dietary folate treatment after the development of carcinomas had the opposite effect 
however, with folate deficiency significantly decreasing the number of adenomas compared 
with supplementation [124, 125]. Together, this evidence suggests that as long as an 
individual is healthy, folate supplementation is protective whereas if a tumour has been 
initiated folate restriction is more important. This dual modulatory role of folate may be of 
even greater influence in an impaired DNA mismatch repair pathway as found in Lynch 
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syndrome patients. In this case folate supplementation may be particularly beneficial or 
deleterious depending upon any early tumour development.  
7. Haemochromatosis HFE gene polymorphisms 
The role of high body iron levels in modifying the risk of colorectal cancer has been 
investigated by several groups but remains unclear [126 – 130]. The genetic iron overload 
disorder hereditary haemochromatosis (HH) is characterised by high iron indices and 
progressive parenchymal iron overload and occurs due to a problem in restricting iron 
uptake (reviewed in [131- 133]. While clear associations have been established between 
haemochromatosis and liver disease, studies investigating the correlation between 
haemochromatosis and other pathologies have yielded conflicting results [134 – 137].  
The primary cause of classical HH has been ascribed to SNPs in the HFE gene, in particular 
the 845G>A SNP which results in the substitution of a tyrosine residue for a cysteine at 
position 282 (C282Y) and is present in 10-15% of individuals of northern European descent. 
The more common but less penetrant 163C>G SNP (H63D) is present in 15-30% of 
individuals [131, 136 – 142]. A longitudinal also study has demonstrated that up to 30% of 
men and 1% of women homozygous for the C282Y polymorphism develop iron overload 
that subsequently manifests as a disease phenotype [143]. The risk of developing colorectal 
cancer increased 3-fold in C282Y homozygotes when compared to matched controls without 
the mutation [144].  
A number of other epidemiological studies have also investigated the impact of HFE 
genotype on colorectal cancer risk, with mixed results [145 -148]. Most studies exploring the 
link between HFE genotype and the risk of developing colorectal cancer have approached 
the problem by selecting subjects diagnosed with colorectal cancer and comparing the 
frequency of HFE polymorphisms to matched controls.  
In regards to Lynch syndrome and the potential influence of disease risk one study has been 
reported suggesting that homozygosity of the HFE H63D mutation may act as a modifier, 
increasing the risk of developing CRC. In addition, there was evidence for earlier CRC onset 
age in H63D homozygotes [24]. The results of this study suggest that the median age of 
disease onset could be as much as 6 years earlier in H63D homozygotes (who represent 
around 2.5% of the Australian and Polish general populations).  
While these findings will require substantiation in other populations, they support a 
possible relationship between iron dysregulation and colorectal cancer risk. While 
mechanisms cannot be established by a genetic epidemiological study of this nature, it 
appears likely that iron is involved, in view of the roles of the HFE gene in iron metabolism, 
the previously reported effects of H63D homozygosity on iron status [149] and existing 
evidence that iron status can modify CRC. Since iron levels in haemochromatosis patients 
can usually be maintained at normal levels through phlebotomy and regulating factors such 
as diet, this might have the potential to substantially reduce colorectal cancer risks or delay 
onset by several years in people with HNPCC-associated MMR gene mutations.  
However the possibility of other mechanisms not directly reflecting abnormal body iron 
status cannot be ruled out. Homozygosity of the H63D polymorphism increases the risk of 
the neurodegenerative brain disease amyotrophic lateral sclerosis in the absence of apparent 
effects of C282Y polymorphism [150 – 152], suggesting that in some tissues the H63D 
mutation might have pathological consequences that are not directly related to whole body 
iron status. It will be important to validate the findings on H63D and also to investigate the 
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gradually in both countries. Between 1995 and 1996 however, the incidence rate in the 
United States showed a slight increase followed by more marked increases in 1997 and 1998. 
A similar finding was observed in the Canadian population, which also corresponded to the 
mandatory supplementation of folic acid. In both populations the increase in CRC incidence 
was highly significant when compared to pre-existing trends in both men and women. 
These observations have lead to a hypothesis that mandatory folic acid supplementation 
was responsible for the spike in CRC rates which after peaking approximately 2-3 years 
after its introduction have begun to decline once again [121].  
The association of increased CRC incidence with folate supplementation has been supported 
by the results of two large-scale studies which have recently emerged from both the United 
States and United Kingdom. In both these phase III studies a common trend was observed 
in participants who supplemented their diets for three years with a daily dose of 1000ug and 
500ug folic acid respectively, and an increased risk of developing a colorectal adenoma, with 
the greater risk in those participants consuming the higher 1000ug dose [122, 123]. Studies in 
mismatch repair or tumour suppressor gene deficient mice have demonstrated that the 
timing of folate supplementation is important in the association it may have on disease risk. 
In the first few months of folate supplementation a threefold decrease in colorectal 
adenomas has been observed when compared to mice with a moderate folate deficient diet. 
Dietary folate treatment after the development of carcinomas had the opposite effect 
however, with folate deficiency significantly decreasing the number of adenomas compared 
with supplementation [124, 125]. Together, this evidence suggests that as long as an 
individual is healthy, folate supplementation is protective whereas if a tumour has been 
initiated folate restriction is more important. This dual modulatory role of folate may be of 
even greater influence in an impaired DNA mismatch repair pathway as found in Lynch 
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syndrome patients. In this case folate supplementation may be particularly beneficial or 
deleterious depending upon any early tumour development.  
7. Haemochromatosis HFE gene polymorphisms 
The role of high body iron levels in modifying the risk of colorectal cancer has been 
investigated by several groups but remains unclear [126 – 130]. The genetic iron overload 
disorder hereditary haemochromatosis (HH) is characterised by high iron indices and 
progressive parenchymal iron overload and occurs due to a problem in restricting iron 
uptake (reviewed in [131- 133]. While clear associations have been established between 
haemochromatosis and liver disease, studies investigating the correlation between 
haemochromatosis and other pathologies have yielded conflicting results [134 – 137].  
The primary cause of classical HH has been ascribed to SNPs in the HFE gene, in particular 
the 845G>A SNP which results in the substitution of a tyrosine residue for a cysteine at 
position 282 (C282Y) and is present in 10-15% of individuals of northern European descent. 
The more common but less penetrant 163C>G SNP (H63D) is present in 15-30% of 
individuals [131, 136 – 142]. A longitudinal also study has demonstrated that up to 30% of 
men and 1% of women homozygous for the C282Y polymorphism develop iron overload 
that subsequently manifests as a disease phenotype [143]. The risk of developing colorectal 
cancer increased 3-fold in C282Y homozygotes when compared to matched controls without 
the mutation [144].  
A number of other epidemiological studies have also investigated the impact of HFE 
genotype on colorectal cancer risk, with mixed results [145 -148]. Most studies exploring the 
link between HFE genotype and the risk of developing colorectal cancer have approached 
the problem by selecting subjects diagnosed with colorectal cancer and comparing the 
frequency of HFE polymorphisms to matched controls.  
In regards to Lynch syndrome and the potential influence of disease risk one study has been 
reported suggesting that homozygosity of the HFE H63D mutation may act as a modifier, 
increasing the risk of developing CRC. In addition, there was evidence for earlier CRC onset 
age in H63D homozygotes [24]. The results of this study suggest that the median age of 
disease onset could be as much as 6 years earlier in H63D homozygotes (who represent 
around 2.5% of the Australian and Polish general populations).  
While these findings will require substantiation in other populations, they support a 
possible relationship between iron dysregulation and colorectal cancer risk. While 
mechanisms cannot be established by a genetic epidemiological study of this nature, it 
appears likely that iron is involved, in view of the roles of the HFE gene in iron metabolism, 
the previously reported effects of H63D homozygosity on iron status [149] and existing 
evidence that iron status can modify CRC. Since iron levels in haemochromatosis patients 
can usually be maintained at normal levels through phlebotomy and regulating factors such 
as diet, this might have the potential to substantially reduce colorectal cancer risks or delay 
onset by several years in people with HNPCC-associated MMR gene mutations.  
However the possibility of other mechanisms not directly reflecting abnormal body iron 
status cannot be ruled out. Homozygosity of the H63D polymorphism increases the risk of 
the neurodegenerative brain disease amyotrophic lateral sclerosis in the absence of apparent 
effects of C282Y polymorphism [150 – 152], suggesting that in some tissues the H63D 
mutation might have pathological consequences that are not directly related to whole body 
iron status. It will be important to validate the findings on H63D and also to investigate the 
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effects of C282Y homozygosity in larger HNPCC samples, preferably in conjunction with 
information on patient iron status, to determine the mechanisms involved and the role of 
iron. 
While this is the first time that the H63D polymorphism has been specifically associated 
with HNPCC, there is some previous evidence for association of both the H63D and the 
C282Y polymorphism with colorectal cancer in general [147, 148]. Power has limited past 
studies, as the homozygous and compound heterozygous mutations that have been 
associated with the greatest increases in iron loading and potentially the highest disease 
risks, are relatively rare. For this reason, some studies have analysed all HFE mutation 
genotypes as a single group, which may dilute observed effects. Although past 
epidemiological studies of HFE genotype and colorectal cancer risk have had mixed results, 
an American study of 475 colorectal cancer case patients and 833 control subjects found an 
odds ratio of 1.4 for participants with any HFE mutation after adjustment for a range of 
factors including age, gender and total iron intake [148]. The increased risk predominantly 
occurred in the quartile with greatest dietary iron intakes. In addition, a recent study of a 
large Australian sample has found that homozygosity for the C282Y SNP is associated with 
a three-fold increase in the risk of developing colorectal cancer in men [144]. This suggests 
that the effects of HFE on colorectal cancer may not be limited only to MMR gene mutation 
carriers, although such effects may be stronger when both types of mutation are present 
simultaneously. 
Heterozygosity for either the H63D or C282Y SNP does not appear to have any modifying 
effect in either the Australian or Polish samples, although it is possible that small effects 
may be detectable with very large samples. While heterozygosity for C282Y or H63D has 
been reported to have a range of effects in other diseases, reviewed in [153], these genotypes 
are not usually associated with significant changes in iron parameters [26, 154 – 156]. For 
these reasons, for our final analyses it was considered more appropriate to compare mutant 
homozygotes to combined heterozygotes and wildtype homozygotes, as is usually done in 
most studies of HFE gene SNPs. However, while this was effective in revealing the potential 
modifying effect of H63D homozygosity on HNPCC development, we were not able to do 
this for the C282Y SNP, due to its relative rarity and the lack of C282Y homozygotes in the 
samples. Stronger modifying effects may occur in C282Y homozygotes or C282Y/H63D 
compound heterozygotes, as it is well established that iron indices are increased most in 
individuals with these genotypes, reviewed in [131, 132, 157].  
Gender affects both the onset age and site of first tumour manifestation in HNPCC. In 
females, the age of onset of colorectal cancer is delayed 5 to 10 years when compared to 
males [158]. Gender is also a factor in the manifestation of iron loading as a result of HFE 
genotype, affecting males much earlier in life than females [159]. In a larger sample it is 
possible that HFE genotype may show a contribution to the earlier onset of CRC in males 
when compared to females.  
8. Candidate polymorphisms not associated with disease risk 
Not all polymorphisms which have been associated with hereditary disease have 
remained consistently significant across cohorts. An example is the delta DNMT3b SNP 
which was reported to have a significant association in a cohort of participants in the 
United States [160]. DNMT3B has been identified as a candidate in disease modifying risk 
due to its role in methylation. DNA methylation is regulated by a family of DNA 
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methyltransferases (DNMTs), of which three active forms (DNMT1, DNMT3A and 
DNMT3B) have been identified in mammalian cells [161]. It has been reported that an 
increase in DNA methyltransferase enzyme activity of the DNA methyltransferases 
DNMT1, and DNMT3A and DNMT3B, is elevated in several types of disease including 
leukemia, prostate, lung, breast and endometrial cancers [162 -165]. A polymorphism 
located within DNMT3b has been reported to influence enzyme expression through 
altering promoter activity. It has been suggested that in in vitro assays the C>T variant 
could lead to an increase of promoter activity of up to 30% [161]. Using a study group of 
over 400 individuals, no association was observed between age of onset and DNMT3b 
genotype in an Australian and Polish Lynch syndrome cohort. The failure to confirm the 
potential modifying influence of a polymorphism in one population compared to another 
could be simply due to insufficient numbers of test subjects. If a polymorphism is an effect 
modifier its response should be similar no matter what population is examined even 
though it may not reach statistical significance. In the case of the delta DNMT3b SNP no 
such trend was observed. The Australian/Polish study group was approximately three 
times larger than the participants of a previous study [160] and the most likely 
explanation for the difference in results is a type 1 error. Notwithstanding, it is worth 
noting that it does not rule out the possibility that DNMT3b expression may be associated 
with Lynch syndrome disease expression. Different isoforms of DNMT3b exist therefore 
expression levels of these may vary influencing disease risk. Numerous other 
polymorphisms have also been reported in the functional domains of DNMT3b which 
could also alter methylation status and thereby alter disease risk.  
Genes involved in DNA repair have also been prime candidates in the search for modifying 
effects due to their important role in the cell cycle. Polymorphisms located within genes 
involved in this process have been widely reported to be associated with cancer 
susceptibility in an extensive range of malignancies that include CRC. For one combined 
cohort (Australian and Polish Lynch syndrome patients), eight common polymorphisms 
were selected across several genes involved in the DNA repair pathway including BRCA2, 
hMSH3, Lig4, hOGG1 and XRCC 1, 2 and 3, which had not previously been assessed for 
disease risk in Lynch syndrome. When considered separately conflicting data were 
identified in the two populations. Cox regression modelling indicated a significant 
protective effect in Polish participants for both polymorphisms hMSH3 A>G (rs26279) and 
XRCC2 G>A (rs1799793). This finding was somewhat contradictory as the homozygote form 
of both rs26279 and rs1799793 have been previously weakly associated with an increased 
risk of CRC and bladder cancer respectively [166, 167]. Two points need to be taken into 
account in interpreting this data. First, since multiple tests were undertaken in evaluating 
the possible influence of DNA repair gene polymorphisms a correction for multiple testing 
must be undertaken to ensure that any observed result is not due to a chance association; 
second, population stratification may adversely affect result outcome but is less likely 
(Reeves et al. 2011 [168]. Differences in the probabilities of an association with the age of 
disease onset in relation to DNA repair gene polymorphisms occurring in small study 
groups is more likely to be a result of a type 1 or 2 statistical error and can be overcome by 
undertaking an appropriate power calculation to determine the expected power to detect an 
association. Furthermore, statistical correction (such as Bonferroni) is required especially 
where multiple testing is undertaken although some types of correction are somewhat 
conservative and could remove an association where one exists.  
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effects of C282Y homozygosity in larger HNPCC samples, preferably in conjunction with 
information on patient iron status, to determine the mechanisms involved and the role of 
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large Australian sample has found that homozygosity for the C282Y SNP is associated with 
a three-fold increase in the risk of developing colorectal cancer in men [144]. This suggests 
that the effects of HFE on colorectal cancer may not be limited only to MMR gene mutation 
carriers, although such effects may be stronger when both types of mutation are present 
simultaneously. 
Heterozygosity for either the H63D or C282Y SNP does not appear to have any modifying 
effect in either the Australian or Polish samples, although it is possible that small effects 
may be detectable with very large samples. While heterozygosity for C282Y or H63D has 
been reported to have a range of effects in other diseases, reviewed in [153], these genotypes 
are not usually associated with significant changes in iron parameters [26, 154 – 156]. For 
these reasons, for our final analyses it was considered more appropriate to compare mutant 
homozygotes to combined heterozygotes and wildtype homozygotes, as is usually done in 
most studies of HFE gene SNPs. However, while this was effective in revealing the potential 
modifying effect of H63D homozygosity on HNPCC development, we were not able to do 
this for the C282Y SNP, due to its relative rarity and the lack of C282Y homozygotes in the 
samples. Stronger modifying effects may occur in C282Y homozygotes or C282Y/H63D 
compound heterozygotes, as it is well established that iron indices are increased most in 
individuals with these genotypes, reviewed in [131, 132, 157].  
Gender affects both the onset age and site of first tumour manifestation in HNPCC. In 
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United States [160]. DNMT3B has been identified as a candidate in disease modifying risk 
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methyltransferases (DNMTs), of which three active forms (DNMT1, DNMT3A and 
DNMT3B) have been identified in mammalian cells [161]. It has been reported that an 
increase in DNA methyltransferase enzyme activity of the DNA methyltransferases 
DNMT1, and DNMT3A and DNMT3B, is elevated in several types of disease including 
leukemia, prostate, lung, breast and endometrial cancers [162 -165]. A polymorphism 
located within DNMT3b has been reported to influence enzyme expression through 
altering promoter activity. It has been suggested that in in vitro assays the C>T variant 
could lead to an increase of promoter activity of up to 30% [161]. Using a study group of 
over 400 individuals, no association was observed between age of onset and DNMT3b 
genotype in an Australian and Polish Lynch syndrome cohort. The failure to confirm the 
potential modifying influence of a polymorphism in one population compared to another 
could be simply due to insufficient numbers of test subjects. If a polymorphism is an effect 
modifier its response should be similar no matter what population is examined even 
though it may not reach statistical significance. In the case of the delta DNMT3b SNP no 
such trend was observed. The Australian/Polish study group was approximately three 
times larger than the participants of a previous study [160] and the most likely 
explanation for the difference in results is a type 1 error. Notwithstanding, it is worth 
noting that it does not rule out the possibility that DNMT3b expression may be associated 
with Lynch syndrome disease expression. Different isoforms of DNMT3b exist therefore 
expression levels of these may vary influencing disease risk. Numerous other 
polymorphisms have also been reported in the functional domains of DNMT3b which 
could also alter methylation status and thereby alter disease risk.  
Genes involved in DNA repair have also been prime candidates in the search for modifying 
effects due to their important role in the cell cycle. Polymorphisms located within genes 
involved in this process have been widely reported to be associated with cancer 
susceptibility in an extensive range of malignancies that include CRC. For one combined 
cohort (Australian and Polish Lynch syndrome patients), eight common polymorphisms 
were selected across several genes involved in the DNA repair pathway including BRCA2, 
hMSH3, Lig4, hOGG1 and XRCC 1, 2 and 3, which had not previously been assessed for 
disease risk in Lynch syndrome. When considered separately conflicting data were 
identified in the two populations. Cox regression modelling indicated a significant 
protective effect in Polish participants for both polymorphisms hMSH3 A>G (rs26279) and 
XRCC2 G>A (rs1799793). This finding was somewhat contradictory as the homozygote form 
of both rs26279 and rs1799793 have been previously weakly associated with an increased 
risk of CRC and bladder cancer respectively [166, 167]. Two points need to be taken into 
account in interpreting this data. First, since multiple tests were undertaken in evaluating 
the possible influence of DNA repair gene polymorphisms a correction for multiple testing 
must be undertaken to ensure that any observed result is not due to a chance association; 
second, population stratification may adversely affect result outcome but is less likely 
(Reeves et al. 2011 [168]. Differences in the probabilities of an association with the age of 
disease onset in relation to DNA repair gene polymorphisms occurring in small study 
groups is more likely to be a result of a type 1 or 2 statistical error and can be overcome by 
undertaking an appropriate power calculation to determine the expected power to detect an 
association. Furthermore, statistical correction (such as Bonferroni) is required especially 
where multiple testing is undertaken although some types of correction are somewhat 
conservative and could remove an association where one exists.  
 




There have been a number of studies that demonstrate the role of modifying genes that 
influence disease risk in Lynch Syndrome. Many studies have been undertaken that have 
failed to identify a range of candidate modifying genes as a result of studies being too small 
in size to provide robust statistical results. Nevertheless, there is a growing body of evidence 
that suggests modifying genes do influence disease risk in Lynch Syndrome and some of 
these are of particular interest as they suggest potential avenues by which disease risk can 
be modulated.  
The role of genome wide association studies in identifying new agnostic modifier genes is 
currently generating special interest and at this point two studies have reported intriguing 
associations that correlate well with disease risk. It remains to be seen if such associations 
can be verified in larger populations. The use of genome wide data or even target 
assessment of several thousand potential modifiers is fraught with difficulties not the least 
of which is the available population size and the number of individual SNPs analysed.  
Despite the difficulties encountered in identifying polymorphic modifier genes, their role in 
improving disease risk assessment is becoming clearer and the search for those that can 
make for individualised patient care will continue. 
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There have been a number of studies that demonstrate the role of modifying genes that 
influence disease risk in Lynch Syndrome. Many studies have been undertaken that have 
failed to identify a range of candidate modifying genes as a result of studies being too small 
in size to provide robust statistical results. Nevertheless, there is a growing body of evidence 
that suggests modifying genes do influence disease risk in Lynch Syndrome and some of 
these are of particular interest as they suggest potential avenues by which disease risk can 
be modulated.  
The role of genome wide association studies in identifying new agnostic modifier genes is 
currently generating special interest and at this point two studies have reported intriguing 
associations that correlate well with disease risk. It remains to be seen if such associations 
can be verified in larger populations. The use of genome wide data or even target 
assessment of several thousand potential modifiers is fraught with difficulties not the least 
of which is the available population size and the number of individual SNPs analysed.  
Despite the difficulties encountered in identifying polymorphic modifier genes, their role in 
improving disease risk assessment is becoming clearer and the search for those that can 
make for individualised patient care will continue. 
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1. Introduction 
Colorectal cancer is the second-leading cause of cancer-related deaths in Europe and the 
United States (Parkin DM, 2001). Although the primary therapy of CRC is surgical, the 
elucidation of different novel prognostic markers may prove to serve as future therapeutic 
options and contribute to the overall understanding of this cancer entity, as well as to 
improver disease outcome. Inflammation has been known to be a key factor of development 
and progression of cancer, and this is particularly notable in colorectal. At the cellular level, 
the colonic epithelium is exposed to a range of toxic and pathogenic challenges, including 
the balance between intestinal microflora. In turn, a shift can result in a change in immune 
response, leading to the induction of inflammation. Interactions between tumor and 
immune cells at the site of inflammation either enhance or inhibit cancer progression. The 
epidemiological data available are very impressive and show a clear association between 
chronic inflammatory conditions and subsequent malignant transformation in the inflamed 
tissue (Macarthur et al., 2004). New evidence suggests that up to 25% of all cancers are due 
to chronic infection or other types of chronic inflammation (Hussain SP, et al., 2007). 
Inflammation is mediated by an array of cytokines, which are synthesized by activated 
immune cells and exert their biological activities upon binding to specific receptors and 
activate the NF-κB transcription factor signal pathway in the epithelial cells. The ubiquitous 
transcription factor family NF-κB is a central regulator of the transcriptional activation of a 
number of genes involved in cell adhesion, immune and proinflammatory responses, 
apoptosis, differentiation, and growth. Induction of these genes in intestinal epithelial cells 
by activated NF-κB profoundly influences mucosal inflammation and repair (Jobin and 
Sartor, 2000). 
There is strong evidence to suggest that cytokines are involved in the control of cancer 
development and also promote tumorigenesis, invasion, propagation, and metastasis of 
tumors, and that they may be relevant for gastrointestinal tumors. More recently, the 
molecular mechanism whereby the inflammation regulates the antitumor immune 
responses has been elucidated. In many tumors, signal transducers and activator of 
transcription (STAT)3 are activated, and thereby antitumor immune surveillance is 
suppressed (H. Yu and R. Jove, 2004).  
In general the genes that encode cytokines involved in regulation of inflammatory 
conditions are genetically polymorphic and different genotypes are responsible for level of 
protein expression. 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
58
[149] Barton JC, et al. Initial screening transferrin saturation values, serum ferritin 
concentrations, and HFE genotypes in Native Americans and whites in the 
Hemochromatosis and Iron Overload Screening Study. Clinical genetics 
2006;69(1):48-57. 
[150] Goodall EF, et al. Association of the H63D polymorphism in the hemochromatosis 
gene with sporadic ALS. Neurology 2005;65:934-7. 
[151] Sutedja NA, et al. The association between H63D mutations in HFE and amyotrophic 
lateral sclerosis in a Dutch population. Archives of neurology 2007;64:63-7. 
[152] Wang XS, et al. Increased incidence of the Hfe mutation in amyotrophic lateral 
sclerosis and related cellular consequences. Journal of the neurological sciences 
2004;227:27-33. 
[153] Weinberg ED. Do some carriers of hemochromatosis gene mutations have higher than 
normal rates of disease and death? Biometals 2002;15:347-50. 
[154] Beutler E, et al.. Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis 
mutation in the USA. Lancet 2002;359:211-8. 
[155] Hunt JR, Zeng H. Iron absorption by heterozygous carriers of the HFE C282Y 
mutation associated with hemochromatosis. The American journal of clinical nutrition 
2004;80:924-31. 
[156] Singh M, et al. Risk of iron overload in carriers of genetic mutations associated with 
hereditary haemochromatosis: UK Food Standards Agency workshop. The British 
journal of nutrition 2006;96:770-3. 
[157] Pietrangelo A. Hereditary hemochromatosis. Biochim Biophys Acta 2006;1763:700-10. 
[158] Parc Y, et al.. Cancer risk in 348 French MSH2 or MLH1 gene carriers. Journal of medical 
genetics 2003;40:208-13. 
[159] Ayonrinde OT, et al. Clinical perspectives on hereditary hemochomatosis. Critical 
reviews in clinical laboratory sciences 2008; 45; 451-458.  
[160] Jones, J.S., et al., DNMT3b polymorphism and hereditary nonpolyposis colorectal 
cancer age of onset. Cancer Epidemiol Biomarkers Prev, 2006. 15: 886-891. 
[161] Shen, H., et al., A novel polymorphism in human cytosine DNA-methyltransferase-3B 
promoter is associated with an increased risk of lung cancer. Cancer Res, 2002. 62: 
4992-4995. 
[162] Jin, F., et al., Up-regulation of DNA methyltransferase 3B expression in endometrial 
cancers. Gynecol Oncol, 2005. 96: 531-538. 
[163] Mizuno, S., et al., Expression of DNA methyltransferases DNMT1, 3A, and 3B in 
normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood, 
2001. 97: 1172-1179. 
[164] Montgomery, K.G., et al., The DNMT3B C-->T promoter polymorphism and risk of 
breast cancer in a British population: a case-control study. Breast Cancer Res, 2004. 
6: 390-394. 
[165] Patra, S.K., et al., DNA methyltransferase and demethylase in human prostate cancer. 
Mol Carcinog, 2002. 33: 163-171. 
[166] Chang, C.H., et al., Significant association of XPD codon 312 single nucleotide 
polymorphism with bladder cancer susceptibility in Taiwan. Anticancer Res, 2009. 
29: 3903-3907. 
[167] Koessler, T., et al., Common variants in mismatch repair genes and risk of colorectal 
cancer. Gut, 2008. 57: 1097-1101. 
[168] Reeves S.G. et al. DNA repair gene polymorphisms and risk of early onset colorectal 
cancer in Lynch syndrome. 2011. doi:10.1016/j.canep.2011.09.003 
4 
Cytokine Gene Polymorphisms  
in Colorectal Cancer 
Spaska Stanilova 
Trakia University, Medical Faculty, 
Department of Molecular Biology, Immunology and Medical Genetics, 
Bulgaria 
1. Introduction 
Colorectal cancer is the second-leading cause of cancer-related deaths in Europe and the 
United States (Parkin DM, 2001). Although the primary therapy of CRC is surgical, the 
elucidation of different novel prognostic markers may prove to serve as future therapeutic 
options and contribute to the overall understanding of this cancer entity, as well as to 
improver disease outcome. Inflammation has been known to be a key factor of development 
and progression of cancer, and this is particularly notable in colorectal. At the cellular level, 
the colonic epithelium is exposed to a range of toxic and pathogenic challenges, including 
the balance between intestinal microflora. In turn, a shift can result in a change in immune 
response, leading to the induction of inflammation. Interactions between tumor and 
immune cells at the site of inflammation either enhance or inhibit cancer progression. The 
epidemiological data available are very impressive and show a clear association between 
chronic inflammatory conditions and subsequent malignant transformation in the inflamed 
tissue (Macarthur et al., 2004). New evidence suggests that up to 25% of all cancers are due 
to chronic infection or other types of chronic inflammation (Hussain SP, et al., 2007). 
Inflammation is mediated by an array of cytokines, which are synthesized by activated 
immune cells and exert their biological activities upon binding to specific receptors and 
activate the NF-κB transcription factor signal pathway in the epithelial cells. The ubiquitous 
transcription factor family NF-κB is a central regulator of the transcriptional activation of a 
number of genes involved in cell adhesion, immune and proinflammatory responses, 
apoptosis, differentiation, and growth. Induction of these genes in intestinal epithelial cells 
by activated NF-κB profoundly influences mucosal inflammation and repair (Jobin and 
Sartor, 2000). 
There is strong evidence to suggest that cytokines are involved in the control of cancer 
development and also promote tumorigenesis, invasion, propagation, and metastasis of 
tumors, and that they may be relevant for gastrointestinal tumors. More recently, the 
molecular mechanism whereby the inflammation regulates the antitumor immune 
responses has been elucidated. In many tumors, signal transducers and activator of 
transcription (STAT)3 are activated, and thereby antitumor immune surveillance is 
suppressed (H. Yu and R. Jove, 2004).  
In general the genes that encode cytokines involved in regulation of inflammatory 
conditions are genetically polymorphic and different genotypes are responsible for level of 
protein expression. 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
60
Genetic polymorphisms have emerged in recent years as important determinants of disease 
susceptibility and severity. Polymorphisms are naturally occurring DNA sequence 
variations, which differ from gene mutations in that they occur in the normal healthy 
population and have a frequency of at least 1%. Approximately 90% of DNA 
polymorphisms are single nucleotide polymorphisms (SNPs) due to single base 
substitutions. Others include insertion/deletion polymorphisms, minisatellite and 
microsatellite polymorphisms. Although most polymorphisms are functionally neutral, 
some have effects on regulation of gene expression or on the function of the coded protein. 
These functional polymorphisms, despite being of low penetrance, could contribute to the 
differences between individuals in susceptibility to and severity of disease. Many studies 
have examined the relationship between certain cytokine gene polymorphism, cytokine 
gene expression in vitro, and the susceptibility to and clinical severity of diseases (Bidwell et 
al., 1999; Hollegaard and Bidwell, 2006). SNPs are the most common sources of human 
genetic variation, and they may contribute to an individual’s susceptibility to cancer. 
Cytokine gene polymorphisms have emerged in recent years as important determinants of 
susceptibility and severity of colorectal cancer. Cytokine polymorphisms directly influence 
interindividual variation in the magnitude of cytokine response, and this clearly contributes 
to an individual's ultimate clinical outcome. Dysregulation of cytokine production strongly 
influenced both tumor progression and host anti-tumor immunity. Cytokines secreted by 
activated immune and inflammatory cells can either promote tumor cell survival and 
growth or exert antitumor effects. In addition, some tumor cells may evade the immune 
system by secreting cytokines which may induce regulatory cells particularly the 
immunosuppressive CD4+CD25+ FoxP3+ T regulatory cells. In this chapter the 
polymorphisms of selected candidate genes for susceptibility to and/or severity of CRC are 
reviewed. Special attention is paid to studies concerning the genes of inflammatory related 
cytokines. 
2. Cytokine gene polymorphisms of proinflammatory cytokines: IL-1; TNF- 
and IL-6 
The most compelling evidence for the role of inflammation in CRC comes from studies 
showing that proinflammatory cytokine gene polymorphisms increase the risk of cancer and 
its precursors.  
IL-1β is a prominent proinflammatory cytokine, which together with tumor necrosis factor-
 (TNF-) serve as primary initiators of the complex inflammatory response and they are 
classical activators of NFkB signaling pathway. IL-1 and TNF- genes have a number of 
functional polymorphisms. The IL-1B-31T/C and TNF-A-308G/A SNPs have been shown to 
be functionally significant with the C allele of IL-1B-31T/C and A allele of TNF-A-308G/A 
being associated with increased production of their respective cytokines (Hwang et al., 2002; 
Abraham and Kroeger, 1999). IL-1 gene cluster polymorphisms suspected of enhancing 
production of IL-1 have been shown to be relevant in the development of H. pylori-
associated gastric adenocarcinoma. A study published in Nature showed for the first time 
that polymorphisms in interleukin-1B (IL-1B) were associated with gastric cancer risk (El 
Omar et al, 2000). Two of these polymorphisms are in near-complete linkage disequilibrium 
and one is a TATA-box polymorphism that markedly affects DNA–protein interactions in 
vitro. These linked IL-1B single nucleotide polymorphisms that increase IL-1β expression 
 
Cytokine Gene Polymorphisms in Colorectal Cancer 
 
61 
(−511 C>T and −31 T>C) were associated with a 2- to 3-fold increased risk of gastric cancer. 
Heterozygosity at the IL1B −31T/C locus has also been associated with colorectal adenoma, 
a precursor of colorectal cancer (Gunter et al., 2006). However, Macarthur et al., 2005 did not 
reveal significant associations between the cytokine polymorphisms of IL-1B-31T/C and risk 
of colorectal cancer. In the same directions are results obtained by Ito et al., 2007 for the 
same SNP in IL-1B. Simultaneously they found that IL-1B-511 heterozygotes and T carriers 
had a significantly low risk for gastric and colorectal carcinoma in the Japanese population. 
The TNF cytokines are well known for their cytotoxic and antitumor activity. TNF- is a 
proinflammatory cytokine secreted mainly by activated monocytes/ macrophages. TNF- 
mediates the early inflammatory response and regulates the production of other cytokines, 
including IL-1 and IL-6. TNF- gene is transcriptionally silent in unstimulated monocytes 
and is rapidly transcribed in response to a variety of signals, such as bacterial endotoxin 
(LPS) and other stimuli. The signaling cascades leading to TNF- production bifurcates to 
control both transcription of TNF- gene and translation of TNF- m RNA (Swantek et al., 
1997). Transcriptional control of the TNF- gene is mediated primarily by NF-kB binding 
sites present within the TNF- gene promoter (Sweet and Hume, 1996; Yao et al., 1997). One 
microsatellite polymorphism in the vicinity of the TNF-α gene (TNF-A) has 14 different 
alleles (a1–a14). The a6 allele was associated with lower TNF-α secretion from activated 
monocytes (Pociot et al., 1993). For this TNF-α polymorphism, one allele was associated 
with an increased risk (a2 allele) and two other TNF-A alleles with decreased risks (a5 and 
a13 allele) of CRC (Gallagher, G et al., 1997; De Jong et al., 2002).  
Among the other investigated polymorphisms of the TNF-α gene, the promoter -308G/A 
SNP was intensively studied. The presence of TNF-α -308A allele involved in gene 
transcription is associated with higher levels of TNF-α. Park et al., investigated TNF-A and 
Ncol RFLP of TNF-B genes and the risk of CRC (Park et al., 1998). The first intron of TNFB 
and the -308 promoter region of TNFA SNP polymorphisms were determined in 136 
colorectal cancer patients and 325 healthy controls in an Asian population. Their results 
indicated that homozygous TNF-B*1/TNF-B*1 genotypes showed an increased risk for 
colorectal cancer, although no association in tumor susceptibility was found for the −308 
G/A polymorphism of the TNF-α gene when comparing colorectal cancer patients and 
healthy controls. Landi et al., 2003 found a trend of reduced risk for CRC in TNF -308A 
allele carriers, but Theodoropoulos et al., 2006 found no effect of this SNP and the risk of 
CRC in Greek population.  
For another SNP in TNF-α gene promoter, the −238 G > A site, has been reported that the A 
allele decreases the risk of developing colorectal cancer (Jang et al., 2001). Up to now, 
however, most studies have focused more on other cancer entities, such as melanoma and 
breast cancer, than on colorectal cancer. 
The TNF-α pro-cancerous effect has recently been established. It’s binding to specific 
receptors sets up signal transduction pathways, leading to cell apoptosis and gene 
regulation, via the MAPKinase and NF-kB pathways (Waterston A, and Bower, 2004).  
Interleukin-6 (IL-6) is a pleiotropic cytokine that is participates in physiological and 
pathological processes for a variety of human malignancies including colorectal cancer. In 
particular, a preoperative IL-6 level is correlated with tumor stage, survival rate, and liver 
metastasis in CRC (Nakagoe et al., 2003). A significant association between serum IL-6 level 
and staging of the tumor (P<0.001), tumoral tissue IL-6 level (r=0.95, P<0.001) in the patients 
was founded (Esfandi F et al, 2006). IL-6 amount of the serum and tumoral tissue in the 
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patients with colorectal cancer correlate significantly with the staging of the tumor and with 
each other. It has been demonstrated that IL-6 acts as a colorectal growth factor and as an 
autocrine growth factor for colorectal cancer cells (Chung and Chang, 2003).  
A common G/C polymorphism located within the IL-6 gene promoter (chromosome 7p21) 
at position 174 bp, upstream from the start site of transcription (−174 G/C locus), has been 
reported (Fishman D et al, 1998). This promoter SNP affects the transcription of the gene, 
and altering the final levels of IL-6 released (Terry et al., 2000, Bonafe et al., 2001). The G 
allele increases IL-6 expression, both in stimulated and non stimulated conditions, the 
highest IL-6 levels being found in subjects homozygous for the G allele. In the same line are 
data of Belluco at al., 2003 for increased serum levels of IL-6 in colorectal cancer patients 
with genotype GG, regardless of the tumor stage, grade and location. Moreover, they also 
found a close correlation between high levels of circulating IL-6 and the presence of hepatic 
metastasis. The association between IL-6 serum level and CRC hepatic metastasis may 
depend on IL-6 properties to up-regulating the expression of adhesion receptors on 
endothelial cells and inducing the production of growth factors, such as hepatocyte growth 
factor and vascular endothelial growth factor, both of which may stimulate tumor 
metastasis. IL-6 promoter activation involves synergism between the transcription factors 
NF-IL-6 and NF-κB (Huang et al, 2000), and this may explain increased IL-6 serum levels in 
the CRC patients with hepatic metastasis. The first report, for investigation the promoter 
polymorphism in IL-6 gene with sporadic colorectal cancer risk has been the study of Landi 
et al., 2003. They found that the allele IL6 −174C is associated with increased risk of CRC. 
This association was seen both under a codominant model as well as when genotypes were 
grouped for both cancer of the colon and cancer of the rectum. A possible explanation of this 
effect is that the -174C allele could cause increased inflammation for colorectal cells in 
response to activated neutrophils (Nusrat et al., 2001). Slattery and colleagues reported that 
the GG genotype of the −174 G/C IL-6 polymorphism was associated with a significantly 
reduced risk of colon, but not rectal, cancers (Slattery et al., 2007). The IL6 −174C allele’s role 
in CRC risk could not be replicated in the studies of others collectives (Theodopoulos et al., 
2006; Cacev et al., 2010).  
A possible cause for the conflicts and mismatches, like those observed here and the earlier 
study in allele and genotype distributions, may be the differences in racial or ethnical 
backgrounds. Duch et al. analyzed 52 patients with multiple myeloma and found that the G 
allele frequency was higher in the Brazilian population than in the European population 
(Duch C et al., 2007). Nowadays Yeh et al. observations on the allele and genotype 
distribution of the IL-6 −174 G/C polymorphism demonstrated that there are low 
frequencies of the G allele and GG genotype in the Taiwanese CRC population compared to 
the Western counterpart (Yeh et al., 2009).  
Experimental data suggest that IL-6 plays an important role not only in developed but also 
in the progression of metastasis from colorectal cancer. In CRC patients, high expression of 
IL-6 has been correlated with poor survival and IL-6 -174 genotype CC was also significantly 
associated with shorter survival time when compared with the heterozygous genotype CG 
(Chung YC et al., 2006; Wilkening et al., 2008). Also, Belluco and colleagues analyzed 62 
CRC patients and observed that patients with the C allele had lower serum IL-6 levels than 
those without the C allele, particularly in the presence of hepatic metastasis (Belluco C et al., 
2003).  
 
Cytokine Gene Polymorphisms in Colorectal Cancer 
 
63 
Specifically, IL-6/IL-6R complexes initiate homodimerization of gp 130, activate a 
cytoplasmic tyrosine kinase, and trigger signaling cascades through the JAK/STAT, 
Ras/MAPK and PI3-K/AKT pathways (Su et al., 2005; Chung YC et al., 2006). It has been 
shown that activation of signal transducers and activators of transcription 3 (STAT3) a 
member of a family of six different transcription factors is constitutively active in CRC cells 
(Corvinus et al., 2005). Ones of main activators of these signal transducers are 
proinflamatory cytokines such as IL-6, TNF- and growth factors. STAT3 activity in CRC 
cells triggered through interleukins was found to be abundant in dedifferentiated cancer 
cells and infiltrating lymphocytes of CRC samples. These actions regulate inflammatory 
reactions, immune responses, and several other pathophysiological processes of malignancy 
including cell growth and survival, differentiation, cell mobility and angiogenesis. Thus, the 
presence of proinflammatory cytokine polymorphisms in colorectal cancer development 
remains a pertinent question and one that we are not aware of other investigators having 
considered.  
3. Cytokine gene polymorphisms of antiinflamatory cytokines: TGF-  
and IL-10 
Anti-inflammatory cytokines play an important role in downregulation of inflammation and 
the prevention of neoplastic disorders. Genetic variations of anti-inflammatory cytokines are 
assumed to influence such responses. Typical anti-inflamatory cytokines (TGF-beta and IL-
10) with immunosuppressive effect are secreted mainly from T regulatory cells (Tregs). 
Transforming growth factor-beta (TGF- or TGFB) is an immunoregulatory cytokine that 
plays an important role in tumor immune response within the gastrointestinal tract and this 
is shown in TGFB gene knockout mice, which proceed to develop uncontrolled 
inflammatory response and early death (Kulkarni et al., 1993). In mammalian cells, there are 
three isoforms described TGFB1, TGFB2, and TGFB3. Among them TGFB1 is the most 
abundant subtype. 
TGF β1 is involved in many critical cellular processes, including cell growth, extracellular 
matrix formation, cell motility, angiogenesis, hematopoiesis, apoptosis, and immune 
function (Moustakas et al., 2002; Schuster & Krieglstein, 2002). All immune cell lineages, 
including B, T and dendritic cells as well as macrophages, secrete TGF-, which negatively 
regulates their proliferation, differentiation and activation by other cytokines. 
The TGF- signaling pathway plays an important role in controlling cell proliferation and 
differentiation involved in colorectal carcinogenesis. Binding of cytokine to the TGF- 
receptor complex leads to phosphorylation of Smad proteins and triggers Smads 
intracellular signaling mediators to modulate gene transcription, mainly by transcription 
factor Sp1. Xu and Pasche, 2007 shown that TGF- signaling alterations have been 
implicated in susceptibility to colorectal cancer. 
In normal intestinal epithelium TGF-β1 acts as a growth inhibitor, however loss of TGF-β1 -
mediated growth restraint has been shown to be associated with the transformation of 
colorectal adenoma to cancer. In addition, there is evidence that excess production and/or 
activation of TGF- by cancer cells can contributed to the tumor progression by paracrine 
mechanisms involving neoangiogenesis, production of stroma and proteases, and 
subversion of immune surveillance mechanisms in tumor hosts (Muraoka-Cook et al., 2005). 
Moreover, TGF- is the most frequently up-regulated in tumor cells (Elliott and Blobe, 2005). 
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patients with colorectal cancer correlate significantly with the staging of the tumor and with 
each other. It has been demonstrated that IL-6 acts as a colorectal growth factor and as an 
autocrine growth factor for colorectal cancer cells (Chung and Chang, 2003).  
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NF-IL-6 and NF-κB (Huang et al, 2000), and this may explain increased IL-6 serum levels in 
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factor Sp1. Xu and Pasche, 2007 shown that TGF- signaling alterations have been 
implicated in susceptibility to colorectal cancer. 
In normal intestinal epithelium TGF-β1 acts as a growth inhibitor, however loss of TGF-β1 -
mediated growth restraint has been shown to be associated with the transformation of 
colorectal adenoma to cancer. In addition, there is evidence that excess production and/or 
activation of TGF- by cancer cells can contributed to the tumor progression by paracrine 
mechanisms involving neoangiogenesis, production of stroma and proteases, and 
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Moreover, TGF- is the most frequently up-regulated in tumor cells (Elliott and Blobe, 2005). 
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TGF-β1 is also a potent effector within the tumor microenvironment. It exerts a 
predominantly immunosuppressive effect on CD8+ cytotoxic T-lymphocytes and has been 
shown an active player in tumor immune evasion (Li et al., 2006). Friedman et al. reported 
that high levels of transforming growth factor β1 correlate with disease progression in 
human colon cancer (Friedman et al. 1995). In light of these finding TGF-β1 gene is a 
functional candidate gene for genetic predisposition in CRC.  
The TGF-1 gene is located on chromosome 19 and several SNPs were described in 
promoter region, in the non-translated region (introns), in the coding region (exons), and in 
the 3’-UTR region of the gene (Watanabe et al., 2002). Certain inherited variants in the 
promoter region of the TGF- gene (-800G/A and -509C/T) have been associated with 
higher cytokine circulating concentrations. The -800G/A SNP is located in a consensus 
cyclic AMP response element binding protein (CREB) half site and may cause reduced 
affinity for CREB transcription factors whose binding is important for transcription control 
(Grainger D et al., 1999). The -509C/T is located within a YY1 consensus binding site and -
509T allele has been associated with increased TGF-1 plasma level (Grainger D et al., 1999) 
and reduced T-cell proliferation (Meng et al., 2005). Moreover these two SNPs of the TGF- 
gene are in linkage disequilibrium. The 509 C/T polymorphism has been implicated in both 
colorectal adenoma and cancer risk. However, published data remains conflicting. 
In the study of Macarthur et al., 2005 no association was found between -509C/T SNP in 
TGF-1 promoter and colorectal cancer. Authors investigated also association between 
cytokine polymorphisms of IL-1, IL-10 and TNF-α genes in a population based case-control 
study of 264 CRC patients and 408 controls in the Northeast of Scotland and analyzed their 
interaction with regular aspirin use. The beneficial association between nonsteroidal anti-
inflammatory drugs use, such as aspirin and decreased risk of colorectal cancer provided 
further evidence to suggest a role for chronic inflammation in the pathogenesis of sporadic 
colorectal cancer. Whereas a statistically significant association was not found between any 
of the SNPs and CRC alone, the authors observed a significant interaction between the IL-
10-592 genotype and aspirin use. The effect of aspirin on CRC risk was limited to carriers of 
low producing A allele (AA and AC) compared with CC genotype. The authors postulated 
that individuals who are genetically prone to producing reduced levels of the anti-
inflammatory IL-10 (i.e., carriers of the variant A allele) are more likely to benefit from the 
anti-inflammatory properties of aspirin in decreasing risk of CRC development. 
Berndt et al., 2007 examined two SNPs in the promoter region of the TGFB1 (-800G/A; -
509C/T) and two in exon 1 (Leu10Pro; Arg25Pro) and one in exon 5 (Thr263Ile) in association 
with advanced colorectal adenoma in population consisted primarily of Caucasians, living in 
the USA. The Leu10Pro and Arg25Pro SNPs encoded non synonymous amino acid 
substitution located in signal peptide sequence of the TGF-β1 pro-peptide.  
Dunning et al., 2003 revealed that the 10Pro variant lead to increased TGF- secretion 
compared with the 10Leu allele. Similarly, the 25Arg allele has been associated with 
increased TGF- production upon stimulation in vitro (Awad MR et al., 1998). 
Berndt et al., reported that the high TGF- produced genotypes, −509TT and 10Pro/Pro 
genotypes were associated with an increased risk of advanced colorectal adenoma 
compared with other genotypes. These increased risks, particularly for -509TT association 
were greater for the subsets of participant with multiple adenomas and those with rectal 
adenomas. Risk factors for hyperplastic and adenomatous polyps were generally similar to 
those for colorectal cancer. Another study investigated the same Leu10Pro polymorphism in 
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association with colorectal adenoma and hyperplastic polyps. In this study no association 
was found with this SNP and adenoma, but a lower risk of hyperplastic polyps was 
suggested for Pro allele carriers who were current or past smokers (Sparks et al, 2004).  
Together these studies give support to the possible role of TGFB1 in the adenoma-carcinoma 
sequence and suggest that high TGFB1 produced genotypes may modulate the risk in this 
transformation.  
To characterize association of genetic variation at the TGFB1 gene with circulating cytokine 
levels of TGF- and risk of colorectal adenoma and adenocarcinoma, Saltzman et al., 2008 
conducted two case-control studies (including 271 colorectal adenoma cases and 544 
controls, and 535 colorectal adenocarcinoma cases and 656 controls) among Japanese 
Americans, Caucasians, and Native Hawaiians in Hawaii. The authors investigated 26 SNPs, 
spanning 39.8 kb region of the TGFB1 gene, distributed in two haplotype blocks of linkage 
disequilibrium named as tagSNPs, including all previously commented SNPs. They found 
that the variant A allele for tagSNP in 3’UTR A/G (rs6957) was associated with an increased 
serum level of TGF-, and no association with promoter -509C/T and Leu10Pro 
polymorphisms was found. However, published data remains conflicting. In the recent 
study the association between -509 C/T and -800 G/A SNPs of the TGFB1 gene, and 
susceptibility to colorectal cancer in Iranian patients was investigated (Amighofran Z et al., 
2009). They found a statistically significant lower frequency of 509T allele and TT genotype 
in patients than in control subjects. At position 800, no significant differences in genotype 
distribution and allele frequencies between the patients and healthy controls were found. 
The authors concluded that the genotype distributions and allele frequencies of the TGFB1 
gene polymorphism at -509 C/T were significantly related to colorectal carcinoma in Iranian 
subjects. In the same directions are the results of Chung et al., 2007, that -509T variant allele 
reduced risk of colorectal cancer, but not adenoma in Koreans. A possible explanation for 
discrepancy in above commented results for involvement of -509 C/T SNP in colorectal 
cancer susceptibility occurs in the investigation of Fang et al., 2010. To derive a more precise 
estimation of the relationship, a meta-analysis of 994 colorectal cases and 2,335 controls from 
five published paper was performed. Overall, significantly increased colorectal cancer risks 
were found for CC versus TT in the subgroup analysis by ethnicity. Fang et al., 2010 
concluded that TGFB1 -509 C/T substitution has a role in genetic predisposition for 
developing colorectal cancer in Asians, but no significant associations were found among 
Europeans.  
Thus far, TGF-β1 −509 T/C gene polymorphisms have been also relevant to Crohn’s disease 
development (Schulte et al., 2001). In the same time patients with Crohn's disease are at 
increased risk for developing colorectal cancer. Several lines of evidence implicate chronic 
inflammation in inflammatory bowel disease (ulcerative colitis and Crohn's disease) as a key 
predisposing factor to distinct subset of colorectal tumors. (Itzkowitz and Yio, 2004). 
IL-10 is an immuno-regulatory cytokine that plays a crucial role in modulating 
gastrointestinal tract inflammation (Moore et al, 2001; Lin and Karin, 2007). IL-10 is 
produced mainly by regulatory T cell and antigen presenting cells. It is pivotal in inhibiting 
inflammation and interrupting carcinogenesis. In cancer patients, the production of immune 
suppressive cytokines: IL-10 and TGF is accelerated, and IL-10-producing type I T-
regulatory (Tr1) cells are highly infiltrated in tumor microenvironment. Thus, tumor cells 
might escape from the immune surveillance. That is the way the IL-10 gene might be 
involved in genetically predisposition and severity of CRC. 
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TGF-β1 is also a potent effector within the tumor microenvironment. It exerts a 
predominantly immunosuppressive effect on CD8+ cytotoxic T-lymphocytes and has been 
shown an active player in tumor immune evasion (Li et al., 2006). Friedman et al. reported 
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human colon cancer (Friedman et al. 1995). In light of these finding TGF-β1 gene is a 
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the 3’-UTR region of the gene (Watanabe et al., 2002). Certain inherited variants in the 
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509T allele has been associated with increased TGF-1 plasma level (Grainger D et al., 1999) 
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gene are in linkage disequilibrium. The 509 C/T polymorphism has been implicated in both 
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further evidence to suggest a role for chronic inflammation in the pathogenesis of sporadic 
colorectal cancer. Whereas a statistically significant association was not found between any 
of the SNPs and CRC alone, the authors observed a significant interaction between the IL-
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that individuals who are genetically prone to producing reduced levels of the anti-
inflammatory IL-10 (i.e., carriers of the variant A allele) are more likely to benefit from the 
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Berndt et al., 2007 examined two SNPs in the promoter region of the TGFB1 (-800G/A; -
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with advanced colorectal adenoma in population consisted primarily of Caucasians, living in 
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Berndt et al., reported that the high TGF- produced genotypes, −509TT and 10Pro/Pro 
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association with colorectal adenoma and hyperplastic polyps. In this study no association 
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Large interindividual differences in the IL-10 inducibility have been observed, which has 
shown to have a genetic component of over 70%. The IL-10 gene comprises 5 exons, and it 
has been mapped to chromosome 1q31-32. To date, at least 49 IL10–associated 
polymorphisms have been reported, and an even larger number of polymorphisms are 
recorded in SNP databases (Ensembl Genome Browser, 2006). Promoter polymorphisms 
have been subject to the most studies, particularly with regard to possible influences on 
gene transcription and protein production. Three SNPs at -1082(A/G), -819(C/T), -592(C/A) 
upstream from the transcription start site (D'Alfonso S et al., 1995; Turner D et al., 1997) 
have been described as well as additional two microsatellite (CA)n repeats, termed IL-10G 
and IL-10R and located at -1151 and -3978 respectively (Eskdale J and Galager G, 1995; 
Eskdale J et al., 1997). In particular, SNP at position -1082A/G of IL-10 gene was associated 
with IL-10 production alone or in haplotypes with other distal SNPs. Turner et al.,1997 have 
shown that -1082A allele is associated with lower in vitro IL-10 production by Con A-
stimulated PBMC from normal subjects. Crawley et al., 1999 have reported that GCC 
haplotype was associated with higher IL-10 level compared to ATA in whole blood cultures 
after LPS stimulation. In our studies, the functional effect of -1082 A/G polymorphism was 
demonstrated among the Bulgarian population in both healthy volunteers and in patients 
with sepsis (Stanilova et al., 2006).  
Positive associations between IL-10 genotype or haplotype and cancer susceptibility, 
progression, or both were reported (Howell and Rose-Zerilli, 2007). The IL-10-1082/-819/-
592 genotype status was associated with an increased risk for gastric cancer in Japan. The 
presence of the ATA/GCC haplotype of IL-10-1082/-819/-592 polymorphisms significantly 
increased the risk of gastric cancer development compared with presence of the ATA/ATA 
haplotype. (Sugimoto et al, 2007). The AA genotype of the -1082 A/G polymorphism in the 
interleukin-10 gene promoter was associated with lower IL-10 production in LPS, PHA or 
PWM stimulated healthy PBMC (Stanilova et al, 2006). This cytokine possess anti-
inflammatory and immunoregulatory role and it is no wonder that IL-10 play a dual role in 
tumor development and progression (Mocellin et al., 2003; Mocellin et al, 2004; Dranoff 
2004; Lin and Karin, 2007). Contradictory results are present in the literature concerning IL-
10 systemic or tissue levels and survival of cancer patients. For instance, Mocellin et al. 
found that IL-10 overexpression within the tumour microenvironment was implicated in 
cancer immune rejection. 
Although IL-10 suppression of pro-inflammatory cytokines synthesis favors its anti-tumor 
immunity, it might also promote tumor growth by stimulating cell proliferation and 
inhibiting cell apoptosis. A high systemic level of IL-10 has been reported for advanced 
colorectal cancer patients (O’Hara et al., 1998; Galizia et al., 2002). Increased level of IL-10 
might better control inflammatory responses and cancer development. Results from our 
study demonstrated a stage dependent association between IL-10 serum level and severity 
of CRC (Stanilov et al., 2010). The highest IL-10 serum level was found in stage-IV CRC 
patients, suggesting a pro-tumorigenic activity of systemic IL-10 in CRC progression and 
play a role in tumor-induced immunosupression in CRC patients. In addition, we 
determined a significantly increased mRNA in tumor tissue compared to normal mucosa 
(Stanilov et al., 2009). Moreover expression of IL-10 mRNA correlated positively with 
increased Foxp3 mRNA expression detected in tumor tissue. These results confirm the role 
of Foxp3 transcription factor in induction of IL-10 production and differentiation of Treg-1 
cells in tumor microenvironment. 
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Cacev et al, 2008 reported a statistically significant decrease in IL-10 mRNA expression in 
tumor tissue then normal mucous depending on IL-10 SNPs. IL-10 promoter genotypes −819 
TT and −592 AA associated with low IL-10 mRNA expression in tumor and corresponding 
normal mucosa. The ‘low-producer genotypes’ were present more frequently in colon 
cancer patients and this difference in genotype distribution was statistically significant. In 
the same study IL-10 -1082AA genotype was associated with lower IL-10 mRNA expression, 
whereas -1082GG genotype was associated with higher IL-10 mRNA expression in tumor 
tissue. In a group of colon cancer patients, an increased frequency of the -1082AA genotype 
compared with control group was observed without statistical significance. The authors 
conclude that IL-10-1082G/A SNP did not influence sporadic colon cancer susceptibility.  
No associations were observed among colorectal cancer patients and controls for IL-10 –
1082G/A and –592C/A genotype frequencies in a case–control study of 62 patients and 124 
matched controls (Crivello et al., 2006). A possible reason for these contradictory results 
might be a small number of patients. 
A recent study of Tsilidis K et al., 2009 investigated the association of 17 candidate SNPs in 
IL-10 with colorectal cancer in 208 patients. The authors established that -1082 promoter 
SNP is implicated. Compared with the AA genotype at the candidate IL10-1082 locus 
(rs1800896), carrying one or two G alleles, a known higher producer of the anti-
inflammatory cytokine IL-10 was associated with lower risk of colorectal cancer (p = 0.03). 
Statistically significant associations with colorectal cancer were observed for three tagSNPs 
in IL10 (rs1800890, rs3024496, rs3024498) and one common haplotype, but these associations 
were due to high linkage disequilibrium with IL10-1082. 
Associations between IL-10 genotypes and cancer chemopreventive strategies and survival 
were also published. Results of Macarthur et al. suggest that IL-10 SNPs may play a role in 
predicting response to chemopreventive strategies. Carriers of the IL-10-592A allele, had a 
statistically significant 50% reduced risk of colorectal cancer when taking regular aspirin, 
whereas risk was not reduced in carriers of the A allele who did not use aspirin, or among 
aspirin users with the CC genotype. It is possible that carriers of the IL-10-592C allele are more 
likely to derive chemopreventive benefits from aspirin in the presence of a lower production of 
their own endogenous anti-inflammatory interleukin-10 (Macarthur et al, 2005).  
In particular proinflammatory genotypes characterized by a low IL-10 producer seem to be 
associated with a worse clinical outcome. Sharma et al. investigated the prognostic value of 
an inflammation-based Glasgow Prognostic Score in advanced colorectal cancer to explore a 
predictive pattern of cytokine gene polymorphisms for clinical outcome (Sharma et al., 
2008). They found that IL-10–592A/C and IL-10 –1082A/G were predictive for overall 
survival. Patients homozygous for IL-10–592 CC had improved overall survival compared 
with those patients with ≥ 1 A allele (median survival, 12.2 ± 0.7 months vs. 8.6 ± 1.6 
months). In contrast, patients homozygous for IL-10–1082 AA had poorer overall survival 
compared with patients with ≥ 1 G allele (median survival, 8.8 months ± 3.2 months vs. 11.2 
± 2.1 months). 
Although the functional effects of polymorphisms in immunosuppressive genes TGFB and 
IL-10 have not yet been elucidated, obviously that they may play a significant role in 
modulating susceptibility, development and survival of colorectal cancer (Fig.1). The 
observation of increased circulating levels of IL-10 in colorectal cancer patients may have 
important implications for future investigations, immunological monitoring and therapeutic 
intervention on neoplastic patients, and suggests a mechanism for tumour cells escaping 
from immune surveillance. 
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Large interindividual differences in the IL-10 inducibility have been observed, which has 
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  Park et al.,1998 
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a2 allele a5 and a13 allele  Gallager et al., 
1997 ; DeJong et 
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TNF-A- 238 G >A  AA and AG  Jang et al., 2001 
IL6 −174G>C C allele    Landi et al., 2003 
  CC 
 
Chung YC  
et al., 2006 
 GG 
 
 Slattery M  
et al., 2007 
ANTIINFLAMATORY 
TGFB1 -509C>T −509TT   Berndt  
et al., 2007 
TGFB1 Leu10Pro 10Pro/Pro   Berndt  
et al., 2007 
TGFB1 -509C>T  −509TT  Amighofran Z 
et al., 2009 
TGFB1 -509C>T  −509T allele  Chung 
et al., 2007 
TGFB1 -509C>T  −509TT  Fang et al., 2010 
IL-10 -1082 A>G  G allele  Tsilidis K  
et al., 2009 
IL-10 -592 C> A −592 AA   Cacev et al, 2008 
IL-10 -819 C>T −819 TT   Cacev et al, 2008 
IL-10 -1082 A>G ; 
-592 C> A 
  IL-10–1082AA 
IL-10–592 AA 
Sharma  
et al., 2008 
Table 1. Involvement of IL-1; TNF, IL-6, IL-10 and TGF- gene polymorphisms into 
colorectal cancer.  
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4. Role of IL-12-related cytokines  
Human interleukin (IL)-12 (IL-12p70) is a disulfide-linked heterodimer composed of two 
subunits p40 and p35. IL-12p40 subunit can be secreted as monomer, which can also form 
IL-23, a heterodimeric pro-inflammatory cytokine composed of p40 and p19 subunits, and a 
homodimer, IL-12p80, which can act as an IL-12 and IL-23 antagonist by competing at their 
receptors (Hoelscher, 2004). The IL-12 family cytokines are produced by antigen-presenting 
cells such as macrophages and dendritic cells and play critical roles in the regulation of Th 
cell differentiation. IL-12 induces IFN-γ production by NK and T cells and differentiation to 
Th1 cells. IL-23 induces IL-17 production by memory T cells and expands and maintains 
inflammatory Th17 cells. IL-27 induces the early Th1 differentiation and generation of IL-10-
producing regulatory T cells. Although IL-12p70 is one of the most powerful antitumor 
cytokine (Colombo and Trinchieri, 2002), accumulating evidence revealed that the 
individual members of the IL-12 family play distinct roles in the regulation of antitumor 
immune responses. 
Several polymorphisms have been described in the IL12B gene, encoding IL-12p40 subunit, 
including a single-nucleotide polymorphism in 3’-untranslated region (UTR) of IL12B with 
number rs3212227 and a complex polymorphism in promoter region of the IL12B 
(IL12Bpro), resulting from 4bp microinsertion combined with an AA/GC transition 
(rs17860508). Moreover, several studies have demonstrated that these two polymorphisms 
affect gene expression and IL-12 production (Morahan et al., 2001; Seegers et al., 2002; 
Muller-Berghaus et al., 2004; Stanilova and Miteva, 2005; Stanilova et al., 2008; Dobreva et 
al., 2009) and consequently could influence the pathogenesis of CRC. To test this hypothesis, 
we performed a case-control study to investigate the association between these gene 
polymorphisms and the risk of colorectal cancer. The paper of Miteva et al., 2009 was the 
first study which investigated the distribution of IL12Bpro polymorphism and the 
+16974A/C SNP in 3’UTR of IL12B among 85 Bulgarian patients with colorectal cancer. No 
differences in genotype and allelic frequencies of the IL12B polymorphisms in the promoter 
and 3’UTR regions between patients with CRC and controls were found, either when 
patients were analyzed as a whole group or when they were separated according to the 
TNM classification or clinical characteristics such as tumor location, differentiation degree, 
lymph node and metastases status. These data are in principal agreement with other studies, 
where no association with SNP in 3’UTR of IL12B was found in pathogenesis of other 
related gastrointestinal diseases. Navaglia et al. have reported that none of the studied IL12B 
gene polymorphisms, including SNP in 3’UTR, was correlated with Helicobacter pylori 
infection and intestinal metaplasia (Navaglia et al., 2005). There was no statistically 
significant association between the SNPs investigated in IL-12A gene ((+7506 A>T, +8707 
A>G, +9177 T>A, +9508 G>A) and colorectal cancer risk in the study of Landi et al., 2006. 
The lack of association suggests that the role of both investigated polymorphisms in IL12B 
in susceptibility of sporadic colorectal cancer can be excluded. However, these findings do 
not exclude a key role for IL-12p40 in development and progression of the CRC. In our 
investigations, we have demonstrated that serum levels for IL-12p40 and IL-23 were 
significantly higher in patients compared to healthy donors. Additionally, we found the 
highest level of IL-12p40 in sera from patients with I stage of CRC and significantly lower in 
patients with more advanced stages. (Miteva et al., 2009; Stanilov et al., 2009; Stanilov et al., 
2010). In respect to recent findings regarding different proteins in IL-12 related family which 
share the p40 subunit, we could attribute the relationship of decreased serum level of IL-
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12p40 and severity of CRC to the action of Th1-promoting form of IL-12, such as IL-12p70, 
or free IL-12p40 in monomeric and homodimeric form.  
In a recent study there were significant differences in the genotype and allele frequencies of 
the IL-12 gene 16974 A/C polymorphism between the group of patients with glioma and the 
control group (Zhao et al., 2009). Moreover, genotypes carrying the IL-12 16974 C variant 
allele were associated with decreased serum IL-12p40 and IL-27p28 levels compared to the 
homozygous wild-type genotype in patients with glioma. 
The promoter polymorphisms in the human IL12B gene could influence JNK and p38 
MAPKs control of IL-12p40 expression in human PBMC in response to mitogens and 
proinflammatory stimuli. The study of Dobreva et al., revealed that JNK and p38 MAPK 
inhibition in PBMC stimulated with C3bgp and LPS, significantly upregulated the IL-12p40 
production from IL12Bpro-1 homozygotes and did not influence the IL-12p40 production 
from 1.2/2.2 genotypes (Dobreva et al., 2009). Also, the p38 inhibition led to significant 
increase of IL-12p40 production in IL12Bpro-1 homozygous PBMC stimulated with PHA. 
IL-12p40 is secreted at a 50-fold excess compared with IL-12p70 in a murine shock model 
(Wysocka et al., 1995) and at a 10-20-fold excess by stimulated human peripheral blood 
mononuclear cells (D’Andrea et al., 1992). IL-12p40 chain may form also a homodimer IL-
12p80 that serves as an IL-12p70 and IL-23 antagonist by competing for binding at the 
receptor complexes of both cytokines (Cooper & Khader, 2006). The proper balance between 
IL-12p40-related cytokines play a key immunoregulatory role and control the appearance of 
protective Th1-mediated immune response. Current results demonstrated an opposite effect 
of JNK and p38 MAPKs inhibition on the IL-12p70 and IL-23 production in LPS and C3bgp-
stimulated PBMC (Dobreva et al., 2008).Our results demonstrated that p38 MAPK inhibition 
down regulates IL-23 and up regulates IL-12p40/p70 inducible expression suggesting the 
benefit of p38 control in the treatment of inflammatory conditions. 
IL-12 related cytokines (IL-12p70; IL-12p40 and IL-23) produced locally or systemic exhibit a 
significant role in progression of CRC. Accumulating evidence revealed that the individual 
members of the IL-12 family play distinct roles in progression of CRC. Studies have defined 
IL-12p70 as an important factor for the differentiation of naive T cells into IFN-γ producing 
Th1 cells and exhibits anti-tumor activity (Brunda et al., 1995; Gri et al., 2002). Although the 
antitumor activities of IL-12p70 are well characterized, studies of the role of IL-23 in 
development of CRC in humans are contradictory. Some authors reported that IL-23, as well 
as IL-12p70, have anti-tumor activity in murine tumor models (Wang et al., 2003; Lo et al., 
2003; Shan et al.,2006). Contradictory results have been reported in studies of Langowski et 
al., 2006 which showed data that IL-23 promotes tumor incidence and growth in various 
human cancers. In this respect our results for enhanced serum levels of IL-23 in cancer 
patients regardless of severity supported the hypothesis that IL-23 promotes tumor 
development unlike IL-12p70 (Stanilov et al., 2010). Besides, the highest increase in 
transcriptional activity in tumor samples for IL-23p19 mRNA has been also reported in our 
study (Stanilov et al., 2009). IL-23p19 mRNA was approximately 29 fold upregulated 
(p=0.0009), whereas IL-12p35 mRNA was not significantly upregulated, when compared to 
their adjacent normal tissue. This difference indicated that IL-23 could be synthesized many 
times more than IL-12p70 in tumor tissue. Based on our and others data, we could assume 
that increased serum and locally produced IL-23 indicates impaired anti-tumor immune 
response and could be associated with poor prognosis of CRC. A molecular mechanism 
involved in IL-23 activities includes STAT3 activation. STAT3 signaling within the tumor 
microenvironment was recently elucidated to induce a protumor cytokine, IL-17 and IL-22, 
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while inhibiting a central antitumor cytokine, IL-12p70, thereby shifting the balance of 
tumor immunity toward tumorigenesis. Interestingly, unlike spleen Treg cells, tumor-
associated Treg cells express IL-23R and activate STAT3 in response to IL-23, leading to 
upregulation of the Treg-specific transcription factor Foxp3 and the immunosuppressive 
cytokine IL-10 (Xu M et al., 2010). Collectively, IL-12 and IL-23 play critical roles in the 
regulation of antitumor or protumor response in respective situation. 
5. Conclusion 
In recent years, efforts have been made to identify genes involved in the genetic 
predisposition or progression of colorectal cancer. During the last two decades, many of the 
‘candidate’ cytokine genes implicated in colorectal tumorigenesis have been identified and 
were summarized in this review. As cancer is a complex genetic disease, it is probable that 
besides oncogenes and tumor suppressor genes a number of cytokine genes also contribute 
to cancer susceptibility and development. Moreover cytokines are a key-player in 
inflammation, which have protumoral effect and mediated anti-tumor immune response. 
Cytokines present in tumor microenvironment have gained much attention due to their 
influence on cell activation, growth, differentiation or cell migration and they are 
increasingly recognized as potential cancer modifying genes. While numerous factors 
influence the inflammatory response in cancer, the role of an individual’s genetic 
background has recently received increasing attention.  
Cytokines and their receptors are often encoded by highly polymorphic genes. Single-
nucleotide polymorphisms in cytokine genes potentially affect their production by either 
creating or eliminating key binding motifs within promoter and other regulatory sequences. 
In investigating disease–gene associations, there is a strong argument for focusing on 
polymorphisms of functional significance. Up to date contradictory results from case-control 
study have been published concerning cytokine gene polymorphisms and colorectal cancer 
development. Obviously reasons for such results included different numbers of patients; 
their ethnicity and differences in clinical and pathological data. In any case-control study, 
there are potential limitations. Despite the limitations of most published studies, the 
preliminary literature indicates that selected cytokine polymorphisms, particularly in IL-10; 
TGF-; IL-6 and TNF- are required in colorectal cancer. Data included in this review 
summarized in table1 suggest that functional cytokine polymorphisms participate more in 
the onset of colorectal cancer progression rather than in its initial development. Due to the 
strong evidence concerning the biological significance of these SNPs further studies and 
meta analysis are needed to evaluate the significance in the clinic. Careful selection of SNPs 
to cover the whole length of a candidate gene sequence so that areas of association can be 
defined and informative haplotypes constructed. Emerging genotyping technologies will 
facilitate such definitive, comprehensive studies.  
The preliminary data indicate that larger studies are required to confirm or reject existing 
results, extend studies to include more detailed genotype and haplotype analysis, and 
combine genotype and gene expression studies in the same subjects. Even larger numbers of 
cases and controls would be required to demonstrate more modest odds ratios with higher 
statistical power. Collection of definitive clinical and pathological data for all cases must be 
an integral part of such an approach. 
Such studies will contribute significantly to our understanding of the biological role of 
cytokine polymorphisms in colorectal cancer development.  
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while inhibiting a central antitumor cytokine, IL-12p70, thereby shifting the balance of 
tumor immunity toward tumorigenesis. Interestingly, unlike spleen Treg cells, tumor-
associated Treg cells express IL-23R and activate STAT3 in response to IL-23, leading to 
upregulation of the Treg-specific transcription factor Foxp3 and the immunosuppressive 
cytokine IL-10 (Xu M et al., 2010). Collectively, IL-12 and IL-23 play critical roles in the 
regulation of antitumor or protumor response in respective situation. 
5. Conclusion 
In recent years, efforts have been made to identify genes involved in the genetic 
predisposition or progression of colorectal cancer. During the last two decades, many of the 
‘candidate’ cytokine genes implicated in colorectal tumorigenesis have been identified and 
were summarized in this review. As cancer is a complex genetic disease, it is probable that 
besides oncogenes and tumor suppressor genes a number of cytokine genes also contribute 
to cancer susceptibility and development. Moreover cytokines are a key-player in 
inflammation, which have protumoral effect and mediated anti-tumor immune response. 
Cytokines present in tumor microenvironment have gained much attention due to their 
influence on cell activation, growth, differentiation or cell migration and they are 
increasingly recognized as potential cancer modifying genes. While numerous factors 
influence the inflammatory response in cancer, the role of an individual’s genetic 
background has recently received increasing attention.  
Cytokines and their receptors are often encoded by highly polymorphic genes. Single-
nucleotide polymorphisms in cytokine genes potentially affect their production by either 
creating or eliminating key binding motifs within promoter and other regulatory sequences. 
In investigating disease–gene associations, there is a strong argument for focusing on 
polymorphisms of functional significance. Up to date contradictory results from case-control 
study have been published concerning cytokine gene polymorphisms and colorectal cancer 
development. Obviously reasons for such results included different numbers of patients; 
their ethnicity and differences in clinical and pathological data. In any case-control study, 
there are potential limitations. Despite the limitations of most published studies, the 
preliminary literature indicates that selected cytokine polymorphisms, particularly in IL-10; 
TGF-; IL-6 and TNF- are required in colorectal cancer. Data included in this review 
summarized in table1 suggest that functional cytokine polymorphisms participate more in 
the onset of colorectal cancer progression rather than in its initial development. Due to the 
strong evidence concerning the biological significance of these SNPs further studies and 
meta analysis are needed to evaluate the significance in the clinic. Careful selection of SNPs 
to cover the whole length of a candidate gene sequence so that areas of association can be 
defined and informative haplotypes constructed. Emerging genotyping technologies will 
facilitate such definitive, comprehensive studies.  
The preliminary data indicate that larger studies are required to confirm or reject existing 
results, extend studies to include more detailed genotype and haplotype analysis, and 
combine genotype and gene expression studies in the same subjects. Even larger numbers of 
cases and controls would be required to demonstrate more modest odds ratios with higher 
statistical power. Collection of definitive clinical and pathological data for all cases must be 
an integral part of such an approach. 
Such studies will contribute significantly to our understanding of the biological role of 
cytokine polymorphisms in colorectal cancer development.  
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Etiologically, sporadic colorectal cancer (CRC) is a complex, multifactorial disease that is 
linked to both exogenic and endogenic factors. Accumulating evidence indicates that 
susceptibility to cancer in general, and to CRC in particular, is mediated by genetically 
determined differences in the effectiveness of detoxification of potential carcinogens and 
reactive oxygen species. The antioxidant enzymes and phase I and II biotransformation 
enzymes are important candidates for involvement in susceptibility to sporadic CRC, due to 
their ability to regulate the metabolism of a wide range of environmental exposures (Perera, 
1997; Potter, 1999; McIlwain et al., 2006; Di Pietro et al., 2010). In addition to carcinogens and 
reactive oxygen species, the majority of anticancer drugs applied in the chemotherapy are 
also substrates and are biotransformed by xenobiotic-metabolizing enzymes, leading to their 
activation and/or detoxification (O'Brien &Tew, 1996; Eaton &Bammler, 1999; Townsend 
&Tew, 2003; Hayes et al., 2005; Michael &Doherty, 2005; Townsend et al., 2005). In this 
respect, great efforts have been focused to clarify the effects of genetic variations, expression 
and activity of xenobiotic-metabolizing enzymes in development, progression and therapy 
of cancers with different histological origin, including CRC (Ranganathan &Tew, 1991; Tew 
&Ronai, 1999; Welfare et al., 1999; Cotton et al., 2000; de Jong et al., 2002; Dogru-Abbasoglu 
et al., 2002; Stoehlmacher et al., 2002; Ates et al., 2005; Romero et al., 2006; Liao et al., 2007; 
Pistorius et al., 2007; Koutros et al., 2009; Di Pietro et al., 2010; Economopoulos & 
Sergentanis, 2010).  
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2. Role of GSTs in cell processes 
Glutathione-S-transferase (GST, EC. 2.5.1.18) isoemzymes are involved in phase II xenobiotic 
biotransformation. GSTs belong to a large superfamily of dimeric enzymes, which play an 
important role in cell defense system. So far, 24 isoenzymes have been described in humans, 
classified into 11 classes: 7 cytosolic - alpha (, A), mu (μ, M), pi (, P), sigma (σ, S), theta (θ, 
T), zeta (ζ, Z), and omega (ω, O), one mitochondrial - kappa (κ, K), and three microsomal 
classes, also referred to as membrane-associated proteins in eicosanoid and glutathione 
metabolism (MAPEG) (Sheehan et al., 2001; Hayes et al., 2005; McIlwain et al., 2006; 
Laborde, 2010) The most abundant mammalian GST enzymes belong to cytosolic classes 
alpha, mu, and pi, and their regulation has been studied in details (Hayes &Pulford, 1995). 
Most of the cytosolic GST classes are coded by several genes, gathered in clusters and thus 
these enzymes have several subunits, which form a number of homo- and/or heterodimeric 
isoenzymes (Table 1) (McIlwain et al., 2006; Laborde, 2010). 
 




location of the 
genes/gene clusters 
Cytosolic








GST-omega (GST, GSTO) 1,2 GSTO1, GSTO2,  10q25.1 
GST-pi (GST, GSTP) 1 GSTP1 11q13 
GST-sigma (GST, GSTS) 1 GSTS  
(a HPGDS; PGDS) 
4q22.3 
GST-theta (GST, GSTT) 1,2 GSTT1, GSTT2 22q11.2 
GST-zeta (GST, GSTZ) 1 GSTZ1 14q24.3 
Mitochondrial
GST-kappa (GST, GSTK) 1 GSTK1 7q34 
Microsomal
bMAPEG  c MGST1,  
c MGST2,  
d ALOX5AP (FLAP) 
e LTC4S 
c MGST3 







aHPGDS - hematopoietic prostaglandin D synthase (PGDS - prostaglandin D synthase) 
bMAPEG - membrane-associated proteins in eicosanoid and glutathione metabolism 
cMGST - microsomal glutathione S-transferase 
dALOX5AP (FLAP) - arachidonate 5-lipoxygenase-activating protein  
eLTC4S - leukotriene C4 synthase 
fPGES - prostaglandin E synthase 
Table 1. Classes, subunits and gene location of human GSTs  
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GSTs catalyze the conjugation of reduced glutathione with a variety of endogenic and 
exogenic electrophilic compounds, including several carcinogens and antineoplastics (Hayes 
&Strange, 1995; Hayes et al., 2005; Michael &Doherty, 2005). This process results in 
alteration, usually a reduction, of the reactivity of the compounds and makes them more 
water soluble and favors their elimination.  
GSTs can also function as peroxidases and isomerases (Hayes &Pulford, 1995; Cho et al., 
2001). Thus GSTA1-1 and GSTA2-2 efficiently catalyze the reduction of fatty acid and 
phospholipid hydroperoxides (Zhao et al., 1999). Moreover, it has been shown that GSTA3-3 
is essential in obligatory double-bond isomerizations of precursors of testosterone and 
progesterone in steroid hormone biosynthesis (Johansson &Mannervik, 2001). Although the 
exact physiological function of omega-class GSTs remains undefined (Board et al., 2000; 
Board, 2011), it has been demonstrated that they can catalyze a range of thiol transferase and 
reduction reactions that are not catalyzed by members of the other classes: GSTO1 has GSH-
dependent reductive activity to dehydroascorbate and to monomethylarsenic acid (V) 
(Board, 2011). GSTZ1 has isomerase activity and catalyzes the conversion of 
maleylacetoacetate to fumarylacetoacetate in the catabolic pathway of phenylalanine and 
tyrosine and also catalyzes the GSH-dependent transformation of -halogenated acids 
(McIlwain et al., 2006).  
There are six MAPEG (membrane associated proteins in eicosanoid and glutathione 
metabolism) subfamily members localized to the endoplasmic reticulum and outer 
mitochondrial membrane. Three of them are involved in the production of leukotrienes and 
prostaglandin E, whereas the other three have glutathione S-transferase and peroxidase 
activities, thus implicated in the protection of membranes from oxidative stress 
(Morgenstern et al., 2011).  
In addition to their catalytic functions GSTs have several complementary functions. Some of 
the GSTs can serve as nonenzymatic binding proteins (known as ligandins) interacting with 
various lipophilic compounds including steroid and thyroid hormones (Litwack et al., 1971; 
Ishigaki et al., 1989; Cho et al., 2001; Vasieva, 2011). Moreover, GST isoenzymes can play a 
regulatory role in cellular signaling by forming protein:protein interactions with key 
signaling tyrosine kinases, involved in controlling stress response, apoptosis, inflammation, 
cellular differentiation and proliferation (Adler et al., 1999; Cho et al., 2001; Wang et al., 
2001; Townsend &Tew, 2003; Townsend et al., 2005; McIlwain et al., 2006; Laborde, 2010; 
Vasieva, 2011).  
There is strong evidence that GST-pi can bind by protein:protein interaction, sequester and 
inhibit c-Jun N-terminal kinase (JNK)/stress-activated protein kinases (SAPKs). JNK is a 
MAP kinase that phosphorylates c-Jun, a component of the activator protein-1 (AP-1) 
transcriptional factor, resulting in the induction of AP-1-dependent target genes which play 
role in cell survival and apoptosis. Thus JNK is implicated in pro-apoptotic/survival 
signaling pathways and may be required for induced cytotoxicity of a variety of antitumor 
drugs (Adler et al., 1999; Wang et al., 2001; Townsend &Tew, 2003; Townsend et al., 2005; 
McIlwain et al., 2006; Laborde, 2010; Vasieva, 2011).  
Recently, GST-pi was shown to affect the apoptosis pathways also by physical association 
with TNF receptor associated factor 2 (TRAF2), an adaptor protein which mediates the 
signal transduction of different receptors and is required for the activation of ASK1 
(apoptosis signal-regulating kinase 1) (Wu et al., 2006; Laborde, 2010; Sau et al., 2010; 
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signal transduction of different receptors and is required for the activation of ASK1 
(apoptosis signal-regulating kinase 1) (Wu et al., 2006; Laborde, 2010; Sau et al., 2010; 
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Vasieva, 2011). ASK1 is a MAP kinase kinase kinase (MAP3 kinase, MAPKKK) that can 
phosphorylate MKK4/7 and MKK3/6 (MAP kinase kinases, MAP2Ks, MAPKK) which are 
involved in stress-induced activation of JNK- and p38 signaling pathways, respectively 
(Dorion et al., 2002; Wu et al., 2006; Sau et al., 2010). 
Isoenzymes of the alpha and mu classes have also been shown in vitro to bind to JNK-Jun 
complexes and inhibit the activation of c-Jun by JNK, however their inhibitory activity was 
weaker than GST-pi (Villafania et al., 2000; Laborde, 2010). In addition, it has been noted 
that GST-mu interacts physically with N-terminal portion of ASK1, thus inhibiting its 
activity and the ASK1-elicited MKK4/7–JNK and MKK3/6–p38 signaling pathways (Dorion 
et al., 2002). 
Another binding partner of GST-pi is the antioxidant enzyme 1-cys peroxiredoxin (1-cysPrx, 
Prx VI), which is a member of the peroxiredoxin superfamily and is able to protect cells 
from membrane peroxidation via GSH-dependent peroxidase activity on phospholipid 
hydroperoxides. The process of heterodimerization of 1-cysPrx with GST-pi leads to 
activation involving also the S-glutathionylation of 1-cysPrx (Manevich et al., 2004; Vasieva, 
2011). 
GST-pi has also been found to function in the S-glutathionylation of oxidized cysteine 
residues of several target proteins following oxidative and nitrosative stress thus playing a 
direct role in the control of posttranslational S-glutathionylation reactions (McIlwain et al., 
2006; Townsend et al., 2006; Townsend et al., 2009; Tew et al., 2011). S-glutathionylation 
occurs on cysteine moieties located in relatively basic environment in response to oxidative 
(ROS) or nitrosative stress (RNS) signaling events. Glutathiolylation is reversible process 
that can occur spontaneously by GSH or catalytically by thioredoxin (Trx), glutaredoxin 
(Grx) or sylphoredoxin (Srx). Thus besides the phosphorylation/dephosphorylation, the 
cells are provided with additional dynamic system of controlling the protein activity 
(Townsend et al., 2009). Proteins sensitive to modification by S-glutathionylation are variety 
of enzymes with thiols in the active centers, cytoskeleton proteins, signaling proteins – 
particularly kinases and phosphatases, transcriptional factors, Ras oncogenic proteins, heat 
shock proteins, ion channels, and calcium pumps (Tew et al., 2011). Since a number of 
proteins that are S-glutathionylated are involved in growth regulatory pathways, the over-
expression of GST-pi in cancers may account for the impaired balance between cell death, 
proliferation and differentiation and could contribute to tumor development, progression 
and treatment response (Townsend et al., 2009; Tew et al., 2011).  
GST-pi was also shown to bind proteins and compounds containing iron and nitric oxide 
and thus may influence the NO metabolism and NO signaling (Vasieva, 2011). It has been 
shown that the natural low molecular mass NO carriers, dinitrosyl-iron complexes (DNIC) 
and S-nitrosoglutathion (GSNO) bind with high affinity to one active site of the dimeric 
GST-pi enzyme, while the enzyme maintains its detoxification activity (Lo Bello et al., 2001; 
Townsend et al., 2006; Vasieva, 2011). Hence, GST-pi (GSTP1-1) may act as a NO carrier, 
which determines it as a player of a number of processes as formation of nitrothiols, 
nitrosylation of proteins, NO mediated iron mobilization from cells, and Zn-homeostasis 
(Vasieva, 2011).  
It has also been reported that certain GSTs play novel roles implicated in cell defense: GST-
theta was suggested to inhibit the pro-apoptotic action of Bax (Kampranis et al., 2000), and 
GST-omega (GSTO1-1) was shown to modulate ryanodine receptors (RyR), which are 
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calcium release channels in skeletal and cardiac sarcoplasmic reticulum, suggesting 
protective functions of GSTO1-1 in mammalian cells from radiation damage and Ca2+  
induced apoptosis (Dulhunty et al., 2001) 
Thereby, these multiple functionalities of the members of GST family, in addition to the 
well-characterized catalytic activities, could contribute and be of importance in GST-highly 
expressing tumors for development and progression of cancers and for acquisition of 
resistance to applied chemotherapeutics.  
3. Polymorphic variants of GSTs 
Numerous polymorphisms have been described in the genes encoding GSTs as most of 
them have been associated with a lack or an alteration of enzymatic activity toward several 
substrates (Ali-Osman et al., 1997; Whyatt et al., 2000; Hayes et al., 2005; McIlwain et al., 
2006). 
3.1 GSTP class 
The GST-pi class is encoded by a single gene spanning approximately 3 kb and located on 
chromosome 11 (11q13). Two GSTP1 single nucleotide polymorphisms (SNPs) have been 
identified. They are characterized by transitions at A1578G (exon 5, A313G) and C2293T (exon 6, 
C341T), resulting in amino acid substitutions Ile105Val and Ala114Val, respectively, which 
appear to be within the active site of the GST-pi protein (Ali-Osman et al., 1997; Watson et 
al., 1998; Hayes et al., 2005; McIlwain et al., 2006). These two SNPs lead to the following four 
alleles: GSTP1*A (105Ile, 114Ala), GSTP1*B (105Val, 114Ala), GSTP1*C (105Val, 114Val), and 
GSTP1*D (105Ile, 114Val).  
It has been proven that the substitutions due to SNPs in GSTP1 are functional: the 
substitution of Ile to Val at position 105 (GSTP1 Ile105Val) results in altered enzyme 
activity to variety of electrophilic molecules (Hayes et al., 2005; McIlwain et al., 2006). 
Thus, there is a strong experimental evidence that the two proteins, encoded by the allelic 
variants, 105Ile and 105Val of the human GSTP1 gene, differ significantly in their catalytic 
activities toward a model substrate; the GST-pi 105Val variant has lower activity toward 
1-chloro-2,4-dinitrobenzene, a standard substrate, than its 105Ile counterpart (Ali-Osman 
et al., 1997; Townsend &Tew, 2003, Coles, 2000 #47). On the other hand, the same variant 
(105Val) displays greater activity toward polycyclic aromatic hydrocarbon (PAH) diol 
epoxides (Sundberg et al., 1998; Coles et al., 2000; Bostrom et al., 2002). The GST-pi 105Val 
enzyme variant is found to be more active than 105Ile variant in conjugation reactions 
with the bulky diol epoxides of PAHs, being up to 3-fold as active toward the anti- and 
syn-diol epoxide enantiomers with R-absolute configuration at the benzylic oxiranyl 
carbon (Sundberg et al., 1998; Coles et al., 2000). The bay-region diol epoxides of PAHs are 
known to be ultimate mutagenic and carcinogenic metabolites (Sundberg et al., 1998; 
Bostrom et al., 2002).  
The frequency of GSTP1 105Ile allele in different Caucasian groups varied from 0.63 to 0.77, 
whereas the frequency of the variant GSTP1 105Val allele ranged between 0.23 and 0.37 
(Table 2) (Katoh et al., 2008). In our previous study we determined the frequency of Ile105Val 
GSTP1 genotypes in 126 ethnic Bulgarian individuals from the region of Stara Zagora (0.54 
for Ile/Ile, 0.39 for Ile/Val and 0.07 for Val/Val) (Vlaykova et al., 2007). The obtained figures 
are consistent with those published for the controls in the case-control study of Bulgarian 
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patients with Balkan endemic nephropathy (Andonova et al., 2004), and for other Caucasian 
type control cohorts in Finland (Mitrunen et al., 2001), Edinburgh area, Scotland (Harries et 
al., 1997), Newcastle and North Tyneside, England (Welfare et al., 1999), East Anglia region 
(Loktionov et al., 2001), etc. (Table 2). Based on these similarities we can conclude that 
despite the heterogeneous origin ethnic Bulgarians do not differ from other Caucasians in 
frequency of Ile105Val GSTP1 genotypes and could be included in larger interinstitutional 
case-control studies for investigation of the effect of this polymorphism on the susceptibility 
to different diseases, including cancers.  
 
Country/racial origin Allele frequencies Genotype frequencies  















(Vlaykova et al., 2007) 
73 27  54 39 7  
Bulgaria/Caucasian  
(Andonova et al., 2004) 
66 34 0.284 47 38 15 0.182 
Finland/Caucasian  
(Mitrunen et al., 2001) 
74 26 0.873 55 38 7 0.989 
Scotland (UK)/Caucasian 
(Harries et al., 1997) 
72.2 27.8 0.899 51 42.5 6.5 0.906     
Surrey, UK/Caucasian  
(Kote-Jarai et al., 2001) 
70.4 29.6 0.684 51.2 38.5 10.3 0.702 
Newcastle, UK/Caucasian 
(Welfare et al., 1999) 
66.5 33.5 0.318 45 43 12 0.312 
East Anglia, 
UK/Caucasian  
(Loktionov et al., 2001) 
65.5 34.5 0.252 40 49 11 0.128 
Germany/ Caucasian 
(Steinhoff et al., 2000) 
73 27 1.00 55 36 9 0.827 
Sweden/ Caucasian 
(Sorensen et al., 2007) 
69 31 0.534 49 40 11 0.564 
Austria/ Caucasian  
(Gsur et al., 2001)  
63.3 36.7 0.142 39.2 48.2 12.6 0.085 
Portugal/ Caucasian 
(Jeronimo et al., 2002) 
67 33 0.356 43.3 47.5 9.2 0.315 
American non-Hispanic/ 
Caucasian  
(Agalliu et al., 2006) 
66 34 0.284 43 46 11 0.258 
Table 2. Allele and genotype frequencies of the GSTP1 Ile105Val gene polymorphism in 
Bulgarians compared to other Caucasian populations. 
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3.2 GSTM class 
GSTM1 together with the other four GSTM class members (GSTM2, GSTM3, GSTM4 and 
GSTM5) are mapped to 1p13.3 (Pearson et al., 1993; McIlwain et al., 2006; Laborde, 2010). 
The close proximity of GSTM1 and GSTM2, as well as the presence of two almost identical 
4.2-kb regions flanking the GSTM1 gene have been suggested to be the reasons for the 
observed entire GSTM1 gene deletion resulting in a null GSTM1 allele (GSTM1*0) (Pearson 
et al., 1993; Bolt &Thier, 2006). Furthermore, a transversion of G with C at position 534 
(534G>C, formerly noted as 519G>C ) was described leading to a substitution of 172Lys with 
172Asn (formerly Lys173Asn) (McLellan et al., 1997; Bolt &Thier, 2006; McIlwain et al., 2006; 
Gao et al., 2010). This SNP results in two new alleles - GSTM1*A and GSTM1*B, which were 
reported to be functionally identical (McLellan et al., 1997). In addition, a duplication of 
GSTM1 gene has been identified and characterized (GSTM1*1x2 allele) in people who 
displayed ultrarapid GSTM1 activity (McLellan et al., 1997).  
Thus, four allele loci have been described in the human GSТМ1 - GSТМ1*А, GSТМ1*B, 
GSТМ1*0 and GSTM1*1x2, which determine several phenotypes. The frequencies of GSTM1 
alleles and genotypes display race and ethnic variations: 42% to 60% of Caucasians, 41% to 
63% of Asians and only 16% to 36% of Africans are homozygous for GSТМ1*0 (null GSTM1 
genotype) (O'Brien &Tew, 1996; Cotton et al., 2000; He et al., 2004; Hayes et al., 2005; Bolt 
&Thier, 2006; McIlwain et al., 2006; Katoh et al., 2008; Gao et al., 2010). Our results showed 
that the frequency of GSTM1 genotype in Bulgarian control individuals (36% and 42%) 
(Figure 1A) (Dimov et al., 2008; Emin et al., 2009; Vlaykova et al., 2009) is commensurable to 
that reported for some other European populations (Cotton et al., 2000; Ates et al., 2005; 
Katoh et al., 2008; Gao et al., 2010). 
Polymorphic variants have been described for the other GSTM members: GSTM2, GSТМ3, 
GSTM4 and GSTM5 (Inskip et al., 1995; Mitrunen et al., 2001; Reszka &Wasowicz, 2001; 
Hayes et al., 2005; Reszka et al., 2007; Yu et al., 2009; Moyer et al., 2010). The most extensive 
studies have been performed on GSTM3 polymorphisms. This gene has an 
insertion/deletion polymorphism (rs1799735, GSTM3*A/*B) with a wild-type GSТМ3*А 
allele and a variant one, GSТМ3*В, which differ in the rate of expression. The variant 
GSTM3*B allele has 3 bp deletion in intron 6, which introduces a recognition site for YY1 
transcriptional factor and results in enhanced expression of the enzyme protein. (Inskip et 
al., 1995; Loktionov et al., 2001; McIlwain et al., 2006; Reszka et al., 2007). Recently, several 
SNPs in GSTM3 have been identified and studied for their functional activity and in 
association with variety of diseases. These are the rare Gln174Trp (G174W), the more common 
Val224Ile (V224I) substitutions, and the transversion of A with C at -63 position in promoter 
region of GSTM3 (-62A>C) (Liu et al., 2005; McIlwain et al., 2006). The variant 174Trp allele, 
as well as the wild-type 224Val allele, were reported to exhibit decreased catalytic activity, 
whereas the variant -63C allele was associated with increased expression of the gene (Liu et 
al., 2005; McIlwain et al., 2006). 
3.3 GSTT class 
A null polymorphism has also been described in T1 locus of GSTT cluster at 22q11.2. 
Analogously to GSTM1, GSTT1 consisting of 5 exons, is flanked by two highly homologous 
18 kb regions (HA3 and HA5). The null GSTT1*0 allele is possibly caused by a homologous 
recombination resulting in 54 kb deletion containing the entire GSTT1 gene (Sprenger et al.,   
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patients with Balkan endemic nephropathy (Andonova et al., 2004), and for other Caucasian 
type control cohorts in Finland (Mitrunen et al., 2001), Edinburgh area, Scotland (Harries et 
al., 1997), Newcastle and North Tyneside, England (Welfare et al., 1999), East Anglia region 
(Loktionov et al., 2001), etc. (Table 2). Based on these similarities we can conclude that 
despite the heterogeneous origin ethnic Bulgarians do not differ from other Caucasians in 
frequency of Ile105Val GSTP1 genotypes and could be included in larger interinstitutional 
case-control studies for investigation of the effect of this polymorphism on the susceptibility 
to different diseases, including cancers.  
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Fig. 1. Distribution of GSTM1 (A) and GSTT1 (B) null and non-null genotypes in Bulgarian 
patients with CRC and control individuals. Frequency of carriers of GSTM1 and GSTT1 
double null genotype among the patients and controls (C). Data are presented in 
percentages and in real numbers (in brackets); the ORs and the 95% CI are also given.  
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2000; Bolt &Thier, 2006). A SNP (310A>C) in exon 3 of GSTT1 is the reason for substitution 
of Tre104 with Pro104 (Tre104Pro) in GST-theta protein, which was associated with a 
decrease in the catalytic activity possibly due to a conformational changes of the protein 
molecule (Alexandrie et al., 2002). The frequency of the null GSTT1 genotype has also been 
found to vary significantly between different races and ethnic groups: between 13% and 
31% (with some exceptions) in Caucasians in Europe and USA and between 35% and 48% in 
Asians (O'Brien &Tew, 1996; Cotton et al., 2000; He et al., 2004; Hayes et al., 2005; Bolt 
&Thier, 2006; McIlwain et al., 2006; Katoh et al., 2008). Our preliminary results concerning a 
small Bulgarian control group showed homozygosity for GSTT1*0 (GSTT1 null genotype) in 
a rate of only 7% (Dimov et al., 2008; Vlaykova et al., 2009). However, when the control 
group was extended the frequency of GSTT1 null genotype turned out to be 20% (Figure 1B) 
(Emin et al., 2009) which is comparable to other Caucasian populations (Bolt &Thier, 2006; 
Katoh et al., 2008). 
Polymorphic variants have been described also in the second theta-class GST gene, GSTT2. 
Coggan et al. reported a pseudogene (GSTT2P), which rises from G to T transition at nt 841 
(841G>T) in intron 2 of GSTT2 and C to T transition at nt 3255 (3255C>T) in exon 5 of 
GSTT2P changing 196Arg to a stop codon. In addition a G to A transition at nt 2732 
(2732G>A) in exon 4 of GSTT2 was defined that results in substitution of 139Met to 139Ile 
(Met139Ile) (Coggan et al., 1998). However, there is still no clear evidence that the latter SNP 
may have influence on the enzyme function. In the meantime, the defined promoter 
polymorphisms in GSTT2 (-537G>A, -277T>C, -158G>A, and -129T>C) were shown to affect 
the gene expression (Guy et al., 2004; Jang et al., 2007). 
3.4 GSTA class  
Although, variety of polymorphisms of alpha-class GST genes has been defined, their 
functional activity has not yet been comprehensively investigated. Nevertheless, it is already 
proven that the SNPs in the promoter (5’-regulatory) region of GSTA1 (-567, -69, and -52) 
and specifically the substitution at -69C>T (determining a variant GSTA1*B allele), result in 
enhanced promoter activity and increased expression (Coles et al., 2001; Sweeney et al., 
2002; McIlwain et al., 2006). However, for 10 SNPs in the coding regions (exons) of GSTA1 
and GSTA2 was shown to have no significant functional effects (Tetlow et al., 2001). In a 
later study, the new Pro110Ser polymorphism in GSTA2 was found to affect the catalysis 
with several substrates, as the Ser containing isoform has significantly diminished enzyme 
activity (Tetlow &Board, 2004). Similar decrease in the glutathione-conjugating activity was 
also shown for the Leu containing isoform of Ile71Leu (I71L) polymorphism of GSTA3 
(Tetlow et al., 2004).  
3.5 GSTO class 
The omega-class GSTs are coded by 2 genes (GSTO1 and GSTO2) both composed of six 
exons and spread by 7.5 kb on chromosome 10q25.1 (Whitbread et al., 2003; Whitbread et al., 
2005). A total of 26 putative variants have been identified in the coding region of GSTO1 in 
different databases. Among them only 10 have been confirmed candidates and only one 
GSTO1*A140D (A140D, Ala140Asp, 419C>T) has been found in the ethnic group studies 
(Whitbread et al., 2003). In addition a 3-bp deletion polymorphism (AGg from the final GAG 
codone [155E, 155Glu]) has been identified in the boundary of GSTO1 exon4 and intron 4. 
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2000; Bolt &Thier, 2006). A SNP (310A>C) in exon 3 of GSTT1 is the reason for substitution 
of Tre104 with Pro104 (Tre104Pro) in GST-theta protein, which was associated with a 
decrease in the catalytic activity possibly due to a conformational changes of the protein 
molecule (Alexandrie et al., 2002). The frequency of the null GSTT1 genotype has also been 
found to vary significantly between different races and ethnic groups: between 13% and 
31% (with some exceptions) in Caucasians in Europe and USA and between 35% and 48% in 
Asians (O'Brien &Tew, 1996; Cotton et al., 2000; He et al., 2004; Hayes et al., 2005; Bolt 
&Thier, 2006; McIlwain et al., 2006; Katoh et al., 2008). Our preliminary results concerning a 
small Bulgarian control group showed homozygosity for GSTT1*0 (GSTT1 null genotype) in 
a rate of only 7% (Dimov et al., 2008; Vlaykova et al., 2009). However, when the control 
group was extended the frequency of GSTT1 null genotype turned out to be 20% (Figure 1B) 
(Emin et al., 2009) which is comparable to other Caucasian populations (Bolt &Thier, 2006; 
Katoh et al., 2008). 
Polymorphic variants have been described also in the second theta-class GST gene, GSTT2. 
Coggan et al. reported a pseudogene (GSTT2P), which rises from G to T transition at nt 841 
(841G>T) in intron 2 of GSTT2 and C to T transition at nt 3255 (3255C>T) in exon 5 of 
GSTT2P changing 196Arg to a stop codon. In addition a G to A transition at nt 2732 
(2732G>A) in exon 4 of GSTT2 was defined that results in substitution of 139Met to 139Ile 
(Met139Ile) (Coggan et al., 1998). However, there is still no clear evidence that the latter SNP 
may have influence on the enzyme function. In the meantime, the defined promoter 
polymorphisms in GSTT2 (-537G>A, -277T>C, -158G>A, and -129T>C) were shown to affect 
the gene expression (Guy et al., 2004; Jang et al., 2007). 
3.4 GSTA class  
Although, variety of polymorphisms of alpha-class GST genes has been defined, their 
functional activity has not yet been comprehensively investigated. Nevertheless, it is already 
proven that the SNPs in the promoter (5’-regulatory) region of GSTA1 (-567, -69, and -52) 
and specifically the substitution at -69C>T (determining a variant GSTA1*B allele), result in 
enhanced promoter activity and increased expression (Coles et al., 2001; Sweeney et al., 
2002; McIlwain et al., 2006). However, for 10 SNPs in the coding regions (exons) of GSTA1 
and GSTA2 was shown to have no significant functional effects (Tetlow et al., 2001). In a 
later study, the new Pro110Ser polymorphism in GSTA2 was found to affect the catalysis 
with several substrates, as the Ser containing isoform has significantly diminished enzyme 
activity (Tetlow &Board, 2004). Similar decrease in the glutathione-conjugating activity was 
also shown for the Leu containing isoform of Ile71Leu (I71L) polymorphism of GSTA3 
(Tetlow et al., 2004).  
3.5 GSTO class 
The omega-class GSTs are coded by 2 genes (GSTO1 and GSTO2) both composed of six 
exons and spread by 7.5 kb on chromosome 10q25.1 (Whitbread et al., 2003; Whitbread et al., 
2005). A total of 26 putative variants have been identified in the coding region of GSTO1 in 
different databases. Among them only 10 have been confirmed candidates and only one 
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This deletion has the potential to alter the existing splice site, may reform a new splice 
donor site and causes the deletion of 155Glu (GSTO1*E155del) resulting in a loss of heat 
stability and increased enzyme activity toward 2-hydroxyethyl disulphide (HEDS) and 
CDNB (Whitbread et al., 2003). Only one variant in GSTO2 has been confirmed and 
identified in the population studies: this variation results from an A>G transition at nt 424 
(424A>G) and causes a substitution of 142Asn to 142Asp (Asn142Asp, N142D) (Whitbread 
et al., 2003). 
3.6 GSTZ class 
A number of genetic polymorphisms in the gene encoding glutathione S-transferase-zeta 
(GSTZ1) have been defined: G-1002A, Glu32Lys, Gly42Arg, Thr82Met. The latter three SNPs 
are functional and determine four GSTZ1 alleles referred to as GSTZ1*A (32Lys, 42Arg, 
82Thr), GSTZ1*B (32Lys, 42Gly, 82Thr), GSTZ1*C (32Glu, 42Gly, 82Thr), and GSTZ1*D 
(32Glu, 42Gly, 82Met) (Blackburn et al., 2001). The B, C and D alleles have been associated 
with a lower activity to dichloroacetic acid compared to GSTZ1A (Blackburn et al., 2001), but 
non of these SNPs affect significantly the risk of bladder cancer in Spain (Cantor et al., 2010) 
and breast cancer in Germany (Andonova et al., 2009).  
4. Role of GSTs polymorphisms as risk factors for development, progression 
and therapeutic response of CRC 
4.1 GSTP1 
Epidemiological studies of GSTP1 (GSTP1 Ile105Val) and colorectal cancer risk have 
suggested a deleterious effect of the low activity genotypes, but findings have been 
inconsistent (Harries et al., 1997; Welfare et al., 1999; Kiyohara, 2000; Ates et al., 2005; Gao et 
al., 2009; Economopoulos &Sergentanis, 2010).  
The results of our case-control study (Vlaykova et al., 2007) based on 80 patients with 
primary sporadic CRC and 98 unaffected control individuals showed that the genotype 
distribution is consistent with those published for other Caucasian type control cohorts. We 
also found a statistically significant prevalence of heterozygous GSTP1 genotype by itself 
(105Ile/Val – co-dominant model) and the prevalence of variant allele-containing GSTP1 
genotypes (105Ile/Val or 105Val/Val – dominant model) in control group compared to the 
CRC cases. This suggests a protective effect of the variant 105Val allele lowering the risk for 
developing of CRC. Based on our observations and on the experimental evidence reported 
by other research groups for greater activity of the enzyme encoded by the valiant 105Val 
allele toward polycyclic aromatic hydrocarbon (PAH) diol epoxides (Sundberg et al., 1998; 
Coles et al., 2000; Bostrom et al., 2002), we suggest that the heterozygous GSTP1 genotype 
may determine a better protection toward GST-pi-metabolized chemical toxins and reactive 
oxygen species (Vlaykova et al., 2007). This genotype may provide enzyme with an 
adequate detoxification of some and relatively weak activation of other carcinogens, 
depending on their characteristics. 
Two recent large meta-analyses summarized the results focused on the role of GSTP1 
Ile105Val from 16 published case-control studies involving a total of 4386 colorectal cancer 
patients and 7127 controls (Gao et al., 2009) and 19 studies with altogether 5421 cases and 
7671 controls (Economopoulos &Sergentanis, 2010) .The results of the meta-analysis 
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performed by Gao et al. (Gao et al., 2009) sowed no strong evidence that the 105Val allele 
conferred increased susceptibility to colorectal cancer compared to 105Ile allele either in the 
whole pooled case-controls groups or in the stratified one: by race - Caucasian and Asian 
descent; by the type of controls - in healthy and hospital controls. They also did not find 
evidence for an association with colorectal cancer in dominant (OR= 1.02, 95% CI:0.94, 1.10) 
and co-dominant (OR= 0.88 , 95% CI: 0.77, 1.01) models for the effect of Val. Only a slight, 
but significant, protective effect of Val allele was observed in the recessive model 0.86 (95% 
CI: 0.76–0.98). The final conclusion of this large meta-analysis was that GSTP1 Ile105Val 
polymorphism is unlikely to increase considerably the risk of sporadic colorectal cancer 
(Gao et al., 2009).  
Similar are the results and final conclusion of the recent meta-analysis performed by 
Economopoulos et al. (Economopoulos &Sergentanis, 2010): there were no significant effects 
of 105Val allele on the risk of colorectal cancer either in dominant model (OR=1.025, 95% CI: 
0.922–1.138), co-dominant model (OR=1.050, 95% CI: 0.945–1.166), or in the recessive model 
(OR=0.936, 95% CI: 0.823–1.065). Hence, the conclusions confirmed that the GSTP1 Ile105Val 
status did not seem to confer additional risk for colorectal cancer (Economopoulos 
&Sergentanis, 2010). 
4.2 GSTM1 and GSTT1 
Because GST-mu and GST-theta are important in the detoxification of carcinogens 
implicated in colorectal cancer, the absence of these enzymes is assumed to increase the risk 
of this common malignancy. In this regard a number of epidemiological studies have 
investigated the association of GSTM1 and GSTT1 genetic polymorphisms with colorectal 
cancer risk, however the results from these studies have also been with quite controversial 
conclusions (Cotton et al., 2000; Economopoulos &Sergentanis, 2010; Gao et al., 2010). The 
preliminary results from our study including very limited number of patients and controls 
(45 and 42), showed a statistically significant case-control difference in the presence of 
GSTT1 null genotype (0.30 vs. 0.07, p=0.006), and only a tendency for prevalence of GSTM1 
null genotype in CRC patient (0.57 vs. 0.36, p=0.052) (Vlaykova et al., 2009). The combined 
null genotypes were determined only in patients (0.20), whereas none of the control 
individual was with such genotype (p<0.0001). We found a 5.69-fold (95% CI, 1.59-20.00) 
and 2.34-fold (95% CI, 0.99-5.49) increased risk associated with GSTT1 and GSTM1 null 
genotypes, respectively and 21.533-fold (95% CI, 3.56-128.71) increased risk associated with 
the combined null genotypes. The colorectal cancer was diagnosed earlier in patients with 
GSTM1 null genotype and those patients had tumors in more advanced stage (III or IV) 
(p=0.033) and were with more aggressive phenotype, such as presence of lymph vessel 
invasion (p=0.042) than the patients with non-null genotype. 
A slight difference was obtained when the control group was extended to 81 persons (Figure 
1A, 1B and 1C): the null GSTT1 and GSTM1 genotypes turned out only to tend to associate 
with an increased risk of colorectal cancer (OR=1.797, 95% CI 0.86-3.72, p=0.116 for GSTM1, 
and OR=1.777, 95% CI 0.78-4.05, p=0.175 for GSTT1), however the carriers of GSTM1 and 
GSTT1 double null genotype had significantly higher risk of development of the disease 
(OR=3.697, 95% CI 1.21-11.28, p=0.021) (Figure 1C). As a conclusion, we suggested that the 
inherited simultaneous lack of GST-theta and GST-mu detoxifying enzymes due to the 
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performed by Gao et al. (Gao et al., 2009) sowed no strong evidence that the 105Val allele 
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CI: 0.76–0.98). The final conclusion of this large meta-analysis was that GSTP1 Ile105Val 
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presence of homozygous null genotypes may be associated with development of sporadic 
colorectal cancer (Vlaykova et al., 2009). 
Our findings are analogous to the one of meta-analyses performed on a large number of 
published case-control studies. The results of these meta-analyses support the suggestion 
that GSTM1 and GSTT1 null polymorphisms are associated with increased risk of CRC, 
especially in the Caucasian population (Economopoulos &Sergentanis, 2010; Gao et al., 
2010). Economopoulos et al. have summarized the results from 44 studies for GSTM1 and 34 
for GSTT1 null polymorphisms and concluded that GSTM1 null genotype carriers exhibited 
increased colorectal cancer risk in Caucasian population (OR=1.15, 95% CI: 1.06-1.25), but 
not in Chinese subjects (OR=1.03, 95% CI: 0.90-1.16). They reported similar results for GSTT1 
null polymorphism: OR=1.31, 95% CI:1.12-1.54 for Caucasian population and OR=1.07, 95% 
CI:0.79-1.45 for Chinese subjects (Economopoulos &Sergentanis, 2010). Gao at al., carried 
out a meta-analysis of GSTM1 genotype data from 36 studied including 9149 patients with 
CRC and 13 916 control individuals (Gao et al., 2010). The results indicated that GSTM1 null 
genotype was associated with CRC (OR=1.13, 95% CI: 1.03–1.23) in the pooled cases and 
controls from a number of different ethnics groups. However, the significance of this 
association remained for Caucasians, but not for Asians (Gao et al., 2010). 
4.3 GSTA1, GSTM3, GSTO2 
According to our knowledge there are only a limited number of studies aiming to evaluate 
the possible role of polymorphisms in the genes encoding other GST isoforms as 
predisposing factors for colorectal cancer. The polymorphisms in GSTA1 have been 
explored in colorectal cancer only by four research teams (Sweeney et al., 2002; van der Logt 
et al., 2004; Martinez et al., 2006; Kury et al., 2008) . The Sweeney at al. have found that the 
GSTA1*B/*B (promoter polymorphisms) genotype is associated with an increased risk of 
colorectal cancer, particularly among consumers of well-done meat and have suggested that 
GSTA1 genotype, in addition to the CYP2A6 phenotype should be evaluated as markers for 
susceptibility to dietary carcinogens (Sweeney et al., 2002). However, other studies did not 
find any associations between the GSTA1 polymorphisms and the risk of CRC (van der Logt 
et al., 2004; Martinez et al., 2006; Kury et al., 2008).  
Kury et al., and Martinez at al, have also attempted to elucidate the influence of GSTM3 
genetic variants on colorectal cancer risk, however no correlation between these 
polymorphisms and CRC susceptibility was found (Martinez et al., 2006; Kury et al., 2008). 
Similarly, no effect of GSTM3 polymorphism was found in a large study investigating the 
role of single SNPs within 11 genes of phase I and 15 genes of phase II of xenobiotic 
metabolism (Landi et al., 2005). Opposite results have been reported for 
GSTM3*A/GSТМ3*В alleles (the latter arising from a 3 bp deletion in intron 6): patients who 
were carriers of genotypes with at least one GSTM3*B allele (GSTM3 AB and GSTM3 BB 
combined) had advanced tumour T-stage, increasing Dukes' stage, higher frequency of 
distant metastases and shorter survival (Holley et al., 2006) Thus, the GSTM3 AA genotype 
was suggested to be associated with improved prognosis of CRC especially in patients with 
GSTM1 null genotype (Holley et al., 2006). Analogous results have been reported by 
Loktionov et al. who found associations between GSTM3*B frequency in patients with distal 
colorectal cancers particularly when combined with the GSTM1 null genotype (Loktionov et 
al., 2001).  
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A very recent study investigated the association between GSTO2 N142D (Asn142Asp) genetic 
polymorphism and susceptibility to colorectal cancer and reported that ND and DD 
genotypes were not associated with CRC risk, in comparison with the NN genotype. 
However subjects with NN genotype and positive family history were at high risk to 
develop colorectal cancer in comparison with subjects with DD or ND genotypes and 
negative family history. Thus, GSTO2 NN genotype was suggested to increase the risk of 
colorectal cancer in persons with positive family history for cancer in the first degree 
relatives (Masoudi et al., 2010).  
The common characteristic of the theta-class GSTs is their high affinity for the organic 
hydroperoxide species and particularly toward cumene hydroperoxide (GSTT2), underling 
the importance of GSTT2 activity in protection of cells against toxic ROS and lipid 
peroxidation products (Tan &Board, 1996), which are a major source of endogenous DNA 
damage and thus contribute significantly to cancer genesis and progression. In this respect 
efforts have been done to determine whether GSTT2 promoter SNPs (-537G>A, -277T>C and 
-158G>A) are associated with colorectal cancer risk (Jang et al., 2007). Jang at al., reported 
that -537A allele was associated with colorectal cancer risk, while the -158A allele was 
protective against colorectal cancer, finally suggesting that SNPs and haplotypes of the 
GSTT2 promoter region are associated with colorectal cancer risk in the Korean population 
(Jang et al., 2007). However, in a Caucasian population there was no such association of 
GSTT2 polymorphisms with the risk of CRC (Landi et al., 2005) 
5. Role of GST-pi in cancer progression  
The isoenzyme of class pi, GST-pi, acidic cytosolic protein, possesses unique enzymatic 
properties: broad substrate specificity (e.g. alkylating antitumor agents such as cisplatin 
derivatives), glutathione peroxidase activity towards lipid hydroperoxides, and high 
sensitivity to reactive oxygen species (ROS) (Tsuchida &Sato, 1992; de Bruin et al., 2000; 
Hoensch et al., 2002). As it was discussed above, GST-pi acts also non-catalytically as 
intracellular binding protein for a large number of non-substrate molecules of either 
endogeneous or exogeneous origin, thus contributing to their intracellular transport, 
sequestration and disposition (Laisney et al., 1984; de Bruin et al., 2000; Hayes et al., 2005). 
Besides that, GST-pi plays a regulatory role in the MAP kinase pathway that participates 
in cellular survival and death signals via direct protein:protein interaction with c-Jun-N-
terminal Kinase 1 (JNK1) and Apoptosis Signal-regulating Kinase (Ask1) (Adler et al., 
1999; Tew &Ronai, 1999; Townsend &Tew, 2003; Hayes et al., 2005; Michael &Doherty, 
2005). 
Therefore, the increased protein levels and activity of GST-pi found in a variety of neoplastic 
cancers with different histological origins, including colorectal carcinoma (Moorghen et al., 
1991; Ranganathan &Tew, 1991; de Bruin et al., 2000; Dogru-Abbasoglu et al., 2002; Murtagh 
et al., 2005), are debated as factors responsible, at least partly, for the progression and 
chemotherapy resistance, observed in many cancers (O'Brien &Tew, 1996; Tew &Ronai, 
1999; Townsend &Tew, 2003; Michael &Doherty, 2005). 
Earlier we reported our preliminary results concerning the survival of 76 patients with 
primary CRC according to the level of expression of GST-pi determined by 
immunohistochemistry (Vlaykova et al., 2005). Further we extended the patient population 
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to 132 and found that the tumors varied according to their GST-pi immune staining: there 
were tumors negative for GST-pi, others had weak staining and finally tumors exhibiting 








Fig. 2. Intensive cytoplasmic immune reaction for GST-pi in the cells of the tumor glands of 
a well-differentiated primary colorectal cancer (х 400). 
The results concerning survival of the patients with CRC with different level of expression 
of GST-pi, showed that the higher expression of GST-pi was significantly associated with 
shorter survival period after surgical therapy (median of 19 months) compared to those 
negative or with weak GST-pi staining (median of 58 months, p=0.004, Log-rang test) 
(Figure 3A). This statistically significant association persisted also after stratification for 
pTNM staging (stage I/II vs. Stage III/IV, p=0.005, Log-rank test) (Figure 3B).  
Interestingly, the strong expression of GST-pi retained its impact as unfavorable prognostic 
factor both for the patients who received an adjuvant chemotherapy (n=63, p=0.008, Log-
rank test) (Figure 4A) and for the once without such treatment (n=66, p=0.019, Log-rank 
test) (Figure 4B). Hence, we suggested that the strong expression of GST-pi may lead to 
lower effectiveness of the administered anticancer drugs or to inhibiting the apoptosis, thus 
influencing the survival of the patients.  
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Fig. 3. Survival of the whole studied patient population with colorectal carcinoma after 
surgical treatment according to the level of expression of GST-pi in tumor cells (A) and after 
stratification to pTNM staging (B).  
 
Colorectal Cancer Biology – From Genes to Tumor 
 
94
to 132 and found that the tumors varied according to their GST-pi immune staining: there 
were tumors negative for GST-pi, others had weak staining and finally tumors exhibiting 








Fig. 2. Intensive cytoplasmic immune reaction for GST-pi in the cells of the tumor glands of 
a well-differentiated primary colorectal cancer (х 400). 
The results concerning survival of the patients with CRC with different level of expression 
of GST-pi, showed that the higher expression of GST-pi was significantly associated with 
shorter survival period after surgical therapy (median of 19 months) compared to those 
negative or with weak GST-pi staining (median of 58 months, p=0.004, Log-rang test) 
(Figure 3A). This statistically significant association persisted also after stratification for 
pTNM staging (stage I/II vs. Stage III/IV, p=0.005, Log-rank test) (Figure 3B).  
Interestingly, the strong expression of GST-pi retained its impact as unfavorable prognostic 
factor both for the patients who received an adjuvant chemotherapy (n=63, p=0.008, Log-
rank test) (Figure 4A) and for the once without such treatment (n=66, p=0.019, Log-rank 
test) (Figure 4B). Hence, we suggested that the strong expression of GST-pi may lead to 
lower effectiveness of the administered anticancer drugs or to inhibiting the apoptosis, thus 
influencing the survival of the patients.  
 
















0 20 40 60 80 100 120
Survival after surgery (months)


















0 20 40 60 80 100 120
Survival after surgery (months)
stage I/II and w eak GST-pi (n=62)
stage I/II and strong GST-pi (n=25)
p=0.005
stage III/IV and w eak GST-pi (n=23)
stage III/IV and strong GST-pi (N=19)
 
B 
Fig. 3. Survival of the whole studied patient population with colorectal carcinoma after 
surgical treatment according to the level of expression of GST-pi in tumor cells (A) and after 
stratification to pTNM staging (B).  
 
















0 10 20 30 40 50 60 70 80
Survival after surgery (months)



















0 20 40 60 80 100 120
Survival after surgery (months)






Fig. 4. Survival according to the GST-pi expression of patients with CRC subjected to 
adjuvant chemotherapy (A), Association between the level of expression of GST-pi and 
survival of patients, who did not receive adjuvant chemotherapy (B). 
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Previously, we also described expression of GST-pi in chromogranin A-positive endocrine 
cells in colorectal cancers, which also expressed some other antioxidant enzymes, such as 
SOD1 and SOD2 (Gulubova &Vlaykova, 2010). Moreover, we found that patients having 
tumors with GST-pi-positive endocrine cells have an unfavorable prognosis. We suggest 
that not the neuroendocrine differentiation in general, but the presence of endocrine cells 
with activated antioxidant defense and probably higher metabolic activity might determine 
a more aggressive type of cancer leading to worse prognosis for patients (Gulubova 
&Vlaykova, 2010). 
The observed heterogeneous expression of GST-pi in tumor glands could be due to different 
genetic or epigenetic factors. We suppose that the reactive oxygen species, which are generated 
in high amount during the metabolism of tumor cells could be such factors resulting in 
overproduction of GST-pi . These ROS are found to induce the expression of the genes of GST-
pi and other phase II xenobiotic-biotransformating enzymes (O'Brien &Tew, 1996; Tew 
&Ronai, 1999; Hoensch et al., 2002). There is a growing evidence that these genes have 
regulatory sequences recognized by Nrf2 transcription factor, which in turn is regulated by the 
antioxidant response element (ARE) (O'Brien &Tew, 1996; Tew &Ronai, 1999; Hoensch et al., 
2002). Another Zn-dependent mechanism for ROS-induced expression of genes coding GST-pi 
and other antioxidant enzymes has been proposed (Chung et al., 2005). 
Another factor, resulting in overproduction of GST-pi, could be its gene amplification. Such 
genetic change has been proven for squamous cell carcinoma of head and neck. GSTP1 
amplification has been shown to be a common event and proposed to be associated with 
cisplatin resistance and poor clinical outcome in head and neck cancer patients treated with 
cisplatin-based therapy (Wang et al., 1997; Cullen et al., 2003).  
On the other hand, the lack of or the low expression of GST-pi could be due to the somatic 
inactivation by hypermethylation of promoter sequences of GST-pi gene (Yang et al., 2003; 
Lasabova et al., 2010). Such hypermethylation is the most common event (about 90%) 
described in prostate adenocarcinoma (Jeronimo et al., 2002).  
The results of our studies demonstrated the association between high expression level of 
GST-pi and unfavorable prognosis for the patients with colorectal carcinoma. This 
association was valid both for patients who had received adjuvant chemotherapy and for 
those without such treatment. We suppose that the shorter survival of patients with higher 
GST-pi could be due to lowering of the effectiveness of administered antineoplastic agents. 
The high protein level of GST-pi could contribute to this process either via its direct 
detoxifying effect towards some of the drugs (oxaliplatin) (O'Brien &Tew, 1996; Michael 
&Doherty, 2005), or via the inhibitory effect of GST-pi on MAP kinase signal pathways of 
apoptosis, triggered by 5-FU, mitomicin C, camtothecin or other antitumor drugs included 
in mono- or polychemotherapeutic regiments (Adler et al., 1999; Townsend &Tew, 2003; 
Hayes et al., 2005; Michael &Doherty, 2005). 
The observed association of high GST-pi level with worse prognosis of the patients, who did 
not received chemotherapy, could also be explained with the ability of this enzyme protein 
directly to interact with and inhibit proteins involved in regulation of apoptosis (JNK1 and 
Ask1) (Adler et al., 1999; Townsend &Tew, 2003; Hayes et al., 2005; Michael &Doherty, 
2005). In tumors, the high levels of free radicals, which in general are triggering factors and 
mediators of apoptosis, probably stimulate the expression of GST-pi that can lead to 
suppression of apoptosis. As a result, the decreased apoptosis can lead to increased tumor 
burden, which negatively affects patients survival.  
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family are important candidates for involvement in susceptibility to carcinogen-associated 
CRC and for developing of tumor chemotherapy resistance. In this work we presented a 
short overview of the main cellular functions of some of the GST isoenzymes, their 
polymorphic nature, and their role as risk factors for development of CRC and of resistance 
to chemotherapy. We also presented the results of our studies focused on the role of the null 
GSTM1 and GSTT1 polymorphisms, the Ile105Val SNP in GSTP1 and GST-pi expression as 
risk and prognostic factors in primary CRC. In conclusion, we suggest that the expression 
level of GST-pi in primary tumors could be a valuable prognostic factor for patients with 
colorectal carcinoma both treated with adjuvant chemotherapy and those not subjected to 
such therapy.  
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1. Introduction  
Colorectal cancer (CRC) is the third most frequent cancer type and the second leading cause 
of cancer-related deaths worldwide (Cunningham et al., 2010; Jemal et al., 2010). This is 
despite the recent trend of stabilizing or declining rates for CRC incidence and mortality in 
economically developed countries (Center et al., 2009; Edwards et al., 2010; Umar & 
Greenwald, 2009). Surgical intervention is the initial treatment for most CRC patients. 
Continuous efforts to optimize surgery for patients with localized CRC has resulted in 
markedly improved 5-year and 10-year survival rates (Cunningham et al., 2010; Wu & Fazio, 
2000). Given the large number of CRC patients who undergo curative surgery, there is now 
a substantial number who are susceptible to recurrent or metastatic tumors and could 
therefore benefit from additional systemic therapies. An increasing array of options and 
protocols for chemotherapies and biologically targeted therapies is now available for use in 
the adjuvant setting and for the treatment of recurrent and metastatic CRC. 
Based on a more detailed knowledge of the molecular characteristics of CRC (Markowitz et 
al., 2009; Walther et al., 2009), biologically-based therapeutics have been developed for the 
treatment of advanced stage CRC patients. Currently approved agents for the treatment of 
advanced and metastatic CRC include therapeutic monoclonal antibodies that target 
vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). 
Despite a substantial biological rationale for the use of these new classes of therapeutic 
agents, large-scale clinical trials have observed only incremental clinical benefits for overall 
patient populations. Clearly, not all patients with recurrent and metastatic CRC benefit from 
these therapies. This is due to inherent and acquired resistance of tumors to the 
chemotherapeutic and biologically-based agents. Moreover, there are few reliable markers 
for predicting the therapeutic and adverse effects of these agents and that would allow 
patients who benefit from these systemic treatments to be identified. Therefore, new 
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therapeutic targets are urgently required to further improve the survival of patients with 
recurrent and metastatic CRC. One such target may be glycogen synthase kinase 3β 
(GSK3β), a serine/threonine protein kinase that has recently been implicated in various 
human cancers.  
In this Chapter, we briefly summarize the scientific basis and current status of systemic 
treatments for CRC, including combinations of surgery, chemotherapy and molecular 
target-directed therapy. Based on our published and ongoing studies, we then focus on 
GSK3β as an emerging therapeutic target in CRC and other cancer types. We describe the 
underlying biological mechanism that allows exploration of a novel therapeutic strategy for 
CRC involving the targeting of aberrant GSK3β. 
2. Molecular basis of colorectal cancer 
2.1 Multistep and multiple molecular alterations 
Colorectal carcinogenesis displays all the major biological hallmarks of cancer (Hanahan & 
Weinberg, 2011). CRC evolves and develops through orchestrated, multistep genetic and 
epigenetic alterations in oncogenes, tumor suppressor genes and DNA mismatch repair 
genes. These include frequent aberrations in certain chromosomes, such as allelic imbalance 
at several chromosomal loci (e.g., chromosome 5q, 8p, 17p, 18q) and chromosome 
amplification and translocation. Various combinations of somatic and germ-line alterations 
in these genes and chromosomes characterize the different genotypes and phenotypes of 
sporadic and hereditary forms of CRC (Cunningham et al., 2010; Markowitz & Bertagnolli, 
2009; Walther et al., 2009). Among the genes involved in the molecular process of CRC 
development, several genetic markers have been reported to harbor diagnostic and 
prognostic information and to predict the benefit from or resistance to systemic therapy 
(Ellis & Hicklin, 2009; Markowitz & Bertagnolli, 2009; Walther et al., 2009). 
Recent advances in DNA sequencing technology have allowed sequencing of the entire 
coding genome of human cancer to become a reality. The high throughput, next-generation 
sequencing of 18,000 genes in the Reference Sequence data-base of the National Center for 
Biotechnology Information in the USA has identified cancer-associated somatic mutations in 
848 genes. Amongst these, 140 are considered as candidate genes responsible for the 
development and phenotype of CRC (Sjőblom et al., 2006; Wood et al., 2007). 
2.2 Oncogene addiction 
The unrestrained survival and proliferation of cancer cells relies on distinct oncogenic 
signalling pathways in which various oncoproteins, growth factor receptors and their 
ligands are aberrantly activated, leading to the concept of “oncogene addiction” (Sharma & 
Settleman, 2007; Weinstein, 2002; Weinstein & Joe, 2006). In theory, acute ablation of 
oncogene function should lead to the rapid dissipation of its pro-survival signal in cancer 
cells, thus resulting in apoptotic cell death. This “oncogenic shock” concept underlies the 
strategy of molecular targeting in cancer therapy (Sharma et al., 2006). The scientific 
rationale behind the development and application of therapeutic monoclonal antibodies 
targeting VEGF and EGFR for the treatment of CRC is based on these concepts. Intriguingly, 
however, the EGFR expression level in primary CRC determined by immunohistochemistry 
was not observed to correlate with the efficacy of therapeutic anti-EGFR antibodies in 
clinical trials of metastatic CRC (Hecht et al., 2010; commented by Grothey, 2010). 
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3. Systemic treatment: An overview 
Surgery remains the cornerstone for the cure of localized CRC (Cunningham et al., 2010; Wu 
& Fazio, 2000). For colon cancer, total resection of the primary tumor with ample surgical 
margins and regional lymphadenectomy are the requisites for curative surgery. For rectal 
cancer, curative resection includes total excision of the mesorectum with adequate 
circumferential and distal surgical margins (R0) and lymphadenectomy along the inferior 
mesenteric vessels. Laparoscopic surgery has now become prevalent and safe, with long-
term oncological outcomes of CRC patients undergoing this surgery reported as comparable 
to those treated by the open surgical approach (Lacy et al., 2008; The Clinical Outcomes of 
Surgical Therapy Study Group, 2004). Within 5 years after curative surgical resection, 
disease relapse (tumor recurrence or metastasis) occurs in 40 to 50% of patients with stage III 
CRC and in 20% of those with stage II CRC (Midgley & Kerr, 1999). Systemic therapy with 
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markers 














Table 1. Key agents and their combinations presently used for the treatment of CRC 
Abbreviations: AREG, amphyregulin; DPD, dihydropyrimidine dehydrogenase; EGFR, epidermal 
growth factor receptor; ERCC-1, excision-repair cross-complementing-1; EREG, epiregulin; 5-FU, 5-
fluorouracil; FOLFIRI, folinate, 5-FU and irinotecan; FOLFOX, folinate, 5-FU and oxaliplatin; 
FOLFOXIRI, FOLFOX and irinotecan; LV, leukovorin; PI3KCA, phosphoinositide 3 kinase (PI3K) p110 
catalytic subunit gene; PO, postoperative; TP, thymidine phosphorylase; TS, thymidylate synthase;  
UGT1A1, uridine diphosphate (UDP)-glucuronosyltransferase 1A1; VEGF, vascular endothelial growth 
factor.  
* The number of TA repeats in the TATA element in UGT1A1 gene predicts the drug toxicity and 
resultant adverse effects. 
** EGFR copy number is measured by fluorescence in-situ hybridization (FISH). 
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3. Systemic treatment: An overview 
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Table 1. Key agents and their combinations presently used for the treatment of CRC 
Abbreviations: AREG, amphyregulin; DPD, dihydropyrimidine dehydrogenase; EGFR, epidermal 
growth factor receptor; ERCC-1, excision-repair cross-complementing-1; EREG, epiregulin; 5-FU, 5-
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either chemotherapy and/or targeted therapies have been demonstrated to provide benefit 
to these CRC patients in both the post-operative adjuvant and advanced disease settings 
(Inoue et al., 2006; Midgley et al., 2009). Table 1 summarizes the key chemotherapeutic 
agents and therapeutic monoclonal antibodies targeting VEGF and EGFR and the 
combinations currently prescribed as adjuvant therapy for relapse-prone CRC patients and 
patients with metastatic tumors (reviewed in Cunningham et al., 2010; Meyerhardt & 
Mayer, 2005; Midgley et al., 2009; Wolpin et al., 2007; Wolpin & Mayer, 2008). The putative 
predictive markers for response to the respective agents are also shown in Table 1 (Walther 
et al., 2009). 
3.1 Adjuvant chemotherapy 
The purpose of postoperative adjuvant chemotherapy for stage II or III CRC is to destroy 
residual tumor cells and/or micrometastatic foci that are latent at the time of curative 
surgery. The chemotherapeutic mainstay for CRC, 5-fluorouracil (5-FU), exerts its anti-
tumor effect by inhibiting thymidylate synthase (TS), a critical enzyme for nucleic acid 
synthesis. Folinic acid (leucovorin: LV) is frequently used to enhance the anti-tumor effect of 
5-FU. The clinical and pharmacological rationale for this combination derives from the 
biological role of LV in stabilizing the ternary complex between TS and fluoro-deoxyuridine 
monophosphate (dUMP), an active metabolite of 5-FU, thereby enhancing TS inhibition. 
Adjuvant treatment regimens consist of oral (capecitabine) or infusional fluoropyrimidine-
based chemotherapy as a single agent with LV, or in combination with irinotecan (a 
topoisomerase I inhibitor), oxaliplatin (a DNA cross-linker) or both (Table 1) (Midgley et al., 
2009; Wolpin et al., 2007; Wolpin & Mayer, 2008).  
Adjuvant fluoropyrimidine-based chemotherapy reduces the risk of cancer-related mortality 
by 30% and increases the 5-year survival rate by 5-12% in patients with stage III (node-
positive) CRC. Adjuvant chemotherapy for stage II (node-negative) CRC patients is 
controversial because it increases the 5-year survival rate by just 3-4%. It has been proposed 
that “high-risk” stage II CRC patients characterized by T4 tumor, luminal stenosis or 
obstruction, poor histological differentiation, extramural vessel invasion, inadequate 
lymphadenectomy or surgical margins (R1) should preferentially undergo adjuvant 
chemotherapy (Cunningham et al., 2010; Midgley et al., 2009). Tumor relapse after curative 
resection occurs mostly within 3 years, irrespective of adjuvant chemotherapy (Sargent et 
al., 2007). Several clinical trials have failed to show a survival benefit from combining 
molecular target-directed agents (e.g., bevacizumab, cetuximab) with adjuvant 
chemotherapy (reviewed in Cunningham et al., 2010). Improvement in the survival of 
patients at high risk of tumor relapse therefore depends on intensive surveillance for early 
diagnosis of metastatic lesions, as well as identification of patients who are susceptible to 
tumor recurrence and who could thus benefit from more aggressive adjuvant treatment. 
3.2 Treatment of metastatic CRC 
A series of systemic, fluoropyrimidine-based combinatorial chemotherapies (Table 1) has 
substantially improved tumor response to treatment and increased the duration of 
progression-free and overall survival in patients with metastatic CRC. The remarkable 
advance in treating metastatic CRC in recent years has been due to the emergence and 
clinical application of molecular targeted therapeutics (Cunningham et al., 2010; Midgley et 
al., 2009). As stated above, a number of therapeutic monoclonal antibodies that target 
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relevant oncogenic pathways have been tested in clinical trials for CRC. Among them, the 
most widely used agents are bevacizumab, a recombinant humanized monoclonal antibody 
against VEGF (Ellis & Hicklin, 2008a; Li & Saif, 2009), cetuximab, a chimeric monoclonal 
antibody against EGFR (Balko et al, 2010) and panitumumab, a fully humanized monoclonal 
antibody against EGFR (Davis & Jimeno, 2010). These therapeutic antibodies have been used 
as monotherapy for the treatment of patients with metastatic CRC, or in combination with 
systemic chemotherapy (Table 1). Many clinical trials have demonstrated the additive effect 
of these antibodies on tumor response rate and progression-free survival (reviewed in 
Cunningham et al., 2010; Midgley et al., 2009). However, the combination of each 
therapeutic antibody with systemic chemotherapy regimens produced incremental but not 
always robust benefits to overall survival when compared to chemotherapy alone (Fojo & 
Parkinson, 2010). 
3.3 Obstacles to systemic therapy 
3.3.1 Drug resistance and predictive markers 
The major obstacles to systemic therapy for CRC include drug resistance (both inherent and 
acquired) and the lack of reliable biomarkers for predicting response or resistance to drugs 
in clinical use (Ellis & Hicklin, 2009). This has led to the recent trend of using intensive 
combinatorial regimens for advanced CRC patients. Surprisingly, some recent clinical trials 
have shown that combinatorial target-directed therapies resulted in decreased survival, 
inferior quality of life and unexpected detrimental effects (Douillard et al., 2010; Hecht et al., 
2009; Li & Saif, 2009; Tol et al., 2009).  
Understanding the molecular mechanisms that underlie drug resistance and identifying 
predictive markers for drug sensitivity are one and the same thing. Pharmacogenomic 
approaches (Furuta et al., 2009; Walther et al., 2009) have identified a number of factors 
involved in drug metabolism and secretion, some of which (e.g., UGT1A1 polymorphism) 
have been tested in clinical practice (Table 1). Several studies have suggested various 
biological mechanisms of resistance to VEGF-targeted cancer therapies (Bergers & Hanahan, 
2008; Ebos et al., 2008; Ellis & Hicklin, 2008b), but to date there are no clinically useful 
predictive markers. Mutational activation of oncogenic pathways that lie downstream of 
EGFR signaling is known to cause intrinsic resistance to therapies that target this receptor. 
This has led to the identification of predictive markers (e.g., K-ras, B-raf, PIK3CA) that allow 
better patient selection for such treatments (Banck & Grothey, 2009; Cantwell-Dorris et al., 
2011; De Roock et al., 2010a; Sartore-Bianchi et al., 2009). However, the complex pathways 
involved in tumor progression are often intercalated and therefore single markers cannot 
accurately predict the efficacy or outcome of CRC patients undergoing molecular targeted 
therapies (Baldus et al., 2010; De Roock et al., 2010b; Hecht et al., 2010). 
Research into the mechanisms of acquired resistance to molecular targeted agents has 
generated new therapeutic strategies and agents aimed at counteracting the resistance 
mechanism (Bowles & Jimeno, 2011; Cidón, 2010; Dasari & Messersmith, 2010; Presen et al., 
2010). Thus, improving the anti-tumor effects of molecular targeted therapies will depend 
on the identification of novel molecular pathways, development of new classes of rationally 
designed biological agents, and identification of predictive markers for response and 
resistance. 
3.3.2 Economic issues 
The high cost of developing the biologically-based therapeutic agents shown in Table 1 is a 
major issue in light of the modest clinical benefits, acquired drug resistance and lack of 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
110 
either chemotherapy and/or targeted therapies have been demonstrated to provide benefit 
to these CRC patients in both the post-operative adjuvant and advanced disease settings 
(Inoue et al., 2006; Midgley et al., 2009). Table 1 summarizes the key chemotherapeutic 
agents and therapeutic monoclonal antibodies targeting VEGF and EGFR and the 
combinations currently prescribed as adjuvant therapy for relapse-prone CRC patients and 
patients with metastatic tumors (reviewed in Cunningham et al., 2010; Meyerhardt & 
Mayer, 2005; Midgley et al., 2009; Wolpin et al., 2007; Wolpin & Mayer, 2008). The putative 
predictive markers for response to the respective agents are also shown in Table 1 (Walther 
et al., 2009). 
3.1 Adjuvant chemotherapy 
The purpose of postoperative adjuvant chemotherapy for stage II or III CRC is to destroy 
residual tumor cells and/or micrometastatic foci that are latent at the time of curative 
surgery. The chemotherapeutic mainstay for CRC, 5-fluorouracil (5-FU), exerts its anti-
tumor effect by inhibiting thymidylate synthase (TS), a critical enzyme for nucleic acid 
synthesis. Folinic acid (leucovorin: LV) is frequently used to enhance the anti-tumor effect of 
5-FU. The clinical and pharmacological rationale for this combination derives from the 
biological role of LV in stabilizing the ternary complex between TS and fluoro-deoxyuridine 
monophosphate (dUMP), an active metabolite of 5-FU, thereby enhancing TS inhibition. 
Adjuvant treatment regimens consist of oral (capecitabine) or infusional fluoropyrimidine-
based chemotherapy as a single agent with LV, or in combination with irinotecan (a 
topoisomerase I inhibitor), oxaliplatin (a DNA cross-linker) or both (Table 1) (Midgley et al., 
2009; Wolpin et al., 2007; Wolpin & Mayer, 2008).  
Adjuvant fluoropyrimidine-based chemotherapy reduces the risk of cancer-related mortality 
by 30% and increases the 5-year survival rate by 5-12% in patients with stage III (node-
positive) CRC. Adjuvant chemotherapy for stage II (node-negative) CRC patients is 
controversial because it increases the 5-year survival rate by just 3-4%. It has been proposed 
that “high-risk” stage II CRC patients characterized by T4 tumor, luminal stenosis or 
obstruction, poor histological differentiation, extramural vessel invasion, inadequate 
lymphadenectomy or surgical margins (R1) should preferentially undergo adjuvant 
chemotherapy (Cunningham et al., 2010; Midgley et al., 2009). Tumor relapse after curative 
resection occurs mostly within 3 years, irrespective of adjuvant chemotherapy (Sargent et 
al., 2007). Several clinical trials have failed to show a survival benefit from combining 
molecular target-directed agents (e.g., bevacizumab, cetuximab) with adjuvant 
chemotherapy (reviewed in Cunningham et al., 2010). Improvement in the survival of 
patients at high risk of tumor relapse therefore depends on intensive surveillance for early 
diagnosis of metastatic lesions, as well as identification of patients who are susceptible to 
tumor recurrence and who could thus benefit from more aggressive adjuvant treatment. 
3.2 Treatment of metastatic CRC 
A series of systemic, fluoropyrimidine-based combinatorial chemotherapies (Table 1) has 
substantially improved tumor response to treatment and increased the duration of 
progression-free and overall survival in patients with metastatic CRC. The remarkable 
advance in treating metastatic CRC in recent years has been due to the emergence and 
clinical application of molecular targeted therapeutics (Cunningham et al., 2010; Midgley et 
al., 2009). As stated above, a number of therapeutic monoclonal antibodies that target 
 
Distinct Pathologic Roles for Glycogen Synthase Kinase 3 in Colorectal Cancer Progression 
 
111 
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suitable predictive markers. A recent study reported significantly higher hospital costs for 
CRC patients with recurrence compared to those without (Macafee et al., 2009). Outside of 
the United States, the high cost of molecular targeted drugs has restricted their use to 
patients with sufficient income and/or health insurance. This issue highlights the 
importance of accurate predictive markers that allow identification of patients who are most 
likely to benefit from targeted agents, thus improving the cost effectiveness. 
4. GSK3 as an emerging therapeutic target 
4.1 GSK3 biology 
GSK3 was identified as a serine/threonine protein kinase that phosphorylates and inhibits 
glycogen synthase (GS), a rate-limiting enzyme in the regulation of glucose/glycogen 
metabolism in response to insulin-mediated signaling (Embi et al., 1980). In contrast to its 
original name and depending on its substrates and binding partners (Table 2) (Medina & 
Wandosell, 2011; Xu et al., 2009), GSK3 has been found to participate in many fundamental 
cellular pathways including proliferation, differentiation, motility, cell cycle and apoptosis 
(Doble & Woodgett, 2003; Harwood, 2001; Jope & Johnson, 2004; Nakada et al., 2011). The 
two isoforms of this kinase, GSK3α and GSK3β, are encoded by their respective genes. Their 
functions do not always overlap (Rayasam et al., 2009) and much recent attention has been 
directed towards the function of GSK3β.  
Unlike most protein kinases, GSK3β is active in normal cells and this activity is controlled 
by its subcellular localization, differential phosphorylation at serine 9 (S9) and tyrosine 216 
(Y216) residues, and different binding partners. A consensus motif and context-based 
computational analysis of in vivo protein phosphorylation sites indicate that GSK3β is one of 
the kinases with the most substrates (Linding et al., 2007). In normal cells, multiple signaling 
pathways mediated by phosphoinositide 3 kinase (PI3K)-Akt, Wnt and mitogen-activated 
protein kinase (MAPK) are known to negatively regulate the activity of GSK3β via S9 
phosphorylation (Medina & Wandosell, 2011). The molecular structure and details of the 
functional and regulatory machinery of GSK3β have been thoroughly described in many 
excellent reviews cited in this section and are not the focus of this Chapter. 
4.2 GSK3 in common chronic diseases 
Accumulating evidence suggests pathological roles for GSK3β in glucose intolerance due to 
inhibition of GS and other signaling cascades involved in the regulation of glucose homeo-
stasis (Frame & Zheleva, 2006; Lee & Kim, 2007) and in neurodegenerative changes through 
accumulation of the neurotoxic substances amyloid Aβ and tau protein (Annaert & De 
Strooper, 2002; Bhat & Budd, 2002). Recognition that GSK3β promotes inflammation also 
implicates this molecule in a broad spectrum of common diseases including type 2 diabetes 
mellitus and neuropsychiatric disorders involving an inflammatory reaction (Jope et al., 
2007). GSK3β has therefore emerged as a therapeutic target in these prevalent diseases 
(Cohen & Goedert, 2004; Kypta, 2005; Meijer et al., 2004; Phukan et al., 2010). Another line of 
studies has demonstrated an osteogenic function for the Wnt/β-catenin signaling pathway 
(Hartman, 2006; Krishnan et al., 2006; Ralston & de Crombrugghe, 2006). This suggests that 
GSK3β may be a putative therapeutic target for osteoporotic bone disease, since under 
physiological conditions it is a well established member of a complex that destroys β-catenin 
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Categories  Substrates 
Metabolism glycogen synthase, ATP citrate lyase, PKA, PDH, acetyl-CoA, 
carboxylase, PP1, PP2A, PP2A inhibitor, cyclin D1, eIF2B, NGF 
receptor, axin, APP, Bax, VDAC, hexokinase II, presenilin, LRP5/6 
Cell structure tau, MAP1B, NCAM, neurofilament, CRMP2, dynein, dynein-like 
protein, maltose binding protein, APC, kinesin light chain 
Signaling & Transcription  
   Wnt β-catenin, snail, smad1, Hath1, smad 3 
   Akt SRC-3, B-cell lymphoma (BCL)-3, p21 
   PI3K-Akt Mcl-1, c-Jun, phosphatase and tensin homologue (PTEN) 
   Ras-PI3K-Akt c-Myc, cyclin D1 
   TNFα nuclear factor (NF)-κB 
   Hedgehog Ci (citrus interruptus), Gli-2 
   hypoxia hypoxia inducible factor (HIF)-1α 
   insulin glycogen synthase, SREBP 
   undetermined &    
others 
cyclin E, AP-1, CREB, C/EBP, cdc25A, Notch, p53, p27Kip1, NFAT, 
GR, HSF-1, FGD-1, FGD-3, c-Myb, mCRY2, NACα, MafA, 
IPF1/PDX1, presenilin 1 C-terminal fragment 
Table 2. Known substrates for phosphorylation by GSK3β 
Abbreviations: AP-1, activator protein 1; APC, adenomatous polyposis coli; APP, amyloid 
precursor protein; ATP, adenosine triphosphate; C/EBP, CCAAT (cytidine-cytidine-
adenosine-adenosine-thymidine)-enhancer-binding protein; CREB, cyclic adenosine 
monophosphate (cAMP) response element binding protein; CRMP2, collapsin response 
mediator protein 2; eIF2B, eukaryotic protein synthesis initiation factor-2B; FGD, FYVE, 
RhoGEF and PH domain-containing protein; GR, glucocorticoid receptor; HSF-1, heat shock 
factor protein 1; IPF1, insulin promoter factor 1; LRP5/6, low-density lipoprotein (LDL) 
receptor-related protein 5/6; MafA, musculoaponeurotic fibrosarcoma oncogene homolog 
A: MAP1B, microtubule-associated protein 1B; mCRY2, mouse cryptochrome 2; NACα, 
nascent polypeptide-associated complex α subunit; NCAM, neural cell adhesion molecule; 
NFAT, nuclear factor of activated T-cells; NGF, nerve growth factor; PDH, pyruvate 
dehydrogenase; PDX1, pancreatic and duodenal homeobox 1; PKA, protein kinase A; PP, 
protein phosphatase; SREBP, sterol regulatory element-binding protein; TNFα, tumor 
necrosis factor α; VDAC, voltage-dependent anion channel. 
(Fuchs et al., 2005). In this context, an orally bioavailable GSK3α/β dual inhibitor was 
generated and tested as a new drug for the treatment of osteoporosis (Kulkarni et al., 2006). 
4.3 GSK3 in cancer 
An increasing number of cellular structural and functional proteins have been identified as 
targets for GSK3β phosphorylation-dependent regulation (Table 2). However, this has also 
generated results that show conflicting roles for the signaling pathways regulated by GSK3β 
in either suppressing or promoting cancer. 
4.3.1 GSK3 suppresses cancer 
In physiologically normal cells, many of the substrates for GSK3β-mediated phosphory-
lation and subsequent ubiquitin-mediated degradation include oncogenic signaling and 
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transcription factors, cell cycle regulators and proto-oncoproteins (Table 2). A previous 
study showed that GSK3β phosphorylates and stabilizes a major cell cycle regulator, p27Kip1 
(Surjit & Lal, 2007). Recent studies have shown that inhibition of GSK3β stabilizes snail and 
induces epithelial-mesenchymal transition (EMT), a morphological and phenotypic change 
closely associated with tumor cell invasion and metastasis (Bachelder et al., 2005; Zhou et 
al., 2004; reviewed in Doble & Woodgett, 2007; Schlessinger & Hall, 2004; Zhou & Hung, 
2005). These findings are mostly observed in normal but not neoplastic cells and have led to 
the hypothesis that GSK3β functions as a tumor suppressor (reviewed in Luo, 2009; 
Manoukian & Woodgett, 2003; Patel & Woodgett, 2008). 
Consistent with this hypothesis, a number of studies in breast, lung and non-melanoma skin 
cancers have shown that GSK3β is inactivated in tumor cells, but that its activation induces 
apoptosis (reviewed in Luo, 2009; Patel & Woodgett, 2008). It has been reported in several 
studies that GSK3β renders cancer cells resistant to chemotherapeutic agents (reviewed in 
Luo, 2009). However, in contrast to the observations described in the next section (4.3.2), 
including our own, none of these studies addressed differences in the expression, activity 
and biological properties of GSK3β between tumor cells and their normal cell counterparts. 
Furthermore, these studies did not investigate the direct consequences of GSK3β inhibition 
for tumor cell survival, proliferation and chemotactic migration and invasion. 
4.3.2 Deregulated GSK3 promotes cancer 
Wnt signaling plays a crucial role in embryonic development, the regeneration of adult 
tissues and in many other cellular processes. Aberrant activation of the Wnt pathway due to 
mutation or deregulated expression of its components mediates the multistep process of 
colorectal tumorigenesis (Kikuchi, 2007; Klaus & Birchmeier, 2008; Lustig & Behrens, 2003; 
Willert & Jones, 2006). Over 90% of CRC develops following activation of the Wnt signaling 
pathway in which β-catenin plays a central role (Fuchs et al., 2005; Giles et al., 2003). GSK3β 
interrupts activation of the canonical Wnt pathway by phosphorylating β-catenin and 
recruiting it to ubiquitin-mediated degradation. GSK3β is therefore believed to antagonize 
tumorigenesis that involves active Wnt signaling (Bienz & Clevers, 2000; Manoukian & 
Woodgett, 2002; Polakis P, 1999), as represented for example by CRC development. This 
notion is also supported by the frequent mutational activation of Ras and PI3K-Akt 
signaling (Markowitz & Bertagnolli, 2009; Parsons et al., 2005), since it is well established 
that Akt kinase phosphorylates the S9 residue of GSK3β and inhibits its activity (Medina & 
Wandosell, 2011). However, few studies had focused on the biological properties of GSK3β 
in cancer until we investigated a putative pathological role for this kinase in CRC, as 
described below. 
Most CRC cell lines and primary CRC tumors in our studies have shown increased 
expression and activity of GSK3β and deregulation of its activity due to imbalance in the 
differential phosphorylation of S9 (inactive) and Y216 (active) residues. This is in 
comparison to non-neoplastic cells (e.g., HEK293) and normal colon mucosa in which 
GSK3β activity appears to be regulated by the differential phosphorylation. These tumor cell 
features are unrelated to the activation of β-catenin or Akt (Mai et al., 2009; Shakoori et al., 
2005). A non-radioisotopic, in vitro kinase assay demonstrated an increased ability of GSK3β 
derived from most CRC cell lines and primary CRC tumors to phosphorylate its substrate, 
as compared to non-neoplastic counterparts (Mai et al., 2006, 2009). These observations 
suggest that, in contrast to having hypothetical tumor suppressor function, GSK3β may 
actually promote cancer.  
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A putative pathological role for GSK3β in cancer was demonstrated by subsequent 
observations that inhibition of GSK3β activity using pharmacological (small-molecule) 
agents and of its expression by RNA interference reduced the survival and proliferation of 
CRC cells. Such inhibition also predisposed the cells to apoptosis in vitro and in tumor 
xenografts, suggesting that CRC cells depend on aberrant GSK3β for their survival and 
proliferation (Mai et al., 2006, 2009; Shakoori et al., 2005, 2007). A series of studies by our 
group led us to propose that aberrant GSK3β is a novel and potentially important 
therapeutic target in cancer (Miyashita et al., 2009b; Motoo et al., 2011; Nakada et al., 2011), 
thus allowing us to apply for domestic and international patents in this field (Minamoto).  
Following our studies on the antitumor effects of GSK3β inhibition, similar observations 
were reported for CRC by other groups (Ghosh & Altieri, 2005; Rottmann et al., 2005; Tan et 
al., 2005; Tsuchiya et al., 2007) (Table 3). Similar results were also published for other cancer 
types with underlying biological mechanisms that included GSK3β inhibition of several 
pathways involved in tumorigenesis (reviewed in Miyashita et al., 2009b; Nakada et al., 
2011). A putative role for GSK3β in cancer is still being debated (Luo, 2009; Manoukian & 
Woodgett, 2003; Patel & Woodgett, 2008) and was discussed in section 4.3.1. However, the 
overall results to date indicate that aberrant expression and activity of GSK3β is likely to be 
a common and fundamental characteristic of a broad spectrum of human cancers. 
4.3.3 Oncogene addiction and the effect of GSK3 inhibition against cancer 
As stated in section 2.2, the hypothesis of oncogene addiction has been proposed as a 
rationale for molecular targeting in cancer treatment. It refers to the observation that a 
cancer cell, despite its plethora of genetic alterations, seemingly exhibits dependence on a 
single oncoprotein or oncogenic pathway for its sustained survival and/or proliferation 
(Sharma & Settleman, 2007; Weinstein, 2002; Weinstein & Joe, 2006). This unique state of 
dependence by cancer cells is highlighted by the fact that inactivation of the normal 
counterpart of such proto-oncogene products in non-neoplastic cells is tolerated without 
obvious consequence. A profound implication of this hypothesis is that acute interruption of 
the critical oncogenic pathways upon which cancer cells are dependent should have a major 
detrimental effect (oncogene shock), while sparing normal cells that are not similarly 
addicted to these pathways (Sharma et al, 2006). In our series of studies, inhibition of GSK3 
had little effect on cell survival, growth, apoptosis or senescence in non-neoplastic cells (e.g., 
HEK293) and on major vital organs in rodents (Mai et al., 2006, 2009; Shakoori et al., 2005, 
2007). This concurs with previous reports showing that GSK3 inhibition does not influence 
the survival or growth of human mammary epithelial cells, embryonic lung fibroblasts 
(WI38) and mouse embryonic fibroblasts (NIH-3T3) (Kunnimalaiyaan et al., 2007; Ougolkov 
et al., 2005). With respect to the oncogene addiction hypothesis (Sharma & Settleman, 2007; 
Weinstein, 2002; Weinstein & Joe, 2006), the selective therapeutic effect of GSK3 inhibition 
against cancer can be explained by differences in biological properties of GSK3β between 
neoplastic and non-neoplastic cells (Mai et al., 2006, 2009; Shakoori et al., 2005). 
5. GSK3 and the hallmarks of colorectal cancer 
Understanding the molecular mechanism behind a pathogenic role for GSK3 in cancer is 
important for the development of treatment strategies that target this kinase. A current 
review highlights 8 hallmarks of cancer in which phenotypic properties are progressively  
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features are unrelated to the activation of β-catenin or Akt (Mai et al., 2009; Shakoori et al., 
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agents and of its expression by RNA interference reduced the survival and proliferation of 
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Table 3. Pathological roles and functions of GSK3β in colorectal cancer 
Abbreviations: hTERT, human telomerase reverse transcriptase; NRIKA, non-radioisotopic 
in vitro kinase assay; siRNA, small interfering RNA; TRAIL, tumor necrosis factor (TNF)-
related apoptosis-inducing ligand. 
acquired during multistep pathogenesis, thus allowing cancer cells to become tumorigenic 
and ultimately malignant (Hanahan & Weinberg, 2011). These hallmarks are sustained 
proliferative signaling, evasion of growth suppressors, resistance to cell death, enabling of 
replicative immortality, induction of angiogenesis, activation of invasion and metastasis, 
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reprogramming of energy metabolism and evasion of immune destruction. The 
development of each hallmark involves multiple signaling pathways. In this section, we 
address how GSK3 modulates some of these hallmark characteristics of CRC by referring 
to the studies shown in Table 3, including our own work. 
5.1 Cell proliferation 
Unrestrained cell proliferation is the most prominent feature of cancer. Our previous study 
showed that the effect of GSK3 inhibition against the proliferative capacity of CRC cells 
was associated with decreased expression of cyclin D1 and cyclin-dependent kinase (CDK) 6 
and phosphorylation of the Rb protein (Mai et al., 2009). These observations suggest that Rb 
function was restored, leading to the binding and inhibition of E2F transcription factor 
(reviewed in Classon & Harlow, 2002; Knudsen & Knudsen, 2008). This is consistent with a 
subsequent report that forced expression of exogenous GSK3 promotes the proliferation of 
ovarian cancer cells by inducing cyclin D1 expression (Cao et al., 2006). Together, the results 
suggest that suppression of excess cancer cell proliferation via the inhibition of GSK3 is 
partly due to negative regulation of cell cycling by cyclin D1. In normal or non-neoplastic 
cells, cyclin D1 is one of the primary targets of GSK3β for phosphorylation and subsequent 
degradation in the ubiquitin-proteasome system (Diehl et al., 1998) (Table 2). The opposing 
role of GSK3β in cyclin D1 expression may explain the lack of effect of GSK3β inhibition on 
cell survival and growth of non-neoplastic cells found in earlier studies (Kunnimalaiyaan et 
al., 2007; Mai et al., 2009; Ougolkov et al., 2005; Shakoori et al., 2005). 
5.2 Resistance to cell death via tumor suppressor pathways 
A major mechanism by which cancer cells evade cell death is via the inactivation of tumor 
suppressor pathways mediated by p53 (Royds & Iacopetta B, 2006; Vousden & Lane, 2007; 
Zilfou & Lowe, 2009) and Rb (Classon & Harlow, 2002; Knudsen & Knudsen, 2008). The 
studies listed in Table 3 showed that inhibition of GSK3β induced apoptosis in human CRC 
cell lines. This effect was associated with increased expression of p53 and of p21 in colon 
cancer cells with wild-type p53, and decreased Rb phosphorylation in colon cancer cells 
irrespective of their p53 status (Ghosh & Altieri, 2005; Mai et al., 2009; Tan et al., 2005). 
Another study showed that GSK3β suppresses the apoptosis of colon cancer cells by 
inhibiting a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) 
receptor-dependent synthetic lethal relationship between c-Myc activation and FBW7 (a 
gene encoding a ubiquitin ligase receptor) loss of function (Rottmann et al., 2005). These 
studies suggest a putative pathological role for aberrant GSK3β in mediating CRC cell 
resistance to apoptosis induced by a pathway involving tumor suppressor proteins, TRAIL 
and c-Myc.  
One of the representative pathways for cell survival is mediated by nuclear factor-κB (NF-
κB) (Inoue et al., 2007; Karin, 2006, 2009). Based on previous studies showing the potential 
involvement of GSK3β in NF-κB-mediated cell survival during mouse embryonic 
development (Hoeflich et al., 2000; Schwabe & Brenner, 2002), it was reported that GSK3β 
sustains pancreatic cancer cell survival by maintaining transcriptional activity of NF-κB 
(Ougolkov et al., 2005; Wilson & Baldwin, 2008). While these studies examined the activity 
of exogenous (transfected) NF-κB, we previously observed no effect of GSK3β inhibition on 
endogenous NF-κB transcriptional activity in gastrointestinal cancer cells (including CRC) 
and glioblastoma cells (Mai et al., 2009; Miyashita et al., 2009a). Therefore, a role for GSK3β 
in regulating NF-κB activity in cancer is controversial. 
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reprogramming of energy metabolism and evasion of immune destruction. The 
development of each hallmark involves multiple signaling pathways. In this section, we 
address how GSK3 modulates some of these hallmark characteristics of CRC by referring 
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showed that the effect of GSK3 inhibition against the proliferative capacity of CRC cells 
was associated with decreased expression of cyclin D1 and cyclin-dependent kinase (CDK) 6 
and phosphorylation of the Rb protein (Mai et al., 2009). These observations suggest that Rb 
function was restored, leading to the binding and inhibition of E2F transcription factor 
(reviewed in Classon & Harlow, 2002; Knudsen & Knudsen, 2008). This is consistent with a 
subsequent report that forced expression of exogenous GSK3 promotes the proliferation of 
ovarian cancer cells by inducing cyclin D1 expression (Cao et al., 2006). Together, the results 
suggest that suppression of excess cancer cell proliferation via the inhibition of GSK3 is 
partly due to negative regulation of cell cycling by cyclin D1. In normal or non-neoplastic 
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cancer cells with wild-type p53, and decreased Rb phosphorylation in colon cancer cells 
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receptor-dependent synthetic lethal relationship between c-Myc activation and FBW7 (a 
gene encoding a ubiquitin ligase receptor) loss of function (Rottmann et al., 2005). These 
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resistance to apoptosis induced by a pathway involving tumor suppressor proteins, TRAIL 
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One of the representative pathways for cell survival is mediated by nuclear factor-κB (NF-
κB) (Inoue et al., 2007; Karin, 2006, 2009). Based on previous studies showing the potential 
involvement of GSK3β in NF-κB-mediated cell survival during mouse embryonic 
development (Hoeflich et al., 2000; Schwabe & Brenner, 2002), it was reported that GSK3β 
sustains pancreatic cancer cell survival by maintaining transcriptional activity of NF-κB 
(Ougolkov et al., 2005; Wilson & Baldwin, 2008). While these studies examined the activity 
of exogenous (transfected) NF-κB, we previously observed no effect of GSK3β inhibition on 
endogenous NF-κB transcriptional activity in gastrointestinal cancer cells (including CRC) 
and glioblastoma cells (Mai et al., 2009; Miyashita et al., 2009a). Therefore, a role for GSK3β 
in regulating NF-κB activity in cancer is controversial. 
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5.3 Replicative cell immortality 
Another critical mechanism used by cancer cells to evade cell death is replicative cell 
immortality. A close relationship exists in cancer cells between the molecular mechanisms 
for immortality and escape from replicative senescence (Finkel et al., 2007). Cancer cells 
acquire constitutive expression and activity of human telomerase reverse transcriptase 
(hTERT) and telomerase in order to circumvent telomere-dependent pathways of cell 
mortality (Harley, 2008).  
We recently observed a decreased level of hTERT mRNA in colon cancer cells following 
inhibition of either the activity or expression of GSK3β. Inhibition of GSK3β attenuates 
telomerase activity and increases the β-galactosidase-positive (senescent) population in 
colon cancer cells. These effects were associated with increased expression of p53, p21 and c-
Jun N-terminal kinase 1 (JNK1) and decreases in CDK6 expression and Rb phosphorylation 
(Mai et al., 2009). The findings are consistent with the known relationship between these 
proteins and cell senescence (reviewed in Kiyono, 2007) and with GSK3β activity (Ghosh & 
Altieri, 2005; Kulikov et al., 2005; Liu et al., 2004; Mai et al., 2009; Qu et al., 2004; Rössig et al., 
2002). Consistent with our observation, a recent study found that inhibition of GSK3β 
suppressed hTERT expression and telomerase activity and shortened the telomere length in 
various cancer cell lines including HCT116 colon cancer cells, and attenuated cell 
proliferation and hTERT expression in ovarian cancer xenografts (Bilsland et al., 2009). The 
putative role for GSK3β in protecting cancer cells from telomere-dependent senescence and 
mortality is attributed to its effects on hTERT expression and telomerase activity. 
5.4 Influence on the cancer microenvironment and tumor invasion 
In cancer, various events are orchestrated to produce a distinct tumor microenvironment 
that dictates the malignant potential. These include depletion of nutrients involved in cell 
proliferation, tumor cell invasion, tumor neovascularization in response to hypoxic 
condition, as well as stromal, inflammatory and immune reactions in the host (Joyce, 2005). 
The promotion of inflammation and immune response by GSK3β (Jope et al, 2007) suggests 
a broad pathological role for this kinase in the cancer microenvironment.  
The pro-invasive phenotype of cancer cells is characterized by EMT, enhanced cell motility 
and their ability to induce neovascularization. As discussed in section 4.3.1, inhibition of 
GSK3β stabilizes snail and induces EMT (Bachelder et al., 2005; Zhou et al., 2004; reviewed 
in Doble & Woodgett, 2007; Schlessinger & Hall, 2004; Zhou & Hung, 2005). A hypoxic 
tumor microenvironment induces the expression of hypoxia-inducible factor-1α (HIF-1α), a 
transcription factor that controls oxygen homeostasis by regulating target genes involved in 
angiogenesis, glycolysis and cell proliferation (reviewed in Semenza, 2009). A previous 
study showed that under physiological conditions, GSK3β inhibits angiogenesis by 
negatively regulating endothelial cell survival and migration in response to PI3K-, MAPK- 
and protein kinase A (PKA)-dependent signaling pathways (Kim et al., 2002). Another study 
demonstrated that hypoxia induces a biphasic effect on HIF-1α stabilization in liver cancer 
cells. Accumulation of HIF-1α occurs in early hypoxia and is dependent on an active 
PI3K/Akt pathway and inactive GSK3β. In contrast, prolonged hypoxia results in the 
inactivation of Akt and activation of GSK3β. This negatively regulates HIF-1α activity by 
inhibiting its accumulation (Mottet et al., 2003). Collectively, it thus appears unlikely that 
GSK3β participates in cancer cell EMT and in tumor angiogenesis. 
Formation of lamellipodia, the characteristic cellular microarchitecture, is responsible not 
only for cell migration under physiological conditions (e.g., embryonic development, 
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wound healing) but also for cancer cell migration and invasion (Machesky, 2008; Small et al., 
2002; Yilmaz & Christofori, 2009). A member of the Rho-GTPase family, Rac1, is known to 
participate in the formation of lamellipodia and may thus play an important role in cancer 
progression (Raftpoulou & Hall, 2004; Sahai & Marshall, 2002). It has been reported that 
GSK3β participates in cell motility by facilitating the formation of lamellipodia (Koivisto et 
al., 2003) and by activating Rac1 (Farooqui et al., 2006; Kobayashi et al., 2006; Vaidya et al., 
2006). Focal adhesion kinase (FAK) is also known to play a key role in regulating cell 
motility and migration and to be deregulated in cancer (McLean et al., 2005). Earlier studies 
reported that FAK is one of the downstream effectors in GSK3β-mediated pathways 
(Kobayashi et al., 2006) and also regulates Rac1 (McLean et al., 2005). Consistent with a recent 
study for glioblastoma (Nowicki et al., 2008), our preliminary study has shown that inhibition 
of GSK3β attenuates pancreatic cancer cell migration and invasion by negatively regulating 
FAK and Rac1 activities (unpublished observation). Therefore, in regard to cancer treatments 
that target GSK3β, it is important to explore a possible role for GSK3β in CRC cell invasion by 
investigating its effects on cellular microarchitecture, motility and migration. 
5.5 Cancer cell stemness and metabolic traits 
Cell stemness and the reprogramming of energy metabolism are primary cell characteristics 
that share distinct molecular pathways and allow cancer cells to survive, proliferate, invade 
their host tissues, metastasize and resist treatment. Here, we address future directions in our 
approach towards ascertaining the potential of GSK3β as a therapeutic target in cancers 
including CRC. 
5.5.1 Cancer cell stemness and GSK3 
Arising from the concept of tissue stem cells, the notion of cancer stem cells has emerged 
and proposes that cancer initiating cells are a distinct subpopulation within a tumor that 
have the ability to self-renew and differentiate (Clarke et al., 2006; O’Brien et al., 2010). 
Similar to other cancer types, a small population of cancer initiating cells has been identified 
and characterized in CRC (Dalerba et al., 2007; O’Brien et al., 2007; Ricci-Vitiani et al., 2007; 
reviewed in Yeung & Mortensen, 2009). Current cancer treatments assume that all cancer 
cells in tumors are homogeneous and have a similar capacity to proliferate, invade and 
metastasize, as well as having similar susceptibility to chemotherapy and radiation. 
However, accumulating evidence suggests that cancer stem cells and cancer cells that are 
undergoing EMT share various biological traits (Polyak & Weinberg, 2009). These cells are 
also strongly resistant to current forms of therapeutics, thereby identifying this 
subpopulation of cancer cells as the ultimate target for cancer treatment (Lou & Dean, 2007). 
Consistent with the physiological roles of GSK3 in Wnt, Hedgehog and Notch signaling 
(Foltz et al., 2002; Manoukian & Woodgett, 2002; Takenaka et al., 2007), GSK3β inhibition by 
pharmacological means promotes embryonic stem cell pluripotency (Sato et al., 2004) and 
hematopoietic stem cell reconstitution (Trowbridge et al., 2006). Conversely, recent studies 
have demonstrated that GSK3β sustains the respective molecular pathways leading to 
tumor cell stemness in a specific type of leukemia and in glioblastoma (Korur et al., 2009; 
Wang et al., 2008). Although the underlying molecular mechanisms are not well understood, 
these differential roles for GSK3 in normal and cancer stem cells could ultimately benefit 
cancer treatment strategies by allowing this kinase to be targeted with little harm to patients. 
As addressed in the next section (5.5.2), anaerobic glycolysis and the presence of a distinct 
niche are thought to be characteristics of cancer stem cells, in addition to their extreme 
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5.3 Replicative cell immortality 
Another critical mechanism used by cancer cells to evade cell death is replicative cell 
immortality. A close relationship exists in cancer cells between the molecular mechanisms 
for immortality and escape from replicative senescence (Finkel et al., 2007). Cancer cells 
acquire constitutive expression and activity of human telomerase reverse transcriptase 
(hTERT) and telomerase in order to circumvent telomere-dependent pathways of cell 
mortality (Harley, 2008).  
We recently observed a decreased level of hTERT mRNA in colon cancer cells following 
inhibition of either the activity or expression of GSK3β. Inhibition of GSK3β attenuates 
telomerase activity and increases the β-galactosidase-positive (senescent) population in 
colon cancer cells. These effects were associated with increased expression of p53, p21 and c-
Jun N-terminal kinase 1 (JNK1) and decreases in CDK6 expression and Rb phosphorylation 
(Mai et al., 2009). The findings are consistent with the known relationship between these 
proteins and cell senescence (reviewed in Kiyono, 2007) and with GSK3β activity (Ghosh & 
Altieri, 2005; Kulikov et al., 2005; Liu et al., 2004; Mai et al., 2009; Qu et al., 2004; Rössig et al., 
2002). Consistent with our observation, a recent study found that inhibition of GSK3β 
suppressed hTERT expression and telomerase activity and shortened the telomere length in 
various cancer cell lines including HCT116 colon cancer cells, and attenuated cell 
proliferation and hTERT expression in ovarian cancer xenografts (Bilsland et al., 2009). The 
putative role for GSK3β in protecting cancer cells from telomere-dependent senescence and 
mortality is attributed to its effects on hTERT expression and telomerase activity. 
5.4 Influence on the cancer microenvironment and tumor invasion 
In cancer, various events are orchestrated to produce a distinct tumor microenvironment 
that dictates the malignant potential. These include depletion of nutrients involved in cell 
proliferation, tumor cell invasion, tumor neovascularization in response to hypoxic 
condition, as well as stromal, inflammatory and immune reactions in the host (Joyce, 2005). 
The promotion of inflammation and immune response by GSK3β (Jope et al, 2007) suggests 
a broad pathological role for this kinase in the cancer microenvironment.  
The pro-invasive phenotype of cancer cells is characterized by EMT, enhanced cell motility 
and their ability to induce neovascularization. As discussed in section 4.3.1, inhibition of 
GSK3β stabilizes snail and induces EMT (Bachelder et al., 2005; Zhou et al., 2004; reviewed 
in Doble & Woodgett, 2007; Schlessinger & Hall, 2004; Zhou & Hung, 2005). A hypoxic 
tumor microenvironment induces the expression of hypoxia-inducible factor-1α (HIF-1α), a 
transcription factor that controls oxygen homeostasis by regulating target genes involved in 
angiogenesis, glycolysis and cell proliferation (reviewed in Semenza, 2009). A previous 
study showed that under physiological conditions, GSK3β inhibits angiogenesis by 
negatively regulating endothelial cell survival and migration in response to PI3K-, MAPK- 
and protein kinase A (PKA)-dependent signaling pathways (Kim et al., 2002). Another study 
demonstrated that hypoxia induces a biphasic effect on HIF-1α stabilization in liver cancer 
cells. Accumulation of HIF-1α occurs in early hypoxia and is dependent on an active 
PI3K/Akt pathway and inactive GSK3β. In contrast, prolonged hypoxia results in the 
inactivation of Akt and activation of GSK3β. This negatively regulates HIF-1α activity by 
inhibiting its accumulation (Mottet et al., 2003). Collectively, it thus appears unlikely that 
GSK3β participates in cancer cell EMT and in tumor angiogenesis. 
Formation of lamellipodia, the characteristic cellular microarchitecture, is responsible not 
only for cell migration under physiological conditions (e.g., embryonic development, 
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wound healing) but also for cancer cell migration and invasion (Machesky, 2008; Small et al., 
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reported that FAK is one of the downstream effectors in GSK3β-mediated pathways 
(Kobayashi et al., 2006) and also regulates Rac1 (McLean et al., 2005). Consistent with a recent 
study for glioblastoma (Nowicki et al., 2008), our preliminary study has shown that inhibition 
of GSK3β attenuates pancreatic cancer cell migration and invasion by negatively regulating 
FAK and Rac1 activities (unpublished observation). Therefore, in regard to cancer treatments 
that target GSK3β, it is important to explore a possible role for GSK3β in CRC cell invasion by 
investigating its effects on cellular microarchitecture, motility and migration. 
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approach towards ascertaining the potential of GSK3β as a therapeutic target in cancers 
including CRC. 
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Arising from the concept of tissue stem cells, the notion of cancer stem cells has emerged 
and proposes that cancer initiating cells are a distinct subpopulation within a tumor that 
have the ability to self-renew and differentiate (Clarke et al., 2006; O’Brien et al., 2010). 
Similar to other cancer types, a small population of cancer initiating cells has been identified 
and characterized in CRC (Dalerba et al., 2007; O’Brien et al., 2007; Ricci-Vitiani et al., 2007; 
reviewed in Yeung & Mortensen, 2009). Current cancer treatments assume that all cancer 
cells in tumors are homogeneous and have a similar capacity to proliferate, invade and 
metastasize, as well as having similar susceptibility to chemotherapy and radiation. 
However, accumulating evidence suggests that cancer stem cells and cancer cells that are 
undergoing EMT share various biological traits (Polyak & Weinberg, 2009). These cells are 
also strongly resistant to current forms of therapeutics, thereby identifying this 
subpopulation of cancer cells as the ultimate target for cancer treatment (Lou & Dean, 2007). 
Consistent with the physiological roles of GSK3 in Wnt, Hedgehog and Notch signaling 
(Foltz et al., 2002; Manoukian & Woodgett, 2002; Takenaka et al., 2007), GSK3β inhibition by 
pharmacological means promotes embryonic stem cell pluripotency (Sato et al., 2004) and 
hematopoietic stem cell reconstitution (Trowbridge et al., 2006). Conversely, recent studies 
have demonstrated that GSK3β sustains the respective molecular pathways leading to 
tumor cell stemness in a specific type of leukemia and in glioblastoma (Korur et al., 2009; 
Wang et al., 2008). Although the underlying molecular mechanisms are not well understood, 
these differential roles for GSK3 in normal and cancer stem cells could ultimately benefit 
cancer treatment strategies by allowing this kinase to be targeted with little harm to patients. 
As addressed in the next section (5.5.2), anaerobic glycolysis and the presence of a distinct 
niche are thought to be characteristics of cancer stem cells, in addition to their extreme 
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resistance to drug treatment. Therefore, clarification of a putative role for GSK3 in 
regulating CRC cell stemness is of great interest. This could lead to a new strategy for 
treatment that targets the biology of cancer cell stemness. 
5.5.2 Distinct metabolic traits of cancer cells and GSK3 
Production of excess energy is thought to provide an intrinsic and selective pressure that 
allows cancer cells to expand clonally and to acquire immortalized and destructive 
phenotypes. Even under normoxic conditions, most cancer cells depend on increased 
glucose uptake and aerobic glycolysis to produce their energy source, adenosine 
triphosphates (ATP) (Kim & Dang, 2006; Vander Heiden & Cantley, 2010). This is known as 
the Warburg effect and involves truncated oxidative phosphorylation in the tricarboxylic 
acid (TCA) cycle, thus resulting in mitochondrial uncoupling (Samudio et al., 2009). These 
properties allow cancer cells to survive and invade host tissues in a microenvironment 
where the supply of both oxygen and nutrients is deficient, as well as conferring resistance 
to apoptosis-inducing therapeutic stimuli (Smallbone et al., 2007). Therefore, the glycolytic 
phenotype of cancer cells is a potential target for cancer diagnosis and treatment (Gatenby & 
Gillies, 2007; Kroemer & Pouyssegur, 2008). For example, enhanced glucose uptake by 
cancer cells can be used to visualize cancer by positron emission tomography (PET) using 
the radioisotope-labeled glucose analogue 2-[18F]-fluoro-2-deoxy-D-glucose (FDG). FDG-
PET in combination with computed tomography (PET-CT) enables the detection of 
metastatic lesions for most cancers with sensitivity and specificity both greater than 90% 
(Mankoff et al., 2007).  
The association between a glycolytic phenotype (i.e., TCA cycle defects) and resistance to 
apoptosis is attributed to decreased mitochondrial hydrogen peroxide production and 
cytochrome C release (Samudio et al., 2009; Vander Heiden & Cantley, 2010). Pyruvate 
dehydrogenase (PDH) plays a crucial role in triggering the TCA cycle by converting 
pyruvate to citric acid. PDH kinase 1 (PDK1), which phosphorylates and inactivates PDH, is 
frequently over-activated in cancer cells, resulting in an impaired TCA cycle and 
mitochondrial hyperpolarization. Thus, inhibition of PDK1 would re-activate PDH and 
restore mitochondrial membrane polarity, thereby facilitating cancer cell apoptosis in 
response to chemotherapeutic agents and radiation. Dichloroacetate (DCA), an orally bio-
available small molecule, is a well characterized PDK1 inhibitor. The ability of DCA to 
inhibit lactate production by stimulating PDH and the TCA cycle has long been used to treat 
lactic acidosis, which is a complication of inherited mitochondrial disorders (Stacpoole, 
2003, 2006). A recent study demonstrated that DCA induces cancer cell apoptosis by 
selectively inhibiting PDK1 in cancer cells, leading to metabolic remodeling from glycolysis 
to glucose oxidation and the normalization of mitochondrial function (Bonnet et al., 2008). A 
clinical trial of oral DCA in children with congenital lactic acidosis reported that DCA was 
well tolerated and safe (Stacpoole, 2006). Thus, orally administered DCA is a promising and 
selective anticancer agent.  
The primary role of GSK3β is to control GS activity (Table 2). It thus acts as a checkpoint at 
the bifurcation between glycogenesis and glycolysis, the two major pathways of 
glucose/glycogen metabolism (Lee & Kim, 2007). We recently found that inhibition of 
GSK3β in colon cancer cells increased GS expression and decreased its S640 phosphorylation 
(unpublished observation), suggesting that GSK3β inhibition may switch cancer cells from a 
glycolytic to a glycogenic phenotype. It was previously reported that GSK3β phosphorylates 
and inactivates PDH (Hoshi et al., 1996) (Table 2), a key enzyme for the TCA cycle in 
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mitochondria. This suggests that deregulated GSK3β contributes to truncation of the TCA 
cycle and mitochondrial uncoupling in cancer cells, resulting in resistance to chemotherapy 
and radiation. It has also been reported that the distinct metabolism of cancer cells involves 
not only anaerobic glycolysis but also other metabolic pathways such as the pentose 
phosphate pathway, amino acid and nucleic acid synthesis and glutaminolysis 
(DeBerardinis et al., 2008). GSK3β has a number of key metabolic enzymes as substrates 
(Table 2), suggesting this molecule could have broad control over various pathological 
metabolic pathways in cancer cells. 
6. Perspectives 
Biologically-based therapy of cancer holds great promise, particularly for patients who are 
refractory to existing forms of therapy. Current paradigms reviewed in the earlier part of 
this Chapter (3. Systemic treatment: an overview) include the targeting of growth factor 
receptor-type protein tyrosine kinases and angiogenic factors. Such therapies are directed 
against cancer cell survival, proliferation and tumor angiogenesis; however they are unable 
to completely eradicate cancer, as demonstrated by most large-scale clinical trials.  
 
 
Fig. 1. GSK3β promotes cell stemness, invasive capacity and excess glucose metabolism that 
interact to produce a distinct cancer microenvironment. 
The distinct pathologic properties of GSK3β in cancer described here highlight its potential to 
be an innovative target for the radical treatment of this disease, including CRC. GSK3β can 
potentially promote cancer cell stemness, invasive capacity and glucose metabolism, thus 
creating the selective pressures that allow cancer cells to persist in a distinct microenvironment 
(Figure 1). Understanding the complex biological mechanisms for the multiple roles of GSK3β 
in promoting cancer should allow elucidation of novel molecular pathways that lead to cancer 
development and progression. This will also provide a detailed scientific basis for the 
development of cancer treatment strategies that target aberrant GSK3β. 
Concerns regarding the therapeutic use of GSK3β inhibitors remain because these may 
activate oncogenic (e.g., Wnt) signaling, thus promoting cell proliferation (Manoukian & 
Woodgett, 2003). However, this issue has not deterred preclinical studies of GSK3β 
inhibitors for the treatment of many cancer types (reviewed in Miyashita et al., 2009b) or 
Phase II clinical trials for the treatment of neurological diseases (Chico et al., 2010). 
Currently, two clinical trials are being undertaken to test a pharmacological GSK3β inhibitor 
(LY2090314) for enhancement of the anti-tumor effect of chemotherapeutic agents for 
advanced solid cancer (phase I: http://clinicaltrials.gov/ct2/show/study/NCT01287520) 
and leukemia (phase II: http://clinicaltrials.gov/ct2/show/study/NCT01214603). Such 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
120 
resistance to drug treatment. Therefore, clarification of a putative role for GSK3 in 
regulating CRC cell stemness is of great interest. This could lead to a new strategy for 
treatment that targets the biology of cancer cell stemness. 
5.5.2 Distinct metabolic traits of cancer cells and GSK3 
Production of excess energy is thought to provide an intrinsic and selective pressure that 
allows cancer cells to expand clonally and to acquire immortalized and destructive 
phenotypes. Even under normoxic conditions, most cancer cells depend on increased 
glucose uptake and aerobic glycolysis to produce their energy source, adenosine 
triphosphates (ATP) (Kim & Dang, 2006; Vander Heiden & Cantley, 2010). This is known as 
the Warburg effect and involves truncated oxidative phosphorylation in the tricarboxylic 
acid (TCA) cycle, thus resulting in mitochondrial uncoupling (Samudio et al., 2009). These 
properties allow cancer cells to survive and invade host tissues in a microenvironment 
where the supply of both oxygen and nutrients is deficient, as well as conferring resistance 
to apoptosis-inducing therapeutic stimuli (Smallbone et al., 2007). Therefore, the glycolytic 
phenotype of cancer cells is a potential target for cancer diagnosis and treatment (Gatenby & 
Gillies, 2007; Kroemer & Pouyssegur, 2008). For example, enhanced glucose uptake by 
cancer cells can be used to visualize cancer by positron emission tomography (PET) using 
the radioisotope-labeled glucose analogue 2-[18F]-fluoro-2-deoxy-D-glucose (FDG). FDG-
PET in combination with computed tomography (PET-CT) enables the detection of 
metastatic lesions for most cancers with sensitivity and specificity both greater than 90% 
(Mankoff et al., 2007).  
The association between a glycolytic phenotype (i.e., TCA cycle defects) and resistance to 
apoptosis is attributed to decreased mitochondrial hydrogen peroxide production and 
cytochrome C release (Samudio et al., 2009; Vander Heiden & Cantley, 2010). Pyruvate 
dehydrogenase (PDH) plays a crucial role in triggering the TCA cycle by converting 
pyruvate to citric acid. PDH kinase 1 (PDK1), which phosphorylates and inactivates PDH, is 
frequently over-activated in cancer cells, resulting in an impaired TCA cycle and 
mitochondrial hyperpolarization. Thus, inhibition of PDK1 would re-activate PDH and 
restore mitochondrial membrane polarity, thereby facilitating cancer cell apoptosis in 
response to chemotherapeutic agents and radiation. Dichloroacetate (DCA), an orally bio-
available small molecule, is a well characterized PDK1 inhibitor. The ability of DCA to 
inhibit lactate production by stimulating PDH and the TCA cycle has long been used to treat 
lactic acidosis, which is a complication of inherited mitochondrial disorders (Stacpoole, 
2003, 2006). A recent study demonstrated that DCA induces cancer cell apoptosis by 
selectively inhibiting PDK1 in cancer cells, leading to metabolic remodeling from glycolysis 
to glucose oxidation and the normalization of mitochondrial function (Bonnet et al., 2008). A 
clinical trial of oral DCA in children with congenital lactic acidosis reported that DCA was 
well tolerated and safe (Stacpoole, 2006). Thus, orally administered DCA is a promising and 
selective anticancer agent.  
The primary role of GSK3β is to control GS activity (Table 2). It thus acts as a checkpoint at 
the bifurcation between glycogenesis and glycolysis, the two major pathways of 
glucose/glycogen metabolism (Lee & Kim, 2007). We recently found that inhibition of 
GSK3β in colon cancer cells increased GS expression and decreased its S640 phosphorylation 
(unpublished observation), suggesting that GSK3β inhibition may switch cancer cells from a 
glycolytic to a glycogenic phenotype. It was previously reported that GSK3β phosphorylates 
and inactivates PDH (Hoshi et al., 1996) (Table 2), a key enzyme for the TCA cycle in 
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mitochondria. This suggests that deregulated GSK3β contributes to truncation of the TCA 
cycle and mitochondrial uncoupling in cancer cells, resulting in resistance to chemotherapy 
and radiation. It has also been reported that the distinct metabolism of cancer cells involves 
not only anaerobic glycolysis but also other metabolic pathways such as the pentose 
phosphate pathway, amino acid and nucleic acid synthesis and glutaminolysis 
(DeBerardinis et al., 2008). GSK3β has a number of key metabolic enzymes as substrates 
(Table 2), suggesting this molecule could have broad control over various pathological 
metabolic pathways in cancer cells. 
6. Perspectives 
Biologically-based therapy of cancer holds great promise, particularly for patients who are 
refractory to existing forms of therapy. Current paradigms reviewed in the earlier part of 
this Chapter (3. Systemic treatment: an overview) include the targeting of growth factor 
receptor-type protein tyrosine kinases and angiogenic factors. Such therapies are directed 
against cancer cell survival, proliferation and tumor angiogenesis; however they are unable 
to completely eradicate cancer, as demonstrated by most large-scale clinical trials.  
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interact to produce a distinct cancer microenvironment. 
The distinct pathologic properties of GSK3β in cancer described here highlight its potential to 
be an innovative target for the radical treatment of this disease, including CRC. GSK3β can 
potentially promote cancer cell stemness, invasive capacity and glucose metabolism, thus 
creating the selective pressures that allow cancer cells to persist in a distinct microenvironment 
(Figure 1). Understanding the complex biological mechanisms for the multiple roles of GSK3β 
in promoting cancer should allow elucidation of novel molecular pathways that lead to cancer 
development and progression. This will also provide a detailed scientific basis for the 
development of cancer treatment strategies that target aberrant GSK3β. 
Concerns regarding the therapeutic use of GSK3β inhibitors remain because these may 
activate oncogenic (e.g., Wnt) signaling, thus promoting cell proliferation (Manoukian & 
Woodgett, 2003). However, this issue has not deterred preclinical studies of GSK3β 
inhibitors for the treatment of many cancer types (reviewed in Miyashita et al., 2009b) or 
Phase II clinical trials for the treatment of neurological diseases (Chico et al., 2010). 
Currently, two clinical trials are being undertaken to test a pharmacological GSK3β inhibitor 
(LY2090314) for enhancement of the anti-tumor effect of chemotherapeutic agents for 
advanced solid cancer (phase I: http://clinicaltrials.gov/ct2/show/study/NCT01287520) 
and leukemia (phase II: http://clinicaltrials.gov/ct2/show/study/NCT01214603). Such 
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trials targeting GSK3β should complement, enhance or substitute the current front line 
therapies that target growth factor receptors and angiogenic factors in refractory colorectal 
cancer. 
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1. Introduction 
The process of cancer cell metastasis is one of the latest steps in cancer progression that 
involves escape from the primary tumor through the vascular system to local lymph nodes 
and distant organs, recently reviewed by Chaffer and Weinberg (Chaffer & Weinberg,  
2011). For a cancer cell to metastasize, it must escape the primary tumor by obtaining 
features that allows detachment from neoplastic epithelial structure, invasion through 
extracellular matrices, intravasation, survival in the blood circulation, extravasation, 
establishment or homing in a novel organ and local de novo proliferation. Colorectal cancers 
(CRC) comprise different subtypes and vary in the degree of differentiation as well as in the 
local invasion pattern in the tumor periphery. The invasion pattern is partly related to the 
metastatic ability of the tumor, and the invasion pattern can be fully discerned by 
microscopy analysis. Molecular characteristics related to the invasion pattern may help in 
the histopathological diagnosis to provide a prognostic perspective for the patient and 
potentially identify which patient would benefit from a certain therapy. For CRC, an 
invasion pattern related to the ability of cancer cells to form buds and focal single cell 
invasion into the neighboring stroma has obtained much attention. The invasive cancer cells 
are known as budding cancer cells and the budding phenomenon describes a morphological 
event, which is becoming better characterized at the molecular level. In this chapter, I will 
go through some of the molecular characteristics linked to the budding cancer cells and link 
the observations to the morphologic and molecular changes related to epithelial-to-
mesenchymal transition (EMT) often assigned to locally disseminating cancer cells.  
1.1 Identification of budding colorectal cancer cells 
Two types of metastatic processes can be considered: active and passive. Passive metastasis 
occurs when cancer cells enter the vascular system, for example by being captured by 
disrupted vessels in the tumors, and subsequently being trapped in microvessels for 
example in the liver or lung, where the cancer cells initially proliferate within the vessel and 
later on disseminate into the parenchyma of the organ. Active metastasis is considered to 
involve a certain level of EMT in the primary tumor followed by invasion into the vascular 
system, extravasation by crossing the vascular wall and invasion into the new organ, and 
then reverting to an epithelial cancer cell capable of de novo proliferation and differentiation 
to form new tumors.  
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1. Introduction 
The process of cancer cell metastasis is one of the latest steps in cancer progression that 
involves escape from the primary tumor through the vascular system to local lymph nodes 
and distant organs, recently reviewed by Chaffer and Weinberg (Chaffer & Weinberg,  
2011). For a cancer cell to metastasize, it must escape the primary tumor by obtaining 
features that allows detachment from neoplastic epithelial structure, invasion through 
extracellular matrices, intravasation, survival in the blood circulation, extravasation, 
establishment or homing in a novel organ and local de novo proliferation. Colorectal cancers 
(CRC) comprise different subtypes and vary in the degree of differentiation as well as in the 
local invasion pattern in the tumor periphery. The invasion pattern is partly related to the 
metastatic ability of the tumor, and the invasion pattern can be fully discerned by 
microscopy analysis. Molecular characteristics related to the invasion pattern may help in 
the histopathological diagnosis to provide a prognostic perspective for the patient and 
potentially identify which patient would benefit from a certain therapy. For CRC, an 
invasion pattern related to the ability of cancer cells to form buds and focal single cell 
invasion into the neighboring stroma has obtained much attention. The invasive cancer cells 
are known as budding cancer cells and the budding phenomenon describes a morphological 
event, which is becoming better characterized at the molecular level. In this chapter, I will 
go through some of the molecular characteristics linked to the budding cancer cells and link 
the observations to the morphologic and molecular changes related to epithelial-to-
mesenchymal transition (EMT) often assigned to locally disseminating cancer cells.  
1.1 Identification of budding colorectal cancer cells 
Two types of metastatic processes can be considered: active and passive. Passive metastasis 
occurs when cancer cells enter the vascular system, for example by being captured by 
disrupted vessels in the tumors, and subsequently being trapped in microvessels for 
example in the liver or lung, where the cancer cells initially proliferate within the vessel and 
later on disseminate into the parenchyma of the organ. Active metastasis is considered to 
involve a certain level of EMT in the primary tumor followed by invasion into the vascular 
system, extravasation by crossing the vascular wall and invasion into the new organ, and 
then reverting to an epithelial cancer cell capable of de novo proliferation and differentiation 
to form new tumors.  
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Budding cancer cells likely belong to the category of active metastasis process because their 
prevalence is directly linked to metastasis and is independent of the TNM classification 
(Nakamura et al, 2005; Okuyama et al, 2003; Prall et al, 2005; Ueno et al, 2002). Japanese 
histopathologists have many years tradition for evaluating growth and invasion patterns in 
CRC including addressing the clinical implications (Fujimori et al, 2009). A clinical 
significance of budding cancer cells was first described in colon cancers in 1993 by Hase et al 
(Hase et al, 1993). Hase et al (Hase et al, 1993) defined the budding cancer cells as “small 
clusters of undifferentiated cancer cells located ahead of the invasive front of the lesion”.  
Hase et al (Hase et al, 1993) evaluated the degree of budding cancer cells in normal 
hematoxylin and eosin (H&E) stained sections, an approach being widely used by others 
(Nakamura et al, 2005; Okuyama et al, 2003; Ueno et al, 2002). Because the budding cancer 
cells are often present in a dense desmoplastic or highly inflamed stroma and because 
budding cancer cells can acquire morphologically odd shapes (see below), a precise 
identification of budding cancer cells in H&E stained sections may not always be straight 
forward (Turner et al, 2007) at least for non-pathologists. Later studies have employed 
cytokeratin immunohistochemistry whereby budding cancer cells are much easier identified 
(Prall, 2007; Prall et al, 2005; Turner et al, 2007; Zlobec et al, 2010). The use of cytokeratin 
immunohistochemistry to detect cancer cell budding versus evaluation in H&E stained 
sections may lower the proportion of misclassified cases.  
The prevalence of tumor cell budding varies strongly from tumor to tumor and Hase et al 
(Hase et al, 1993) stratified tumors into BD-1 (none or mild) and BD-2 (moderate or severe) 
based on the H&E stained sections. Prall et al (Prall et al, 2005) stratified tumors into low 
and high budding based on sections immunohistochemically stained for cytokeratins and 
counted all cytokeratin-positive cancer cell clusters with less than 5 nuclei. Hase et al (Hase 
et al, 1993) classified approximately 25% of all CRC analyzed as BD-2 and Prall et al  (Prall et 
al, 2005) classified approximately 30% as high level budding. 
Cancer cell budding as it is observed in colon and rectal adenocarcinomas should not be 
confused with the diffuse growth pattern, which is common in other gastrointestinal cancers 
and in contrast to tumors with a solid (or expanding) growth pattern. CRC showing a 
diffuse growth pattern are low differentiated neoplasms and do not show signs of tubular or 
glandular formations. Therefore quantitative estimation of cancer cell budding even done 
using cytokeratin immunohistochemistry should be done with some caution.  
The degree of cancer cell budding as stratified into groups with none, mild, moderate and 
strong budding, or less or more than 5 cells in a cluster, indicate that cancer cell budding is 
not an “all or none” phenomenon, but reflects gradual differences. Nonetheless, both studies 
(Hase et al, 1993; Prall et al, 2005) showed that tumors with the highest level of budding 
significantly more often linked to lymph node metastasis than tumors with a low level of 
budding. The highest level of budding was, not surprisingly, seen in patients with the 
poorest survival rate, however, cancer biology reflects individual heterogeneity and in fact, 
some tumors with low budding also show metastatic events (Hase et al, 1993; Prall et al, 
2005; Tanaka et al, 2003; Ueno et al, 2002).  
1.2 Histo-morphological characterization 
One of the morphological features of the budding cancer cells in CRC is their characteristics 
of dedifferentiation and acquisition of odd shapes as described at the ultra-structural level 
by Gabbert et al in 1985 (Gabbert et al, 1985).  These authors studied DMH-induced colon 
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cancers in rats and found that poorly differentiated tumors, which showed frequency of 
lymph vessel invasion, also had isolated cancer cells along the invasive front. Gabbert et al 
(Gabbert et al, 1985) states about the cancer cells located ahead of the invasive front that 
“Their nuclei are very large and at their cell surface show no signs of differentiation such as 
formation of microvilli or formation of a basement membrane are discernible.” Thus the 
cellular characteristics of isolated cancer cells suggested general dedifferentiation compared 
to the cancer cells placed within the adjacent glandular structures.  In addition, the isolated 
cancer cells at the invasive front showed overt cell shape: “The cell shape of more or less 
isolated tumor cells at the foremost invasion front is extremely variable … ranging from a 
round or oval to a sand glass-like.” These observations are consistent with the budding 
cancer cells in human CRC identified both in H&E stained sections as well as cytokeratin 
immuno-peroxidase stained sections, see for example the studies by Prall and Turner et al 
(Prall, 2007; Prall et al, 2005; Turner et al, 2007). According to the histological characteristitcs 
of the budding CRC cells at the invasive front, the stepwise process of budding-directed 
growth can be divided into the following steps 1) the budding cancer cells detach from the 
glandular structures, 2) morphologically change cell shape and 3) invade a short distance, 
say up to 400µm, through the adjacent tumor-associated stroma and 4) settle and 5) found 
novel glandular structures. Budding CRC cells are rarely seen in the central areas of the 
tumors, suggesting that the local environment, the stroma constituting the tumor periphery, 
is dictating the budding process together with the cancer cells. Interestingly, the 
morphological characteristics of dedifferentiation and dynamic change in cell shape are 
consistent with characteristics of cells undergoing EMT as described for cultured cells  
(Kirkland, 2009; Thuault et al, 2006).  
Together with the findings that the prevalence of budding cancer cells is linked to more 
metastatic cancers, strongly suggests that the budding cancer cells also possess cancer stem 
cell activity. Thus the budding CRC cells possess all canonical requirements for actively 
metastasizing cancer cells, including the abilities to undergo EMT and the ability of self-
renewal. The stepwise process of the budding cancer cell requires significant molecular 
changes of the cell: for detachment from neoplastic epithelium, dedifferentiation, EMT, cell 
migration and invasion, and progenitor activity for de novo proliferation. Considering that 
budding CRC cells undergo such a dramatic transient program, probably within a relatively 
short time frame, the budding CRC cells as an entire cell population constitute a 
heterogeneous group of cancer cells that possess a strongly modulating molecular profile. In 
the following I will go through some of the molecular characteristics reported for the 
budding CRC cells, first cell surface associated proteins and thereafter intracellular 
molecules. The molecular characteristics involve proteins that participate in regulating 
differentiation, transcription, translation, cell migration, cell-cell interactions, and adhesion.  
2. Laminin-2 (Ln-2)  
The mRNA encoding the Ln-2 chain is the first described molecular marker of the budding 
CRC cells (Pyke et al, 1994). Pyke et al (Pyke et al, 1994) found Ln-2 mRNA positive cancer 
cells in all of 16 colon cancers varying in the presence of positive cells. In a later report, Pyke 
et al (Pyke et al, 1995) confirmed that the mRNA expression observed in budding colon 
cancer cells is followed by protein expression in the same cells using a Ln-2 specific 
antibody.  Sordat et al (Sordat et al, 1998) reported similar observations in colon cancers 
using other Ln-2 antibody preparations. Laminins are a group of extracellular 
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antibody.  Sordat et al (Sordat et al, 1998) reported similar observations in colon cancers 
using other Ln-2 antibody preparations. Laminins are a group of extracellular 
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glycoproteins being important constituents of basement membrane. They are heterotrimers 
composed of ,  and  chains of which there are 5, 4 and 3 isoforms, respectively. The 
currently used systematic nomenclature defines the composition of a laminin heterotrimers 
(Aumailley et al, 2005), for example laminin-111 is composed of 1, 1 and 1 chains and has 
replaced the earlier used name laminin-1, the most predominant laminin in basement 
membrane.  
The Ln-2 chain is only present in the laminin-332 variant, previously known as laminin-5 
(Guess & Quaranta, 2009). Laminin-332 links the basement membrane via integrins to 
hemidesmosomes and thereby stabilizes the polarized positioning of epithelial cell to the 
basement membrane. Laminins are generally secreted from cells as fully composed 
heterotrimers, Ln-2 being the only exception (Guess & Quaranta, 2009). Ln-2 can be 
secreted as monomer or in complex with the Ln-3 chain (Guess & Quaranta, 2009) and may 
have an important significance during budding in CRC (Guess et al, 2009). Pyke et al (Pyke 
et al, 1995) found Ln-2 within the cytoplasm of the budding colon cancer cells and only in 
rare cases observed basement membrane associated Ln-2 immunoreactivity. Sordat et al 
(Sordat et al, 1998) in contrast found prominent Ln-2 immunoreactivity both in the 
cytoplasm of budding CRC cells and in basement membrane along differentiated tumor cell 
islands. Today, several monoclonal antibodies against Ln-2 are commercially available, 
some recognize both cytoplasmic and basement membrane associated Ln-2, and others are 
specific for the cytoplasmic precursor form (Hansen et al, 2008; Lindberg et al, 2006). Using 
Ln-2 as marker for budding CRC cells, the antibody employed should therefore be chosen 
with some consideration.  
An interesting finding reported by Sordat et al (Sordat et al, 1998), is that budding cancer 
cells in addition to express Ln-2 also express the Ln-3 chain, but only at a low level 
express the Ln-3 chain. These observations suggest that the secreted Ln-2 monomer and 
Ln-3-2 heterodimer may not function by direct integration into the basement membrane. 
Other functions have in contrast been found for the secreted Ln-2 and Ln-3 chains. Cell 
surface directed proteolyic activity performed by matrix metalloproteinase (MMP)-2 
(Giannelli et al, 1997) and membrane type-1 (MT1)-MMP (Koshikawa et al, 2000) generates 
fragments of the Ln-2 chain constituting epithelial growth factor (EGF)-like domains that 
stimulates cell motility. In addition, a cleavage product of Ln-3 chain generated by MT1-
MMP promotes cell migration (Udayakumar et al, 2003). The observations taken together 
suggest that Ln-2 and Ln-3 chains are contributing to the migratory processes of the 
budding CRC cells.  
In clinical studies, the level of tumor budding in CRC correlated with the level of Ln-2 
positive budding cells (Shinto et al, 2005). Shinto et al (Shinto et al, 2005) also reported that 
high-grade Ln-2 expression was an independent prognostic indicator, and Aoki et al (Aoki 
et al, 2002) reported a significant association with synchronous liver metastases. Today, Ln-
2 expression is considered a strong and potentially clinically applicable prognostic marker 
that reflects the level of cancer cell budding not only in CRC but also in other cancer types 
including bladder, esophageal and oral cancer (Guess & Quaranta, 2009). 
3. Urokinase Plasminogen Activator Receptor (uPAR)  
uPAR (CD87) is a 3-domain highly glycosylated, glycolipid anchored protein. uPAR is a 
specific high affinity binding receptor for (pro-)uPA, but also binds a number of other 
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proteins in the extracellular matrix, in particular vitronectin (Eden et al, 2011; Gardsvoll & 
Ploug, 2007). The glycosyl-phosphatidylinositol (GPI) moiety of uPAR attaches the protein 
to the outer lipid layer of the cell membrane and allows uPAR to move laterally on cell 
surfaces and hence rapidly concentrate at focal sites where it mediates its uPA-directed 
activity and its interaction with vitronectin to the extracellular matrix. Active plasmin is 
generated from circulating plasminogen on the cell surfaces by a cascade mechanism 
involving plasmin-mediated conversion of pro-uPA to active uPA. uPA directed 
plasminogen activation is strongly enhanced after binding of uPA to uPAR on the cell 
surface (Ploug, 2003; Romer et al, 2004).  
The active plasmin enzymatically cleaves or degrades fibrin and fibronectin deposited in the 
extracellular matrix (ECM), laminins, including the Ln-3 chain (Goldfinger et al, 1998), 
L1CAM described below (Mechtersheimer et al, 2001), and activates other matrix degrading 
protease including MMPs. Through activation of pro-MMPs, MMP-3 (stromelysin-1), MMP-
9 (gelatinase-B), MMP-13 (collagenase-3) and MMP-2 (Hald et al, 2011; Juncker-Jensen & 
Lund, 2011; Monea et al, 2002; Suzuki et al, 2007), plasmin may also mediate degradation of 
other ECM components including fibrillar collagens. In addition, plasmin activates growth 
factors like TGF- (Odekon et al, 1994). Active TGF- can transform fibroblasts into 
myofibroblasts (Ronnov-Jessen & Petersen, 1993) and initiate the EMT process in mammary 
epithelial cells  (Fuxe et al, 2010; Thuault et al, 2006). Thus acceleration of the plasminogen 
activation cascade pathway may elevate the pericellular proteolytic activity and cause 
dramatic changes in cellular phenotypes.  
uPAR was described in budding CRC cells first time in 1994 identified both at the mRNA 
and protein level (Pyke et al, 1995). Direct comparison with Ln-2 expression indicated a 
strong overlap with Ln-2 mRNA (Pyke et al, 1995). Later studies have shown co-expression 
of uPAR and Ln-2 in double immunofluorescence analyses in budding CRC cells (Illemann 
et al, 2009). uPAR is highly expressed at the invasive front of most CRC not only in budding 
cancer cells, but also in the complex stromal environment constituting inflammatory cells 
and myofibroblasts. Activated macrophages located at the invasive front of CRC express 
high levels of uPAR on the cell surface, hampering an easy discrimination between uPAR-
positive budding cancer cells and macrophages. Therefore, to unambiguously identify 
uPAR-positive budding CRC cells, combining antibodies against uPAR and the epithelial 
marker cytokeratin (or Ln-2) in a double immunofluorescence analysis, would be necessary 
(Illemann et al, 2009; Romer et al, 2004). uPA mRNA is also expressed in the budding CRC 
cells (Illemann et al, 2009) indicating that uPAR may function directly through mediation of 
uPA-directed activities.  
In normal colon tissue, uPAR is expressed in a group of differentiated epithelial cells located 
at the luminal edge of the villi. It has been suggested that uPAR on these cells serve to 
promote detachment of terminally differentiated colonocytes to be shedded into the colon 
lumen (Pyke et al, 1994). One may speculate that detachment of budding CRC cells from the 
main neoplastic glandular structures may mimic the shedding of terminally differentiated 
cells. In the case of cancer invasion the cancer cells are shed into the tumor stroma. 
However, this hypothesis does not corroborate with the fact that budding CRC cells show 
characteristics of dedifferentiation. Nevertheless, this is an interesting interpretation and the 
invasion of budding CRC cells remain an abnormal process. 
Tissue extracts from colon cancers contain highly elevated levels of uPAR compared to the 
normal tissue, and the high uPAR levels are associated with adverse outcome. uPAR levels 
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In clinical studies, the level of tumor budding in CRC correlated with the level of Ln-2 
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high-grade Ln-2 expression was an independent prognostic indicator, and Aoki et al (Aoki 
et al, 2002) reported a significant association with synchronous liver metastases. Today, Ln-
2 expression is considered a strong and potentially clinically applicable prognostic marker 
that reflects the level of cancer cell budding not only in CRC but also in other cancer types 
including bladder, esophageal and oral cancer (Guess & Quaranta, 2009). 
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uPAR (CD87) is a 3-domain highly glycosylated, glycolipid anchored protein. uPAR is a 
specific high affinity binding receptor for (pro-)uPA, but also binds a number of other 
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proteins in the extracellular matrix, in particular vitronectin (Eden et al, 2011; Gardsvoll & 
Ploug, 2007). The glycosyl-phosphatidylinositol (GPI) moiety of uPAR attaches the protein 
to the outer lipid layer of the cell membrane and allows uPAR to move laterally on cell 
surfaces and hence rapidly concentrate at focal sites where it mediates its uPA-directed 
activity and its interaction with vitronectin to the extracellular matrix. Active plasmin is 
generated from circulating plasminogen on the cell surfaces by a cascade mechanism 
involving plasmin-mediated conversion of pro-uPA to active uPA. uPA directed 
plasminogen activation is strongly enhanced after binding of uPA to uPAR on the cell 
surface (Ploug, 2003; Romer et al, 2004).  
The active plasmin enzymatically cleaves or degrades fibrin and fibronectin deposited in the 
extracellular matrix (ECM), laminins, including the Ln-3 chain (Goldfinger et al, 1998), 
L1CAM described below (Mechtersheimer et al, 2001), and activates other matrix degrading 
protease including MMPs. Through activation of pro-MMPs, MMP-3 (stromelysin-1), MMP-
9 (gelatinase-B), MMP-13 (collagenase-3) and MMP-2 (Hald et al, 2011; Juncker-Jensen & 
Lund, 2011; Monea et al, 2002; Suzuki et al, 2007), plasmin may also mediate degradation of 
other ECM components including fibrillar collagens. In addition, plasmin activates growth 
factors like TGF- (Odekon et al, 1994). Active TGF- can transform fibroblasts into 
myofibroblasts (Ronnov-Jessen & Petersen, 1993) and initiate the EMT process in mammary 
epithelial cells  (Fuxe et al, 2010; Thuault et al, 2006). Thus acceleration of the plasminogen 
activation cascade pathway may elevate the pericellular proteolytic activity and cause 
dramatic changes in cellular phenotypes.  
uPAR was described in budding CRC cells first time in 1994 identified both at the mRNA 
and protein level (Pyke et al, 1995). Direct comparison with Ln-2 expression indicated a 
strong overlap with Ln-2 mRNA (Pyke et al, 1995). Later studies have shown co-expression 
of uPAR and Ln-2 in double immunofluorescence analyses in budding CRC cells (Illemann 
et al, 2009). uPAR is highly expressed at the invasive front of most CRC not only in budding 
cancer cells, but also in the complex stromal environment constituting inflammatory cells 
and myofibroblasts. Activated macrophages located at the invasive front of CRC express 
high levels of uPAR on the cell surface, hampering an easy discrimination between uPAR-
positive budding cancer cells and macrophages. Therefore, to unambiguously identify 
uPAR-positive budding CRC cells, combining antibodies against uPAR and the epithelial 
marker cytokeratin (or Ln-2) in a double immunofluorescence analysis, would be necessary 
(Illemann et al, 2009; Romer et al, 2004). uPA mRNA is also expressed in the budding CRC 
cells (Illemann et al, 2009) indicating that uPAR may function directly through mediation of 
uPA-directed activities.  
In normal colon tissue, uPAR is expressed in a group of differentiated epithelial cells located 
at the luminal edge of the villi. It has been suggested that uPAR on these cells serve to 
promote detachment of terminally differentiated colonocytes to be shedded into the colon 
lumen (Pyke et al, 1994). One may speculate that detachment of budding CRC cells from the 
main neoplastic glandular structures may mimic the shedding of terminally differentiated 
cells. In the case of cancer invasion the cancer cells are shed into the tumor stroma. 
However, this hypothesis does not corroborate with the fact that budding CRC cells show 
characteristics of dedifferentiation. Nevertheless, this is an interesting interpretation and the 
invasion of budding CRC cells remain an abnormal process. 
Tissue extracts from colon cancers contain highly elevated levels of uPAR compared to the 
normal tissue, and the high uPAR levels are associated with adverse outcome. uPAR levels 
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were found to constitute an independent prognostic parameter, importantly being 
independent of progression stage (Ganesh et al, 1994). A soluble form of uPAR, generated 
after enzymatic cleavage by uPA or plasmin (Hoyer-Hansen et al, 1997), can be measured in 
blood, and studies of plasma samples from colon cancer patients substantiate the prognostic 
significance of uPAR (Stephens et al, 1999; Thurison et al, 2010). As noted above, several 
different cell types in colon cancers express uPAR, and therefore the prognostic value of 
uPAR cannot be ascribed solely to the uPAR-positive budding CRC cells. However, in 
adenocarcinomas, macrophages are by far the predominant uPAR expressing cell type, and 
therefore most likely account for the elevated levels of uPAR in tumor tissue extracts and in 
the blood from the cancer patients (Illemann et al, 2009; Romer et al, 2004). uPAR expressing 
budding cancer cells may nevertheless also contribute to the malignant stage of CRC.  uPAR 
positive cancer cells likely represent a particular malignant cell population since gastric 
cancer patients with poor prognosis associated with micro-metastatic disease more frequently 
had uPAR positive cancer cells identified in the bone marrow (Heiss et al, 2002), and uPAR is 
indeed expressed on invasive cancer cells in gastric cancer (Alpizar-Alpizar et al, 2010). 
4. L1 Cell Adhesion Molecule (L1CAM) 
L1CAM (L1, CD171) is one of four single-pass trans-membrane proteins forming the group 
of L1CAM. L1 was first described in 1984 as a neural cell adhesion molecule distinct from 
the closely related N-CAM group of proteins (Faissner et al, 1984). The other three members 
of the L1CAM family are NrCAM, CHL1 and neurofascin. All four genes are thoroughly 
characterized and highly expressed in the nervous system (Chen & Zhou, 2010). The 
L1CAMs contain 6 immunoglobulin-like motifs and 4 or 5 fibronectin type III repeats. The 
Cytoplasmic domain allows binding to cytoskeletal ankyrin and ERM proteins (ezrin-
radixin-moesin) that associates with actin filaments (Bretscher et al, 2002). L1 is involved in 
cell-cell adhesion by homophilic interactions, cell-ECM interactions and cell surface 
interactions by binding integrins and can directly mediate cytoskeletal changes and signal 
transduction through its cytoplasmic domain (Chen & Zhou, 2010; Kadmon & Altevogt, 
1997; Schmid & Maness, 2008). L1 is highly expressed in normal and diseased brain, and 
plays a critical role for development and organization of neuronal cell groups (Demyanenko 
et al, 2001; Sakurai et al, 2001). L1 has functions overlapping with NrCAM identified in 
double-deficient mice that show postnatal lethality in contrast to the corresponding single 
deficient mice (Sakurai et al, 2001). L1 has been reported to mediate cell adhesion and 
transendothelial migration also of dendritic cells (Maddaluno et al, 2009). 
Expression of L1 in budding CRC cells has been shown both at the protein (Gavert et al, 
2005; Kajiwara et al, 2011) and the mRNA level (Kajiwara et al, 2011). Gavert et al (Gavert et 
al, 2005) found L1 positive budding cancer cells in 68% of 19 colon cancer cases studied.  
Kajiwara et al (Kajiwara et al, 2011) studied 275 cases of CRC and also found L1 expression 
at the invasive front. Furthermore the authors showed that the L1 expression increased 
according to the grade of tumor budding and that L1 expression was correlated with nodal 
involvement both at the protein and mRNA level. In normal colon mucosa, L1 is expressed 
on sporadic intramucosal nerve axons and L1 positive enteric nerve axons were found in the 
deeper layers of the bowel wall (Gavert et al, 2005). In fact, the authors also noted that L1-
positive colon cancer cells invaded along L1 positive nerve axons, and suggested that L1-
mediated adhesive interactions between the two cell populations may facilitate the invasion 
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of cancer cells. In this connection, it is curious that also uPAR can be found in enteric nerve 
bundles (Laerum et al, 2008). It is also interesting to note that L1 has been detected in human 
and murine myeloid and lymphoid cells (Ebeling et al, 1996; Kowitz et al, 1992) and that no 
L1 immunoreactivity has been reported in tumor stroma of the CRC. Whether the level of L1 
in these cells is below the detection limit, is lost by proteolytic shedding, transcriptional or 
translational downregulation (Hubbe et al, 1993) remains to be clarified.   
Proteolytic shedding of the L1 ectodomain has been reported to be performed by the 
disintegrin and metalloproteinases (ADAM) ADAM10 (Gutwein et al, 2003; Maretzky et al, 
2005; Mechtersheimer et al, 2001), ADAM17 (Maretzky et al, 2005), and plasmin 
(Mechtersheimer et al, 2001). Shedding of the L1 ectodomain will prevent cell-cell 
interactions and binding interactions with other cell surface proteins and matrix 
components affecting the biochemical functions of the protein. Cleavage of L1 by ADAM10 
releases an approximately 200kDa L1 fragment that can promote cell migration (Gutwein et 
al, 2003; Maretzky et al, 2005; Mechtersheimer et al, 2001). Similar activity was reported for 
the plasmin released L1 fragment (Mechtersheimer et al, 2001). In this connection it is 
important to note that ADAM10 immunoreactivity has been reported to be co-expressed in 
budding CRC cells (Gavert et al, 2005), and that cleavage can occur to an extent that a 
soluble L1 fragment can be measured in serum from cancer patients (Fogel et al, 2003). L1 
expression in budding CRC cells may therefore be involved in at least 3 different processes 
during CRC cell budding: detachment from the differentiated neoplastic glandular 
structures, cell-cell interactions with L1-positive nerve axons or dendritic cells as well as in 
the contribution to CRC cell migration upon extracellular enzymatic processing.  
5. Matrix Metalloproteinase 7 (MMP-7) 
A number of other genes have been found to be focally expressed in the budding colon 
cancer cells. I have already mentioned some of the MMPs in connection with Ln-2 
processing and plasmin-activated MMPs. MMP-7 (matrilysin-1) belongs to the group of 
matrix metalloproteinases (MMPs) (Das et al, 2003; Folgueras et al, 2004), which are zinc 
dependent endopeptidases known for their ability to cleave several ECM proteins. The 
activity of MMPs is regulated at the level of pro-MMP conversion and blocking by specific 
tissue inhibitors of metalloproteinases (TIMP) of which 4 are known (Nagase et al, 2006). 
MMP-7 can digest several ECM proteins including elastin, collagen IV and vitronectin (Ii et 
al, 2006). In addition, MMP7 has been shown to play important roles in the regulation of a 
variety of biochemical processes, such as the activation of MMP-2 and MMP-9 and shedding 
of Fas-ligand, pro-tumor necrosis factor-, and E-cadherin (Curino et al, 2004; Ii et al, 2006; 
Nagase et al, 2006). MMP-7 itself is activated by other endoproteinases including plasmin 
and trypsin. MMP-7 was recently shown to bind and cleave the Ln-3 chain. The cleaved 
Ln-3 fragments was found to mediate cell migration (Remy et al, 2006). MMP-7 
immunoreactivity has been reported in budding CRC cancer cells (Kurokawa et al, 2005; 
Masaki et al, 2001) and was found to co-localize with laminin-5 and Ln-3 chain in human 
xenografted colon tumors (Remy et al, 2006). In the relatively small prognostic study by 
Masaki et al (Masaki et al, 2001), including 38 patients with early CRC, scoring the MMP-7 
immunoreactive budding cancer cells was linked to distant metastasis and adverse outcome. 
However, MMP-7 immunoreactivity was seen in less than half of the cases with moderate to 
severe budding as determined on H&E stained sections, indicating that MMP-7 is not 
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were found to constitute an independent prognostic parameter, importantly being 
independent of progression stage (Ganesh et al, 1994). A soluble form of uPAR, generated 
after enzymatic cleavage by uPA or plasmin (Hoyer-Hansen et al, 1997), can be measured in 
blood, and studies of plasma samples from colon cancer patients substantiate the prognostic 
significance of uPAR (Stephens et al, 1999; Thurison et al, 2010). As noted above, several 
different cell types in colon cancers express uPAR, and therefore the prognostic value of 
uPAR cannot be ascribed solely to the uPAR-positive budding CRC cells. However, in 
adenocarcinomas, macrophages are by far the predominant uPAR expressing cell type, and 
therefore most likely account for the elevated levels of uPAR in tumor tissue extracts and in 
the blood from the cancer patients (Illemann et al, 2009; Romer et al, 2004). uPAR expressing 
budding cancer cells may nevertheless also contribute to the malignant stage of CRC.  uPAR 
positive cancer cells likely represent a particular malignant cell population since gastric 
cancer patients with poor prognosis associated with micro-metastatic disease more frequently 
had uPAR positive cancer cells identified in the bone marrow (Heiss et al, 2002), and uPAR is 
indeed expressed on invasive cancer cells in gastric cancer (Alpizar-Alpizar et al, 2010). 
4. L1 Cell Adhesion Molecule (L1CAM) 
L1CAM (L1, CD171) is one of four single-pass trans-membrane proteins forming the group 
of L1CAM. L1 was first described in 1984 as a neural cell adhesion molecule distinct from 
the closely related N-CAM group of proteins (Faissner et al, 1984). The other three members 
of the L1CAM family are NrCAM, CHL1 and neurofascin. All four genes are thoroughly 
characterized and highly expressed in the nervous system (Chen & Zhou, 2010). The 
L1CAMs contain 6 immunoglobulin-like motifs and 4 or 5 fibronectin type III repeats. The 
Cytoplasmic domain allows binding to cytoskeletal ankyrin and ERM proteins (ezrin-
radixin-moesin) that associates with actin filaments (Bretscher et al, 2002). L1 is involved in 
cell-cell adhesion by homophilic interactions, cell-ECM interactions and cell surface 
interactions by binding integrins and can directly mediate cytoskeletal changes and signal 
transduction through its cytoplasmic domain (Chen & Zhou, 2010; Kadmon & Altevogt, 
1997; Schmid & Maness, 2008). L1 is highly expressed in normal and diseased brain, and 
plays a critical role for development and organization of neuronal cell groups (Demyanenko 
et al, 2001; Sakurai et al, 2001). L1 has functions overlapping with NrCAM identified in 
double-deficient mice that show postnatal lethality in contrast to the corresponding single 
deficient mice (Sakurai et al, 2001). L1 has been reported to mediate cell adhesion and 
transendothelial migration also of dendritic cells (Maddaluno et al, 2009). 
Expression of L1 in budding CRC cells has been shown both at the protein (Gavert et al, 
2005; Kajiwara et al, 2011) and the mRNA level (Kajiwara et al, 2011). Gavert et al (Gavert et 
al, 2005) found L1 positive budding cancer cells in 68% of 19 colon cancer cases studied.  
Kajiwara et al (Kajiwara et al, 2011) studied 275 cases of CRC and also found L1 expression 
at the invasive front. Furthermore the authors showed that the L1 expression increased 
according to the grade of tumor budding and that L1 expression was correlated with nodal 
involvement both at the protein and mRNA level. In normal colon mucosa, L1 is expressed 
on sporadic intramucosal nerve axons and L1 positive enteric nerve axons were found in the 
deeper layers of the bowel wall (Gavert et al, 2005). In fact, the authors also noted that L1-
positive colon cancer cells invaded along L1 positive nerve axons, and suggested that L1-
mediated adhesive interactions between the two cell populations may facilitate the invasion 
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of cancer cells. In this connection, it is curious that also uPAR can be found in enteric nerve 
bundles (Laerum et al, 2008). It is also interesting to note that L1 has been detected in human 
and murine myeloid and lymphoid cells (Ebeling et al, 1996; Kowitz et al, 1992) and that no 
L1 immunoreactivity has been reported in tumor stroma of the CRC. Whether the level of L1 
in these cells is below the detection limit, is lost by proteolytic shedding, transcriptional or 
translational downregulation (Hubbe et al, 1993) remains to be clarified.   
Proteolytic shedding of the L1 ectodomain has been reported to be performed by the 
disintegrin and metalloproteinases (ADAM) ADAM10 (Gutwein et al, 2003; Maretzky et al, 
2005; Mechtersheimer et al, 2001), ADAM17 (Maretzky et al, 2005), and plasmin 
(Mechtersheimer et al, 2001). Shedding of the L1 ectodomain will prevent cell-cell 
interactions and binding interactions with other cell surface proteins and matrix 
components affecting the biochemical functions of the protein. Cleavage of L1 by ADAM10 
releases an approximately 200kDa L1 fragment that can promote cell migration (Gutwein et 
al, 2003; Maretzky et al, 2005; Mechtersheimer et al, 2001). Similar activity was reported for 
the plasmin released L1 fragment (Mechtersheimer et al, 2001). In this connection it is 
important to note that ADAM10 immunoreactivity has been reported to be co-expressed in 
budding CRC cells (Gavert et al, 2005), and that cleavage can occur to an extent that a 
soluble L1 fragment can be measured in serum from cancer patients (Fogel et al, 2003). L1 
expression in budding CRC cells may therefore be involved in at least 3 different processes 
during CRC cell budding: detachment from the differentiated neoplastic glandular 
structures, cell-cell interactions with L1-positive nerve axons or dendritic cells as well as in 
the contribution to CRC cell migration upon extracellular enzymatic processing.  
5. Matrix Metalloproteinase 7 (MMP-7) 
A number of other genes have been found to be focally expressed in the budding colon 
cancer cells. I have already mentioned some of the MMPs in connection with Ln-2 
processing and plasmin-activated MMPs. MMP-7 (matrilysin-1) belongs to the group of 
matrix metalloproteinases (MMPs) (Das et al, 2003; Folgueras et al, 2004), which are zinc 
dependent endopeptidases known for their ability to cleave several ECM proteins. The 
activity of MMPs is regulated at the level of pro-MMP conversion and blocking by specific 
tissue inhibitors of metalloproteinases (TIMP) of which 4 are known (Nagase et al, 2006). 
MMP-7 can digest several ECM proteins including elastin, collagen IV and vitronectin (Ii et 
al, 2006). In addition, MMP7 has been shown to play important roles in the regulation of a 
variety of biochemical processes, such as the activation of MMP-2 and MMP-9 and shedding 
of Fas-ligand, pro-tumor necrosis factor-, and E-cadherin (Curino et al, 2004; Ii et al, 2006; 
Nagase et al, 2006). MMP-7 itself is activated by other endoproteinases including plasmin 
and trypsin. MMP-7 was recently shown to bind and cleave the Ln-3 chain. The cleaved 
Ln-3 fragments was found to mediate cell migration (Remy et al, 2006). MMP-7 
immunoreactivity has been reported in budding CRC cancer cells (Kurokawa et al, 2005; 
Masaki et al, 2001) and was found to co-localize with laminin-5 and Ln-3 chain in human 
xenografted colon tumors (Remy et al, 2006). In the relatively small prognostic study by 
Masaki et al (Masaki et al, 2001), including 38 patients with early CRC, scoring the MMP-7 
immunoreactive budding cancer cells was linked to distant metastasis and adverse outcome. 
However, MMP-7 immunoreactivity was seen in less than half of the cases with moderate to 
severe budding as determined on H&E stained sections, indicating that MMP-7 is not 
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consistently expressed in budding CRC. In a study of 494 CRC cases, MMP-7 mRNA was 
found to be an independent risk factor predicting nodal metastasis (Kurokawa et al, 2005). 
In the context of budding CRC cells, the ability of MMP-7 to shed E-cadherin and cleave the 
Ln-3 chain into a motility stimulating fragment suggest that MMP-7 takes part in the early 
steps involving detachment from the glandular structures and mobilizing cancer cell 
migration.  
6. Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) 
MT1-MMP (MMP-14) immunoreactivity has also been demonstrated in budding CRC cells 
(Hlubek et al, 2004). MT1-MMP belongs to the group of membrane-bound MMPs and is a 
trans-membrane protein capable of cleaving fibrillar collagen. This MMP is essential for 
normal development (Holmbeck et al, 1999). MT1-MMP binds extracellular MMP-2 and 
TIMP-2 into a ternary complex that is important for the regulation of enzymatic activity on 
the cell surface (Sato & Takino, 2010; Strongin, 2010). The active enzyme can also cleave a 
number of other membrane-associated proteins including pro-tumor necrosis factor- and 
CD44 (Folgueras et al, 2004). Expression of MT1-MMP mRNA is prominent in colon cancer 
associated stroma (Okada et al, 1995). As also noted above for evaluation of uPAR 
expression, strong stromal MT1-MMP expression in the invasive front area will prevent 
unambiguous identification of the protein in budding cancer cells. Expression of MT1-MMP 
on the surface of budding CRC cells would allow significant surface associated proteolysis 
either directly or through activation of MMP-2, which together with TIMP-2 would be 
provided by adjacent stromal cells (Holten-Andersen et al, 2005; Okada et al, 1995; Poulsom 
et al, 1992). As already mentioned, MT1-MMP can cleave Ln-2 alone or in cooperation with 
MMP-2, which results in a Ln-2 fragment with capacity to stimulate migration (Koshikawa 
et al, 2005; Koshikawa et al, 2004). More immunohistochemical studies are needed to better 
clarify the expression patterns of MT1-MMP in budding CRC cells.  
The activities of the above mentioned proteins Ln-2, uPAR, L1, MMP-7 and MT1-MMP are 
all taking place on the cell surface and pericellular matrix. The following molecules will be 
related to intracellular acitivities. 
7. -catenin (Wnt pathway) 
-catenin is an important intracellular protein to consider in the characterization of budding 
CRC cells. Nuclear -catenin activates transcription of a number of genes including those 
encoding Ln-2, uPAR and MMP-7 (Brabletz et al, 2004; Crawford et al, 1999; Hlubek et al, 
2001; Mann et al, 1999). -catenin is a protein that binds the cytoplasmic domain of E-
cadherin and by concomitantly binding actin filaments contributes to maintain the 
cytoskeleton and the epithelial integrity. The intracellular localization of -catenin is linked 
to the status of Wnt activity directed through the trans-membrane receptor Frizzled. 
Cellular activation by Wnt cause trans-localization of -catenin to the nuclei, which through 
binding to transcription factors, affects transcription. -catenin is expressed both in the 
differentiated glandular structures and in the budding CRC cells, but the localization 
changes from cytoplasmic to nuclear. In the case of budding CRC cells, -catenin is seen in 
the nuclei (Brabletz et al, 2001; Brabletz et al, 2004; Gavert et al, 2005; Gavert et al, 2011; 
Hlubek et al, 2001; Jass et al, 2003). Translocation of -catenin to the nuclei has been used as 
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a reference marker for CRC cell budding to show co-expression of Ln-2 (Hlubek et al, 2001), 
L1 (Gavert et al, 2011), and disruption of E-cadherin (Brabletz et al, 2001). The EMT process 
and stem cell characteristics has been associated with the activity of -catenin in cooperation 
with TGF- (Brabletz et al, 2005; Fuxe et al, 2010). For a further discussion on signal 
transduction in budding CRC cells I suggest to consult the review by Prall (Prall, 2007). 
8. Hepatocyte growth factor activator inhibitor type 2-Related Small Peptide 
(H2RSP) 
An interesting novel protein identified to be specifically up-regulated in connection with 
CRC cell budding is hepatocyte growth factor activator inhibitor type 2-related small 
peptide (H2RSP) (Uchiyama et al, 2007). The H2RSP gene was first described in 2001 by Itoh 
et al (Itoh et al, 2001), who observed H2RSP expression in tissues obtained from the 
gastrointestinal tract. H2RSP protein, which is identical to immortalization-upregulated 
protein (IMUP-1), is a small protein constituting 106 amino acids. Its interaction partner(s) 
and function(s) remains to be established. An interaction with single stranded G-rich DNA 
probably via a lysine-rich domain of the protein was discussed to be involved in nuclear 
translocalization (Uchiyama et al, 2007). Uchiyama et al (Uchiyama et al, 2007) found by 
immunohistochemistry that H2RSP was located in the cytoplasm of normal un-
differentiated epithelial cells in the colon, but found a change in localization to the nuclei in 
the differentiated epithelial cells. The authors suggested that H2RSP is involved in the 
transition process from the proliferation phase to terminal differentiation of intestinal 
epithelium. Looking at colon tumors, they found H2RSP immunoreactivity to be fully lost in 
the central differentiated tumor areas, but focally upregulated in the invasive front, 
including in budding CRC cells. In these cells, the H2RSP staining was located in the 
cytoplasm. The expression of H2RSP coincided with nuclear localization of -catenin, focal 
co-expression of p16 and focal loss of proliferation marker Ki67. Thus, H2RSP, as confined 
to the epithelial cell population, is an interesting marker of budding CRC indicating a stage 
of dedifferentiation and growth arrest. A potential function in the related hepatocyte growth 
factor/scatter factor signaling pathway through Met receptor, which is taking place at the 
cell surface, seems unlikely so far. 
9. microRNA-21 (miR-21)  
MicroRNAs (miRNA) constitute a group of short, 18-23 base-pair long, non-coding RNAs. 
MiRNAs are processed from precursor RNA transcripts into mature active forms by a 
mechanism only partially understood. A generally accepted sequence of steps for the 
biochemical processing of precursor miRNA to the mature forms is known as the ‘‘linear” 
canonical pathway (Winter et al, 2009). MiRNAs have been found to play particular 
important roles in cell differentiation by negatively regulating translation (Calin & Croce, 
2009; Iorio & Croce, 2009; Lim et al, 2005; Liu & Olson, 2010). miRNAs bind to specific 
3’UTR sequences of mRNAs and thereby prevent efficient translation or mediate 
degradation of target mRNAs. For identification of miRNAs in tissue sections, in situ 
hybridization is an indispensable technique, which different from mRNA in situ 
hybridization cannot be replaced by immunohistochemistry. Specific detection of miRNA in 
situ therefore sets high requirements to the detection probes. Here LNA:DNA chimeric oligo 
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consistently expressed in budding CRC. In a study of 494 CRC cases, MMP-7 mRNA was 
found to be an independent risk factor predicting nodal metastasis (Kurokawa et al, 2005). 
In the context of budding CRC cells, the ability of MMP-7 to shed E-cadherin and cleave the 
Ln-3 chain into a motility stimulating fragment suggest that MMP-7 takes part in the early 
steps involving detachment from the glandular structures and mobilizing cancer cell 
migration.  
6. Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) 
MT1-MMP (MMP-14) immunoreactivity has also been demonstrated in budding CRC cells 
(Hlubek et al, 2004). MT1-MMP belongs to the group of membrane-bound MMPs and is a 
trans-membrane protein capable of cleaving fibrillar collagen. This MMP is essential for 
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TIMP-2 into a ternary complex that is important for the regulation of enzymatic activity on 
the cell surface (Sato & Takino, 2010; Strongin, 2010). The active enzyme can also cleave a 
number of other membrane-associated proteins including pro-tumor necrosis factor- and 
CD44 (Folgueras et al, 2004). Expression of MT1-MMP mRNA is prominent in colon cancer 
associated stroma (Okada et al, 1995). As also noted above for evaluation of uPAR 
expression, strong stromal MT1-MMP expression in the invasive front area will prevent 
unambiguous identification of the protein in budding cancer cells. Expression of MT1-MMP 
on the surface of budding CRC cells would allow significant surface associated proteolysis 
either directly or through activation of MMP-2, which together with TIMP-2 would be 
provided by adjacent stromal cells (Holten-Andersen et al, 2005; Okada et al, 1995; Poulsom 
et al, 1992). As already mentioned, MT1-MMP can cleave Ln-2 alone or in cooperation with 
MMP-2, which results in a Ln-2 fragment with capacity to stimulate migration (Koshikawa 
et al, 2005; Koshikawa et al, 2004). More immunohistochemical studies are needed to better 
clarify the expression patterns of MT1-MMP in budding CRC cells.  
The activities of the above mentioned proteins Ln-2, uPAR, L1, MMP-7 and MT1-MMP are 
all taking place on the cell surface and pericellular matrix. The following molecules will be 
related to intracellular acitivities. 
7. -catenin (Wnt pathway) 
-catenin is an important intracellular protein to consider in the characterization of budding 
CRC cells. Nuclear -catenin activates transcription of a number of genes including those 
encoding Ln-2, uPAR and MMP-7 (Brabletz et al, 2004; Crawford et al, 1999; Hlubek et al, 
2001; Mann et al, 1999). -catenin is a protein that binds the cytoplasmic domain of E-
cadherin and by concomitantly binding actin filaments contributes to maintain the 
cytoskeleton and the epithelial integrity. The intracellular localization of -catenin is linked 
to the status of Wnt activity directed through the trans-membrane receptor Frizzled. 
Cellular activation by Wnt cause trans-localization of -catenin to the nuclei, which through 
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a reference marker for CRC cell budding to show co-expression of Ln-2 (Hlubek et al, 2001), 
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including in budding CRC cells. In these cells, the H2RSP staining was located in the 
cytoplasm. The expression of H2RSP coincided with nuclear localization of -catenin, focal 
co-expression of p16 and focal loss of proliferation marker Ki67. Thus, H2RSP, as confined 
to the epithelial cell population, is an interesting marker of budding CRC indicating a stage 
of dedifferentiation and growth arrest. A potential function in the related hepatocyte growth 
factor/scatter factor signaling pathway through Met receptor, which is taking place at the 
cell surface, seems unlikely so far. 
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MicroRNAs (miRNA) constitute a group of short, 18-23 base-pair long, non-coding RNAs. 
MiRNAs are processed from precursor RNA transcripts into mature active forms by a 
mechanism only partially understood. A generally accepted sequence of steps for the 
biochemical processing of precursor miRNA to the mature forms is known as the ‘‘linear” 
canonical pathway (Winter et al, 2009). MiRNAs have been found to play particular 
important roles in cell differentiation by negatively regulating translation (Calin & Croce, 
2009; Iorio & Croce, 2009; Lim et al, 2005; Liu & Olson, 2010). miRNAs bind to specific 
3’UTR sequences of mRNAs and thereby prevent efficient translation or mediate 
degradation of target mRNAs. For identification of miRNAs in tissue sections, in situ 
hybridization is an indispensable technique, which different from mRNA in situ 
hybridization cannot be replaced by immunohistochemistry. Specific detection of miRNA in 
situ therefore sets high requirements to the detection probes. Here LNA:DNA chimeric oligo 
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probes have shown to fulfill at least  some of the requirement for sufficient specificity and 
sensitivity (Jorgensen et al, 2010; Kloosterman et al, 2006). In an in situ hybridization study 
of miR-21 expression in stage II CRC, expression of miR-21 was seen in some budding CRC 
cell located at the invasive front of the tumors (Nielsen et al, 2011). A clear identification and 
quantitative estimation of the miR-21 positive budding cancer cells was however 
confounded by high miR-21 signal also in the tumor stroma. Therefore further studies are 
needed to better address the association of miR-21 to budding CRC cells, including double 
fluorescence labeling as also discussed above for uPAR. In this case, in situ hybridization 
and immunohistochemistry should be combined as exemplified by Sempere et al 
(Sempere et al, 2010), who applied this technology in routinely processed clinical paraffin 
samples.  
miR-21 is highly upregulated in CRC compared to normal colon tissue (Nielsen et al, 2011; 
Schetter et al, 2008) and high expression is linked to adverse outcome in stage II CRC 
(Nielsen et al, 2011; Schetter et al, 2008). The mechanisms of action of miR-21 in budding 
cancer cells and in cancer progression in general are unclear. In mice lacking miR-21 (Ma et 
al, 2011) the number of chemically induced skin tumors was significantly lower than in wild 
type mice. In keratinocytes from the miR-21 deficient mice, increased expression of SPRY1, 
PTEN and PDCD4 was found, which is consistent with findings of miR-21 target genes in 
different human cell lines: Spry1 in cardiac fibroblasts (Thum et al, 2008), the tumor 
suppressor Pten in hepatocytes and cardiac fibroblasts (Meng et al, 2007; Roy et al, 2009), 
and the tumor suppressor Pdcd4 in a variety of cell lines (Asangani et al, 2008; Talotta et al, 
2009). In budding CRC cells, miR-21 may suppress the expression level of PTEN and 
PDCD4 and thereby prevent cell death. miR-21 has also been attributed a central role in 
TGF- induced EMT (Zavadil et al, 2007). Whether these regulatory events occur at the 
invasive front and in budding cancer cells remain to be established. 
10. p16, Ki67 and cdx2 
In connection with the studies mentioned above a couple of other proteins have been 
reported to focally change expression pattern in the budding CRC cells. These include p16 
(Jass et al, 2003; Uchiyama et al, 2007) and cdx2 (Brabletz et al, 2004). The tumor suppressor 
p16 plays an important role in regulation of the cell cycle through interaction with p53 and 
as an inhibitor of cyclin dependent kinase 4 (CDK4). Both Uchiyama et al (Uchiyama et al, 
2007) and Jass et al (Jass et al, 2003) noted that p16 was strongly expressed as a cytoplasmic 
immunoreactivity in the budding CRC cells. The increased expression may block 
translocation of CDK4 to the nuclei and thereby increase cyclin D1 levels and reduce 
proliferation (Jass et al, 2003). In fact, the proliferation marker Ki67 is lost in budding CRC 
cells (Brabletz et al, 2001; Uchiyama et al, 2007). The homeobox Cdx2 encodes an intestine-
specific transcription factor and is considered a tumor suppressor. Cdx2 immunoreactivity 
was absent in budding CRC cells in contrast to nuclei-related staining in the more 
differentiated tumor areas (Brabletz et al, 2004). It is intriguing that p16 and Cdx2, as so-
called tumor suppressors, present themselves differently with respect to their presence in 
these highly malignant cells.  
Although positive markers of the budding CRC cells provide clues to a mechanistic 
interpretation, loss of expression or intracellular translocation may provide significant help 
to characterize the budding process as well. As a final comment, I would like to suggest 
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including the following 3 proteins as reference markers for the dedifferentiated budding 
CRC cells: Ln-2 giving a positive reaction in the cytoplasm, -catenin giving a positive 
reaction in the nuclei, and Ki67 being negative (in constrast to the neighboring cancer cells). 
These markers will complement each other sufficiently as a reference profile and well-
characterized antibodies are commercially available and applicable in paraffin embedded 
specimens. 
11. Conclusion 
A successful budding CRC cell encounters dramatic challenges during the short local 
expedition: dedifferentiation and detachment from the established differentiated glandular 
structure, migration through a foreign stromal tissue rich in inflammatory cells and 
desmoplastic cells, settlement in the new stromal environment and re-initiation of its own 
proliferation program. In this chapter I have reviewed current literature in order to compile 
the molecular traits linked to these cells and put the proteins’ function into the budding 
processes. I propose that budding-initiating factors, such as TGF- and Wnts, derived from 
in the stromal environment in the tumor periphery, and that the factors are received by 
cancer cells with progenitor capacity and which are able to address an activation program 
involving -catenin mediated dedifferentiation and migration. From the compiled data, the 
following sequence of steps could be anticipated: increased levels of ECM degrading 
proteases, mediated by uPAR/uPA and MT1-MMP/MMP2, and MMP7 taking care of E-
cadherin processing. The proliferation program is halted. This could be followed by a 
discrete EMT program, which transiently changes the morphology of the cells and allows 
detachment and budding. Upregulation and secretion of Ln-3 and Ln-2 and subsequent 
extracellular processing will result in strongly motility-inducing fragments that allow 
migration through the stromal tissue. At the same time L1 is introduced changing the 
preferred cellular interaction partners to neuronal axons and dendritic cells as well as 
introducing yet  other migration stimulating factors: the ADAM10 and plasmin processed 
L1 ectodoamins. Budding cancer cells invade as distant as possible into the stroma. One 
mechanism that could make the invasive cells stop and settle in the stromal environment 
could be a change in balance between active proteases and protease inhibitors, which may 
be shifted in favor of the inhibitors. Both PAI-1 and TIMPs are highly expressed in stromal 
cells at the invasive front (Holten-Andersen et al, 2005; Illemann et al, 2004; Poulsom et al, 
1992). Increased protease inhibitor levels would prevent the formation of migration 
stimulating laminin fragments and also the surface associated proteases needed for invasion 
through the ECM. After settlement the excess laminins will be deposited and may contribute 
to form a loose basement membrane for the cancer cell to stick to and polarize, L1 will again 
be replaced by E-cadherin and proliferation and differentiation programs are reinitiated. 
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1. Introduction  
During oxidative stress, membrane lipids are one of the major targets of Reactive Oxygen 
Species (ROS) that are known to elicit oxidative decomposition of polyunsaturated fatty 
acids (PUFAs) of membrane phospholipids, a process usually referred to lipid peroxidation 
(Esterbauer et al., 1991). During this process, a number of carbonylic compounds are 
generated as final products, including acrolein, malondialdehyde (MDA) and 4-
hydroxyalkenals (Esterbauer et al., 1991). Among the 4-hydroxyalkenal class, 4-
hydroxynonenal (HNE) is the most abundant aldehyde produced (Dianzani et al., 1999). 
Over the years, HNE has achieved a status as one of the best recognized and most studied of 
the cytotoxic products of lipid peroxidation (Poli et al., 2008). In addition to studies on its 
bioactivity, HNE is commonly used as a biomarker for the occurrence and/or the extent of 
oxidative stress. It appears to be produced specifically by peroxidation of ω-6 PUFAs, such 
as linoleic acid, arachidonic acid (AA) and γ-linolenic acid (Esterbauer et al., 1982). HNE has 
three main functional groups: the aldehyde group, the C=C double bond and the hydroxyl 
group, which can participate, alone or in sequence, in chemical reactions with other 
molecules (Esterbauer et al., 1991). HNE is a highly electrophilic molecule, which 
predisposes it to localize in the cell membranes. It can easily react with low molecular 
weight compounds, such as glutathione, with proteins, with lipids and, at higher 
concentration, with DNA (Esterbauer et al., 1991; Uchida, 2003). The double bond, the 
carbonyl group and the hydroxyl group, all contribute to making HNE highly reactive with 
nucleophiles with the primary reactivity of the molecule lying at the unsaturated bond of 
the C-3 atom. HNE has been shown to form Michael adducts via the C-3 atom with the 
sulfhydryl group of Cys residues, the imidazole group of His residues, and the ε-amino 
group of Lys residues on a large number of proteins (Esterbauer et al., 1991). Recently, it has 
been proposed that HNE can also modify Arg residues of proteins (Isom et al., 2004). In 
addition to Michael adduct formation, Lys residues also form Schiff bases and pentylpyrrole 
adducts with HNE via the C-1 aldehyde group (Sayre et al., 1993; Petersen & Doorn, 2004; 
Schaur, 2003) 
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HNE-modified proteins can be removed by the proteasomal system (Siems & Grune, 
2003).  
Once formed, HNE is rapidly degraded and its metabolism is dependent upon a set of 
specific enzymes presenting high affinity toward HNE. In particular HNE metabolism can 
be divided into glutathione-mediated and oxidative/reductive categories (Siems & Grune, 
2003). In the first case, HNE binds the thiol group of GSH resulting in the correspondent 
emiacetal (Balogh & Atkins, 2011). The reaction with GSH can occur in a spontaneous 
manner, with low efficiency or through the reaction catalized by Glutathione S Transferases 
(GSTs). Moreover, although a number of isoforms of GST manifested HNE conjugating 
activity, it has been widely reported that the isoform GST A4 presents the highest HNE 
affinity (Balogh & Atkins , 2011). The oxidative/reductive pathway of HNE involves its 
NAD/NADP-dependent oxidative conversion to 4-hydroxy-2-nonenoic Acid (HNA) 
catalyzed by aldheyde dehydrogenases (ALDHs) or the reductive conversion to 1,4-
dihydroxy-2-nonene (DHN) catalyzed by alchool dehydrogenase (ADH) or aldhehyde 
reductase (AR) (Hartley et al., 1995; Vander Jagt et al., 1995). However, the majority of HNE 
is metabolized through forming GS-HNE (Forman et al., 2003). HNE-GSH is then further 
metabolized and found in urine, mostly, as the mercapturic acid derivative, HNE-MA 
(Alary, 1995). Indeed, HNE-GSH adduct is further metabolized by γ-glutamyltranspeptidase 
(γ-GT) and dipeptidases (DP) to the cysteinyl (CYS)-HNE thioether adduct. The cysteinyl 
thioether adduct is a substrate for acetyltransferases (AT) that catalyze the acetylation of the 
cysteinyl adduct to generate the acetylcysteinyl (AcCYS), or mercapturic acid, adduct. HNE 
metabolites also can be found associated with mercapturic acid, such as DHN-MA, HNE-
MA and HNA-lactone (Alary et al., 2003). HNE is also partially excreted first with the bile, 
then with the faeces, under the form of conjugated metabolites. However, biliary 
metabolites undergo an enterohepatic cycle that limits the final excretion of faecal 
metabolites (Alary et al., 2003). 
HNE, and in general aldehydes formed during membrane lipid peroxidation, are quite long 
lived, as compared to reactive free radicals and can widely diffuse and react around the site 
of origin (Esterbauer 1991). As a consequence, HNE and related aldehydes were proposed as 
putative ultimate toxic messengers, potentially able to mediate stress-related injury at the 
molecular level (Uchida, 2003). Indeed, HNE has been detected in vivo in several 
pathological conditions, which entail increased lipid peroxidation, including inflammation, 
atherosclerosis, chronic degenerative diseases of the nervous system, and chronic liver 
diseases, reaching a concentration up to about 10 µM (Parola et al., 1999).  
However, under physiological conditions, HNE can be found at low concentrations in 
human tissues and plasma (0.07-2.8 µM) (Esterbauer et al., 1991, Poli et al., 2008) where it 
participates in the control of biological processes, such as signal transduction, cell 
proliferation and differentiation. Indeed, HNE, similarly to ROS, plays an important role in 
controlling the intracellular signal transduction pathways involved in a number of cell 
responses (Parola et al., 1999; Dianzani et al., 2003; Leonarduzzi et al., 2004). 
The contribution of HNE and lipid peroxidation in carcinogenesis is still controversial. 
Beside pro-tumoral effects, several authors pointed out their protective role. This “two-
faced” role has already emerged for ROS (Halliwell, 2007; Wang & Yi, 2008; Pan et al., 2009; 
Acharya et al., 2010) and increasing evidence is emerging also for a dual role of lipid 
peroxidation products (Zhi-Hua et al., 2006; Pizzimenti et al., 2010a). 
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2. HNE and carcinogenesis 
2.1 DNA-adducts, mutagenicity and genotoxicity  
2.1.1 DNA-adducts 
The most substantial evidence of the genotoxic and mutagenic effect of HNE is the 
formation of HNE-DNA adducts. ROS and HNE seem to share this feature and this has been 
proposed as the mechanism of tumor induction (Bartsch & Nair, 2005).  
One of the most studied HNE-adducts is the propane-type DNA adduct with 
deoxyguanosine, the 6-(1-hydroxyhexanyl)-8-hydroxy-1, N2-propano-2’deoxyguanine 
(HNE-dG) (Winter et al., 1986). AA appears to be a major source of HNE-DNA adducts, 
producing a total of 20.6 μmol of HNE-dG adducts (Chung et al., 2000), by an in vitro assay 
using 1 mM AA. HNE-dG is also the main lesion produced upon the addition of HNE to 
DNA (Chung et al., 2000; Wacker et al., 2001); moreover, an increase of HNE-dG adducts 
was observed in the liver DNA of rats after treatment with CCl4, a well known inducer of 
lipid peroxidation (Chung et al., 2000). Taken together, these results generate substantial 
evidence for the endogenous formation of these adducts, thus it has been proposed that 
lipid peroxidation is a main endogenous pathway leading to propano adduction in DNA 
(Chung et al., 1999). 
In the presence of peroxides and reactive oxygen species, HNE can be further metabolized 
to an epoxide intermediate that interacts with DNA, forming etheno-type DNA adducts 
(Chung et al., 1996). However the etheno-type DNA adducts are produced in significantly 
lower yield, with respect to the HNE-dG adducts, when a pro-oxidant stimulus, such H2O2, 
or HNE is added to cells. Indeed, in these experimental conditions, HNE-dG represent more 
than 95% of the overall adducts to DNA, suggesting that HNE-dG may represent the best 
biomarker of the genotoxic effects of HNE (Douki et al., 2004).  
All four bases of DNA are the targets for HNE adduct formation (Chung et al., 1996; De 
Bont et al., 2004), but with different efficiency: G>C>A>T (Kowalczyk et al., 2004).  
HNE-DNA adducts have been identified in tissues of untreated rats and humans (Chung et 
al., 2000), suggesting that the endogenously produced HNE can form adducts with DNA in 
the physiological condition also.  
Removal of these modified bases from DNA plays an important role in the prevention of 
mutagenesis and carcinogenesis. Each cell has an efficient defence mechanism to repair 
these types of damage via DNA repair pathways such as base excision repair (BER), 
nucleotide excision repair (NER), and mismatch repair (MMR) pathways (Min & Eberel, 
2009). In human leukocyte treated with 200 μM HNE, DNA damage was repaired after 12 h 
and returned to the control level at 24 h (Park & Park, 2011). 
It has been demonstrated that NER is a major pathway for repairing HNE-dG adducts, since 
HNE-dG adducts induce a significantly higher level of genotoxicity and mutagenicity in 
NER-deficient human and E. coli cells than in NER-proficient cells (Feng et al., 2003). 
Moreover, other authors suggested that HNE can also contribute to carcinogenesis, by 
inhibiting the nucleotide excision repair (NER) of DNA damage in cancer cells with 
concentration higher than 50 μM (Feng et al., 2004). In any case, HNE forms adducts with 
DNA only at higher concentrations, since it can react quickly with amino and sulphydrylic 
groups of proteins and, primarly, with the sulphydrylic group of GSH. Indeed, it has been 
calculated that GSH conjugates were 20000 times more numerous than DNA adducts when 
HNE was exogenously added to the cultured cells (Falletti & Douki, 2008).  
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In this context, it would be important to know whether the HNE-dG adducts are mutagenic. 
Several authors suggest this possibility, since HNE has been shown to be mutagenic in 
mammalian cells (Cajelli et al., 1987). HNE was negative in bacterial mutagenicity tests, 
however its epoxidized form has been tested positive (Chung et al., 1993). HNE was found 
to be responsible for recombination, base substitutions and frameshift mutations in M13 
phage transfected in E.coli (Kowalczyk et al., 2004). 
Moreover it has been reported that 50 μM HNE treatment in human cells induces a high 
frequency of G.C to T.A mutations at the third base of codon 249 (AGG*) of the p53 gene 
(Hussain et al., 2000), a mutational hot spot in human cancers, particularly in hepatocellular 
carcinoma (Hsu et al., 1991). Both eheno and propane type HNE-DNA-adduct at codon 249 
can be responsible for such transitions (Feng et al., 2003).  
The stereochemistry of HNE-dG adducts seems to play an important role in determining 
mutations. Indeed, two of the HNE-dG adducts, (6R, 8S, 11R) and (6S, 8R, 11S), were 
significantly more mutagenic than (6R, 8S, 11S) and (6S, 8R, 11R) HNE-dG adducts. Only 
one of the HNE stereoisomers was able to form interstrand DNA–DNA cross-links. 
(Fernandes et al., 2003). 
2.1.3 Genotoxicity  
The genotoxic property of HNE was demonstrated in different cell types, such as on 
cultured human lymphocytes (Emerit et al., 1991), in primary hepatocytes (Esterbauer et al., 
1991) and cerebral microvascular endothelial cells (Eckl, 2003). In these cell lines an increase 
of micronuclei (a biomarker of chromosome breakage and/or whole chromosome loss), 
chromosomal aberrations and sister chromatid exchanges was observed after exposure to 
HNE at relatively low doses, ranging 0.1-10 μM. However these clastrogenic features of low 
doses of HNE failed to be confirmed in a recent multicentrum study on DNA of normal 
peripheral blood lymphocytes (Katic et al., 2010). 
Currently, the comet assay has been extensively used to measure DNA strand breaks, since 
it represents a sensitive and rapid assay to detect the mutagenic and genotoxicity of 
chemicals and xenobiotics (Tice, et al., 1991). 
Unfortunately, most HNE-induced DNA lesions are the stable 1,N2-propano adducts and 
they are not detected by this technique. By using this assay, the genotoxic property of 5-10 
μM HNE in the K562 leukemic cell line has been shown; this feature was highly dependent 
on cellular GSH/GST/AR system (Yadav et al., 2008). The comet test was also used to 
demonstrate the genotoxicity of 200 μM HNE in human leukocytes (Park & Park, 2011). 
2.2 Results in laboratory animals 
To date, in contrast with several in vitro experimental results, tumor bioassays in laboratory 
animals failed to demonstrate the carcinogenic and mutagenic properties of HNE. HNE, in 
particular its epoxy derivate, has shown that to be a weak tumor-initiating agent, causing 
the development of renal preneoplastic tubule lesions in new-born mice (Chung et al., 1993). 
More interestingly, HNE lacks in vivo genotoxicity in lacI transgenic mice, a model for 
detecting mutagenicity in target organs, even when lethal doses are applied (Nishikawa et 
al., 2000).  
The big gap between the in vitro and the in vivo data can be partially explained by carefully 
considering the elevated doses frequently used to demonstrated the carcinogenic properties 
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of HNE in vitro. Indeed, several mutagenic assays with HNE have been performed with 
high doses of HNE (more than 100 µM). It seems rather unlikely that HNE or other 
aldehydes can reach overall concentrations in the range of 100 µM in cells and organs 
(Esterbauer et al., 1991). It is conceivable that such levels may be built up locally, near or 
within peroxidizing membranes for a short time because of their high lipophilicity. It has 
been calculated, for example, that the concentration of HNE in the lipid bilayer of isolated 
peroxidizing microsomes is about 4.5 mM (Koster et al., 1986). Nevertheless, a convincing 
demonstration that this very high concentration can be reached into the cells has remained 
elusive. On the other hand, when HNE diffuses out from membranes, its concentration is 
reduced by the surrounding aqueous phase. Moreover, the cytosolic HNE-metabolizing 
enzymes destroy HNE produced in excess so that the steady-state HNE concentration into 
the cells, around 1 μM,  is reached quickly (Esterbauer et al., 1991; Dianzani et al., 1999). 
2.3 Cellular responses and signal transduction 
As previously indicated, the adduct formation between HNE and DNA is only one of the 
several biological effects determined by this aldehyde. Indeed, HNE is considered as a 
signalling molecule influencing proliferation, differentiation and apoptosis of cancer cells 
(Dianzani, 2003; Leonarduzzi et al., 2004; Poli et al., 2008; Pizzimenti et al., 2010b). The 
majority of experimental evidence indicate an antiproliferative role of HNE, when added at 
low doses (1-10 μM) to cultured cells. The inhibition of proliferation has been observed in 
leukemic (HL-60, K562, U937, MEL, ML-1) (Barrera et al., 1991; Barrera et al., 1987, Rinaldi et 
al., 2000; Pizzimenti et al., 2006), neuroblastoma (SK-N-BE) (Laurora et al. 2005), hepatoma 
(7777, J42) (Muzio et al., 2001; Canuto et al., 1999), osteosarcoma (SaOS2; HOS) (Calonghi et 
al., 2002; Sunjic et al., 2005), prostate cancer (PC3) (Pettazzoni et al., 2011) cells. This anti-
proliferative effect is sustained by the modulation of key genes involved in cell growth 
control, such as oncogenes (c-myc, c-myb, fos, AP1, cyclins) and anti-oncogenes (pRB, p53, 
SUFU-1, Mad-1) (Poli et al., 2008; Pizzimenti et al., 2009). 
Interestingly, the effect of HNE in normal cell proliferation is more variable if not opposite 
to that observed in tumor cells. For example, HNE has no effect on normal myeloid stem 
cells (Hassane et al., 2008) or on human peripheral blood lymphocytes (Semlitsch et al., 
2002), while the respective tumour was sensitive to the anti-proliferative effect of aldehyde. 
On the contrary, in vascular smooth muscle cells 0.1 μM HNE stimulated cell proliferation 
(Kakishita et al., 2001). 
In several cell lines, the inhibition of proliferation was accompanied by apoptosis. The 
mechanisms of HNE-induced apoptosis through the extrinsic and intrinsic pathways, its 
self-regulatory role in this process and its interaction with Fas (CD95), p53, and Daxx has 
been recently reviewed (Awasti et al., 2008).  
HNE is also able to induce differentiation, as observed in HL-60, MEL, K562 and SaOS 
osteosarcoma cells (Barrera et al., 1991; Rinaldi et al., 2000; Calonghi et al., 2002; Cheng et al., 
1999; Fazio et al., 1992). Moreover, HNE was shown to induce features of typical 
differentiated cells, such as chemotaxis (Curzio et al., 1988), phagocytosis and the ability to 
induce respiratory burst (Barrera et al., 1991) in myeloid cells. HNE also demonstrated the 
ability to regulate the replicative potential of cells, by inhibiting the telomerase activity. 
Indeed, in HNE-treated leukemic cells, the expression of the hTERT gene was down-
regulated by modulating the expression of transcription factors belonging to the 
Myc/Mad/Max network (Pizzimenti et al., 2006). 
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The anti-tumoral properties of HNE are also sustained by the demonstration of anti-
angiogenic properties. Stagos and collaborators demonstrated that 5 and 10 μM HNE were 
able to inhibit the tube formation of human bone marrow endothelial cells (HBMEC) (Stagos 
et al., 2009). However, conflicting results have been reported, since it has been demonstrated 
that 1 μM HNE induces an increase of VEGF expression in human retinal pigment epithelial 
cells (Ayalasomayajula & Kompella, 2002).  
The cellular responses to HNE are sustained by affecting cell signalling at multiple levels. 
Relevant findings in this area have been extensively reviewed (Poli et al., 2008; Leonarduzzi 
et al., 2004; Dianzani et al., 1999).  
In addition to the above cellular responses presented, HNE activates various cytoprotective, 
stress response pathways, promoting changes in gene expression that facilitate cell survival 
and recovery from stress (West & Marnett, 2005). For example, HNE activates the 
transcription factors Nrf2 (Nuclear factor erythroid-derived 2-like 2) and HSF1 (heat shock 
factor 1), which mediate the antioxidant and heat shock responses, respectively (Jacobs & 
Marnett, 2007). Nrf2 acts by binding Antioxidant Responsive Elements (ARE) sequences on 
promoters of certain genes promoting their expression (Thimmulappa et al., 2002). In regard to 
HNE metabolism, functional ARE sequences have been found on promoter of GST A4 ALDH 
and ADH (Reddy et al., 2007; Malhotra et al., 2010). Moreover, Nrf2 promotes de novo GSH 
synthesis by up-regulating expression of the GSH synthesis pathway (Harvey 2009). Nrf2 is 
controlled by both translational and post-translational mechanisms, in particular the protein 
Kelch-like ECH-associated protein 1 (KEAP1) mediates Nrf2 ubiquitinaltion followed by 
proteasomal destruction (Kaspar et al., 2010). In conditions of oxidative stress or in response to 
many chemicals KEAP1 undergo conformational changes responsible for loss of Nrf2 binding 
activity. As a consequence Nrf2 can accumulate, translocate in the nucleus and drive 
expression of the antioxidant program (Reddy et al., 2007).  
The heat shock response mediates the induction of a highly conserved set of heat shock 
proteins (Hsps) (Mosley, 1997). The inducible expression of Hsps is mediated by heat shock 
transcription factor 1 (HSF1), which translocates to the nucleus upon activation and 
enhances the expression of genes to form promoters containing heat shoch elements (HSE), 
such as Hsp70 (Sarge et al., 1993; Baler et al., 1993). A principal function of Hsps is to 
chaperone other proteins, binding to nascent polypeptide chains as well as to unfolded and 
damaged proteins. Their function as protein chaperones aids in the recovery of cells from 
thermal and chemical-induced damage (Hahn & 1982; Howard, 1993). In addition to acting 
as protein chaperones, Hsps inhibit cell death by directly inhibiting a variety of pro-
apoptotic mediators, such as HNE (Jacobs et al., 2007). 
It is very likely that the majority of effects observed on cell signalling and cellular responses 
can be mediated by the reaction of HNE to proteins and peptides. Quantitatively, proteins 
and, among peptides, the GSH, represent the most important group of HNE-targeted 
biomolecules. It was estimated that 1–8% of the HNE formed in cells will modify proteins 
(Siems & Grune, 2003). Most of the identified targets are enzymes, carriers, receptors, ion 
channels, transport proteins, cytoskeletal, heat shock proteins and others. The biological 
significance of the HNE-protein adducts identified have been reviewed by several authors 
(Uchida, 2003; Poli et al., 2008). Some of the protein-adducts identified can explain the anti-
tumoral effect exerced by this aldehyde. For example, it was demonstrated that the 
inhibition of cell proliferation in the human colorectal carcinoma cell line (RKO) and human 
lung carcinoma cell line (H1299) by HNE was mediated by the direct reaction of HNE with 
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IκB kinase (IKK), the key enzyme regulating the NF-κB activation (Ji et al., 2001b). Moreover 
the HNE adducts with alpha-enolase, at the cellular surface of leukemic cells, suggest a new 
role for HNE in the control of tumour growth and invasion, since HNE causes a dose- and 
time-dependent reduction of the plasminogen binding to alpha-enolase. As a consequence, 
HNE reduces adhesion of HL-60 cells to HUVECs (human umbilical vein endothelial cells) 
(Gentile et al., 2009).  
New perspectives of HNE role in cancer-inducing signaling pathways have recently 
emerged, by recent findings on microRNA (miRNA) (Pizzimenti et al., 2009), a class of 
conserved non-coding small RNAs, which regulate gene expression by translation 
repression of coding mRNAs (Bartel, 2004). 
2.4 HNE content in human cancers  
Several studies on human cancer tissues have analysed the HNE or HNE-protein adduct 
content, in order to find a possible correlation between this marker of lipid peroxidation and 
the progression of cancer. 
HNE content has been reported to increase along with the progression of breast cancer 
(Karihtala et al., 2011) and astrocytoma (Zarkovic et al., 2005). In human renal cell 
carcinoma, immunohistochemistry for HNE-modified proteins showed positive staining in 
the cytoplasm of tumor cells, with respect to controls, without correlation to the clinical 
stage (Okamoto et al., 1994).  
However other reports have demonstrated the opposite: a low or undetectable lipid 
peroxidation, as well as HNE content, such as in hepatomas (Dianzani, 1993).  
Several studies have shown elevated lipid peroxidation markers in the sera, plasma or urine 
of breast carcinoma (Hung et al., 1999; Chandramathi et al., 2009), cervical intraepithelial 
neoplasia and carcinoma of the cervix (Looi et al., 2008), head and neck squamous cell 
carcinoma (Gupta et al., 2009) and prostate tumor (Kotrikadze et al., 2008), compared to 
healthy controls. However, these extratumoral measurement are likely, at least partly, to 
reflect generalized oxidative stress and /or inflammation in the whole body. 
3. HNE and colorectal carcinogenesis 
3.1 Sources and fate of HNE in colon 
Colon cells can be exposed to HNE derived form different sources (Figure 1). It is possible to 
find HNE directly in the food (Gasc et al., 2007), since it can derived from lipid peroxidation 
of PUFAs introduced with diet or from endogenous PUFAs presents in cellular membranes. 
A small amount of HNE can reach the colon also via bile. Following a single intravenous 
administration of [3H]-HNE, five metabolites were present in the bile, namely GSH–HNE, 
GSH–DHN, DHN, and HNA-lactone mercapturic acid conjugates (Laurent et al., 1999). 
Within 4 hr from injection of the radiolabel 3[H]-HNE, 19.5% of the injected radioactivity 
was found in the bile, whereas only 3% was found in the feces within 48 hr (Laurent et al., 
1999). The existence of an enterohepatic circulation for HNE metabolites has been 
unequivocally demonstrated (Laurent et al., 1999) using a model linking donor rats (injected 
intravenously with [4-3H]HNE) and recipient rats (to which the bile from donor rats was 
delivered intraduodenaly). This enterohepatic circulation, approximately 8% of the total 
dose, may explain the low amount of radioactivity recovered from faeces when rat were 
dosed intravenously with [4-3H]HNE. 
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Fig. 1. Sources and fate of HNE in colon 
Metabolic transformation of HNE starts in enterocites, where GSH-HNE is the main 
metabolite produced (Grune et al., 1991). The majority of HNE metabolites are found in the 
urine. Indeed, following the intravenous administration of [3H]-HNE in rats, 67%, 3%, 
0.16%, and 6.5% of the injected radioactive dose was recovered from urine, faeces, liver and 
remaining tissues, respectively (Alary et al., 2003). The urinary HNE metabolites were 
separated by HPLC and the resolved peaks were identified as mercapturic acid conjugates 
of HNA, DHN, HNE and HNA-lactone, where DHN-MA, and to a lesser extent HNA 
lactone-MA, have been found to be the major urinary metabolites of HNE in rats (Boon et 
al., 1999). DHN-MA has been confirmed to be the major urinary HNE metabolite also in 
human urine (Alary et al., 1998). 
The microflora of the human intestine can also affect levels of lipid peroxidation, since the 
antioxidative effect of lactic acid bacteria has been demonstrated (Lin et al., 1999). In 
particular, the antioxidative activity of Bifidobacterium longum ATCC 15708 and 
Lactobacillus acidophilus ATCC 4356 was measured based on the inhibition of linoleic acid 
peroxidation. Both intact cells and intracellular cell-free extracts of B. longum and L. 
acidophilus demonstrated an antioxidative effect on inhibiting lipid peroxidation. The 
antioxidative activity ranged from 38 to 48% inhibition of linoleic acid peroxidation. This 
indicates that B. longum and L. acidophilus have a very strong antioxidative effect on 
inhibiting lipid peroxidation (Lin et al., 1999). 
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Low level of HNE and its metabolites can be found also in faecal water (Alary et al., 2003) 
and numerous studies have emphasized the lipid peroxidation products of faecal water in 
colon cancer as diet-related factors (Lapre et al., 1992; Glinghammar et al., 1997). 
3.2 Pro-tumoral and anti-tumoral role of HNE in colon carcinogenesis 
Several authors have reported evidence that sustains the pro-tumoral activity of HNE and 
other products of lipid peroxidation in colon carcinogenesis. These findings include in vitro 
(see table 1) and in vivo studies, which demonstrate the genotoxic properties of HNE on 
coloncarcinoma cell lines, the increase of HNE content along with the progression of 
colorectal cancer and the increase of HNE-DNA adducts in vivo. However other studies, 
seem to demonstrate the opposite (see table 1). Consistent with the hypothesis of an anti-
tumoral role of HNE are the results showing the inhibition of cell growth, the induction of 
apoptosis in several colon cancer cell lines, as well as the demonstration that HNE content 
decreases in biopsies of colon-cancer tissues with respect to normal mucosa. A deeper 
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Low level of HNE and its metabolites can be found also in faecal water (Alary et al., 2003) 
and numerous studies have emphasized the lipid peroxidation products of faecal water in 
colon cancer as diet-related factors (Lapre et al., 1992; Glinghammar et al., 1997). 
3.2 Pro-tumoral and anti-tumoral role of HNE in colon carcinogenesis 
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seem to demonstrate the opposite (see table 1). Consistent with the hypothesis of an anti-
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3.2.1 HNE-DNA adducts in colon and colon cancer 
HNE-dG adducts, were found in normal human colon tissue, as well as DNA adducts with 
other lipid peroxidation products, such as acrolein and MDA (Chung et al., 2000). The levels 
of HNE-dG in tissue DNA examined so far are estimated to be in the range of 3-9 adducts 
per billion bases (3-9 nmol/mol guanine) (Chung et al,. 2000). 
The etheno-DNA adducts, inter alia formed from epoxidized HNE, were found at increased 
level in colonic polyps of familial adenomatous polyposis (FAP) patients. Mean adduct 
levels in FAP polyps were 65 εdA/109 and 59 εdC/109 parent nucleotides, being 2 to 3 times 
higher than in unaffected colon tissue (Schmid et al., 2000). Interestingly, the level of etheno-
DNA adducts in colon carcinoma tissues were found to be similar to unaffected colon 
(Schmid et al., 2000), suggesting a possible HNE role in the early events of colon 
carcinogenesis.  
On the contrary, Obtułowicz and collaborators (2010) have found that, in colon cancer 
patients, the DNA-HNE adducts εdA and εdG, measured both in colon tissues and blood 
leukocytes, were lower in patients than in controls (Obtułowicz et al., 2010). These authors 
have measured the two corresponding metabolites also, 1,N6- Ethenoadenine (εAde) and 
3,N4-ethenocytosine (εCyt), catalized by BER, the major pathway of etheno adduct 
elimination from DNA (Obtułowicz et al., 2010). Both excision activities were significantly 
higher in tumor than in normal colon tissues and this feature could be explained by the 
increased level of abasic site endonuclease (APE1), belonging to BER system, in coloncancer 
patients with respect to controls (Obtułowicz et al., 2010).  
A possible pro-cancinogenic role of etheno-DNA adducts is also sustained by the finding 
that in the colon of patients with inflammatory bowel disease εdC, but not εdA, are 
increased. In particular it has been demonstrated that εdC was 19-fold higher in colonic 
mucosa of Crohn’s disease and 4-fold higher in the colonic mucosa of ulcerative colitis 
patients, when compared to normal tissues (Nair et al., 2006). Since patients with ulcerative 
colitis (UC), and Crohn’s (CD) have an elevated risk for developing colon cancer (Konner et 
al., 2003), the authors suggest that the promutagenic etheno-DNA adducts, generated as a 
consequence of chronic inflammation, can act as a driving force to malignancy in cancer-
prone inflammatory diseases (Nair et al., 2006). 
HNE can also contribute to induce colon carcinogenesis, by inhibiting the DNA repair 
mechanism of such adducts. Indeed, Feng and collaborators (2004) demonstrated that 50 μM 
HNE inhibits NER in the human colon epithelial cell line HCT116. The repair capacity for 
benzo[a]pyrene diol-epoxide and UV light-induced DNA damage was greatly compromised 
in cells treated with HNE.  
3.2.2 Genotoxicity and mutagenicity of HNE in colon cancer  
Comet assay demonstrated that HNE, at concentration higher than 150 μM, displays a 
genotoxic effect in the colon carcinoma cell line HT-29 (Glei et al., 2006; Ebert et al., 2001; 
Knoll et al., 2005) and in HT29clone19A, a permanently differentiated sub-clone treated with 
sodium butyrate (Augeron & Laboisse, 1984). Moreover, such high doses of HNE were able 
to affect DNA integrity in primary human colon cells (Schaferhenrich et al., 2003; Glei et al., 
2007) and in LT97, an established cell line derived from a differentiated microadenoma, 
representing a model of an early premalignant genotype, carrying adenomatous polyposis 
coli (APC) and Ki-ras mutated, but normal p53 (Richter et al., 2002), three well-characterized 
genes involved in coloncancer progression (Fearon et al., 1990). 
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leukocytes, were lower in patients than in controls (Obtułowicz et al., 2010). These authors 
have measured the two corresponding metabolites also, 1,N6- Ethenoadenine (εAde) and 
3,N4-ethenocytosine (εCyt), catalized by BER, the major pathway of etheno adduct 
elimination from DNA (Obtułowicz et al., 2010). Both excision activities were significantly 
higher in tumor than in normal colon tissues and this feature could be explained by the 
increased level of abasic site endonuclease (APE1), belonging to BER system, in coloncancer 
patients with respect to controls (Obtułowicz et al., 2010).  
A possible pro-cancinogenic role of etheno-DNA adducts is also sustained by the finding 
that in the colon of patients with inflammatory bowel disease εdC, but not εdA, are 
increased. In particular it has been demonstrated that εdC was 19-fold higher in colonic 
mucosa of Crohn’s disease and 4-fold higher in the colonic mucosa of ulcerative colitis 
patients, when compared to normal tissues (Nair et al., 2006). Since patients with ulcerative 
colitis (UC), and Crohn’s (CD) have an elevated risk for developing colon cancer (Konner et 
al., 2003), the authors suggest that the promutagenic etheno-DNA adducts, generated as a 
consequence of chronic inflammation, can act as a driving force to malignancy in cancer-
prone inflammatory diseases (Nair et al., 2006). 
HNE can also contribute to induce colon carcinogenesis, by inhibiting the DNA repair 
mechanism of such adducts. Indeed, Feng and collaborators (2004) demonstrated that 50 μM 
HNE inhibits NER in the human colon epithelial cell line HCT116. The repair capacity for 
benzo[a]pyrene diol-epoxide and UV light-induced DNA damage was greatly compromised 
in cells treated with HNE.  
3.2.2 Genotoxicity and mutagenicity of HNE in colon cancer  
Comet assay demonstrated that HNE, at concentration higher than 150 μM, displays a 
genotoxic effect in the colon carcinoma cell line HT-29 (Glei et al., 2006; Ebert et al., 2001; 
Knoll et al., 2005) and in HT29clone19A, a permanently differentiated sub-clone treated with 
sodium butyrate (Augeron & Laboisse, 1984). Moreover, such high doses of HNE were able 
to affect DNA integrity in primary human colon cells (Schaferhenrich et al., 2003; Glei et al., 
2007) and in LT97, an established cell line derived from a differentiated microadenoma, 
representing a model of an early premalignant genotype, carrying adenomatous polyposis 
coli (APC) and Ki-ras mutated, but normal p53 (Richter et al., 2002), three well-characterized 
genes involved in coloncancer progression (Fearon et al., 1990). 
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Genotoxicity of HNE is higly dependent on cellular GSH level. Indeed, GSH depletion leads 
to and increase of HNE genotoxicity in the HT-29 colon carcinoma cell line (Knoll et al., 
2005). Moreover, HNE displayed a higher genotoxicity in LT97 than in HT29clone19A and 
primary human colon cells. This result can be explained by the lower GST expression found 
in LT97 compared to HT29clone19A and primary human colon cells (Schaferhenrich et al., 
2003). 
Recently, by using a refined comet assay (Comet-FISH) (Glei et al., 2009), which combined 
the classical comet assay with the fluorescence in situ hybridisation, it has been 
demonstrated that HNE concentrations higher than 150 μM were able to affect DNA 
integrity on the p53 (Schaferhenrich et al., 2003; Glei et al., 2007), Ki-Ras and APC genes 
(Glei et al., 2007), in primary human colon cells and the colon adenoma cell LT97. After cell 
incubation with HNE, the p53 gene, the crucial target gene for the progression of adenoma 
to carcinoma, migrated more efficiently into the comet tail than the global DNA, indicating a 
high susceptibility of the p53 gene to HNE (Glei et al., 2007). Moreover, the TP53 gene 
sensitivity to the DNA damage induced by HNE was significantly higher with respect to 
APC and KRAS genes. This particular sensitivity is especially apparent in LT97 cells (Glei et 
al., 2007). This may be due to the fact that LT97 cells normally carry damaged APC and 
KRAS, but undamaged TP53 (Richter et al., 2002). In normal colonocytes, APC and KRAS 
were also sensitive to damage (Glei et al., 2007). These findings are highly interesting when 
considering the sequence of mutational events that occur during human colon 
carcinogenesis (Vogelstein et al., 1988). APC and KRAS mutations transform normal 
epithelial (stem) cells into initiated, more rapidly proliferating cells to yield dysplasia and 
small adenoma. TP53 mutations in adenoma are then crucial alterations leading to further 
progression and to carcinoma. Based on studies of Glei and collaborators (2007), it is 
possible to conclude that HNE could potentially contribute to both cancer initiation and 
progression in the colon, if produced in sufficient amounts. However, as mentioned in the 
previously chapter, it is unlikely that HNE is reaching such high concentrations (150 μM) in 
colon in vivo. Moreover it still remains to be studied to what extent the observed 
genotoxicity of HNE is related to mutagenicity. Consistent with this hypothesis, as 
previously reported, it has been demonstrated that 50 μM HNE treatment in human TK-6 
lymphoblastoid cell line induces a high frequency of G.C to T.A mutations at the third base 
of codon 249 (AGG*) of the p53 gene (Hussain et al., 2000), a mutational hot spot in human 
cancers, particularly in hepatocellular carcinoma (Hsu et al., 1991). The adduct of HNE to 
codon 249 of the p53 gene has been also found by Hu and collaborators (2002). These 
authors exposed DNA of exons 5, 7 and 8 of human p53 gene, where the large majority of 
p53 mutations occur, to a very high concentration of HNE (192 mM or more). They 
identified two main HNE adducts, the first already mentioned at codon 249 (exon 7) and the 
second at codon 174 (exon 5) (Hu et al., 2002). However, the possible contribution of HNE to 
p53 mutations, through the formation of DNA adducts remains to demonstrated, since 
codon 249 and codon 174 of p53 usually are not mutated in colorectal rectal. Indeed, 
mutations at codon 175, 245, 248, 273, and 282 account for approximately 43% of all p53 
mutations in CRC (Soong et al., 2000; Soussi et al., 2000; Soussi & Beroud, 2003).  
3.2.3 HNE role in controlling cell proliferation, apoptosis of colon cancer cell 
Several findings have been collected through the years related to the anti-proliferative and 
pro-apoptotic in colon cancer cells. These results, even obtained with very low doses of 
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HNE, easily reacheable in vivo, cast doubt on the pro-tumoral HNE role. 1 μM HNE is able 
to inhibit cell proliferation of Caco-2 and HT-29 colon cancer cells (Cerbone et al., 2007; 
Pizzimenti et al., 2010b; Vizio et al., 2005) and concentrations ranging form 1 to 100 μM are 
able to induce apoptosis in Caco-2, HT-29, RKO, HCT15 colon cancer cells. (see table I for 
references). A number of genes or cell signalling pathways have been found to be affected 
by HNE, and their modulation can explain the biological effects observed.  
Results obtained in our laboratories demonstrated that the inhibition of proliferation in 
Caco-2 and HT-29 colon carcinoma cells by 1 μM HNE is sustained by the down-regulation 
of telomerase activity and hTERT expression, the catalytic subunit of telomerase (Pizzimenti 
et al., 2010b). The major mechanism of HNE action seems to be the modulation of expression 
and activity of transcription factors belonging to the Myc/Mad/Max network (Pizzimenti et 
al., 2010b). 
After HNE treatment, apoptosis of several colon cancer cell lines was investigated by 
different authors and different pathways were considered to be involved. In Caco-2 human 
colon adenocarcinoma cell line, 1 μM HNE caused an increase of bax expression (Cerbone et 
al., 2007) and the apoptosis induction is mediated by JNK activation. Indeed, the HNE-
mediated apoptotic cell death was significantly prevented by preincubating the cells with 
the selective JNK inhibitor SP600125 (Biasi et al., 2006).  
Ji and collaborators investigated the mechanism of HNE-induced cell death in human 
colorectal carcinoma cells and found that HNE-induced apoptosis depends on alteration of 
mitochondrial function, leading to the release of cytochrome c and subsequent activation of 
caspase cascade (Ji et al., 2001a). The authors have further demonstrated that HNE inhibited 
IκB kinase activity by direct interaction with IκB kinase and suggested that HNE is an 
endogenous inhibitor of NF-κB activation that acts by preventing IκB kinase activation and 
subsequent IκB degradation (Ji et al., 2001b). 
The molecular mechanism of HNE induced apoptosis was investigated in RKO colon cancer 
cells also. In this cell line, beside the pro-apoptotic stimuli, HNE activates the stress response 
pathways, that abrogate programmed cell death. Moreover, HNE elicits the nuclear 
translocation of HSF1 and promotes Hsp40 and Hsp72 expression (Jacobs & Marnett, 2007). 
The silencing of HSF1 sensitizes the colon cancer cells to HNE-induced apoptosis, through a 
mechanism involving the control of BCL-XL, BAG3 protein turnover (Jacobs & Marnett, 
2007; Jacobs & Marnett, 2009)  
3.2.4 HNE content in human colon cancers 
Only a few studies have investigated the level of the lipid peroxidation products, in 
particular HNE, in human colon cancers and results are contradictory. It has been 
demonstrated that the levels of proteins modified by HNE and MDA in colorectal cancer 
tissues were significantly increased (Murawaki et al., 2008). By immunohystochemical 
analysis, Murawaki and collaborators (2008) have demonstrated that the proteins modified 
by HNE were stained diffusely in the cytoplasm of cancer cells, while they were weakly 
stained in normal tissues. Similar results have been obtained by Kondo and collaborators 
(1999). Immunostaining of HNE-histidine adducts was observed in the cytoplasm of colon 
cancer tissues. Immunoreactivity was also found in the cytosol of infiltrating inflammatory 
cells. Western blot analysis of HNE-histidine adducts confirmed the results, since larger 
amounts of modified proteins were detected in carcinomas than in nontumorous epithelial 
counterparts (Kondo et al., 1999). The authors also demonstrated that HNE content 
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increased along with the progression of colorectal cancer, since tubular adenoma cells 
revealed a weaker staining, similar to the staining of non-tumorous epithelial cells (Kondo et 
al., 1999). An increase of HNE content in colon cancer tissues have been found also by 
Skrzydlewska and collaborators (2005). These authors analyzed the HNE content in 
homogenates of human colon cancer tissues, by measuring HNE as a fluorimetric 
derivative. These authors have demonstrated that the level of HNE was significantly 
increased (P<0.001) in cancer tissue compared to control group, with highest in G3-grade 
adenocarcinoma and mucinous adenocarcinoma and clinical IV stage of colorectal cancer.  
In contrast with these results, other scientists demonstrated a decrease of HNE in colon 
cancer tissues. Indeed, it was demonstrated that HNE was significantly decreased in cancer 
specimens, with respect to normal tissues, by measuring the HNE content in tissue biopsies 
from patients with colon adenocarcinoma of different TNM and G stage (Biasi et al., 2002; 
Zanetti et al., 2003). This result was confirmed later by the same group (Biasi et al., 2006). 
Moreover, Chiarpotto and collaborators (1997) have demonstrated that the fluorescent 
adducts with plasma proteins and HNE were significantly lower in the plasma from cancer 
patients (all stage G3, pT3pN0) than in controls.  
3.2.5 HNE metabolism in colon cancer 
In colon cells, the enzymes of HNE metabolism are present. Staining with anti GST A4 
specific antibodies revealed a significant expression of GST A4 in columnar and crypt 
epithelial cells of normal colon mucosae (Desmots et al., 2001), as well as in colon cancer cell 
lines (Scharmach et al., 2009; Knoll et al., 2005). Moreover, both the oxidative and reductive 
metabolisms of HNE are well represented in colon cells, since both ALDH or ADH have 
been found to be significantly expressed in colon mucosae (Seitz et al., 1996; Yin et al., 1994). 
The expression of AR is also enhanced in various forms of cancer, such as hepatoma 
(Zeindl-Eberhart et al., 1997) and melanoma cancer (Kawamura et al., 1999).  
By affecting HNE metabolism enzymes, it is possibly to modulate the HNE concentration 
inside cells. This could be critical for cancer growth regulation or DNA genotoxicity. Indeed, 
butyrate, produced during gut fermentation, has a chemoprotective role toward HNE 
injury, when added at high concentration, such as 100-200 μM in HT-29 colon cancer cells 
(Knoll et al., 2005). The chemoprotective effect of butyrate seems to be related to the 
increasing the expression of glutathione S-transferases GSTP1 (Ebert et al., 2001) and 
hGSTA4-4 (Knoll et al., 2005) able to catalyze the conjugation of HNE with glutathione. 
Similar results were obtained in HT-29 cells by using two wheat bran-derived 
arabinoxylans, fermented under anaerobic conditions in human feces. These two 
fermentation products inhibited growth and reduced the genotoxicity of HNE (100-200 μM) 
via up-regulation of the activity of GSTs, in absence of a GSTP1 or hGSTA4-4 increase (Glei 
et al., 2006). 
There is a growing interest in targeting aldose reductase (AR), as a novel therapeutic 
approach in preventing progression of colon cancer (Tammali et al., 2011). AR besides 
reducing aldo-sugars efficiently reduces toxic lipid aldehydes and their conjugates with 
glutathione (Tammali et al., 2006). Indeed, inhibition of AR by sorbinil or by antisense 
ablation, prevented FGF–induced and PDGF–induced proliferation of Caco-2 cells at S-
phase (Tammali et al., 2006). Similar results were also obtained in other colon cancer cell 
lines, by Ramana and collaborators which show that the inhibition of AR prevents 
epidermal growth factor (EGF)– and basic fibroblast growth factor (bFGF)–induced HT29, 
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and cell proliferation, by accumulating cells at the G1 phase of the cell cycle, through the 
AKT/Phosphoinositide 3-Kinase/E2F-1 pathway. Analogous results were obtained in 
SW480 and HCT-116 colon cancer cells (Ramana et al., 2010).  
More interestingly, in vivo studies showed that administration of aldose reductase-small 
interfering RNA (siRNA), or the AR inhibitor fidarest, to nude mice bearing SW480 human 
colon adenocarcinoma cells, led to a complete arrest of tumor progression. Such evidence 
suggests a key role for aldose reductase in growth factor-induced proliferation in colon 
cancer cells and it points to inhibition of aldose reductase as a novel therapeutic approach in 
preventing progression of colon cancer (Tammali et al., 2006; Ramana et al., 2010). 
Recently, the ATP-depent transporter RLIP76 (Ral binding protein1) has been considered for 
its role in controlling HNE content inside the cells. Indeed, it has been demonstrated that 
this transporter with multi-specific transport activity towards glutathione-conjugates and 
chemotherapeutic agents, is also specific for GSH-HNE (Sharma et al., 2002). The expulsion 
of GS-HNE from cells represents another critical step in HNE detoxification since it avoids 
the accumulation of adducted GSH and permits the restoration of GSH/GSSG equilibrium. 
RLIP76 protein is frequently overexpressed in cancer lesions (Vatsyayan et al., 2010), 
included colon cancers (Singhal et al., 2007), thus there is a growing interest in considering 
this protein as target in cancer therapy (Vatsyayan et al., 2010). When RLIP76 is inhibited, a 
rapid increase in HNE-GSH is observed, both in vitro (Awasthi et al., 2003; Cheng et al., 
2001; Yang et al., 2003) and in vivo (Vatsyayan et al., 2010). Recent studies show that the 
inhibition and/or depletion of RLIP76 by antibodies, siRNA, or antisense can lead to a 
drastic and sustained regression of lung, kidney, melanoma, prostate, and colon cancer 
xenografts with no observed recurrence of tumors (Vatsyayan et al., 2010). In particular, it 
has been shown that xenografts of SW480 human colon cancer cells in nude mice can be 
completely regressed by anti-RalBP1 immunoglubulin G or by suppression of RalBP1 
expression using phosphorothioate antisense against it (Singhal et al., 2007). 
The super family of aldo–keto reductase (AKR) enzymes seems to be involved in tumor 
development, and growing evidence is accumulating, suggesting them as a new class of 
tumor marker. These enzymes are hydroxysteroid dehydrogenases with a broad substrate 
specificity for other carbonyl compounds including HNE. The isoform AKR1B10 seems to be 
particulary involved in the transformation of HNE to the oxidized counterpart 4-oxonon-2-
enal (4-ONE) (Martin et al., 2009). AKR1B10 is also up-regulated in many types of solid 
tumors (Fukumoto et al., 2005; Yoshitake et al., 2007; Breton et al., 2008; Satow et al., 2010), 
and its gene silencing results in growth inhibition of colorectal cancer cells (Yan et al., 2007), 
as well as in increasing HNE-elicited cell death (Matsunaga et al., 2011).  
Recently, some family members of AKR enzymes have been shown to be overexpressed and 
linked to resistance against anticancer drugs such as anthracyclines, cisplatin, and 
methotrexate (Veitch et al., 2009; Cheng al., 2008; Selga et al., 2008). As regarding colon 
cancer, experimental data suggest that the up-regulation of AKR1B10 was related with 
acquisition of resistance to the anticancer drug mitomycin-c (MMC) in HT-29 colon cancer 
cells (Matsunaga et al., 2011). The cytotoxic effects of MMC seems to be mediated by the 
formation of HNE. Thus, the biological significance of the increasing of AKR1B10 in MCC 
resistant cancer cells would be an ability to better detoxify cytotoxic aldehydes including 
HNE. (Matsunaga et al., 2011). In the resistant cells, treatment with an AKR1B10 inhibitor 
decreased their MMC tolerance (Matsunaga et al., 2011), suggesting its use as adjuvant 
therapy in drug resistant cells, in which AKR1B10 is over-expressed. 
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Many dietary cancer chemopreventive compounds, such as cruciferous vegetables, could 
activate the antioxidant responsive element (ARE), a critical regulatory element in the 
promoter sequence of genes encoding cellular Phase II detoxifying and antioxidant 
enzymes. Transcriptional activation of ARE is typically mediated by the transcription  
Nuclear factor-erythroid 2-related factor 2 (Nrf2). Thus, this transcription factor has 
emerged as a novel target for the prevention of colon cancer (Saw & Kong, 2011). However, 
stable RNAi-mediated knockdown of Nrf2 in human colon cancer cells suppressed tumor 
growth in mouse xenograft settings and colon tumor angiogenesis by inhibiting Hypoxia-
Induced Activation of HIF-1a (Kim et al., 2011). Thus, the role of Nfr2 in colon 
carcinogenesis still has to be explored.  
3.2.6 HNE and nutrition 
It is well accepted that development and progression of colon cancer is generally associated 
with lifestyle-dependent risk factors, such as dietary choices (Pearson et al., 2009). HNE can 
be directly found in food (Gasc et al., 2007) or its production can be enhanced by the 
presence of some nutrients, i.e. ω-6 PUFAs, or some fermentation products of diet, i.e. 
butyrate, can modulate the metabolism of this aldehyde, thus modifying its concentration. 
In this context, it is very interesting to explore the connection between HNE, nutrition and 
colon carcinogenesis. 
HNE has been founded in different foods, correlating with the amount of ω-6 (Surh et al., 
2010). UsingGC–MS technology, scientists measured 4-hydroxy-alkenaks content in 
vegetable oils, fish and shellfish, calculating the HNE dietary intake of the Korean 
population (Surh et al., 2005). Korean daily exposure to 4-hydroxy- 2-alkenals was found to 
be of 4.3 mg/day and HNE was found to be more represented (2.7 mg). There was an 
additional exposure to more than 11.8 mg/day 4-hydroxy-2-alkenal from fried foods. The 
combined exposure would be, therefore, 16.1 mg/day corresponding to 0.3 mg/kg body 
weight/day for a 60 kg Korean adult. Additionally, the screening of PUFA-fortified foods 
including infant formulas and baby foods commercially available on the Korean markets 
were screened, and it was estimated that 3- month to 1-year-old babies sticking exclusively 
to these products could be exposed to a maximum 20.2 μg/kg BW/ day of 4-hydroxy-2-
alkenals (Surh et al., 2007). However, in spite of the biological toxicity of 4-hydroxy-2-
alkenals, the risk for humans cannot be quantified due to the lack of a virtually safe dose of 
the compound (Surh et al., 2005). 
A diet high in red and processed meats can increase colon cancer risk by 12–20%. The 
mechanism of promotion by haem iron is not known, but may be linked to oxidative stress 
and subsequent events such as lipid pro-oxidation and HNE production (Sesink et al., 1999; 
Sawa et al., 1998). Indeed, the dietary haem, in the form of either haemoglobin or meat, 
promotes precancerous lesions, aberrant crypt foci (ACF) and mucin-depleted foci in the 
colon of rats (Pierre et al., 2003; Pierre et al., 2004). This haem-induced promotion was 
associated with increased lipid peroxidation in faecal water and strong cytotoxycity activity 
of faecal water on the cancerous colonic epithelial cell line (Pierre et al., 2003). Further, Pierre 
and collaborators (2007), have explored the effect of faecal water components of haem-fed 
rats, on normal APC +/+ or premalignant APC -/+ cells, demonstrating that the toxic effects 
observed correlated with the presence of HNE in the faeces. Moreover, the premalignat APC 
-/+ cells were more resistant to apoptosis with respect to normal APC +/+. The authors 
suggested, thus, that the premalignant mutation confer to cells the resistance to the 
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inhibitory signal, allowing them to undergo further mutations and follow a tumoural 
pathway (Pierre et al., 2007). 
In a randomized human study, the urinary excretion of DHN-MA, the major metabolite of 
HNE detectable in urine was compared in volunteers consuming different levels of heme 
iron. The volunteers fed with a low red meat diet (60 g/day) showed a twofold increase of 
DHN-MA when supplemented with heme iron as blood sausage (70 g/day). Since colon 
preneoplastic lesions and DHN-MA excretion in the experimental animal were clearly 
associated with dietary heme iron, urinary DHN-MA was suggested as a promising 
biomarker of colon carcinogenesis (Pierre et al., 2006). 
The role of fat present in the diet in coloncarcinogenesis has been explored by several 
authors and comprehensive reviews have been published. In particular, diets rich in ω-6 
PUFAs, contained in vegetable oils, seem to enhance the development of colon tumors, 
whereas ω-3 PUFA-containing diets, such as fish oil, reduce colon cancer incidence (Reddy, 
2002; Kim & Milner, 2007). Thus, it is possible to suggest a putative HNE role in colon 
carcinogenesis, since HNE is derived from peroxidation of ω-6. However, the complexity of 
the issue forces us to be more cautious. Indeed, Eder and collaborators investigated the 
impact of different fatty-acids composition in the diet on cancer development, measuring 
the formation of the promutagenic HNE-dG in the mucosa of several organs, such as colon. 
The correlation between adduct levels and the different fatty acids assumption was not 
uniform for all organs and they didn’t find a clear relationship between fatty acids and 
adduct levels in the colon (Eder et al., 2008). Moreover, beside lipid peroxidation products it 
is necessary to consider the eicosanoids, also derived from PUFAs. Indeed, eicosanoids have 
different properties in cancer cell growth, invasion and angiogenesis when derived from ω-6 
or ω-3 fatty acids (Berquim et al., 2008), thus suggesting a role in carcinogenesis. 
Epidemiological studies show a reduction in risk for individuals and populations 
consuming high amounts of vegetables. The protective effect of vegetables may be due to 
their content of complex carbohydrates such as dietary fiber and starch (Scheppach et al., 
1999). A substantial amount of starch escapes digestion in the small intestine (Englyst et al., 
1992) and this fraction is called enzyme-resistant starch (RS). Starch and dietary fiber 
together are the principal substrates controlling the pattern of fermentation in the colon and, 
thus, the metabolism of compounds, like bile acids, nitrate and enzyme activityes (bacterial 
and antioxidant enzymes), which have been implicated in carcinogenesis. The effect of 
enzyme-resistant starch (RS) on the development of colon cancer was reported to include 
both chemopreventive and tumorigenic activity in humans. Indeed, an inverse association 
between starch consumption and large bowel cancer incidence has been found in an 
international comparison in 12 populations worldwide (Cassidy et al., 1994). However, an 
increased cancer risk with high-starch intake has been also reported (Franceschi et al., 1998; 
Favero et al., 1999). Wacker and collaborators (2002) have studied the number of 1,N2-
propanodeoxyguanosine-30- monophosphate (HNE-dGp) adducts in the colonic mucosa of 
volunteers fed with starchy foods enriched with a highly resistant amylomaize starch 
(Hylon VII) and they found an increase of the HNE-dGp adduct, whereas there was no 
evidence for an increased cell proliferation in the upper crypt.  
Finally, as already mentioned, nutrients can modulate the HNE level in the colon, by 
affecting its metabolism. This is the case of fermented products of diet, such as butyrate 
(Knoll et al., 2005; Glei et al., 2006) and wheat bran-derived arabinoxylans, that can affect the 
HNE levels, by upregulating GSTs activities.  
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Lipid peroxidation is a physiological and pathological process that elicits a number of 
electrophilic compounds able to modulate several cellular processes. Among these, HNE is 
the most studied aldehyde, due to its high biological activity. Since HNE is a normal 
constituent of the diet or can be produced in the gut, colon cells can be exposed to this 
aldehyde. 
Low doses of HNE are able to inhibit cell proliferation and induce differentiation of colon 
cancer cells. Conversely, a high concentration of HNE exhibits genotoxic and mutagenic 
activity. We believe that the concentration of HNE and other lipid peroxidation products in 
the colon, represent a steady state level between production and catabolism. The alteration 
of this equilibrium elicits a stress condition for colon cells and, possibly, could be involved 
in colon carcinogenesis, although there is no scientific consensus in supporting its pro-
tumoral action.  
Results on HNE content in human biopsies of coloncancer tissues are contradictory, and the 
positive correlation between HNE content and cancer progression doesn’t allow an 
assumption whether the HNE increase during the progression of colon cancer may 
represent a cause or a consequence of this process. However, in colon cancer cells, HNE 
induces apoptosis and telomerase inhibition. Thus, we can hypothesize that HNE, produced 
during radiotherapy or chemotherapy, can participate to the control of tumor growth and 
tumor cell death. 
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1. Introduction 
Colorectal cancer (CRC) is an important health problem in many western countries due to 
its significant morbidity/mortality. Despite advances in its diagnosis and treatment, 
survival associated with this cancer when it has extended to adjacent organs, lymphatic 
nodules or distal organs is drastically reduced. The liver is the most common site of CRC 
metastasis, since it represents a unique microenvironment for the formation of metastases, 
not only due to its sinusoidal endothelium (Barberá-Guillén et al., 1989), but also due to its 
abundant expression of growth factors (GFs) (Stoeltzing et al., 2003). 
At present, curative treatment of localized metastases is possible via partial liver resection. 
However, this surgical procedure is only potentially curative, since 65% of patients 
subjected to resection of liver metastases experience relapse within 5 years (Sun & Tang, 
2003; Allendorf et al., 2004). In the light of this frequent recurrence, it is essential to develop 
new preventive therapeutic strategies, which require a detailed knowledge of the biological 
events that occur following hepatectomy. In this sense, we have previously demonstrated 
the tumor-enhancing effect associated with liver resection in a mouse tumor model; in 
addition, we showed that hepatectomized rat serum increased cell proliferation in vitro, 
when compared with laparotomized rat serum or fetal calf serum (García-Alonso et al., 
2003; García-Alonso et al., 2008a, 2008b). These findings indicated that GFs produced by the 
liver promote the development of metastases.  
At present, CRC treatment includes various active drugs, either as individual agents or in 
combination: 5-fluorouracil (5-FU), capecitabine, irinotecan and oxaliplatin, among others. 
Despite this wide array of anti-tumor agents, relapse often occurs in CRC patients, due in 
large part to the resistance of the tumor cells to these anti-neoplastic agents. Various 
different mechanisms have been reported as being responsible for the development of 
chemoresistance and, though each may be important in itself, they take on an even greater 
significance if we consider how they may be interrelated. 
One of these mechanisms of resistance to anti-neoplastic agents is the presence of GFs, 
which may be able to protect certain tumor cells against cytotoxic cell death. For this reason, 
one of the most promising cell targets nowadays are these GFs and their receptors. Thus, 
since 2004, three new agents have been approved which in combination with cytotoxic 
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addition, we showed that hepatectomized rat serum increased cell proliferation in vitro, 
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2003; García-Alonso et al., 2008a, 2008b). These findings indicated that GFs produced by the 
liver promote the development of metastases.  
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combination: 5-fluorouracil (5-FU), capecitabine, irinotecan and oxaliplatin, among others. 
Despite this wide array of anti-tumor agents, relapse often occurs in CRC patients, due in 
large part to the resistance of the tumor cells to these anti-neoplastic agents. Various 
different mechanisms have been reported as being responsible for the development of 
chemoresistance and, though each may be important in itself, they take on an even greater 
significance if we consider how they may be interrelated. 
One of these mechanisms of resistance to anti-neoplastic agents is the presence of GFs, 
which may be able to protect certain tumor cells against cytotoxic cell death. For this reason, 
one of the most promising cell targets nowadays are these GFs and their receptors. Thus, 
since 2004, three new agents have been approved which in combination with cytotoxic 
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agents are administered in cases of advanced and metastatic CRC: bevacizumab, a 
monoclonal antibody to vascular endothelial growth factor (VEGF) (Hurwitz et al., 2004), 
and cetuximab and panitumumab, which are monoclonal antibodies to the epidermal 
growth factor receptor (EGFR) (Cunningham et al., 2004; Odom et al., 2011). 
An increasing amount of evidence indicates that the intracellular redox state plays an 
essential role in the mechanisms underlying the actions of GFs. In particular, GFs have been 
reported to generate reactive oxygen species (ROS) which can function as second 
messengers, mediating important cellular functions, such as proliferation and programmed 
cell death. Intracellular redox homeostasis is sustained primarily by glutathione (GSH), 
which has long been known to be an important factor in cancer chemoresistance. 
In the present chapter, we analyze three important concerns in relation to CRC 
chemoresistance: 
 The influence of GFs in CRC biology and in the response to current cytotoxic therapies. 
 The involvement of the redox state in the mechanisms of action of GFs in CRC cells.  
 The exogenous modulation of the redox state as a new pharmacological strategy to 
improve the response to chemotherapeutic agents. 
2. Growth factors and colorectal cancer 
GFs play a fundamental role in CRC biology, mediating critical functions in cancerous cells, 
such as proliferation, angiogenesis and the inhibition of cell death. The recurrence of cancer 
after excision surgery is still a major clinical problem. Accumulating clinical and 
experimental evidence has indicated that specific factors involved in liver regeneration may 
influence the growth patterns of residual or dormant micrometastases after resection, 
suggesting that the process of hepatic regeneration has a significant proliferative effect on 
tumor cells. In this regard, GFs appear to be involved in tumor recurrence and in metastasis 
formation. Thus, after partial resection of liver metastases, various types of GFs, which are 
responsible for liver regeneration, are locally released. However, these may also stimulate 
the proliferation of undetected tumor cells in the remaining liver, i.e. highly metastatic colon 
cancer cells can respond to liver regeneration associated mitogens, whose expression is 
induced after hepatectomy. GFs such as hepatocyte growth factor (HGF), epidermal growth 
factor (EGF), transforming growth factor alpha (TGF-), transforming growth factor beta 
(TGF-), basic-fibroblastic growth factor (b-FGF), insulin growth factor–I (IGFI) and vascular 
endothelial growth factor (VEGF) have been reported to be associated with tumor 
progression and metastasis (Christophi et al., 2008).  
Hepatocyte Growth Factor (HGF) is essential for the process of hepatic regeneration. It is a 
potent mitogenic agent produced by stellate, endothelial and Kupffer sinusoidal cells, which 
binds to a receptor of the tyrosine kinase (TK) family. This family of genes is encoded by the 
proto-oncogene c-Met which is expressed in hepatocytes, as well as in other cell types, 
including tumor cells (Di Renzo et al., 1991). It has a pro-angiogenic effect and stimulates 
cell motility as well as the secretion of matrix metalloproteinases (MMPs) by pericytes, 
suggesting an important role in tumor invasion. In the case of CRC, the co-expression of 
HGF and its receptor is correlated with tumor pathogenesis and with the metastatic 
phenotype, and for this reason, it has been proposed as a possible molecular marker to be 
incorporated into CRC staging procedures (Kammula et al., 2007). Moreover, it is known 
that epithelial tumor metastases undergo an epithelial to mesenchymal transition (EMT) 
before becoming invasive. The stimuli which promote this transition include HGF and other 
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GFs such as b-FGF, EGF, TGF-, as well as extracellular matrix (ECM) constituents including 
MMPs (Kalluri & Zeisberg, 2006; Christophi et al., 2008). For these reasons, HGF is 
considered to be a potentially valuable new therapeutic target for different tumors. Studies 
using NK4, a HGF antagonist, have shown an inhibitory effect on proliferation, invasion 
and angiogenesis in cell lines of gastric and pancreatic carcinoma, and of CRC (Hirao et al., 
2002; Wen et al., 2007). In addition, anti-HGF monoclonal antibodies have been developed, 
thereby blocking binding to its receptor (Cao et al., 2001). Other developments include anti 
c-Met antibodies (Jin et al., 2008), and strategies aimed at silencing the expression of c-Met 
or HGF via antisense oligonucleotides (Stabile et al., 2004), o iRNA (Shinomiya et al., 2004). 
Epidermal Growth Factor Receptor (EGFR) ligands, the most physiologically relevant of 
which include EGF, TGF-α, and Amphiregulin (AR). All of these bind to the extracellular 
domain of EGFR, which is a member of the ErbB transmembrane TK receptor family (Hynes 
& Lane, 2005). Binding of these ligands to the receptor activates the Ras/Raf/MAPK and 
PI3K-AKT signaling pathways which are involved in tumor cell proliferation, inhibition of 
apoptosis, invasion, migration and angiogenesis (Le Golvan & Resnick, 2010; Wanebo & 
Berz, 2010). Abnormal expression of these ligands has been demonstrated in many 
advanced tumors, including breast cancers, gliomas, and lung cancer. In the case of CRC, 
EGFR overexpression has been detected in 60-80% of cases (Le Golvan & Resnick, 2010) and 
a correlation has been reported with early tumor recurrence and extra-hepatic metastasis 
(Christophi et al., 2008). However, its exact role in the CRC metastatic cascade has not yet 
been characterized due to controversial results obtained with anti-EGFR antibody therapy. 
In this regard, the therapeutic use of two monoclonal antibody agents (cetuximab and 
panitumumab) has been authorized in patients with metastatic CRC; although they have a 
modest effect when used as single agents, they have been found to be beneficial in some 
patients when used in combination with conventional chemotherapeutic agents (Wanebo & 
Berz, 2010; Tol & Punt, 2010). In fact, it has been shown that the response to this therapy is 
independent of EGFR expression in tumor tissue (Chung et al., 2005). Thus, some studies 
suggest that EGFR expression in the primary tumor does not necessarily correspond with 
the same level of expression in metastatic tissue, while other studies have reported 78-100% 
concordance in EGFR expression in both tissue compartments (Tol & Punt, 2010). These 
discrepancies may partially be due to differences in the detection techniques employed. 
Nevertheless, recent studies have demonstrated that the therapeutic efficacy of the anti-
EGFR antibody is limited to patients in whom the K-Ras oncogene is not mutated, since 
mutation of this oncogene can induce constitutive activation of the Ras/Raf/MAPK 
signaling pathway, which is independent of the activation of EGFR via ligand binding 
(Benvenuti et al., 2007; Tol & Punt, 2010). 
Transforming Growth Factor β (TGF-β) acts as a tumor suppressor due to its inhibition of 
growth and its activation of apoptosis. However, in CRC, this suppressor activity is lost due 
to the existence of mutations in the genes which encode TGF-β, the type II receptor (TGFR β 
2), or SMAD proteins, in such a way that the antiproliferative signal associated with this 
factor is interrupted (Markowitz & Bertagnolli, 2009). On the other hand, TGF-β has a pro-
tumor effect due to its effect on the stroma, promoting angiogenesis, and on the tumor cells 
themselves, stimulating their motility and their invasive capacity (Blobe & Gordon, 2000). 
Thus, TGF-β, whose serum values are correlated with a poor CRC prognosis, acts as a tumor 
promoter, inducing the development of hepatic metastasis (Shim et al., 1999). 
Insulin Growth Factor I (IGF-I) and its TK receptor are implicated in the development and 
progression of CRC due to their induction of proliferation. A correlation has been found 
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agents are administered in cases of advanced and metastatic CRC: bevacizumab, a 
monoclonal antibody to vascular endothelial growth factor (VEGF) (Hurwitz et al., 2004), 
and cetuximab and panitumumab, which are monoclonal antibodies to the epidermal 
growth factor receptor (EGFR) (Cunningham et al., 2004; Odom et al., 2011). 
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 The involvement of the redox state in the mechanisms of action of GFs in CRC cells.  
 The exogenous modulation of the redox state as a new pharmacological strategy to 
improve the response to chemotherapeutic agents. 
2. Growth factors and colorectal cancer 
GFs play a fundamental role in CRC biology, mediating critical functions in cancerous cells, 
such as proliferation, angiogenesis and the inhibition of cell death. The recurrence of cancer 
after excision surgery is still a major clinical problem. Accumulating clinical and 
experimental evidence has indicated that specific factors involved in liver regeneration may 
influence the growth patterns of residual or dormant micrometastases after resection, 
suggesting that the process of hepatic regeneration has a significant proliferative effect on 
tumor cells. In this regard, GFs appear to be involved in tumor recurrence and in metastasis 
formation. Thus, after partial resection of liver metastases, various types of GFs, which are 
responsible for liver regeneration, are locally released. However, these may also stimulate 
the proliferation of undetected tumor cells in the remaining liver, i.e. highly metastatic colon 
cancer cells can respond to liver regeneration associated mitogens, whose expression is 
induced after hepatectomy. GFs such as hepatocyte growth factor (HGF), epidermal growth 
factor (EGF), transforming growth factor alpha (TGF-), transforming growth factor beta 
(TGF-), basic-fibroblastic growth factor (b-FGF), insulin growth factor–I (IGFI) and vascular 
endothelial growth factor (VEGF) have been reported to be associated with tumor 
progression and metastasis (Christophi et al., 2008).  
Hepatocyte Growth Factor (HGF) is essential for the process of hepatic regeneration. It is a 
potent mitogenic agent produced by stellate, endothelial and Kupffer sinusoidal cells, which 
binds to a receptor of the tyrosine kinase (TK) family. This family of genes is encoded by the 
proto-oncogene c-Met which is expressed in hepatocytes, as well as in other cell types, 
including tumor cells (Di Renzo et al., 1991). It has a pro-angiogenic effect and stimulates 
cell motility as well as the secretion of matrix metalloproteinases (MMPs) by pericytes, 
suggesting an important role in tumor invasion. In the case of CRC, the co-expression of 
HGF and its receptor is correlated with tumor pathogenesis and with the metastatic 
phenotype, and for this reason, it has been proposed as a possible molecular marker to be 
incorporated into CRC staging procedures (Kammula et al., 2007). Moreover, it is known 
that epithelial tumor metastases undergo an epithelial to mesenchymal transition (EMT) 
before becoming invasive. The stimuli which promote this transition include HGF and other 
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GFs such as b-FGF, EGF, TGF-, as well as extracellular matrix (ECM) constituents including 
MMPs (Kalluri & Zeisberg, 2006; Christophi et al., 2008). For these reasons, HGF is 
considered to be a potentially valuable new therapeutic target for different tumors. Studies 
using NK4, a HGF antagonist, have shown an inhibitory effect on proliferation, invasion 
and angiogenesis in cell lines of gastric and pancreatic carcinoma, and of CRC (Hirao et al., 
2002; Wen et al., 2007). In addition, anti-HGF monoclonal antibodies have been developed, 
thereby blocking binding to its receptor (Cao et al., 2001). Other developments include anti 
c-Met antibodies (Jin et al., 2008), and strategies aimed at silencing the expression of c-Met 
or HGF via antisense oligonucleotides (Stabile et al., 2004), o iRNA (Shinomiya et al., 2004). 
Epidermal Growth Factor Receptor (EGFR) ligands, the most physiologically relevant of 
which include EGF, TGF-α, and Amphiregulin (AR). All of these bind to the extracellular 
domain of EGFR, which is a member of the ErbB transmembrane TK receptor family (Hynes 
& Lane, 2005). Binding of these ligands to the receptor activates the Ras/Raf/MAPK and 
PI3K-AKT signaling pathways which are involved in tumor cell proliferation, inhibition of 
apoptosis, invasion, migration and angiogenesis (Le Golvan & Resnick, 2010; Wanebo & 
Berz, 2010). Abnormal expression of these ligands has been demonstrated in many 
advanced tumors, including breast cancers, gliomas, and lung cancer. In the case of CRC, 
EGFR overexpression has been detected in 60-80% of cases (Le Golvan & Resnick, 2010) and 
a correlation has been reported with early tumor recurrence and extra-hepatic metastasis 
(Christophi et al., 2008). However, its exact role in the CRC metastatic cascade has not yet 
been characterized due to controversial results obtained with anti-EGFR antibody therapy. 
In this regard, the therapeutic use of two monoclonal antibody agents (cetuximab and 
panitumumab) has been authorized in patients with metastatic CRC; although they have a 
modest effect when used as single agents, they have been found to be beneficial in some 
patients when used in combination with conventional chemotherapeutic agents (Wanebo & 
Berz, 2010; Tol & Punt, 2010). In fact, it has been shown that the response to this therapy is 
independent of EGFR expression in tumor tissue (Chung et al., 2005). Thus, some studies 
suggest that EGFR expression in the primary tumor does not necessarily correspond with 
the same level of expression in metastatic tissue, while other studies have reported 78-100% 
concordance in EGFR expression in both tissue compartments (Tol & Punt, 2010). These 
discrepancies may partially be due to differences in the detection techniques employed. 
Nevertheless, recent studies have demonstrated that the therapeutic efficacy of the anti-
EGFR antibody is limited to patients in whom the K-Ras oncogene is not mutated, since 
mutation of this oncogene can induce constitutive activation of the Ras/Raf/MAPK 
signaling pathway, which is independent of the activation of EGFR via ligand binding 
(Benvenuti et al., 2007; Tol & Punt, 2010). 
Transforming Growth Factor β (TGF-β) acts as a tumor suppressor due to its inhibition of 
growth and its activation of apoptosis. However, in CRC, this suppressor activity is lost due 
to the existence of mutations in the genes which encode TGF-β, the type II receptor (TGFR β 
2), or SMAD proteins, in such a way that the antiproliferative signal associated with this 
factor is interrupted (Markowitz & Bertagnolli, 2009). On the other hand, TGF-β has a pro-
tumor effect due to its effect on the stroma, promoting angiogenesis, and on the tumor cells 
themselves, stimulating their motility and their invasive capacity (Blobe & Gordon, 2000). 
Thus, TGF-β, whose serum values are correlated with a poor CRC prognosis, acts as a tumor 
promoter, inducing the development of hepatic metastasis (Shim et al., 1999). 
Insulin Growth Factor I (IGF-I) and its TK receptor are implicated in the development and 
progression of CRC due to their induction of proliferation. A correlation has been found 
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between serum levels of IGF-I, high levels of IGF-IR expression in tumor cells and the 
development of hepatic metastasis. This pro-tumor effect is due to the fact that the signal 
induced by the binding of IGF-I to its receptor promotes the migration of endothelial cells, 
invasion and the formation of new blood vessels following the stimulation of VEGF 
production by endothelial cells (Wu et al., 2002), suggesting that IGF-I is an important 
contributor to tumor growth and hepatic metastatic development after hepatectomy 
(Christophi et al., 2008). 
Vascular Endothelial Growth Factor (VEGF) is an endothelial cell mitogen which induces 
cell migration, proliferation, invasion and increased vascular permeability and has a potent 
pro-angiogenic activity. It has been shown that a large percentage of tumors which produce 
high levels of VEGF are associated with a high density of vessels in the tumor, metastasis, 
chemoresistance and poor prognosis (Sullivan & Brekken, 2010). 
The VEGF family is made up of six growth factors. These exert their effects via binding to 
one of the three VEGFRs which belong to the tyrosine kinase receptor (TKR) family. These 
are localized predominantly on endothelial cells and angioblasts (Tol & Punt, 2010). In 
addition, in solid tumors, it is postulated that the production of VEGF is increased following 
liberation of hypoxia-inducible factor 1α (HIF-1α) (Kaur et al., 2005), EGF (Niu et al., 2002) 
and HGF (Dong et al., 2001). In turn, VEGF induces the synthesis of other factors related to 
tumor development, such as stroma-derived factor 1 (SDF-1) which induces an increase in 
the population of cancer-associated fibroblasts (CAFs) (Kalluri & Zeisberg, 2006, Christophi 
et al., 2008). 
The risk of developing hepatic metastasis associated with CRC may be related to the 
expression of different VEGF isoforms which bind to the different VEGFRs. Thus, it has 
been shown that in 50% of CRCs, VEGFR-2 is expressed on the surface of the tumor cells 
(Duff et al., 2006). This extensive expression, which reflects the dependence of some solid 
tumors on neoangiogenesis, has led to the proposal that VEGF and VEGFR may be 
therapeutic targets in the treatment of CRC. Bevacizumab is a humanized monoclonal 
antibody which binds to VEGFA blocking the binding of this GF to VEGFR, thereby 
avoiding the corresponding intracellular signal transduction. Although parameters which 
allow a prediction of the efficacy of this monoclonal antibody have not been reported, 
bevacizumab has been approved as a first and second-line therapy for the treatment of 
metastatic CRC, enhancing survival, stabilizing the disease and achieving partial regression 
when used with chemotherapy. Two recent and complete reviews by Tol & Punt (2010) and 
Wanebo & Berz, (2010) analyze randomized and non-randomized trials of neo-adjuvant 
therapy using bevacizumab in metastatic CRC. 
3. The role of the redox state in the mechanism of action of growth factors 
The redox state is a key characteristic which influences important cell biological processes 
including enzymatic reactions, cell signaling, cell proliferation and apoptosis. The term 
redox signaling refers to a regulatory process in which the signal is transmitted through 
redox reactions. The intra- and extracellular redox levels allow the carrying out of different 
extra and intracellular signaling (intra-cytoplasmic and nuclear), which subsequently give 
rise to the cascade of effector signals that regulate diverse cellular activities such as cell 
proliferation. 
GF signals are transmitted from the cell surface by means of the activation of TK-type 
transmembrane receptors and the induction of the corresponding intracellular effects. 
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Among these signal transduction pathways, protein phosphorylation plays a fundamental 
role. This process is reversible and dynamic, being controlled by the opposing actions of 
protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). As a consequence 
of the binding of GF to its specific receptor, dimerization occurs followed by the 
autophosphorylation of tyrosine residues in the intracellular domain of the receptor 
(Cadena & Gill, 1992). These residues are key sites of interaction with cytoplasmic proteins 
which contain SH2 (Src homology type 2) domains; these mediate the signal transduction of 
GFs, such as PLC- γ, GAP-ras (GTP-ase-activating protein of ras), PIK3 and Grb2 (Johnson & 
Vaillancourt, 1994). The action of all these proteins, via different mechanisms, converges to 
activate the Ras protein, which in its turn, activates the Raf tyrosine. Subsequently, a 
phosphorylation cascade is produced in such a manner that Raf phosphorylates another 
kinase, the MAPK kinase which phosphorylates members of a family of serine/threonine 
kinases, the MAP kinases. Finally, MAP kinases phosphorylate the transcription factors 
which promote the transcription of genes necessary for the final cellular response (Davis, 
1993). 
Many studies have demonstrated that the cellular redox status plays a key role in GF-
mediated signaling systems (Thannickal & Fanburg, 2000). Although there is evidence that 
GFs generate ROS, it is not yet clear how ROS activate these cell signaling pathways. One 
plausible mechanism is that ROS could act as second messengers which participate in 
phosphorylation/dephosphorylation processes (Storz, 2005). ROS, such as hydrogen 
peroxidase (H2O2), induce the phosphorylation and activation of some PTKs, such as the 
kinases implicated in the MAP kinase cascade (Rao, 1996). In contrast, PTPs have a cysteine 
residue in their catalytic domain, which must be in its reduced form for total activity of the 
receptor. It has been shown that in cell signaling phenomena, ROS may induce the 
inactivation of PTPs (Rhee et al., 2000). Interestingly, ROS play a crucial role in vascular 
angiogenesis, not only due to their induction of VEGF (Sen et al., 2002), but also to their 
implication in the VEGF signaling pathway. Thus, VEGF stimulates ROS production via the 
activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which is 
essential for the satisfactory propagation of the angiogenic signal (Roy et al., 2008); in fact, 
NADPH oxidase has been proposed as a target for anticancer therapy (Ushio-Fukai & 
Nakamura, 2008). 
Similarly, it has been demonstrated that EGF stimulates ROS production in cells and that 
inhibition of this production leads to a weakening of the signaling system of the 
corresponding factor (Mills et al., 1998). A ROS mediated signaling cascade has also been 
reported to be activated following stimulation of the c-Met/HGF system; this cascade has 
been found to be associated with the crucial role of the receptor in the development of 
metastasis (Ferraro et al., 2006). 
All of these biological effects occur at low to moderate concentrations of ROS. For this 
reason, redox regulation is essential for the maintenance of an optimal level of oxidation 
which permits precise signal transduction and the appropriate cellular response.  
4. Glutathione metabolism in colorectal cancer 
Cells are exposed to oxidative stress which is generated by normal metabolism and also by 
exogenous factors, such as ionizing radiation, some chemotherapeutic drugs and 
xenobiotics. The oxidative modification of cell components via ROS is one of the most 
potentially damaging processes for normal cellular activity (Halliwell, 1991). However, ROS 
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between serum levels of IGF-I, high levels of IGF-IR expression in tumor cells and the 
development of hepatic metastasis. This pro-tumor effect is due to the fact that the signal 
induced by the binding of IGF-I to its receptor promotes the migration of endothelial cells, 
invasion and the formation of new blood vessels following the stimulation of VEGF 
production by endothelial cells (Wu et al., 2002), suggesting that IGF-I is an important 
contributor to tumor growth and hepatic metastatic development after hepatectomy 
(Christophi et al., 2008). 
Vascular Endothelial Growth Factor (VEGF) is an endothelial cell mitogen which induces 
cell migration, proliferation, invasion and increased vascular permeability and has a potent 
pro-angiogenic activity. It has been shown that a large percentage of tumors which produce 
high levels of VEGF are associated with a high density of vessels in the tumor, metastasis, 
chemoresistance and poor prognosis (Sullivan & Brekken, 2010). 
The VEGF family is made up of six growth factors. These exert their effects via binding to 
one of the three VEGFRs which belong to the tyrosine kinase receptor (TKR) family. These 
are localized predominantly on endothelial cells and angioblasts (Tol & Punt, 2010). In 
addition, in solid tumors, it is postulated that the production of VEGF is increased following 
liberation of hypoxia-inducible factor 1α (HIF-1α) (Kaur et al., 2005), EGF (Niu et al., 2002) 
and HGF (Dong et al., 2001). In turn, VEGF induces the synthesis of other factors related to 
tumor development, such as stroma-derived factor 1 (SDF-1) which induces an increase in 
the population of cancer-associated fibroblasts (CAFs) (Kalluri & Zeisberg, 2006, Christophi 
et al., 2008). 
The risk of developing hepatic metastasis associated with CRC may be related to the 
expression of different VEGF isoforms which bind to the different VEGFRs. Thus, it has 
been shown that in 50% of CRCs, VEGFR-2 is expressed on the surface of the tumor cells 
(Duff et al., 2006). This extensive expression, which reflects the dependence of some solid 
tumors on neoangiogenesis, has led to the proposal that VEGF and VEGFR may be 
therapeutic targets in the treatment of CRC. Bevacizumab is a humanized monoclonal 
antibody which binds to VEGFA blocking the binding of this GF to VEGFR, thereby 
avoiding the corresponding intracellular signal transduction. Although parameters which 
allow a prediction of the efficacy of this monoclonal antibody have not been reported, 
bevacizumab has been approved as a first and second-line therapy for the treatment of 
metastatic CRC, enhancing survival, stabilizing the disease and achieving partial regression 
when used with chemotherapy. Two recent and complete reviews by Tol & Punt (2010) and 
Wanebo & Berz, (2010) analyze randomized and non-randomized trials of neo-adjuvant 
therapy using bevacizumab in metastatic CRC. 
3. The role of the redox state in the mechanism of action of growth factors 
The redox state is a key characteristic which influences important cell biological processes 
including enzymatic reactions, cell signaling, cell proliferation and apoptosis. The term 
redox signaling refers to a regulatory process in which the signal is transmitted through 
redox reactions. The intra- and extracellular redox levels allow the carrying out of different 
extra and intracellular signaling (intra-cytoplasmic and nuclear), which subsequently give 
rise to the cascade of effector signals that regulate diverse cellular activities such as cell 
proliferation. 
GF signals are transmitted from the cell surface by means of the activation of TK-type 
transmembrane receptors and the induction of the corresponding intracellular effects. 
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Among these signal transduction pathways, protein phosphorylation plays a fundamental 
role. This process is reversible and dynamic, being controlled by the opposing actions of 
protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). As a consequence 
of the binding of GF to its specific receptor, dimerization occurs followed by the 
autophosphorylation of tyrosine residues in the intracellular domain of the receptor 
(Cadena & Gill, 1992). These residues are key sites of interaction with cytoplasmic proteins 
which contain SH2 (Src homology type 2) domains; these mediate the signal transduction of 
GFs, such as PLC- γ, GAP-ras (GTP-ase-activating protein of ras), PIK3 and Grb2 (Johnson & 
Vaillancourt, 1994). The action of all these proteins, via different mechanisms, converges to 
activate the Ras protein, which in its turn, activates the Raf tyrosine. Subsequently, a 
phosphorylation cascade is produced in such a manner that Raf phosphorylates another 
kinase, the MAPK kinase which phosphorylates members of a family of serine/threonine 
kinases, the MAP kinases. Finally, MAP kinases phosphorylate the transcription factors 
which promote the transcription of genes necessary for the final cellular response (Davis, 
1993). 
Many studies have demonstrated that the cellular redox status plays a key role in GF-
mediated signaling systems (Thannickal & Fanburg, 2000). Although there is evidence that 
GFs generate ROS, it is not yet clear how ROS activate these cell signaling pathways. One 
plausible mechanism is that ROS could act as second messengers which participate in 
phosphorylation/dephosphorylation processes (Storz, 2005). ROS, such as hydrogen 
peroxidase (H2O2), induce the phosphorylation and activation of some PTKs, such as the 
kinases implicated in the MAP kinase cascade (Rao, 1996). In contrast, PTPs have a cysteine 
residue in their catalytic domain, which must be in its reduced form for total activity of the 
receptor. It has been shown that in cell signaling phenomena, ROS may induce the 
inactivation of PTPs (Rhee et al., 2000). Interestingly, ROS play a crucial role in vascular 
angiogenesis, not only due to their induction of VEGF (Sen et al., 2002), but also to their 
implication in the VEGF signaling pathway. Thus, VEGF stimulates ROS production via the 
activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which is 
essential for the satisfactory propagation of the angiogenic signal (Roy et al., 2008); in fact, 
NADPH oxidase has been proposed as a target for anticancer therapy (Ushio-Fukai & 
Nakamura, 2008). 
Similarly, it has been demonstrated that EGF stimulates ROS production in cells and that 
inhibition of this production leads to a weakening of the signaling system of the 
corresponding factor (Mills et al., 1998). A ROS mediated signaling cascade has also been 
reported to be activated following stimulation of the c-Met/HGF system; this cascade has 
been found to be associated with the crucial role of the receptor in the development of 
metastasis (Ferraro et al., 2006). 
All of these biological effects occur at low to moderate concentrations of ROS. For this 
reason, redox regulation is essential for the maintenance of an optimal level of oxidation 
which permits precise signal transduction and the appropriate cellular response.  
4. Glutathione metabolism in colorectal cancer 
Cells are exposed to oxidative stress which is generated by normal metabolism and also by 
exogenous factors, such as ionizing radiation, some chemotherapeutic drugs and 
xenobiotics. The oxidative modification of cell components via ROS is one of the most 
potentially damaging processes for normal cellular activity (Halliwell, 1991). However, ROS 
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are well recognized for playing a dual role. Thus, a number of studies have provided 
convincing evidence that, depending on the level of oxidative stress, ROS can function as 
pro-life signals in certain contexts (as mentioned above, low or mild increases in ROS play a 
pivotal role in many physiological reactions, such as the regulation of transcription factors 
and cellular signaling pathways) (Maellaro et al., 2000) and pro-death signals in others (high 
concentrations of ROS can induce apoptosis) (Le Bras et al., 2005). Consequently, the 
maintenance of the redox status is a key factor for cell survival, in the case of both normal 
and cancer cells. 
In order to maintain redox balance and also to protect themselves from oxidative stress, cells 
possess powerful redox regulation systems, known as the “redox buffer”, including GSH and 
thioredoxin (TRX), as well as antioxidant enzymes, such as superoxide dismutase (SOD), 
catalase, GSH peroxidase (GPx) and thioredoxin reductase (TrxR). In addition, cells also 
have available other non-enzymatic antioxidants which are obtained via the diet, among 
which are ascorbic acid (vitamin C), α-tocopherol (vitamin E), flavonoids, carotenoids and 
selenium. 
Intracellular redox homeostasis is sustained primarily by GSH, the most prevalent intracellular 
non-protein thiol. In fact, the ratio between its reduced and oxidized states (GSH/GSSG) is 
considered to be an indicator of the redox status of the cell. GSH is intracellularly synthesized 
from the three amino acids glutamic acid, cysteine and glycine; it possesses an unusual  
peptide bond between glutamic acid and cysteine, and has a thiol group on the latter 
aminoacid. The biosynthesis and degradation of GSH occurs within the -glutamyl cycle, in 
which GSH is transported to the extracellular space and -glutamyl-aminoacids are 
transported to the intracellular space. GSH is synthesized from glutamate by two consecutive 
reactions which are catalyzed by the -glutamylcysteine synthetase (-GCS) and GSH 
synthetase enzymes. GSH can be exported outside the cell, although its constituent aminoacids 
can be reincorporated into the cell, thanks to a transpeptidation reaction catalyzed by the -
glutamyl transpeptidase (-GT) enzyme, which is a glycoprotein localized on the outer surface 
of the plasma membrane. Transpeptidation occurs in the presence of aminoacids, giving rise to 
-glutamyl-aminoacids and cysteinylglycine (Cys-Gly). The -glutamyl-aminoacids are 
transported into the cell, whereas in the case of cysteinylglycine, bond breakage by means of a 
dipeptidase is first required. This dipeptidase is present on the outer surface of the plasma 
membrane, thereby allowing the incorporation of the peptides into the cell. The -glutamyl-
aminoacids are the substrate of the -glutamyl cyclotransferase enzyme, which transforms the 
glutamyl residue into 5-oxoproline, liberating the remaining aminoacids. Next, by means of 
the 5-oxo-L-prolinase (5-OPase) enzyme, 5-oxoproline is transformed into glutamate and this 
reaction involves the consumption of ATP. The cycle is completed with the action again of -
GCS and GSH synthetase (Fig. 1) (Meister & Anderson, 1983). 
Due to its structural characteristics, GSH participates in numerous processes which are 
essential for cell physiology. GSH and its related enzymes are involved in cell proliferation 
and participate in the cell cycle, in the synthesis of proteins and in DNA synthesis and repair 
(Higuchi, 2004). In addition, its capacity as a reducing and antioxidant agent renders GSH 
an essential component for the maintenance of the integrity of the protein and lipid 
components of the cell, as well as a substrate for antioxidant GSH peroxidase enzymes, a 
selenium-dependent system. As indicated previously, another of its important functions 
consists in the protection of the cell from free radicals, endogenous and exogenous toxic 
substances, and carcinogens. GSH also defends the cell against the effects produced by 
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radiation and some chemotherapeutic drugs, such as alkylating agents. The formation of 
GSH S-conjugated products generated during intracellular detoxification may occur due to 
the non-enzymatic reaction of exogenous electrophilic compounds or to the action of GSH S-
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In addition to its essential role in normal growth, GSH is also involved in cell differentiation. 
Thus, it has been reported that as the cell progresses from proliferation to differentiation, 
cellular GSH content decreases. For example, it has been observed that butyrate-induced 
differentiation of the HT-29 human colon cell line is associated with reduced levels of cellular 
GSH (Bernard & Balasubramanian, 1997). These findings led to the notion that thiol status may 
be dependent on cellular energy metabolism. In this regard, the tumor cells have a very high 
cellular metabolism and, consequently, they generate high levels of ROS. Here, we should 
underline the importance of regulation of redox balance for the survival of malignant cells; the 
activation of redox regulatory systems, in which GSH plays an important role, could be 
considered to be the first line of adaptation of cancerous cells to oxidative stress. In fact it has 
been reported that non-differentiated and highly metastatic melanoma cells have a 
significantly higher GSH content than non-tumorigenic melanocytes (Thrall et al., 1991). 
Moreover, it has been demonstrated that whereas elevation of intracellular GSH is associated 
with mitogenic stimulation (Palomares et al., 1997), GSH depletion decreases the rate of cell 
proliferation and inhibits cancer growth (Del Olmo et al., 2000).  
Increased levels of ROS in cancerous cells may have profound consequences, including 
enhanced cell proliferation, increased incidence of mutations and genetic instability, and 
reduced sensitivity of cells to anticancer agents, leading to resistance. In the case of CRC, 
intense oxidative stress and significant oxidative DNA adducts have been found during all 
stages of colorectal carcinogenesis (Schmid, et al., 2000). In fact, these DNA adducts, as well 
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are well recognized for playing a dual role. Thus, a number of studies have provided 
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essential for cell physiology. GSH and its related enzymes are involved in cell proliferation 
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an essential component for the maintenance of the integrity of the protein and lipid 
components of the cell, as well as a substrate for antioxidant GSH peroxidase enzymes, a 
selenium-dependent system. As indicated previously, another of its important functions 
consists in the protection of the cell from free radicals, endogenous and exogenous toxic 
substances, and carcinogens. GSH also defends the cell against the effects produced by 
 
Growth Factors and the Redox State as New Therapeutic Targets for Colorectal Cancer 
 
195 
radiation and some chemotherapeutic drugs, such as alkylating agents. The formation of 
GSH S-conjugated products generated during intracellular detoxification may occur due to 
the non-enzymatic reaction of exogenous electrophilic compounds or to the action of GSH S-




Fig. 1. The γ-glutamyl cycle. Abbreviations: -glu-AA, -glutamyl-aminoacids; Glu, glutamic 
acid; Cys, cysteine; Gly, glycine.  
In addition to its essential role in normal growth, GSH is also involved in cell differentiation. 
Thus, it has been reported that as the cell progresses from proliferation to differentiation, 
cellular GSH content decreases. For example, it has been observed that butyrate-induced 
differentiation of the HT-29 human colon cell line is associated with reduced levels of cellular 
GSH (Bernard & Balasubramanian, 1997). These findings led to the notion that thiol status may 
be dependent on cellular energy metabolism. In this regard, the tumor cells have a very high 
cellular metabolism and, consequently, they generate high levels of ROS. Here, we should 
underline the importance of regulation of redox balance for the survival of malignant cells; the 
activation of redox regulatory systems, in which GSH plays an important role, could be 
considered to be the first line of adaptation of cancerous cells to oxidative stress. In fact it has 
been reported that non-differentiated and highly metastatic melanoma cells have a 
significantly higher GSH content than non-tumorigenic melanocytes (Thrall et al., 1991). 
Moreover, it has been demonstrated that whereas elevation of intracellular GSH is associated 
with mitogenic stimulation (Palomares et al., 1997), GSH depletion decreases the rate of cell 
proliferation and inhibits cancer growth (Del Olmo et al., 2000).  
Increased levels of ROS in cancerous cells may have profound consequences, including 
enhanced cell proliferation, increased incidence of mutations and genetic instability, and 
reduced sensitivity of cells to anticancer agents, leading to resistance. In the case of CRC, 
intense oxidative stress and significant oxidative DNA adducts have been found during all 
stages of colorectal carcinogenesis (Schmid, et al., 2000). In fact, these DNA adducts, as well 
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as GST polymorphisms, have been suggested as molecular biomarkers for the detection of 
early CRC and the prediction of the clinical effectiveness of chemopreventive drugs (Garcea 
et al., 2003). Elevated GST expression (Naidu et al., 2003) and a significant increase in GSH 
levels (Balendiran et al., 2004) have been found in CRC; these are often associated with an 
increased resistance to cancer chemotherapy drugs via GSH conjugation. Elevated GSH 
levels may also be related to γ-GCS, another GSH-related enzyme whose levels have also 
been found to be elevated in CRC (Tatebe et al., 2002). Finally, it should be remembered that 
GSH and its related enzymes is only one of the redox regulation systems which are 
implicated in CRC, since an increased expression of TRX-1 in human CRC has been found to 
be associated with reduced survival times of patients (Raffel et al., 2003). 
In summary, the GSH system involves complex and dynamic processes in which several 
related enzymes participate. Although it may be difficult to know a priori what type of GSH 
metabolism a given CRC may have, the fact that some CRC cells contain high levels of GSH 
has led to the suggestion that it may be an important factor in limiting the therapeutic 
efficiency of conventional cancer treatment. 
5. The influence of glutathione metabolism in the response to chemotherapy 
A common cause of treatment failure in CRC is chemoresistance. This resistance to current 
cytotoxic therapies limits their success in the majority of advanced cancer patients. This is 
particularly true in the case of liver metastases.  
GSH is able to modulate cell susceptibility to chemotherapy. In particular, GSH plays an 
important role in the protection against cell injury caused by various anticancer agents (see 
Balendiran et al., 2004 for review), and elevated GSH levels render tumor cells resistant to 
chemotherapeutic drugs. In the particular case of CRC, there is also evidence that the GSH 
status of colon cancer cells is a critical determinant of cell damage by various agents. Indeed, 
it has been proposed that elevated intracellular GSH levels may be a cause of acquired 
resistance to 5-FU, platinum agents and camptothecins. In this regard, it has been suggested 
that the increased levels of antioxidant enzymes in response to the generation of ROS by 5-
FU, a standard drug for the treatment of this disease, may underlie the acquired resistance 
to this anti-tumor agent (Hwang et al., 2007). In in vitro studies, we have shown that 
treatment with 5-FU produced the greatest antiproliferative effect after 24 hours of 
incubation and that later, once drug treatment had been stopped, the growth of tumor cells 
rebounded (Palomares et al., 2009). This finding may be due to the recovery of GSH levels 
after the initial 5-FU-induced reduction, which has also been suggested by other authors 
(Chen et al., 1995). 
It has also been reported that GSH may modulate the cytotoxicity of platinum agents 
(Sadowitz et al., 2002). However, intracellular GSH levels do not appear to influence the cell 
growth-inhibiting activity of these compounds in cells not previously exposed to platinum 
complexes (Boubakari et al., 2004), suggesting that GSH may be more relevant in acquired 
resistance. Furthermore, several authors have reported the influence of GSH on sensitivity 
to camptothecins (Yoshida et al., 2006). 
In order to decrease the resistance of tumor cells to chemotherapeutic drugs, many GSH-
based therapeutic strategies have focused on lowering GSH levels, principally via the use of 
agents which reduce this tripeptide or inhibit its synthesis. The agent which is most 
frequently used to reduce the levels of this thiol, not only in basic research but also in 
clinical assays, is L-buthionine-S,R-sulfoximine (BSO) (Fig. 2). We found that this potent 
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inhibitor of γ-GCS enhances the sensitivity of tumor cells to treatment with ionizing 
radiation and cytostatic drugs, such as alkylating agents (Palomares et al., 1999). We have 
also found that the reduction in GSH content (around 52%) produced by BSO significantly 
inhibits the proliferation of colon cancer WiDr cells (Palomares et al., 2009). 
 
 
Fig. 2. Inhibition of -glutamylcysteine synthetase by L-buthionine-S,R-sulfoximine (BSO). 
However, the anti-tumor efficacy of BSO is accompanied by increased toxicity, due to the 
fact that BSO exerts its effects in a non-selective manner. In fact, it reduces GSH levels in 
both tumor and normal cells and thus sensitizes both cell populations to the toxic effect of 
anticancer agents. This finding has been reported in clinical studies, such as that of Bailey et 
al. (1998), who upon combining BSO and melphalan, found an important increase in 
medullar toxicity with respect to that produced by the administration of the alkylating agent 
alone. Thus, BSO treatment produces toxicity at the level of the immune, gastrointestinal, 
urinary and central nervous systems. This toxicity limits, de facto, the therapeutic potential of 
BSO and of other non-selective GSH reducing agents. 
One of the principal reasons for the limited effects of chemotherapy is the insufficient 
therapeutic index of available drugs. This index could be increased by regimes which 
protect healthy tissues against toxicity and at the same time enhance the sensitivity of tumor 
tissue to anticancer drugs. Since GSH is highly relevant in protecting both normal and 
tumor cells, one way of achieving this objective would be to selectively modulate GSH 
levels. An increase in GSH levels or in the capacity of normal cells to synthesize GSH, would 
enhance their resistance, leading to a protector effect. In contrast, a reduction in GSH 
content or in the capacity of tumor cells to synthesize this tripeptide would enhance 
sensitivity to the effects of anti-tumor agents. In this regard, it was suggested many years 
ago that agents which induce a selective modulation in GSH levels could be beneficially 
added to conventional treatments in order to enhance the anti-tumor efficacy of 
radiotherapy and/or chemotherapy (Russo et al., 1986). 
Selective modulation of GSH as a therapeutic strategy requires an in-depth knowledge of 
the physiological differences in GSH synthesis and metabolism between healthy and tumor 
cells, as well as of the level of expression of GSH-related enzymes. In this regard, lower 
expression of the 5-OPase enzyme has been found in some tumor cell lines in comparison to 
healthy cells, leading to the suggestion that this enzyme may be a key player in obtaining 
the required selective modulation of GSH (Chen & Batist, 1998). 
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Within the -glutamyl cycle, 5-OPase catalyses the hydrolysis of 5-oxo-L-proline to L-
glutamate, one of the three aminoacids which participate in GSH synthesis, joining in this 
way the reactions of GSH synthesis and metabolism in this cycle (see Fig. 1). It has also been 
observed that L-2-oxothiazolidine-4-carboxylate (OTZ) –an analog of 5-oxo-proline– also 
acts as a substrate of 5-OPase, thereby converting this cysteine prodrug into S-
carboxycysteine, hydrolyzing it subsequently to cysteine and CO2 (Fig. 3). 
Some studies have found that in contrast to BSO, OTZ treatment is selective, increasing GSH 
levels in healthy tissue and reducing it paradoxically in tumor tissue (Chen & Batist, 1998). 
These authors have suggested that OTZ, by competing with 5-oxo-L-proline for 5-OPase, 
could exert two different effects on GSH levels, depending on the level of expression of the 
5-OPase enzyme and on the quantity of aminoacids necessary for the synthesis of the said 
tripeptide. In this way, OTZ would increase intracellular levels of GSH in healthy cells by 
means of increasing the contribution of cysteine – in normal conditions, the limiting 
aminoacid in GSH synthesis in these cells - (Meister A, 1983), but would reduce GSH 
content in tumor cells by means of the inhibition of glutamate synthesis from 5-oxo-L-
proline. In fact, it has been observed that in tumor cells and in other cells under conditions 
of oxidative stress, glutama`te is the limiting factor in GSH synthesis (Kang, 1993) 
 
.  
Fig. 3. Metabolism of L-2-oxothiazolidine-4-carboxylate (OTZ) and of 5-oxo-L-proline by 
means of the 5-OPase enzyme. 
In in vitro studies, OTZ has been found to be useful as a protector in human lymphocytes 
against toxicity due to nitrogenated mustard, or in cultures of human fibroblasts against 
radio-induced toxicity. In in vivo studies using mouse models, OTZ has demonstrated its 
efficacy in protecting against liver damage produced by alcohol, by reducing the degree of 
cystitis induced by cyclophosphamide (CY) or of hepatotoxicity produced by 
acetaminophen, among others. OTZ has been used in diverse clinical assays for the 
treatment of a variety of pathologies associated with ROS generation and with reduced GSH 
levels. Diseases in which OTZ treatment has been successfully employed include acute 
respiratory distress syndrome (Morris et al., 2008), amyotrophic lateral sclerosis (Cudkowicz 
et al., 1999) and atherosclerosis (Vita et al., 1998). Patients subjected to peritoneal dialysis 
(Moberly et al., 1998) and patients infected with the AIDS virus (Barditch-Crovo et al., 1998) 
have also benefited from this treatment. 
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Paradoxically, in contrast to the effect produced in healthy tissue, OTZ reduces GSH levels 
in some human tumor cell lines including breast adenocarcinoma and ovary 
adenocarcinoma (Chen & Batist, 1998). In the same way, we have also demonstrated the 
selective character of GSH modulation by OTZ, in vitro as well as in vivo. Thus, OTZ was 
found to reduce the intracellular content of GSH in melanoma cells, producing reduced 
proliferation and increased chemosensitivity, whereas it increased GSH levels in peripheral 
blood mononuclear cells, exhibiting a corresponding cytoprotector effect (Del Olmo et al., 
2000, 2006; Bilbao et al., 2002). 
Several authors have pointed to the usefulness of GSH modulating agents as an adjuvant in 
chemotherapy treatments for CRC. Regarding 5-FU, a number of studies support the 
therapeutic use of antioxidant compounds in combination with this drug. Thus, therapy 
with high doses of antioxidants such as pyrrolidine dithiocarbamate (PDTC) and N-
acetylcysteine (NAC) seem to enhance the therapeutic efficacy of 5-FU (Bach et al., 2001). 
NAC is a prodrug of cysteine, which is an essential element for GSH synthesis. It was 
developed to avoid the important toxicity produced as a consequence of the direct 
administration of this aminoacid. The mechanisms of protection of this thiol against 
mutagenesis and carcinogenesis are related to a large number of biological effects, including 
antioxidant activity, involvement in DNA repair mechanisms, modulation of gene 
expression and of signal transduction, immunological activity, regulation of cell survival 
and of apoptosis, inhibition of cell transformation, of invasion and metastasis and of 
angiogenic activity, among others (Morini et al., 1999). However, some authors have 
reported contradictory effects of NAC in its anticancer action. Moreover, it has been 
demonstrated that antioxidant protection therapy in cancer patients should be used with 
caution, since it can give rise to counterproductive effects (Brizel & Overgaard, 2003). The 
reduction in the concentration of free radicals due to the excessive administration of 
antioxidants can stimulate the survival of damaged cells, enhancing the neoplastic stage, 
thereby promoting carcinogenesis more than inhibiting it. Furthermore, we and others have 
demonstrated that the increase in GSH levels induced by NAC is not specific to normal cells; 
rather, this can also occur in tumor cells, such as melanoma, increasing its proliferative 
capacity and protecting it against the cytotoxic effects of acrolein, one of the active 
metabolites of CY (Del Olmo et al., 2000).  
It has also been found that the reduced levels of GSH induced by BSO and OTZ, lead to an 
increased cytotoxic effect of 5-FU in different human CRC cells (Meurette et al., 2005; 
Palomares et al., 2009). It has also been observed that BSO enhances the activity of SN-38 (an 
active metabolite of the anticancer drug irinotecan) in WiDr colon cancer cells (Caramés et 
al., 2010), and in cell lines of ovary cancer resistant to cisplatin, as well as of breast cancer. 
BSO is also capable of reverting resistance to SN-38 in leukemia cells with increased GSH 
levels (Yoshida et al., 2006). This increased anti-tumor effect of SN-38 may be related to the 
reduced activity of the transcription factor NF-κB, which is dependent on the intracellular 
redox status and thus sensitive to a reduced content of intracellular GSH. In fact, SN-38 is 
known to activate NF-κB and so the pharmacological inhibition of this NF-κB signaling 
pathway can enhance the anti-tumor activity of SN-38 in colon cancer cells in vitro and of 
irinotecan in vivo (Lagadec et al., 2008). 
Regarding platinum compounds, various authors have demonstrated that GSH participates 
in the detoxification of these agents and that reduced GSH levels sensitize cancer cells to the 
cytotoxic effects of these anti-tumor agents (Jansen et al., 2002). We have found that both 
BSO and OTZ increase the efficacy of oxaliplatin in the WiDr human colon cancer cell line 
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(Caramés et al., 2010). Thus, reduced GSH levels mediated by BSO or OTZ lead to an 
increase in cytotoxicity induced by drugs which are more frequently used nowadays for 
CRC therapy, with an additive effect being observed in the antiproliferative effects of these 
combinations.  
6. The influence of growth factors in the sensitivity of tumor cells to 
chemotherapy 
Research on the phenomenon of chemotherapy resistance has traditionally focused on the 
tumor cells themselves. However, it has become apparent that the tumor microenvironment 
may also influence chemoresistance in an important way. In this regard, it is necessary to 
underline the fundamental role of GFs in cancer biology and in the formation of metastasis, 
since they control critical functions in cancer cells, such as proliferation, angiogenesis and 
the inhibition of apoptosis. Thus, GFs, due to their capacity to modulate the sensitivity of 
tumor cells to cytotoxic drugs, have become important targets for the development of new 
anti-cancer therapies, either as individual agents or in combination with conventional 
chemotherapy, with the aim of enhancing the efficacy of anti-cancer drugs.  
It has been demonstrated that the presence of GFs significantly reduces the cytotoxic activity 
of a number of commonly used drugs. In this regard, some authors have pointed out that 
HGF protects tumor cells against the cytotoxicity and apoptosis induced by DNA-damaging 
agents, such as ionizing radiation or adriamycin (Shen et al., 2007), and that it may 
contribute to the resistance of RMS cells to conventional treatment (Jankowski et al., 2003). 
Similarly, it has been suggested that this factor could induce resistance to cisplatin in lung 
cancer cells (Chen et al., 2008). Nevertheless, in contrast to expectations, it has also been 
observed that HGF sensitizes ovary cancer cells to the drugs paclitaxel and cisplatin 
(Bardella et al., 2007). These findings indicate that HGF effects depend on the targeted 
tumor type. Indeed, various other studies have reported the effect of VEGF in reducing the 
efficacy of endocrine therapy in breast cancer (Qu et al., 2008). It has also been found that 
VEGF diminishes the response to drugs in myeloid leukemia (De Jonge et al., 2008) and that 
doxorubicin exerts a milder inhibitory effect in the presence of VEGF overexpression in soft-
tissue sarcoma (Zhang et al., 2006). Regarding EGF, it has been widely demonstrated that 
this GF reduces the response of tumors, such as human breast carcinoma, to cytotoxic 
compounds and to radiotherapy (Schmidt & Lichtner, 2002). 
In the case of CRC, we (Palomares et al., 2009) and others (Sun & Tang, 2003; Allendorf et 
al., 2004) have demonstrated that HGF, EGF and VEGF significantly reduce the efficacy of 
drugs currently used in CRC. In particular, the increased expression of HGF and VEGF 
results in fluoropyrimidine-based adjuvant chemotherapy being less effective, increasing the 
risk of recurrence. In relation to EGF, it has been shown that its receptor, EGFR, increases 
resistance to 5-FU. Moreover, 5-FU itself induces the activation of EGFR, which protect 
colon cancer cells against chemotherapy (Hiro et al., 2008). Moreover, it has been reported 
that SN-38, through a mechanism involving ROS, induces the activation of EGF and EGFR, 
and this could contribute to resistance to irinotecan (Kishida et al., 2005). These data suggest 
that inhibition of the EGFR signaling pathway could revert resistance to treatment with the 
fluoropyrimidines and irinotecan. On the basis of this hypothesis, some authors have 
carried out assays using tyrosine kinase inhibitors of EGFR, such as gefitinib (Stebbing et al., 
2008), as well as inhibitors of the Src tyrosine kinase (Ischenko et al., 2008). 
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The molecular mechanisms underlying GF-mediated resistance continue to be largely 
unknown. On the one hand, GFs induce cell proliferation and the activation of anti-
apoptotic signaling pathways, via proteins such as Bcl-XL, thereby contributing to the 
resistance to apoptosis in CRC cells following treatment with 5-FU, oxaliplatin and 
irinotecan (Schulze-Bergkamen et al., 2008). In addition, it has also been suggested that GFs 
may also induce an increase in the repair of damaged DNA (Hiro et al., 2008). On the other 
hand, it has been observed that the EGFR-Src-STAT3 oncogenic signaling pathway plays an 
important role in CRC, contributing to proliferation, cell survival and treatment resistance 
(Hbibi et al., 2008). In fact, it has been demonstrated that this pathway is activated in 
response to treatment with topoisomerase I inhibitors, such as camptothecins, reducing 
DNA damage and enhancing cell survival (Vigneron et al, 2008). 
Moreover, as we have recently shown, GFs give rise to an increase in GSH levels which, as 
mentioned earlier, is an important mechanism of cell defense against oxidative stress and 
against the effects produced by radiation and by some chemotherapeutic agents; this 
increase in GSH levels has been correlated with diminished 5-FU anti-tumor activity in 
colon cancer cells (Palomares et al., 2009). In this regard, it has been reported that the 
combination of an EGFR inhibitor with doxorubicin leads to enhanced cytotoxic effects via 
the generation of oxidative stress, due to ROS induction and reduced GSH content in rat 
hepatoma cells (Ortiz et al., 2008). 
Additionally, it has been suggested that GF-induced increases in intracellular GSH levels 
and the activation of the redox-sensitive transcription factor NF-κB could play a major role 
in inducible chemoresistance. This cell survival transcription factor, which is subject to 
regulation by GSH (Lou  Kaplowitz, 2007), has been shown to be constitutively activated 
in many colon cancer cells. NF-κB has been shown to be associated with the proliferation of 
tumor cells, with invasion, angiogenesis and the production of metastasis (Bours et al., 
1994). It has been demonstrated that HGF, via the PI3K/Akt signaling pathway, leads to the 
activation of NF-κB, by means of which cells are protected against adriamycin and 
irinotecan (Fan et al., 2005). In the same way, the transmission of the proliferative signal 
induced by EGF is also mediated by the activation of NF-κB (Sethi et al., 2007), which plays 
an important role in the regulation of EGFR ligands via a ROS-mediated mechanism 
(Murillo et al., 2007). Moreover, NF-κB activation in response to exposure to anti-cancer 
drugs has been shown to be one of the mechanisms of tumor resistance to chemotherapy, as 
has been reported in the cases of 5-FU and irinotecan (Ahn et al., 2008). In contrast, 
inhibition of NF-κB has been shown to enhance the sensitivity of colon cancer tumor cells to 
HT-29 and 5-FU (Voboril et al., 2004). 
Overall, these data indicate that GFs play a critical role in the resistance of colon cancer cells 
to chemotherapeutic agents. In consequence, these factors are potential therapeutic targets 
for increasing the anti-tumor activity of cytotoxic drugs.  
7. New therapeutic strategies to enhance the response of CRC to 
chemotherapy by reversion of the growth factor pro-tumour effects 
Based on the aforementioned data, GFs have been identified as important targets to be 
considered in the development of new anticancer drugs and, consequently, many 
experimental studies have been carried out to evaluate the effects of blocking GF effects on 
tumor cells. These attempts could be classified into three categories, according to the 
mechanism chosen to avoid the GF stimulation of these cells. The first approach was to 
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administer monoclonal antibodies (MoAb) against one or several GFs, and the results have 
been quite exciting. Another idea was to produce MoAb against the membrane receptors for 
different GFs, and again the results have been very promising. In fact, several of these 
MoAb have already entered the armamentarium for cancer therapy and others are currently 
at different stages of clinical trials. The third exciting arm of these GF-based therapies 
consists of the so-called "small molecules" which block the activation of the intracellular part 
of GF receptors.  
The combination of conventional cytotoxic drugs with new agents that specifically interfere 
with GF signaling pathways presents the advantage of avoiding crossed resistance, since 
these approaches are directed against different cell targets and have different underlying 
mechanisms of action. In this regard, many studies have indicated that inhibitors of GFs or 
of their receptors enhance the efficacy of conventional cytotoxic agents (Wanebo & Berz, 
2010). The GF inhibitors bevacizumab and cetuximab are particularly noteworthy. 
Currently, bevacizumab is used in combination with regimes which contain 5-FU (FOLFOX 
or FOLFIRI) as a first line therapy in advanced or metastatic CRC (Giantonio et al., 2007; Tol 
& Punt, 2010). On the other hand, combined therapy consisting of irinotecan and cetuximab 
is indicated after progression in patients who have previously received 5-FU based therapy 
(Cunningham et al., 2004). 
Other agents, such as gefitinib, have been found in preclinical studies to exhibit synergistic 
inhibitory effects when administered in combination with different cytotoxic drugs. For 
example, some authors have observed that gefitinib and irinotecan act synergistically in 
WiDr cells, as a result of the inhibition of the survival signal induced by irinotecan via the 
phosphorylation of EGFR (Koizumi et al., 2004). Similarly, in vitro studies have shown that 
the combination of gefitinib and oxaliplatin has a synergistic effect in colon cancer cells due, 
at least in part, to the fact that the EGFR inhibitor reduces the activity of γ-GT. This enzyme, 
which participates in the γ-glutamyl cycle, helps to salvage extracellular GSH and 
contributes to redox control by providing a substrate for GSH synthesis during oxidative 
stress, thereby preventing apoptosis, as we have showed previously (Castro et al., 2002). 
Reduced γ-GT activity thereby leads to increased cellular oxaliplatin accumulation and 
platinum-DNA adducts (Xu et al., 2003). 
However, these anti-tumor agents also have their inconveniences. They induce diverse side 
effects which complicates their clinical use (Mulder et al., 2011). Also, as happens with other 
chemotherapeutic agents, the development of resistance to these GF-based agents has 
already been reported (Giaccone & Wang, 2011). For these reasons, it is important to 
continue the search for new therapeutic strategies which could be used in combination in 
order to enhance the efficacy of GF-related targeted agents. In this sense, the therapeutic 
biomodulation of GSH metabolism may hold promise for the improvement of the efficacy of 
anticancer treatments. Many lines of evidence indicate that this may be an effective 
approach to treating cancer: i) the fact that tumor cells are under high levels of oxidative 
stress may represent a great opportunity given that it means they are particularly vulnerable 
to further increases in ROS levels; ii) colon cancer cells contain particularly high levels of 
GSH; iii) GF-induced signal transduction pathways are redox sensitive, and accordingly, 
alterations in cellular GSH content may affect the growth of GF-sensitive cells; and iv) the 
fact that NF-κB is involved in GF-dependent proliferation and that the activity of this 
transcription factor might also be subject to regulation by GSH suggests that depletion of 
cellular GSH could interrupt NF-κB activity and consequently lead to growth inhibition.  
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In this regard, we have recently demonstrated that GSH-induced depletion by BSO or OTZ 
abrogated the growth-promoting effects of GFs in WiDr colon cancer cells (Palomares et al., 
2009). Similarly, other authors have demonstrated that BSO inhibits GSH upregulation 
induced by HGF, thereby blocking its mitogenic effect (Yang et al., 2008) and the protection 
against apoptosis afforded by this factor. It has likewise been reported that BSO interferes 
with EGF-induced proliferation and that extended exposure (for 48 h or more) of cells to 
BSO induces cell death, probably via a necrotic mechanism (Carmona-Cuenca et al., 2006). 
Regarding VEGF, it has also been reported that BSO treatment reverts increased GSH 
activity induced by this factor and, in this way, its vasculoprotective function (Kuzuya et al., 
2001). In contrast, decreased GSH levels produced by BSO have been shown to promote the 
autocrine secretion of VEGF (Sreekumar et al., 2006).  
Thus, the two effects derived from the biomodulation of GSH intracellular content with BSO 
or OTZ, i.e. i) the reversion of the pro-tumor effect of GFs and ii) the enhanced efficacy of 
chemotherapy, may contribute to enhancing the therapeutic benefit of chemotherapy 
treatment. In fact, we have shown that, in the presence of GFs, the combination of either of 
the GSH modulators with chemotherapeutic drugs produced greater anti-tumor activity 
than the cytotoxic drugs alone. Thus, we found that both BSO and OTZ completely reverted 
the resistance (due to the presence of GFs) of WiDr colon cancer cells to 5-FU, a finding 
which holds promise for more successful anticancer treatment, particularly after surgical 
resection of hepatic metastases (Palomares et al., 2009). Indeed, 5-FU activity was enhanced 
by 40% following the addition of GSH modulators. The activity of oxaliplatin was also 
found to be significantly enhanced (by nearly 25%). Moreover, combined therapy with SN-
38 was found to produce the optimal chemotherapeutic combination; thus, OTZ 
pretreatment combined with SN-38 resulted in an increase of almost 70% in the cytotoxic 
activity of SN-38 (Caramés et al., 2010). To this benefit, we must also add the advantage of 
OTZ with respect to BSO, i.e. the selective reduction of GSH levels in tumor cells, protecting 
healthy cells, as mentioned above. 
Other interesting approaches to the GF problem in cancer therapy have been developed. 
Thus, as cell proliferation and differentiation are deregulated in tumor cells, the induction of 
cell differentiation with retinoids could help to neutralize the pro-tumor effect of GFs. The 
mechanisms of action which underlie the effects of retinoids include the activation of 
nuclear retinoic acid receptors (RAR), but also, curiously, the induction of enhanced ROS 
levels (Palomares et al. , 2006) and a direct interaction of retinoids with the GSH-dependent 
protein kinase C, a key regulatory enzyme in signal transduction (Radominska-Pandya et 
al., 2000). In this sense, we have analyzed the effect of all-trans-retinoic acid (ATRA), a well 
known pro-differentiating agent, on the growth-promoting effect of GFs in two tumor 
models. This drug was found to reduce the proliferative rate of RMS (García-Alonso et al., 
2005) and CRC cells (Martínez-Astorquiza et al., 2008), and hindered or completely 
abolished the stimulus produced by serum obtained from hepatectomized rats, and by a 
wide variety of GFs (HGF, VEGF, PDGF, EGF, bFGF). Furthermore, we also found that cells 
cultured in medium containing ATRA do not develop resistance to the drug, and these 
ATRA-preexposed cells responded to subsequent ATRA treatments in the same manner as 
non-treated cells. However, we observed that the antiproliferative effect of ATRA in vitro is 
not permanent: forty eight hours after removing the drug from the culture medium the cells 
recovered their normal proliferative rate (Díaz et al., 2009). Nevertheless, in in vitro studies, 
we found that ATRA did not interfere with the antiproliferative effect of chemotherapeutics 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
202 
administer monoclonal antibodies (MoAb) against one or several GFs, and the results have 
been quite exciting. Another idea was to produce MoAb against the membrane receptors for 
different GFs, and again the results have been very promising. In fact, several of these 
MoAb have already entered the armamentarium for cancer therapy and others are currently 
at different stages of clinical trials. The third exciting arm of these GF-based therapies 
consists of the so-called "small molecules" which block the activation of the intracellular part 
of GF receptors.  
The combination of conventional cytotoxic drugs with new agents that specifically interfere 
with GF signaling pathways presents the advantage of avoiding crossed resistance, since 
these approaches are directed against different cell targets and have different underlying 
mechanisms of action. In this regard, many studies have indicated that inhibitors of GFs or 
of their receptors enhance the efficacy of conventional cytotoxic agents (Wanebo & Berz, 
2010). The GF inhibitors bevacizumab and cetuximab are particularly noteworthy. 
Currently, bevacizumab is used in combination with regimes which contain 5-FU (FOLFOX 
or FOLFIRI) as a first line therapy in advanced or metastatic CRC (Giantonio et al., 2007; Tol 
& Punt, 2010). On the other hand, combined therapy consisting of irinotecan and cetuximab 
is indicated after progression in patients who have previously received 5-FU based therapy 
(Cunningham et al., 2004). 
Other agents, such as gefitinib, have been found in preclinical studies to exhibit synergistic 
inhibitory effects when administered in combination with different cytotoxic drugs. For 
example, some authors have observed that gefitinib and irinotecan act synergistically in 
WiDr cells, as a result of the inhibition of the survival signal induced by irinotecan via the 
phosphorylation of EGFR (Koizumi et al., 2004). Similarly, in vitro studies have shown that 
the combination of gefitinib and oxaliplatin has a synergistic effect in colon cancer cells due, 
at least in part, to the fact that the EGFR inhibitor reduces the activity of γ-GT. This enzyme, 
which participates in the γ-glutamyl cycle, helps to salvage extracellular GSH and 
contributes to redox control by providing a substrate for GSH synthesis during oxidative 
stress, thereby preventing apoptosis, as we have showed previously (Castro et al., 2002). 
Reduced γ-GT activity thereby leads to increased cellular oxaliplatin accumulation and 
platinum-DNA adducts (Xu et al., 2003). 
However, these anti-tumor agents also have their inconveniences. They induce diverse side 
effects which complicates their clinical use (Mulder et al., 2011). Also, as happens with other 
chemotherapeutic agents, the development of resistance to these GF-based agents has 
already been reported (Giaccone & Wang, 2011). For these reasons, it is important to 
continue the search for new therapeutic strategies which could be used in combination in 
order to enhance the efficacy of GF-related targeted agents. In this sense, the therapeutic 
biomodulation of GSH metabolism may hold promise for the improvement of the efficacy of 
anticancer treatments. Many lines of evidence indicate that this may be an effective 
approach to treating cancer: i) the fact that tumor cells are under high levels of oxidative 
stress may represent a great opportunity given that it means they are particularly vulnerable 
to further increases in ROS levels; ii) colon cancer cells contain particularly high levels of 
GSH; iii) GF-induced signal transduction pathways are redox sensitive, and accordingly, 
alterations in cellular GSH content may affect the growth of GF-sensitive cells; and iv) the 
fact that NF-κB is involved in GF-dependent proliferation and that the activity of this 
transcription factor might also be subject to regulation by GSH suggests that depletion of 
cellular GSH could interrupt NF-κB activity and consequently lead to growth inhibition.  
 
Growth Factors and the Redox State as New Therapeutic Targets for Colorectal Cancer 
 
203 
In this regard, we have recently demonstrated that GSH-induced depletion by BSO or OTZ 
abrogated the growth-promoting effects of GFs in WiDr colon cancer cells (Palomares et al., 
2009). Similarly, other authors have demonstrated that BSO inhibits GSH upregulation 
induced by HGF, thereby blocking its mitogenic effect (Yang et al., 2008) and the protection 
against apoptosis afforded by this factor. It has likewise been reported that BSO interferes 
with EGF-induced proliferation and that extended exposure (for 48 h or more) of cells to 
BSO induces cell death, probably via a necrotic mechanism (Carmona-Cuenca et al., 2006). 
Regarding VEGF, it has also been reported that BSO treatment reverts increased GSH 
activity induced by this factor and, in this way, its vasculoprotective function (Kuzuya et al., 
2001). In contrast, decreased GSH levels produced by BSO have been shown to promote the 
autocrine secretion of VEGF (Sreekumar et al., 2006).  
Thus, the two effects derived from the biomodulation of GSH intracellular content with BSO 
or OTZ, i.e. i) the reversion of the pro-tumor effect of GFs and ii) the enhanced efficacy of 
chemotherapy, may contribute to enhancing the therapeutic benefit of chemotherapy 
treatment. In fact, we have shown that, in the presence of GFs, the combination of either of 
the GSH modulators with chemotherapeutic drugs produced greater anti-tumor activity 
than the cytotoxic drugs alone. Thus, we found that both BSO and OTZ completely reverted 
the resistance (due to the presence of GFs) of WiDr colon cancer cells to 5-FU, a finding 
which holds promise for more successful anticancer treatment, particularly after surgical 
resection of hepatic metastases (Palomares et al., 2009). Indeed, 5-FU activity was enhanced 
by 40% following the addition of GSH modulators. The activity of oxaliplatin was also 
found to be significantly enhanced (by nearly 25%). Moreover, combined therapy with SN-
38 was found to produce the optimal chemotherapeutic combination; thus, OTZ 
pretreatment combined with SN-38 resulted in an increase of almost 70% in the cytotoxic 
activity of SN-38 (Caramés et al., 2010). To this benefit, we must also add the advantage of 
OTZ with respect to BSO, i.e. the selective reduction of GSH levels in tumor cells, protecting 
healthy cells, as mentioned above. 
Other interesting approaches to the GF problem in cancer therapy have been developed. 
Thus, as cell proliferation and differentiation are deregulated in tumor cells, the induction of 
cell differentiation with retinoids could help to neutralize the pro-tumor effect of GFs. The 
mechanisms of action which underlie the effects of retinoids include the activation of 
nuclear retinoic acid receptors (RAR), but also, curiously, the induction of enhanced ROS 
levels (Palomares et al. , 2006) and a direct interaction of retinoids with the GSH-dependent 
protein kinase C, a key regulatory enzyme in signal transduction (Radominska-Pandya et 
al., 2000). In this sense, we have analyzed the effect of all-trans-retinoic acid (ATRA), a well 
known pro-differentiating agent, on the growth-promoting effect of GFs in two tumor 
models. This drug was found to reduce the proliferative rate of RMS (García-Alonso et al., 
2005) and CRC cells (Martínez-Astorquiza et al., 2008), and hindered or completely 
abolished the stimulus produced by serum obtained from hepatectomized rats, and by a 
wide variety of GFs (HGF, VEGF, PDGF, EGF, bFGF). Furthermore, we also found that cells 
cultured in medium containing ATRA do not develop resistance to the drug, and these 
ATRA-preexposed cells responded to subsequent ATRA treatments in the same manner as 
non-treated cells. However, we observed that the antiproliferative effect of ATRA in vitro is 
not permanent: forty eight hours after removing the drug from the culture medium the cells 
recovered their normal proliferative rate (Díaz et al., 2009). Nevertheless, in in vitro studies, 
we found that ATRA did not interfere with the antiproliferative effect of chemotherapeutics 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
204 
drugs, such as 5-FU; moreover, when both drugs were administered together, an additive 
effect was observed (García-Alonso et al., 2010). 
In order to corroborate these findings in vivo, we designed an experimental model in which 
daily intraperitoneal doses of ATRA were administered for two weeks, starting three days 
before a partial hepatectomy was performed in animals bearing liver metastases. These in 
vivo experiments confirmed the efficacy of ATRA in reducing the proliferative rate of tumor 
cells. In rats bearing RMS S4MH liver metastases, the mean number of liver metastases, as 
well as their mean size, were significantly reduced and significantly longer survival was 
achieved. Using this tumor model, we also analyzed the synergistic effect of ATRA with 
commonly used chemotherapeutic agents such as CY. Once again, animals treated with 
ATRA+CY presented a significant reduction in the mean number of liver metastases and 
also an increase in survival compared to animals treated with CY alone. Similar experiments 
were carried out with the murine CC-531 colon cancer cell line, and similar, albeit not so 
dramatic, results were found (unpublished data). Thus, the mean number of liver metastases 
was unmodified by ATRA, but the mean size of the liver foci was significantly reduced, 
suggesting that tumor progression had been retarded. However, survival remained 
unaltered. Regarding drug tolerance, ATRA was well tolerated by the animals, with no 
repercussion on hematological cell counts, serum enzymes or weight gain. These findings 
point to the need to enhance ATRA effects via other mechanisms. In this regard, it has 
recently been shown that the selective COX-2 inhibitor celecoxib, increased the expression of 
RARbeta in human colon cancer cells, as well as sensitivity to ATRA through COX-2-
independent mechanisms (Liu et al., 2010). 
Novel synthetic derivatives of ATRA have been developed recently and examined in clinical 
trials (Sogno et al, 2010). However, these trials involve administration of the drug as a 
conventional chemotherapeutic agent (Kummar et al, 2011). In the light of the above, it is 
apparent that retinoids (or pro-differentiating agents in general) should be tested as a 
complementary treatment, and administered as part of a combined therapy during the early 
postoperative period, when their action would be most effective. Otherwise, it is unlikely 
that significant improvements will be found in patients treated with these agents in 
monotherapy. 
Overall, and in the light of the important role of GFs in tumor recurrence following surgical 
resection of hepatic metastases, the use of GSH modulators and pro-differentiating agents 
seems to hold promise as a novel therapeutic strategy for metastatic CRC, by reversing GF 
pro-tumor effects and improving the efficacy of chemotherapy.  
8. Conclusion 
Growth factors play a pivotal role in the regulation of CRC progression and metastasis. 
They are involved not only in promoting tumor growth, but also in reducing the 
responsiveness of tumor cells to cytotoxic compounds. The mechanisms of action 
underlying GF effects include the redox state of the tumor, in particular GSH metabolism, 
and the level of expression of related enzymes. The biomodulation of GSH metabolism via 
agents such as BSO or OTZ, could reverse the growth-promoting effects of GFs and enhance 
the therapeutic benefit of chemotherapeutic drugs. The use of pro-differentiating agents 
may also represent a promising anti-tumor strategy to block the pro-tumor effects of GFs. 
The development of more effective retinoids, used either alone or preferably in combination 
with other dugs, may also provide more effective anti-tumor benefits. These new types of 
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strategies to neutralize the pro-tumor effects of GFs may well be crucial in the treatment of 
metastatic disease and the prevention of the recurrence of liver metastases arising from 
CRC.  
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1. Introduction  
Recent publications implicate human Tip60 (NuA4) complex in colorectal and other 
cancers. Our lab and others discovered deregulations in the components of human Tip60 
(NuA4) complex in advanced colon cancers, and the functional significance and the 
potential as a therapeutic target, has been investigated. Human Tip60 (NuA4) complex 
likely represents a fusion form of yeast NuA4 and SWR1 complexes, and the functions 
seem to be evolutionarily preserved. This notion has greatly contributed in understanding 
functions of human Tip60 (NuA4) complex. The Tip60 (NuA4) complex is a multiprotein 
complex with at least 16 subunits. It is thought to function in at least  two ways; (a) as a 
chromatin remodeling factor, it controls chromatin structure and transcription through its 
Histone Acetyl Transferase (HAT) activity, and (b) it controls activities of other non-
histone proteins, such as metabolic enzymes, through protein acetylation. Through the 
enzymatic activity and other interactions, Tip60 (NuA4) complex is involved in wide 
variety of cellular functions, including transcriptional activation, DNA repair, cell cycle 
progression, chromosome stability, stem cell maintenance and differentiation, and cell 
migration and invasion. This review will discuss functions of Tip60 (NuA4) complex, 
consequences of the defect in the subunit, its connection to human cancer, and its 
potential as a therapeutic target in clinic.  
2. A chromatin remodeling factor with Histone Acetyl Transferase (HAT) 
activity, Tip60 (NuA4) complex  
Readout of genomic information is regulated through multiple mechanisms. A major part 
of the regulatory role is played by chromatin remodeling factors; enzyme complexes that 
modify DNA or chromatin proteins. The modifications change local chromatin structure, 
thus change accessibility of transcription factors and availability of genomic information 
(Kouzarides 2007). In the case of Histones and major chromatin proteins, protein 
modifications occur in a variety of ways, including phosphorylation, acetylation, 
methylation, ubiquitylation, and ADP-ribosylation. These different types of modifications 
may functionally influence each other, creating possibilities of multiple layers of 
regulations, which have been referred as the “Histone code”. Although the possibility has 
been pointed out, the multiple layers of regulations (the “Histone code”) have not fully 
been deciphered yet.   
Among the modifications, acetylation has a defined role: To change surface charge 
distribution of the target protein and change accessibility to DNA and/or to other proteins. 
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The histones are acetylated and deacetylated on lysine residues in the N-terminal tail. These 
acetylation/deacetylation reactions are catalyzed by two groups of enzymes, Histone Acetyl 
Transferase (HAT) and Histone DeACetylase (HDAC), respectively. Histones are not the 
only target for these enzymes. HATs and HDACs can acetylate/deacetylate non-histone 
proteins as well.   
In this review, we will focus on a human multisubunit and multifunctional HAT complex, 
Tip60 (NuA4) (Nucleosomal Acetyltransferase of H4) complex. We will describe the 
complex and known functions from the standpoint of each subunit and discuss new insights 
relevant to cancer, especially in colon cancer. We will also discuss the possibility of targeting 
Tip60 (NuA4) subunits for therapeutic purposes.  
3. Human Tip60 (NuA4) complex; Its components and functions  
Human Tip60 (NuA4) complex is a multiprotein complex with at least 16 subunits, and it 
has HAT activity (Cai et al., 2003, Doyon et al., 2004). The subunit composition suggests that 
Human Tip60 (NuA4) complex is a fusion form of two yeast HAT complexes, NuA4 and 
SWR (Allard et al, 1999) (Table 1). As seen in Table1, these two yeast HAT complexes share 
four components (Eaf2, Arp4, Act1 and Yaf9), together they correspond to all human 
subunits. Supporting the fusion theory, the expression of a chimeric Eaf1-Swr1 protein 
provides a scaffold for the complex assembly and recreates a single human-like complex in 
yeast cells (Auger et al, 2008).   
Historically speaking, yeast has been a superior model system to investigate functions of 
molecular and cellular machineries with its genetical tractability, its ease of experimental 
manipulations, feasibility for biochemistry and its short life cycle and time span for 
experiments. Several cellular functions of NuA4 and SWR complex were identified directly 
with yeast studies and later confirmed in human cultured cells. The known acetylation 
targets of yeast NuA4 in vivo are histone H4 (Mitchell et al., 2008) and the histone H2A 
variant Htz1 (Babiarz et al., 2006, Keogh et al., 2006, Mizuguchi et al., 2004). Yeast NuA4 
complex also targets non-histone proteins, which are equally important to evaluate cellular 
functions of NuA4 complex. With yeast protein array, Lin et al. (2009) screened the target 
proteins. Among 5800 proteins screened for in vitro acetylation with NuA4 complex, 91 
candidates were identified, 20 were selected for validation, and 13 were validated. The 
functions of validated proteins encompass metabolism, transcription, cell cycle, RNA 
processing, and stress response. The authors focused on Pck1, a key metabolic enzyme that 
regulates gluconeogenesis, and showed that Pck1 activity and glucose secretion is regulated 
through NuA4-mediated acetylation in yeast and in human hepatocellular carcinoma cells 
HepG2. Thus NuA4 is implicated in metabolism and energy generation through its non-
histone targets.  
The human TIP60 complex has at least three interrelated enzymatic activities: histone 
H4/H2A acetyltransferase, ATP-dependent H2AZ-H2B histone dimer exchange, and DNA 
helicase (Auger et al., 2008). Only a limited number of non-histone targets, including human 
Pck1, has been identified so far (Liu et al., 2009).  
Knockdown and/or mutational studies have been performed to identify functions of the 
subunits of human Tip60 (NuA4) complex. The studies implicate following biological events 
to Tip60 (NuA4) complex, directly or indirectly.  
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- DNA repair 
- Transcriptional regulation 
- Chromatin structure alteration 
- Interaction and/or regulation with factors relevant to tumorigenesis (e.g. c-myc, E1A, 
E2F1, p53, STAT3, NF-kappaB) 
- Cell migration and invasion 
- Mitosis 
- Genomic instability 
- Stem cell maintenance and differentiation  
In addition, RNAi-based screening with nematode C. elegans implicated Tip60 (NuA4) 
complex in attenuation of ras-signaling involving development of vulva in the model. The C. 
elegans MLL (Mixed Lineage Leukaemia (MLL)) complex-like complex cooperates with the 
TIP60 (NuA4) complex to regulate the expression of a novel ras-signaling attenuator, AJM-1 
(Fischer et al., 2010).  
4. Functions of each subunit  
In the following section we will discuss each of the subunits.  
4.1 TRRAP/Tra1/*  
(human protein/yeast protein in NuA4 complex/ yeast protein in Swr complex. Asterisk * 
if not applicable)   
Human TRRAP (transformation/transcription domain-associated protein) has a FATC 
(FRAP, ATM, TRRAP C-terminal) domain and a kinase domain, and belongs to ATM/PI3K 
family. However, TRRAP does not appear to possess kinase activity, because the kinase 
domain in TRRAP lacks the conserved amino acids required for ATP binding and catalytic 
activity for phosphate transfer. For that reason, it is speculated that TRRAP has evolved as a 
specialized PIKK member to serve as an adaptor/scaffold for protein–protein interaction 
and multiprotein assemblies or as a platform for recruitment of different regulatory factors 
and complexes to chromatin (Murr et al 2007). The FATC domain in the C-terminus likely 
affects the protein stability in an oxidation/redox-dependent manner (Dames et al., 2005).  
TRRAP is a common component of many HAT complexes (e.g. SAGA, PCAF and Tip60 
(NuA4) complex). As such, targeting TRRAP will influence a broader range of biological 
events and pathways than targeting more specialized components in Tip60 (NuA4) complex. 
TRRAP is one of the frequently mutated genes in melanoma. TRRAP harbored a recurrent 
mutation that clustered in one position (p. Ser722Phe) in 6 out of 167 affected individuals 
(∼4%), although the effects of the mutation on the protein function is unclear (Wei et al.,  
2011). Expression profiling revealed that TRRAP is frequently both amplified and 
overexpressed in Pancreatic Ductal AdenoCarcinoma (PDAC), and the overexpression is 
associated with poor prognosis (Bashyam et al., 2005, Loukopoulos et al,2007). In brain 
tumor-initiating cell, knockdown of TRRAP significantly increased differentiation and 
decreased cell cycle progression, leading to overall inhibition of tumor formation. The result 
indicates a critical role for TRRAP in maintaining a tumorigenic, stem cell-like state 
(Wurdak et al., 2010). TRRAP is shown to regulate a major player in colon cancer,  
beta-catenin. TRRAP interacts with Skp1/SCF and mediates its recruitment to beta-catenin  
target promoter in chromatin. TRRAP deletion leads to a reduced level of beta-catenin  
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Table 1. Subunits of Human Tip60 (NuA4); (columns from left) subunits of the yeast 
counterpart complexes NuA4 and SWR1; notable protein domains; yeast mutant 
phenotypes that implicate functions; inhibition in cultured cells and mice; and information 
relevant to cancer. ND: Not Determined. The order listed is following the size of the protein. 
Larger subunit is shown on top. 
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ubiquitination, lower degradation rate and accumulation of beta-catenin protein. 
Furthermore, recruitment of Skp1 to chromatin and ubiquitination of chromatin-bound 
beta-catenin are abolished upon TRRAP knock-down, leading to an abnormal retention of  
beta-catenin at the chromatin and concomitant hyperactivation of the canonical Wnt 
pathway (Finkbeiner et al., 2008). TRRAP is also involved in DNA damage repair. TRRAP 
depletion impairs both DNA-damage-induced histone H4 hyperacetylation and 
accumulation of repair molecules at sites of Double Strand Breaks (DSBs), resulting in 
defective homologous recombination (HR) repair, albeit with the presence of a functional 
ATM-dependent DNA-damage signaling cascade (Murr et al., 2006). TRRAP regulates 
expressions of many cancer-relevant genes, including mitotic checkpoint proteins Mad1 and 
Mad2 (Li et al., 2004) and mdm2 (Ard et al., 2002). 
Consistent with the loss of mitotic checkpoint proteins essential for cellular survival, null 
mutation of Trrap (mouse homolog of human TRRAP) results in peri-implantation lethality 
due to a blocked proliferation of blastocysts. Loss of Trrap blocks cell proliferation because 
of an aberrant mitotic exit accompanied by cytokinesis failure and endoreduplication. Trrap-
deficient cells failed to sustain mitotic arrest despite chromosome missegregation and 
disrupted spindles, and display compromised cdk1 activity. Thus, Trrap is essential for 
early development and required for the mitotic checkpoint, presumably through expression 
control of mad1 and mad2, and normal cell cycle progression (Herceg et al., 2001).   
In yeast, deletion of TRRAP homolog Tra1 is also lethal. Tra1 is identified as a component of 
multiple yeast transcription regulator complexes, Ada-Spt, SAGA and NuA4 (Saleh et al., 
1998; Grant et al., 1998; Allard et al., 1999). Tra1 directly interacts with the acidic 
transcriptional activators Gcn4, Hap4, and Gal4 (Brown et al., 2001). Tra1 is required for 
both the acetylation of Histone H4 surrounding the promoters and the transcription of Gcn4-
dependent genes, suggesting that Tra1 may mediate the recruitment of NuA4 to certain 
promoters.  
4.2 hDomino p400/Eaf1/Swr1  
hDomino (also known as p400, EP400, E1A binding protein p400) is a DEXH-box class of 
RNA-dependent ATPase subunit in Tip60 (NuA4) complex, and can destabilize histone-
DNA interactions in reconstituted nucleosomes in an ATP-dependent manner. hDomino 
also contains a highly conserved SANT (SWI3–ADA2–NcoR–TFIIIB) domain, a histone tail-
binding module (Boyer et al. 2004). The protein is related to yeast Swi2/Snf2 (SWItch 
2/Sucrose NonFermentable 2) and to Domino in fruit fly Drosophila. Drosophila Domino was 
isolated in search of immune system mutants devoid of circulating larval hemocytes from P-
element insertion-based mutant library. Because of the very striking lymph gland 
phenotype that results in mutant larvae with two black dots visible on the anterior half, the 
authors named the mutation domino (Braun et al., 1997). 
Through the Swi2/Snf2 domain, hDomino binds to adenovirus oncoprotein E1A. 
Mutational loss of E1A binding results in the loss of transformation, indicating that the 
binding plays a critical role in cellular transformation. hDomino also binds to c-myc with 
different protein components (Fuchs et al., 2001). In most human colorectal carcinoma, the 
ratio between Tip60 and p400 mRNAs is affected. Reversing the p400/Tip60 imbalance by 
Tip60 overexpression or the use of siRNAs resulted in increased apoptosis and decreased 
proliferation of colon-cancer-derived cells, suggesting that this ratio defect is important for 
cancer progression (Mattera et al., 2009).  
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binding module (Boyer et al. 2004). The protein is related to yeast Swi2/Snf2 (SWItch 
2/Sucrose NonFermentable 2) and to Domino in fruit fly Drosophila. Drosophila Domino was 
isolated in search of immune system mutants devoid of circulating larval hemocytes from P-
element insertion-based mutant library. Because of the very striking lymph gland 
phenotype that results in mutant larvae with two black dots visible on the anterior half, the 
authors named the mutation domino (Braun et al., 1997). 
Through the Swi2/Snf2 domain, hDomino binds to adenovirus oncoprotein E1A. 
Mutational loss of E1A binding results in the loss of transformation, indicating that the 
binding plays a critical role in cellular transformation. hDomino also binds to c-myc with 
different protein components (Fuchs et al., 2001). In most human colorectal carcinoma, the 
ratio between Tip60 and p400 mRNAs is affected. Reversing the p400/Tip60 imbalance by 
Tip60 overexpression or the use of siRNAs resulted in increased apoptosis and decreased 
proliferation of colon-cancer-derived cells, suggesting that this ratio defect is important for 
cancer progression (Mattera et al., 2009).  
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In mice, p400 knockout results in embryonic lethality. Homozygous knockout mice died on 
embryonic day 11.5 (E11.5), and displayed an anemic appearance and slight deformity of the 
neural tube. Their results suggest that p400/mDomino plays a critical role in embryonic 
hematopoiesis by regulating the expression of developmentally essential genes such as those 
in the Hox gene cluster (Ueda et al., 2007). Tip60-p400 is necessary to maintain characteristic 
features of Embryonic Stem Cells (ESCs) (Fazzio et al., 2008). Through an RNAi screen in 
mouse ESCs of 1008 loci encoding chromatin protein, the authors identified 68 proteins that 
exhibit diverse phenotypes upon knockdown, including seven subunits of the Tip60-p400 
complex, Trrap, Tip60, p400, DMAP1, RuvBL1, RuvBL2 and GAS41. Phenotypic analyses 
revealed that p400 localization to the promoters of both silent and active genes is dependent 
upon histone H3 lysine 4 trimethylation (H3K4me3). The Tip60-p400 knockdown gene 
expression profile is enriched for developmental regulators and significantly overlaps with 
that of the transcription factor Nanog. Depletion of Nanog reduces p400 binding to target 
promoters without affecting H3K4me3 levels. Together, these data indicate that Tip60-p400 
integrates signals from Nanog and H3K4me3 to regulate gene expression in ESCs (Fazzio et 
al., 2008).  
Yeast p400 homolog Eaf1 (Esa1-associated Factor 1, VID21) is the only subunit exclusively 
found in the NuA4 complex in biochemical preparation. Eaf1 is the platform on which four 
different functional modules of the other subunits are assembled into the native complex 
(Auger et al., 2008). Although eaf1 deletion strain is viable, the cells show genome instability 
and high incidences of sporulation defects and aneuploidy. The mutant is also highly 
sensitive to DNA damage-inducing stress such as X-ray (Auger et al., 2008; Hughes et al., 
2000; Krogan et al., 2004).  
4.3 Brd8/*/Bdf1  
Human Brd8 was functionally identified as a Thyroid hormone receptor coactivator p120 
(Monden et al., 1997; Yuan et al., 1998). Later, its role as a transcriptional coactivator with 
RXR/PPAR-gamma was also reported, establishing the role as a nuclear receptor coactivator 
(Monden et al., 1999). Human Brd8 has one or two Bromodomain(s), depending on the 
isoform. The Bromodomain is a domain that can bind to acetylated lysine, typically 
observed in histones, suggesting its role in regulating protein-protein interactions in 
histone-directed chromatin remodeling and gene transcription. (Zeng and Zhou, 2002; 
Mujtaba et al., 2007).  
Brd8 was isolated through a HeLa cell-based expression cloning for genes that influence 
sensitivity to a microtubule inhibitor (Yamada and Gorbsky, 2006). Ectopic expression of 
Brd8 provides partial resistance to microtubule inhibitors and proteasome inhibitor, and 
knockdown sensitized cells to the drugs, suggesting Brd8 influences sensitivity to 
microtubule inhibitors and proteasome inhibitor (Yamada and Rao, 2008). Human Brd8 
protein is overexpressed in human metastatic colorectal cancer cell lines. Brd8 is also 
overexpressed in advanced colon adenocarcinoma in rats induced with Dextran sulfate and 
azoxymethane (an inflammatory colon cancer model system). SiRNA-mediated Brd8 
knockdown resulted in cell death in HCT116 and growth delay in DLD1, both are colorectal 
cancer cells (Yamada and Rao, 2008). With shRNA, an independent lab showed that 
inhibition of Brd8 resulted in growth inhibition (Yamaguchi et al., 2010), thus Brd8 is 
suspected to provide survival fitness and growth advantage. In our lab, transcriptome 
analysis showed little difference in the amount of Brd8 transcripts in colonic normal-looking 
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epithelial and cancer cells, yet the protein accumulates in cancer cells. The protein 
accumulation is enhanced with an addition of proteasome inhibitor in cultured human 
colon cancer cells, suggesting that a post translational, proteasome-dependent pathway is 
involved in the regulation (unpublished results).  
Yeast homolog Bdf1p (Bromo Domain Factor 1) contains two bromodomains and is thought 
to correspond to a missing piece of TFIID (Matangkasombut et al., 2000). Bdf1 deletion in 
yeast is viable, but affects general transcription including small nuclear RNA, sporulation, 
mitochondrial function and stress-induced cell death (Lygerou et al., 1994; Liu et al, 2009). 
Overexpression of Bdf1 can suppress phenotypes and defects of yaf9 (human GAS41 
homolog) deletion, indicating functional overlap between Bdf1 and Yaf9 (Bianchi et al., 
2004).  
4.4 Epc1/Epl1/* 
In Drosophila, EPC1 (Enhancer of PolyComb 1) mutation was isolated as a mutation that 
enhances the effect of homeotic proteins Polycomb. Although homozygotic mutations of 
Epc1 in Drosophila are lethal in the embryo, heterozygous mutations do not by themselves 
result in a zygotic homeotic phenotype (Stankunas et al, 1998). Epc1 protein is a chromatin 
protein with no known enzymatic activity by itself.  
EPC1 deregulation is observed in Adult T-cell leukemia/lymphoma (ATLL), a malignant 
tumor caused by latent human T-lymphotropic virus 1 (HTLV-1) infection. In acute-type 
ATLL, there is a common breakpoint cluster region at 10p11.2. The chromosomal 
breakpoints are localized within the enhancer of polycomb 1 (EPC1) gene locus (Nakahata et 
al., 2009).  
In mice development, Epc1 is involved in skeletal muscle differentiation. The expression of 
Epc1 mRNA is gradually decreased with aging from embryonic day 11.5 to postnatal week 
8. Epc1 is highly expressed in skeletal muscles and heart ventricle in week 8 mice (Kee et al., 
2007). Epc1 knockdown caused a decrease in the acetylation of histones associated with 
serum response element (SRE) of the skeletal alpha-actin promoter. The Epc1.SRF (Serum 
Response Factor) complex bound to the SRE, and the knockdown of Epc1 resulted in a 
decrease in SRF binding to the skeletal alpha-actin promoter. Epc1 recruited histone 
acetyltransferase activity, which was potentiated by cotransfection with p300 but abolished 
by siRNA-mediated p300 inhibition. Epc1 directly bound to p300 in myoblast cells. Epc1 
heterozygous mice showed distortion of skeletal alpha-actin, and the isolated myoblasts 
from the mice had impaired muscle differentiation. These results suggest that Epc1 is 
required for skeletal muscle differentiation by recruiting both SRF and p300 to the SRE of 
muscle-specific gene promoters (Kim et al., 2009).  
Deletion of Yeast homolog Epl1 (Enhancer of Polycomb Like 1) is inviable, causes cells to 
accumulate in G2/M and global loss of acetylated histones H4 and H2A (Boudreault et al., 
2003).  
4.5 Tip60/Esa1/* 
TIP60 in humans and Esa1 in yeast are the catalytic (acetyltransferase) subunit of the NuA4 
complex (Ikura et al., 2000; Smith et al., 1998) and play a central role in Tip60 (NuA4) 
complex function. MYC associates with TIP60 and recruits it to chromatin in vivo with four 
other components of the TIP60 complex: TRRAP, p400, RuvBL1 and RuvBL2 (Frank et al., 
2003)  
 
Colorectal Cancer Biology – From Genes to Tumor 
 
222 
In mice, p400 knockout results in embryonic lethality. Homozygous knockout mice died on 
embryonic day 11.5 (E11.5), and displayed an anemic appearance and slight deformity of the 
neural tube. Their results suggest that p400/mDomino plays a critical role in embryonic 
hematopoiesis by regulating the expression of developmentally essential genes such as those 
in the Hox gene cluster (Ueda et al., 2007). Tip60-p400 is necessary to maintain characteristic 
features of Embryonic Stem Cells (ESCs) (Fazzio et al., 2008). Through an RNAi screen in 
mouse ESCs of 1008 loci encoding chromatin protein, the authors identified 68 proteins that 
exhibit diverse phenotypes upon knockdown, including seven subunits of the Tip60-p400 
complex, Trrap, Tip60, p400, DMAP1, RuvBL1, RuvBL2 and GAS41. Phenotypic analyses 
revealed that p400 localization to the promoters of both silent and active genes is dependent 
upon histone H3 lysine 4 trimethylation (H3K4me3). The Tip60-p400 knockdown gene 
expression profile is enriched for developmental regulators and significantly overlaps with 
that of the transcription factor Nanog. Depletion of Nanog reduces p400 binding to target 
promoters without affecting H3K4me3 levels. Together, these data indicate that Tip60-p400 
integrates signals from Nanog and H3K4me3 to regulate gene expression in ESCs (Fazzio et 
al., 2008).  
Yeast p400 homolog Eaf1 (Esa1-associated Factor 1, VID21) is the only subunit exclusively 
found in the NuA4 complex in biochemical preparation. Eaf1 is the platform on which four 
different functional modules of the other subunits are assembled into the native complex 
(Auger et al., 2008). Although eaf1 deletion strain is viable, the cells show genome instability 
and high incidences of sporulation defects and aneuploidy. The mutant is also highly 
sensitive to DNA damage-inducing stress such as X-ray (Auger et al., 2008; Hughes et al., 
2000; Krogan et al., 2004).  
4.3 Brd8/*/Bdf1  
Human Brd8 was functionally identified as a Thyroid hormone receptor coactivator p120 
(Monden et al., 1997; Yuan et al., 1998). Later, its role as a transcriptional coactivator with 
RXR/PPAR-gamma was also reported, establishing the role as a nuclear receptor coactivator 
(Monden et al., 1999). Human Brd8 has one or two Bromodomain(s), depending on the 
isoform. The Bromodomain is a domain that can bind to acetylated lysine, typically 
observed in histones, suggesting its role in regulating protein-protein interactions in 
histone-directed chromatin remodeling and gene transcription. (Zeng and Zhou, 2002; 
Mujtaba et al., 2007).  
Brd8 was isolated through a HeLa cell-based expression cloning for genes that influence 
sensitivity to a microtubule inhibitor (Yamada and Gorbsky, 2006). Ectopic expression of 
Brd8 provides partial resistance to microtubule inhibitors and proteasome inhibitor, and 
knockdown sensitized cells to the drugs, suggesting Brd8 influences sensitivity to 
microtubule inhibitors and proteasome inhibitor (Yamada and Rao, 2008). Human Brd8 
protein is overexpressed in human metastatic colorectal cancer cell lines. Brd8 is also 
overexpressed in advanced colon adenocarcinoma in rats induced with Dextran sulfate and 
azoxymethane (an inflammatory colon cancer model system). SiRNA-mediated Brd8 
knockdown resulted in cell death in HCT116 and growth delay in DLD1, both are colorectal 
cancer cells (Yamada and Rao, 2008). With shRNA, an independent lab showed that 
inhibition of Brd8 resulted in growth inhibition (Yamaguchi et al., 2010), thus Brd8 is 
suspected to provide survival fitness and growth advantage. In our lab, transcriptome 
analysis showed little difference in the amount of Brd8 transcripts in colonic normal-looking 
 
Human Tip60 (NuA4) Complex and Cancer 
 
223 
epithelial and cancer cells, yet the protein accumulates in cancer cells. The protein 
accumulation is enhanced with an addition of proteasome inhibitor in cultured human 
colon cancer cells, suggesting that a post translational, proteasome-dependent pathway is 
involved in the regulation (unpublished results).  
Yeast homolog Bdf1p (Bromo Domain Factor 1) contains two bromodomains and is thought 
to correspond to a missing piece of TFIID (Matangkasombut et al., 2000). Bdf1 deletion in 
yeast is viable, but affects general transcription including small nuclear RNA, sporulation, 
mitochondrial function and stress-induced cell death (Lygerou et al., 1994; Liu et al, 2009). 
Overexpression of Bdf1 can suppress phenotypes and defects of yaf9 (human GAS41 
homolog) deletion, indicating functional overlap between Bdf1 and Yaf9 (Bianchi et al., 
2004).  
4.4 Epc1/Epl1/* 
In Drosophila, EPC1 (Enhancer of PolyComb 1) mutation was isolated as a mutation that 
enhances the effect of homeotic proteins Polycomb. Although homozygotic mutations of 
Epc1 in Drosophila are lethal in the embryo, heterozygous mutations do not by themselves 
result in a zygotic homeotic phenotype (Stankunas et al, 1998). Epc1 protein is a chromatin 
protein with no known enzymatic activity by itself.  
EPC1 deregulation is observed in Adult T-cell leukemia/lymphoma (ATLL), a malignant 
tumor caused by latent human T-lymphotropic virus 1 (HTLV-1) infection. In acute-type 
ATLL, there is a common breakpoint cluster region at 10p11.2. The chromosomal 
breakpoints are localized within the enhancer of polycomb 1 (EPC1) gene locus (Nakahata et 
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In mice development, Epc1 is involved in skeletal muscle differentiation. The expression of 
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Response Factor) complex bound to the SRE, and the knockdown of Epc1 resulted in a 
decrease in SRF binding to the skeletal alpha-actin promoter. Epc1 recruited histone 
acetyltransferase activity, which was potentiated by cotransfection with p300 but abolished 
by siRNA-mediated p300 inhibition. Epc1 directly bound to p300 in myoblast cells. Epc1 
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from the mice had impaired muscle differentiation. These results suggest that Epc1 is 
required for skeletal muscle differentiation by recruiting both SRF and p300 to the SRE of 
muscle-specific gene promoters (Kim et al., 2009).  
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2003).  
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TIP60 in humans and Esa1 in yeast are the catalytic (acetyltransferase) subunit of the NuA4 
complex (Ikura et al., 2000; Smith et al., 1998) and play a central role in Tip60 (NuA4) 
complex function. MYC associates with TIP60 and recruits it to chromatin in vivo with four 
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2003)  
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The Tip60 histone acetyltransferase has been recently shown to be underexpressed in many 
human cancers from various origins (Lleonart et al., 2006; Gorrini et al., 2007). Moreover, in 
a model of tumor induction mice, it has been shown to function as a haploinsufficient tumor 
suppressor, providing a causal link between Tip60 underexpression and tumorigenesis 
(Gorrini et al., 2007). 
A down-regulation of the TIP60 gene was observed in 28 out of 46 (61%) specimens of 
primary gastric cancer (Sakuraba et al, 2011). As mentioned in p400, in colon cancer 
expression ratio of Tip60-p400 is altered, and it may be involved in tumor growth (Mattera 
et al., 2009).  
In yeast the catalytic subunit Esa1 is the only HAT protein essential for viability and is 
responsible for the bulk of histone H4 and H2A acetylation in vivo (Doyon and Cote, 2004). 
esa1 temperature sensitive (ts) mutants provoke a RAD9-dependent G2/M delay (Megee et 
al., 1995; Clarke et al., 1999). Yeast Esa1 mutation is inviable, and esa1 conditional mutation 
serve to dissolve whole complex (Allard et al., 1999).  
4.6 DMAP1/Eaf2/Eaf2  
Human DMAP1 and its yeast homolog Eaf2 contain a highly conserved SANT (SWI3–
ADA2–NcoR–TFIIIB) domain, a histone tail-binding module (Boyer et al. 2004). DMAP1 
(DNA methyltransferase (DNMT)-1 associated protein 1) is a subunit of the TIP60-p400 
complex that maintains embryonic stem (ES) cell pluripotency (Fazzio et al., 2008) and also a 
subunit of a complex containing the somatic form of DNA methyltransferase 1 (DNMT1s). 
The lack of DNMT1 in the purified TIP60-p400 complex indicates that DMAP1 interacts with 
DNMT1 in a distinct complex, thus DMAP1 functions in two distinct manner, as a Tip60 
(NuA4) complex and with DNMT1 (Cai et al. 2003, Doyon et al., 2004). The non-catalytic 
amino terminus of DNMT1 binds to HDAC2 and can mediate transcriptional repression 
(Rountree et al, 2000). DNMT1 is essential for epidermal progenitor cell function and 
replenishing the tissue (Sen et al., 2010).   
DMAP1 associated proteins (DNMT1,3A and 3B) were progressively upregulated in 
colorectal adenoma-carcinoma sequence (Schmidt et al., 2007). Since counteracting 
demethylase MBD2 amount remained unchanged, the authors suggested that epigenetic 
regulation in the adenoma-carcinoma sequence may be driven by increased methylating 
activity by DNMTs rather than suppressed demethylation.  
In mice, DMAP1 homozygous knockout resulted in lethality during preimplantation 
(Mohan et al., 2010). Reduction of the expression of DMAP1 caused a loss of characteristic 
ES cell morphology and activation of genes associated with cell differentiation (Fazzio et al., 
2008), and it is a likely cause of the embryonic lethal phenotype. Dmap1 knockdown in 
mouse embryonic fibroblasts (MEFs) lead to spontaneous double-strand breaks (DSBs), 
resulting in growth arrest because of p53-dependent cell cycle checkpoint activation 
(Negishi et al., 2009).  
Yeast homolog Eaf2 (also known as SWC4) is a shared component of NuA4 and SWR1 
complexes. Mutant yeasts are highly sensitive to DNA breaks induced by DNA-damaging 
agents, suggesting an essential role for these two proteins in DNA repair (Auger et al., 2008).  
4.7 Ing3/Yng2/* 
Human ING1 (Inhibitor of Growth 1) was identified as a tumor suppressor candidate, and 
subsequently the “Ing family” proteins (ING1-ING5) were investigated. Human Ing3 is  a 
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47kd protein with a C-terminal plant homeodomain (PHD)-finger motif, common in 
proteins involved in chromatin remodeling and is a sequence-specific histone recognition 
protein module (Gunduz et al., 2002; Nagashima et al., 2003; Sanchez and Zhou, 2011). 
p47ING3 activates p53-transactivated promoters, including promoters of p21/waf1 and bax. 
Thus p47ING3 modulates p53-mediated transcription, cell cycle control, and apoptosis. 
Later, ING family proteins are identified as components of chromatin remodeling 
complexes; ING1 in mSin3A HDAC, ING2 in an HDAC complex similar to ING1, ING3 in 
Tip60 (NuA4) HAT complex, ING4 in HBO1 HAT, and ING5 fractionates with two distinct 
complexes containing HBO1 or nucleosomal H3-specific MOZ/MORF HATs. (Doyon et al., 
2006).  
Consistent with the proposed function as a tumor suppressor, a decrease of ING3 expression 
or LOH are observed in tumors. Decreased or no expression of ING3 mRNA was observed 
in 50% of primary head and neck squamous cell carcinomas (HNSCC) as compared with 
that of matched normal samples. About 63% of tongue and larynx tumors showed the 
decrease, and a tendency of higher mortality was observed in cases with decreased ING3 
expression. It suggests that the ING3 gene functions as a tumor suppressor in a subset of 
HNSCC (Gunduz et al., 2002). Expression of ING3 is correlated with poor prognosis in 
HNSCC (Gunduz et al., 2008). Distorted ING3 expression has been found in several 
lymphoma-derived cell lines (Fadlelmola et al., 2008). Nuclear ING3 expression was 
reduced in melanomas in a Skp2-ubiquitin/proteasome pathway-dependent manner (Chen 
et al., 2010). This reduction was correlated with a poorer patient survival (Wang et al., 2007). 
Decreased ING3 expression is associated with melanoma progression and poor prognosis.  
The yeast Saccharomyces cerevisiae has three homologs of ING family proteins. Homolog of 
human ING3 is Yng2 (Loewith et al., 2000). Yng2 is a plant homeodomain (PHD)-finger 
protein and a NuA4 complex subunit. Deletion of YNG2 results in several phenotypes, 
including an abnormal multibudded morphology, an inability to utilize nonfermentable 
carbon sources, heat shock sensitivity, slow growth, temperature sensitivity, and sensitivity 
to caffeine (Loeweth et al., 2000). Also notable was its requirement for normal progression 
through mitosis and meiosis. Some of the phenotypes were suppressed by HDAC inhibitor 
Tricostatin A, demonstrating that the phenotypes are based on defects in acetylation cycle 
(Choy et al., 2001). Yng2p is stabilized by the proteasome inhibitor MG-132, and is likely 
regulated through an ubiquitin-proteasome pathway (Lin et al., 2008).  
4.8 YL-1/*/Vps72 
Human YL-1 is a nuclear protein with an acidic region and a proline-rich region (Horikawa 
et al., 1995), and was identified as a component of Tip60 (NuA4) complex with biochemical 
purification and mass spectrometry. YL-1 is also a part of human counterpart of yeast SWR1 
complex (Cai et al., 2005). Notably, mammalian SRCAP and Drosophila Tip60 complexes are 
associated with histone H2AZ or its fly counterpart H2AvD. These similarities suggest that 
YL-1 may serve as a binding module for histone H2AZ in metazoans, as does Swc2 in yeast 
(Wu et al., 2005).  
In the Kirsten sarcoma virus–transformed NIH3T3 cells highly expressing the exogenous 
human YL-1 protein, the anchorage-independent growth (colony-forming ability in soft agar 
medium) was markedly suppressed. However, in contrast to the suppression of anchorage-
independent growth, the forced expression of YL-1 did not affect the transformed 
phenotypes in adherent culture and tumorigenicity in nude mice. The data suggest that YL-
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et al., 1995), and was identified as a component of Tip60 (NuA4) complex with biochemical 
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complex (Cai et al., 2005). Notably, mammalian SRCAP and Drosophila Tip60 complexes are 
associated with histone H2AZ or its fly counterpart H2AvD. These similarities suggest that 
YL-1 may serve as a binding module for histone H2AZ in metazoans, as does Swc2 in yeast 
(Wu et al., 2005).  
In the Kirsten sarcoma virus–transformed NIH3T3 cells highly expressing the exogenous 
human YL-1 protein, the anchorage-independent growth (colony-forming ability in soft agar 
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phenotypes in adherent culture and tumorigenicity in nude mice. The data suggest that YL-
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1 is involved in the transformation process, and once cells are transformed, additional YL-1 
expression does not play additional role in tumor growth (Horikawa et al., 1995).  
Yeast homolog VPS72 (Vascular Protein Sorting 72, also known as SWC2) is a histone 
variant H2AZ (Htz1p)-binding component of the SWR1 complex, which exchanges Htz1p 
for chromatin-bound histone H2A (Wu et al., 2005). 
4.9 RuvBL1/*/Rvb1(Tip49A) and 
4.10 RuvBL2/*/Rvb2(Tip49B)  
RuvBL1 and RuvBL2 belong to the family of AAA+ ATPases (ATPases Associated with 
various cellular Activities). Ruvbl1 is also called Pontin, NMP238, ECP54, TAP54α, TIH1 or 
Tip49, while Ruvbl2 is also called Reptin, ECP51, TAP54α, TIH2 or Tip48. RuvBL1 and 
RuvBL2 bind each other and function as a hexameric helicase (Ikura et al., 2000; Shen et al., 
2000). The names come from their homology with the bacterial RuvB helicase, which is 
involved in DNA recombination and repair. In bacteria, the ruvA-ruvB complex in the 
presence of ATP renatures cruciform structure in supercoiled DNA with palindromic 
sequence, indicating that it may promote strand exchange reactions in homologous 
recombination. RuvAB is a helicase that mediates the Holliday junction migration by 
localized denaturation and reannealing.  
Human RuvBL1 and RuvBL2 are components of multiple multiprotein complexes, INO80, 
SRCAP, URI-1, R2TP and Tip60 (NuA4) complex. RuvBL1 and RuvBL2 were co-
immunoprecipitated or affinity-purified with at least 48 proteins (Grigoletto et al., 2011).  
Human RuvBL1 and RuvBL2 are overexpressed in a variety of cancers inculding colorectal 
(Carlson et al., 2003). Regulation of COX-2 transcription in a colon cancer cell line by 
Pontin52/TIP49a, (Lauscher et al.; 2007; Ki et al., 2007), gastric (Li et al., 2010), bladder 
(Sanchez-Carbayo et al., 2006), mesothelioma (Zhan et al., 2007), non-small cell lung cancer 
(Dehan et al., 2007), as well as in several types of acute (Andersson et al., 2007) or chronic 
leukemias (Haslinger et al., 2004), in multiple myeloma (Zhan et al., 2007) and high-grade 
lymphoma (Nishiu et al., 2002). In ovarian cancer cell lines, microcell-mediated chromosome 
transfer and expression microarray analysis identified nine genes associated with functional 
suppression of tumorogenicity; AIFM2, AKTIP, AXIN2, CASP5, FILIP1L, RBBP8, RGC32, 
RUVBL1 and STAG3. Two SNPs in RUVBL1 were associated with increased risk of serous 
ovarian cancer (Notaridou et al., 2011). The expression of an ATPase-deficient mutant form 
of RuvBL1/TIP49 substantially inhibited β-catenin-mediated neoplastic transformation of 
immortalized rat epithelial cells and anchorage-independent growth of human colon cancer 
cells with deregulated β-catenin (Feng et al., 2003).  
Disruption of the yeast RuvBL1 (Kanemaki et al., 1999; Lim et al., 2000) or RuvBL2 genes 
(Lim et al., 2000) is lethal.  
4.11 BAF53a (ACTL6a)/Arp4/Arp4  
Human BAF53a (BRG1-associated factor 53a) is also known as ACTL6a (Actin-like 6a). As 
the name implies, the protein  has a 36% identity and 50% similarity with the human beta-
actin. BAF53 is a part of Tip60 (NuA4) complex (Cai et al., 2003, Doyon et al., 2004, 2006). In 
addition, BAF53a is also a part of other multiple multiprotein complexes, including INO80, 
SWI/SNF, and myc-containing nuclear cofactor complex (Park et al., 2002; Sung et al., 2001). 
For SWI/SNF-like protein complex, beta-actin and BAF53 are required for maximal ATPase 
activity of BRG1 and are also required with BRG1 for association of the complex with 
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chromatin/matrix (Zhao et al., 1998). Baf53 protein was also identified as a major binding 
target for HIV Tat protein through affinity chromatography coupled with mass 
spectrometry. The result suggests that Baf53 and Tip60 (NuA4) complex is a major target for 
HIV-1 proviral gene silencing and activation (Gautier et al., 2009).  
In yeast, Arp4/Act3 was identified as a component of NuA4 complex with affinity-
purification followed by mass spectrometry (Galarneau et al., 2000). ARP4 gene is essential 
for growth in yeast (Harata et al., 1994). In temperature-sensitive arp4 mutants, NuA4 
complex disintegrated and lost its activity in restrictive temperature, demonstrating the 
critical role of Arp4 in the NuA4 complex (Galarneau et al., 2000). Upon DNA damage, Arp4 
recognizes and interacts with histone H2A phosphorylated at serine 129. This action recruits 
NuA4 to regions of DNA double-strand breaks where histone H4 acetylation is required for 
DNA double-strand break repair (Bird et al., 2002; Downs et al., 2004).  
4.12 Actin/Act1/Act1  
A major cytoskeletal protein beta-actin is also a subunit of Tip60 (NuA4) complex (Cai et al., 
2003; Doyon et al., 2004, 2006). As in BAF53a, Actin is also a subunit of other multiprotein 
complex. Inhibition of Actin with the Actin monomer sequestering natural product 
Latrunculin B blocks chromatin-dependent ATPase activation of the BAF complex, 
indicating that Actin is a functionally critical component of SWI/SNF complex (Zhao et al., 
1998). As a major cytoskeletal component, beta-actin (Actb) gene is an essential gene, and its 
hypomorph is embryonic lethal in mice (Tondeleir et al., 2009).   
In yeast, in addition to cytoskeletal roles, Act1 is shown to be a component of distinctive 
chromatin remodeling complexes including INO80, SWR and NuA4 (Shen et al., 2000; 
Krogan et al., 2003; Galarneau et al., 2000). Act1 deletion is lethal.  
4.13 MRG15/Eaf3/* 
MRG 15 (Morf-related genes (Mrg) on chromosomes 15 (Mrg15)) belongs to Morf family 
proteins. From cellular senescent study to identify single chromosomes from normal human 
cells that can inhibit growth of immortal human cells, an intronless transcription factor-like 
protein, mortality factor on chromosome 4 (MORF4) was identified. From structural 
homology, other family proteins including MRG15 and MRGX were identified and 
investigated. MRG15 has helix-loop-helix and leucine zipper domains, which are typically 
found in transcriptional regulators, and a chromodomain thought to be involved in protein-
protein interaction in chromatin remodeling factors. MRG15 and -MRGX are expressed 
ubiquitously in all cells and tissues. Currently, MRG proteins, which have pro-growth 
activity, are hypothesized to antagonize growth inhibition activity by Morf4.  
Mrg15 knockout mice are embryonic lethal, and mouse embryonic fibroblasts derived from 
Mrg15 null embryos proliferate poorly, enter senescence rapidly, and have impaired DNA repair 
compared to wild type mice (Tominaga et al., 2005). Mrg15 null embryonic neural stem and 
progenitor cells also have a decreased capacity for proliferation and differentiation (Garcia et al., 
2007). Expression of the cyclin-dependent kinase inhibitor p21 is specifically up-regulated in 
Mrg15 deficient neural stem/progenitor cells (NSCs). Mrg15 deficient NSCs exhibit severe 
defects in DNA damage response following ionizing radiation (Chen et al., 2011). 
So far, cancer association of Mrg15 has been poorly shown. No alterations or mutations were 
identified for MRG15/MORF4L1 in unclassified FA patients and Breast Cancer (BrCa) 
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familial cases. No significant associations between common MORF4L1 variants and BrCa 
risk for BRCA1 or BRCA2 mutation carriers were identified (Martrat et al., 2011).  
Yeast Eaf3 is a shared component of the NuA4 complex and Rpd3 histone deacetylase 
complex. The loss of Eaf3 greatly alters the genomic profile of histone acetylation (Reid et 
al., 2004).  
4.14 GAS41/Yaf9/Yaf9  
GAS41 (Glioma Amplified Sequence 41) is a nuclear protein containing a C-terminal alpha-
acidic activation domain and an N-terminal YEATS domain (Fischer et al., 1997). The 
YEATS domain family of proteins is well conserved from yeast to human, and functions as 
transcriptional regulators as a part of multiprotein complexes. GAS41 is associated with 
TFIIF via its YEATS domain. GAS41 is also a subunit of the human TIP60 and SCRAP 
complexes (Doyon et al., 2004; Cai et al., 2005). In addition, GAS41 physically interacts with 
transforming acidic coiled-coil 1(TACC1) protein, microtubule-associated colonic and 
hepatic tumor overexpressed (ch-TOG) protein and nuclear matrix (NuMA) protein 
(Lauffart et al., 2002; Harborth et al., 2000).  
Yeast homolog Yaf9 encodes a protein of 226 residues, containing an N-terminal YEATS 
domain and a C-terminal predicted coiled-coil sequence (Le Masson et al., 2003). Deletion of 
Yaf9 shows pleiotropic effect, including sensitivity to a variety of drugs such as cadmium, 
cecium chrolide, cycloheximide, and microtubule inhibitor benomyl. The phenotype is 
associated with a change in transcriptome. The transcriptomic change can be suppressed by 
Bdf1 multicopy expression, suggesting functional overlapping between these two 
components (Bianchi et al., 2004). Since human Brd8 (Bdf1) was isolated from a screen that 
influenced sensitivity to microtubule inhibitors, it is tempting to speculate that Brd8-GAS41 
(Bdf1-yaf9) may be an interface module to genes involved in sensitivity to microtubule 
inhibitors.  
4.15 */Eaf5/* 
Yeast Eaf5 (Esa1p-associated factor 5) is a component of yeast NuA4 complex (Nourani et 
al., 2001). Its direct human counterpart is unclear. Eaf5 protein forms subcomplex with Eaf7, 
and Eaf5 interacts with NuA4 complex (Mitchell et al., 2008). Eaf5 deletion strain is viable, 
and shows resistance to chemicals such as acetic acid and lactic acid (Kawahata et al., 2006).   
Deletion strains of eaf5 and eaf7 display similarity in microarray transcriptional profiles 
(Krogan et al., 2006). 
4.16 MRGBP/Eaf7/* 
MRGBP (MRG Binding Protein) was identified as a NuA4 component with biochemical 
purification (Cai et al., 2003). MRGBP is also a component of the human INO80 complex (Jin 
et al., 2005). Crystal structure determination of the MRG domain indicated that MRGBP has 
structural similarity to DNA binding domains of the tyrosine site-specific recombinases 
XerD, lambda integrase, and Cre (Bowman et al., 2006).  
In human colon cancer, MRGBP was upregulated in the majority of the cancers. Inhibition of 
MRGBP with shRNA in vitro resulted in an inhibition of cell growth (Yamaguchi et al., 
2010). High levels of MRGBP expression were observed more frequently in human colonic 
carcinomas (45%) than adenomas (5%), linking its role to malignant properties of colorectal 
tumors (Yamaguchi et al., 2011).  
 






Fig. 1. Tip60 (NuA4) complex is assembled by combining subcomplexes and subunits. Each 
subunit of Tip60 (NuA4) complex is linked to different biological events, presumably 
because each subunit represents an interface to the proteins involved in the particular 
events. Inhibition of a subunit results in different phenotypes, which may provide 
intervention opportunities for cancer prevention and/or therapeutic purpose. 
Abbreviations: PDAC (Pancreatic Ductal Adeno Carcinoma); ES cell (Embryonic Stem cell); 
NSCLC (Non Small Cell Lung Cancer); HNSCC (Head and Neck Small Cell Carcinoma).  
4.17 hEaf6/Eaf6/* 
Human Eaf6 was isolated as a component of Tip60 (NuA4) complex (Doyon et al., 2004). 
hEaf6 is also a component of HBO and/or MOZ/MORF HAT complex (Ullah et al., 2008; 
Saksouk et al., 2009).  
5. Relevance to colon cancer  
Among multiple subunits, Brd8, MRGBP, RuvBL1 and RuvBL2 show particularly strong 
connections to colon cancer. These subunits are overexpressed in colon cancer (Yamada and 
Rao, 2009; Yamaguchi et al.,2010, 2011; Carlson et al., 2003; Lauscher et al., 2007; Graudens et 
al., 2006; Ki et al., 2007). Brd8 plays a role in survival and/or drug resistance of cultured 
colon cancer cells. MRGBP also plays a role in survival of cultured colon cancer cells. 
RuvBL1 is an important cofactor in beta-catenin/TCF gene regulation, and expression of its 
dominant-negative form inhibited β-catenin-mediated neoplastic transformation of 
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immortalized rat epithelial cells and anchorage-independent growth of human colon cancer 
cells with deregulated β-catenin (Feng et al., 2003). 
In addition, DMAP1 associated proteins (DNMT1,3A and 3B) were progressively 
upregulated in colorectal adenoma-carcinoma sequence (Schmidt et al., 2007). DNMT1 may 
play a role in colon cancer progression directly or indirectly.  
6. Subunit-specific targeting strategy  
As in above, deregulations in subunits of human Tip60 (NuA4) complex are common in 
various cancers, and the complex is gaining attention as a potential target for cancer 
therapy. However, concerns for targeting whole Tip60 (NuA4) complex are raised because 
the complex plays essential roles for cellular survival and targeting the core components of 
the complex would impair the essential functions, which may lead to general toxicity to both 
normal and cancer cells. Although many successful drugs in existence do target essential 
and ubiquitous cellular components (e.g. Taxol for microtubule, Velcade for proteasome), 
the concern needs to be addressed.  
As a rebuttal, targeting of each component has been proposed. Although the Tip60 (NuA4) 
complex is thought to function as a complex, targeting each subunit does not necessarily 
show the same biological effect and phenotype empirically, suggesting unique roles of each 
subunit. This fact may be exploited for developing therapeutic strategy. Further 
investigation of the unique roles of each subunit would allow us to develop subunit-specific 
targeting strategies for therapeutic purpose.   
Extrapolating from yeast and mice results, the following subunits of Tip60 (NuA4) complex 
are essential for cellular survival; TRRAP, p400, EPC1, Tip60, DMAP1, RuvBL1, RuvBL2, 
BAF53a and Actin. Inhibiting these subunits may require caution. Components whose 
inhibition may not directly or immediately kill cells are; Brd8, ING3, YL-1, MRG15, GAS41, 
MRGBP and hEaf6. Inhibition of these components may prove valuable as an adjuvant 
approach to improve other therapies such as chemo- and radio-therapies.  
In some subunits and associating factors (Brd8, MRGBP, DNMT1), overexpression is 
correlated to stage advancement of colon cancer, thus drug-mediated inhibition seems 
intuitively appropriate. GAS41 and Brd8 may have a more prominent effect on cellular 
sensitivity to anti-microtubule drugs. It is possible that chemoresistance of colon cancer is at 
least in part provided by deregulation of these subunits, and drug-mediated inhibition of 
these subunits results in enhancement of the effect of these drugs.   
7. Conclusion  
Accumulating evidence supports that the Tip60 (NuA4) complex plays a role in various 
cancers including that in colon, and possibly in drug sensitivity/resistance of cells. Targeting 
the components may prove successful in preventing cancer and/or in killing or 
chemosensitizing cancer cells. Since the major hindrance to a colon cancer cure is its 
chemoresistance, chemosensitizing through modulation of the Tip60 (NuA4) complex 
component seems to be a novel and attractive strategy. However, thus far validation of Tip60 
(NuA4) complex, or the subunit(s), as a therapeutic target is yet to be performed. Continuing 
investigation is required to translate current knowledge to clinical or translational studies. 
Strategies for targeting (e.g. siRNA, small molecule) should be explored.  
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1. Introduction 
Colorectal cancer is one of the most common cancers diagnosed worldwide. The 
development of colorectal cancer, like many types of cancer is a multistage process that 
involves many different pathways. In particular, deregulation of cell-cell communication 
plays an important role. Moreover, cell-cell comunication is indispensable for the 
maintenance of homeostasis in a multicellular organism. Gap-type junctions are one of the 
most common and perhaps most interesting, mediators of intercellular communications. 
Digestive tract gap junctions are also important and are flanked by various cell types within 
each layer of the wall. The composition and organisation of gap junction channel subunits 
plays a critical role in determining the properties of these channels, including conductance 
properties and pH sensitivity. Structurally, gap junctions are composed of transmembrane 
proteins which form structures called connexons, with a single connexon consistings of six 
peripherally arranged subunits of integral membrane proteins known as connexins. 
Correspondingly, normal human epithelial cells in the colon have been found to express the 
connexins, Cx32 and Cx43. Moreover, in our previous studies Cx26 expression was detected 
in normal colon epithelium as well as in colorectal cancer tissues (Contreras et al., 2002, 
Cascio, 2005, van Zeijl et al., 2007). 
A number of biological and chemical substances affect the function of gap junctions. For 
example junctions can be inhibited following the phosphorylation of connexin proteins or 
following exposure to agents that disrupt the accumulation of connexin or mediate local 
damage to cellular membranes. The function of membrane channels also require the 
presence of particular species of lipid in the surrounding membrane. Locke and Harris were 
the first to identify endogenous phospholipids tightly associated with connexin channels 
and these results suggested that specific phospholipids are associated with different 
connexin isoforms to form connexin-specific regulatory networks and/or structural 
interactions with lipid membranes. Ongoing studies of connexin channel function and cell 
biology to characterize lipid-protein interactions and membrane biophysics are providing 
valuable insight into these processes (Locke & Harris, 2009). 
Phenomena associated with changes in cell membranes are suspected to play an important 
role during the cancer transformation. At physiological pH, the cell membrane surface is 
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negatively charged, which is determined based on the number of negative and positive 
charge carriers present (i.e., phosphates, carboxyl and amino groups of proteins and 
phospholipids). Furthermore, electrical properties of a membrane are determined by acid-
base and complex formation equilibria at the membrane and in response to surrounding 
medium components. For example, membrane components including – proteins, 
phospholipids, and free fatty acids contribute to this equilibria. Correspondingly, we 
hypothesis that the electrical charge of tumor cells can indirectly represent changes that 
have occurred during cell transformation and may indicate tumor cell status. 
2. The cell membrane 
Biological membranes are essential boundaries within a living cell. The cell membranes 
separate the interior of the cell from its microenvironment and also participate in 
intercellular communication.  
2.1 Electric properties of cell membranes 
For a biological membrane, its electrical charge and difference in potential between the 
membrane and surrounding solution are key properties. Cell membrane charge has been 
found to increase during tumorigenesis and decrease during necrosis (Dołowy, 1984). 
Correspondingly, investigations of factors that influence membrane electric charge during 
cancer transformation have been performed. These factors include determining pH, acidic 
(CTA) and basic (CTB) functional group concentrations and their average association 
constants with hydrogen (KAH) or hydroxyl (KBOH) ions (Dobrzyńska et al., 2006).  
The electrical properties of a membrane are determined by acid-base and complex formation 
equilibria. Both membrane and surrounding medium components contribute to this 
equilibria, with the former including proteins, phospholipids and fatty acids (Gennis, 1989; 
Tien, 1974). As a result, we hypothesise that the electrical charge of tumor cells can be 
indirectly estimated from changes detected in tumor cells that are concomitant with their 
transformation during tumorigenesis. 
2.1.1 Surface charge density cell membrane 
Surface charge density dependence on pH of normal and tumor large intestine cell 
membrane are similarly shaped (Fig. 1). For example, an increase in positive surface charge 
density is observed at low pH values until a plateau is reached. Conversely, at high pH 
values, the proportion of negative charges present increases until it reaches a plateau. 
Overall, an increase in negative charge at low pH values as well as in positive charge at high 
pH is observed in human large intestine tumor cells compared to unaffected cells 
(Szachowicz-Petelska et al., 2002).  
2.1.2 Theory 
The dependence of surface charge density of a cell membrane on pH of electrolyte solution 
can be described according to four equilibria factors. Two equilibria concern negative 
groups and involve sodium and hydrogen ions, and two other equilibria refer to positive 
groups and involve hydroxide and chloride ions. These factors can then be expressed as 
follows written in the form:  
 A- + H+  AH (1) 
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Fig. 1. The dependence of surface charge density on pH for normal and colorectal cancer cell 
membranes from several patients. 
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Surface charge density (  ) is expressed as follows:  
     B A(a a ) F   (9) 
where F=96487 [C/mol] - Faraday constant.  
And functional group concentration balances can be expressed as follows: 
   TA AH ANaAC a a a   (10) 
   TB BOH BClBC a a a   (11) 
where TAC  and TBC  represent the total surface concentrations functional groups. 
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F a (1 K a ) K K K a K a 1
 (12) 
It is difficult to carry out the regression function of Eqn. (12) to determine the CTA, CTB, KAH 
and KBOH constants.  
Simplifying to one fraction and making transformations described in this work (Dobrzyńska 
et al., 2006), we can receive the equation of a straight line for high and low ion concentration 
H+, from which CTA, CTB, KAH and KBOH values can be established. 
The coefficients could be determined using linear regression and CTA, CTB, KAH and KBOH 
values could be calculated. However, in determining each values, there are points that 
would need to be considered in the regression, both for high and low H+ concentration 
ranges. 
2.1.3 Parameters characterizing the cell membrane 
In this study CTA, CTB and KBOH values for a cell membrane were found to be affected by 
cancer cell transformation, and were higher than the same parameters assayed in 
unmodified cells (Figs. 2-4). Meanwhile KAH was found to decrease in cancer cells versus 
normal cells (Fig. 3). 
In normal cells, the aminophospholipids such as phoshatidylserine (PS) and 
phosphatidylethanolamine (PE) are asymmetrically distributed across the plasma 
membrane e.g., they primarily localize to the cell’s inner membrane leaflet (Stafford & 
Thorpe, 2011; Marconescu & Thorpe, 2008). This membrane lipid asymmetry is maintained 
by a group of P-type ATPases known as aminophospholipid translocases (APTLs). These 
APTLs catalyze the active transport of PS and PE from the external side to the internal side 
of the leaflet of the plasma membrane (Devaux, 1992). The distribution of PS, a component 
of the skeleton, has been shown to undergo changes, which could cause an increase in the 
proportion of negatively charged groups present at high pH values. As a result, anionic 
phospholipids present on tumor vessels could potentially represent tumor-specific markers 
for targeting and imaging (Ran et al., 2002). 
Hypoxia/reoxygenation and acidity-induced exposure of anionic phospholipids, most likely 
phosphatidylserine and phosphatidylethanolamine (Zhao et al., 1998; Ran et al., 2002). 
According to previous studies both hypoxia and acidity can exist in a tumor. In particular,  
 






Fig. 2. The concentration of acidic functional groups present on pT3 stage, G2 grade human 
colorectal cancer cell membranes associated with metastasis (N+) and not associated with 




Fig. 3. The concentration of basic functional groups present on pT3 stage, G2 grade human 
colorectal cancer cell membranes associated with metastasis (N+) and not associated with 
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Fig. 3. The concentration of basic functional groups present on pT3 stage, G2 grade human 
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Fig. 4. The average association constant for hydrogen ions associated with pT3 stage,  
G2 grade human colorectal cancer cell membranes associated with metastasis (N+) and not 
associated with metastasis (N-). a p<0.05, compared with control. 
 
 
Fig. 5. The average association constant for hydroxyl ions associated with pT3 stage,  
G2 grade human colorectal cancer cell membranes associated with metastasis (N+) and not 
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hypoxia represents an important cellular stressor that can trigger a survival program by 
which cells attempt to adapt to a new environment. Typically, these adaptations will largely 
affect cell metabolism and/or stimulation of oxygen delivery (Bos et al., 2004).  
Cell membrane charge is also affected by sialic acid present in glycolipids and glycoproteins. 
It has previously been hypothesized that sialic acid influences the concentrations of acid and 
basic groups present on the cell surface as well as association constants of positively and 
negatively charged groups during cancer transformation. An increase in the content of sialic 
acid in glycolipids and glycoproteins has been confirmed in, and increased sialic acid 
content has been found to provoke an increase in the surface concentration of acid groups 
(Erbil et al., 1986; Narayanan, 1994; Wang, 2005).  
2.2 The compounds present in the cell membranes of human colorectal cancer  
Neoplasms produce and secrete agents at trace levels inside of cells. These agents can 
include carcinogenic antigens, hormones, metabolites, growth factors, enzymes and 
cytokines (Skrzydlewska et al., 2005; Koda et al., 2004). In malignant cells, the ultrastructural 
architecture of the cell membrane is altered, partially as a result of changes in the quantities 
of membrane components present. Correspondingly, the transport of agents through the cell 
membrane is affected, thereby altering the biological properties of a cell. In many cases, 
expression levels of proteins, phospholipids and free unsaturated fatty acids are also 
affected due to enzyme disorders associated with biosynthesis processes that are altered. It 
is hypothesized that quantitation of the changes in the levels of phospholipids and 
structural proteins at the cell surface can reflect the extent of disintegration and impairment 
of genomic functioning that has occurred as a result of mutations associated with malignant 
transformation (Baldassarre et al., 2004; Tsunada et al., 2003).  
Changes in membrane composition have the potential to affect cell growth and interactions 
between cells (including cells of the immune system), as well as the function of proteins and 
other components present at the cell membrane. For example, the immune system depends 
on interactions between different cell types for its function and these interactions are 
mediated by the membrane composition of the cells involved (Yaqoob, 2003). Moreover, 
immune cell activation (e.g., cell proliferation, phagocytosis) and tumor growth 
(malignancy) are processes associated with an increased rate of de novo synthesis and 
turnover of membrane phospholipids (Field & Schley, 2004).  
2.2.1 Changes in the phospholipids composition of human colorectal cancer cell 
membranes 
Phospholipids are an integral part of a cell membrane and determine its structure. 
Accordingly, different biological conditions are associated with differences in membrane 
phospholipids composition particularly during cancer transformation (Dobrzyńska et al., 
2005; Szachowicz-Petelska et al., 2007).  
For example, most cases of colorectal cancer involve an increase in the concentration of all 
phospholipid types at the cell membrane, including: phosphatidylinositol (PI), 
phosphatidylserine (PS), phosphatidylethanolamine (PE) and phosphatidylcholine (PC) 
(Table 1).  
Previous studies have shown that an increase in the concentration of phospholipids in the 
cell membrane is associated with human colon cancer cells (Dueck et al., 1996) and murine 
mammary tumor cells (Monteggia et al., 2000). Moreover, this increase has been proposed to 
be the result of enhanced cell membrane synthesis related to accelerated neoplasm cell  
replication (Ruiz-Cabello & Cohen, 1992). Furthermore, the mechanisms involved can vary 
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0.010  0.002 
0.016  0.003 
0.550  0.010 
0.675  0.011 
0.225  0.020a 
0.100  0.010a 
0.890  0.030a 
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0.028  0.002 
0.510  0.020 
0.116  0.010 
0.239  0.040a 
0.151  0.022a 
0.740  0.081a 
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0.086  0.006 
0.494  0.021 
0.648  0.024 
0.081  0.007 
0.131  0.010a 
0.902  0.051a 





0.087  0.009 
0.097  0.007 
0.901  0.050 
1.139  0.061 
0.248  0.020a 
0.097  0.006 
0.932  0.050 





0.064  0.005 
0.086  0.004 
0.498  0.012 
0.677  0.018 
0.109  0.010a 
0.114  0.015a 
0.768  0.080a 





0.020  0.002 
0.024  0.002 
0.432  0.012 
0.707  0.019 
0.056  0.006a 
0.096  0.009a 
0.951  0.092a 
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0.010  0.011 
0.419  0.023 
0.675  0.034 
0.030  0.015a 
0.021  0.010 
0.828  0.052a 





0.036  0.012 
0.042  0.015 
0.468  0.028 
0.686  0.039 
0.136  0.016a 
0.103  0.050a 
0.895  0.039a 
1.287  0.070a 
Table 1. The phospholipid content of pT3 stage, G2 grade human colorectal cancer cell 
membranes not associated with metastasis (N-). a p<0.05, compared with control. 
depending on the cell type, cell growth phase and malignancy status. For example, the 
greatest changes in the content of PC and PE have been observed in the G1 phase of the cell 
cycle, during which activity of the enzymes controlling biosynthesis, catabolism and 
metabolism of phospholipids is maximal (Jackowski et al., 1996; Jackowski et al., 1994). As 
shown in Table 1 the PC content detected in normal mucosa in lesions of colorectal cancer 
cells and in other cancer cells was found to be higher than that of other phospholipids. 
These observations are consistent with the results of previous studies. 
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0.783    0.012 
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0.039    0.003a 
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0.546    0.014a 
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Table 2. The phospholipid content of pT3 stage, G2 grade human colorectal cancer cell 
membranes associated with metastasis (N+). a p<0.05, compared with control. 
Differences in membrane phospholipid content can also affect the potential for metastasis 
(Podo, 1999; Dobrzyńska et al., 2005). For example, malignant neoplasm cells associated 
with a greater number of metastases were characterized by a higher PC/PE ratio than 
malignant neoplasm cells with fewer metastases (Table 2). 
2.2.2 Changes in the membrane free unsaturated fatty acid composition of human 
colorectal cancer cells 
Free fatty acids are present in cell membranes, with the former present at low levels and the 
latter having a strong influence on the structure, properties and functions of the cell 
membrane. Polyunsaturated free fatty acids (PUFAs) also participate in the normal 
functioning of a cell, particularly by contributing to intracellular cell signaling. In addition, 
PUFAs represent nutritional components of a human diet and can indirectly affect 
tumorigenesis. For example, long-chain n-3 fatty acids have been shown to alter co-
stimulatory molecules and activation markers, as well as calcium signaling and protein 
kinase C translocation at the cell membrane of immune cells (Hughes & Pinder, 2000). 
Similarly, the incorporation of n-3 fatty acids in the membrane of other cell types has been 
shown to alter membrane permeability, membrane fluidity and hormone and growth factor 
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metabolism of phospholipids is maximal (Jackowski et al., 1996; Jackowski et al., 1994). As 
shown in Table 1 the PC content detected in normal mucosa in lesions of colorectal cancer 
cells and in other cancer cells was found to be higher than that of other phospholipids. 
These observations are consistent with the results of previous studies. 
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0.642    0.011 
0.783    0.012 
0.225    0.011a 
0.145    0.009a 
0.909    0.019a 





0.150    0.009 
0.055    0.003 
0.540    0.012 
0.925    0.022 
0.160   0.008 
0.055   0.003 
0.545   0.013 





0.044    0.002 
0.025    0.001 
0.381    0.018 
0.475    0.020 
0.144   0.009a 
0.075    0.005a 
0.396    0.011 





0.018    0.001 
0.031    0.003 
0.551    0.018 
0.698    0.021 
0.113    0.008a 
0.110    0.007a 
0.592    0.013a 
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0.013  0.001 
0.433    0.019 
0.770    0.030 
0.039    0.003a 
0.026    0.002a 
0.546    0.014a 
1.240    0.019a 
Table 2. The phospholipid content of pT3 stage, G2 grade human colorectal cancer cell 
membranes associated with metastasis (N+). a p<0.05, compared with control. 
Differences in membrane phospholipid content can also affect the potential for metastasis 
(Podo, 1999; Dobrzyńska et al., 2005). For example, malignant neoplasm cells associated 
with a greater number of metastases were characterized by a higher PC/PE ratio than 
malignant neoplasm cells with fewer metastases (Table 2). 
2.2.2 Changes in the membrane free unsaturated fatty acid composition of human 
colorectal cancer cells 
Free fatty acids are present in cell membranes, with the former present at low levels and the 
latter having a strong influence on the structure, properties and functions of the cell 
membrane. Polyunsaturated free fatty acids (PUFAs) also participate in the normal 
functioning of a cell, particularly by contributing to intracellular cell signaling. In addition, 
PUFAs represent nutritional components of a human diet and can indirectly affect 
tumorigenesis. For example, long-chain n-3 fatty acids have been shown to alter co-
stimulatory molecules and activation markers, as well as calcium signaling and protein 
kinase C translocation at the cell membrane of immune cells (Hughes & Pinder, 2000). 
Similarly, the incorporation of n-3 fatty acids in the membrane of other cell types has been 
shown to alter membrane permeability, membrane fluidity and hormone and growth factor 
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binding (Hashimoto et al., 1999; Lund et al., 1999). In colorectal cancer cells, reduced levels 
of PUFAs have been detected in the membrane, concomitant with increased levels of 
arachidonic and oleic acids, and lower levels of linoleic and -linolenic acids (Table 3) 
(Szachowicz-Petelska et al., 2002, 2007).  
Moreover, decreased levels of linoleic and -linolenic acids have been detected in the 
plasma and erythrocytes of colorectal cancer patients. These changes are probably due to 
metabolic alterations caused by the illness and not necessarily by malnutrition (Baro et al., 
1998). In addition, two clinical investigations have reported a significant increase in plasma 
and tissue concentrations of arachidonic acid (AA) in colorectal cancer patients compared 
with control patients (Neoptolemos et al., 1991; Hendrickse et al., 1994). This increase may 
be related to an enhancement of lipid peroxidation, which is a feature of rapidly growing 
cells (Skrzydlewska et al., 2001, 2005). Alternatively, increased AA levels could be due to 
elevated desaturase activity involving linoleic acid (LA) and -linolenic acid (ALA), 
possibly leading to increased formation of prostaglandins and other lipoxygenase products 
(Dommels et al., 2002).  
Other classes of unsaturated fatty acids include the palmitoleic (n-7) and oleic (n-9) family, 
both of which can be produced by most cells in humans and, thus, are not essential (Pandian 
et al., 1999). Levels of oleic acids have been found to be increased in colon cancer cells (Table 
3). Furthermore, a significant elevation in the concentration of oleic acid has been detected 
in the plasma of colorectal cancer patients (Baro et al., 1998). Correspondingly, an almost 
statistically significant increase in the intake of oleic acid was found in another study of 
high-risk subjects for colorectal cancer (Schloss et al., 1997). These results may be due to 
changes in oleic acid metabolism as part of the pathogenic process. It has also been shown 
that human colon tumor growth is promoted by oleic acid (Calder et al., 1998) via 
mechanisms of increased fatty acid oxidation and a disturbance of membrane enzymes 
(Suziki et al., 1997). 
Work by Rakheja et al., demonstrated that an overall reduction in free unsaturated fatty 
acids was associated with cancer cell membranes, while another recent report detected an 
elevated proportion of saturated versus unsaturated total fatty acids in colonic 
adenocarcinoma (Rakheja et al., 2005). In the latter case, the increase in saturated total fatty 
acids was attributed to elevated levels of the enzyme fatty acid synthase (Rashid et al., 1997). 
Furthermore, saturated fatty acids may be targeted to lipid raft microdomains, which are 
rich in cholesterol, sphingolipids and phospholipids with saturated fatty acid side chains 
(Swinnen et al., 2003; Rakheja et al., 2005). Recently, an increased intake of dietary n-3 fatty 
acids has been shown to decrease levels of sphingomyelin, cholesterol and caveolin-1 
collectively, suggesting that n-3 fatty acids can modulate the composition of lipid rafts 
(Martin et al., 2005). Moreover, polyunsaturated fatty acids have been proposed to play a 
role in cancer therapy and to perturb membrane lipids rafts, thereby affecting cell functions 
(Hardman, 2004; Ma et al., 2004).  
Under pathological conditions, such as hypoxia/reoxygenation, byproducts of AA that are 
generated can reduce gap junction-mediated coupling (Martinez & Saez, 2000). Dommels et. 
al., demonstrated that short-term incubation with LA, -ALA or AA did not influence gap 
junctional intercellular communication (GJIC), yet long-term incubation with LA and -
ALA did inhibit GJIC of colon cells. Although the exact mechanisms mediating the 
inhibition of GJIC remain unclear, it is hypothesized that the associated cytotoxicity releated 
to the disruption of gap junctions is mediated by lipid peroxidation products. This 
hypothesis is supported by the observation that incubation with PUFAs, such as AA, can 
completely abolish GJIC (Dommels et. al., 2002). 
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0.059    0.005 
0.045    0.002 
0.032    0.009 
0.036    0.008 
0.014    0.002a 
0.032    0.005a 
0.027    0.007 
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0.064    0.007 
0.014    0.005a 
0.071    0.011 
0.028    0.005 





0.033    0.006 
0.055    0.005 
0.022    0.003 
0.044    0.009 
0.011    0.003a 
0.039    0.008a 
0.022    0.004 





0.022    0.004 
0.034    0.006 
0.016    0.003 
0.028    0.005 
0.003    0.001a 
0.028    0.005 
0.016    0.003 






0.014    0.004 
0.034    0.006 
0.010    0.002 
0.027    0.004 
0.058    0.007 
0.007    0.001a 
0.017    0.003a 
0.014    0.002 
0.041    0.006a 






0.016    0.004 
0.024    0.005 
0.005    0.001 
0.024    0.004 
0.011    0.002 
0.003    0.001a 
0.019    0.004 
0.008    0.001a 
0.035    0.005a 






0.009    0.002 
0.019    0.004 
0.005    0.001 
0.015    0.003 
0.009    0.002 
0.002    0.001a 
0.009    0.002a 
0.005    0.001 
0.026    0.005a 






0.057    0.008 
0.071    0,009 
0.028    0.005 
0.064    0.007 
0.019    0.004 
0.007    0.001a 
0.036    0.005a 
0.043    0.004a 
0.071    0.007 
0.056    0.006a 
18:2n-6, linoleic acid;18:3n-3, -linolenic acid;16:1, palmitoleic acid;20:4n-6, arachidonic acid;18:1, oleic acid. 
Table 3. PUFA content of pT3 stage, G2 grade human colorectal cancer cells not associated 
with metastasis (N-). a p<0.05, compared with control. 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
250 
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Moreover, decreased levels of linoleic and -linolenic acids have been detected in the 
plasma and erythrocytes of colorectal cancer patients. These changes are probably due to 
metabolic alterations caused by the illness and not necessarily by malnutrition (Baro et al., 
1998). In addition, two clinical investigations have reported a significant increase in plasma 
and tissue concentrations of arachidonic acid (AA) in colorectal cancer patients compared 
with control patients (Neoptolemos et al., 1991; Hendrickse et al., 1994). This increase may 
be related to an enhancement of lipid peroxidation, which is a feature of rapidly growing 
cells (Skrzydlewska et al., 2001, 2005). Alternatively, increased AA levels could be due to 
elevated desaturase activity involving linoleic acid (LA) and -linolenic acid (ALA), 
possibly leading to increased formation of prostaglandins and other lipoxygenase products 
(Dommels et al., 2002).  
Other classes of unsaturated fatty acids include the palmitoleic (n-7) and oleic (n-9) family, 
both of which can be produced by most cells in humans and, thus, are not essential (Pandian 
et al., 1999). Levels of oleic acids have been found to be increased in colon cancer cells (Table 
3). Furthermore, a significant elevation in the concentration of oleic acid has been detected 
in the plasma of colorectal cancer patients (Baro et al., 1998). Correspondingly, an almost 
statistically significant increase in the intake of oleic acid was found in another study of 
high-risk subjects for colorectal cancer (Schloss et al., 1997). These results may be due to 
changes in oleic acid metabolism as part of the pathogenic process. It has also been shown 
that human colon tumor growth is promoted by oleic acid (Calder et al., 1998) via 
mechanisms of increased fatty acid oxidation and a disturbance of membrane enzymes 
(Suziki et al., 1997). 
Work by Rakheja et al., demonstrated that an overall reduction in free unsaturated fatty 
acids was associated with cancer cell membranes, while another recent report detected an 
elevated proportion of saturated versus unsaturated total fatty acids in colonic 
adenocarcinoma (Rakheja et al., 2005). In the latter case, the increase in saturated total fatty 
acids was attributed to elevated levels of the enzyme fatty acid synthase (Rashid et al., 1997). 
Furthermore, saturated fatty acids may be targeted to lipid raft microdomains, which are 
rich in cholesterol, sphingolipids and phospholipids with saturated fatty acid side chains 
(Swinnen et al., 2003; Rakheja et al., 2005). Recently, an increased intake of dietary n-3 fatty 
acids has been shown to decrease levels of sphingomyelin, cholesterol and caveolin-1 
collectively, suggesting that n-3 fatty acids can modulate the composition of lipid rafts 
(Martin et al., 2005). Moreover, polyunsaturated fatty acids have been proposed to play a 
role in cancer therapy and to perturb membrane lipids rafts, thereby affecting cell functions 
(Hardman, 2004; Ma et al., 2004).  
Under pathological conditions, such as hypoxia/reoxygenation, byproducts of AA that are 
generated can reduce gap junction-mediated coupling (Martinez & Saez, 2000). Dommels et. 
al., demonstrated that short-term incubation with LA, -ALA or AA did not influence gap 
junctional intercellular communication (GJIC), yet long-term incubation with LA and -
ALA did inhibit GJIC of colon cells. Although the exact mechanisms mediating the 
inhibition of GJIC remain unclear, it is hypothesized that the associated cytotoxicity releated 
to the disruption of gap junctions is mediated by lipid peroxidation products. This 
hypothesis is supported by the observation that incubation with PUFAs, such as AA, can 
completely abolish GJIC (Dommels et. al., 2002). 
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Table 3. PUFA content of pT3 stage, G2 grade human colorectal cancer cells not associated 
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2.2.3 Changes in membrane proteins of human colorectal cancer cells 
Currently, membrane proteins are classified into five groups according to their putative 
functions. These include: 1) receptor proteins associated with various extracellular ligands 
such as growth factors and hormones, 2) channel proteins that mediate the transportation of 
ions and small molecules across the membrane, 3) various enzyme proteins such as 
phospholipases and phosphatases, 4) regulatory proteins associated with functional proteins 
such as p21 and 5) cellular adhesion proteins such as cell - CAMs. In the latter case, most 
CAMs belong to one of four protein families: immunoglobulin (Ig), superfamily (IgSF), 
integrins, cadherins or selectins.  
Structural changes in membrane proteins are associated with changes in the electrical 
potential of tumor cell membranes. These changes also correspond with altered biological 
properties exhibited by tumor cells. For example, a decrease in levels of E-cadherin 
expression in colorectal cancer cells has been shown to affect the diversification of cells in 
a tumor as well as the probability that tumor cells will contribute to distant metastasis. 
While characterization of membrane proteins of tumor cells has made progress and 
provided valuable insight into the role of the cell membrane in tumorigenesis, additional 
studies are still needed to elucidate tumor-specific mechanisms associated with these 
changes (Kojima, 1993). 
3. Conclusions 
A higher proportion of phospholipids present in cell membranes results in a larger number 
of functional groups present at the cell surface and these can include: amino, carboxy and 
phosphate functional groups. Correspondingly, in acidic medium (e.g., a low pH), the 
charge associated with the phospholipid population at the cell surface is mainly determined 
by the amino groups present. In contrast, carboxy and phosphate groups present in a basic 
medium (e.g., a high pH) are key. For large intestine cell membranes, the main component 
of the outer layer is PC and at higher concentrations, PC can provoke an increase in both 
CTA and CTB values. In addition, when cells undergo transformation the association constant 
of negatively charged groups present (e.g., KAH) decreases while the association constant of 
positively charged groups (e.g., KBOH) increases. 
Anionic phospholipids associated with tumor vessels also potentially represent markers for 
tumor vessel targeting and imaging (Ran et al., 2002). In addition, alterations in the 
distribution of PS, a component of the skeleton, can cause an increase in CTA values.  
Therefore, an evaluation of the membrane status of tumor cells may be an important 
consideration in future studies of tumor biology. 
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1. Introduction 
Cancer is one of the world’s top killers accounting for 7.4 million deaths, or 13% of all deaths 
(World Health Organization [WHO], 2011). Colorectal cancer is the third most common and 
deadly cancer worldwide (Jemal et al., 2011). An unequal geographic distribution of the 
disease burden exists, with less developed areas of the world exhibiting the lowest incidence 
and mortality (Pitari et al., 2003). In contrast, populations dwelling in western countries are 
at increased risk to develop and die of colorectal cancer. In the US, 141,210 new cases are 
estimated to be diagnosed in 2011 and 49,380 patients are expected to die for this disease, 
representing an intolerable socio-economical toll (Siegel et al., 2011). 
Promises derive from substantial advancements in early detection and prevention strategies, 
which have contributed to reduce colorectal cancer incidence and mortality rates in recent 
years (Siegel et al., 2011). However, new chemotherapeutic approaches have not emerged 
and terminal clinical stages of the disease remain incurable. Specifically, invasion and 
metastatic disease progression, traditionally unnameable to surgical resection, are largely 
refractory to pharmacological therapy. About 90% of patients with distant metastasis die of 
the disease within 5 years from diagnosis (Siegel et al., 2011). Moreover, racial and 
educational health-disparities exist in which minorities and less educated individuals of the 
affected population exhibit the worst clinical prognosis and the highest mortality, in part 
reflecting their more advanced stages at diagnosis compared to other patient segments 
(Siegel et al., 2011). Together, these considerations underscore the enormous impact that 
therapeutic target discovery might have on western societies, especially if they would 
translate into innovative, curative pharmacological approaches that will prolong the 
survival of patients with colorectal cancer. 
Crucial systems regulating the intestinal crypt-villus axis are also important determinants of 
the carcinogenetic process (Aoki et al., 2003; Fodde et al., 2001; Korinek et al., 1998). Among 
these, the signalling pathway orchestrated by the surface receptor guanylyl cyclase C (GCC) 
has recently emerged as both an integral component of intestinal mucosa homeostasis and a 
negative regulator of the malignant cell phenotype. GCC, expressed in the epithelial layer of 
the gastrointestinal wall, and its endogenous ligands guanylin and uroguanylin control 
fluid balance and renewal crypt dynamics by operating sophisticated biochemical circuits in 
both the small and large intestine. Intriguingly, a bacterial mimicry of endogenous 
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hormones exists, the E. coli heat-stable enterotoxin (ST), which may confer both harmful 
(watery diarrhea) and beneficial (colorectal cancer resistance) effects to exposed individuals 
(Lucas et al., 2000; Pitari et al., 2001). In this model, the uneven epidemiological distribution 
of colon cancer incidence across different geographic areas of the world reflect, in part, 
inverse differences in the prevalence of enterotoxigenic E. coli infections (Pitari et al., 2003). 
Moreover, an unexplained mutation early in colorectal tumorigenesis leads to the loss of 
guanylin and uroguanylin expression, producing a dormant GCC pathway in neoplastic 










































Fig. 1. Significance of the dormant guanylyl cyclase C (GCC) pathway for colorectal 
carcinogenesis.  
Selected GCC signalling components with reported impact on tumorigenesis are depicted. 
A) In normal intestinal physiology, the GCC pathway is constitutively activated by 
paracrine hormonal regulation with the endogenous GCC agonists guanylin and 
uroguanylin. The active GCC pathway promotes signalling by proximal cGMP effectors 
cyclic nucleotide-gated channel (CNG), phosphodiesterases (PDE) and protein kinase G 
(PKG) that, in turn, affect the function of key distal effectors, including the v-akt murine 
thymoma viral oncogene homolog (AKT), Ca2+-sensing receptor (CaR), β-catenin, matrix 
metalloproteinase 9 (MMP-9), transforming growth factor β (TGF-β), and vasodilator-
stimulated phosphoprotein (VASP). As a result, tumorigenic forces are restrained and 
normal intestinal mucosa homeostasis is maintained. B) During neoplastic transformation 
the GCC pathway becomes dormant, principally because of the loss of endogenous hormone 
expression. Loss of signalling between GCC and the proximal cGMP effectors deregulates 
the distal components of the pathway, thereby producing an oncogenic system favouring 
colorectal cancer progression and metastasis. EMT, epithelial-mesenchymal transition. 
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This chapter will details the consequences at the functional and cellular level of the silenced 
GCC signalling for colorectal tumor formation and progression. Key molecular effectors 
comprising the GCC pathway with high clinical translational significance will be presented 
and their potential impacts for both diagnostic and therapeutic advances discussed. 
2. GCC and the intestinal crypt-villus axis 
GCC is a member of membrane-bound guanylyl cyclases (GCA to GCG), enzymes which 
catalyze the formation of cyclic guanosine monophosphate (cGMP) from GTP. Although 
they exhibit unique physicochemical and antigenic properties, particulate guanylyl cyclases 
are homodimeric transmembrane domain proteins sharing conserved cytoplasmic portions 
with tyrosine kinase-like and cyclase catalytic domains (Lucas et al., 2000). The amino acid 
sequence of GCC considerably diverges from the other isoforms in the extracellular domain, 
which represents the ligand binding domain for the E. coli heat-stable enterotoxin ST and 
the endogenous peptides guanylin and uroguanylin (Lucas et al., 2000). Beyond selected 
dopaminergic neurons in the central nervous system (Gong et al., 2011), in mammals GCC 
expression is principally restricted to brush-border membranes of epithelial cells lining the 
intestinal inner surface from the duodenum to the rectum, uniformly distributed along the 
crypt-villus axis (Lucas et al., 2000). This unique anatomical distribution subserves the 
functional role of GCC as a critical regulator of the intestinal mucosa homeostasis. In 
particular, the signalling pathway regulated by GCC and its second messenger cGMP 
contributes to the control of epithelial self-renewal and maturation dynamics underlying the 
integrity of the crypt-villus axis (Pitari et al., 2007). 
2.1 The GCC pathway 
Modulation of intracellular cGMP concentrations represents the fundamental event of a 
variety of signal transduction circuits shaping cellular behaviour. Synthesis (by guanylyl 
cyclases) and breakdown (by phosphodiesterases) are recognized as the major mechanisms 
defining cGMP levels in tissues. In intestinal epithelial cells, GCC is the principle source of 
cGMP (Lucas et al., 2000). GCC activity defines the type, intensity and duration of biological 
responses mediated by cGMP through unique physical, spatial and temporal dynamics at 
intestinal mucosal surfaces. The most important modality to regulate GCC activity is by 
ligand binding to its extracellular domain, which induces an intramolecular conformational 
change that is transmitted down to the cytoplasmic C-terminus catalytic domain. In this 
way, cellular cGMP levels can be raised numerous folds over basal states (Lucas et al., 2000; 
Schulz et al., 1989). Furthermore, the three ligand peptides know to induce GCC activation 
in mammalian cells exhibit different affinities and potencies for GCC, resulting in different 
patterns of cGMP concentrations/effects. The exogenous ligand ST, produced by E. coli and 
responsible for life-threatening diarrhoeagenic syndromes, is the most potent GCC agonist 
and consists of 18 amino acids with three intrachain disulfide bonds (Guarino et al., 1989). In 
contrast the endogenous paracrine hormones, guanylin and uroguanylin, are 15-16 amino 
acid long with two intrachain disulfide bonds and uneven tissue distributions and physico-
chemical characteristics. Thus, while uroguanylin is a more potent (~100 fold) and abundant 
GCC agonist at acidic pH of proximal intestinal tracts, guanylin is more potent (~4 fold) as a 
GCC agonist at basic pH and is highly expressed in the colon and rectum (Forte, 1999; 
Hamra et al., 1997). Finally, elegant spatio-temporal constrains along the crypt-villus axis 
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hormones exists, the E. coli heat-stable enterotoxin (ST), which may confer both harmful 
(watery diarrhea) and beneficial (colorectal cancer resistance) effects to exposed individuals 
(Lucas et al., 2000; Pitari et al., 2001). In this model, the uneven epidemiological distribution 
of colon cancer incidence across different geographic areas of the world reflect, in part, 
inverse differences in the prevalence of enterotoxigenic E. coli infections (Pitari et al., 2003). 
Moreover, an unexplained mutation early in colorectal tumorigenesis leads to the loss of 
guanylin and uroguanylin expression, producing a dormant GCC pathway in neoplastic 










































Fig. 1. Significance of the dormant guanylyl cyclase C (GCC) pathway for colorectal 
carcinogenesis.  
Selected GCC signalling components with reported impact on tumorigenesis are depicted. 
A) In normal intestinal physiology, the GCC pathway is constitutively activated by 
paracrine hormonal regulation with the endogenous GCC agonists guanylin and 
uroguanylin. The active GCC pathway promotes signalling by proximal cGMP effectors 
cyclic nucleotide-gated channel (CNG), phosphodiesterases (PDE) and protein kinase G 
(PKG) that, in turn, affect the function of key distal effectors, including the v-akt murine 
thymoma viral oncogene homolog (AKT), Ca2+-sensing receptor (CaR), β-catenin, matrix 
metalloproteinase 9 (MMP-9), transforming growth factor β (TGF-β), and vasodilator-
stimulated phosphoprotein (VASP). As a result, tumorigenic forces are restrained and 
normal intestinal mucosa homeostasis is maintained. B) During neoplastic transformation 
the GCC pathway becomes dormant, principally because of the loss of endogenous hormone 
expression. Loss of signalling between GCC and the proximal cGMP effectors deregulates 
the distal components of the pathway, thereby producing an oncogenic system favouring 
colorectal cancer progression and metastasis. EMT, epithelial-mesenchymal transition. 
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This chapter will details the consequences at the functional and cellular level of the silenced 
GCC signalling for colorectal tumor formation and progression. Key molecular effectors 
comprising the GCC pathway with high clinical translational significance will be presented 
and their potential impacts for both diagnostic and therapeutic advances discussed. 
2. GCC and the intestinal crypt-villus axis 
GCC is a member of membrane-bound guanylyl cyclases (GCA to GCG), enzymes which 
catalyze the formation of cyclic guanosine monophosphate (cGMP) from GTP. Although 
they exhibit unique physicochemical and antigenic properties, particulate guanylyl cyclases 
are homodimeric transmembrane domain proteins sharing conserved cytoplasmic portions 
with tyrosine kinase-like and cyclase catalytic domains (Lucas et al., 2000). The amino acid 
sequence of GCC considerably diverges from the other isoforms in the extracellular domain, 
which represents the ligand binding domain for the E. coli heat-stable enterotoxin ST and 
the endogenous peptides guanylin and uroguanylin (Lucas et al., 2000). Beyond selected 
dopaminergic neurons in the central nervous system (Gong et al., 2011), in mammals GCC 
expression is principally restricted to brush-border membranes of epithelial cells lining the 
intestinal inner surface from the duodenum to the rectum, uniformly distributed along the 
crypt-villus axis (Lucas et al., 2000). This unique anatomical distribution subserves the 
functional role of GCC as a critical regulator of the intestinal mucosa homeostasis. In 
particular, the signalling pathway regulated by GCC and its second messenger cGMP 
contributes to the control of epithelial self-renewal and maturation dynamics underlying the 
integrity of the crypt-villus axis (Pitari et al., 2007). 
2.1 The GCC pathway 
Modulation of intracellular cGMP concentrations represents the fundamental event of a 
variety of signal transduction circuits shaping cellular behaviour. Synthesis (by guanylyl 
cyclases) and breakdown (by phosphodiesterases) are recognized as the major mechanisms 
defining cGMP levels in tissues. In intestinal epithelial cells, GCC is the principle source of 
cGMP (Lucas et al., 2000). GCC activity defines the type, intensity and duration of biological 
responses mediated by cGMP through unique physical, spatial and temporal dynamics at 
intestinal mucosal surfaces. The most important modality to regulate GCC activity is by 
ligand binding to its extracellular domain, which induces an intramolecular conformational 
change that is transmitted down to the cytoplasmic C-terminus catalytic domain. In this 
way, cellular cGMP levels can be raised numerous folds over basal states (Lucas et al., 2000; 
Schulz et al., 1989). Furthermore, the three ligand peptides know to induce GCC activation 
in mammalian cells exhibit different affinities and potencies for GCC, resulting in different 
patterns of cGMP concentrations/effects. The exogenous ligand ST, produced by E. coli and 
responsible for life-threatening diarrhoeagenic syndromes, is the most potent GCC agonist 
and consists of 18 amino acids with three intrachain disulfide bonds (Guarino et al., 1989). In 
contrast the endogenous paracrine hormones, guanylin and uroguanylin, are 15-16 amino 
acid long with two intrachain disulfide bonds and uneven tissue distributions and physico-
chemical characteristics. Thus, while uroguanylin is a more potent (~100 fold) and abundant 
GCC agonist at acidic pH of proximal intestinal tracts, guanylin is more potent (~4 fold) as a 
GCC agonist at basic pH and is highly expressed in the colon and rectum (Forte, 1999; 
Hamra et al., 1997). Finally, elegant spatio-temporal constrains along the crypt-villus axis 
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represent additional determinants of cGMP signalling by GCC. At the tissue level, maximal 
GCC activity and the dependant cGMP functions are imposed at the epithelial crypt/villus 
interface by increased GCC ligand expression (Cohen et al., 1995; Whitaker et al., 1997). In 
addition at the cellular level, compartmentalization of GCC-ligand interactions at luminal 
membrane borders establishes an increasing baso-apical cGMP gradient, wherein highest 
nucleotide concentrations are ensured at microvillus cell domains (Lucas et al., 2000). 
Beyond GCC activation, the functional consequences of cGMP rises in intestinal epithelial 
cells reflect the specific expression and compartmentalization of downstream target 
molecules. Two evolutionarily distinct allosteric binding sites for cGMP exist in eukaryotic 
cells: one is present in cGMP- (PKG) and cAMP- (PKA) dependent protein kinases and in 
the cyclic nucleotide gated (CNG) cation channels, while the other is expressed in cGMP-
regulated phoshodiesterases (PDEs). These proteins represent the intracellular receptors for 
cGMP and permit the selective transmission of information in a cell-(and subcellular-) 
specific manner. PKGs are Ser/Thr protein kinases comprising the soluble type I, widely 
distributed across tissues and including the isoforms Iα and Iβ, and the particulate type II, 
mainly expressed in the intestine (Pfeifer et al., 1999). PKA is a tetrameric kinase 
preferentially activated by cAMP (Chao et al., 1994). CNG channels are heterotetrameric 
proteins of α- and β-subunits, which mediate membrane Na+ and Ca2+ influx by cGMP in 
intestine as well as different other tissues (Bielet al., 1999). Further, cGMP-regulated PDEs 
(eg, PDE2, PDE5) are hydrolytic enzymes specialized in cleaving the cyclic nucleotide 
phosphodiester bond, thereby terminating correspondent biological activities (Corbin & 
Francis, 1999; Francis et al., 2011). Cyclic GMP binding to the consensus site of these 
intracellular targets results in regulation of important downstream effectors which control 
specific biochemical networks and cellular functions. Molecules distal to cGMP with 
paramount significance for intestinal cell biology include ions, ion channels, cytoskeleton 
regulators and enzymes. For instance, cGMP binding to two allosteric sites present at the 
amino-terminal region of PKG II fully activates the enzyme and induces phosphorylation 
and opening of the cystic fibrosis transmembrane conductance regulator (CFTR), a pivotal 
mechanism underlying control of intestinal fluid homeostasis (Pfeifer et al., 1999). For an in 
depth discussion on the regulation of the various biochemical cGMP-dependent targets, 
such as the CFTR channel, the reader is referred to other comprehensive reviews (Browning 
et al., 2010; Lucas et al., 2000; Steinbrecher & Cohen, 2011). Here, the focus will be on those 
molecular elements of the GCC and cGMP pathway that affect the epithelial cell phenotype, 
including its proliferative, morphogenetic and migratory attributes that greatly influence the 
crypt-villus homeostasis and the process of neoplastic transformation. 
2.2 Regulation of the intestinal epithelial cell phenotype 
The human intestinal mucosa is characterized by minute tubular invaginations called crypts, 
of maximal length in large intestinal tracts. In addition, the small intestinal mucosa exhibits 
lumenal protrusions of multi- (villi) and sub-cellular (microvilli) dimensions devoted to 
digestive activities. As a result, the inner intestinal surface is enormously expanded to 
optimally serve fundamental processes, from food processing and absorption to pathogen 
protection and immune system control (Montgomery et al., 1999). In this context, the 
complexity of those processes, constantly exposing the organism to potentially harmful 
external factors, is reflected by the sophisticated functional organization adopted by the 
columnar monolayer of epithelial cells lining the intestine. First, a self-renewal epithelial 
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ability is conferred by multipotent stem cells located at crypt bottoms, ensuring weekly 
cycles of cellular replacement to eliminate damaged or aging cells worn out by the 
demanding intestinal functions (Potten & Loeffler, 1990). Also, intriguing maturation 
dynamics are operating that turn proliferating progenitor cells into differentiated, cell cycle-
arrested epithelial cells with specialized functions, mostly populating the upper crypt and 
villus areas. They include a) the enterocytes, absorptive cells with food digestive functions 
(Montgomery et al., 1999), b) goblet cells, mucus-producing cells with detergent activities 
(Koldovsky et al., 1995), c) enteroendocrine cells, hormone-secreting cells comprising an 
intestinal endocrine system (Koldovsky et al., 1995), and d) Paneth cells, which secrete 
antimicrobial peptides and growth factors and are uniquely located at crypt bases (Bry et al., 
1994). Further, incompletely understood check-up mechanisms constantly detect genetic or 
epigenetic defects and direct epithelial cells to the appropriate maintenance (e.g., cell 
resistance), self-repair (e.g., DNA excision repair) or death (e.g., apoptosis, autophagy) 
program (Potten & Loeffler, 1990). Finally, the spatio-temporal coordination of this variety 
of processes is ensured by the migratory nature of the epithelial monolayer that physically 
maps the proliferation-differentiation transition at crypt/villus (small intestine) or 
lower/upper crypt (colon) interfaces, and drives the shedding of senescent cells at mucosal 
tips (Montgomery et al., 1999). 
The GCC signalling pathway represents one of the elaborate homeostatic mechanisms 
evolved to direct the integration of each component supporting the intestinal epithelial cell 
phenotype. Indeed, targeted deletion of guanylin expression induces expansion of the 
proliferating crypt compartment and accelerated cell migration in mouse colon, presumably 
as a consequence of reduced GCC activation and cGMP-dependent signalling (Steinbrecher 
et al., 2002). In agreement with this notion, elimination of GCC in mice produces 
hyperplastic colonic crypts, populated by a higher number of fast-cycling and fast-migrating 
progenitor cells, associated with impaired cell maturation and death dynamics, with fewer 
Paneth and goblet cells but increased apoptotic events (Li et al., 2007a). Moreover, 
compound mice in which the expression of uroguanylin or GCC has been disrupted exhibit 
similar structural alterations in the crypt-villus axis, with loss of tight junction-mediated 
intestinal barrier function and increased mucosal permeability (Han et al., 2011). Of 
relevance, intestine-specific expression of GCC is under the control of the caudal homeobox 
gene Cdx2, a transcriptional factor regulating development and cell fate specification of 
intestinal epithelial cells (Park et al., 2000). The Cdx2 gene product binds a consensus site 
present in the GCC proximal promoter and stimulates GCC transcription in an intestine-
specific fashion (Di Guglielmo et al., 2001). Thus, it is tempted to speculate that GCC 
expression and the dependant cGMP signalling are part of the universal developmental 
program supporting the integrity of the intestinal crypt-villus axis. 
Molecular mechanisms underlying effects of the GCC pathway on the intestinal cell 
phenotype have only recently been investigated. In one paradigm, lumenal Ca2+ is the key 
distal mediator of GCC activity (Pitari et al., 2003, 2008). The role of dietary Ca2+ as 
antiproliferative agent and promoter of differentiation and cell death along the epithelial 
crypt-villus axis is well defined (Lipkin & Newmark, 1995; Whitfield, 1992), and Ca2+-
deficient diets induce larger proliferative compartments in mouse colonic crypts (Rozen et 
al., 1989). One key molecular target for antiproliferative effects by dietary Ca2+ is the Ca2+-
sensing receptor (CaR), a G protein-coupled receptor present at apical membranes of 
intestinal epithelial cells (Sheinin et al., 2000). Binding of Ca2+ to the N-terminal extracellular 
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represent additional determinants of cGMP signalling by GCC. At the tissue level, maximal 
GCC activity and the dependant cGMP functions are imposed at the epithelial crypt/villus 
interface by increased GCC ligand expression (Cohen et al., 1995; Whitaker et al., 1997). In 
addition at the cellular level, compartmentalization of GCC-ligand interactions at luminal 
membrane borders establishes an increasing baso-apical cGMP gradient, wherein highest 
nucleotide concentrations are ensured at microvillus cell domains (Lucas et al., 2000). 
Beyond GCC activation, the functional consequences of cGMP rises in intestinal epithelial 
cells reflect the specific expression and compartmentalization of downstream target 
molecules. Two evolutionarily distinct allosteric binding sites for cGMP exist in eukaryotic 
cells: one is present in cGMP- (PKG) and cAMP- (PKA) dependent protein kinases and in 
the cyclic nucleotide gated (CNG) cation channels, while the other is expressed in cGMP-
regulated phoshodiesterases (PDEs). These proteins represent the intracellular receptors for 
cGMP and permit the selective transmission of information in a cell-(and subcellular-) 
specific manner. PKGs are Ser/Thr protein kinases comprising the soluble type I, widely 
distributed across tissues and including the isoforms Iα and Iβ, and the particulate type II, 
mainly expressed in the intestine (Pfeifer et al., 1999). PKA is a tetrameric kinase 
preferentially activated by cAMP (Chao et al., 1994). CNG channels are heterotetrameric 
proteins of α- and β-subunits, which mediate membrane Na+ and Ca2+ influx by cGMP in 
intestine as well as different other tissues (Bielet al., 1999). Further, cGMP-regulated PDEs 
(eg, PDE2, PDE5) are hydrolytic enzymes specialized in cleaving the cyclic nucleotide 
phosphodiester bond, thereby terminating correspondent biological activities (Corbin & 
Francis, 1999; Francis et al., 2011). Cyclic GMP binding to the consensus site of these 
intracellular targets results in regulation of important downstream effectors which control 
specific biochemical networks and cellular functions. Molecules distal to cGMP with 
paramount significance for intestinal cell biology include ions, ion channels, cytoskeleton 
regulators and enzymes. For instance, cGMP binding to two allosteric sites present at the 
amino-terminal region of PKG II fully activates the enzyme and induces phosphorylation 
and opening of the cystic fibrosis transmembrane conductance regulator (CFTR), a pivotal 
mechanism underlying control of intestinal fluid homeostasis (Pfeifer et al., 1999). For an in 
depth discussion on the regulation of the various biochemical cGMP-dependent targets, 
such as the CFTR channel, the reader is referred to other comprehensive reviews (Browning 
et al., 2010; Lucas et al., 2000; Steinbrecher & Cohen, 2011). Here, the focus will be on those 
molecular elements of the GCC and cGMP pathway that affect the epithelial cell phenotype, 
including its proliferative, morphogenetic and migratory attributes that greatly influence the 
crypt-villus homeostasis and the process of neoplastic transformation. 
2.2 Regulation of the intestinal epithelial cell phenotype 
The human intestinal mucosa is characterized by minute tubular invaginations called crypts, 
of maximal length in large intestinal tracts. In addition, the small intestinal mucosa exhibits 
lumenal protrusions of multi- (villi) and sub-cellular (microvilli) dimensions devoted to 
digestive activities. As a result, the inner intestinal surface is enormously expanded to 
optimally serve fundamental processes, from food processing and absorption to pathogen 
protection and immune system control (Montgomery et al., 1999). In this context, the 
complexity of those processes, constantly exposing the organism to potentially harmful 
external factors, is reflected by the sophisticated functional organization adopted by the 
columnar monolayer of epithelial cells lining the intestine. First, a self-renewal epithelial 
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ability is conferred by multipotent stem cells located at crypt bottoms, ensuring weekly 
cycles of cellular replacement to eliminate damaged or aging cells worn out by the 
demanding intestinal functions (Potten & Loeffler, 1990). Also, intriguing maturation 
dynamics are operating that turn proliferating progenitor cells into differentiated, cell cycle-
arrested epithelial cells with specialized functions, mostly populating the upper crypt and 
villus areas. They include a) the enterocytes, absorptive cells with food digestive functions 
(Montgomery et al., 1999), b) goblet cells, mucus-producing cells with detergent activities 
(Koldovsky et al., 1995), c) enteroendocrine cells, hormone-secreting cells comprising an 
intestinal endocrine system (Koldovsky et al., 1995), and d) Paneth cells, which secrete 
antimicrobial peptides and growth factors and are uniquely located at crypt bases (Bry et al., 
1994). Further, incompletely understood check-up mechanisms constantly detect genetic or 
epigenetic defects and direct epithelial cells to the appropriate maintenance (e.g., cell 
resistance), self-repair (e.g., DNA excision repair) or death (e.g., apoptosis, autophagy) 
program (Potten & Loeffler, 1990). Finally, the spatio-temporal coordination of this variety 
of processes is ensured by the migratory nature of the epithelial monolayer that physically 
maps the proliferation-differentiation transition at crypt/villus (small intestine) or 
lower/upper crypt (colon) interfaces, and drives the shedding of senescent cells at mucosal 
tips (Montgomery et al., 1999). 
The GCC signalling pathway represents one of the elaborate homeostatic mechanisms 
evolved to direct the integration of each component supporting the intestinal epithelial cell 
phenotype. Indeed, targeted deletion of guanylin expression induces expansion of the 
proliferating crypt compartment and accelerated cell migration in mouse colon, presumably 
as a consequence of reduced GCC activation and cGMP-dependent signalling (Steinbrecher 
et al., 2002). In agreement with this notion, elimination of GCC in mice produces 
hyperplastic colonic crypts, populated by a higher number of fast-cycling and fast-migrating 
progenitor cells, associated with impaired cell maturation and death dynamics, with fewer 
Paneth and goblet cells but increased apoptotic events (Li et al., 2007a). Moreover, 
compound mice in which the expression of uroguanylin or GCC has been disrupted exhibit 
similar structural alterations in the crypt-villus axis, with loss of tight junction-mediated 
intestinal barrier function and increased mucosal permeability (Han et al., 2011). Of 
relevance, intestine-specific expression of GCC is under the control of the caudal homeobox 
gene Cdx2, a transcriptional factor regulating development and cell fate specification of 
intestinal epithelial cells (Park et al., 2000). The Cdx2 gene product binds a consensus site 
present in the GCC proximal promoter and stimulates GCC transcription in an intestine-
specific fashion (Di Guglielmo et al., 2001). Thus, it is tempted to speculate that GCC 
expression and the dependant cGMP signalling are part of the universal developmental 
program supporting the integrity of the intestinal crypt-villus axis. 
Molecular mechanisms underlying effects of the GCC pathway on the intestinal cell 
phenotype have only recently been investigated. In one paradigm, lumenal Ca2+ is the key 
distal mediator of GCC activity (Pitari et al., 2003, 2008). The role of dietary Ca2+ as 
antiproliferative agent and promoter of differentiation and cell death along the epithelial 
crypt-villus axis is well defined (Lipkin & Newmark, 1995; Whitfield, 1992), and Ca2+-
deficient diets induce larger proliferative compartments in mouse colonic crypts (Rozen et 
al., 1989). One key molecular target for antiproliferative effects by dietary Ca2+ is the Ca2+-
sensing receptor (CaR), a G protein-coupled receptor present at apical membranes of 
intestinal epithelial cells (Sheinin et al., 2000). Binding of Ca2+ to the N-terminal extracellular 
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domain of CaR initiates discreet intracellular events mediated by the second messengers 
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), which result in mobilization of 
intracellular Ca2+ and protein kinase C (PKC) activation, respectively (Berridge et al., 2000; 
Gama et al., 1997; Rhee, 2001). Intriguingly, elimination of GCC expression in mice is 
associated with loss of CaR from enterocyte brush borders (Pitari et al., 2008). Moreover, 
expression of CaR and GCC ligands is maximal at upper-crypt areas (Chakrabarty et al., 
2005; Cohen et al., 1995; Whitaker et al., 1997), where epithelial cells stop proliferation and 
enter the maturation program, suggesting that CaR activity may be subordinated to GCC 
signalling along the crypt–villus axis (Pitari et al., 2008). Further, lumenal Ca2+ (1-3 mM) 
triggering cell cycle arrest at colonic mid-crypts (Whitfield et al., 1995) opposes pro-
proliferative β–catenin activity and favour p21- and p27-mediated differentiation 
(Chakrabarty et al., 2003, 2005), molecular effectors also regulated by cGMP signalling in the 
intestine (Lin et al., 2010; Liu et al., 2001). Thus, GCC signalling may promote the 
proliferation-differentiation transition of intestinal epithelial cells through CaR regulation 
(Pitari et al., 2008). This is important as CaR is also the receptor for other polyvalent cations 
(i.e., Gd3+, Mg2+, Ni2+) and polyamines (i.e., spermine, spermidine, putrescine) produced by 
commensal colonic bacteria (Hofer & Brown, 2003), pointing to a crucial role of the GCC-
CaR pathway as regulator of a variety of antiproliferative signals in intestine (Pitari et al., 
2008). In addition, lumenal Ca2+ may mediate intestinal GCC actions through CaR-
independent mechanisms, including ionic currents by CNG channels (Biel et al., 1999; Pitari 
et al., 2003, 2008). Cyclic GMP-gated Ca2+ current through CNG is a major regulator of 
signal generation and transmission in excitable cells (Ames et al., 1999; Zufall et al., 1997). Of 
relevance, in colon cancer cells GCC signalling slows cell cycle progression, in part, by 
inducing cGMP-dependent CNG channel activation, intracellular Ca2+ influx and cytosolic 
Ca2+ rises (Pitari et al., 2003). 
Another model proposes the v-akt murine thymoma viral oncogene homolog (AKT) as the 
master biological effector of the GCC pathway (Lin et al., 2010). AKT regulates survival 
and metabolic circuits in proliferating intestinal cells, and AKT over activation promotes 
crypt hyperplasia and tumorigenesis in mouse intestine (Sakatani et al., 2005). 
Importantly, elimination of GCC expression in mice results in hyperactivation of AKT 
signalling pathways, associated with expanded crypt compartments populated by 
glycolytic cells with accelerated G1-S cell cycle transition (Lin et al., 2010). Conversely, loss 
of GCC and cGMP signalling restricts the differentiated villus compartment and 
diminishes mitochondria-dependent oxidative metabolism in intestinal epithelial cells 
(Lin et al., 2010). Investigations employing genetic and pharmacologic manipulation of 
AKT confirmed that GCC signalling through cGMP control the proliferative cell 
metabolism by decreasing the function of AKT (Lin et al., 2010). Thus, AKT-dependent 
regulation of cell survival and glycolytic metabolism along the crypt-villus axis, at the 
basis of intestinal mucosa development and homeostasis, may be conditionally regulated 
by the activity of the GCC pathway, whose increasing crypt-villus gradient directly 
correlates with differentiation and oxidative phosphorylation. 
2.3 Regulation of epithelium-stroma interactions 
Beyond the epithelium, the intestinal wall also encompasses mesenchymal and a smooth 
muscle layers. The intestinal mesenchymal compartment comprises mucosal and 
submucosal layers of connective tissues, composed of both acellular (e.g., glycoproteins, 
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hyaluronic acid, proteoglycans, collagen I and III) and cellular components (e.g., fibroblasts, 
myofibroblasts, leukocytes, endothelial cells). The basement membrane, a balanced mix of 
matrix components (e.g., nidogen, laminin, collagen IV, perlecan), physically separates the 
enterocytes from the underlying mesenchyme. The basement membrane and all the other 
mesenchymal components significantly contribute to the dynamic renewal of intestinal 
epithelial cells. Indeed, intestinal epithelium-stroma interactions contribute to maintain the 
crypt-villus homeostasis through direct cell-matrix and cell-cell contacts or paracrine 
signalling (Montgomery et al., 1999; Pinchuk et al., 2010). In contrast, corrupted epithelium-
stroma interactions promote the initiation and progression of an array of intestinal 
pathologies (Kraus & Arber, 2009; Suzuki et al., 2011). 
Studies with targeted deletion of GCC in mice revealed striking morphogenetic alterations 
affecting the extra-epithelial layers of the intestine (Gibbons et al., 2009). Indeed, the 
intestinal wall of these mice is significantly enlarged compared to mice with normal GCC 
expression. The mesenchymal compartment exhibits hypertrophy as a result of both 
exaggerated activation of its cellular elements and increased deposition of its interstitial 
matrix components (Gibbons et al., 2009). In particular, an increased ratio of activated 
myofibroblasts over quiescent fibroblasts is present in mice with loss of GCC signalling, an 
alteration which contributes to the establishment of a reactive stromal environment 
characterized by overexpression of collagen I, tenascin C and matrix metalloproteinase 9 
(MMP-9) (Gibbons et al., 2009). In part, these alterations appear to be the consequence of an 
increased interstitial activity of the profibrinogenic transforming growth factor β (TGF-β), as 
GCC signalling through cGMP inhibits TGF-β secretion and function in intestinal epithelial 
cells and opposes stromal remodelling underlying inflammatory processes (Gibbons et al., 
2009). Further, intestinal smooth muscle layers of mice lacking GCC signalling exhibit 
hyperplasia and hypertrophy, which represent important contributors of the transmural gut 
enlargement in these animals (Gibbons et al., 2009). Thus, the GCC pathway operating in 
intestinal mucosal cells exerts strong developmental and functional influences on the 
underlying stroma, presumably by regulating discreet hormonal circuits supporting 
epithelial-mesenchymal crosstalk (Pitari et al., 2007). Given the established role of the 
intestinal mesenchyme in inflammation and tumorigenesis (Kraus & Arber, 2009; Pinchuk et 
al., 2010; Suzuki et al., 2011), it is possible to speculate that dysregulation of GCC signalling 
in intestinal epithelial cells may favour the emergence of a reactive stromal environment 
promoting pathological processes. 
3. GCC and intestinal transformation 
Colorectal carcinogenesis comprises a pathological continuum turning pre-cancerous lesions 
into invasive malignant tumors. The process begins with single (epi)genetic mutations 
driven by carcinogenic insults that disrupt the physiological epithelial cell phenotype (Gryfe 
et al., 1997; van Engeland et al., 2011). As a result, the balance of migration, proliferation, 
differentiation and cell death along the colonic crypt-surface axis is perturbed and 
neoplastic cells with limitless replicative potential emerge. Remodelling of the surrounding 
stroma also participates to the promotion and progression of transformation, imposing cell 
non-autonomous drivers of tumorigenesis such us angiogenesis and inflammation (Kraus & 
Arber, 2009; Suzuki et al., 2011). Ultimately, malignant cells lose their epithelial 
characteristics and acquire a mesenchymal phenotype that enables them to translocate and 
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domain of CaR initiates discreet intracellular events mediated by the second messengers 
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), which result in mobilization of 
intracellular Ca2+ and protein kinase C (PKC) activation, respectively (Berridge et al., 2000; 
Gama et al., 1997; Rhee, 2001). Intriguingly, elimination of GCC expression in mice is 
associated with loss of CaR from enterocyte brush borders (Pitari et al., 2008). Moreover, 
expression of CaR and GCC ligands is maximal at upper-crypt areas (Chakrabarty et al., 
2005; Cohen et al., 1995; Whitaker et al., 1997), where epithelial cells stop proliferation and 
enter the maturation program, suggesting that CaR activity may be subordinated to GCC 
signalling along the crypt–villus axis (Pitari et al., 2008). Further, lumenal Ca2+ (1-3 mM) 
triggering cell cycle arrest at colonic mid-crypts (Whitfield et al., 1995) opposes pro-
proliferative β–catenin activity and favour p21- and p27-mediated differentiation 
(Chakrabarty et al., 2003, 2005), molecular effectors also regulated by cGMP signalling in the 
intestine (Lin et al., 2010; Liu et al., 2001). Thus, GCC signalling may promote the 
proliferation-differentiation transition of intestinal epithelial cells through CaR regulation 
(Pitari et al., 2008). This is important as CaR is also the receptor for other polyvalent cations 
(i.e., Gd3+, Mg2+, Ni2+) and polyamines (i.e., spermine, spermidine, putrescine) produced by 
commensal colonic bacteria (Hofer & Brown, 2003), pointing to a crucial role of the GCC-
CaR pathway as regulator of a variety of antiproliferative signals in intestine (Pitari et al., 
2008). In addition, lumenal Ca2+ may mediate intestinal GCC actions through CaR-
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hyaluronic acid, proteoglycans, collagen I and III) and cellular components (e.g., fibroblasts, 
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establish new colonies at distant sites, such as the liver, lung and peritoneum (Nicolson, 
1988; Polyak & Weinberg 2009; Suzuki et al., 2011). 
The paracrine hormone hypothesis of colorectal cancer suggests that sporadic intestinal 
tumorigenesis is a process initiated by loss of endogenous GCC ligand expression, which 
induces a state of guanylinopenia and uroguanylinopenia (Pitari et al., 2007). Indeed, 
extensive studies have demonstrate that early in transformation intestinal epithelial cells 
acquire a mysterious mutation that renders pre-cancerous adenomatous lesions devoid of 
guanylin and uroguanylin (Birkenkamp-Demtroder et al., 2002; Cohen et al., 1998; 
Notterman et al., 2001; Steinbrecher et al., 2000). Those reports suggest that guanylin and 
uroguanylin, organized in a tail-to-tail configuration on human chromosome 1p, are the 
most commonly lost gene products in colorectal cancer in both animals and humans, 
exhibiting mutational frequency rates comparable to that of APC. Conversely, GCC is 
retained in colorectal cancer cells, which often exhibit higher GCC expression levels 
compared to normal epithelial tissues (Schulz et al., 2006; Witek et al., 2005). Increased GCC 
in the context of reduced guanylin and uroguanylin expression probably reflects the 
common pharmacological paradigm of receptor upregulation following specific ligand 
deprivation. More importantly, dysregulation of GCC signalling with an intact, but silent 
(for failure of ligand-dependent activation), intracellular molecular pathway produces a 
dormant cGMP-regulated system, which might be pathognomonically associated with 
neoplastic disease progression (Pitari et al., 2007). In this model, colorectal carcinogenesis 
following paracrine GCC ligand insufficiency reflects the central role of GCC in 
coordinating processes maintaining epithelial cell homeostasis and the crypt-villus axis, 
including the proliferation-differentiation balance, migration, metabolic programming and 
mesenchymal development (Li et al., 2007a; Pitari et al., 2007). 
3.1 Regulation of the colon cancer cell phenotype 
Neoplastic cell transformation ensues from the stepwise accumulation of mutations that 
produce hyper functioning oncogenes and silenced tumor suppressors (Bishop & 
Weinberg, 1996). Universally, the final combination of all the mutations and signalling 
deregulations occurring in cancers has similar functional consequences, the promotion of 
tumor cell growth and dissemination, and the evasion of host mechanisms of elimination 
(e.g., immuno-surveillance) (Hanahan & Weinberg, 2000). In intestinal tumorigenesis, 
acquisition of these malignant traits resembles a pathological amplification of the crypt 
stem cell phenotype, which self-perpetuates through relentless rounds of cell proliferation 
and migration (Montgomery et al., 1999; Potten & Loeffler, 1990). Conversely, invasive 
cancer cells progressively lose the morphology and metabolism of the differentiated 
epithelium, acquiring the ancestral functional plasticity of pluripotent stem cells. Indeed, 
overexpression of molecules (Wnt, β-catenin, Tcf) that support the crypt cell compartment 
(Gregorieff & Clevers, 2005; Korinek et al., 1998), or disruption of gene products (the 
adenomatous polyposis coli gene APC, Smad, CDX-2) restricting it (Aoki et al., 2003; 
Fodde et al., 2001; Tang et al., 2005) promotes intestinal tumorigenesis in animal models. 
In close agreement with these observations, the majority of sporadic human colorectal 
cancers exhibits a perturbed APC signalling as the initial mutational event, which 
crystallizes crypt-like nuclear proliferative programs driven by the β-catenin/Tcf complex 
(Fodde et al., 2001). 
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Since it regulates crypt compartments and the proliferation-differentiation balance along the 
crypt-villus axis (Li et al., 2007a; Pitari et al., 2007), dormancy of the GCC signalling 
pathway contributes to neoplastic transformation in the intestine (Li et al., 2007a; Pitari et 
al., 2007). Indeed, the increased migration and proliferation induced by loss of GCC 
signalling in mucosal colonocytes (Li et al., 2007a) represents a significant oncogenic stress 
(Aoki et al., 2003; Spruck et al., 1999) that creates the pre-neoplastic intestinal crypt (Pitari et 
al., 2007). Accordingly, cell cycle progression and growth of human colon cancer cells, 
experimental mimicry of the GCC dormancy characterizing the human disease because they 
express GCC but not the endogenous ligands (Lucas et al., 2000; Pitari et al., 2001), are 
greatly impaired upon reactivation of GCC signalling with exogenous supplementation of 
its specific agonists (Pitari et al., 2001, 2003, 2005, 2008). Ligand-dependent GCC activation 
restores lost cGMP-regulated circuits and imposes cancer cytostasis by reducing nuclear 
DNA synthesis and the G1/S transition (Lin et al., 2010; Pitari et al., 2001). Antiproliferation 
by GCC, in part, is mediated by extracellular Ca2+ actions at cancer cell membrane surfaces, 
through its dependant effects on CaR activation and CNG channel-mediated Ca2+ influx 
(Pitari et al., 2003; Pitari et al., 2008). In addition, reactivation of GCC signalling through 
cGMP opposes the Wnt/β-catenin/Tcf4 signalling axis, the regulator of the proliferative 
crypt phenotype and tumor promoter in intestine (Pinto & Clevers 2005; Reya & Clevers 
2005; van Es et al., 2005), by directly inhibiting β-catenin stability (Liu et al., 2001; Thompson 
et al., 2000). Underscoring the significance of the dormant GCC pathway in colon cancer, 
elimination of GCC in mice significantly enhances intestinal tumor initiation and 
progression (Li et al., 2007b). Mice deficient of GCC signalling exhibit enhanced sensitivity 
to tumorigenesis induced by ApcMin/+ and the carcinogen azoxymethane, reflected by 
increased tumor incidence, multiplicity, and burden (Li et al., 2007b). A principal 
mechanism by which GCC promotes colorectal tumorigenesis is the perturbation of 
regulators of G1/S cell cycle transition, including increased expression of oncogenes cyclin 
D1 and pRb, and decreased activity of tumor suppressor p27 (Li et al., 2007b). Beyond 
hyperproliferation, GCC-deficient mice also exhibit increased genomic instability in their 
intestinal mucosa cells. In particular, an increased incidence of DNA breaks, loss of 
heterozygosity and point mutations in genes central to tumorigenesis, including APC and β-
catenin, are observed along the crypt-villus axis (Li et al., 2007b). Although it remains 
unclear, the molecular mechanism mediating maintenance of the genome by GCC, including 
damage detection or mutational repair, appears to be distinct from that regulating 
proliferation (Li et al., 2007b). Rather, proliferative restriction and genomic quality control 
reflect two reinforcing systems by which the GCC pathway opposes intestinal 
carcinogenesis (Li et al., 2007b; Pitari et al., 2007). While accelerated G1/S cell cycle 
transition favours inheritance and amplification of genetic mutations (Aoki et al., 2003; 
Spruck et al., 1999), instability involving tumor suppressors or oncogenes further 
deregulates the cancer cell cycle (Spruck et al., 1999). 
Another consequence of a dormant GCC pathway in colorectal transformation is the 
promotion of the cancer cell metabolism (Lin et al., 2010). As discussed above, intestinal 
crypt stem cells principally rely on glycolysis to produce ATP and support their metabolism. 
Activation of GCC signalling restricts the glycolytic crypt compartment and favours the 
acquisition of mitochondria-mediated oxidative phosphorylation by differentiated epithelial 
cells in villi (Lin et al., 2010). Importantly, neoplastic cells utilize glycolytic ATP as their 
source of energy, even in the context of optimal environmental oxygen levels (Capuano et 
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al., 1997; Kroemer, 2006; Pelicano et al., 2006). Dr. Otto Warburg first described this 
malignant paradox suggesting that cancer cells undergo metabolic reprogramming, wherein 
they switch from oxidative phosphorylation to aerobic glycolysis to produce ATP (Warburg, 
1956). This malignant transition provides a competitive advantage to cancer cells that have a 
readily accessible supply of energy and substrates to support proliferation, adapt to the 
hypoxic tumor microenvironment, and promote invasion. Of relevance, restoration of GCC 
signalling by exogenous ligand administration increases the number, size and function of 
mitochondria in human colon cancer cells (Lin et al., 2010). Tumor reversion to 
mitochondria-dependent oxidative metabolism is associated with concurrent reduction in 
rate-limiting glycolytic enzymes, and reflects modulation of AKT and its downstream 
effectors (e.g., mTOR) by GCC signalling reactivation (Lin et al., 2010). Thus, while GCC 
signalling in human colon cancer cells induces expression of critical transcription factors 
required for mitochondrial biogenesis (PGC1α, mtTFA, NRF1), inhibition of glycolysis by 
GCC results in a reduced ability of tumors to uptake glucose and produce lactate (Lin et al., 
2010). Importantly, elimination of AKT rescues the tumorigenic intestinal phenotype of mice 
deficient in GCC signalling (Lin et al., 2010), underscoring the central role of metabolic 
circuits in mediating inhibition of colorectal carcinogenesis by GCC. Together, these 
observations suggest that the dormant GCC pathway, produced by hormone deprivation 
early in transformation (Birkenkamp-Demtroder et al., 2002; Cohen et al., 1998; Notterman 
et al., 2001; Steinbrecher et al., 2000), can be envisioned as a loss-of-function mutation of a 
tumor suppressor system, which promotes crypt stem-like proliferation and metabolism and 
favours genomic instability and the development of the colon cancer cell phenotype. 
3.2 Regulation of the colon tumor microenvironment 
The tumor microenvironment is recognized as a major determinant of cancer formation, 
growth and dissemination (Fidler, 2001; Kraus & Arber, 2009; Suzuki et al., 2011). Both 
cellular and acellular components comprising the tumor stroma contribute to intestinal 
transformation, reflecting the intimate crosstalk between tumor epithelial cells and the 
underneath mesenchyme (Kraus & Arber, 2009; Suzuki et al., 2011; Witz & Levy-
Nissenbaum, 2006). Thus, interstitial matrix remodelling, secretion of paracrine factors by 
stromal cells, lymphocyte-mediated immunoresponses, and neo-angiogenesis significantly 
influence cancer development (Fidler, 2001; Kraus & Arber, 2009; Suzuki et al., 2011). 
Among the molecular mediators of cancer-mesenchyme interactions, the matrix 
metalloproteinases (MMPs) play an essential role (Zucker & Vacirca, 2004). MMPs are a 
family of zinc-dependent metalloendopeptidases that cleave interstitial matrix components, 
growth factors, chemokines and cell surface receptors creating a nurturing niche for cancer 
growth and invasion (Cox & O'Byrne, 2001; Curran & Murray, 2000; McCawley & Matrisian, 
2001). Depending on their substrate specificities, MMPs are divided into collagenases, 
gelatinases, stromelysins, and matrilysins (Stamenkovic, 2003). 
The soluble collagenase MMP-9 has been conclusively linked with colorectal carcinogenesis 
(Chu et al., 2011; Lubbe et al., 2006; Nascimento et al., 2010; Zucker & Vacirca 2004; Zuzga et 
al., 2008). Structurally, MMP-9 (92-kDa protein) consists of a pro-peptide sequence, a 
catalytic domain containing the zinc binding site and fibronectin type II-like repeats, which 
promote MMP-9 binding to gelatin and elastin (Fridman et al., 2003; Shipley et al., 1996). 
Although enzymatic-independent signalling also has been reported (Bjorklund et al., 2004; 
Librach et al., 1991), the catalytic activity of MMP-9 is the principal mediator of tumor 
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matrix remodelling (Fridman et al., 2003; Lubbe et al., 2006). In this way, MMP-9 degrades 
basement membrane collagen type IV, allowing intestinal tumor epithelial cells to invade 
the adjacent stromal compartment (Fridman et al., 2003). Moreover, MMP-9 promotes tumor 
angiogenesis by specifically processing and releasing TGF-β and VEGF from cancer cell 
surfaces and the interstitial matrix, respectively (Bergers et al., 2000; Qian et al., 1997; Yu & 
Stamenkovic, 2000). Given its crucial role in those pathological processes, MMP-9-
dependent proteolytic activity is considered a driving force conferring the migratory and 
invasive phenotype to cancer cells and favouring tumor progression (Bergers et al., 2000; 
Fridman et al., 2003; Lubbe et al., 2006; Yu & Stamenkovic, 2000). Consequently, MMP-9 
activity needs to be tightly controlled in biological tissues. Indeed, normally MMP-9 is a 
silent protease, secreted by cancer cells as a pro-zymogen that is activated only upon 
cleavage of its 10-kDa N-terminal pro-peptide by various proteases (e.g., MMP-2, MMP-3, 
MMP-13, plasmin, thrombin) (Ahmed et al., 2003; Fridman et al., 2003; Ramos-DeSimone et 
al., 1999). Endogenous inhibitors of MMP-9 also exists (e.g., the tissue inhibitor of matrix 
metalloproteinase 1) which bind to both the pro- and the active-form of MMP-9 and 
neutralize its proteolytic activity (Goldberg et al., 1992; Stamenkovic, 2003). 
Beyond inhibition of catalytic activity, regulation of zymogen expression and secretion 
represents additional effective modalities to contain tumorigenic MMP-9 functions (St-Pierre 
et al., 2003; Zhang et al., 2006). Cyclic GMP inhibits the synthesis and secretion of MMP-9 in 
various cell systems (Akool el et al., 2003; Gurjar et al., 1999). Accordingly, restoration of 
ligand-dependent GCC signalling though cGMP induces a compartmental redistribution of 
colon cancer cell MMP-9, in which intracellular retention results in reciprocal extracellular 
depletion of that collagenase (Lubbe et al., 2009). As a consequence, MMP-9 proteolytic 
activities at the pericellular tumor space are suppressed, with abrogation of MMP-9-
dependent interstitial matrix remodelling and cell spreading (Lubbe et al., 2009). 
Conversely, mutational dormancy of the GCC pathway early in transformation 
(Birkenkamp-Demtroder et al., 2002; Cohen et al. 1998; Notterman et al., 2001; Steinbrecher 
et al., 2000) may permit the emergence of a pro-tumorigenic stromal environment 
characterized by increased MMP-9 secretion, break-down of epithelial basement membranes 
by MMP-9 catalytic activity and disruption of homeostatic epithelial-mesenchymal 
interactions. It has been proposed that GCC effect on spatiotemporal MMP-9 dynamics in 
colon cancer cells has a profound impact on the overall tumor phenotype, because by 
disrupting its surface localization, membrane anchoring and focal catalytic activity it 
suppresses oncogenic MMP-9 functions (Lubbe et al., 2009). 
4. GCC and colorectal cancer metastasis 
Cancer metastasis consists in the dissemination of tumor cells to distant locations (Fidler, 
2003). Clinically, metastasis coincides with the most terminal disease stages, incurable 
conditions associated with poor prognosis and survival (Mehlen & Puisieux, 2006; Siegel et 
al., 2011). Pathogenetically, it comprises a sequence of distinct, individual processes 
including cancer cell invasion of the primary site, intravasation and distribution through 
blood or lymphatic vessels, and colonization of target organs (Fidler, 2003; Folkman, 1986; 
Nicolson, 1988). Following organ seeding, tumor cells have to migrate into and invade tissue 
parenchyma (Wanget al., 2004; Steeg, 2006), resist to local immune defences and establish a 
nurturing micro-environment to develop and growth (Fidler, 2003; Folkman, 1986). In colon 
cancer, preferred organs of metastatic colonization include the liver, lung and peritoneum. 
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Stamenkovic, 2000). Given its crucial role in those pathological processes, MMP-9-
dependent proteolytic activity is considered a driving force conferring the migratory and 
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Fridman et al., 2003; Lubbe et al., 2006; Yu & Stamenkovic, 2000). Consequently, MMP-9 
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cleavage of its 10-kDa N-terminal pro-peptide by various proteases (e.g., MMP-2, MMP-3, 
MMP-13, plasmin, thrombin) (Ahmed et al., 2003; Fridman et al., 2003; Ramos-DeSimone et 
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dependent interstitial matrix remodelling and cell spreading (Lubbe et al., 2009). 
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(Birkenkamp-Demtroder et al., 2002; Cohen et al. 1998; Notterman et al., 2001; Steinbrecher 
et al., 2000) may permit the emergence of a pro-tumorigenic stromal environment 
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by MMP-9 catalytic activity and disruption of homeostatic epithelial-mesenchymal 
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colon cancer cells has a profound impact on the overall tumor phenotype, because by 
disrupting its surface localization, membrane anchoring and focal catalytic activity it 
suppresses oncogenic MMP-9 functions (Lubbe et al., 2009). 
4. GCC and colorectal cancer metastasis 
Cancer metastasis consists in the dissemination of tumor cells to distant locations (Fidler, 
2003). Clinically, metastasis coincides with the most terminal disease stages, incurable 
conditions associated with poor prognosis and survival (Mehlen & Puisieux, 2006; Siegel et 
al., 2011). Pathogenetically, it comprises a sequence of distinct, individual processes 
including cancer cell invasion of the primary site, intravasation and distribution through 
blood or lymphatic vessels, and colonization of target organs (Fidler, 2003; Folkman, 1986; 
Nicolson, 1988). Following organ seeding, tumor cells have to migrate into and invade tissue 
parenchyma (Wanget al., 2004; Steeg, 2006), resist to local immune defences and establish a 
nurturing micro-environment to develop and growth (Fidler, 2003; Folkman, 1986). In colon 
cancer, preferred organs of metastatic colonization include the liver, lung and peritoneum. 
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Once colorectal cancer has spread to these organs, the risk of mortality increases 
dramatically, and ~90% of patients diagnosed with distant metastasis die within 5 years 
from diagnosis (Siegel et al., 2011). Indeed, the management of patients with colorectal 
cancer metastasis is characterized by the highest incidence of therapeutic failure, in which 
surgery is not practicable (Pihlet al., 1981; Shapiro, 1992) and adjuvant chemotherapy is 
ineffective (increasing median survival only few months) (Meyerhardt & Mayer, 2005). 
The functional phenotype of metastatic cells is unique and very selective. It has been 
calculated that of intravasated tumor cells, only a minute fraction remains viable after 24 
hour, and >99.99% are eliminated before reaching their target organ (Fidler, 1970). This 
metastatic inefficiency reflects the scarcity of cancer cell clones exhibiting the full molecular 
machinery to execute all the individual steps comprising the metastatic process (Fidler, 1970; 
Weiss, 1990). In that context, since its inception primary colorectal cancer consists of 
biologically heterogeneous cell subpopulations, among which are present those possessing 
the ability to migrate and spread to distant parenchyma (Fidler, 2003; Heppner, 1984). 
Intriguingly as demonstrated by extensive immune detection and mRNA analyses of clinical 
specimens, GCC is uniformly expressed in metastatic colon tumors regardless of anatomical 
location (Carrithers et al., 1994; Carrithers et al., 1996; Waldman et al., 1998). Moreover, the 
structural and functional integrity of GCC and its principal downstream effectors appears to 
be preserved in metastasis, as colorectal cancer cells at extra-intestinal sites exhibit identical 
binding characteristics to, and signalling activation by, the exogenous ligand ST to those of 
normal intestinal cells (Carrithers et al., 1994; Schulz et al., 2006; Witek et al., 2005). However 
away from its primary organ, GCC is a ligand-starved receptor with an intracellular 
dormant pathway, as normal mucosal cells in intestine are the principal producers of 
endogenous hormones guanylin and uroguanylin (Forte, 1999). Thus, the loss of GCC ligand 
expression early in transformation (Birkenkamp-Demtroder et al., 2002; Cohen et al., 1998; 
Notterman et al., 2001; Steinbrecher et al., 2000) may be part of the exclusive phenotypic 
mutations conferring a pro-metastatic evolutionary advantage to selected colon cancer 
clones (Lubbe et al., 2009; Pitari et al., 2007; Zuzga et al., 2011). 
4.1 Control of invasive cell shape 
To successfully execute the metastatic program, transformed cells require a dynamic actin 
cytoskeleton. Thus, a hallmark of metastasis is the abandon of the static epithelial cell 
polarity and the acquisition of plastic membrane borders with specialized actin-based 
organelles promoting locomotion and invasion (Fidler, 2003; Steeg, 2006). Similarly to 
lymphocytes or neutrophils at inflammatory sites, cancer cells constantly remodel their actin 
to assume atypical morphological architectures, a process often referred to as epithelial-
mesenchymal transition (Polyak & Weinberg, 2009). Changes in cell shapes reflect profound 
molecular rearrangements at tumor surfaces, including loss of E-cadherin-dependent cell-
cell contacts and transient assembly of integrin-driven cell-matrix adhesions (Avizienyte et 
al., 2004, 2005; Polyak & Weinberg, 2009). These processes permit de novo development of 
membrane protrusions, such as filopodia and lamellipodia for probing the matrix during 
spreading and migration, and invadopodia for focal proteolytic matrix degradation in 
invasion (Linder, 2007; Yamaguchi & Condeelis, 2007). 
In general, common molecular regulators coordinate tumor cytoskeletal remodelling by 
transducing external signals into actin processes. In colon cancer cells, tyrosine kinase 
receptors (e.g., EGF receptor, Eph receptors, Met receptors), G protein-coupled receptors 
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(e.g., cholecystokinin receptors) and cytokine receptors (e.g., chemokine receptors, TGF-β 
receptor) have been established as important inducers of the metastatic cell morphology 
(Dienstmann & Tabernero 2010; Dong et al., 2009; Fulton, 2009; Kitamura et al., 2010; Larsen 
& Dashwood, 2010; Ongchin et al., 2009; Yuet al., 2006). They activate the intracellular 
signalling system controlling cytoskeletal actin (e.g., focal adhesion kinases, rho-GTPases, 
Arp2/3 complex), which assembles the membrane protrusive structures mediating invasion 
(Linder, 2007; Yamaguchi & Condeelis, 2007). Normally restricted at intestinal epithelial 
brush borders (Lucas et al., 2000), GCC is ideally positioned to affect those molecular 
networks and exert spatio-temporal control of actin remodelling. Indeed, ligand-dependent 
GCC signalling through cGMP appears to act as a suppressor of metastatic cell morphology 
in intestine (Lubbe et al., 2009; Zuzga et al., 2011). Thus, colon cancer cells assume a rounded 
shape upon GCC signalling activation, with elimination of F-actin rich filopodia and 
lamellipodia (Lubbe et al., 2009). The number and length of cancer cell invadopodia also 
significantly decreases after activation of the GCC pathway (Zuzga et al., 2011). Importantly, 
failure to form protrusive structures forces tumor cells to aggregate into compact colonies 
devoid of spreading and invading abilities (Lubbe et al., 2009; Zuzga et al., 2011). Together, 
these observations suggest that the GCC pathway is one of the intrinsic homeostatic systems 
that maintain the stable epithelial cell polarity, shape and tight junctions, which form the 
essential mucosal barrier between the intestine and the external environment (Han et al., 
2011). This notion is further supported by the inhibitory role that GCC signalling exerts on 
known inducers of epithelial-mesenchymal transition (Polyak & Weinberg, 2009), including 
the reactive stromal environment (with enhanced TGF-β and MMP-9 activities) (Gibbons et 
al., 2009) and the stem cell-promoting PI3K/AKT system (Lin et al., 2010). Hence, 
dysregulation of GCC signalling in intestinal tumorigenesis may enable the epithelial-
mesenchymal transition required for cancer cell dissemination (Lubbe et al., 2009). 
A key intracellular effector of the GCC pathway that regulates colon cancer cell shape is the 
vasodilator-stimulated phosphoprotein (VASP) (Zuzga et al., 2011). Ena/VASP family 
proteins control F-actin geometry supporting cell motility (Krause et al., 2003). VASP 
promotes filopodia and lamellipodia formation and extension by organizing molecular 
complexes comprising G-actin, F-actin and actin regulatory proteins (Krause et al., 2003). It 
functions by protecting actin barbed ends from binding to capping proteins, thereby 
permitting filament elongation (Bear et al., 2002; Mejillano et al., 2004). Three critical 
domains enable VASP to intimately interact with the actin cytoskeleton (Krause et al., 2003), 
including 1) the N-terminus Ena/VASP homology 1 (EVH1), which binds to focal adhesion 
proteins vinculin and zyxin, 2) the central prolin-rich region, which contains a consensus 
binding motif for the G-actin-binding protein profilin, and 3) the C-terminus EVH2, which 
binds to both G- and F-actin and mediates VASP oligomerization. Importantly, Ser239 
within the EVH2 VASP domain is a preferred phosphorylation site for PKG, functioning as a 
biological marker for cGMP signalling in intestinal (Deguchi et al., 2002) and other cells 
(Krause et al., 2003; Yaroslavskiy et al., 2005). Cyclic GMP-dependent VASP 
phosphorylation inhibits membrane protrusion formation in normal cells (Krause et al., 
2003; Lindsay et al., 2007). Accordingly, in colorectal cancer cells VASP Ser239 
phosphorylation induced by ligand activation of GCC signalling through cGMP and PKG 
induces rapid disassembly (less than 10 minutes) of invasive and migratory membrane 
organelles (Zuzga et al., 2011). Herein, GCC promotes VASP removal from tumor 
membrane protrusions with subsequent collapse of the F-actin infrastructure supporting 
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cancer metastasis is characterized by the highest incidence of therapeutic failure, in which 
surgery is not practicable (Pihlet al., 1981; Shapiro, 1992) and adjuvant chemotherapy is 
ineffective (increasing median survival only few months) (Meyerhardt & Mayer, 2005). 
The functional phenotype of metastatic cells is unique and very selective. It has been 
calculated that of intravasated tumor cells, only a minute fraction remains viable after 24 
hour, and >99.99% are eliminated before reaching their target organ (Fidler, 1970). This 
metastatic inefficiency reflects the scarcity of cancer cell clones exhibiting the full molecular 
machinery to execute all the individual steps comprising the metastatic process (Fidler, 1970; 
Weiss, 1990). In that context, since its inception primary colorectal cancer consists of 
biologically heterogeneous cell subpopulations, among which are present those possessing 
the ability to migrate and spread to distant parenchyma (Fidler, 2003; Heppner, 1984). 
Intriguingly as demonstrated by extensive immune detection and mRNA analyses of clinical 
specimens, GCC is uniformly expressed in metastatic colon tumors regardless of anatomical 
location (Carrithers et al., 1994; Carrithers et al., 1996; Waldman et al., 1998). Moreover, the 
structural and functional integrity of GCC and its principal downstream effectors appears to 
be preserved in metastasis, as colorectal cancer cells at extra-intestinal sites exhibit identical 
binding characteristics to, and signalling activation by, the exogenous ligand ST to those of 
normal intestinal cells (Carrithers et al., 1994; Schulz et al., 2006; Witek et al., 2005). However 
away from its primary organ, GCC is a ligand-starved receptor with an intracellular 
dormant pathway, as normal mucosal cells in intestine are the principal producers of 
endogenous hormones guanylin and uroguanylin (Forte, 1999). Thus, the loss of GCC ligand 
expression early in transformation (Birkenkamp-Demtroder et al., 2002; Cohen et al., 1998; 
Notterman et al., 2001; Steinbrecher et al., 2000) may be part of the exclusive phenotypic 
mutations conferring a pro-metastatic evolutionary advantage to selected colon cancer 
clones (Lubbe et al., 2009; Pitari et al., 2007; Zuzga et al., 2011). 
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lymphocytes or neutrophils at inflammatory sites, cancer cells constantly remodel their actin 
to assume atypical morphological architectures, a process often referred to as epithelial-
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(e.g., cholecystokinin receptors) and cytokine receptors (e.g., chemokine receptors, TGF-β 
receptor) have been established as important inducers of the metastatic cell morphology 
(Dienstmann & Tabernero 2010; Dong et al., 2009; Fulton, 2009; Kitamura et al., 2010; Larsen 
& Dashwood, 2010; Ongchin et al., 2009; Yuet al., 2006). They activate the intracellular 
signalling system controlling cytoskeletal actin (e.g., focal adhesion kinases, rho-GTPases, 
Arp2/3 complex), which assembles the membrane protrusive structures mediating invasion 
(Linder, 2007; Yamaguchi & Condeelis, 2007). Normally restricted at intestinal epithelial 
brush borders (Lucas et al., 2000), GCC is ideally positioned to affect those molecular 
networks and exert spatio-temporal control of actin remodelling. Indeed, ligand-dependent 
GCC signalling through cGMP appears to act as a suppressor of metastatic cell morphology 
in intestine (Lubbe et al., 2009; Zuzga et al., 2011). Thus, colon cancer cells assume a rounded 
shape upon GCC signalling activation, with elimination of F-actin rich filopodia and 
lamellipodia (Lubbe et al., 2009). The number and length of cancer cell invadopodia also 
significantly decreases after activation of the GCC pathway (Zuzga et al., 2011). Importantly, 
failure to form protrusive structures forces tumor cells to aggregate into compact colonies 
devoid of spreading and invading abilities (Lubbe et al., 2009; Zuzga et al., 2011). Together, 
these observations suggest that the GCC pathway is one of the intrinsic homeostatic systems 
that maintain the stable epithelial cell polarity, shape and tight junctions, which form the 
essential mucosal barrier between the intestine and the external environment (Han et al., 
2011). This notion is further supported by the inhibitory role that GCC signalling exerts on 
known inducers of epithelial-mesenchymal transition (Polyak & Weinberg, 2009), including 
the reactive stromal environment (with enhanced TGF-β and MMP-9 activities) (Gibbons et 
al., 2009) and the stem cell-promoting PI3K/AKT system (Lin et al., 2010). Hence, 
dysregulation of GCC signalling in intestinal tumorigenesis may enable the epithelial-
mesenchymal transition required for cancer cell dissemination (Lubbe et al., 2009). 
A key intracellular effector of the GCC pathway that regulates colon cancer cell shape is the 
vasodilator-stimulated phosphoprotein (VASP) (Zuzga et al., 2011). Ena/VASP family 
proteins control F-actin geometry supporting cell motility (Krause et al., 2003). VASP 
promotes filopodia and lamellipodia formation and extension by organizing molecular 
complexes comprising G-actin, F-actin and actin regulatory proteins (Krause et al., 2003). It 
functions by protecting actin barbed ends from binding to capping proteins, thereby 
permitting filament elongation (Bear et al., 2002; Mejillano et al., 2004). Three critical 
domains enable VASP to intimately interact with the actin cytoskeleton (Krause et al., 2003), 
including 1) the N-terminus Ena/VASP homology 1 (EVH1), which binds to focal adhesion 
proteins vinculin and zyxin, 2) the central prolin-rich region, which contains a consensus 
binding motif for the G-actin-binding protein profilin, and 3) the C-terminus EVH2, which 
binds to both G- and F-actin and mediates VASP oligomerization. Importantly, Ser239 
within the EVH2 VASP domain is a preferred phosphorylation site for PKG, functioning as a 
biological marker for cGMP signalling in intestinal (Deguchi et al., 2002) and other cells 
(Krause et al., 2003; Yaroslavskiy et al., 2005). Cyclic GMP-dependent VASP 
phosphorylation inhibits membrane protrusion formation in normal cells (Krause et al., 
2003; Lindsay et al., 2007). Accordingly, in colorectal cancer cells VASP Ser239 
phosphorylation induced by ligand activation of GCC signalling through cGMP and PKG 
induces rapid disassembly (less than 10 minutes) of invasive and migratory membrane 
organelles (Zuzga et al., 2011). Herein, GCC promotes VASP removal from tumor 
membrane protrusions with subsequent collapse of the F-actin infrastructure supporting 
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filopodia and invadopodia (Zuzga et al., 2011). However, colorectal cancer cells expressing a 
mutant VASP construct not-phosphorylatable at Ser239 are resistant to GCC effects on 
VASP intracellular distribution and membrane protrusions (Zuzga et al., 2011). These 
findings are the most significant because they uncover the novel paradigm of a single 
intracellular biochemical reaction, VASP Ser239 phosphorylation, as an invasion 
suppressive mechanism for colon cancer (Zuzga et al., 2011). Hence, the loss of this 
mechanism during colorectal tumorigenesis, reflecting silencing of the GCC-cGMP-VASP 
system following hormonal deprivation (Birkenkamp-Demtroder et al., 2002; Cohen et al., 
1998; Notterman et al., 2001; Steinbrecher et al., 2000), may favour the acquisition of the 
metastatic cell morphology, characterized by dissolution of normal cell-matrix and cell-cell 
contacts, increased actin polymerization dynamics, and enhanced formation of membrane 
protrusions (Zuzga et al., 2011). 
4.2 Control of cancer cell dissemination 
Relocation of cancer cells to distant sites requires acquisition of novel motor abilities, 
enabling them to spread through remodelled matrix surfaces at both primary and secondary 
tissues. In primary tumors, cancer cell spreading in the direction of blood vessels initiates 
the migratory journey of the intravasation process (Fidler et al., 1978; Fidler, 2003). In 
secondary organs, tumor cell adhesion and spreading onto vascular endothelial surfaces 
starts cancer invasion of target parenchyma (Im et al., 2004; Wang et al., 2004). In this 
context, polarized cell spreading drives cancer cell migration in the direction of invasion by 
permitting the establishment of specialized cell-matrix contacts at membrane protrusions, 
which mediates actin cytoskeleton-driven anchorage and traction of the cell body (Small et 
al., 1996). Thus, regulators of the cytoskeleton, adhesion receptors and extracellular 
proteases, which universally control spreading and migration in cells, are key players 
underlying cancer dissemination (Yamaguchi & Condeelis, 2007). Since its signalling 
through cGMP and VASP controls actin cytoskeletal dynamics and membrane protrusions 
in colon cancer cells (Zuzga et al., 2011), the GCC pathway may exert substantial impacts on 
those processes underlying formation of distant metastasis. Consistent with this hypothesis, 
elimination of GCC signalling in mice accelerates cell migration along the intestinal crypt-
villus axis (Li et al., 2007a). Of relevance, basal GCC activity appears insufficient to 
restraining epithelial cell motility, as demonstrated by the increased migration of intestinal 
mucosa cells in mice with targeted ligand (guanylin) deletion (Steinbrecher et al., 2002). 
These observations suggest a model in which loss of hormone expression at the beginning of 
colorectal tumorigenesis (Birkenkamp-Demtroder et al., 2002; Cohen et al., 1998; Notterman 
et al., 2001; Steinbrecher et al., 2000) results in the acquisition of increased migratory abilities 
by transformed cells, driven by the accelerated formation of locomotory organelles 
mediating cell spreading and invasion (Zuzga et al., 2011). 
A significant regulator of colorectal cancer cell migration and dissemination is the MMP-9 
secreted by tumor epithelial cells (Lubbe et al., 2006). Beyond matrix degradation, this 
MMP-9 promotes the spreading and migration of colon cancer cells along two dimensional 
surfaces (Lubbe et al., 2006). Moreover, the catalytic activity of cancer cell MMP-9 is 
required for optimal colon tumor cell seeding of target mouse organs (Lubbe et al., 2006), an 
effect probably reflecting remodelling of the tumor pericellular microenvironment by MMP-
9 (Fridman et al., 2003). Accordingly, inhibitors of MMP-9 suppress the formation of 
colorectal liver metastasis in an animal model (Aparicio et al., 1999). The significance of 
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MMP-9 for colon cancer metastasis is further underscored by its universal role in regulating 
migration and invasion across different cell types (Buisson et al., 1996; Leppert et al., 1995; 
Sanceau et al., 2003; Schultz et al., 1988; Yu & Stamenkovic, 1999). Importantly, ligand-
dependent GCC signalling through cGMP suppresses the function of the MMP-9 produced 
by colorectal cancer cells (Lubbe et al., 2009). Activation of the GCC pathway suppresses 
tumor cell spreading, migration and dissemination by specifically inhibiting the secretion of 
cancer cell MMP-9 in the extracellular space (Lubbe et al., 2009). Further, colon tumor cells 
treated with GCC ligands fail to form metastatic colonies on mouse diaphragms following 
intraperitoneal injections (Lubbe et al., 2009). This effect also depends on the ability of GCC 
to inhibit cancer cell MMP-9, as demonstrated by the resistance of cells overexpressing 
MMP-9 to GCC-mediated inhibition of peritoneal metastasis (Lubbe et al., 2009). 
Conceivably, a silent GCC pathway in colorectal carcinogenesis (Birkenkamp-Demtroder et 
al., 2002; Cohen et al., 1998; Notterman et al., 2001; Steinbrecher et al., 2000) facilitates colon 
tumor invasion and metastatic dissemination by removing a key inhibitory mechanism 
restraining the oncogenic activity of cancer cell MMP-9. 
5. The GCC pathway as a source of novel clinical targets 
As discussed above, the loss of ligand-dependent GCC signalling produces a dormant 
GCC/cGMP pathway, which has significant impacts on the initiation, progression and 
metastasis of colorectal cancer. Conversely, deregulation of that pathway and its individual 
molecular components uncovers novel targets with unexploited clinical potential for 
improved diagnosis and therapy of patients. Thus, detection of hormone downregulation in 
colon biopsies could indicate presence of intestinal carcinogenesis and demand appropriate 
follow-up (Cohen et al., 1998; Notterman et al., 2001). The selective expression of GCC in 
colorectal tumor cells at metastatic sites (Carrithers et al., 1994, 1996; Waldman et al., 1998), 
suggests its utility as a diagnostic marker and specific target for delivering imaging and 
therapeutic agents in vivo (Gali et al., 2001; Wolfe et al., 2002). Indeed, clinical trials are 
confirming the value of GCC as a diagnostic marker for molecular staging of patients and 
prognostic indicator of colorectal cancer recurrence (Mejia et al., 2010; Waldman et al., 2009). 
Moreover, the structural preservation of GCC and its intracellular effectors offers the GCC 
hormone replacement therapy as a novel clinical paradigm for the prevention and treatment 
of colorectal cancer (Pitari et al., 2007). In this context, oral administration of uroguanylin 
prevents polyp formation in an animal model of intestinal tumorigenesis (Shailubhai et al., 
2000). Further, the resistance to colon cancer initiation and progression exhibited by 
populations living in the developing world (Pitari et al., 2003; Shailubhai et al., 2000), where 
enterotoxigenic infections are highest, suggests that replacement therapy with the 
exogenous GCC ligand ST, the enterotoxin produced by E. coli, might be an effective 
treatment for colorectal cancer patients (Pitari et al., 2007). This latter consideration is 
supported by observations that ST is the most potent GCC agonist available (Lucas et al., 
2000), and the only ligand successfully investigated to fully restore the tumor suppressor 
activities of the GCC pathway in colorectal cancer cells (Lubbe et al., 2009; Pitari et al., 2001, 
2003, 2005, 2007; Zuzga et al.,2011). 
Distal components of the GCC pathway also could be exploited in original clinical 
applications against colon cancer. As expected for its significance in intestinal mucosa 
homeostasis, the intracellular GCC signalome comprises a complex molecular network 
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supported by observations that ST is the most potent GCC agonist available (Lucas et al., 
2000), and the only ligand successfully investigated to fully restore the tumor suppressor 
activities of the GCC pathway in colorectal cancer cells (Lubbe et al., 2009; Pitari et al., 2001, 
2003, 2005, 2007; Zuzga et al.,2011). 
Distal components of the GCC pathway also could be exploited in original clinical 
applications against colon cancer. As expected for its significance in intestinal mucosa 
homeostasis, the intracellular GCC signalome comprises a complex molecular network 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
272 
(Pitari et al., 2007), probably still incomplete and in which each of the molecular elements 
may deserve critical translational evaluations. For some of these, preclinical testing is 
currently ongoing that is revealing emerging features as promising colorectal cancer bio-
targets (Table 1). One model is the CaR, whose surface expression in colon cancer cells is 
conditionally regulated by activation of GCC signalling (Pitari et al., 2008). The dormant 
GCC pathway probably contributes to the reduced CaR expression observed in colorectal 
tumors (Chakrabarty et al., 2003; Kallay et al., 2003), a mutational event with clinical 
potential as a diagnostic marker of disease progression (Pitari et al., 2008). Moreover, CaR 
activation by extracellular Ca2+ inhibits cell proliferation (Chakrabarty et al., 2003), and 
dietary Ca2+ supplementation has been proposed as a chemopreventive strategy for colon 
cancer (Cho et al., 2004). Since restoration of the GCC pathway with exogenous ST 
administration potentiates antitumorigenic CaR signalling in human colon carcinoma cells 
(Pitari et al., 2008), combinatorial therapies including dietary Ca2+ and GCC ligand 
replacement may represent promising clinical regimens for the prevention and treatment of 
colorectal cancer. 
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Table 1. Examples of emergent colon cancer molecular targets from the GCC pathway. 
Another intriguing effector of the GCC pathway is MMP-9, whose cancer cell 
compartmentalization depends on intracellular cGMP signalling (Lubbe et al., 2009). A silent 
GCC network may favour increased release and proteolytic activity of MMP-9 at the tumor 
pericellular space (Lubbe et al., 2009), thereby promoting matrix remodelling and invasion 
(Curran & Murray, 1999). Importantly, colon cancer cell MMP-9 behaves as a selective 
prognostic and predictive biomarker for disease stage stratification and therapeutic regimen 
selection in patients (Bendardaf et al., 2010; Zuzga et al., 2008). Reactivation of the GCC 
pathway with ST, in turn, is one successful strategy to specifically inhibit MMP-9 in tumor 
epithelial cells, without collateral damage in normal tissue, that has been suggested for the 
chemoprevention of colorectal cancer metastasis (Lubbe et al., 2009). Further, recent studies 
are indicating VASP as yet another GCC target with attractive translational applications for 
patients with colon cancer (Zuzga et al., 2011). VASP is a crucial actin-binding protein 
controlling membrane protrusion geometry, cell adhesion and migration (Bear et al., 2002; 
Krause et al., 2003; Mejillano et al., 2004). Dormancy of the GCC pathway in tumorigenesis 
depletes colon cancer cells of the cGMP-dependent VASP Ser phosho-species, molecular 
regulators of VASP activity at dynamic membrane regions (Krause et al., 2003). Thus, loss of 
VASP Ser phosphorylation may represent a novel prognostic biomarker of colon cancer 
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progression (Zuzga et al., 2011). Conversely, reconstitution of VASP Ser phosphorylation 
could be exploited as an original paradigm for the chemoprevention of cancer migration and 
invasion, because the potent GCC ligand ST suppresses the malignant cell morphology and 
its pathological functions in colon cancer (Zuzga et al., 2011). 
6. Conclusion 
A novel paradigm is emerging in which colorectal cancer, one of the top cancer killers in the 
world, is pathogenetically conditioned by a dormant GCC pathway, developed early in 
tumorigenesis following specific ligand downregulation. Indeed, GCC and its paracrine 
hormones restrict the proliferative crypt phenotype and promote the normal epithelial cell 
morphology by orchestrating an articulated intracellular network comprising 
interconnected, but functionally distinct molecular effectors. Silencing of the pathway for 
loss of agonist-induced GCC/cGMP signalling alters the activity of those molecules with 
profound consequences for the initiation and progression of colorectal transformation (Fig. 
1). Virtually all the key processes underlying carcinogenesis and metastasis are enhanced by 
dysregulation of the GCC pathway components, including proliferation, survival, genetic 
instability, migration, matrix remodelling and invasion. At the same time, the dormant 
pathway creates unexplored opportunities for novel diagnostic applications. This is because 
the biochemical deregulation that ensues from the silent cGMP-dependent machinery can be 
traced by analysis of the single pathway components at the molecular level. As a result, 
novel molecular fingerprints of colorectal carcinogenesis are emerging from the GCC 
pathway that can be exploited as clinical prognostic or predictive indicators of disease. 
Restoration of the lost function by the GCC pathway in colorectal tumors also is proving its 
great translational value. Preclinical studies indicate that, though dormant, the pathway is 
largely intact and can be reconstituted simply by ligand replacement. Thus, administration 
of bacterial enterotoxin STs, potent GCC agonists, suppresses proliferation, migration, 
matrix degradation, invasion and metastasis by colorectal cancer cells. Altogether, these 
findings support the notion that oral replacement therapy with GCC ligands could represent 
a novel strategy for both the chemoprevention and cure of colorectal cancer. Additional 
therapies targeting the individual pathway components, either alone or in combination, also 
are being developed with the goal to improve clinical efficacy and selectivity. However, 
information from clinical testing is still missing and important questions remain to be 
addressed before this knowledge could be applied to the patient bed. In particular, general 
gastrointestinal toxicity worries need to be dissipated as GCC ligands such as ST are known 
for their potent diarrheagenic effects. Also, the temporal profile of GCC-targeted therapy 
will require complete characterization, including estimation of duration of treatments and 
effects. Finally, pharmacokinetics evaluation will need to be performed to accurately define 
dosing and timing regimens. In summary, the intestinal GCC pathway is an exciting 
potential source of novel diagnostic and therapeutic targets that could significantly affect 
the clinical management and disease outcome of patients with colorectal cancer. 
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1. Introduction 
Colorectal cancer (CRC) is the third most common cancer worldwide. Considering the high 
rate of incidence and mortality of CRC it is critical to determine the mechanisms of its 
dissemination. Although one of the better characterised tumours the prognosis of patients 
decreases dramatically when lymphatic metastasis occurs. In addition, the main important 
prognostic factor of CRC is the stage of tumour at the time of diagnosis, which is defined by 
the TNM system from the American Joint Committee on Cancer and the International Union 
Against Cancer. Therefore, during surgical treatment not only the primary tumour but also 
the draining lymph nodes have to be removed. From multivariate analysis it is known, that 
the number of examined lymph nodes is an independent prognostic factor. In this context, a 
prognostic relevance has been demonstrated not only for N0-, but also for N1- and N2-
status. Adjuvant chemotherapy is recommended for stage UICC III colon cancer. It has been 
shown to reduce tumour recurrence and improve overall survival (Schmiegel, Reinacher-
Schick et al. 2008). The five-year survival rate drops significantly from the UICC stage I to IV 
(Table 1). Patients with an early stage tumour (UICC I) have an excellent prognosis and a 
five-year survival rate of 90%, compared to those with advanced tumours and lymph node 
metastasis, who have a five-year survival rate of 30-60%. Patients with distant metastasis 
have a five-year survival rate below 10%.  
Thus the prognosis of CRC is significantly influenced by the occurrence of lymph node 
metastasis and in addition to its value as a prognostic indicator it also affects the 
therapeutically management of patients. The understanding of molecular mechanisms 
involved in lymphatic metastases may open the door for future treatment strategies. 
2. The lymphatic system 
2.1 Development of the lymphatic system 
Aspects of the lymphatic fluid and the associated transport system were already mentioned 
by the ancient Greeks, but it was poorly considered until the 17th century. In 1622 the Italian 
physician Gasparo Asselli re-identified lymphatic vessels as “milky veins” in the gut of a 
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1. Introduction 
Colorectal cancer (CRC) is the third most common cancer worldwide. Considering the high 
rate of incidence and mortality of CRC it is critical to determine the mechanisms of its 
dissemination. Although one of the better characterised tumours the prognosis of patients 
decreases dramatically when lymphatic metastasis occurs. In addition, the main important 
prognostic factor of CRC is the stage of tumour at the time of diagnosis, which is defined by 
the TNM system from the American Joint Committee on Cancer and the International Union 
Against Cancer. Therefore, during surgical treatment not only the primary tumour but also 
the draining lymph nodes have to be removed. From multivariate analysis it is known, that 
the number of examined lymph nodes is an independent prognostic factor. In this context, a 
prognostic relevance has been demonstrated not only for N0-, but also for N1- and N2-
status. Adjuvant chemotherapy is recommended for stage UICC III colon cancer. It has been 
shown to reduce tumour recurrence and improve overall survival (Schmiegel, Reinacher-
Schick et al. 2008). The five-year survival rate drops significantly from the UICC stage I to IV 
(Table 1). Patients with an early stage tumour (UICC I) have an excellent prognosis and a 
five-year survival rate of 90%, compared to those with advanced tumours and lymph node 
metastasis, who have a five-year survival rate of 30-60%. Patients with distant metastasis 
have a five-year survival rate below 10%.  
Thus the prognosis of CRC is significantly influenced by the occurrence of lymph node 
metastasis and in addition to its value as a prognostic indicator it also affects the 
therapeutically management of patients. The understanding of molecular mechanisms 
involved in lymphatic metastases may open the door for future treatment strategies. 
2. The lymphatic system 
2.1 Development of the lymphatic system 
Aspects of the lymphatic fluid and the associated transport system were already mentioned 
by the ancient Greeks, but it was poorly considered until the 17th century. In 1622 the Italian 
physician Gasparo Asselli re-identified lymphatic vessels as “milky veins” in the gut of a 
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Table 1. UICC stage and 5-year cancer related survival of patients with CRC.  
dog. The embryonic origin of lymphatic vessels remains further unclear. Since the beginning 
of the 20th century, two developmental theories -the centrifugal and the centripetal- have 
been controversial debated. The centrifugal theory by Sabin based upon dye and ink 
injection experiments in pigs. According to her view, lymphatic vessel formation occurs 
early during embryonic development from isolated primitive lymph sacs that originate from 
endothelial cells that bud from the veins. The peripheral lymphatic system originates from 
these primary lymph sacs by endothelial sprouting into the surrounding tissues and organs, 
where local capillaries are formed (Oliver and Detmar 2002). Simultaneously Huntington 
and McClure suggested an alternative model, the centripetal theory. In their opinion 
primary lymph sacs arise from mesenchymal precursor cells, independent of the veins and 
secondarily establish venous connections.  
To date, the development of the lymphatic vasculature system has not been ultimately 
resolved. Recent molecular analyses describe a polarized expression of the homeobox 
transcription factor Prox-1 in anterior cardinal vein endothelial cells, which is required for 
specification of lymphatic endothelial cells (LECs). Prox-1 is a master regulator which drives 
the transcription of a variety of genes whose expression is associated with key LEC 
characteristics (Tammela, Petrova et al. 2005). 
2.2 Structure and function of the lymphatic system 
The lymphatic vascular system is a hierarchical network comprising blind-ended capillaries, 
collecting vessels, lymph nodes, lymphoid organs and circulation lymphocytes. A number 
of important physiological functions have been described. It maintains fluid homeostasis by 
absorbing and draining e.g. interstitial fluids, plasma proteins and cells extravasated from 
blood vessels and returning them back into the blood circulation (Butler, Isogai et al. 2009). 
Furthermore, the lymphatic system is also known to be an important part of the body´s 
immunological surveillance system (Wiig, Keskin et al. 2010). Lymphatic vessels are 
distributed to most organs, with the exceptions of the central nervous system, bone marrow, 
cartilage, cornea and epidermis. Due to its dual role, fluid absorption and lymph transport, 
the structure of lymphatic vessels differ from blood vessels (Schulte-Merker, Sabine et al. 
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2011). Lymph capillaries are characterized by loose intercellular junctions, no or an 
incomplete basement membrane. The wall of lymphatic endothelial cells (LECs) is joined to 
the extracellular matrix by anchoring filaments. These filaments help the vessels open and 
function. Collecting lymphatic vessels consist of pericytes, which reduce lymphatic fluid 
extravasation and they are surrounded by smooth muscle cells (Figure 1) (Shayan, Achen et 
al. 2006).  
Tumour cells can take advantage of these structural characteristics to promote their 
dissemination to lymph nodes or other organs by the process of permeation into 
peritumoural lymphatics. In addition, LECs secrete chemotactic agents, which can attract 
tumours cells toward lymphatics, such as CCL21, whose receptor (CCR7) is expressed on 
some tumour cells (Shields, Emmett et al. 2007). Chemokines may mediate the tumour LEC 





Fig. 1. Structure of lymphatic vessels compared against blood vessels. The initial lymphatics 
have no or an incomplete basement membrane and no pericytes, which makes them suitable 
for the uptake of tumour cells. Anchoring filaments attach LECs to the extracellular matrix 
(ECM) and prevent vessel collapse.  
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Gene expression profiles of LECs and blood endothelial cells (BECs) have been analysed and 
compared (Figure 2). The most obvious differences were detected in genes coding for pro-
inflammatory cytokines/chemokines and their receptors, cytoskeletal and cell matrix 
organisation (Saharinen, Tammela et al. 2004). For example Interleukin (IL)-8, IL-6, the 
chemokine receptor CXCR4, ICAM-1, Integrin α5 are expressed in higher levels in the BECs. 
 
 
Abbreviations: Stat6 (signal transducer and activator of transcription 6), MCP-1 (monocyte chemotactic 
protein-1), IL-6/8 (Interleukin-6/-8), ICAM (intracellular adhesion molecule), Ang-1 (Angiopoietin-1), 
VEGF/ R ( Vascular endothelial growth factor/receptor), CD-44 (Cluster of Differentiation 44), IGF-1/2 
(Insulin like growth factor 1/2), FGF-2 (Fibroblast growth factor 2),  HGF (Hepatocyte growth factor),  
c-MET (mesenchymal epithelial transition factor), Tie-2 (angiopoietin receptor 2). Note that not all 
molecular markers are shown. 
Fig. 2. Molecular characteristics of BECs and LECs.  
3. Lymphangiogenesis  
3.1 Lymphangiogenesis and cancer metastasis 
Lymphangiogenesis takes place in a variety of physiological and pathophysiological 
processes, such as embryonic development, regeneration and wound healing on the one 
hand, and in lymph vascular malformations, inflammation and cancer on the other hand 
(Witte, Jones et al. 2006). Carcinogenesis is a complex multi-step process and despite the 
importance, that the lymphatic system provided one of the main routes for cancer 
progression, little information has been available about the molecular mechanisms by which 
the tumour cells gain access to the lymph system and are able to spread.  
Traditionally, lymphatic metastasis of tumours was considered to be a passive process, 
where tumour cells metastasized to lymph nodes by utilizing pre-existing lymphatic vessels 
via open junctions or that lymphatic vessel entry occurred by tumour eroding. The process 
of new lymphatic formation (lymphangiogenesis) does not occur.  
This view has been challenged (Achen and Stacker 2008). The identification of lymphatic 
specific markers, lymphangiogenic growth factors and their ligand receptor pathways, the 
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isolation of lymphatic endothelial cells and the development of specific in vitro culture 
systems in the past decades led to a broader understanding of the molecular mechanisms 
that control lymphatic metastasis.  
Yet there is mounting evidence that lymphangiogenesis does occur in tumours and that it 
promotes cancer progression. A shift in the balance between lymphangiogenic and anti-
lymphangiogenic signalling, like in the process of angiogenesis, might lead to 
lymphangiogenesis. Therefore a wide range of interactions at the tumour host interface have 
to take place, which support tumour proliferation, migration and survival. These processes 
are controlled by growth factors, adhesion molecules, fibroblasts, blood vessels, cytokines 
and chemo attractants (Figure 3) (Cueni and Detmar 2006; Ji 2006).  In the following section 
the most widely studied molecular mediators of lymphangiogenesis are reviewed.  
 
 
Fig. 3. Schematic overview of processes involved in tumour lymphangiogenesis and 
metastasis. Growth factors, cytokines, chemokines and tumour stroma contributes to 
tumour formation, growth, lymphangiogenesis and cancer progress. The tumour stroma 
consists of fibroblasts, ECM (extracellular matrix), blood vessels, lymphatic vessels and 
immune cells.  
3.2 Molecular players in tumour lymphangiogenesis 
3.2.1 Vascular endothelial growth factor 
The human VEGF family of growth factors includes VEGF-A, -B, -C, -D and placental 
growth factor (PIGF). They bind with different specificity to three tyrosine kinase receptors: 
VEGFR-1 (fms-like tyrosine kinase 1), VEGFR-2 (human kinase insert domain receptor), 
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VEGFR-3 (fms-like tyrosine kinase 4) and two non-protein kinase co-receptors (neuropilin-1 
and neuropilin-2). All VEGFRs have an extracellular binding region containing seven 
immunoglobulin-like domains (excepted VEGFR-3 who has only 6 domains), a single 
transmembrane helix and a conserved cytoplasmic domain that contains the catalytic core 
and regulatory sequences (Lohela, Bry et al. 2009). Activation of VEGFR by its ligands leads 
to receptor dimerization, autophosphorylation of tyrosine residues and initiation of 
signalling pathways (Roskoski 2008). 
VEGF-C, VEGF-D and their ligand VEGFR-3 were the first discovered and most exensively 
studied lymphangiogenic factors (Baldwin et al. 2002; Nagy et al. 2002). After activation of 
VEGFR-3 by its ligands, autophosphorylation of tyrosine residues results in binding of the 
signalling adaptor proteins Shc (adaptor protein p66), Grb-2 (growth factor receptor-bound 
protein) and in activation of the ERK 1/2 (extracellular signal regulated kinase) signal 
transduction cascade in a protein kinase C dependent manner and via PI3K-Akt  
(phosphatidylinositol 3-kinase protein kinase B) signalling cascade (Figure 4). Binding of the 
adaptor protein CRK 1/2 initiates the MKK4-JNK 1/2 (mitogen-activated protein kinase 
kinase 4- Jun N-terminal kinase) pathway and results in induction of c-JNK (c-Jun N-
terminal kinase) expression. The VEGFR-3 pathway mediates lymph endothelial growth, 
survival and migration (Wissmann and Detmar 2006). 
 
 
Fig. 4. The VEGF-C and VEGF-D pathways via VEGFR-3. Proteolytic processing, signal 
adaptor binding and activation of downstream signalling molecules results in lymph 
endothelial growth, proliferation and survival. 
There are several studies, which suggested a correlation between the expression level of 
VEGF-C and lymph node metastasis (LNM) in e.g. CRC, gastric, prostate, esophageal and 
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lung cancers (Achen and Stacker 2008). The mechanisms regulating the VEGF-C/VEGF-D 
expression in tumours are not fully revealed. It is known, that pro-inflammatory cytokines 
such as tumour necrosis factor (TNF) and Interleukins induce the expression of VEGF-C in 
tumour cells. The local ECM environment is assumed to trigger different VEGF receptors, 
resulting in signalling pathways which promote lymphangiogenesis.  
In fact, the results of some studies showed that the expression levels of VEGF-D and 
VEGFR-3 in colorectal carcinoma tissues are significantly higher than in normal tissues 
(Omachi, Kawai et al. 2007). Furthermore, recent reports have linked the VEGF-C/VEGF-D 
expression to lymphatic metastasis and poor patient outcome (Nagahashi, Ramachandran et 
al. 2010; Lin, Lin et al. 2011). Our histopathological examination also revealed that VEGF-C 
was present in CRC tissue, whereas the surrounding tissue was negative.   
 
 
Fig. 5. CRC immunohistochemically staining for VEGF-C expression. The strong VEGF-C 
expression appears in the colon carcinoma tissue, while the surrounding tissue is negative. 
VEGF-A is associated with angiogenesis, but it may also contribute to lymphangiogenesis. 
During angiogenesis VEGF-A induces proliferation and migration of endothelial cells, 
protease production and promotes cell survival. Fibroblasts, macrophages and endothelial 
cells are cells in the tumour microenvironment which are known to secrete VEGF-A. 
Evidence indicates that transforming growth factor α (TGF) plays a role in regulating 
VEGF-A expression. The biological activity of VEGF-A is mainly mediated direct via 
activating of VEGFR-2 and indirectly by recruiting monocytes and neutrophils, which 
express VEGFR-1 and produce VEGF-C/VEGF-D.  
A number of reports describe in CRC a correlation between VEGF-A expression levels and 
lymph node metastasis (Sundlisaeter, Dicko et al. 2007).  
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3.2.2 Prox-1 
Prox-1 is a homeobox transcription factor. In several tissues, such as liver and pancreas 
Prox-1 is an important regulator of cell differentiation and oncogenesis. As mentioned 
before, the expression of Prox-1 is also essential for the lymphatic development and 
downstream signalling results in up-regulation of e.g. LYVE-1, VEGFR-3 and other 
lymphatic endothelial specific molecules.  
Prox-1 expression is revealed to be significantly increased in CRC (Parr and Jiang 2003). The 
precise function must be further clarified. 
3.2.3 Podoplanin 
Podoplanin is a 38-kDa single transmembrane mucin-type glycoprotein and in normal 
human tissue it is expressed e.g. by osteoblasts, kidney podocytes and lung alveolar type 1 
cells (Cueni, Hegyi et al. 2010). Due to its expression on lymphatic endothelial cells but not 
on blood vessels it is used as a specific marker for LECs.  
Under normal conditions podoplanin is involved in the regulation of the shape of 
podocytes, LV formation and it is supposed to be involved in platelet aggregation. The 
expression of podoplanin is regulated by Prox-1 (Raica, Cimpean et al. 2008). 
Since podoplanin expression is up-regulated in a number of different carcinomas such as 
vascular tumours, mesotheliomas and in squamous cell carcinomas, it is suggested that 
podoplanin is involved in carcinogenesis (Yamanashi et al. 2009). In addition, recent data in 
numerous of squamous cell carcinomas indicated that podoplanin is expressed at the 
invasive edge (Wicki and Christofori 2007). Podoplanin might favour tumour invasion via  
 
 
Fig. 6. Immunohistochemical detection of podoplanin positive lymphatic vessels, filled with 
cancer cells, in CRC. 
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its ability to remodel the cytoskeleton (Cueni, Hegyi et al. 2010). About the role of 
podoplanin in CRC little information is available. Lu et al. revealed, that the expression of 
podoplanin was significantly higher in patients with lymph node metastasis than in those 
without metastasis (Lu, Yang et al. 2007). While the group of Yamanashi suggested, that a 
positive podoplanin expression in stromal fibroblasts in patients with CRC is a significant 
indicator for a good prognosis (Yamanashi, Nakanishi et al. 2009). Figure 6 shows a 
lymphatic vessel stained with podoplanin and filled with a tumour cell embolus   
3.2.4 LYVE-1 
LYVE-1 is a homologue of the blood vascular endothelium specific hyaluronan receptor CD 
44 and accordingly a member of the Link protein family. CD44 is directly involved in 
leucocyte migration (Jackson 2009). Lyve-1 is one of the most specific and widely used 
lymphatic endothelial markers (Hirakawa 2011). During embryogenesis it is expressed in 
cardinal vein endothelium and is involved in vascular development. On LECs LYVE-1 is 
expressed on the luminal and ab-luminal surface and functional studies demonstrated that it 
is able to act as an endocytic receptor for hyaluronan (Al-Rawi, Mansel et al. 2005). 
Hyaluronan is an important component of the extracellular matrix with versatile features for 
the interaction of cells during embryogenesis and woundhealing. LYVE-1 is also expressed 
by sinusoidal endothelial cells in the liver, spleen and by macrophages. Its exact function 
remains unclear.  
3.2.5 Hepatocyte growth factor  
Hepatocyte growth factor (HGF) belongs to the plasminogen-prothrombin gene 
superfamily. C-Met, the HGF receptor is a tyrosine kinase receptor and composed of an 
extracellular α chain and a transmembrane β chain. HGF activity has been reported to play a 
role in embryogenesis and organogenesis (Lee et al. 2010).  
HGF is also supposed to be a potent lymphangiogenic factor. In this context HGF is 
involved in proliferation, migration, and tube formation of LECs (Cueni and Detmar 2006). 
The HGF downstream pathway is mediated via ERK 1/2 and PI3K and resulted in cell 
growth and inhibition of apoptosis. In many solid tumours c-Met is differently expressed. 
Novel investigations in CRC revealed an over expression of HGF and c-Met, and increased 
expression is associated with advanced disease stage and poor outcome (Kammula, Kuntz et 
al. 2007; Organ, Tong et al. 2011). 
3.2.6 Fibroblast growth factors 
The fibroblast growth factor family consists of structurally related ligands and four 
receptors (FGFR-1, FGFR-2, FGFR-3, FGFR-4), which consist the classical receptor tyrosine 
kinase structure: a extracellular Immunglobulin-like domain, a transmembrane domain and 
a intracellular tyrosine kinase domain, which initiated downstream signalling. The FGFs are 
involved in multi biological processes such as proliferation, survival, migration and 
differentiation during organogenesis and in adult life. A deregulation in human cancer has 
been found e.g. in breast cancer, prostate cancer, bladder cancer and cancer of the lung 
(Wesche, Haglund et al. 2011). FGF-2 is able to induce angiogenesis and lymphangiogenesis. 
Recent studies suggest that in LECs lymphangiogenic signalling is mediated through the 
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downstream signalling results in up-regulation of e.g. LYVE-1, VEGFR-3 and other 
lymphatic endothelial specific molecules.  
Prox-1 expression is revealed to be significantly increased in CRC (Parr and Jiang 2003). The 
precise function must be further clarified. 
3.2.3 Podoplanin 
Podoplanin is a 38-kDa single transmembrane mucin-type glycoprotein and in normal 
human tissue it is expressed e.g. by osteoblasts, kidney podocytes and lung alveolar type 1 
cells (Cueni, Hegyi et al. 2010). Due to its expression on lymphatic endothelial cells but not 
on blood vessels it is used as a specific marker for LECs.  
Under normal conditions podoplanin is involved in the regulation of the shape of 
podocytes, LV formation and it is supposed to be involved in platelet aggregation. The 
expression of podoplanin is regulated by Prox-1 (Raica, Cimpean et al. 2008). 
Since podoplanin expression is up-regulated in a number of different carcinomas such as 
vascular tumours, mesotheliomas and in squamous cell carcinomas, it is suggested that 
podoplanin is involved in carcinogenesis (Yamanashi et al. 2009). In addition, recent data in 
numerous of squamous cell carcinomas indicated that podoplanin is expressed at the 
invasive edge (Wicki and Christofori 2007). Podoplanin might favour tumour invasion via  
 
 
Fig. 6. Immunohistochemical detection of podoplanin positive lymphatic vessels, filled with 
cancer cells, in CRC. 
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its ability to remodel the cytoskeleton (Cueni, Hegyi et al. 2010). About the role of 
podoplanin in CRC little information is available. Lu et al. revealed, that the expression of 
podoplanin was significantly higher in patients with lymph node metastasis than in those 
without metastasis (Lu, Yang et al. 2007). While the group of Yamanashi suggested, that a 
positive podoplanin expression in stromal fibroblasts in patients with CRC is a significant 
indicator for a good prognosis (Yamanashi, Nakanishi et al. 2009). Figure 6 shows a 
lymphatic vessel stained with podoplanin and filled with a tumour cell embolus   
3.2.4 LYVE-1 
LYVE-1 is a homologue of the blood vascular endothelium specific hyaluronan receptor CD 
44 and accordingly a member of the Link protein family. CD44 is directly involved in 
leucocyte migration (Jackson 2009). Lyve-1 is one of the most specific and widely used 
lymphatic endothelial markers (Hirakawa 2011). During embryogenesis it is expressed in 
cardinal vein endothelium and is involved in vascular development. On LECs LYVE-1 is 
expressed on the luminal and ab-luminal surface and functional studies demonstrated that it 
is able to act as an endocytic receptor for hyaluronan (Al-Rawi, Mansel et al. 2005). 
Hyaluronan is an important component of the extracellular matrix with versatile features for 
the interaction of cells during embryogenesis and woundhealing. LYVE-1 is also expressed 
by sinusoidal endothelial cells in the liver, spleen and by macrophages. Its exact function 
remains unclear.  
3.2.5 Hepatocyte growth factor  
Hepatocyte growth factor (HGF) belongs to the plasminogen-prothrombin gene 
superfamily. C-Met, the HGF receptor is a tyrosine kinase receptor and composed of an 
extracellular α chain and a transmembrane β chain. HGF activity has been reported to play a 
role in embryogenesis and organogenesis (Lee et al. 2010).  
HGF is also supposed to be a potent lymphangiogenic factor. In this context HGF is 
involved in proliferation, migration, and tube formation of LECs (Cueni and Detmar 2006). 
The HGF downstream pathway is mediated via ERK 1/2 and PI3K and resulted in cell 
growth and inhibition of apoptosis. In many solid tumours c-Met is differently expressed. 
Novel investigations in CRC revealed an over expression of HGF and c-Met, and increased 
expression is associated with advanced disease stage and poor outcome (Kammula, Kuntz et 
al. 2007; Organ, Tong et al. 2011). 
3.2.6 Fibroblast growth factors 
The fibroblast growth factor family consists of structurally related ligands and four 
receptors (FGFR-1, FGFR-2, FGFR-3, FGFR-4), which consist the classical receptor tyrosine 
kinase structure: a extracellular Immunglobulin-like domain, a transmembrane domain and 
a intracellular tyrosine kinase domain, which initiated downstream signalling. The FGFs are 
involved in multi biological processes such as proliferation, survival, migration and 
differentiation during organogenesis and in adult life. A deregulation in human cancer has 
been found e.g. in breast cancer, prostate cancer, bladder cancer and cancer of the lung 
(Wesche, Haglund et al. 2011). FGF-2 is able to induce angiogenesis and lymphangiogenesis. 
Recent studies suggest that in LECs lymphangiogenic signalling is mediated through the 
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Akt-mammalian target of rapamycin (mTOR)-p70S6 kinase pathway (Matsuo, Yamada et al. 
2007). 
3.2.7 Angiopoietins 
Ang-1 and Ang-2 are the more intensive analysed members of the angiopoietin family.  Both 
bind to the Tie-2 receptor, which is expressed on the surface of LECs. The expression of 
Ang-1 and Ang-2 differs in human tissue. While Ang-1 is widely expressed in adult tissues, 
where it promotes vessel maturation and stabilization, Ang-2 expression occurs during 
vascular remodelling and via acting in conjugation with VEGF-A Ang-2 is supposed to be a 
stimulator of angiogenesis (Makinen, Norrmen et al. 2007).  
About the role and function of the angiopoietins Ang-1/Ang-2 in lymphangiogenesis little 
information is known. Ang-1 is involved in LEC proliferation and lymphatic vessel sprouting. 
From analysis of pancreatic cancer, we know that Ang-2 drives lymphatic metastasis via a Tie-
2 dependent manner and in a Tie-2 independent manner through enhancing the capacity of 
tumour cells for adherence to endothelial cells (Schulz, Fischer et al. 2011). 
3.2.8 Insulin like growth factors 
The insulin like growth factor system consists of the ligands insulin, insulin like growth 
factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) and acts via four receptors: the 
insulin receptor (IR), the type I IGF receptor, the type II IGF receptor and the hybrid IR/IGF-
1R receptor. The IGF-IR receptor consists of two α and two β chains. IGF-IR ligand binding 
induces multiple downstream signal transduction pathways such as the MAPK, ERK and 
PI3-K pathway. It is well known, that IGF family members are frequently expressed in many 
solid tumours like CRC and breast cancer (Werner, Roberts et al. 1996; Reinmuth, Liu et al. 
2002). In addition IGF-1R contributes to cancer development by regulation cell proliferation, 
differentiation and by preventing apoptosis. Other researchers investigated that IGF-1 and 
IGF-2 induce lymphangiogenesis (Bjorndahl, Cao et al. 2005) in a VEGFR-3 independent 
signalling pathway. 
3.2.9 Chemokines 
The chemokines, are a super family of chemotactic cytokines. They are key regulators of 
leukocyte, endothelial and epithelial cell migration and play a functional role in 
embryogenesis. Chemokines are low molecular weight proteins with cysteins at well 
conserved domains. According to the position of the cystein residue 4 chemokine 
subfamilies (CXC, CXC3, CC, C) have been identified so far. The chemokine CXCL12 is 
supposed to be involved in lymphogenesis via its receptor CXCR4 and CCL21 mediates 
homing of lymphocytes and migration of dendritic cells into lymphatic vessel.  
Nonetheless, it has been reported that chemokines and their receptors are expressed in a 
variety of human cancers such as melanoma, breast cancer, gastric cancer or prostate cancer 
(Hoon, Kitago et al. 2006). Recent findings about the direct role of chemokines in LNM in 
CRC, suggested an involvement of CXCR3, CXCL12/CXCR4 and CCL21/CCR7 (Kawada 
and Taketo 2011; Singh et al. 2011; Raman et al. 2010). In addition CXCL12 is supposed to be 
a prognostic factor for local recurrence and liver metastasis and CXCR4 expression was 
significantly positive in CRCs with high tumour stage and LNM. 
Taken together, Table 2 summarizes factors which are involved in lymphangiogenesis. 
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Factor Function during lymphangiogenesis 
VEGF-C/VEGF-D via VEGFR-3 Growth factor/receptor:  proliferation, migration, survival 
VEGF-A via VEGFR-2 Activating VEGF-C/VEGF-D/VEGFR-3 signaling pathway 
Prox-1 Transcription factor: LEC identity 
Podoplanin Cell motility 
LYVE-1 Hyaluronan receptor 
HGF Growth factor:  proliferation, migration, tube formation of LECs 
FGF LEC migration, proliferation 
Ang-1/2 Growth factor 
IGF Growth factor: proliferation,  differentiation and preventing apoptosis 
Chemokines CCL21 Lymphocytes homing 
Table 2. Molecules which are involved in lymphangiogenesis 
3.3 Lymphatic vessel density and tumour progression 
Since, microvessel density (MVD), a parameter for the ability of angiogenesis in tumours, is 
a prognostic marker in numerous cancers, the quantification of lymphatic vessel density 
(LVD) is of growing interest. Screening the literature, the prognostic significance of LVD in 
tumours remains controversial (Royston and Jackson 2009). Some studies reported that high 
LVD was associated with lymph node metastasis and patient outcome, while others could 
not confirm these findings (Gao, Knutsen et al. 2009). Furthermore, there is a debate about 
the dominant role of intratumoural vs. peitumoural lymphatic vessels.  By some researchers  
it has been demonstrated that LVD in the intratumoural areas but not in peritumoural areas 
were associated with lymph node metastasis and poor outcome. Others reported that LVD 
in peritumoural areas was correlated to advanced tumour stage (Longatto-Filho, Pinheiro et 
al. 2008). In patients with colorectal cancer, a significant correlation between the number of 
intratumoural and peritumoural lymphatic vessels with the occurrence of lymph node 
metastases was evaluated (Matsumoto, Nakayama et al. 2007). These findings again 
underline the hypothesis of active lymphatic vessel formation within the tumour. These new 
lymphatic vessels may facilitate the drainage of tumour cells to regional lymph nodes. 
3.4 Future perspectives 
Further characterization of the exact molecular pathways which are involved in lymphatic 
metastasis is needed and essential for the development of new forecast estimates and 
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Akt-mammalian target of rapamycin (mTOR)-p70S6 kinase pathway (Matsuo, Yamada et al. 
2007). 
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Ang-1 and Ang-2 are the more intensive analysed members of the angiopoietin family.  Both 
bind to the Tie-2 receptor, which is expressed on the surface of LECs. The expression of 
Ang-1 and Ang-2 differs in human tissue. While Ang-1 is widely expressed in adult tissues, 
where it promotes vessel maturation and stabilization, Ang-2 expression occurs during 
vascular remodelling and via acting in conjugation with VEGF-A Ang-2 is supposed to be a 
stimulator of angiogenesis (Makinen, Norrmen et al. 2007).  
About the role and function of the angiopoietins Ang-1/Ang-2 in lymphangiogenesis little 
information is known. Ang-1 is involved in LEC proliferation and lymphatic vessel sprouting. 
From analysis of pancreatic cancer, we know that Ang-2 drives lymphatic metastasis via a Tie-
2 dependent manner and in a Tie-2 independent manner through enhancing the capacity of 
tumour cells for adherence to endothelial cells (Schulz, Fischer et al. 2011). 
3.2.8 Insulin like growth factors 
The insulin like growth factor system consists of the ligands insulin, insulin like growth 
factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) and acts via four receptors: the 
insulin receptor (IR), the type I IGF receptor, the type II IGF receptor and the hybrid IR/IGF-
1R receptor. The IGF-IR receptor consists of two α and two β chains. IGF-IR ligand binding 
induces multiple downstream signal transduction pathways such as the MAPK, ERK and 
PI3-K pathway. It is well known, that IGF family members are frequently expressed in many 
solid tumours like CRC and breast cancer (Werner, Roberts et al. 1996; Reinmuth, Liu et al. 
2002). In addition IGF-1R contributes to cancer development by regulation cell proliferation, 
differentiation and by preventing apoptosis. Other researchers investigated that IGF-1 and 
IGF-2 induce lymphangiogenesis (Bjorndahl, Cao et al. 2005) in a VEGFR-3 independent 
signalling pathway. 
3.2.9 Chemokines 
The chemokines, are a super family of chemotactic cytokines. They are key regulators of 
leukocyte, endothelial and epithelial cell migration and play a functional role in 
embryogenesis. Chemokines are low molecular weight proteins with cysteins at well 
conserved domains. According to the position of the cystein residue 4 chemokine 
subfamilies (CXC, CXC3, CC, C) have been identified so far. The chemokine CXCL12 is 
supposed to be involved in lymphogenesis via its receptor CXCR4 and CCL21 mediates 
homing of lymphocytes and migration of dendritic cells into lymphatic vessel.  
Nonetheless, it has been reported that chemokines and their receptors are expressed in a 
variety of human cancers such as melanoma, breast cancer, gastric cancer or prostate cancer 
(Hoon, Kitago et al. 2006). Recent findings about the direct role of chemokines in LNM in 
CRC, suggested an involvement of CXCR3, CXCL12/CXCR4 and CCL21/CCR7 (Kawada 
and Taketo 2011; Singh et al. 2011; Raman et al. 2010). In addition CXCL12 is supposed to be 
a prognostic factor for local recurrence and liver metastasis and CXCR4 expression was 
significantly positive in CRCs with high tumour stage and LNM. 
Taken together, Table 2 summarizes factors which are involved in lymphangiogenesis. 
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Factor Function during lymphangiogenesis 
VEGF-C/VEGF-D via VEGFR-3 Growth factor/receptor:  proliferation, migration, survival 
VEGF-A via VEGFR-2 Activating VEGF-C/VEGF-D/VEGFR-3 signaling pathway 
Prox-1 Transcription factor: LEC identity 
Podoplanin Cell motility 
LYVE-1 Hyaluronan receptor 
HGF Growth factor:  proliferation, migration, tube formation of LECs 
FGF LEC migration, proliferation 
Ang-1/2 Growth factor 
IGF Growth factor: proliferation,  differentiation and preventing apoptosis 
Chemokines CCL21 Lymphocytes homing 
Table 2. Molecules which are involved in lymphangiogenesis 
3.3 Lymphatic vessel density and tumour progression 
Since, microvessel density (MVD), a parameter for the ability of angiogenesis in tumours, is 
a prognostic marker in numerous cancers, the quantification of lymphatic vessel density 
(LVD) is of growing interest. Screening the literature, the prognostic significance of LVD in 
tumours remains controversial (Royston and Jackson 2009). Some studies reported that high 
LVD was associated with lymph node metastasis and patient outcome, while others could 
not confirm these findings (Gao, Knutsen et al. 2009). Furthermore, there is a debate about 
the dominant role of intratumoural vs. peitumoural lymphatic vessels.  By some researchers  
it has been demonstrated that LVD in the intratumoural areas but not in peritumoural areas 
were associated with lymph node metastasis and poor outcome. Others reported that LVD 
in peritumoural areas was correlated to advanced tumour stage (Longatto-Filho, Pinheiro et 
al. 2008). In patients with colorectal cancer, a significant correlation between the number of 
intratumoural and peritumoural lymphatic vessels with the occurrence of lymph node 
metastases was evaluated (Matsumoto, Nakayama et al. 2007). These findings again 
underline the hypothesis of active lymphatic vessel formation within the tumour. These new 
lymphatic vessels may facilitate the drainage of tumour cells to regional lymph nodes. 
3.4 Future perspectives 
Further characterization of the exact molecular pathways which are involved in lymphatic 
metastasis is needed and essential for the development of new forecast estimates and 
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individually oriented therapies. Gene expression profiling by microarray technique, which 
allows the investigation of thousands of differentially expressed genes, provide therefore a 
promising tool to further clarify the molecular signature for lymphatic metastasis in CRC. 
These signatures can provide new players which are responsible for lymphatic metastasis or 
identify patients with a high risk for the development of lymph node metastases. New 
treatment targets could be evaluated and high risk patients can be selected for individual 
treatment regiments. (Croner, Peters et al. 2005; Croner, Fortsch et al. 2008; Croner, 
Schellerer et al. 2010).  
4. Conclusion  
Metastasis via tumour cell invasion into lymphatic vessels and lymph nodes is a common 
feature of various carcinomas. Our knowledge of the mechanisms controlling lymphatic 
metastasis has increased significantly in the last decades since the identification of LEC 
specific markers such as LYVE-1, podoplanin and Prox-1. The visualisation of the lymphatic 
system led to a new understanding of tumour activities involved in lymphatic vessel 
differentiation and growth. Take together, lymphangiogenesis is a complex multi step 
process, which is regulated by numerous molecular players and additional studies are 
needed to devise new and more efficient strategies against CRC.   
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system led to a new understanding of tumour activities involved in lymphatic vessel 
differentiation and growth. Take together, lymphangiogenesis is a complex multi step 
process, which is regulated by numerous molecular players and additional studies are 
needed to devise new and more efficient strategies against CRC.   
5. References  
Achen, M. G. and S. A. Stacker (2008). "Molecular control of lymphatic metastasis." Ann N Y 
Acad Sci 1131: 225-234. 
Al-Rawi, M. A., R. E. Mansel, et al. (2005). "Lymphangiogenesis and its role in cancer." 
Histol Histopathol 20(1): 283-298. 
Bjorndahl, M., R. Cao, et al. (2005). "Insulin-like growth factors 1 and 2 induce 
lymphangiogenesis in vivo." Proc Natl Acad Sci U S A 102(43): 15593-15598. 
Butler, M. G., S. Isogai, et al. (2009). "Lymphatic development." Birth Defects Res C Embryo 
Today 87(3): 222-231. 
Croner, R. S., T. Fortsch, et al. (2008). "Molecular signature for lymphatic metastasis in 
colorectal carcinomas." Ann Surg 247(5): 803-810. 
Croner, R. S., A. Peters, et al. (2005). "Microarray versus conventional prediction of lymph 
node metastasis in colorectal carcinoma." Cancer 104(2): 395-404. 
Croner, R. S., V. Schellerer, et al. (2010). "One step nucleic acid amplification (OSNA) - a new 
method for lymph node staging in colorectal carcinomas." J Transl Med 8: 83. 
Cueni, L. N. and M. Detmar (2006). "New insights into the molecular control of the 
lymphatic vascular system and its role in disease." J Invest Dermatol 126(10): 2167-
2177. 
Cueni, L. N., I. Hegyi, et al. (2010). "Tumor lymphangiogenesis and metastasis to lymph 
nodes induced by cancer cell expression of podoplanin." Am J Pathol 177(2): 1004-
1016. 
Gao, J., A. Knutsen, et al. (2009). "Clinical and biological significance of angiogenesis and 
lymphangiogenesis in colorectal cancer." Dig Liver Dis 41(2): 116-122. 
 
Molecular Mechanisms of Lymphatic Metastasis 297 
Hirakawa, S. (2011). "Regulation of pathological lymphangiogenesis requires factors distinct 
from those governing physiological lymphangiogenesis." J Dermatol Sci 61(2): 85-
93. 
Hoon, D. S., M. Kitago, et al. (2006). "Molecular mechanisms of metastasis." Cancer 
Metastasis Rev 25(2): 203-220. 
Jackson, D. G. (2009). "Immunological functions of hyaluronan and its receptors in the 
lymphatics." Immunol Rev 230(1): 216-231. 
Ji, R. C. (2006). "Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix." 
Lymphat Res Biol 4(2): 83-100. 
Ji, R. C. (2006). "Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New 
insights into intratumoral and peritumoral lymphatics." Cancer Metastasis Rev 
25(4): 677-694. 
Kammula, U. S., E. J. Kuntz, et al. (2007). "Molecular co-expression of the c-Met oncogene 
and hepatocyte growth factor in primary colon cancer predicts tumor stage and 
clinical outcome." Cancer Lett 248(2): 219-228. 
Lin, M., H. Z. Lin, et al. (2011). "Vascular endothelial growth factor-A and -C: expression 
and correlations with lymphatic metastasis and prognosis in colorectal cancer." 
Med Oncol 28(1): 151-158. 
Lohela, M., M. Bry, et al. (2009). "VEGFs and receptors involved in angiogenesis versus 
lymphangiogenesis." Curr Opin Cell Biol 21(2): 154-165. 
Longatto-Filho, A., C. Pinheiro, et al. (2008). "Peritumoural, but not intratumoural, 
lymphatic vessel density and invasion correlate with colorectal carcinoma poor-
outcome markers." Virchows Arch 452(2): 133-138. 
Lu, Y., Q. Yang, et al. (2007). "Expression analysis of lymphangiogenic factors in human 
colorectal cancer with quantitative RT-PCR." Cancer Invest 25(6): 393-396. 
Makinen, T., C. Norrmen, et al. (2007). "Molecular mechanisms of lymphatic vascular 
development." Cell Mol Life Sci 64(15): 1915-1929. 
Matsumoto, K., Y. Nakayama, et al. (2007). "Lymphatic microvessel density is an 
independent prognostic factor in colorectal cancer." Dis Colon Rectum 50(3): 308-
314. 
Matsuo, M., S. Yamada, et al. (2007). "Tumour-derived fibroblast growth factor-2 exerts 
lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat 
lymphatic endothelial cells." Eur J Cancer 43(11): 1748-1754. 
Nagahashi, M., S. Ramachandran, et al. (2010). "Lymphangiogenesis: a new player in cancer 
progression." World J Gastroenterol 16(32): 4003-4012. 
Oliver, G. and M. Detmar (2002). "The rediscovery of the lymphatic system: old and new 
insights into the development and biological function of the lymphatic 
vasculature." Genes Dev 16(7): 773-783. 
Omachi, T., Y. Kawai, et al. (2007). "Immunohistochemical demonstration of proliferating 
lymphatic vessels in colorectal carcinoma and its clinicopathological significance." 
Cancer Lett 246(1-2): 167-172. 
Organ, S. L., J. Tong, et al. (2011). "Quantitative Phospho-Proteomic Profiling of Hepatocyte 
Growth Factor (HGF)-MET Signaling in Colorectal Cancer." J Proteome Res 10(7): 
3200-3211. 
Parr, C. and W. G. Jiang (2003). "Quantitative analysis of lymphangiogenic markers in 
human colorectal cancer." Int J Oncol 23(2): 533-539. 
 
Colorectal Cancer Biology – From Genes to Tumor 298 
Raica, M., A. M. Cimpean, et al. (2008). "The role of podoplanin in tumor progression and 
metastasis." Anticancer Res 28(5B): 2997-3006. 
Reinmuth, N., W. Liu, et al. (2002). "Blockade of insulin-like growth factor I receptor 
function inhibits growth and angiogenesis of colon cancer." Clin Cancer Res 8(10): 
3259-3269. 
Royston, D. and D. G. Jackson (2009). "Mechanisms of lymphatic metastasis in human 
colorectal adenocarcinoma." J Pathol 217(5): 608-619. 
Saharinen, P., T. Tammela, et al. (2004). "Lymphatic vasculature: development, molecular 
regulation and role in tumor metastasis and inflammation." Trends Immunol 25(7): 
387-395. 
Schmiegel, W., A. Reinacher-Schick, et al. (2008). "[Update S3-guideline "colorectal cancer" 
2008]." Z Gastroenterol 46(8): 799-840. 
Schulte-Merker, S., A. Sabine, et al. (2011). "Lymphatic vascular morphogenesis in 
development, physiology, and disease." J Cell Biol 193(4): 607-618. 
Schulz, P., C. Fischer, et al. (2011). "Angiopoietin-2 drives lymphatic metastasis of pancreatic 
cancer." FASEB J. 
Shayan, R., M. G. Achen, et al. (2006). "Lymphatic vessels in cancer metastasis: bridging the 
gaps." Carcinogenesis 27(9): 1729-1738. 
Shields, J. D., M. S. Emmett, et al. (2007). "Chemokine-mediated migration of melanoma cells 
towards lymphatics--a mechanism contributing to metastasis." Oncogene 26(21): 
2997-3005. 
Sundlisaeter, E., A. Dicko, et al. (2007). "Lymphangiogenesis in colorectal cancer--prognostic 
and therapeutic aspects." Int J Cancer 121(7): 1401-1409. 
Tammela, T., T. V. Petrova, et al. (2005). "Molecular lymphangiogenesis: new players." 
Trends Cell Biol 15(8): 434-441. 
Werner, H., C. T. Roberts, Jr., et al. (1996). "Regulation of insulin-like growth factor I 
receptor gene expression by the Wilms' tumor suppressor WT1." J Mol Neurosci 
7(2): 111-123. 
Wesche, J., K. Haglund, et al. (2011). "Fibroblast growth factors and their receptors in 
cancer." Biochem J 437(2): 199-213. 
Wicki, A. and G. Christofori (2007). "The potential role of podoplanin in tumour invasion." 
Br J Cancer 96(1): 1-5. 
Wiig, H., D. Keskin, et al. (2010). "Interaction between the extracellular matrix and 
lymphatics: consequences for lymphangiogenesis and lymphatic function." Matrix 
Biol 29(8): 645-656. 
Wissmann, C. and M. Detmar (2006). "Pathways targeting tumor lymphangiogenesis." Clin 
Cancer Res 12(23): 6865-6868. 
Witte, M. H., K. Jones, et al. (2006). "Structure function relationships in the lymphatic system 
and implications for cancer biology." Cancer Metastasis Rev 25(2): 159-184. 
Yamanashi, T., Y. Nakanishi, et al. (2009). "Podoplanin expression identified in stromal 
fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma." 




Colorectal Cancer Biology – From Genes to Tumor 298 
Raica, M., A. M. Cimpean, et al. (2008). "The role of podoplanin in tumor progression and 
metastasis." Anticancer Res 28(5B): 2997-3006. 
Reinmuth, N., W. Liu, et al. (2002). "Blockade of insulin-like growth factor I receptor 
function inhibits growth and angiogenesis of colon cancer." Clin Cancer Res 8(10): 
3259-3269. 
Royston, D. and D. G. Jackson (2009). "Mechanisms of lymphatic metastasis in human 
colorectal adenocarcinoma." J Pathol 217(5): 608-619. 
Saharinen, P., T. Tammela, et al. (2004). "Lymphatic vasculature: development, molecular 
regulation and role in tumor metastasis and inflammation." Trends Immunol 25(7): 
387-395. 
Schmiegel, W., A. Reinacher-Schick, et al. (2008). "[Update S3-guideline "colorectal cancer" 
2008]." Z Gastroenterol 46(8): 799-840. 
Schulte-Merker, S., A. Sabine, et al. (2011). "Lymphatic vascular morphogenesis in 
development, physiology, and disease." J Cell Biol 193(4): 607-618. 
Schulz, P., C. Fischer, et al. (2011). "Angiopoietin-2 drives lymphatic metastasis of pancreatic 
cancer." FASEB J. 
Shayan, R., M. G. Achen, et al. (2006). "Lymphatic vessels in cancer metastasis: bridging the 
gaps." Carcinogenesis 27(9): 1729-1738. 
Shields, J. D., M. S. Emmett, et al. (2007). "Chemokine-mediated migration of melanoma cells 
towards lymphatics--a mechanism contributing to metastasis." Oncogene 26(21): 
2997-3005. 
Sundlisaeter, E., A. Dicko, et al. (2007). "Lymphangiogenesis in colorectal cancer--prognostic 
and therapeutic aspects." Int J Cancer 121(7): 1401-1409. 
Tammela, T., T. V. Petrova, et al. (2005). "Molecular lymphangiogenesis: new players." 
Trends Cell Biol 15(8): 434-441. 
Werner, H., C. T. Roberts, Jr., et al. (1996). "Regulation of insulin-like growth factor I 
receptor gene expression by the Wilms' tumor suppressor WT1." J Mol Neurosci 
7(2): 111-123. 
Wesche, J., K. Haglund, et al. (2011). "Fibroblast growth factors and their receptors in 
cancer." Biochem J 437(2): 199-213. 
Wicki, A. and G. Christofori (2007). "The potential role of podoplanin in tumour invasion." 
Br J Cancer 96(1): 1-5. 
Wiig, H., D. Keskin, et al. (2010). "Interaction between the extracellular matrix and 
lymphatics: consequences for lymphangiogenesis and lymphatic function." Matrix 
Biol 29(8): 645-656. 
Wissmann, C. and M. Detmar (2006). "Pathways targeting tumor lymphangiogenesis." Clin 
Cancer Res 12(23): 6865-6868. 
Witte, M. H., K. Jones, et al. (2006). "Structure function relationships in the lymphatic system 
and implications for cancer biology." Cancer Metastasis Rev 25(2): 159-184. 
Yamanashi, T., Y. Nakanishi, et al. (2009). "Podoplanin expression identified in stromal 
fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma." 




Modulation of Tumor Angiogenesis by a Host 
Anti-Tumor Response in Colorectal Cancer 
N. Britzen-Laurent1, V.S. Schellerer2, R.S. Croner2,  
M. Stürzl1 and E. Naschberger1 
1Division of Molecular and Experimental Surgery, Department of Surgery,  
University Medical Center Erlangen, Erlangen, 
2Department of Surgery, University Medical Center Erlangen, Erlangen, 
Germany 
1. Introduction 
Colorectal carcinoma (CRC) is the second most frequently occurring cancer in industrialized 
countries, in both men and women. The cumulative lifetime risk of developing colorectal 
carcinoma is about 6%, and the cancer-related five year survival rate is 62% (Smith et al., 
2002). Malignant transformation of CRC occurs in a multistep process via three different 
pathways: the chromosomal instability pathway, the microsatellite instability pathway 
(Vogelstein et al., 1988) and the methylation pathway (Jass, 2002). Moreover, putative 
tumor-initiating cells with increased malignancy were isolated from CRC (O'Brien et al., 
2007; Ricci-Vitiani et al., 2007). These cells exhibited stem cell-like characteristics; however, 
their role in CRC pathogenesis is still controversial (Shmelkov et al., 2008). Tumor 
development and metastasis require the presence of a newly formed vasculature. Tumor 
cells can directly promote angiogenesis but the tumor microenvironment plays also a crucial 
role in this process. The tumor microenvironment consists of a variety of conjunctive tissue 
components and cells, as well as infiltrating immune cells. It is inflammatory and undergoes 
constant remodelling. Immune cells are not only recruited in order to eliminate the tumor, 
they can also be attracted by tumor cells in order to support a tumor-promoting 
inflammation. In CRC, the type of immune cells infiltrating the tumor has been shown to 
influence tumor growth and patient survival (Galon et al., 2007; Tosolini et al., 2011). In 
addition, immune cells have been shown to exert antagonistic effects on tumor angiogenesis. 
In this chapter, we focus on the modulation of tumor angiogenesis by tumor infiltrating 
immune cells and on its implications in terms of diagnosis and prognosis in CRC.  
2. Tumor angiogenesis and tumor vessels 
Tumor growth beyond two to three millimeters in diameter and metastasis requires 
angiogenesis, the formation of new blood vessels. Angiogenesis plays a crucial role in the 
development and progression of CRC, and this has been convincingly documented in the 
literature. It has been shown that microvessel density is increased in primary tumors 
compared to normal mucosa or adenoma tissues (Bossi et al., 1995), and this is a strong 
 14 
Modulation of Tumor Angiogenesis by a Host 
Anti-Tumor Response in Colorectal Cancer 
N. Britzen-Laurent1, V.S. Schellerer2, R.S. Croner2,  
M. Stürzl1 and E. Naschberger1 
1Division of Molecular and Experimental Surgery, Department of Surgery,  
University Medical Center Erlangen, Erlangen, 
2Department of Surgery, University Medical Center Erlangen, Erlangen, 
Germany 
1. Introduction 
Colorectal carcinoma (CRC) is the second most frequently occurring cancer in industrialized 
countries, in both men and women. The cumulative lifetime risk of developing colorectal 
carcinoma is about 6%, and the cancer-related five year survival rate is 62% (Smith et al., 
2002). Malignant transformation of CRC occurs in a multistep process via three different 
pathways: the chromosomal instability pathway, the microsatellite instability pathway 
(Vogelstein et al., 1988) and the methylation pathway (Jass, 2002). Moreover, putative 
tumor-initiating cells with increased malignancy were isolated from CRC (O'Brien et al., 
2007; Ricci-Vitiani et al., 2007). These cells exhibited stem cell-like characteristics; however, 
their role in CRC pathogenesis is still controversial (Shmelkov et al., 2008). Tumor 
development and metastasis require the presence of a newly formed vasculature. Tumor 
cells can directly promote angiogenesis but the tumor microenvironment plays also a crucial 
role in this process. The tumor microenvironment consists of a variety of conjunctive tissue 
components and cells, as well as infiltrating immune cells. It is inflammatory and undergoes 
constant remodelling. Immune cells are not only recruited in order to eliminate the tumor, 
they can also be attracted by tumor cells in order to support a tumor-promoting 
inflammation. In CRC, the type of immune cells infiltrating the tumor has been shown to 
influence tumor growth and patient survival (Galon et al., 2007; Tosolini et al., 2011). In 
addition, immune cells have been shown to exert antagonistic effects on tumor angiogenesis. 
In this chapter, we focus on the modulation of tumor angiogenesis by tumor infiltrating 
immune cells and on its implications in terms of diagnosis and prognosis in CRC.  
2. Tumor angiogenesis and tumor vessels 
Tumor growth beyond two to three millimeters in diameter and metastasis requires 
angiogenesis, the formation of new blood vessels. Angiogenesis plays a crucial role in the 
development and progression of CRC, and this has been convincingly documented in the 
literature. It has been shown that microvessel density is increased in primary tumors 
compared to normal mucosa or adenoma tissues (Bossi et al., 1995), and this is a strong 
 
Colorectal Cancer Biology – From Genes to Tumor 302 
independent predictor of poor outcome (Takebayashi et al., 1996). A high microvessel 
density is associated with a more than threefold increased relative risk of cancer-related 
death from CRC (Choi et al., 1998). Moreover, the expression of vascular endothelial growth 
factor (VEGF), a potent angiogenesis-promoting factor, is significantly increased in all stages 
of colorectal carcinoma (Kumar et al., 1998). The major sources of VEGF are either the tumor 
cells themselves or monocytes/macrophages recruited into the tumor tissue through 
paracrine signalling. Intratumor expression of VEGF was also found to increase the relative 
risk of cancer-related death from CRC by twofold (Kang et al., 1997; Ishigami et al., 1998; 
Kahlenberg et al., 2003).  
The recruitment and growth of tumor vessels is a critical adaption step that has to be 
achieved during the development of clinically relevant solid tumors such as the CRC. This 
process has been termed “angiogenic switch” (Folkman, 1995) and the “induction of 
angiogenesis” has been included in the eight hallmarks of cancer defined by Hanahan and 
Weinberg (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011). New vessels may arise 
through different ways in the organism under physiological and/or pathological conditions. 
During embryonic development angioblasts differentiate into endothelial cells in a process 
called vasculogenesis whereas new vessels in adults are generated through angiogenesis 
(Risau, 1997). The major driving molecules for angiogenic processes are VEGF, VEGF-C, 
angiopoietin-2, fibroblast growth factors and chemokines (Carmeliet & Jain, 2011). Active 
angiogenesis is achieved either by vessel sprouting, non-sprouting intussusception (splitting 
of existing vessels), vessel co-option (tumor cells hijack vasculature), vascular mimicry 
(tumor cells line vessels), luminal incorporation of bone marrow-derived endothelial 
progenitor cells or a recently described non-VEGF-dependent biomechanical mechanism 
(Risau, 1997; Kilarski et al., 2009; Carmeliet & Jain, 2011).  
The role of so called “tumor stem cells” in tumor angiogenesis is currently heavily 
discussed. Cancer stem cells might not only have an impact on the growth and assembly of 
the CRC tumor cells themselves (O'Brien et al., 2007; Ricci-Vitiani et al., 2007) but also on the 
formation of tumor vessels (Ricci-Vitiani et al., 2010; Wang et al., 2010). The two latter 
studies described for the first time the differentiation of putative cancer stem cells not only 
into functional tumor cells but also into tumor endothelial cells. However, these findings 
were demonstrated for the brain tumor glioblastoma. Of note, normal neuronal stem cells 
are able to differentiate into endothelial cells under physiological conditions, which 
questions whether these findings can be also applied to non-brain tumors such as colorectal 
carcinoma. 
Tumor vessels are structurally and functionally abnormal compared to vessels in healthy 
tissues (Carmeliet & Jain, 2000; Hida et al., 2008). In contrast to normal vessels, they show a 
deficient support provided by only few perivascular cells with loose connections to the 
endothelium and the vessels maintain an immature structure. The tumor vasculature is 
commonly disorganized and heterogenous, with excessive branching and shunts, reduced 
interendothelial cell contacts, reduced barrier function and uneven vessel lumen. This 
disturbs the blood flow in the tumors, leads to hypoxia and acidification as well as high 
fluid pressure concomitant with increased resistance to the application of systemic drugs 
[reviewed in (Carmeliet & Jain, 2000; Hida et al., 2008; Carmeliet & Jain, 2011)]. Tumor cells 
attempt to overcome this issue by the expression of more pro-angiogenic factors such as 
VEGF resulting in amplified formation of abnormal vessels. However, tumor hypoxia 
cannot be rescued by the formation of abnormal vessels (Leite de Oliveira et al., 2011). 
 
Modulation of Tumor Angiogenesis by a Host Anti-Tumor Response in Colorectal Cancer 303 
When anti-angiogenic treatment was initially developed, tumor endothelial cells (TECs) 
were thought to be similar in all tumor types and, in contrast to tumor cells, genetically 
stable. However, subsequent studies showed that TECs are different in tumors from 
different organs and are actually genetically instable. It has been suggested that this is due 
to the involvement of endothelial cells (ECs) from different vascular beds. In addition, 
tumor cells and TECs interact strongly with each other and with additional cells present in 
the stroma via paracrine and possibly also juxtacrine pathways. Importantly, these 
interactions might induce microenvironment-dependent abnormalities in TECs that could 
differentiate them from normal endothelial cells. Recently, studies in mice and humans 
showed that abnormalities observed in TECs are maintained over long periods in cell 
culture, and include chromosomal abnormalities (Streubel et al., 2004; Hida & Klagsbrun, 
2005; Akino et al., 2009), resistance to apoptosis (Bussolati et al., 2003), increased 
adhesiveness for tumor cells (Bussolati et al., 2003), drug resistance (Xiong et al., 2009), 
abnormal angiogenic capability (Ghosh et al., 2008; Xiong et al., 2009), and pronounced 
growth in the absence of serum (Bussolati et al., 2003).  
TECs have been isolated from numerous animal models and from a limited number of 
human tumors mentioned above (Bussolati et al., 2003; Streubel et al., 2004; Buckanovich et 
al., 2007; Xiong et al., 2009). Until recently, no viable, pure TEC cultures from human 
colorectal carcinomas were available, and the biological phenotype of these cells was not 
characterized at the functional level. We have developed the first protocol for the routine 
isolation of both CRC TECs and the corresponding ECs from normal colon tissue (NECs) by 
collagenase II-digestion followed by multiple CD31-MACS selections (Schellerer et al., 2007). 
It was demonstrated that the cells were of endothelial blood cell origin (CD31-, CD105-, VE-
cadherin-positive; E-selectin-, VCAM-1-, ICAM-1-positive after stimulation with 
inflammatory cytokines; capability to form capillaries in matrigel, take up acetylated LDL 
and bind ulex europaeus; CD45-, CD68-, CK-20-, podoplanin-negative). Moreover, the 
isolated TECs maintained differences from NECs during long-term culture for example by 
decreased von Willebrand factor (vWF) levels in the isolated tumor endothelial cells as well 
as in the original cancer tissue biopsies compared to the corresponding normal endothelial 
cells and normal colon biopsy (Schellerer et al., 2007). Meanwhile, we could show that the 
TEC isolated from CRC differ from each other also at the transcriptome and genome level 
(data unpublished). 
TEC-specific markers were isolated from CRC by serial analysis of gene expression after 
laser-microdissection of tumor vessels (St Croix et al., 2000). The identified genes were 
designated as tumor endothelial markers (TEMs) (St Croix et al., 2000; Nanda et al., 2004). 
However, out of the nine different TEMs initially described, five were not pursued in future 
studies and two were shown to be expressed by other cells rather than tumor endothelial 
cells (Lee et al., 2006; Christian et al., 2008). These results indicated that the initial samples 
were most likely contaminated with non-endothelial cells such as pericytes that cover the 
mature vessel. Up to now, no widely accepted specific marker for tumor vessel endothelial 
cells in the CRC or other human tumors has been identified. Accordingly, a superior 
approach would be to specifically isolate pure, viable TEC cultures from CRC and then use 
these cells to identify TEC-specific markers. 
In summary, the described results indicate that the induction and maintenance of tumor 
angiogenesis is an important feature in CRC growth and progression and that the 
interaction of TECs with tumor cells and other stromal cells changes the TEC phenotype. 
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Furthermore, pure viable TEC cultures isolated from CRC might be a valuable tool, allowing 
functional analysis of the TEC phenotype in CRC and the identification of TEC-specific 
markers. Pure CRC-derived TEC cultures will shed light on the manifold interactions 
between tumor and endothelial cells and their impact on the pathogenesis and prognosis of 
this tumor. This understanding will lead to improved anti-angiogenic treatment strategies in 
the CRC.  
3. Host anti-tumor response and angiogenesis in colorectal cancer 
3.1 Tumor infiltrating immune cells and angiogenesis in CRC 
In CRC, tumor progression is tightly associated with and partly promoted by the tumor 
microenvironment. The tumor microenvironment consists of extracellular matrix, the 
vasculature and tumor-infiltrating cells. Infiltrating cells are recruited through inflammation 
and chemoattractants produced by the tumor cells or by cells of the stroma. Tumor 
infiltrating cells comprise cancer-associated fibroblasts (CAFs), endothelial cells, platelets, 
mesenchymal stem cells and various types of immune cells. Initial studies addressing the 
prognostic role of intratumoral immune cells infiltrates in colorectal cancer were partly 
contradictory. Some studies supported a protective role of inflammatory infiltrates (Jass, 
1986; Harrison et al., 1994; Ropponen et al., 1997; Naito et al., 1998; Leo et al., 2000; 
Guidoboni et al., 2001; Galon et al., 2006) but other reports did not (Roncucci et al., 1996; 
Nielsen et al., 1999). 
It is now clear that the type, the subtype and the localization of the infiltrating immune cells 
determine their effects on the tumor cells and the tumor microenvironment. Both the innate 
and the adaptive immune responses are involved in this process. For instance, the 
infiltration of cytotoxic T cells and type I helper T cells (Th1 cells) in CRC correlates with a 
prolonged disease-free survival, whereas the presence of infiltrating Th17 cells is of poor 
prognosis (Galon et al., 2006). In the same way, polarization of tumor-associated 
macrophages towards either M1 or M2 subpopulation results in anti-tumorigenic (M1) or 
pro-tumorigenic (M2) effects (Mantovani & Sica, 2010). Some forms of inflammatory 
infiltrates participate to the anti-tumor immune response while other immune cells are 
actively recruited by the tumor to exploit their pro-angiogenic and pro-metastatic effects 
(Balkwill & Mantovani, 2001; Coussens & Werb, 2001). 
In addition, there is a growing body of evidence that tumor infiltrating immune cells can 
modulate tumor angiogenesis in cancer and particularly in CRC as summarized in table 1 
and discussed in more detail below.  
 
Pro-angiogenic Anti-angiogenic 
Tumor-associated macrophages (M2) Lymphocytes (Th1) 
TIE-2 expressing monocytes NK cells 
Mast cells NKT cells 
Neutrophils Dendritic cells 
MDSCs  
Immature DCs  
Th17 lymphocytes  
Immature dendritic cells  
Table 1. Pro-angiogenic or anti-angiogenic features of tumor infiltrating immune cells. 
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3.1.1 Tumor-associated macrophages  
The recruitment of tumor-associated macrophages (TAMs) is mediated by various factors 
such as colony-stimulating factor-1 (CSF-1), which is produced by colon carcinoma cells, or 
the chemokines CCL2, CCL3, CCL4 and CCL5 (Sica et al., 2008a; Sica et al., 2008b). Tumors 
are predominantly infiltrated by TAMs with M2 polarization and high TAM infiltration in 
CRC is associated with a poor prognosis (Bacman et al., 2007). TAMs express pro-angiogenic 
factors including VEGF, basic fibroblast growth factor (bFGF), TNF-, IL-8, IL-1 or platelet 
derived growth factor- (PDGF-) (Figure 1) (Barbera-Guillem et al., 2002; Sica et al., 2008a; 
Sica et al., 2008b). In addition, TAMs secrete matrix metalloproteases (MMP-7, MMP12) 
which participate in tumor angiogenesis by remodelling the extracellular matrix 




Fig. 1. Tumor-infiltrating immune cells exert opposite effects on angiogenesis. 
3.1.2 TIE-2 expressing monocytes  
TIE-2 expressing monocytes (TEMs) represent a subset of monocytes differing from the 
classical inflammatory monocytes (De Palma et al., 2005). The number of TEMs is increased 
in the blood of cancer patients and the tumor stroma of various types of cancers including 
CRC (De Palma et al., 2007; Venneri et al., 2007). TIE-2 is an angiopoietin receptor which is 
normally found at the surface of endothelial cells or haematopoietic stem cells. TEM 
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infiltration of cytotoxic T cells and type I helper T cells (Th1 cells) in CRC correlates with a 
prolonged disease-free survival, whereas the presence of infiltrating Th17 cells is of poor 
prognosis (Galon et al., 2006). In the same way, polarization of tumor-associated 
macrophages towards either M1 or M2 subpopulation results in anti-tumorigenic (M1) or 
pro-tumorigenic (M2) effects (Mantovani & Sica, 2010). Some forms of inflammatory 
infiltrates participate to the anti-tumor immune response while other immune cells are 
actively recruited by the tumor to exploit their pro-angiogenic and pro-metastatic effects 
(Balkwill & Mantovani, 2001; Coussens & Werb, 2001). 
In addition, there is a growing body of evidence that tumor infiltrating immune cells can 
modulate tumor angiogenesis in cancer and particularly in CRC as summarized in table 1 
and discussed in more detail below.  
 
Pro-angiogenic Anti-angiogenic 
Tumor-associated macrophages (M2) Lymphocytes (Th1) 
TIE-2 expressing monocytes NK cells 
Mast cells NKT cells 
Neutrophils Dendritic cells 
MDSCs  
Immature DCs  
Th17 lymphocytes  
Immature dendritic cells  
Table 1. Pro-angiogenic or anti-angiogenic features of tumor infiltrating immune cells. 
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3.1.1 Tumor-associated macrophages  
The recruitment of tumor-associated macrophages (TAMs) is mediated by various factors 
such as colony-stimulating factor-1 (CSF-1), which is produced by colon carcinoma cells, or 
the chemokines CCL2, CCL3, CCL4 and CCL5 (Sica et al., 2008a; Sica et al., 2008b). Tumors 
are predominantly infiltrated by TAMs with M2 polarization and high TAM infiltration in 
CRC is associated with a poor prognosis (Bacman et al., 2007). TAMs express pro-angiogenic 
factors including VEGF, basic fibroblast growth factor (bFGF), TNF-, IL-8, IL-1 or platelet 
derived growth factor- (PDGF-) (Figure 1) (Barbera-Guillem et al., 2002; Sica et al., 2008a; 
Sica et al., 2008b). In addition, TAMs secrete matrix metalloproteases (MMP-7, MMP12) 
which participate in tumor angiogenesis by remodelling the extracellular matrix 




Fig. 1. Tumor-infiltrating immune cells exert opposite effects on angiogenesis. 
3.1.2 TIE-2 expressing monocytes  
TIE-2 expressing monocytes (TEMs) represent a subset of monocytes differing from the 
classical inflammatory monocytes (De Palma et al., 2005). The number of TEMs is increased 
in the blood of cancer patients and the tumor stroma of various types of cancers including 
CRC (De Palma et al., 2007; Venneri et al., 2007). TIE-2 is an angiopoietin receptor which is 
normally found at the surface of endothelial cells or haematopoietic stem cells. TEM 
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recruitment in tumors is mediated by the chemokines CCL3, CCL5 and CCL8, and the 
expression of angiopoietin-2 by tumor cells or tumor endothelial cells (De Palma & Naldini, 
2009; De Palma & Naldini, 2011). TEMs have been shown to promote tumor angiogenesis 
and tumor growth in tumor mouse models (De Palma & Naldini, 2011). 
3.1.3 Mast cells  
Mast cells are myeloid-derived cells which contain numerous granules rich in histamine and 
heparin. They are resident in tissues and represent key effectors of allergic reactions. Mast 
cells can also infiltrate tumors where they localize in the vicinity of blood vessels (Maltby et 
al., 2009). A high mast cell infiltration is usually associated with increased tumor growth, 
invasion and vascularisation. It has been shown that low mast cell numbers in CRC samples 
correlate with a better patient survival and hypovascularization (Gulubova & Vlaykova, 
2009). Mast cells are able to produce numerous pro-angiogenic factors such as VEGF, bFGF, 
angiopoietin-1, TNF-, heparin, histamine or various proteases (Maltby et al., 2009). It has 
been suggested that mast cell infiltration triggers the “angiogenic switch” during tumor 
growth: mast cells might be involved in angiogenesis at early stages of tumor growth, while 
at late stages the tumor cells control growth and angiogenesis in a mast cell-independent 
manner (Coussens et al., 1999). 
3.1.4 Neutrophils  
Infiltrates of neutrophils have been observed in various cancers including CRC (Roncucci et 
al., 2008; Tazzyman et al., 2009). In addition, neutrophils are involved in the pathogenesis of 
inflammatory bowel disease (Roessner et al., 2008). The recruitment of neutrophils is 
mediated by the chemokines CXCL1 and CXCL8 (Eck et al., 2003). Neutrophils stimulate 
tumor angiogenesis by releasing proteins including VEGF, CXCL1, CXCL8 or MMP9. The 
latter induces the release of VEGF from the extracellular matrix by cleavage of heparan 
sulfates (Hawinkels et al., 2008; Tazzyman et al., 2009). 
3.1.5 Tumor infiltrating lymphocytes 
Recent studies have highlighted the prognostic importance of tumor infiltrating 
lymphocytes (TILs) in colorectal carcinoma (Galon et al., 2006; Katz et al., 2009). The type, 
density and localization of T-cells in colorectal tumors have been found to be a better 
predictor of patient survival than the classical histopathological staging (Galon et al., 2006). 
T-cells can be divided in different subtypes. Naïve CD4+ T-cells differentiate in T helper 
(Th) cells of type 1 (Th1) in the presence of IL-12 or of type 2 (Th2) in the presence of IL-4 
(Zhou et al., 2009). Th1 and Th2 cells inhibit each other. The presence of a Th1 adaptive 
immune response in CRC correlates with a better survival and an anti-angiogenic 
phenotype (Galon et al., 2006; Naschberger et al., 2008). Th1 cells facilitate the recruitment 
and the action of CD8+ cytotoxic T cells (Zhang et al., 2009). In CRC, CD8+ infiltrating T 
cells are the cell type most strongly associated with an improved survival (Galon et al., 
2006). Th1 cells and CD8+ T-cells produce IL-12 and IFN-, both anti-angiogenic cytokines 
(Figure 1) (Zhu & Paul, 2010; Briesemeister et al., 2011). IL-12 promotes the production of 
IFN- by CD8+ T-cells and reduces the production of pro-angiogenic proteases such as 
MMP-9 by endothelial cells (Tartour et al., 2011). IFN- induces the production of angiostatic 
chemokines (CXCL9 and CXCL10) by endothelial cells and blocks the production of both 
VEGF and bFGF (Tartour et al., 2011). 
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Besides Th1 and Th2 cells, two other populations of T-cells have been shown to be involved in 
cancer, namely the regulatory T-cells (Treg) and the Th17 cells. In CRC, the infiltration of Treg, 
as well as of Th2 cells, seems to have no influence on patient survival (Tosolini et al., 2011). 
However, a direct association was found between the presence of a Th17 response and a worse 
prognosis (Tosolini et al., 2011). Th17 cells differentiate from naïve CD4+ T-cells upon 
exposure to IL-6 or TGF-, and produce IL-17, IL-17F and IL-22 (Zhou et al., 2009). IL-17 
promotes angiogenesis by inducing the production of angiogenic growth factors and 
chemokines by tumor cells and fibroblasts (Figure 1). Furthermore, IL-17 exerts a direct effect 
on endothelial cells, increasing migration and tube formation. Finally, IL-17 can indirectly 
promote angiogenesis by recruiting neutrophils to the tumor site (Tartour et al., 2011). 
3.1.6 Myeloid-derived suppressor cells  
Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells including 
progenitors of macrophages, granulocytes and DCs. The number of MDSCs has been shown 
to be increased in the blood of CRC patients (Mandruzzato et al., 2009). MDSCs are 
immunosuppressive and in particular inhibit T-cells (Condamine & Gabrilovich, 2011). In 
addition, they modulate the action of NK cells and induce Treg cells. MDSCs exert their 
functions through up-regulation of NO, arginase or ROS (Gabrilovich & Nagaraj, 2009). In 
mouse models, MDSCs have been shown to promote angiogenesis, tumor cell invasion and 
metastasis (Youn & Gabrilovich, 2010). MDSCs are very heterogenic but one can distinguish 
two different subtypes: the granulocytic (G)-MDSCs and the monocytic (M)-MDSCs (Youn 
& Gabrilovich, 2010). G-MDSCs are found in the spleen or in peripheral lymphoid organs, 
use primarily ROS for immune suppression, require cell-cell contact with T cells and are 
dependent on antigen-specific interactions (Youn & Gabrilovich, 2010). M-MDSCs are found 
in tumors, use primarily iNOS, arginase and cytokines for immune suppression, their action 
does not require direct cell-cell contact. M-MDSCs exert a non-specific suppression and are 
more potent (Youn & Gabrilovich, 2010). M-MDSCs are able to differentiate towards TAMs 
under hypoxic conditions (Corzo et al., 2010). Some MDSCs express endothelial markers 
such as CD31 or VEGFR2 and are able to incorporate into the tumor endothelium (Figure 1) 
(Yang et al., 2004). 
3.1.7 Dendritic cells 
Dendritic cells (DCs) are bone-marrow derived cells and represent the most important 
antigen-presenting cells (Salama & Platell, 2008). In CRC, DCs localize at the invasive 
margin of the tumor and in lymph nodes (Ambe et al., 1989; Suzuki et al., 2002). The 
presence of a high number of DCs in CRC correlates with a better prognosis, in particular 
when DCs infiltrate the intra-epithelial compartment of the tumor (Dadabayev et al., 2004; 
Sandel et al., 2005). Mature DCs are able to produce IL-12 which induces the polarization of 
immune cells towards the Th1 anti-tumorigenic and anti-angiogenic phenotype. Tumors are 
in addition able to recruit immature DCs (iDCs) which have been shown in ovarian cancer 
to secrete pro-angiogenic factors and to be capable of incorporating in newly formed vessels 
(Figure 1) (Curiel et al., 2004). 
3.1.8 NK and NKT cells 
NK cells are lymphocytes from the innate immune system which are able to recognize 
tumor cells as target. The immune infiltration of NK cells represents a positive prognostic 
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recruitment in tumors is mediated by the chemokines CCL3, CCL5 and CCL8, and the 
expression of angiopoietin-2 by tumor cells or tumor endothelial cells (De Palma & Naldini, 
2009; De Palma & Naldini, 2011). TEMs have been shown to promote tumor angiogenesis 
and tumor growth in tumor mouse models (De Palma & Naldini, 2011). 
3.1.3 Mast cells  
Mast cells are myeloid-derived cells which contain numerous granules rich in histamine and 
heparin. They are resident in tissues and represent key effectors of allergic reactions. Mast 
cells can also infiltrate tumors where they localize in the vicinity of blood vessels (Maltby et 
al., 2009). A high mast cell infiltration is usually associated with increased tumor growth, 
invasion and vascularisation. It has been shown that low mast cell numbers in CRC samples 
correlate with a better patient survival and hypovascularization (Gulubova & Vlaykova, 
2009). Mast cells are able to produce numerous pro-angiogenic factors such as VEGF, bFGF, 
angiopoietin-1, TNF-, heparin, histamine or various proteases (Maltby et al., 2009). It has 
been suggested that mast cell infiltration triggers the “angiogenic switch” during tumor 
growth: mast cells might be involved in angiogenesis at early stages of tumor growth, while 
at late stages the tumor cells control growth and angiogenesis in a mast cell-independent 
manner (Coussens et al., 1999). 
3.1.4 Neutrophils  
Infiltrates of neutrophils have been observed in various cancers including CRC (Roncucci et 
al., 2008; Tazzyman et al., 2009). In addition, neutrophils are involved in the pathogenesis of 
inflammatory bowel disease (Roessner et al., 2008). The recruitment of neutrophils is 
mediated by the chemokines CXCL1 and CXCL8 (Eck et al., 2003). Neutrophils stimulate 
tumor angiogenesis by releasing proteins including VEGF, CXCL1, CXCL8 or MMP9. The 
latter induces the release of VEGF from the extracellular matrix by cleavage of heparan 
sulfates (Hawinkels et al., 2008; Tazzyman et al., 2009). 
3.1.5 Tumor infiltrating lymphocytes 
Recent studies have highlighted the prognostic importance of tumor infiltrating 
lymphocytes (TILs) in colorectal carcinoma (Galon et al., 2006; Katz et al., 2009). The type, 
density and localization of T-cells in colorectal tumors have been found to be a better 
predictor of patient survival than the classical histopathological staging (Galon et al., 2006). 
T-cells can be divided in different subtypes. Naïve CD4+ T-cells differentiate in T helper 
(Th) cells of type 1 (Th1) in the presence of IL-12 or of type 2 (Th2) in the presence of IL-4 
(Zhou et al., 2009). Th1 and Th2 cells inhibit each other. The presence of a Th1 adaptive 
immune response in CRC correlates with a better survival and an anti-angiogenic 
phenotype (Galon et al., 2006; Naschberger et al., 2008). Th1 cells facilitate the recruitment 
and the action of CD8+ cytotoxic T cells (Zhang et al., 2009). In CRC, CD8+ infiltrating T 
cells are the cell type most strongly associated with an improved survival (Galon et al., 
2006). Th1 cells and CD8+ T-cells produce IL-12 and IFN-, both anti-angiogenic cytokines 
(Figure 1) (Zhu & Paul, 2010; Briesemeister et al., 2011). IL-12 promotes the production of 
IFN- by CD8+ T-cells and reduces the production of pro-angiogenic proteases such as 
MMP-9 by endothelial cells (Tartour et al., 2011). IFN- induces the production of angiostatic 
chemokines (CXCL9 and CXCL10) by endothelial cells and blocks the production of both 
VEGF and bFGF (Tartour et al., 2011). 
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Besides Th1 and Th2 cells, two other populations of T-cells have been shown to be involved in 
cancer, namely the regulatory T-cells (Treg) and the Th17 cells. In CRC, the infiltration of Treg, 
as well as of Th2 cells, seems to have no influence on patient survival (Tosolini et al., 2011). 
However, a direct association was found between the presence of a Th17 response and a worse 
prognosis (Tosolini et al., 2011). Th17 cells differentiate from naïve CD4+ T-cells upon 
exposure to IL-6 or TGF-, and produce IL-17, IL-17F and IL-22 (Zhou et al., 2009). IL-17 
promotes angiogenesis by inducing the production of angiogenic growth factors and 
chemokines by tumor cells and fibroblasts (Figure 1). Furthermore, IL-17 exerts a direct effect 
on endothelial cells, increasing migration and tube formation. Finally, IL-17 can indirectly 
promote angiogenesis by recruiting neutrophils to the tumor site (Tartour et al., 2011). 
3.1.6 Myeloid-derived suppressor cells  
Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells including 
progenitors of macrophages, granulocytes and DCs. The number of MDSCs has been shown 
to be increased in the blood of CRC patients (Mandruzzato et al., 2009). MDSCs are 
immunosuppressive and in particular inhibit T-cells (Condamine & Gabrilovich, 2011). In 
addition, they modulate the action of NK cells and induce Treg cells. MDSCs exert their 
functions through up-regulation of NO, arginase or ROS (Gabrilovich & Nagaraj, 2009). In 
mouse models, MDSCs have been shown to promote angiogenesis, tumor cell invasion and 
metastasis (Youn & Gabrilovich, 2010). MDSCs are very heterogenic but one can distinguish 
two different subtypes: the granulocytic (G)-MDSCs and the monocytic (M)-MDSCs (Youn 
& Gabrilovich, 2010). G-MDSCs are found in the spleen or in peripheral lymphoid organs, 
use primarily ROS for immune suppression, require cell-cell contact with T cells and are 
dependent on antigen-specific interactions (Youn & Gabrilovich, 2010). M-MDSCs are found 
in tumors, use primarily iNOS, arginase and cytokines for immune suppression, their action 
does not require direct cell-cell contact. M-MDSCs exert a non-specific suppression and are 
more potent (Youn & Gabrilovich, 2010). M-MDSCs are able to differentiate towards TAMs 
under hypoxic conditions (Corzo et al., 2010). Some MDSCs express endothelial markers 
such as CD31 or VEGFR2 and are able to incorporate into the tumor endothelium (Figure 1) 
(Yang et al., 2004). 
3.1.7 Dendritic cells 
Dendritic cells (DCs) are bone-marrow derived cells and represent the most important 
antigen-presenting cells (Salama & Platell, 2008). In CRC, DCs localize at the invasive 
margin of the tumor and in lymph nodes (Ambe et al., 1989; Suzuki et al., 2002). The 
presence of a high number of DCs in CRC correlates with a better prognosis, in particular 
when DCs infiltrate the intra-epithelial compartment of the tumor (Dadabayev et al., 2004; 
Sandel et al., 2005). Mature DCs are able to produce IL-12 which induces the polarization of 
immune cells towards the Th1 anti-tumorigenic and anti-angiogenic phenotype. Tumors are 
in addition able to recruit immature DCs (iDCs) which have been shown in ovarian cancer 
to secrete pro-angiogenic factors and to be capable of incorporating in newly formed vessels 
(Figure 1) (Curiel et al., 2004). 
3.1.8 NK and NKT cells 
NK cells are lymphocytes from the innate immune system which are able to recognize 
tumor cells as target. The immune infiltration of NK cells represents a positive prognostic 
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marker in various solid tumors including CRC (Coca et al., 1997). They represent together 
with CD8+ T cells the most likely effectors of the anti-tumor immunity. NK cells exert their 
anti-tumorigenic effects notably through the production of IFN- and participate therefore 
in the anti-angiogenic immune response (Levy et al., 2011).  
NKT cell are a small population of T cells which also exhibit NK cells markers. They have 
the property to modulate immune responses and to link the innate and the adaptive 
immune responses. NKT cells are able to recognize lipid antigens that are not recognized by 
other T cell subsets (Terabe & Berzofsky, 2008). Two subtypes of NKT cells have been 
described. The most frequent type of NKT cells, called type I, has a very restricted T-cell 
receptor (TCR) repertoire and expresses the invariant V24J18 TCR. On the contrary, the 
type II NKT cells express different TCRs (Terabe & Berzofsky, 2008). NKT type I cells exert 
anti-tumor effects through IFN- but independently of perforin (van der Vliet et al., 2008). In 
addition, they activate DCs to produce IL-12. In colorectal carcinoma, a high infiltration of 
type I NKT cells, which are V24 positive, correlates with a better overall and disease-free 
survival (Tachibana et al., 2005). Through their production of IFN- and their activation of 
DCs, type I NKT cells participate in the Th1 anti-angiogenic immune response in CRC 
(Figure 1). While type I NKT cells enhance anti-tumor immunity, mouse models showed 
that type II NKT cells repress it (Terabe & Berzofsky, 2008). 
Tumor angiogenesis is promoted by the production of VEGF from the tumor cells but also 
from mast cells, M2 macrophages and neutrophils. In addition, macrophages and mast cells 
produce IL-1 and TNF-, which can promote a local pro-angiogenic inflammation through 
the further recruitment of macrophages in vivo, even if their direct action on endothelial cells 
in vitro is anti-angiogenic. Neutrophils and macrophages produce MMPs, inducing a matrix 
remodeling necessary for angiogenesis. Th17 cells directly promote angiogenesis through 
the secretion of IL-17, which enhances the recruitment of neutrophils. Immature MDSCs can 
differentiate towards M2 macrophages or, like immature dendritic cells, can be incorporated 
into newly formed vessels. On the contrary, a Th1 dominated immune response exerts anti-
angiogenic effects, mainly through the production of IFN- by Th1 cells, CD8+ T cells, NK or 
NKT cells. Th1 cells are activated by IL-12, notably produced by some DCs. 
3.2 Markers for the interplay of angiogenesis and a host anti-tumor response in CRC 
The impact of angiogenesis on colorectal tumor growth and progression described in the 
previous paragraphs was convincingly supported by a clinical phase III study in which an 
anti-VEGF antibody (bevacizumab) was added to fluorouracil-based combination 
chemotherapy. The combination therapy led to a statistically significant and clinically 
meaningful improvement in overall survival (20.3 months vs. 15.6 months for the control 
group) and progression-free survival among patients with metastatic CRC (Hurwitz et al., 
2004). Based on these results bevacizumab was approved as the first solely anti-angiogenic 
drug used as anti-cancer agent by the FDA in 2004. Moreover, two additional anti-
angiogenic drugs for the same molecular target have been approved for the clinics 
meanwhile: sunitinib and sorafenib. These drugs are both broad-spectrum receptor tyrosine 
kinase (RTK) inhibitors that target VEGFR1, VEGFR2, VEGFR3 or PDGFR-/ among other 
RTKs (Escudier et al., 2007; Motzer et al., 2007).  
However, in all of the clinical studies employing anti-angiogenic treatment for human 
tumors including CRC, only a fraction of the treated patients responded completely or 
partially to the therapy (10-49.3% maximum partial response rates) (Hurwitz et al., 2004; 
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Demetri et al., 2006; Escudier et al., 2007; Motzer et al., 2007; Sobrero et al., 2009). 
Additionally, in some cases, severe side effects such as cardiovascular damage, perforation 
of the colon or venous thromboembolic events have been observed (Hurwitz et al., 2004; 
Sobrero et al., 2009). Furthermore, anti-angiogenic treatment is very expensive and puts a 
significant cost burden on the health system. This raises important questions: (1) which 
subset of patients will benefit most from these therapies? (2) How can these patients be 
preselected? (3) Can the side effects be decreased by patient preselection?  
From these questions it becomes obvious that valid biomarkers able to indicate different 
angiogenic or angiostatic tumor microenvironments, and in consequence patients who will 
benefit most from anti-angiogenic therapy, are urgently required. Numerous efforts have 
been undertaken to identify predictive and/or prognostic biomarkers and this research field 
is rapidly expanding. By definition a predictive biomarker is able to foretell the response of 
the patient to a certain treatment whereas a prognostic biomarker predicts the potential 
outcome of the disease independently of the applied therapy. Promising results have been 
reported in the last few years, however, none of the proposed markers has been accepted 
widely (Asghar et al., 2010; Gerger et al., 2011).  
Different kinds of potential biomarkers for anti-angiogenic treatment have been reported in 
the literature in the past few years: serum, tissue and genetic markers. Initially, for obvious 
reasons, VEGF tissue and serum levels were heavily investigated but surprisingly did not 
make it into the clinics due to the inability to predict response at the tissue level (Jubb et al., 
2006) and contradictory results at the serum level (Loupakis et al., 2007; Willett et al., 2009). 
Efforts have also been undertaken to investigate the impact of genetic polymorphisms of 
VEGF and VEGFR-2 as potential biomarkers (Schneider et al., 2008). Many other potential 
biomarkers were reported in the last few years in the literature to be measured either at the 
tissue or serum/plasma level. Examples for these markers are tissue CD31 and PDGFR- 
expression in breast cancer (Yang et al., 2008), soluble angiopoietin-2 (Goede et al., 2010), 
circulating endothelial cells (Ronzoni et al., 2010), TNF-, MMP-9 (Perez-Gracia et al., 2009), 
soluble KIT (Deprimo et al., 2009) as well as IL-8 (Kopetz et al., 2010). However, all of these 
potential markers require confirmation in larger cohorts and unfortunately lack either 
prognostic or predictive value.  
From these results it becomes clear that very likely different biomarkers will be required for 
the different kinds of anti-angiogenic treatments and the different kinds of cancers. In 
addition, as discussed in the section 3 of this review, a broad range of immune cells can 
infiltrate tumors and have been detected in CRC samples. These cells interact with tumor 
endothelial cells during their extravasation and some of them are able to modulate tumor 
angiogenesis (Figure 1). While tumor infiltrating macrophages, mast cells, Th17 
lymphocytes and neutrophils are recognized to exert pro-angiogenic effects in CRC, Th1 
lymphocytes are associated with an anti-angiogenic microenvironment. On the other end, 
tumor vessels can be more or less permissive for the infiltration of immune cells. Therefore, 
the interplay between immune cells and tumor endothelial cells represents an important 
issue with implications for the anti-tumor host response and angiogenesis. 
3.2.1 GBP-1 as a marker for the anti-angiogenic Th1 immune response in CRC  
As mentioned above, the presence of a Th1 microenvironment is associated with a 
significantly improved prognosis in CRC (Galon et al., 2006). A Th-1 microenvironment is 
characterized by increased IFN- expression, often combined with the increased expression 
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marker in various solid tumors including CRC (Coca et al., 1997). They represent together 
with CD8+ T cells the most likely effectors of the anti-tumor immunity. NK cells exert their 
anti-tumorigenic effects notably through the production of IFN- and participate therefore 
in the anti-angiogenic immune response (Levy et al., 2011).  
NKT cell are a small population of T cells which also exhibit NK cells markers. They have 
the property to modulate immune responses and to link the innate and the adaptive 
immune responses. NKT cells are able to recognize lipid antigens that are not recognized by 
other T cell subsets (Terabe & Berzofsky, 2008). Two subtypes of NKT cells have been 
described. The most frequent type of NKT cells, called type I, has a very restricted T-cell 
receptor (TCR) repertoire and expresses the invariant V24J18 TCR. On the contrary, the 
type II NKT cells express different TCRs (Terabe & Berzofsky, 2008). NKT type I cells exert 
anti-tumor effects through IFN- but independently of perforin (van der Vliet et al., 2008). In 
addition, they activate DCs to produce IL-12. In colorectal carcinoma, a high infiltration of 
type I NKT cells, which are V24 positive, correlates with a better overall and disease-free 
survival (Tachibana et al., 2005). Through their production of IFN- and their activation of 
DCs, type I NKT cells participate in the Th1 anti-angiogenic immune response in CRC 
(Figure 1). While type I NKT cells enhance anti-tumor immunity, mouse models showed 
that type II NKT cells repress it (Terabe & Berzofsky, 2008). 
Tumor angiogenesis is promoted by the production of VEGF from the tumor cells but also 
from mast cells, M2 macrophages and neutrophils. In addition, macrophages and mast cells 
produce IL-1 and TNF-, which can promote a local pro-angiogenic inflammation through 
the further recruitment of macrophages in vivo, even if their direct action on endothelial cells 
in vitro is anti-angiogenic. Neutrophils and macrophages produce MMPs, inducing a matrix 
remodeling necessary for angiogenesis. Th17 cells directly promote angiogenesis through 
the secretion of IL-17, which enhances the recruitment of neutrophils. Immature MDSCs can 
differentiate towards M2 macrophages or, like immature dendritic cells, can be incorporated 
into newly formed vessels. On the contrary, a Th1 dominated immune response exerts anti-
angiogenic effects, mainly through the production of IFN- by Th1 cells, CD8+ T cells, NK or 
NKT cells. Th1 cells are activated by IL-12, notably produced by some DCs. 
3.2 Markers for the interplay of angiogenesis and a host anti-tumor response in CRC 
The impact of angiogenesis on colorectal tumor growth and progression described in the 
previous paragraphs was convincingly supported by a clinical phase III study in which an 
anti-VEGF antibody (bevacizumab) was added to fluorouracil-based combination 
chemotherapy. The combination therapy led to a statistically significant and clinically 
meaningful improvement in overall survival (20.3 months vs. 15.6 months for the control 
group) and progression-free survival among patients with metastatic CRC (Hurwitz et al., 
2004). Based on these results bevacizumab was approved as the first solely anti-angiogenic 
drug used as anti-cancer agent by the FDA in 2004. Moreover, two additional anti-
angiogenic drugs for the same molecular target have been approved for the clinics 
meanwhile: sunitinib and sorafenib. These drugs are both broad-spectrum receptor tyrosine 
kinase (RTK) inhibitors that target VEGFR1, VEGFR2, VEGFR3 or PDGFR-/ among other 
RTKs (Escudier et al., 2007; Motzer et al., 2007).  
However, in all of the clinical studies employing anti-angiogenic treatment for human 
tumors including CRC, only a fraction of the treated patients responded completely or 
partially to the therapy (10-49.3% maximum partial response rates) (Hurwitz et al., 2004; 
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Demetri et al., 2006; Escudier et al., 2007; Motzer et al., 2007; Sobrero et al., 2009). 
Additionally, in some cases, severe side effects such as cardiovascular damage, perforation 
of the colon or venous thromboembolic events have been observed (Hurwitz et al., 2004; 
Sobrero et al., 2009). Furthermore, anti-angiogenic treatment is very expensive and puts a 
significant cost burden on the health system. This raises important questions: (1) which 
subset of patients will benefit most from these therapies? (2) How can these patients be 
preselected? (3) Can the side effects be decreased by patient preselection?  
From these questions it becomes obvious that valid biomarkers able to indicate different 
angiogenic or angiostatic tumor microenvironments, and in consequence patients who will 
benefit most from anti-angiogenic therapy, are urgently required. Numerous efforts have 
been undertaken to identify predictive and/or prognostic biomarkers and this research field 
is rapidly expanding. By definition a predictive biomarker is able to foretell the response of 
the patient to a certain treatment whereas a prognostic biomarker predicts the potential 
outcome of the disease independently of the applied therapy. Promising results have been 
reported in the last few years, however, none of the proposed markers has been accepted 
widely (Asghar et al., 2010; Gerger et al., 2011).  
Different kinds of potential biomarkers for anti-angiogenic treatment have been reported in 
the literature in the past few years: serum, tissue and genetic markers. Initially, for obvious 
reasons, VEGF tissue and serum levels were heavily investigated but surprisingly did not 
make it into the clinics due to the inability to predict response at the tissue level (Jubb et al., 
2006) and contradictory results at the serum level (Loupakis et al., 2007; Willett et al., 2009). 
Efforts have also been undertaken to investigate the impact of genetic polymorphisms of 
VEGF and VEGFR-2 as potential biomarkers (Schneider et al., 2008). Many other potential 
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tissue or serum/plasma level. Examples for these markers are tissue CD31 and PDGFR- 
expression in breast cancer (Yang et al., 2008), soluble angiopoietin-2 (Goede et al., 2010), 
circulating endothelial cells (Ronzoni et al., 2010), TNF-, MMP-9 (Perez-Gracia et al., 2009), 
soluble KIT (Deprimo et al., 2009) as well as IL-8 (Kopetz et al., 2010). However, all of these 
potential markers require confirmation in larger cohorts and unfortunately lack either 
prognostic or predictive value.  
From these results it becomes clear that very likely different biomarkers will be required for 
the different kinds of anti-angiogenic treatments and the different kinds of cancers. In 
addition, as discussed in the section 3 of this review, a broad range of immune cells can 
infiltrate tumors and have been detected in CRC samples. These cells interact with tumor 
endothelial cells during their extravasation and some of them are able to modulate tumor 
angiogenesis (Figure 1). While tumor infiltrating macrophages, mast cells, Th17 
lymphocytes and neutrophils are recognized to exert pro-angiogenic effects in CRC, Th1 
lymphocytes are associated with an anti-angiogenic microenvironment. On the other end, 
tumor vessels can be more or less permissive for the infiltration of immune cells. Therefore, 
the interplay between immune cells and tumor endothelial cells represents an important 
issue with implications for the anti-tumor host response and angiogenesis. 
3.2.1 GBP-1 as a marker for the anti-angiogenic Th1 immune response in CRC  
As mentioned above, the presence of a Th1 microenvironment is associated with a 
significantly improved prognosis in CRC (Galon et al., 2006). A Th-1 microenvironment is 
characterized by increased IFN- expression, often combined with the increased expression 
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of pro-inflammatory cytokines IL-1 and TNF- (Dayer, 2002b; Dayer, 2002a; Cui et al., 
2007). The guanylate-binding protein 1 (GBP-1) has been identified as a marker of the Th1 
microenvironment in CRC (Naschberger et al., 2008). GBP-1 expression is induced upon 
stimulation by IFN- but also by other pro-inflammatory cytokines such as IL-1 and/or 
TNF- (Guenzi et al., 2001; Lubeseder-Martellato et al., 2002). In CRC, GBP-1 is strongly 
expressed in infiltrating cells and in the vasculature. Its expression correlates with 
expression of IFN--induced genes, chemokines and immune reaction-associated genes 
(Naschberger et al., 2008). Among them, three anti-angiogenic chemokines known to play a 
role in tumors (CXCL9, CXCL10, CXCL11) could also be detected (Romagnani et al., 2004). 
GBP-1 expression in CRC stroma is associated with an increase of the cancer-related five-
year survival rate and GBP-1 represents an independent prognostic factor indicating a 
reduction of the relative risk of cancer-related death by the half (Naschberger et al., 2008). In 
tumor-associated endothelial cells the presence of GBP-1 is associated with a decreased 
angiogenic activity (Naschberger et al., 2008; Guenzi et al., 2001; Guenzi et al., 2003). GBP-1 
is presently the only marker available to specifically indicate whether endothelial cells in 
tissues are exposed to an angiostatic Th-1-like tumor microenvironment.  
3.2.2 Modulation of lymphocytes infiltration by endothelial cells 
The relationship between tumor angiogenesis and immunity is actually bidirectional. As 
described above, infiltrating immune cells can positively or negatively regulate angiogenesis 
in tumors. On the other hand, tumor endothelial cells are able to regulate extravasation of 
immune cells, notably through the expression of surface molecules. Among the potential 
molecular effectors identified, endothelin, endothelin receptor and CD137 seem to play a 
prominent role. 
The endothelin-endothelin receptor axis 
The endothelin (ET) family comprises four members designated ET-1 to -4 (Kandalaft et al., 
2009). ETs derive from precursor proteins after cleavage by membrane-bound 
metalloproteinases. ET-1 is the most potent ligand and the most widely expressed in 
endothelial cells (Kandalaft et al., 2009). In addition, ET-1 is overexpressed in many tumor 
cell lines and many tumors, including CRC (Kusuhara et al., 1990; Arun et al., 2004; Bagnato 
& Rosano, 2008). Two endothelin receptors have been identified: the endothelin A and the 
endothelin B receptor, respectively ETAR and ETBR (Kandalaft et al., 2009). In normal 
tissues, ETAR and ETBR regulate vasoconstriction and are also involved in inflammation. 
Both receptors exert opposite effects. In particular, ETAR promote T-cell adhesion to 
endothelial cells, whereas ETBR inhibits it. In tumor cells, concomitant up-regulation of ET-1 
and ETAR inhibits apoptosis and promotes cell proliferation, invasion and metastasis 
(Kedzierski & Yanagisawa, 2001; Kandalaft et al., 2009). In a study comparing the expression 
profiles of tumor associated endothelial cells (TECs) in ovarian cancer with or without TILs, 
ETBR has been associated with the absence of TILs and short patient survival time 
(Buckanovich et al., 2008). Of note, in this study, GBP-1 expression in TECs correlated with 
the presence of TILs. The inhibition of T cells homing in tumor by ETBR is mediated by an 
increase of NO synthase and NO release and by a decrease in the expression of the adhesion 
molecule ICAM-1. In CRC, ET-1 and ETAR are expressed by the tumor cells, generating a 
stimulatory loop, while ETBR expression in TECs is reduced as compared to normal colon 
blood vessels (Ali et al., 2000a; Ali et al., 2000b; Asham et al., 2001; Hoosein et al., 2007). 
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Investigation of the expression of ETBR in TECs in relation to TILs infiltration might provide 
further insights into the molecular regulation of immune cells extravasation by endothelial 
cells in CRC.  
CD137 (TNFRSF9) 
CD137 is a surface glycoprotein of the TNF- receptor family involved in T-cell co-
stimulation (Shao & Schwarz, 2011). CD137 is expressed on the surface of activated T cells, 
NK cells, DCs, macrophages or B cells, while its ligand, CD137L is expressed by APCs (Shao 
& Schwarz, 2011). CD137 is induced under hypoxia and by TNF-, LPS or IL-1. CD137 is 
however also expressed in human tumor capillaries, notably in CRC (Broll et al., 2001; Wang 
et al., 2008). In tumors, CD137 is expressed on the vessel walls whereas CD137L is expressed 
on tumor cells (Salih et al., 2000; Broll et al., 2001). The effects of CD137 are mediated by the 
up-regulation of V-CAM, I-CAM and E-selectin, inducing thereby the recruitment of T 
lymphocytes (Palazon et al., 2011). In addition, it has been shown that the ligation of 
CD137L on lung squamous carcinoma cells with CD137 on T cells induced IFN-γ production 
by T cells (Salih et al., 2000). Therefore, expression of CD137 by TECs might promote the 
recruitment of T cells in CRC and their polarization towards the anti-tumorigenic and anti-
angiogenic Th1 subtype.  
4. Conclusions 
In this review we tried to shed light on the current understanding of tumor angiogenesis 
and its modulation by a potential host anti-tumor response with a specific focus on 
colorectal carcinoma. Our major aim was to point out the connection of these two processes. 
A host anti-tumor response does not only have a direct effect on the tumor cells but also a 
major impact on the development and function of the tumor vasculature. Different tumor 
microenvironments, which can either inhibit or foster angiogenesis, are established during a 
specific immune response. These various microenvironments are achieved by different 
means: (1) immune cells such as Th1-T-cells are attracted into the tumor tissue within the 
context of a specific host anti-tumor response that secrete soluble mediators (e.g. IFN-) 
directly acting on tumor endothelial cells in an anti-angiogenic manner. (2) The tumor cells 
themselves also attract immune cells such as M2 macrophages or Th17-T-cells that might 
release mediators which modulate the microenvironment in a pro-angiogenic manner. (3) 
Endothelial cells can also modulate the stromal composition of infiltrating leukocytes which 
alters the soluble mediator profile to which the tumor and its vasculature are exposed. 
Therefore, biomarkers are required in order to characterize the specific angiogenic 
phenotype of each CRC patient. Moreover, these biomarkers should have prognostic and/or 
predictive potential for anti-angiogenic treatment and at best also give information about 
the presence of a host anti-tumor immune response. A potential candidate for such a 
biomarker might be the guanylate binding protein-1 (GBP-1). 
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1. Introduction 
The progression of colorectal cancer (CRC), like that of other solid tumors, has been first 
conceptualized by pathological staging (initially according to Dukes and later by the 
AJCC/UICC TNM staging system) as a step-wise invasion of bowel layers, followed by 
lymph-node involvement, to culminate into distant organ metastasis 1. Additionally, the 
recognition of pre-cancerous lesions (i.e., adenoma) set up the notion that cancer develops 
from a benign lesion, according to an adenoma-to-adenocarcinoma sequence. In the last two 
decades, the anatomic frame of progression has been embraced by the molecular genetic 
model of CRC, according to which accumulation of gene damage drives progression from 
adenoma to cancer, subsequently leading to the emergence of invasive and spreading clones 
2. Gene damage is known to be driven from two types of genetic instabilities: microsatellite 
(MSI) and chromosomal (CIN) instability. More recently, the epigenetic silencing of tumor 
suppressor genes, namely CpG island methylator phenotype (CIMP), has been claimed as a 
distinct pathway of colorectal carcinogenesis (Table 1) 3.  
Moving from this cornerstone, current research is exploring non-clonal determinants of 
tumor progression (Table 1)4,5. Collectively referred to as “tumor microenvironment” these 
factors can restrain or fuel tumor development and fate, and comprise infiltrating immune 
cells, neo-vessels, activated fibroblasts, and mesenchymal stem cells 6. Not acting like a 
tumor scaffold, rather actively signaling with neoplastic cells, microenvironment influences 
the selection and emergence of aggressive clones, as well as their dissemination. In a bi-
directional way, tumor molecular features influence the nearby environment by expressing 
tumor antigens, while tumor microenvironment influences the molecular changes, 
controlling the tumor growth. Additionally, chemokines and their receptors can be 
expressed as well by cancer cells and by non-neoplastic cells, influencing clonal expansion 
and cancer spread 4. The role of microenvironment in cancer promoting dynamics is well 
established, providing cancer cells with oxygen, growth factors and nutrients, which can 
impact on tumor growth, progression and dissemination. However, the contribution of 
persistent inflammation in the carcinogenesis process encourages anti-inflammatory drug 
administration as the most effective chemopreventive strategy. More recently, a growing 
body of evidence suggests a dual role of immunity in cancer pathogenesis (Figure 1), 
including tumor protective functions, tightly linked to patient’s prognosis. Endogenous 
responses may inhibit tumor growth and modulate the clinical course of disease 7, 8.  
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Fig. 1. Elements fueling and braking colorectal cancer progression 
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We review the builders of the CRC microenvironment, focusing on innate immunity and 
adaptive immunity. Although there is enormous heterogeneity of results and many open 
issues in methodological standardization strongly limit definitive conclusions, promising 
evidences support the clinical utility of tumor infiltrating subpopulations, in particular as 
prognostic biomarkers and potential therapeutic targets.  
2. The players 
2.1 Innate immunity 
It is well known that innate immunity, not involving specific recognition of immunogenic 
peptides, represents the first defense to pathological stresses, including cancer. Innate 
immune cells orchestrate an inflammatory response that may stimulate or inhibit cancer 
growth. A number of innate immune cells have been implicated in CRC development and 
progression, including macrophages, mast cells (MC), neutrophils, natural killer (NK) cells 
and dendritic cells (DC) 9-12. 
Macrophages. They are a heterogeneous cell population of the myeloid linage derived from 
monocytes. These cells show two different polarization states, M1 and M2, in response to 
different micro environmental signals 13. M1-macrophages, involved in cancer protecting 
mechanism, interface susceptible target cells through several different mechanisms, 
including secretion of tumor necrosis factor-α (TNF-α), nitric oxide, interleukin-1β (IL-1β) 
and reactive oxygen intermediates. Additionally, M1s can support T-helper 1 (Th1) adaptive 
immunity. Conversely, M2 macrophages can secrete factors stimulating the growth and 
migration of tumor cells, such as platelet-derived growth factor (PDGF), epidermal growth 
factor (EGF), and transforming growth factor-β (TGF- β), and angiogenesis-promoting 
factors like vascular endothelial growth factor (VEGF) and TNF-α, as well as produce 
proteases (such as metalloproteinases, MMPs) that potentially could facilitate tumor 
invasion and metastasis 13-16.  
In patients with CRC, tumor associated macrophages (TAM) are usually found located 
around necrotic areas and the advancing tumor margin. It was originally thought that the 
main function of TAMs was a direct cytotoxic effect on tumor cells, phagocytosis 
apoptotic/necrotic cell debris, and present tumor-associated antigens to T lymphocytes.  
Current associative evidence is in line with this view, as a high density of TAM at the CRC 
invasion front, particularly the highest TAM density scored as a “hot-spot”, is associated 
with a better patient outcome 17.  More data are likely still needed as to TAM role in CRC, as 
well as on the state of their activation (M1 versus M2) 10. 
Among the M2 population, TAMs have been shown as capable of secreting proteases that 
enhance invasion and metastases, together with a range of cytokines inhibiting an adaptive 
tumor-specific immune response, and angiogenic factors that increase neovascularity. The 
pro-angiogenetic ability of M2-macrophages has been well characterized and it is mediated 
by secretion of specific factors, including VEGF, IL-1β, TNF-α, angiogenin or, indirectly, by 
the release of MMPs. MMPs are responsible for extracellular matrix degradation and 
invasiveness through the connective tissue. They are released by TAMs after cancer cell 
stimulation and they can act locally or be recruited to cancer cell membrane for their trip 
toward progression and invasion 6. Increased frequencies of intra-tumoural TAMs have 
mainly been associated with high levels of MMP type 2 and 9 expression in CRC cells. These 
findings are in accord with a previous cell-line study showing that co-culturing of tumor 
cells with macrophages enhances cancer cell migration, invasiveness, and MMP-2 and 
MMP-9 secretion 18.  
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We review the builders of the CRC microenvironment, focusing on innate immunity and 
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invasion front, particularly the highest TAM density scored as a “hot-spot”, is associated 
with a better patient outcome 17.  More data are likely still needed as to TAM role in CRC, as 
well as on the state of their activation (M1 versus M2) 10. 
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pro-angiogenetic ability of M2-macrophages has been well characterized and it is mediated 
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Several authors have also shown that macrophages can release various cytokines. Kaler et al. 
have recently established that macrophages promote Wnt signaling pathway in CRC cells 
and enhance their proliferation, and demonstrated that macrophages exert their 
protumorigenic activity mainly through the release of IL-1β. The same authors 
demonstrated that Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) 
induced apoptosis of CRC cells is inhibited by macrophage derived IL-1β, and showed that 
macrophages and recombinant IL-1β counteract TRAIL-induced apoptosis through 
activation of Wnt signaling and stabilization of the nuclear transcription factor Snail in 
tumor cells 19. Li et al. first reported that IL-6 released by macrophage directly promotes 
CRC cell progression, also suggesting that the interaction between IL-6 and IL-10 released 
from macrophages is involved in CRC progression and prognosis 20. The above findings 
suggest that TAMs might play a regulatory role in the tumor microenvironment, supporting 
cancer cells to manipulate their microenvironment and facilitate cancer growth. 
Among M1 population, TAM secreting IL-12 and IL-23, infiltrating the tumor invasive front 
are positively correlated with a favorable outcome. As mentioned above, Forssell et al. 
showed that the higher CD68+ macrophage infiltration along the tumor invasive front 
correlated with improved survival in colon cancer compared to rectal cancer. They 
concluded that a dense macrophage infiltration at the tumor invasive front positively 
influences prognosis in colon cancer and that the degree of cell-to-cell contact may influence 
the balance between pro-tumorigenic and anti-tumorigenic properties of macrophages 17. 
High levels of tissue macrophages have been also associated with earlier disease stage, 
absence of nodal and lympho-vascular metastases and an overall better prognosis. Zhou et 
al. by analyzing the relationship between the density of TAMs and the potential of hepatic 
metastasis and survival have shown that a higher density of macrophages along the tumor 
invasive front of CRC was associated with a higher 5-year survival rate 21. In addition, 
according to Forssell’s scoring system that defines CD68 hot-spots as small areas among 
which the infiltration of macrophages is above the average level of CD68-positive cells, the 
highest CD68 hot-spot is associated with the lowest incidence of hepatic metastasis and a 
long interval between colon resection and the occurrence of hepatic metastasis 17, 21.  
The mechanisms behind the anti-tumor effects of TAMs have still not been fully elucidated, 
and seem to potentially be ascribed to the M1 phenotype, which is in part controlled by the 
CD4+T-lymphocytes and the death of cancer cells 22. It has been ascertained that recruitment 
of TAMs contributes to the development of an adaptive immune response against cancer, 
and the balance between antigen availability and clearance through phagocytosis and 
subsequent degradation of senescent or apoptotic cells. 
Mast Cells (MC) originate from the bone-marrow hematopoietic progenitors and migrate to 
peripheral tissue close to the blood vessels, nerves and mucosal surfaces, in order to provide 
a quick defense against any external attack. They participate in tissue remodeling, wound 
healing and angiogenesis, but also they are responsible for pathological conditions such as 
acute and chronic allergic disorders or autoimmune disorders. Recently, increasing 
evidences in animal models and humans support their involvement in cancer. In APC 
deficient and KitW-KitW-v mice, polyps contain significantly higher amount of MC 23, while 
depletion of MC, either pharmacologically or in MC deficient mice, correspond to tumor 
suppression24. In accordance, MC infiltration has been reported in human CRC. MC are 
involved in angiogenesis as well as in tumor microenvironment remodeling. Based on the 
close association between MC and vasculature, their role in angiogenesis is intuitive, and it 
is supported by the evidence of increasing densities of MC during tumor growth, which 
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goes with neo-vessels. Although MC tryptase has been claimed as the major player in this 
association, human MC also constitutively expresses VEGF isoforms. Beyond the 
angiogenesis, MC can play other functions in tumor microenvironment, mainly through 
stimulatory signals, such as Fc receptors and Toll-like receptors (TLR). When activated MC 
release mediators involved in inflammation, matrix destruction and tissue remodeling, 
promoting cancer invasion and metastasis 10, 25, 26. Accordingly, it has been reported that the 
increase in MC count correlated with a worse prognosis in patients. Gulubova and Vlaykova 
proposed the MCs density along the tumor invasive front as a helpful tool for prognosis of 
patients after surgical therapy, showing a correlation between high MCs density and poor 
prognosis 27. Moreover, interactions between MC and regulatory T cells (Treg) have been 
reported 28. MCs have been reported to mobilize T cells and antigen-presenting dendritic 
cells. They modulate Treg-induced tolerance, shifting the local balance of immune 
surveillance toward pro-inflammatory Treg activation and cancer progression29. In light of 
these evidences, modulating mast cell recruitment, viability, activity, or mediator release 
patterns could also have important implication in cancer therapy strategies.  
However, some conflicting data still need to be solved. Analyzing a old large cohort of 
patients, MC infiltration resulted an independent prognostic marker of favorable outcome 
30, and in a recent report by Xia et al. there was no association between MC and prognosis in 
stage IIIB CRCs 24. More studies are required to solve contradictions and validate the role of 
MC as potential prognostic markers and therapeutic target. 
Neutrophils may form up to 15% of the inflammatory infiltrate associated with CRCs 
(tumor associated neutrophils, TAN) and this proportion increases within areas of tumor 
necrosis. Neutrophils secrete substances such as reactive oxygen species and proteinases 
that are capable of altering cell behavior and tumor microenvironment, with both pro-host 
and pro-tumor effects.  
In patients with rectal cancer a high density of neutrophils has been shown as an 
independent predictor of improved prognosis, especially when microscopic abscesses form 
10, 31. On the other hand, an elevated neutrophil/lymphocyte ratio was found by Halazun et 
al. to contribute to a poorer survival time and higher rate of recurrence in CRC patients 
undergoing surgery for liver metastasis 10, 32. It has been proposed that TANs impact on 
tumor growth depends on their activation state. When moderately activated, they promote 
tumor growth and remodel extra cellular matrix via Reactive Oxygen Species (ROS) and 
proteinases. In contrast, when TANs are highly activated they release higher concentrations 
of the same mediators with toxic consequences on tumor cells31.  
Natural killer (NK) cells are granular lymphocytes that form part of the innate cellular 
immune response. In CRC, high numbers of NK cells in the inflammatory infiltrate are 
associated with better prognosis.  The number of NK cells decreases with increasing cancer 
stage 10. Similarly, low preoperative levels of NK cell activity in patients undergoing 
curative resections are associated with disease recurrence. Because of these effects, it has 
been suggested that NK cells can rapidly eliminate tumor cells without prior exposure, 
whereas cytotoxic T cells require prior sensitization and therefore more time to become 
effective 10. The ratio of NK cells in the peripheral blood has also been proposed as a 
prognostic indicator in patients with colon cancer and it is of interest to note that 5-
fluorouracil (FU)-based chemotherapy increases the numbers of NK cells 33. 
Dendritic cells (DCs), antigen-presenting cells (APCs) that are critical to the stimulation of 
effective anti-tumor adaptive immune responses, can become defective in the tumor 
microenvironment and aid in tumor immune evasion by failing to stimulate T lymphocytes. 
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Several authors have also shown that macrophages can release various cytokines. Kaler et al. 
have recently established that macrophages promote Wnt signaling pathway in CRC cells 
and enhance their proliferation, and demonstrated that macrophages exert their 
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from macrophages is involved in CRC progression and prognosis 20. The above findings 
suggest that TAMs might play a regulatory role in the tumor microenvironment, supporting 
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goes with neo-vessels. Although MC tryptase has been claimed as the major player in this 
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It has been suggested that the presence of DCs may be of significant benefit in patients with 
CRC 34. Xie et al. also demonstrated that the presence of DCs was found predominantly in 
early compared to later disease stages and mostly located in tumor surrounding tissue 35. 
2.2 Adaptive immunity  
It is well known that the adaptive, or specific, immunity, occurs several days after the 
exposure to a particular antigen, and it is distinct from the innate immunity with respect to: 
a) the specificity towards the different macromolecules, b) the immunological memory, c) 
the ability to respond in a more powerful and effective way in case of repeated exposure to a 
single pathogen, and d) immunological tolerance i.e. the ability to discriminate between self 
and non-self.  
The adaptive immunity consists of a cellular component represented by T- and B-
lymphocytes, and soluble components represented by the immunoglobulin (Ig) or antibodies. 
From a functional point of view, it can be distinguished between an adaptive humoral 
immunity and a cell-mediated immunity. The antibodies represent the humoral effectors 
and are produced following the activation of specific bone marrow derived B-lymphocytes, 
while cell-mediated effectors are represented by T-lymphocytes. 
T-lymphocytes participate in inflammation, cancer development and progression, as well as 
in anticancer immunity 4, 9. In colitis-associated tumors (CAC) the adaptive immune system 
seems to have mainly a pro-tumorigenic role, while in CRC it may play a double-faced role, 
being the balance between immune-surveillance (carried out by CD8+ and CD4+ T-
lymphocytes) and tumor-promoting inflammation (by various sub-types of T-lymphocytes) 
to change over time, and eventually dictating disease progression. 
Cytotoxic T lymphocytes (CD8+ T-lymphocytes, or CTL) constitute one of the leading 
effectors of antitumor immunity. In order for CD8+ T cells to recognize antigens, these need 
to be exposed on the tumor cells in association with the human leukocyte antigen (HLA) 
class I proteins 36. Upon encounter of a tumor cell antigen/HLA I complex for which their T 
cell receptor (TCR) is specific, CD8+ T-lymphocytes clonally expand and differentiate 36. 
Once activated, cytotoxic T-lymphocytes can mediate specific destruction of tumor cells 
through the release of lytic components via cell-cell interaction 36, 37. Perforin, a cytolytic 
protein found in the granules of CD8+ T-lymphocytes and NK cells, and enzymatic 
proteases, including granzyme B, are secreted determining cell death by disruption of the 
cell membrane and activation of the apoptotic pathway respectively.  
CD4+ T-lymphocytes, which only respond to antigens presented by the HLA class II 
proteins expressed by DCs, are important for antitumor immunity. CD4+ T-lymphocytes are 
mainly subdivided into T helper-1 (Th1) or -2 (Th2) lymphocytes 38. Th1 cells secrete 
cytokines such as interferon-gamma (IFN-γ) and TNF-α, and support cytotoxic T-
lymphocytes by producing IL-2, required for CD8+ T cells proliferation. Conversely, Th2 
cells principally secrete IL-10, IL-4, and IL-5, and limit cytotoxic T-lymphocytes 
proliferation.  
Regulatory T cells (Treg cells) have been defined as a T-cell population that functionally 
suppresses an immune response by influencing the activity of another cell type. Treg cells 
have been mainly categorized into two classes based on their ontogeny: naturally occurring 
Treg (nTreg), which develop in the thymus and are present in mice and healthy humans 
from an early postnatal period, and Treg which can arise in the periphery (or in vitro). nTreg 
are characterized by their high expression of CD25 (CD4+CD25+) and co-expression of the 
FoxP3 39. 
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Although the role of B-lymphocytes in cancer has been overshadowed by the interest in 
developing T-cell-mediated cellular responses, it is now apparent that B-lymphocytes can 
play a complementary role in the host response against tumor. B-lymphocytes represent a 
cell population that express clonally diverse cell surface Ig receptors recognizing specific 
antigenic epitopes 40. In addition to the role of B-lymphocytes in antibody production, these 
cells mediate/regulate several other functions fundamental for immune homeostasis. Of 
significant importance is the antigen-presenting role of B-lymphocytes in the initiation of T-
cell immune responses. Moreover, B-lymphocytes can play a significant role in infection and 
autoimmunity as regulatory cells (indicated as Breg) via the elaboration of suppressive 
cytokines, such as IL-10, TGF-, or IL-4. The role played by B cells in cancer immunology 
remains still complex and somewhat controversial. Depending upon their state of activation, 
B-lymphocytes have had divergent roles on T-cell differentiation and effector function. 
Oversimplifying, resting B-lymphocytes have been reported to suppress T-cell-mediated 
antitumor immunity, by acting on both CD4+ and CD8+ T-lymphocytes. In contrast, a 
number of reports suggest the efficacy of activated B-lymphocytes in cellular immunotherapy 
of malignancies. In particular, activated B-lymphocytes have been reported to enhance the 
ability to generate tumor-infiltrating lymphocytes in vitro involving anti-CD3 and IL-2. 
The therapeutic targeting of tumors or components of the immune system with molecule-
specific monoclonal antibodies (mAb) is now considered a viable treatment option for 
cancer patients  41. One of the currently applied antibodies in clinics is represented by 
rituximab (Rituxan) that targets B cells for elimination by binding the B cell-associated 
marker CD20. Interestingly, Haynes et al. have recently developed a C57BL/6 TRAIL-
sensitive tumor model with the aim of being able to use gene-targeted mice to better 
evaluate the innate and adaptive immune cells contributing to the tumoricidal activity of the 
MD5-1 mAb (i.e. an anti-mDR5 mAb) in more clinically relevant established tumors. 
C57BL/6 gene-targeted or immune cell-depleted mice were used to examine the antitumor 
activity of MD5-1 against the TRAIL-sensitive mouse MC38 colon adenocarcinoma. They 
found that an intact B cell compartment was critical for the therapeutic activity of MD5-1 
against established tumors. B cells were confirmed to trigger tumor cell apoptosis by FcR-
mediated cross-linking of the MD5-1 mAb in vitro and in vivo B lymphocytes were critical for 
directly triggering MD5-1–mediated tumor cell apoptosis.  
Although the role of B-cells in human CRCs is still not completely characterized, B-cell-
deficient mice exhibit spontaneous regression of MC38 colon carcinoma cells. Studies 
involving BCR transgenic mice indicated that B-cells might inhibit antitumor T-lymphocytes 
responses by antigen-nonspecific mechanisms. Shah et al. investigated the role of B cells in 
tumor immunity by studying immune responses of mice genetically lacking B cells to 
primary tumors. They highlight that although the effects of B-lymphocytes on anti-tumor 
response warrant further study, adoptive transfer of CD40(-/-) B cells into B cell-deficient 
mice resulted in restored growth of MC38 colon carcinoma cells suggesting additional 
factors other than CD40 are involved in dampening anti-tumor responses 42.  
3. Immune cells in the colorectal cancer playground  
Nowadays, it is well accepted that the host mounts both an innate and adaptive immune 
response against the cancer with variable effects. The strength of this response can be 
measured and has prognostic significance 43. Dendritic cells, M1 macrophages, Th1 CD4+ T 
lymphocytes, cytotoxic CD8+ T-lymphocytes and NK cells are associated with a tumor 
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It has been suggested that the presence of DCs may be of significant benefit in patients with 
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the ability to respond in a more powerful and effective way in case of repeated exposure to a 
single pathogen, and d) immunological tolerance i.e. the ability to discriminate between self 
and non-self.  
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From a functional point of view, it can be distinguished between an adaptive humoral 
immunity and a cell-mediated immunity. The antibodies represent the humoral effectors 
and are produced following the activation of specific bone marrow derived B-lymphocytes, 
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seems to have mainly a pro-tumorigenic role, while in CRC it may play a double-faced role, 
being the balance between immune-surveillance (carried out by CD8+ and CD4+ T-
lymphocytes) and tumor-promoting inflammation (by various sub-types of T-lymphocytes) 
to change over time, and eventually dictating disease progression. 
Cytotoxic T lymphocytes (CD8+ T-lymphocytes, or CTL) constitute one of the leading 
effectors of antitumor immunity. In order for CD8+ T cells to recognize antigens, these need 
to be exposed on the tumor cells in association with the human leukocyte antigen (HLA) 
class I proteins 36. Upon encounter of a tumor cell antigen/HLA I complex for which their T 
cell receptor (TCR) is specific, CD8+ T-lymphocytes clonally expand and differentiate 36. 
Once activated, cytotoxic T-lymphocytes can mediate specific destruction of tumor cells 
through the release of lytic components via cell-cell interaction 36, 37. Perforin, a cytolytic 
protein found in the granules of CD8+ T-lymphocytes and NK cells, and enzymatic 
proteases, including granzyme B, are secreted determining cell death by disruption of the 
cell membrane and activation of the apoptotic pathway respectively.  
CD4+ T-lymphocytes, which only respond to antigens presented by the HLA class II 
proteins expressed by DCs, are important for antitumor immunity. CD4+ T-lymphocytes are 
mainly subdivided into T helper-1 (Th1) or -2 (Th2) lymphocytes 38. Th1 cells secrete 
cytokines such as interferon-gamma (IFN-γ) and TNF-α, and support cytotoxic T-
lymphocytes by producing IL-2, required for CD8+ T cells proliferation. Conversely, Th2 
cells principally secrete IL-10, IL-4, and IL-5, and limit cytotoxic T-lymphocytes 
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Regulatory T cells (Treg cells) have been defined as a T-cell population that functionally 
suppresses an immune response by influencing the activity of another cell type. Treg cells 
have been mainly categorized into two classes based on their ontogeny: naturally occurring 
Treg (nTreg), which develop in the thymus and are present in mice and healthy humans 
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Although the role of B-lymphocytes in cancer has been overshadowed by the interest in 
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protective behavior, while M2 macrophages, neutrophils, Th2 and Th17 CD4+ T cells, and 
Treg stimulate cancer progression 34 (Table 2). 
 
 
Table 2. Dula role of immunity in colorectal cancer 
Chronic inflammation, mediated by infections, autoimmune disorders or inflammatory 
disease (i.e. Inflammatory Bowel Disease, IBD), is a well recognized cancer-trigger and 
represents the conceptual basis for using anti inflammatory drugs in CRC prevention. 
Macrophages (M2 subtype), secreting growth-, angiogenic- and chemotactic-factors, are the 
main determinant of this process and they are associated with poor patients’ survival. 
Growing evidence suggests that other factors take part in this process, with negative 
consequences on prognosis, such as the pro-inflammatory Th17 cells or Treg 44.  However, 
expression of the transcription factor STAT3 was correlated with higher disease specific 
mortality in CRC 45. In stage IIIB CRC, abnormal expression of the High Motility Group Box 
1 protein (HMGB1) predicted poor survival 46. It has been postulated that STAT3 and 
HMGB1 may have negative effects on the recruitment of anti-cancer effectors. 
In contrast to chronic inflammation, immunosurveillance protects against cancer formation 
and progression. In this scenario, the presence of high numbers of T-lymphocytes has been 
reported to be a positive prognostic factor. The first reports on the beneficial effect of 
lymphocytic infiltration in CRC appeared already in the 1980’s. They were subsequently 
confirmed until recent studies highlighting a prominent function for memory T-
lymphocytes and CD8+ T-lymphocytes in predicting disease-free survival (DFS) and overall 
survival (OS) 47.  
In general terms, it has been suggested that prognosis in patients with cancer is mainly 
positively affected by a) the presence of a tumor gene signature consistent with a type I 
adaptive immune response (i.e., increased antigen presentation, IFN-γ signaling, and TCR 
signaling), and b) the presence of T cells that penetrate through tumor stroma and deeply 
infiltrate the parenchyma to become intra-tumoural T cells 9. Thus, besides a Th-1 response 
signature, the other key feature of an effective immune response is the ability of T cells to 
reach the site of the tumor and to infiltrate it (Table 2).  
ANTI-TUMORIGENIC IMMUNITY PRO-TUMORIGENIC IMMUNITY 
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A number of studies have reported that MSI, CIMP, BRAF mutation, PIK3CA mutation, and 
tumor LINE-1 hypomethylation are associated with CRC prognosis and that lymphocytic 
infiltration is associated with many of these molecular variables. The association of a 
prognostic biomarker with a given disease, strongly suggests its stage-dependency as 
outcome predictor. This is best exemplified by MSI CRC, whose overall prognostic 
advantage is associated with a low frequency of stage III and IV cases at diagnosis as 
compared to MSS counterpart 48. Most MSI CRCs show a pronounced intra-tumoral 
inflammatory infiltrate (which remains a criterion for MSI testing), the mechanistic 
explanation of which, however, is still incompletely understood. Within these tumors, 
infiltrating lymphocytes have been identified as predominantly activated CD8+ T- 
lymphocytes. The presence of CTLs has been attributed to the inherently greater production 
of abnormal peptides as a result of unreliable DNA repair in MSI-positive tumors. It is 
known that truncated peptides produced by frameshift mutations due to MSI may be 
immunogenic and contribute to the host immune response. However, the interrelationship 
between tumor-infiltrating T-lymphocytes, MSI status, and other tumor molecular features 
is still unknown. In any event, the data concerning the prognostic implications of T cells 
have reached now a large volume and support a clear positive correlation between the 
density of T cells and a better prognosis. In this respect, most seminal work has been 
produced by Galon et al. 49, who first showed that  a given immunological signature was 
associated with the absence of pathological evidence of early metastasis and with better 
survival. Such signature featured a high number of CD8+ T cells (including early and 
effector memory T cells). The presence of a high density of infiltrating memory CD45RO+ 
cells, at immunohistochemical analysis of tumor samples, was associated with the absence 
of signs of early metastatic invasion, a less advanced pathological stage, and increased 
survival 47. Subsequently, the same group showed that a high density of CD3+ T cells at the 
tumor invasion front or located in the center of the tumor, once combined, can predict 
patient outcome better than the AJCC stage in patients with stage I to III CRC 49. The 
question as to whether infiltrating T cells are such a powerful prognostic marker to overrun 
the prognostic predictive value of AJCC staging system was faced even by other groups. 
Laghi et al. 50 found that, in the absence of node metastasis, CD3+ T infiltrating cells at the 
tumor invasive front were associated with a low risk of metachronous metastasis and 
consequent survival advantage, independently of the MS-status. This finding challenged the 
view that the density of the T cell infiltrate is a stage independent predictor of survival in 
CRC, and that the positive prognostic value of T cells is dependent upon the CRC MS-status. 
More relevant, is the issue of the real relevance of the adaptive immune cell infiltrate in the 
clinical field. Overall, one would like to know whether the density of T-cells can predict 
patient’s outcome, and at what stage of the disease it can be safely applied, rather than 
whether this is a stage-dependent or independent prognostic factor. It now appears that the 
density of T cells, whether CD3+, CD8+, or CD45RO+, can predict outcome in early stage 
CRC 49-51. Inherently new issues arise from these data. One concerns the CD marker with the 
strongest prognostic value, and the other the standardization of the methods to assess T-cell 
density and their location with respect to CRC (i.e., within the tumor or at its invasive 
margin). It remains controversial whether the T cells infiltration has a prognostic impact 
beyond the stage of lymph-node invasion, a point at which immunoevasion may overcome 
immunosurveillance, although recent data still support the view that even at this disease 
stage T-cells retain a positive prognostic impact 52.  
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Recently, Nosho et al. examined the prognostic role of tumor-infiltrating T-cell subsets in a 
database of 768 CRCs from two prospective cohort studies. They concurrently assessed the 
densities of CD3+, CD8+, CD45RO+, and FoxP3+ lymphocytes as well as other relevant 
molecular (including KRAS, BRAF, and PIK3CA mutations, MSI, CIMP, and LINE-1 
hypomethylation) and pathological features, therefore making possible to estimate the 
independent effect of each T-cell subset density on patient survival. They found that the 
density of CD45RO+ cells, but not that of CD3+, CD8+, or FoxP3+ cells, was an independent 
prognostic biomarker of longer survival in CRC patients, while MSI-high and tumor LINE-1 
methylation level are independent predictors of CD45RO+-cell density 53.  In contrast, 
Salama et al. 54 by analyzing T-cell infiltrates in 967 CRCs including 593 stage II and 374 
stage III cases, reported that FoxP3+ lymphocytes density had stronger prognostic 
significance than CD8+ and CD45RO+ cells, and predicted a better outcome. FoxP3+ 
lymphocytes were found not associated with any histopathological features. At multivariate 
analysis, stage, vascular invasion, and FoxP3+ cell density in tumoural tissue were found to 
be independent prognostic indicators. These results led Salama et al. to conclude that the 
inclusion of FoxP3+ cell density may help to improve the prognostication of early-stage 
CRC. Again, some contradiction exists, as data by other authors suggest that a high density 
of intraepithelial FoxP3+ is associated with a worse survival 55. It should be mentioned that 
in the study by Salama, tissue sampling was obtained randomly, while in the study by 
Sinicrope et al. the density of FoxP3+ cells was measured within the tumor. Thus a low ratio 
of CD3+/FoxP3+ and a low CD3+ numbers were associated with a poor outcome, 
underscoring that even the interplay between effector and Treg cells might be relevant for 
cancer progression 55. However, it is surprising how density of FoxP3+ resulted to be a 
positive prognostic factor when assessed in unspecified tumor regions and a negative one 
when assessed within the tumor. This contradiction calls for further studies aimed to re-
appraise FoxP3+ cells role in CRC, but also underlines the methodological issue of T cells 
topographic assessment 56. More recently, Chew et al. investigated whether Secreted Protein 
Acidic and Rich in Cysteine (SPARC), a matricellular protein involved in tissue remodeling, 
cell migration and angiogenesis, FoxP3, CD8 and CD45RO expression levels were associated 
with CRC stage, disease outcome and long-term cancer specific survival (CSS) in stage II 
and III 57. They found that high levels of SPARC and FoxP3 protein (which seems to have an 
anti-tumorigenic role in cancer progression) were associated with better disease outcome in 
stage II CRC and may be prognostic indicators of CSS.  
As a concluding remark, it should be pointed out that the prognostic value of a given CD set 
likely overlaps with that of a neighbor or subset, and that the overall prognostic value is 
likely the sum of different action exerted by each subset, including the balance between 
effector and regulatory arms.  
It might not exist a T-cell marker that has the highest performance, as the overlapping 
nature of CD includes more than one cell subset.  
Targeting the immune system represents an attractive strategy for the new frontiers in colon 
cancer treatment. Strategy interfering cancer-promoting inflammation: it has been widely 
recognized that the use of anti-inflammatory agents reduces the risk of developing CRC. In 
randomized clinical trials, the administration of celecoxib diminished the cumulative adenoma 
incidence and the frequency of advanced adenomas, suggesting their efficacy in both polyp 
formation and progression. In patients with familial adenomatous polyposis, celecoxib and 
sulindac decrease the incidence of colorectal and duodenal polyps. It is unlikely that anti-
inflammatory drugs alone can represent effective monotherapies for CRC patients, but they 
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might find place in combination withchemo- or radio-therapy or in chemoprevention. The 
non- selective cyclooxygenase (COX) inhibitor sulindac resulted effective in CRC prevention 
and treatment, while aspirin, which reduces CRC risk in a dose- and time-dependent manner, 
is mostly considered as chemopreventive agent. However, a more complete understanding of 
the mechanisms underlying tumor-promoting/protecting inflammation has identified more 
selective targets for intervention. Among non-steroidal anti-inflammatory drugs, specific 
COX2 inhibitors, such as celecoxib and rofecoxib, reduced CRC risk and slowed progression of 
colorectal adenomatous polyps to carcinomas, interfering with the COX isoform whose 
increased activity is specifically associated with CRC pathogens. In the late Nineties and early 
2000s, a great deal of expectations arose from COX-2 inhibitors as tools for primary prevention 
that were lately banned from clinical practice, due to the burden of cardiovascular side effects. 
Highly selective inhibitors of prostaglandin E2 (PGE2) signaling, such as ONO-8711 receptor 
antagonists, are expected to reduce the cardiovascular risks associated with COX inhibition 
but still prevent CRC 58, 59.  Recently biologic agents have been introduced in clinical practice in 
combination with classical chemotherapy for some subtype of disease, as a form of passive 
immunotherapy 60. In contrast to traditional chemotherapeutic drugs, they target specific 
signaling pathways.  For example, VEGF inhibition (i.e. bevacizumab) blocks tumor 
angiogenesis while the interfering with the EGF receptor signaling (i.e. cetuximab) reduces 
survival and growth of cancer cells. Bevacizumab and cetuximab are currently approved in the 
metastatic disease treatment 61. Additionally, it has recently demonstrated that Bevacizumab-
based therapy is able to increase B- and T-lymphocytes compartments 62. It is known that the 
expansion of T lymphocytes could imply an amelioration of dendritic cell-presenting capacity. 
These effects correlate with a more favorable clinical outcome and could be taken into account 
in clinical protocols aimed at combining anti-angiogenetic-therapy with immunotherapy in 
metastatic CRC. 
Inhibitors of pro-inflammatory cytokines might also be developed to block inflammation. A 
number of studies have been conducted using anti-IL6, anti-TNF, anti-IL-1, anti- IL-17, or 
anti-IL-23, but, although some of them have already been approved in IBD or autoimmune 
disorders (i.e. infliximab, etanercept), there is a lack of clinical trials in oncologic settings. 
Similarly, anti-adhesion molecules drugs, currently applied for IBD and rheumatologic 
disorders (i.e. the  (4)-integrin subunit inhibitor Natalizumab) could be potential cancer 
protective agents, preventing an excessive inflammatory response. A monoclonal antibody 
against CD3 (visilizumab), which prevents T-cell activation, had promising preliminary 
results in patients with active Crohn disease 10, 61, 63. In this scenario, colitis associated cancer 
represents an ideal model where such drugs can be helpfully tested. Of notice, the 
mentioned strategies interfere with the tumor promoting inflammation. In the light of the 
dual role of inflammation in CRC, it is important to determine which agents block tumor-
promoting inflammation without reducing antitumor immunity.  
Strategy enhancing cancer-protective inflammation: the immune system in cancer patients 
can be stimulated by active specific immunotherapy (vaccine) in order to eradicate tumor 
cells. Vaccines are expected to be specific for the tumor cells, self sustaining and systemic. 
However a successful vaccine strategy should address and overcome the suppressor 
response that tumor cells are able to mount 10. 
So far, vaccines to treat cancer have been largely investigated with disappointing results in 
terms of clinical response. In advanced CRC patients, although some measurable immune 
response can be registered, the current trails failed to obtain meaningful improvement in 
survivals. Similarly, in adjuvant setting randomized control trials did not show promising 
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result; in this setting, only the autologous tumor cell vaccines combined with Bacilles 
Calmette-Guerin (BCG) seems to significantly improve patients’ survival 64.  
Finally, among passive immunotherapies, a novel charming strategy consists in removing 
anti-tumor T cells from the body for ex vivo culture, followed by reinfusion (adoptive T cell 
transfer)65. Although the first trial failed mostly due to technical issues, the researcher 
remains optimistic that increasing competences will make this strategy a feasible form of 
immunotherapy in the future. 
4. Open issues 
Although the well established role of immune system provides concrete opportunities for 
clinical applications, the heterogeneity of results among studies suggest that many issues 
need to be solved before moving into clinical practice.  
The existing discrepancies in literature may be due to a number of factors such as intra-
tumor distribution of the immune cells and type of subpopulations, type of organ, tumor 
genetic background, and the assessment methods employed. Recent studies have reported 
that different macrophage phenotypes localized to different regions of the carcinoma have 
variable effects on tumor cells 49, 66. Furthermore, evidence has shown that the relationship 
between TAMs and tumor progression is tumor type-dependent. Nevertheless, since the 
tumor microenvironment includes different T-cell sub-populations (Figure 2), which do not 
display a homogeneous infiltration of tumor tissues, potential different impact on prognosis 
may depend on type of sub-population and peri/intra tumor distribution. Because T cell 
infiltration is not spatially homogeneous in CRC, attention has been focused on the 
predictive values of T-lymphocytes located in the center of the tumor, along the invasive 
margin and in lymphoid aggregate (i.e. tertiary lymphoid structures) mainly detectable in 
proximity of the tumor 43, 67. However, the interrelationship between tumor-infiltrating T-
lymphocytes, MSI status, and other tumor molecular features remains to be elucidated. It is 
indubitable that to define the prognostic effect of tumor-infiltrating T cells, large studies of 
CRC with extensive molecular characterization are needed. Additionally, caution is needed 
before incorporating tumor-infiltrating T cells into tumor staging. To minimize the risk of 
inappropriate tumor down-staging at diagnosis, survival data need to be confirmed in 
independent series of patients studied in the past decade. Moreover, the association has to 
be conclusively proven between low densities of tumor-infiltrating T cells and the clinical 
detection of metachronous metastases, which remains the most appropriate outcome 
measure for recognizing a role of the local immune response in micrometastasis 
suppression. Laghi et al. 50 investigated the relationship between the density of CD3+ T 
infiltrating lymphocytes along the tumor invasive margin, and the occurrence of 
metachronous distant-organ metastases after potentially curative resection, in a large, 
consecutive series of patients with deeply invading (pT3 or pT4) MSI-typed CRC, and no 
evidence of distant organ metastasis at diagnosis. They found that large areas covered by 
CD3+ cells at the tumor invasive front are associated with a low risk of metachronous 
metastasis and consequently a survival advantage, only in patients with node-negative 
cancers, but not in patients whose cancers involved lymph nodes. The prognostic advantage 
conferred by a high density of CD3+ cells was independent of tumor MS-status in patients 
with stage II CRC. CD3-immunostaining of CRC tissue might therefore be useful for 
selecting stage II patients who, because they are at very low risk for cancer progression, 
could be spared adjuvant treatments. The usefulness in the clinical scenario of T-cell density 
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in patients with more advanced disease, who are subject to chemotherapy remains to be 
assessed. With respect to this, the relationship between T-cells and current chemotherapy 
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It is clear that as tumors are heterogeneous cell populations that show distinctive genetic 
and epigenetic profiles, there may not be a single biomarker that will prove sufficient 
information for predicting treatment response and patient outcome. However, it remains to 
be solved, several critical issues related to the heterogeneity and complexity between the 
actual studies, in terms of sample size; study setting; disease stage; the presence versus 
absence of treatment data; and treatment modality (no therapy to chemotherapy, radiation 
therapy, or both) 8. Laboratory methods to assess immune response (tissue microarray versus 
whole tissue; objective image analysis versus subjective pathologist qualitative or semi-
quantitative interpretation); immunophenotyping markers; covariates and potential 
confounders assessed (in particular the presence versus absence of tumor molecular 
characteristics); and statistical method and multivariate analysis models all represent issues 
to take in account when comparing results from different laboratories. It is clear that to 
standardize research methods and appropriately evaluate evidence, we need to develop 
general and specific consensus on immune-cell evaluation in oncology research. 
In conclusion, it can be stressed that the standardized analysis of the type, quantity, location 
and the functions of the immune infiltrate becomes a primary step in understanding CRC 
natural history, and, in a clinical perspective, its prognostic determinants. A comprehensive 
analysis of all components of the lymphocytic infiltrates in the context of their localization, 
organization and impact at various steps of tumor progression remains largely, if not 
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result; in this setting, only the autologous tumor cell vaccines combined with Bacilles 
Calmette-Guerin (BCG) seems to significantly improve patients’ survival 64.  
Finally, among passive immunotherapies, a novel charming strategy consists in removing 
anti-tumor T cells from the body for ex vivo culture, followed by reinfusion (adoptive T cell 
transfer)65. Although the first trial failed mostly due to technical issues, the researcher 
remains optimistic that increasing competences will make this strategy a feasible form of 
immunotherapy in the future. 
4. Open issues 
Although the well established role of immune system provides concrete opportunities for 
clinical applications, the heterogeneity of results among studies suggest that many issues 
need to be solved before moving into clinical practice.  
The existing discrepancies in literature may be due to a number of factors such as intra-
tumor distribution of the immune cells and type of subpopulations, type of organ, tumor 
genetic background, and the assessment methods employed. Recent studies have reported 
that different macrophage phenotypes localized to different regions of the carcinoma have 
variable effects on tumor cells 49, 66. Furthermore, evidence has shown that the relationship 
between TAMs and tumor progression is tumor type-dependent. Nevertheless, since the 
tumor microenvironment includes different T-cell sub-populations (Figure 2), which do not 
display a homogeneous infiltration of tumor tissues, potential different impact on prognosis 
may depend on type of sub-population and peri/intra tumor distribution. Because T cell 
infiltration is not spatially homogeneous in CRC, attention has been focused on the 
predictive values of T-lymphocytes located in the center of the tumor, along the invasive 
margin and in lymphoid aggregate (i.e. tertiary lymphoid structures) mainly detectable in 
proximity of the tumor 43, 67. However, the interrelationship between tumor-infiltrating T-
lymphocytes, MSI status, and other tumor molecular features remains to be elucidated. It is 
indubitable that to define the prognostic effect of tumor-infiltrating T cells, large studies of 
CRC with extensive molecular characterization are needed. Additionally, caution is needed 
before incorporating tumor-infiltrating T cells into tumor staging. To minimize the risk of 
inappropriate tumor down-staging at diagnosis, survival data need to be confirmed in 
independent series of patients studied in the past decade. Moreover, the association has to 
be conclusively proven between low densities of tumor-infiltrating T cells and the clinical 
detection of metachronous metastases, which remains the most appropriate outcome 
measure for recognizing a role of the local immune response in micrometastasis 
suppression. Laghi et al. 50 investigated the relationship between the density of CD3+ T 
infiltrating lymphocytes along the tumor invasive margin, and the occurrence of 
metachronous distant-organ metastases after potentially curative resection, in a large, 
consecutive series of patients with deeply invading (pT3 or pT4) MSI-typed CRC, and no 
evidence of distant organ metastasis at diagnosis. They found that large areas covered by 
CD3+ cells at the tumor invasive front are associated with a low risk of metachronous 
metastasis and consequently a survival advantage, only in patients with node-negative 
cancers, but not in patients whose cancers involved lymph nodes. The prognostic advantage 
conferred by a high density of CD3+ cells was independent of tumor MS-status in patients 
with stage II CRC. CD3-immunostaining of CRC tissue might therefore be useful for 
selecting stage II patients who, because they are at very low risk for cancer progression, 
could be spared adjuvant treatments. The usefulness in the clinical scenario of T-cell density 
 
Adaptive and Innate Immunity, Non Clonal Players in Colorectal Cancer Progression 
 
335 
in patients with more advanced disease, who are subject to chemotherapy remains to be 
assessed. With respect to this, the relationship between T-cells and current chemotherapy 




Fig. 2. Adaptive immunity: different Clusters of Differentiation (CD) are expressed by 
subsets of T-lymphocytes 
It is clear that as tumors are heterogeneous cell populations that show distinctive genetic 
and epigenetic profiles, there may not be a single biomarker that will prove sufficient 
information for predicting treatment response and patient outcome. However, it remains to 
be solved, several critical issues related to the heterogeneity and complexity between the 
actual studies, in terms of sample size; study setting; disease stage; the presence versus 
absence of treatment data; and treatment modality (no therapy to chemotherapy, radiation 
therapy, or both) 8. Laboratory methods to assess immune response (tissue microarray versus 
whole tissue; objective image analysis versus subjective pathologist qualitative or semi-
quantitative interpretation); immunophenotyping markers; covariates and potential 
confounders assessed (in particular the presence versus absence of tumor molecular 
characteristics); and statistical method and multivariate analysis models all represent issues 
to take in account when comparing results from different laboratories. It is clear that to 
standardize research methods and appropriately evaluate evidence, we need to develop 
general and specific consensus on immune-cell evaluation in oncology research. 
In conclusion, it can be stressed that the standardized analysis of the type, quantity, location 
and the functions of the immune infiltrate becomes a primary step in understanding CRC 
natural history, and, in a clinical perspective, its prognostic determinants. A comprehensive 
analysis of all components of the lymphocytic infiltrates in the context of their localization, 
organization and impact at various steps of tumor progression remains largely, if not 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
336 
entirely, to be reported to prospective studies. In parallel, understanding the mechanisms of 
efficient immune reactions, the place where they are initiated, the cells and key cytokines 
and chemokines involved, and their impact at different stages of the disease should provide 
new tools and goals for more effective and less toxic targeted therapies. 
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Infectious agents have been increasingly recognized as bona fide etiologic factors of human 
malignancies, particularly gastrointestinal cancers. The estimated total of infection-
attributed malignancies per year is 1.9 million cases, accounting for 17.8% of the global 
cancer burden (Parkin, 2006). Given that colorectal cancer (CRC) is the third most common 
incident cancer worldwide (World health organization, 2003), it seems prudent to explore 
the role of microbial pathogens in colorectal carcinogenesis. By elucidating the probable 
mechanisms by which infectious agents contribute to colorectal oncogenesis, the 
management of CRC may one day parallel what is already in place for cancers such as 
gastric lymphoma and cervical cancer. Antimicrobial therapy and vaccination against some 
of these infections may herald a future with a curtailed role for traditional therapies of 
surgery and chemo-radiotherapy. 
Unlike gastric cancer, which is chiefly linked to a single infectious agent, multiple organisms 
may contribute to the genesis of CRC. Epidemiological and experimental evidence strongly 
implicate several bacterial and parasitic agents in promotion of colorectal carcinogenesis. 
Most of these agents incite continual inflammation, which generates a procarcinogenic 
microenvironment (Parsonnet, 1995; Vennervald & Polman, 2009). Viruses have not attained 
the same status as other microorganisms as probable causative agents, though merit 
attention because of their inherent oncogenic properties and the increasing strength of their 
association with other malignancies (McLaughlin-Drubin & Munger, 2008). Yet, putative 
viral agents seemingly display an immense geographic variation that has led to much 
debate regarding the relative importance of one organism versus another. The present 
review summarizes the data available on the possible relationship of certain micro-
organisms and CRC. These include but not limited to Helicobacter pylori, Streptococcus bovis, 
Bacteroides fragilis, JC virus (JCV), and human papillomavirus (HPV), and intestinal 
schistosomes. The consistency and nature of these associations are discussed, as are the 
mechanisms whereby each pathogen participates in the malignant transformation of the 
colonic mucosa.  
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2. Bacteria  
2.1 Helicobacter pylori 
H. pylori is a gastric microbiome that colonizes approximately 50% of the population 
worldwide (EUROGAST study group, 1993). Gastric infection with H. pylori fosters chronic 
inflammation and significantly increases the risk of developing peptic ulcer disease and 
gastric cancer. Indeed, the bacterium has been designated by the International Agency for 
Research in Cancer (IARC, 1994), as a class I carcinogen in human causing gastric cancer. 
Recently, promotion of tumour development by H. pylori infection in extragastric target 
organs, such as the colorectum, has been reported, though causal relationship is presently 
controversial.  
Cancer in human 
Numerous comparative and case-control studies have examined the relationship between H. 
pylori IgG seropositivity and colorectal neoplasia risk, but the results have been inconsistent. 
While some studies demonstrated positive correlations between colorectal neoplastic 
lesions, especially adenomas, and H. pylori seroprevalence (Aydin et al., 1999; Hartwich et 
al., 2001b; Meucci et al., 1997; Mizuno et al., 2005; Zumkeller et al., 2007), others showed null 
or inverse associations (Moss et al., 1995; Penman et al., 1994; Fireman et al., 2000; Shmuely 
et al., 2001; Siddheshwar et al., 2001; Machida-Montani et al., 2007; D’Onghia et al., 2007). 
Most of these studies were, however, confounded by uncontrolled extraneous variables. 
Breuer-Katschinski et al. (1999) compared H. pylori serostatus between 98 colorectal 
adenoma patients and age/sex-matched hospitalized and populations-based control groups. 
The results clearly demonstrated an increase in the risk of colorectal adenoma in association 
with H. pylori infection following adjustment for dietary and lifestyle factors. Importantly, 
two case-control studies nested in large population-based cohorts failed to establish any 
association between H. pylori seroprevalence and incident CRC, irrespective of adjustment 
for potential confounders (Thorburn et al., 1998; Limburg et al., 2002). In each study, the 
presence of H. pylori was determined in subjects who developed CRC years after serum 
donation. The inconclusive findings in these studies have been partially attributed to small 
sample size, lack of control heterogeneity, and incomplete colonoscopic evaluation (Takeda 
& Asaka, 2005). Besides, serologic methods may not always reflect real-time H. pylori 
infection and likely yield positive results for infections caused by Helicobacter species other 
than H. pylori, which commonly colonize the human colonic mucosa (Keenan et al., 2010). 
Other studies have utilized more reliable diagnostic tools for detection of H. pylori infection. 
Lin et al. (2010) conducted a cross-sectional study using biopsy urease test, and 
demonstrated a significantly increased risk of colorectal adenoma among H. pylori infected-
patients, particularly those with concomitant metabolic syndrome. Conversely, two case 
control studies, using 13C-Urea breath test (UBT), did not substantiate any significant 
associations of H. pylori infection with colorectal tumours (Penman et al., 1994; Liou et al., 
2006). Fujimori et al. (2005) evaluated 699 patients for H. pylori infection using combination 
of three tests; UBT, rapid urease test, and gastric biopsy histology. Their analysis revealed a 
significantly higher prevalence of colorectal adenoma and adenocarcinoma among H. pylori-
positive female patients compared to their H. pylori-free counterparts.  
Of note, in a metanalysis of 11 case-control studies, the summary odd ratio for the 
association of H. pylori infection with the risk for colorectal carcinoma or adenoma was 
found to be 1.4 (95% CI, 1.1–1.8). Different testing methods were, nevertheless, combined to 
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assess the H. pylori infection status in these studies (Zumkeller et al., 2006). More recently, a 
meta-analysis comprising 13 studies and 1709 patients with colorectal neoplasms, arrived at 
summary odd ration of 1.49 (95% CI 1.17–1.91). Further analysis of studies using serologic 
response as the sole indicator of infection revealed a higher summary odd ratio of 1.56 (95% 
CI, 1.14–2.14) (Y. S. Zhao et al., 2008).  
Recently, Soylu et al. (2008) have investigated the presence of H. pylori in colorectal 
neoplasms using immunohistochemical methods, which allowed more accurate detection of 
the non-spiral forms of the bacterium. The prevalence of H. pylori was higher in villous type 
polyps than in tubular type polyps and adenocarcinomas. Contrary to this finding, Jones et 
al. (2007) demonstrated that villous adenoma had the lowest rate of H. pylori positivity 
compared to other premalignant and malignant colonic lesions. Their results also showed 
significant associations of H. pylori positivity with tubular and tubulovillous adenomas, and 
adenocarcinomas, but not with villous adenomas.  
Likewise, studies employing PCR analysis for detection of H. pylori genomic material in the 
cancerous tissue have yielded conflicting results. A Swedish group detected H. pylori DNA 
in 27% of CRC specimens (Bulajic et al., 2007). In contrast, Grahn et al. (2005) identified H. 
pylori DNA in 1.2% of the malignant tissues and, unexpectedly, in 6% of normal mucosal 
samples among patients with CRC. Additionally, there was no statistical correlation 
between H. pylori PCR positivity and CRC. This finding was further confirmed in a later 
study on a separate population (Keenan et al., 2010). 
Cancer in experimental animals 
Studies have shown that amidated gastrins have no stimulatory effect on colon mucosal 
growth or progression of colon cancer in different experimental models (Hakanson et al., 
1986, 1988). Others demonstrated that non-amidated gastrins, including progastrin and Gly-
gastrin, have a mitogenic effect on the colonic mucosa in transgenic mice (T.C. Wang., 1996; 
Koh et al., 1999). Singh et al. (2000a, 2000b) reported that transgenic mice with elevated 
plasma progastrin, but not amidated gastrins, exhibit increased aberrant crypt foci, 
adenomas, and adenocarcinomas after treatment with azoxymethane, whilst no tumours 
developed in mice exposed to either progastrin or azoxymethane only. These results suggest 
that non-amidated gastrin is not a carcinogen on its own, but rather promotes oncogenic 
progression. 
Mechanisms/Mechanistic studies 
Various pathogenetic mechanisms have been suggested by which H. pylori exerts its 
oncogenic potential. First, persistent H. pylori exposure induces hypergastrinemia, which is a 
putative trophic factor for the human colorectal mucosa, thereby increasing the mutation 
susceptibility (Renga et al., 1997). Moreover, studies showed that most human colon cancers 
secrete gastrin, primarily non-amidated gastrins, which likely function in autocrine fashion 
(Baldwin et al., 1998). Non-amidated gastrin induces proliferation and invasiveness of 
human tumour cells in vitro (Kermorgant & Lehy, 2001). In conjunction with these findings, 
the overexpression of cyclooxygenase-2 (COX-2) was shown to stimulate the cancer cells to 
release excessive amount of prostaglandin E2 (PGE2), leading to further proliferation 
(Hartwich et al., 2001b).  
Although some reports, including a well-controlled prospective study, provided statistical 
evidence that high fasting plasma gastrin level is associated with increased risk of colorectal 
adenoma and carcinoma (Hartwich et al., 2001b; Thorburn et al., 1998; Georgopoulos et al., 
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adenoma and carcinoma (Hartwich et al., 2001b; Thorburn et al., 1998; Georgopoulos et al., 
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2006), others showed no associations (Penman et al., 1994; Fireman et al., 2000; Machida-
Montani et al., 2007; Robertson et al., 2009). In a majority of these studies only amidated 
gastrin was measured, which may have contributed to the discrepancy in results (Dickinson, 
1995). In a recent study, circulating forms of both amidated and non-amidated gastrins were 
measured. Non-amidated gastrins were significantly higher in patients with colorectal 
carcinomas, compared with levels in control patients (Ciccotosto et al., 1995). 
Second, H. pylori-related chronic gastritis might contribute to colorectal carcinogenesis by 
reducing gastric acid secretion with consequent alteration in the normal gastrointestinal 
flora (Kanno et al., 2009). Another possibility is that CagA protein (Fig 1.), which is 
produced by virulent strain of H. pylori, may contribute to colorectal carcinogenesis by 
inducing an enhanced inflammatory response and potentiating gastrin secretion (Peek et al., 
1995; J.H. Kim et al., 1999). As for the correlation between colorectal neoplasia and CagA+ H. 
pylori serostatus, three studies indicated positive correlations between CagA+ H. pylori 
seropositivity and colorectal tumours (Hartwich et al., 2001b; Shmuely et al., 2001; 
Georgopoulos et al., 2006), while two other studies found no such correlation (Zumkeller et 
al., 2007; Limburg et al., 2002).  
 
Fig. 1. Illustration of the possible mechanisms of bacterial-toxin-induced carcinogenesis. 
2.2 Streptococcus bovis  
S. bovis, a nonenterococcal lancefield group D streptococcus, is a transient colonic commensal 
with fecal carriage rate of 5 - 13 % in healthy adults (Potter et al., 1998; Dubrow et al., 1991), 
and accounts for 11-12% of infective endocarditis (Ballet et al., 1995; Kupferwasser et al., 
1998). Traditionally, S. bovis has been classified into three distinct biotypes; I, II/1, and II/2, 
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based on phenotypical and genetic characteristics (Coykendall & Gustafson, 1985). Further 
studies using phylogenetic analysis allowed clear and unambiguous differentiation of 
human clinical isolates and indicated that all strains of S. bovis I and II/2 be identified as S. 
gallolyticus (Schlegel et al., 2003). The latter accounts for most of the human strains isolated 
from blood or faeces, and is often responsible for endocarditis cases associated with colonic 
cancer (Schlegel et al., 2003).  
Cancer in humans 
The association between S. bovis endocarditis and colorectal carcinoma was first brought to 
light by Keusck (1974). Subsequent case studies showed a wide range of prevalence of 
colorectal neoplasms in patients with S. bovis bacteraemia (6 - 67%), depending on the 
diligence with which the diagnosis was sought (Pigrau et al., 1988; Klein et al, 1979; H.W. 
Murray & Roberts, 1978; Friedrich et al., 1982a; Reynolds et al., 1983; Zarkin et al., 1990; 
Gold et al, 2004; Alazmi et al, 2006; Beeching et al., 1985). Additionally, some patients 
developed new colonic tumours 2 to 4 years following the incidence of S. bovis endocarditis, 
pointing to a possible temporal relationship between the two events (Zarkin et al., 1990; 
Robbins & Klein, 1983; Muhlemann et al., 1999; Friedrich et al., 1982b). Other studies 
reported that patients with S. bovis endocarditis had significantly higher rates of colorectal 
neoplasms than those with endocarditis due to other pathogens or non-endocarditis patients 
(Pergola et al., 2001; Hoen et al., 1994). More particularly, Ruoff et al. (1989) showed that S. 
bovis I bacteraemia was highly correlated with malignant and premalignant colonic lesions, 
compared to bacteraemia due to other S. bovis biotypes. This conclusion was affirmed by 
several recent analyses, in which the incidence of colonic tumours in patients with S. bovis I 
infection ranged between 27 - 94% (Herrero et al., 2002; Tripodi et al., 2004; Corredoira et al., 
2008; Vaska & Faoagali, 2009; Ruoff et al, 1999). 
Several investigators have studied the association between the fecal carriage rate of S. bovis 
and both malignant and premalignant colorectal lesions, with the results being 
contradictory (Klein et al., 1977; Potter et al., 1998; Norfleet & Mitchell, 1993; Burns et al., 
1985). Comparing the growth of S. bovis from tissue biopsy of adenomas or carcinomas did 
not show increased frequency compared to normal mucosa from the same patients or non-
cancer-patients group (Potter et al., 1998; Norfleet & Mitchell, 1993). In contrast, Abdulamir 
et al. (2010), using bacteriological studies and molecular techniques to detect S. gallolyticus in 
tissue or faeces, revealed a significantly higher frequency of S. gallolyticus isolation from 
tumorous and non-tumorous tissue in CRC patients than from normal mucosa in control 
subjects. In parallel, the faecal carriage rate of S. gallolyticus was similar in cancer and control 
groups.  
In another aspect, Darjee and Gibb (1993) used immunoblotting and enzyme-linked 
immunosorbent assay (ELISA) to compare anti-S. bovis IgG levels in sera of 16 colonic cancer 
patients and 16 age-matched controls. Immunoblot assay showed no significant difference in 
the serologic parameters between patients and controls, whilst ELISA demonstrated higher 
median S. bovis IgG antibody titres in patients with colonic cancer, compared to controls. 
Using immunocapture mass spectrometry, Tjalsma et al. (2006) showed a higher frequency 
of anti-S. bovis seropositivity in patients with colonic polyps and cancer than age-matched 
controls. Importantly, recent studies reported that CRC and adenoma were associated with 
higher levels of serum anti-S. gallolyticus IgG antibody in comparison with healthy and 
tumour-free control subjects (Abdulamir et al., 2009).  
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It is clear that a strong association does exist between symptomatic S. bovis infection and 
colorectal neoplasia, which has important clinical implications. Patients who have S. bovis 
bacteraemia, with or without endocarditis, require extensive endoscopic evaluation for 
occult premalignant and malignant colonic cancer (Konda & Duffy, 2008). Further, recent 
evidence indicates that serum antibodies to S. bovis represent a promising potential for early 
diagnosis and prevention of CRC (Tjalsma et al., 2006). 
Cancer in experimental animals 
Studies have shown that administration of S. bovis or S. bovis wall extracted antigens (WEA) 
to azoxymethane- treated rats resulted in almost two-fold increase in the number of aberrant 
colonic crypts, compared to azoxymethane-only treated control rats. Fifty percent of the rats 
receiving WEA developed colonic adenomas, whereas no tumour was detected in the other 
groups. It is noteworthy to mention that normal rats did not develop hyperplastic colonic 
crypts upon treatment with S. bovis suspension, implying that S. bovis proteins are involved 
in promoting rather than initiating oncogenesis (Ellmerich et al., 2000b). Similar results were 
obtained by Biarc et al., (2004) who also reported that a purified form of S. bovis WEA (S300 
fraction) is even more potent inducer of neoplastic progression than WEA or the intact 
bacteria.  
Mechanisms/Mechanistic studies 
Although Klein et al. (1977) originally theorized that S. bovis may play a role in producing 
carcinogens in the large bowel, recent data showed that S. bovis wall proteins (Fig. 1.) have 
proinflammatory potential and procarcinogenic properties (Nguyen et al., 2006). In vitro 
studies indicated that activation of human colonic epithelial cell line Caco-2 by S. bovis cell 
wall proteins, especially S300 fraction, resulted in significant increase in IL-8 production, 
COX-2 expression, and PGE2 release (Biarc et al., 2004), whereas binding of S. bovis activated 
human leucocytes cell line to release TNF-α (Ellmerich et al., 2000a). These results are in 
agreement with those obtained in in vivo experiments showing that S. bovis as well as cell 
wall antigens from this bacterium are able to increase the production of IL-8 and PGE2 in the 
colonic mucosa of rats (Ellmerich et al., 2000b; Biarc et al., 2004). More recently, human 
studies have provided evidence for a strong association between S. gallolyticus IgG 
seropositivity and nuclear factor kappa B (NF-κB) and IL-8 expression in tumorous sections 
of both colorectal adenomas and carcinomas (Abdulamir et al., 2009). Using quantitative 
PCR analysis to measure bacterial count in cancerous tissue, the same group observed a 
positive correlation between the levels of expression of IL-1, COX-2, and IL-8 and the S. 
gallolyticus load in tumorous colorectal tissue (Abdulamir et al., 2010). Apart from its 
inflammatory potential, S. bovis cell wall proteins may activate mitogen-activated protein 
kinases (MAPKs), stimulating a proliferative response in the host cells and increasing the 
likelihood of cell transformation (Biarc et al., 2004). 
Notably, the chemokine 1L-8 is potent angiogenic factor and neutrophil chemoattractant (Li 
et al., 2001), which as well as other cytokine such as TNF-α, IL-1β, and IL-6, trigger a chronic 
inflammation with resultant production of highly mutagenic reactive oxygen and nitrogen 
species (Ohshima & Bartsch., 1994). COX-2, through production of excessive amounts of 
prostaglandins, inhibits apoptosis, and promotes tumour cell proliferation, angiogenesis, 
and tumour invasiveness (Hartwich et al., 2001a). In addition, activation of NF-κB pathway 
induces the expression of downstream mediators such as COX-2, TNF-α, and IL-6, all 
contributing to inflammation-related tumorigenesis (S. Wang et al., 2009).  
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2.3 Bacteroides fragilis 
B. fragilis is a gram-positive, anaerobic colonic microflora in most mammals, and is the 
leading cause of anaerobic bacteraemia and intraabdominal suppurative infection in human 
adults (Wexler et al., 2007). The pathogenicity of this bacterium is attributed to several 
virulence determinants, including a recently identified metalloprotease toxin, called 
fragilysin. Fragilysin-producing B. fragilis, termed enterotoxigenic B. fragilis (ETBF), causes 
acute inflammatory diarrheal disease and asymptomatically colonizes up to 20 -35 % of 
adults (Sears et al., 2008). As well, it has been recently linked to flare-ups of inflammatory 
bowel disease (Basset et al., 2004; Prindiville et al., 2000).  
Cancer in human 
The epidemiological evidence on the association B. fragilis infection and colorectal neoplasia 
is limited. Early studies by Legakis et al. (1981) indicated that the incidence of fecal B. fragilis 
in CRC patients was significantly higher than in healthy subjects, suggesting a possible role 
for B. fragilis in colon carcinogenesis. Moore et al. (1995), however, did not find any 
significant difference in the frequency of fecal carriage of B. fragilis between colorectal 
adenoma patients and low-risk healthy controls. Similarly, a seroepidemiological study 
showed lack of associations between B. fragilis IgG serostatus and colorectal adenoma and 
carcinoma (Abdulamir et al., 2009). Using PCR methods, Toprak et al. (2006) recently 
compared the prevalence of ETBF in stool specimens from 73 patients with CRC with 59 
age-matched controls. The frequency of isolation of the organism was significantly higher in 
the CRC patients (38%) than in the control group (12%). These findings, however, have not 
been replicated in another population. 
Cancer in experimental animals 
Studies of murine models have demonstrated that ETBF induced persistent subclinical 
colonic inflammation and hyperplasia in specific pathogen-free C57BL/6 mice (Rhee et al., 
2009). The same group used the adenomatous polyposis coli multiple intestinal neoplasia 
(ApcMin/+) mice to model human CRC. ETBF-colonized ApcMin/+ mice developed 
inflammatory colitis and unusually early onset microadenomas. In addition, de novo colon 
tumours appeared as early as 4 weeks and distributed predominantly in the distal colon, 
similar to those found in humans (Wu et al., 2009).  
Mechanisms/Mechanistic studies 
The current experimental evidence suggests a potential role of fragilysin in the oncogenic 
transformation of the colonic mucosa (Fig. 1.). In vitro studies have shown that fragilysin 
induces IL-8 expression and NF-κB activation in human colonic epithelial cell lines HT29 
and Caco-2 (Sanfiloppo et al., 2000; J.M. Kim et al., 2001). IL-8 is a potent neutrophil 
chemokine, whereas NF-κB is an essential transcription factor that regulates neutrophils 
migration and the host epithelial cell chemokine response (J.M. Kim et al., 2002). 
Additionally, it was demonstrated that fragilysin binds to human colonic epithelial cell line 
HT29/C1 and stimulates cleavage of the tumour suppressor protein, E-cadherin. The 
resultant nuclear translocation of the adhesion molecule β-catenin causes increased 
expression of T-cell factor-target genes, including c-myc, with consequent persistent cellular 
proliferation (Wu et al., 1998, 2003).  
Recent showed that all ETBF-induced tumours in ApcMin/+ mice exhibited intense Stat3 
protein activation, which in turn induces dominant colonic IL-17-producing CD4+ T-cells 
infiltrate. Tumour formation was significantly inhibited by administration of blocking 
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antibodies to IL-17 (Wu et al., 2009). The latter is known to promote tumour growth in vitro 
and in vivo through induction of IL-6 synthesis (L. Wang et al., 2009). These results 
emphasized the contribution of endogenous T cell immune response in ETBF infection- 
derived colorectal carcinogenesis.  
In addition, B. fragilis may indirectly promote colon carcinogenesis through production of 
cytotoxic metabolites such as deoxycholic acid and fecapentaenes. Studies have shown that 
deoxycholic acid induce proliferation of colonic cells in vitro and promote colonic tumour 
progression in experimental animals (Peiffer et al., 1997; T. Hori et al., 1998). Several 
epidemiological studies found a positive association between high faecal deoxycholic acid 
concentration and colorectal adenoma and carcinoma risk (Little et al., 2002; Reddy & 
Wynder, 1977), including a prospective study assessing faecal deoxycholic acid levels before 
the diagnosis of colorectal tumours (Kawano et al., 2010). Fecapentaenes are other fecal 
mutagens synthesized by Bacteroides species, which were shown to be highly genotoxic in 
both mammalian and bacterial in vitro assays (Plummer et al., 1986; Curren et al., 1987). 
Clinical studies, however, indicated that fecal fecapentaenes levels are not associated with 
colorectal adenomas and inversely associated with carcinomas (de Kok et al., 1993; 
Schiffman et al., 1989). It was concluded that if fecapentaenes form a relevant factor in 
colorectal carcinogenesis, their role is more likely to be related to the transformation of late 
adenomas into malignant tumors. 
2.4 Other bacterial species 
There are very few reports on the role of enteric bacterial flora other than B. fragilis in 
colorectal tumorigenesis. Severe distal colitis, rectal dysplasia, and adenocarcinoma were 
observed in IL-10 knockout mice colonized with Enterococcus faecalis (Balish & Warner, 2002; 
S.C. Kim et al., 2005). E. faecalis has been shown to produce reactive oxygen species and 
induce DNA damage, aneuploidy and tetraploidy in colonic epithelial cells both in vivo and 
in vitro (Huycke et al., 2002; X. Wang et al., 2008). Furthermore, it was demonstrated that E. 
faecalis promotes chromosomal instability in mammalian cells, possibly through COX-2 
dependent mechanism (X. Wang & Huycke, 2007). Epidemiological studies, however, could 
not establish any association between colonic colonization of E. faecalis and development of 
CRC (Winters et al., 1998). 
Studies showed that mucosa-associated and intramucosal Escherichia coli were significantly 
associated with Crohn’s disease, and colorectal adenomas and carcinomas (Swidsinski et al., 
1998; Martin et al., 2004). E. coli stimulates IL-8 release from the I407 and HT29 cell lines 
(Martin, 2004), and acts synergistically with E. faecalis to induce aggressive pancolitis with 
reactive atypia in IL-10 deficient mice (S.C. Kim et al., 2007). Recently, Maddocks et al. 
(2009) reported that enteropathogenic E. coli downregulates DNA mismatch repair proteins 
which increases the susceptibility of colonic epithelial cells to mutations and therefore 
promotes colonic tumorigenesis.  
3. Viruses 
3.1 Human papilloma virus 
Human papilloma virus is a double stranded DNA virus that is transmitted through direct 
contact with infected skin or mucous membrane, and causes the most common sexually 
transmitted disease among sexually active individuals (Koutsky, 1997). While it is well 
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established that HPV is a necessary cause of cervical cancer, studies suggest HPV may be 
involved in the malignant transformation of the oropharynx and the anogenital tract 
(D’Souza et al., 2007;  Steenbergen et al.,  2005). There are more than 100 subtypes of HPV; 
some of these subtypes, particularly HPV-16 and HPV-18, are referred to as high risk 
oncogenic infections (Wiley & Masongsong, 2006; Munoz et al., 2003).  
Cancer in human 
Early case studies have failed to show any association between HPV infection and colorectal 
carcinoma in relatively small samples of colorectal carcinoma tissue (Boguszakova et al., 
1988; Koulos et al., 1991; Shah et al., 1992; Shroyer et al., 1992). Subsequent studies have 
employed more stringent methods for HPV detection, including PCR and 
immunohistochemistry. Despite the variation in the control specimen, all studies confirmed 
an association between HPV detection rates, specifically subtypes 16 and 18, and CRC with 
odd ratio ranging between 2.7 (95% CI, 1.1–6.2) and 9.1 (95% CI, 3.7–22.3). (Cheng et al., 
1995; Kirgan et al., 1990). Moreover, the strength of association was related to the degree of 
tumour dysplasia. On the contrary, two of three large prospective cohort studies, with 
sample sizes ranging between 21,222 and 104,760 cases of cervical cancer, reported no 
increased risk of subsequent CRC in patients with cervical cancer (Weinberg et al., 1999; 
Rex, 2000). The other study has shown increased risk of anorectal cancer among patients 
with cervical cancer, though with lack of clarity over whether it was due to HPV infection or 
radiation (Chaturvedi et al., 2007).  
Mechanism/ mechanistic studies 
The oncogenic property of the virus is related to early genes which encode the regulatory 
proteins E6 an E7. It was hypothesized that these proteins interact and inactivate suppressor 
genes p53 and pRb, and thus inhibiting apoptosis (Steenbergen et al., 2005). Although about 
50% of all colorectal cancer has mutated p53 (Slattery et al., 2002), Buyru et al. (2003) 
reported that only 3.6% of HPV-positive colorectal cancers contained mutations in p53, 
suggesting that HPV may have direct oncogenic effects independent of any p53 mutations.  
3.2 John Cunningham virus 
JC virus is a widespread neurotropic polyoma virus, with seroprevalence rates of 39-90% 
among healthy adult population (Kean et al., 2009; Shah, 1996). Primary JCV infection 
typically occurs during early childhood, probably via fecal-oral route, followed by latency of 
the virus in the kidney and gastrointestinal tract (Khalili et al., 2003, Ricciardiello et al., 
2000). The virus may be reactivated in the presence of severe immunosuppression, and 
replicates in the central nervous system causing a fatal demyelinating disease, progressive 
multifocal leukoencephalopathy. Furthermore, there is mounting evidence suggesting that 
JCV infection may be associated with several human malignancies including brain tumours 
and upper gastrointestinal cancers (Caldarelli-Stefano et al., 2000; Del Valle et al., 2001, 2005; 
Shin et al., 2006). 
Cancer in human 
The potential association between JCV infection and colorectal neoplasia has been examined 
using nested PCR, Southern blotting and in situ hybridization techniques. Ten studies, with 
sample sizes ranging from 18 to 186, detected JCV genomic sequences in 9-89% of colorectal 
carcinomas and 5-82% of adenomatous tissue (Laghi et al., 1999; Theodoropoulos et al., 2005; 
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antibodies to IL-17 (Wu et al., 2009). The latter is known to promote tumour growth in vitro 
and in vivo through induction of IL-6 synthesis (L. Wang et al., 2009). These results 
emphasized the contribution of endogenous T cell immune response in ETBF infection- 
derived colorectal carcinogenesis.  
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cytotoxic metabolites such as deoxycholic acid and fecapentaenes. Studies have shown that 
deoxycholic acid induce proliferation of colonic cells in vitro and promote colonic tumour 
progression in experimental animals (Peiffer et al., 1997; T. Hori et al., 1998). Several 
epidemiological studies found a positive association between high faecal deoxycholic acid 
concentration and colorectal adenoma and carcinoma risk (Little et al., 2002; Reddy & 
Wynder, 1977), including a prospective study assessing faecal deoxycholic acid levels before 
the diagnosis of colorectal tumours (Kawano et al., 2010). Fecapentaenes are other fecal 
mutagens synthesized by Bacteroides species, which were shown to be highly genotoxic in 
both mammalian and bacterial in vitro assays (Plummer et al., 1986; Curren et al., 1987). 
Clinical studies, however, indicated that fecal fecapentaenes levels are not associated with 
colorectal adenomas and inversely associated with carcinomas (de Kok et al., 1993; 
Schiffman et al., 1989). It was concluded that if fecapentaenes form a relevant factor in 
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observed in IL-10 knockout mice colonized with Enterococcus faecalis (Balish & Warner, 2002; 
S.C. Kim et al., 2005). E. faecalis has been shown to produce reactive oxygen species and 
induce DNA damage, aneuploidy and tetraploidy in colonic epithelial cells both in vivo and 
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faecalis promotes chromosomal instability in mammalian cells, possibly through COX-2 
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CRC (Winters et al., 1998). 
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associated with Crohn’s disease, and colorectal adenomas and carcinomas (Swidsinski et al., 
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established that HPV is a necessary cause of cervical cancer, studies suggest HPV may be 
involved in the malignant transformation of the oropharynx and the anogenital tract 
(D’Souza et al., 2007;  Steenbergen et al.,  2005). There are more than 100 subtypes of HPV; 
some of these subtypes, particularly HPV-16 and HPV-18, are referred to as high risk 
oncogenic infections (Wiley & Masongsong, 2006; Munoz et al., 2003).  
Cancer in human 
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odd ratio ranging between 2.7 (95% CI, 1.1–6.2) and 9.1 (95% CI, 3.7–22.3). (Cheng et al., 
1995; Kirgan et al., 1990). Moreover, the strength of association was related to the degree of 
tumour dysplasia. On the contrary, two of three large prospective cohort studies, with 
sample sizes ranging between 21,222 and 104,760 cases of cervical cancer, reported no 
increased risk of subsequent CRC in patients with cervical cancer (Weinberg et al., 1999; 
Rex, 2000). The other study has shown increased risk of anorectal cancer among patients 
with cervical cancer, though with lack of clarity over whether it was due to HPV infection or 
radiation (Chaturvedi et al., 2007).  
Mechanism/ mechanistic studies 
The oncogenic property of the virus is related to early genes which encode the regulatory 
proteins E6 an E7. It was hypothesized that these proteins interact and inactivate suppressor 
genes p53 and pRb, and thus inhibiting apoptosis (Steenbergen et al., 2005). Although about 
50% of all colorectal cancer has mutated p53 (Slattery et al., 2002), Buyru et al. (2003) 
reported that only 3.6% of HPV-positive colorectal cancers contained mutations in p53, 
suggesting that HPV may have direct oncogenic effects independent of any p53 mutations.  
3.2 John Cunningham virus 
JC virus is a widespread neurotropic polyoma virus, with seroprevalence rates of 39-90% 
among healthy adult population (Kean et al., 2009; Shah, 1996). Primary JCV infection 
typically occurs during early childhood, probably via fecal-oral route, followed by latency of 
the virus in the kidney and gastrointestinal tract (Khalili et al., 2003, Ricciardiello et al., 
2000). The virus may be reactivated in the presence of severe immunosuppression, and 
replicates in the central nervous system causing a fatal demyelinating disease, progressive 
multifocal leukoencephalopathy. Furthermore, there is mounting evidence suggesting that 
JCV infection may be associated with several human malignancies including brain tumours 
and upper gastrointestinal cancers (Caldarelli-Stefano et al., 2000; Del Valle et al., 2001, 2005; 
Shin et al., 2006). 
Cancer in human 
The potential association between JCV infection and colorectal neoplasia has been examined 
using nested PCR, Southern blotting and in situ hybridization techniques. Ten studies, with 
sample sizes ranging from 18 to 186, detected JCV genomic sequences in 9-89% of colorectal 
carcinomas and 5-82% of adenomatous tissue (Laghi et al., 1999; Theodoropoulos et al., 2005; 
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R. Hori et al., 2005; Casini et al., 2005; Enam et al., 2002; Goel et al., 2006; P. Y. Lin et al., 2008, 
Niv et al., 2010a; Karpinski et al., 2011; Jung et al., 2008). Comparing neoplastic tissues with 
normal mucosa, three of these studies showed consistently higher detection rates for JCV in 
colorectal cancerous tissues and adenomas than in normal tissue (Theodoropoulos et al., 
2005; R. Hori et al., 2005; Enam et al., 2002). As well, significantly higher viral copy numbers 
were observed in colorectal carcinomas and adenomas compared to adjacent normal 
mucosa (Laghi et al., 1999; Theodoropoulos et al., 2005). Of note, a sequence of the Mad-1 
variant of JCV, which lacks 98 nucleotides repeats, has been found preferentially in colon 
cancers, raising the possibility that certain strains may be selectively activated in colonic 
epithelial cells (Ricciardello et al., 2001). Other studies have employed real-time PCR, a less 
sensitive molecular technique, to detect JCV genetic material in colorectal carcinomas, 
adenomas, normal mucosa, and urine samples from CRC patients and controls. While JCV 
carrier frequencies in urine were comparable to previously published reports (Agostini et 
al., 1999), none of the neoplastic tissues and less than 1% of the normal tissues tested 
positive for JCV DNA (Newcomb et al., 2004; Campello et al., 2010; Militello et al., 2009). The 
discordant results in previous investigations may be explained by the small sample sizes, 
variable prevalence of viral infection among the studied populations, inherent lack of 
uniformity in the sensitivity of the assay used, and possible laboratory contamination 
particularly in studies where Mad 1 viral sequence was used as a positive template control 
(Newcomb et al., 2004).   
The expression pattern of JCV T-antigen has also been studied in both colorectal neoplastic 
and normal mucosa. About 35%-94% of CRC tissues and 5-50% of colorectal adenomas were 
found to host JCV T-antigen, which is often concentrated in the nucleus (Enam et al., 2002; P. 
Y. Lin et al., 2008; Goel et al., 2006; Link et al., 2009; Nosho et al., 2008, 2009; Ogino et al., 
2009; Selgrad et al., 2008; Jung et al., 2008). The expression of JCV T-antigen was 
significantly higher in colorectal adenomas from liver transplant recipients compared to 
adenomas in normal controls, pointing to a possible etiologic role for immunosuppression 
(Selgrad et al., 2008). Interestingly, viral DNA has always been detected more frequently 
than Tag expression in both colonic adenomas and carcinomas. This suggests that either in 
some samples, the viral copy number is too low to determine expression of the early gene 
or, alternatively, that the growing tumour tends to lose viral sequences (Ricciardello et al., 
2003). In another aspect, two prospective nested case-control investigated the association 
between JC seroprevalence and colorectal neoplasms in large groups of patients from whom 
blood samples were collected months or years before colorectal cancer diagnosis (Rollison et 
al., 2009; Lundstig et al., 2007). Although there was no association between JC seropositivity 
and colorectal cancer, one study showed a significantly increased risk of adenomas among 
seropositive male subjects (Rollison et al., 2009). More recently, Niv et al. (2010b) observed 
positive correlation between the presence of neoplastic colonic lesion and the titre of JCV 
antibody in the serum, pointing to JCV infection as an early event for the formation of 
colorectal adenoma. 
Mechanism/ mechanistic studies 
The JCV T-antigen is a potent oncogenic protein capable of transforming mammalian cells 
and is likely involved the early stages of colorectal carcinogenesis though “hit and run” 
mechanisms. These include disruption of the Wnt signalling pathway and inactivation of 
tumour suppressor genes such as pRb and p53 (Ludlow, 1993). Both in vitro and in vivo 
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studies have shown that coexpression of p53 and JCV T-antigen in CRC cells (Enam et al., 
2002; Nosho et al., 2009; Ricciardello et al., 2003). Similarly, colocalization of T-antigen and 
B-catenin was observed in the nuclei of neoplastic columnar cells (Enam et al., 2002; nosho et 
al., 2009). Cooperativity between B-catenin and JCV T-antigen increased in vitro 
transcription of c-myc, leading to chromosomal instability (Enam et al., 2002). Ricciardiello et 
al. (2003) demonstrated that JCV can induce chromosomal instability in vitro using the 
diploid CRC cell line, which defines loss of heterozygosity (LOH). Subsequent studies 
reported a significant association between JCV T-antigen expression and CRC with LOH 
(Nosho et al., 2009; Goel et al., 2006; Ogino et al., 2009). This deletional event probably 
provides the second hit at the tumour suppressor genes, and eventually leads to clonal 
expansion. The role of DNA hypermethylation has recently been explored in both colorectal 
carcinoma and adenoma, nevertheless the results were contradictory (Nosho et al., 2008, 
2009; Goel et al., 2006). 
3.3 Other viruses 
Epstein-Barr virus (EBV) is a DNA virus with strong association with several 
lymphoreticular malignancies, especially Burkett’s lymphoma, as well as certain epithelial 
tumours such as the nasopharyngeal carcinoma (Parkin, 2006). Additionally, EBV has also 
been reported with gastric cancer (Koriyama et al., 2001; Takada, 2000), breast (Labrecque et 
al., 1995; Bonnet et al., 1999; Fina et al., 2001) and lung cancer (Castro et al., 2001; Han et al., 
2001; M.P. Wong et al., 1995). For colorectal cancer, although early studies have detected 
high rates of EBV infection in colorectal carcinoma tissue, using PCR, 
immunohistochemisrty and fluorescence in situ hybridization (Song et al., 2006; Liu et al., 
2002, 2003), only one study reported significant difference in EBV detection rates between 
colorectal carcinoma tissue and adjacent normal mucosa (Song et al., 2006). Follow-up 
studies failed to show any evidence that EBV was detected at a significantly higher rate in 
colorectal carcinoma (Grinstein et al., 2002; Yuen et al., 1994), even in higher risk 
populations such as patients with ulcerative colitis (N.A. Wong et al., 2003).  
In the case of Cytomegalovirus (CMV), early limited studies have detected CMV genome in 
the colon carcinoma tissue, whereas controls from normal colons and cases of Crohn disease 
were negative (Huang & Roche, 1978; Hashiro et al., 1979).    Further studies then showed 
that CMV was not detected at a significantly higher rate in carcinoma tissue than normal 
tissue by multiple detection methods, such as FISH, immunohistochemistry, or DNA 
hybridization (Hart et al., 1982; Ruger & Fleckenstein, 1985).  It was found that patients with 
colorectal cancer who were treated with chemotherapy had significantly increased CMV IgG 
titre (Avni et al., 1981). However, this finding appeared to be related to CMV infection or 
reactivation secondary to immunosuppression by chemotherapy rather than primary 
infection causing colorectal cancer.  
4. Helminths 
4.1 Schistosoma japonicum 
The epidemiologic parallel between schistosomiasis japonica endemicity and the 
distribution of large bowel cancer has been noted in the eastern provinces of China in the 
1970s (E. S. Zhao, 1981). Subsequently, ecological studies in the same endemic areas showed 
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epithelial cells (Ricciardello et al., 2001). Other studies have employed real-time PCR, a less 
sensitive molecular technique, to detect JCV genetic material in colorectal carcinomas, 
adenomas, normal mucosa, and urine samples from CRC patients and controls. While JCV 
carrier frequencies in urine were comparable to previously published reports (Agostini et 
al., 1999), none of the neoplastic tissues and less than 1% of the normal tissues tested 
positive for JCV DNA (Newcomb et al., 2004; Campello et al., 2010; Militello et al., 2009). The 
discordant results in previous investigations may be explained by the small sample sizes, 
variable prevalence of viral infection among the studied populations, inherent lack of 
uniformity in the sensitivity of the assay used, and possible laboratory contamination 
particularly in studies where Mad 1 viral sequence was used as a positive template control 
(Newcomb et al., 2004).   
The expression pattern of JCV T-antigen has also been studied in both colorectal neoplastic 
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(Selgrad et al., 2008). Interestingly, viral DNA has always been detected more frequently 
than Tag expression in both colonic adenomas and carcinomas. This suggests that either in 
some samples, the viral copy number is too low to determine expression of the early gene 
or, alternatively, that the growing tumour tends to lose viral sequences (Ricciardello et al., 
2003). In another aspect, two prospective nested case-control investigated the association 
between JC seroprevalence and colorectal neoplasms in large groups of patients from whom 
blood samples were collected months or years before colorectal cancer diagnosis (Rollison et 
al., 2009; Lundstig et al., 2007). Although there was no association between JC seropositivity 
and colorectal cancer, one study showed a significantly increased risk of adenomas among 
seropositive male subjects (Rollison et al., 2009). More recently, Niv et al. (2010b) observed 
positive correlation between the presence of neoplastic colonic lesion and the titre of JCV 
antibody in the serum, pointing to JCV infection as an early event for the formation of 
colorectal adenoma. 
Mechanism/ mechanistic studies 
The JCV T-antigen is a potent oncogenic protein capable of transforming mammalian cells 
and is likely involved the early stages of colorectal carcinogenesis though “hit and run” 
mechanisms. These include disruption of the Wnt signalling pathway and inactivation of 
tumour suppressor genes such as pRb and p53 (Ludlow, 1993). Both in vitro and in vivo 
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studies have shown that coexpression of p53 and JCV T-antigen in CRC cells (Enam et al., 
2002; Nosho et al., 2009; Ricciardello et al., 2003). Similarly, colocalization of T-antigen and 
B-catenin was observed in the nuclei of neoplastic columnar cells (Enam et al., 2002; nosho et 
al., 2009). Cooperativity between B-catenin and JCV T-antigen increased in vitro 
transcription of c-myc, leading to chromosomal instability (Enam et al., 2002). Ricciardiello et 
al. (2003) demonstrated that JCV can induce chromosomal instability in vitro using the 
diploid CRC cell line, which defines loss of heterozygosity (LOH). Subsequent studies 
reported a significant association between JCV T-antigen expression and CRC with LOH 
(Nosho et al., 2009; Goel et al., 2006; Ogino et al., 2009). This deletional event probably 
provides the second hit at the tumour suppressor genes, and eventually leads to clonal 
expansion. The role of DNA hypermethylation has recently been explored in both colorectal 
carcinoma and adenoma, nevertheless the results were contradictory (Nosho et al., 2008, 
2009; Goel et al., 2006). 
3.3 Other viruses 
Epstein-Barr virus (EBV) is a DNA virus with strong association with several 
lymphoreticular malignancies, especially Burkett’s lymphoma, as well as certain epithelial 
tumours such as the nasopharyngeal carcinoma (Parkin, 2006). Additionally, EBV has also 
been reported with gastric cancer (Koriyama et al., 2001; Takada, 2000), breast (Labrecque et 
al., 1995; Bonnet et al., 1999; Fina et al., 2001) and lung cancer (Castro et al., 2001; Han et al., 
2001; M.P. Wong et al., 1995). For colorectal cancer, although early studies have detected 
high rates of EBV infection in colorectal carcinoma tissue, using PCR, 
immunohistochemisrty and fluorescence in situ hybridization (Song et al., 2006; Liu et al., 
2002, 2003), only one study reported significant difference in EBV detection rates between 
colorectal carcinoma tissue and adjacent normal mucosa (Song et al., 2006). Follow-up 
studies failed to show any evidence that EBV was detected at a significantly higher rate in 
colorectal carcinoma (Grinstein et al., 2002; Yuen et al., 1994), even in higher risk 
populations such as patients with ulcerative colitis (N.A. Wong et al., 2003).  
In the case of Cytomegalovirus (CMV), early limited studies have detected CMV genome in 
the colon carcinoma tissue, whereas controls from normal colons and cases of Crohn disease 
were negative (Huang & Roche, 1978; Hashiro et al., 1979).    Further studies then showed 
that CMV was not detected at a significantly higher rate in carcinoma tissue than normal 
tissue by multiple detection methods, such as FISH, immunohistochemistry, or DNA 
hybridization (Hart et al., 1982; Ruger & Fleckenstein, 1985).  It was found that patients with 
colorectal cancer who were treated with chemotherapy had significantly increased CMV IgG 
titre (Avni et al., 1981). However, this finding appeared to be related to CMV infection or 
reactivation secondary to immunosuppression by chemotherapy rather than primary 
infection causing colorectal cancer.  
4. Helminths 
4.1 Schistosoma japonicum 
The epidemiologic parallel between schistosomiasis japonica endemicity and the 
distribution of large bowel cancer has been noted in the eastern provinces of China in the 
1970s (E. S. Zhao, 1981). Subsequently, ecological studies in the same endemic areas showed 
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a strong geographical correlation between the prevalence of schistosomiasis japonica and 
CRC incidence and mortality (Xu & Su, 1984). Likewise, significant association was 
observed between the mortality from CRC and from schistosomiasis japonica in rural China, 
even after adjustment for dietary factors (Chen et al., 1990; Guo et al., 1993). The authors 
attributed the continuing high incidence of colorectal cancer in endemic regions to persistent 
large populations of chronically infected individuals. This conclusion was further bolstered 
by a retrospective cohort study conducted in an endemic area in Japan, where the 
standardized mortality ratio for colonic cancer was significantly high in females who lived 
in the area for 50 years or more (Inaba, 1984). 
More importantly, a case-control study carried out in the endemic area of Jiangsu Province, 
China, showed that the risk of rectal cancer was increased among subjects with a previous 
diagnosis of S. japonicum infection with odds ratios of 4.5 and 8.3 (depending on the type of 
controls used), but the risk of colon cancer was not significantly increased in the same 
patients group (Xu & Su, 1984). A similar investigation in the same endemic area has 
confirmed strong associations between colon cancer and early and late-stage S. japonicum 
infection, regardless of the type of control used for comparison. When the results were 
adjusted to smoking and family history of colon cancer, statistically significant associations 
were still noted. In addition, the estimated relative risk increased with the duration of 
exposure to S. japonicum infection (Mayer & Fried, 2007). Of interest also is a recent matched 
case-control study which reported that patients with chronic schistosomiasis japonica have 
more than three times risk to develop colon cancer than those with no previous exposure to 
schistosomal infection. Moreover, the authors attributed 24% of colon cancer cases to long-
standing schistosomal infestation (Qiu et al., 2005). 
The consensus of available pathological data strongly implicates an association between S. 
japonicum infestation and induction of CRC. In a review of the literature between 1898 and 
1974, 276 cases of schistosomiasis japonica associated with cancer of the large intestine were 
analysed. The results showed significant differences between carcinoma with 
schistosomiasis and ordinary carcinoma in symptoms, age range, sex ratio, and 
histopathologic findings, indicating that schistosomiasis may induce carcinoma (Shindo, 
1976). Ming-Chai et al. (1965) reported similar findings in their study of 90 cases of 
simultaneous CRC and schistosomiasis, and proposed that S. japonicum colitis, in its late 
phases, is a premalignant condition not infrequently leading to cancer. Supporting their 
previous results and giving better insight into the pathogenesis of schistosomal colorectal 
carcinoma, the same group has examined the mucosal changes in the immediate vicinity of 
the tumours of patients with schistosomiasis, and referred to the close similarity between 
certain schistosome-induced lesions and those associated with long-standing ulcerative 
colitis. Pointing to mimicry of cancer evolution in these two clinical entities, they described 
presence of pseudopolyps, multiple ulcers, and hyperplastic ectopic submucosal glands, 
with evidence of oviposition and precancerous and cancerous transformation in these 
lesions (Ming-Chai et al., 1980). It was also demonstrated that the closer to the tumour the 
area is the more ova tend to be detected (Matsuda et al., 1999). In a following study, Ming-
Chai et al. (1981) observed variable degree of colonic epithelial dysplasia in 60% of cases 
with S. japonicum colitis and regarded these changes as the transition on the way towards 
cancer development in schistosomal colonic disease. A similar conclusion was drawn by Yu 
et al. (1991) from their studies on different types of schistosomal egg polyps. 
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Of note, distinct clinico-pathologic characteristics of S. japonicum-related colorectal cancer 
seem emerge from the existing literature. Bearing in mind the early environmental exposure 
to schistosomal infection in childhood, schistosomal colorectal cancer was notably shown to 
occur in younger age group with a maximum age incidence 6 to 16 years earlier than 
ordinary colorectal cancer (Shindo, 1976; Ming-Chai et al., 1965, 1980). Furthermore, the 
gender ratio of male to female in schistosomal colorectal cancer is consistently higher than in 
nonschistosomal cancer (Shindo, 1976; Ming-Chai et al., 1980). This can be attributed to the 
fact that men are more prone to schistosomal infection through contact with cercariae-
infested waters during agricultural activities.  
4.2 Schistosoma mansoni 
The epidemiological evidence associating S. mansoni infection with CRC is lacking, of poor 
quality, or conflicting. Supporting the absence of such a causal association, Parkin et al. 
(1986) pointed out that although there is a great disparity in the geographical distribution of 
S. mansoni, CRC occurs in the African continent with clear uniformity. In a recent hospital-
based study in Uganda and Zimbabwe, Waku et al. (2005) compared 950 cases of infective 
gastrointestinal disease, particularly schistosomiasis and amebiasis, with 249 patient 
controls admitted for various diseases other than GI disease. The cases were thoroughly 
investigated and further stratified into three groups on the basis of the stage of the disease; 
cured, acute, and chronic patients group. Colorectal cancer was found in 34 patients; nearly 
all of them had chronic schistosomiasis or amebiasis, whereas no CRC was detected in the 
other patients or control groups. It was concluded that large bowel cancer is strongly 
associated with chronic infectious gastrointestinal diseases. This study, though, was limited 
by the inability to adjust for potential confounders such as age and gender. Furthermore, the 
issue of correspondence between the population giving rise to the cases and that sampled 
for the controls was not addressed. To date, there have been no epidemiological studies 
conducted at the population level to verify the link between S. mansoni infestation and large 
bowel cancer. 
The pathological evidence supporting an association between S. mansoni infestation and 
colorectal carcinoma is rather weak. In 1956, Dimmette et al. (1956) failed to demonstrate 
any specific pathological changes in patients with simultaneous CRC and S. mansoni 
infestation, and considered the two conditions unrelated. Contrasting to these results, a 
recent study by Madbouly et al. (2007) has shown that S. mansoni-associated colorectal 
cancer has distinctive pathological features often similar to those of colitis-induced 
carcinoma (Fig. 2a,b). These include high percentage of multicentric tumours and mucinous 
adenocarcinoma, and the tendency of the tumour to present at an advanced stage with high 
risk of malignant lymph node invasion. Although direct causal inference is limited, this study 
indicates that S. mansoni infestation may exercise some influence on the prognosis of patients 
with CRC. Other studies have examined the pathological changes in endoscopic biopsies and 
cadaveric specimens from the colon of patients with S. mansoni colitis (Mohamed et al., 1990; 
Cheever et al., 1987). The gross pathological lesions were akin to those observed in patients 
with S. japonicum colitis. However, histological analysis of the specimens showed no evidence 
of atypism or carcinomatous changes. This discrepancy in pathologic findings may be 
explained by the larger number of eggs deposited by S. japonicum than S. mansoni worms, thus 
causing more pathological problems (Ishii et al., 1994). 
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a strong geographical correlation between the prevalence of schistosomiasis japonica and 
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China, showed that the risk of rectal cancer was increased among subjects with a previous 
diagnosis of S. japonicum infection with odds ratios of 4.5 and 8.3 (depending on the type of 
controls used), but the risk of colon cancer was not significantly increased in the same 
patients group (Xu & Su, 1984). A similar investigation in the same endemic area has 
confirmed strong associations between colon cancer and early and late-stage S. japonicum 
infection, regardless of the type of control used for comparison. When the results were 
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Of note, distinct clinico-pathologic characteristics of S. japonicum-related colorectal cancer 
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infested waters during agricultural activities.  
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cancer has distinctive pathological features often similar to those of colitis-induced 
carcinoma (Fig. 2a,b). These include high percentage of multicentric tumours and mucinous 
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risk of malignant lymph node invasion. Although direct causal inference is limited, this study 
indicates that S. mansoni infestation may exercise some influence on the prognosis of patients 
with CRC. Other studies have examined the pathological changes in endoscopic biopsies and 
cadaveric specimens from the colon of patients with S. mansoni colitis (Mohamed et al., 1990; 
Cheever et al., 1987). The gross pathological lesions were akin to those observed in patients 
with S. japonicum colitis. However, histological analysis of the specimens showed no evidence 
of atypism or carcinomatous changes. This discrepancy in pathologic findings may be 
explained by the larger number of eggs deposited by S. japonicum than S. mansoni worms, thus 
causing more pathological problems (Ishii et al., 1994). 
 




Fig. 2a. Photomicrograph showing S. mansoni egg shell in a background of mucinous 
adenocarcinoma. H&E × 40 
 
Fig. 2b. Photomicrograph showing calcified and viable S. mansoni ova with granuloma 
formation in the muscularis propria of the sigmoid colon. H&E × 20 
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4.3 Mechanisms of tumorigenesis 
The exact etiopathogenesis of schistosomal colorectal cancer is enigmatic. Several 
explanations have been advanced for the possible role of schistosomiasis in colorectal 
tumorigenesis: the presence of endogenously produced carcinogens (Rosin et al., 1994), 
chronic immunomodulation resulting in impairment of immunological surveillance (van 
Riet et al., 2007), symbiotic action of other infective agents (Shindo, 1976), and the presence 
of schistosomal toxins (Long et al., 2004). While these factors may interact to induce 
carcinogenesis, chronic inflammation appears to play a central role. In support of this view 
are data showing that CRC tends to occur mainly in patients who had history of 
schistosomiasis for 10 years or more and in whom the large bowel is wholly involved 
(Shindo, 1976; Ming-Chai et al., 1980). Moreover, there is significantly higher rate of 
synchronous tumours in patients with schistosomal colorectal cancer than in patients with 
spontaneous colorectal cancer (Ming-Chai et al., 1980; Madbouly et al., 2007). This can be 
ascribed to the field effect caused by chronic schistosomal inflammation throughout the 
colon, a phenomenon analogous to that described in the context of colitis-associated cancer. 
It has been suggested that chronic inflammatory reaction provoked by schistosome antigens 
provides the proliferative stimulus necessary to promote cancer growth from potentially 
malignant foci produced by other carcinogens (Ming-Chai et al., 1980). However, whereas 
increased epithelial cell proliferation likely contributes to carcinogenesis, it is insufficient to 
cause cancer. Rather, inflammatory cells generate potentially genotoxic mediators during 
the course of schistosomal infection such as reactive oxygen and nitrogen species and 
proinflammatory cytokines, which cause genomic instability and dysregulation of 
oncogenes and oncosuppresor genes (Herrera et al., 2005; Trakatelli et al., 2005). The 
accumulation of these molecular disturbances, in turn, drives the progression toward 
dysplasia and carcinoma. Another factor that may play a major role in colorectal 
carcinogenesis of schistosomiasis patients is the presence of concomitant enterobacterial 
infections. In both clinical and experimental studies, various strains of enterobacteriaceae 
have been described in association with schistosome infection which confers a survival 
advantage to bacteria by inducing immunosuppression (Chieffi, 1992; Tuazon et al., 1985). 
Some of these organisms are thought to promote colorectal carcinogenesis through multiple 
pathways such as production of reactive oxygen intermediates, dysregulation in the T cell 
response, and alterations in host epithelial carbohydrate expression (Hope et al., 2005). 
A further explanation for the carcinogenic process of schistosomal CRC is a possible direct 
mutagenic effect of the schistosome soluble antigens. Evidence against this hypothesis has 
come from a study by Ishii et al. (1989), who evaluated the mutagenicity of S. japonicum 
extracts using the Ames Salmonella/E. coli test in the presence and absence of rat liver S9 
mixture. They did not identify any mutagenic activity for the soluble extracts of both eggs 
and adult worms. Nevertheless, a weak but significant tumour-promoting activity was 
noted for the S. japonicum soluble egg antigen when tested using cultured viral genome-
carrying human lymphoblastoid cells. Osada et al. (2005) tested the adult worm and egg 
extracts of S. mansoni using more reliable genetic toxicology assays, the Salmonella Umu test 
and the hypoxanthine guanine phosphoribosyltransferase (HGPRT) gene mutation assay. 
They could not demonstrate any mutagenic potential in either parasite extracts of S. mansoni 
before and after addition of S9 mixture. 
Recent studies have thrown some light on the molecular events associated with schistosomal 
colorectal cancer, taking the latter as a separate clinical entity. Zhang et al. (1998) investigated 
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the mutation pattern in the p53 gene in S. japonicum-associated rectal carcinomas. They 
observed a higher proportion of base-pair substitutions at CpG dinucleotides and arginine 
missense mutations among schistosomal rectal cancer patients than in patients with ordinary 
CRC, albeit the differences were of marginal significance. Their results also indicated that the 
majority of mutations in p53 gene were in exon 7 in schistosomal group compared to exon 5 in 
non-schistosomal group. Barrowing from the ulcerative colitis example, nitric oxide, an 
endogenously produced genotoxic agent, is capable of inducing similar transition mutations 
and activation of p53 gene in the inflamed colonic mucosa (Goodman et al., 2004). Conceivably 
therefore, it seems plausible that chronic colonic inflammation induced by schistosomal 
infection may follow a similar pathway. 
For S. mansoni-associated colorectal carcinomas, it was demonstrated that parasitism is 
strongly associated with microsatellite instability, which is a sign of defective DNA repair 
(Soliman et al., 2001). This genomic instability results in DNA replication errors that 
preferentially affect target genes such as transforming growth factor (TGH)βRII and insulin-
like growth factor (IGF)2R, and render them incapable of normal colonocytes homeostasis 
resulting in malignant growth (Itzkowitz & Yio, 2004). In another aspect, Madbouly et al. 
(2007) evaluated the expression of p53 in patients with S. mansoni-related colorectal cancer, 
and found that mutant p53 overexpression was significantly more frequent in schistosomal 
than in non-schistosomal colorectal cancer. Moreover, p53 overexpression in schistosomal 
CRC correlated well with mucinous carcinoma, nodal metastasis, and tumour 
multicentricity. Zalata et al. (2005) developed a more comprehensive study of the expression 
pattern of p53, Bcl-2, and c-myc in seventy five CRC cases, 24 of these had pathological 
evidence of S. mansoni infection. Although they did not find a significant association 
between parasitism and p53 and c-myc expression, their results showed that S. mansoni-
associated colorectal tumours characterized by Bcl-2 overexpression and less apoptotic 
activity than ordinary colorectal tumours. This supports the contention that evasion of 
apoptosis through change in the expression of Bcl-2 may be an alternative molecular 
pathway through which genotoxic agents can induce carcinogenesis in intestinal 
schistosomiasis. 
5. Concluding remarks 
It is clearly evident that a wide array of microbial agents is associated with colorectal cancer. 
Nonetheless, establishing a causal link between a certain organism and colorectal cancer is a 
complicated process, considering the long latency of infection during which numerous 
endogenous and exogenous factors interact to obscure causality. For most of these putative 
agents, the association has been inconsistent, and may either define subsets of the tumour, 
or may act to modify phenotype of an established tumour, possibly contributing to some 
phase of oncogenesis.  
Despite the fact that H. pylori and S. bovis were discovered in colorectal tumours and linked 
to the malignancy by seroepidemiologic studies and molecular analyses, these pathogens 
are considered to be at most contributing cofactors. The two reasons for this loss of 
etiological status were the inconsistency in the epidemiological data regarding H. pylori and 
S. bovis infections and risk of colorectal cancer (Gold et al, 2004; Y. S. Zhao et al., 2008), 
whereas none of these agents produced de novo colorectal cancer in animal models (Singh et 
al., 2000a; Biarc et al., 2004). The relation between gut mictobiota such as B. fragilis and E. 
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faecalis and colorectal cancer is far less convincing. Although the oncogenic potential of B. 
fragilis and E. faecalis is not disputed, the scarcity of epidemiological evidence renders any 
association hypothetical.  
In case of viral agents, while HPV and JCV have oncogenic properties both in cell culture 
and experimental animals (Butel, 2000), the detection of viral genomes in tumour tissues is 
inconsistent, which can be attributed to the fact that PCR technique, used for detection of 
viral DNA in most studies, is subject to contamination. At this point, this precludes a 
causative role for these viruses in colorectal cancer, and obtaining more credible results 
mandates employment of combination of in situ methods for detection of viral genome and 
its products such as in situ cytohybridization and immunohistochemistry (Panago et al., 
2004). 
In case of S. japonicum, the growing epidemiological evidence and the unique clinic-
pathological features of schistosome-related colorectal cancer point to a reasonably 
consistent association. However, S. japonicum has been classified by IARC as possible and 
not as definite carcinogen in human leading to colorectal cancer (IARC, 1994). This perhaps 
reflects the confounding uncertainties presented by epidemiological studies and the lack of 
experimental evidence. For S. mansoni species, it is still a matter of controversy as to whether 
or not S. mansoni infection is an association factor in colorectal cancer development and 
progression. 
Infection-related colorectal carcinogenesis is a complex multistage process that utilizes 
several mechanisms. For most bacterial species and helminths associated with colorectal 
cancer, chronic inflammatory response and immunomodulation induced by secretory or 
structural proteins are the principal mechanisms of carcinogenesis. These involve release of 
protumorigenic mediators and dysregulation of multiple cellular transcriptional pathways 
including NF-κB and β–catenin. Others such as H. pylori primarily induce production of 
growth factor resulting disruption of proliferation-antiproliferation pathways. DNA tumour 
viruses, such as HPV and JCV, primarily target cellular tumour suppressor proteins, thus 
modulating cell cycle progression (Butel, 2000).   
Together, our observations underpin the necessity of epidemiological studies focusing on 
specific strains such as CagA+ H. pylori, S. gallolyticus, ETBF, and Mad-1 JCV. In addition, 
the interaction between various infectious agents in relation to carcinogenesis, as illustrated 
in the additive effect of B. fragilis and E. faecalis needs further evaluation. Finally it is likely 
that more agents, both known and unidentified, have yet to be implicated in human 
colorectal cancer. In the meantime, study of tumorigenic infectious agents will continue to 
illuminate molecular oncogenic processes. 
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1. Introduction  
The role, of microbial agents and the infection of the intestinal mucosa in the carcinogenesis, 
or the development of colorectal cancer (CRC) is one of the hot topics in the field of CRC 
where much research has been done. However, this topic has long been underestimated by 
most of the related books. This chapter is intended to cover the relationship of CRC 
development with bacteria implicated in the development of CRC such as S. bovis, S. 
gallolyticus, S. equines, S. infantarius, E .coli, C. difficile…etc. However, S. gallolyticus and S. 
bovis will be discussed thoroughly in this chapter as they are considered the prototype for 
intestinal microorganisms related to CRC and colorectal premalignant lesions.  
Studying CRC association with infection of intestinal mucosa is not complete without 
studying the underlying mechanisms. There is compelling evidence that CRC is largely 
affected by the status of intestinal bioflora. CRC has been found to be affected by certain 
microbial agents that have particular characteristics capable of inducing dysplastic changes 
in intestinal mucosa. However, the underlying mechanisms of the association of implicated 
infective agents with CRC development are yet not clear. In addition, the role of oncogenic 
factors, cell growth factors, and pro-inflammatory cytokines in the association of bacterial 
infection in intestinal mucosa with CRC has not yet been clarified well. Therefore, the 
current chapter attempts to scrutinize the nature and the underlying mechanisms of the 
association of infective agents represented by S. bovis/gallolyticus with CRC. Nevertheless, 
the association of S. bovis/gallolyticus with CRC is still under controversy regarding whether 
the bacterial infection of intestine, along with associated bacteremia/endocarditis, is a 
consequence or the etiological factor of CRC. Hence, this chapter also attempts to explore 
the facts available in the field to assess which scenario is more favorable for the association 
of S. bovis/gallolyticus with CRC namely, the consequence or the etiology scenario.  
One of the bacterial agents that have been most associated with cancer is Streptococcus bovis 
(S. bovis). S. bovis has been shown to be important in human health because 25 to 80% of 
patients with S. bovis bacteremia had also colorectal tumor, and the incidence of association 
of colonic neoplasia with S. bovis endocarditis was shown to be 18 to 62% (Gupta et al., 2009; 
Kok et al., 2007; Leport et al., 1987; Malkin et al., 2008; Reynolds et al., 1983; Wilson et al., 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
374 
Zarkin, B. A., Lillemoe, K. D., Cameron, J. L., Effron, P. N., Magnuson, T. H. & Pitt, H. A. 
(1990). The triad of Streptococcus bovis bacteremia, colonic pathology, and liver 
disease. Ann Surg, 211, 6, 786 – 791 
Zhang, R., Takahashi, S., Orita, S., Yoshida, A., Maruyama, H., Shirai, T. & Ohta, N. (1998). 
p53 gene mutations in rectal cancer associated with schistosomiasis japonica in 
Chinese patients. Cancer Lett, 131, 2, 215-221. 
Zhao, E. S. (1981). Cancer of the colon and schistosomiasis. J R Soc Med, 74, 9, 645. 
Zhao, Y. S., Wang, F., Chang, D., Han, B. & You, D. Y. (2008). Meta-analysis of different test 
indicators: Helicobacter pylori infection and the risk of colorectal cancer. Int J 
Colorectal Dis, 23, 9, 875-882. 
Zumkeller, N., Brenner, H., Chang-Claude, J., Hoffmeister, M., Nieters, A., Rothenbacher, D. 
(2007). Helicobacter pylori infection, interleukin-1 gene polymorphisms and the risk 
of colorectal cancer: evidence from a case-control study in Germany. Eur J Cancer, 
43, 8, 1283–1289. 
Zumkeller, N., Brenner, H., Zwahlen, M. & Rothenbacher, D. (2006). Helicobacter pylori 
infection and colorectal cancer risk: a meta-analysis. Helicobacter, 11, 2, 75 – 80. 
17 
Streptococcus bovis/gallolyticus Induce the 
Development of Colorectal Cancer  
 A.S. Abdulamir1,2, R.R. Hafidh1,3 and F..Abu Bakar1 
1Institute of Bioscience, University Putra Malaysia, Serdang, Selangor,  
2Microbiology Department, College of Medicine, Alnahrain University PO, Baghdad,  
3Microbiology Department, College of Medicine, Baghdad University,  
1Malaysia 
2,3Iraq 
1. Introduction  
The role, of microbial agents and the infection of the intestinal mucosa in the carcinogenesis, 
or the development of colorectal cancer (CRC) is one of the hot topics in the field of CRC 
where much research has been done. However, this topic has long been underestimated by 
most of the related books. This chapter is intended to cover the relationship of CRC 
development with bacteria implicated in the development of CRC such as S. bovis, S. 
gallolyticus, S. equines, S. infantarius, E .coli, C. difficile…etc. However, S. gallolyticus and S. 
bovis will be discussed thoroughly in this chapter as they are considered the prototype for 
intestinal microorganisms related to CRC and colorectal premalignant lesions.  
Studying CRC association with infection of intestinal mucosa is not complete without 
studying the underlying mechanisms. There is compelling evidence that CRC is largely 
affected by the status of intestinal bioflora. CRC has been found to be affected by certain 
microbial agents that have particular characteristics capable of inducing dysplastic changes 
in intestinal mucosa. However, the underlying mechanisms of the association of implicated 
infective agents with CRC development are yet not clear. In addition, the role of oncogenic 
factors, cell growth factors, and pro-inflammatory cytokines in the association of bacterial 
infection in intestinal mucosa with CRC has not yet been clarified well. Therefore, the 
current chapter attempts to scrutinize the nature and the underlying mechanisms of the 
association of infective agents represented by S. bovis/gallolyticus with CRC. Nevertheless, 
the association of S. bovis/gallolyticus with CRC is still under controversy regarding whether 
the bacterial infection of intestine, along with associated bacteremia/endocarditis, is a 
consequence or the etiological factor of CRC. Hence, this chapter also attempts to explore 
the facts available in the field to assess which scenario is more favorable for the association 
of S. bovis/gallolyticus with CRC namely, the consequence or the etiology scenario.  
One of the bacterial agents that have been most associated with cancer is Streptococcus bovis 
(S. bovis). S. bovis has been shown to be important in human health because 25 to 80% of 
patients with S. bovis bacteremia had also colorectal tumor, and the incidence of association 
of colonic neoplasia with S. bovis endocarditis was shown to be 18 to 62% (Gupta et al., 2009; 
Kok et al., 2007; Leport et al., 1987; Malkin et al., 2008; Reynolds et al., 1983; Wilson et al., 
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1981; Zarkin et al., 1990). Later, it was shown that a new species resembling S. bovis is 
actually most implicated in CRC development; S. bovis infecting human intestine has been 
named as S. gallolyticus (Osawa et al., 1995). More precisely, S. bovis biotype I and II/2 
isolates were shown to be S. gallolyticus (Devriese et al., 1998). Accordingly, S. bovis biotype I 
was replaced by S. gallolyticus subspecies gallolyticus and biotype II/2 was replaced by S. 
gallolyticus subspecies pasterianus and S. gallolyticus subspecies macedonicus (Schlegel et al., 
2003). S. gallolyticus subspecies gallolyticus, rather than other related taxa, have been found to 
be constantly associated with underlying colorectal cancer.  
2. The association of colorectal cancer with S. bovis/gallolyticus 
bacteremia/endocarditis  
S. bovis, has long been linked to the development of CRC. However, the extent, nature, and 
basis of this association are still not completely understood. S. bovis/gallolyticus became 
important in human health since it was shown that 25 to 80% of patients who presented S. 
bovis/gallolyticus bacteremia had also a colorectal tumor and the incidence of association of 
colonic neoplasia with S. bovis/gallolyticus endocaditis was shown to be 18 to 62% (Gupta et 
al., 2009; Kok et al., 2007; Leport et al., 1987; Malkin et al., 2008; Murray & Roberts, 1978; 
Reynolds et al., 1983; Wilson et al., 1981; Zarkin et al., 1990). The knowledge that there is an 
association between endocarditis from S. bovis/gallolyticus and carcinoma of the colon has 
important clinical implications (Boleij et al., 2009a; Kok et al., 2007). The majority of the 
studies that found clues on the association of S. bovis/gallolyticus with CRC was in Europe 
and North America. Actually, it is true that the association of S. bovis/gallolyticus bacteremia 
with colorectal cancer has been found variable among different geographical and ethnic 
groups (Boleij et al., 2009a), but this association is not restricted to certain geographical 
region. A recent study done in Malaysia found that 48.6% of S. bovis isolates was found in 
patients with colonic polyps, adenocarcinomas, inflammatory bowel diseases. It was also 
found that colorectal cancer incidence was 24.7%, adenocarinomas accounting for 51% with 
the highest incidence in the sigmoid part of the colon(Al-Jashamy et al., 2010). This study 
indicates a strong relationship between S. bovis/gallolyticus and colonic premalignant as well 
as malignant lesions in a geographical region that was considered of low incidence for CRC 
cases associated with bacterial infections. Moreover, an epidemiological study conducted in 
Hong Kong on S. bovis bacteremia and its relation to colorectal cancer, confirmed the 
association of S. bovis/gallolyticus with CRC and found that S. bovis biotype II/2 is the 
dominant in Hong Kong rather than biotype I (S. gallolyticus) which is dominant in Western 
countries (Lee et al., 2003).  
Thorough studies on S. bovis have shown that associations between S. bovis bacteraemia and 
carcinoma of the colon and infective endocarditis were biotype-specific. It was shown that 
there is 94% association between S. bovis biotype I bacteraemia and infective endocarditis 
and 71% association between S. bovis biotype I bacteraemia and colonic carcinoma. On the 
other hand, it is only 18% association between S. bovis biotype II bacteraemia and infective 
endocarditis and 17% association between S. bovis biotype II bacteraemia and colonic 
carcinoma (Murray & Baron, 2007). Following the description of S. gallolyticus, Devriese 
team used whole-cell protein analysis to show that all six bacterial isolates studied, which 
were derived from patients with endocarditis and identified by conventional techniques as 
S. bovis, were in fact S. gallolyticus. Therefore, they suggested that S. gallolyticus is more likely 
to be involved in human infections than is S. bovis (Devriese et al., 1998). 
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The underlying mechanisms for the association of CRC with S. bovis/gallolyticus 
bacteremia/endocarditis have been obscure for a long time. The possible reason behind that, 
maybe, S. bovis/gallolyticus is a member of intestinal flora in 2.5 to 15% of individuals which 
usually make scientists counteract any malicious role of this bacteria (Burns et al., 1985; 
Murray & Roberts, 1978). It was conceived in the beginning that the ulceration of neoplastic 
lesions might form a pathway for the microorganism to enter the bloodstream (Gupta et al., 
2009). However, the latter scenario of bacterial access into the circulation does not explain 
the cases of patients with infectious endocarditis and non-ulcerated colonic polyps (Cutait et 
al., 1988). Furthermore, colonic neoplasia may arise years after the presentation of the 
condition of bacterial bacteremia or infectious endocarditis (Fagundes et al., 2000; Zarkin et 
al., 1990). For this reason, patients with infectious endocarditis and normal colonoscopy may 
be included in the group who present risk for developing colonic cancer because of the late 
appearance of such lesions after the infectious episode of S. bovis/gallolyticus (Fagundes et al., 
2000). Moreover, in supporting the second scenario, it has been shown that the relative risk 
of developing infectious endocarditis from S. bovis/gallolyticus in the presence of carcinoma 
of the colon is merely 3 to 6% (Bisno & 12.ed. New York: , 1991) while 60 to 75% of patients 
with endocarditis by S. bovis/gallolyticus simultaneously present malignant gastrointestinal 
disease that was not previously diagnosed (Grinberg et al., 1990).  
3. The association of premalignant colorectal lesions with  
S. bovis/gallolyticus 
There is a high incidence of colorectal cancer in individuals with polyps; about 90% of 
preinvasive neoplastic lesions of the colorectum are polyps or polyp precursors, namely 
aberrant crypt foci (Nielsen et al., 2007). Neoplastic polyps are often referred to more 
specifically as adenomas or adenomatous polyps (Srivastava et al., 2001). Adenomatous 
polyps are considered as good and few surrogate end point markers for colorectal cancer 
(Kelly et al., 1989; Nielsen et al., 2007). 
It would be of interest to substantiate any relationship between bacterial colonic carriage, 
colonic polyps and the type of polyp and its malignant potential (Boleij et al., 2009a; Schlegel 
et al., 2003). Contrary to the more commonly reported association between S. 
bovis/gallolyticus bacteremia and colorectal cancer, a link to pre-neoplastic adenomatous 
polyps was less frequently reported (Burns et al., 1985; Ellmerich et al., 2000a). Nevertheless, 
the relationship between colorectal bacterial infection and the progressive development of 
malignant disease in pre-neoplastic adenomatous polyps was supported by recent reports 
(Abdulamir et al., 2009; Kahveci et al., 2010; Murinello et al., 2006). Interestingly, benign 
lesions (diverticulosis, inflammatory bowel disease, cecal volvulus, perirectal abscess 
hemorrhoids, benign polyps) were found to be mildly associated with intestinal bacterial 
infections such as S. bovis/gallolyticus while a strong relationship between more malignant 
diseases of the colon (cancer and neoplastic polyps) and S. bovis/gallolyticus was found 
(Abdulamir et al., 2009; Burns et al., 1985; Klein et al., 1979; Nielsen et al., 2007; Reynolds et 
al., 1983; Smaali et al., 2008). It was also revealed that S. bovis/gallolyticus septicemia and/or 
endocarditis is selectively related to the presence of villous or tubulovillous adenomas in the 
large intestine (Fagundes et al., 2000; Smaali et al., 2008). In fact, Villous and tubulovillous 
adenomas, which have risk of malignant transformation about 15-25%, were found to be 
associated with S. bovis/gallolyticus bacteria more often than other types of adenomas (Bond, 
2005). For example, Hoen team performed a case-control study on subjects underwent 
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1981; Zarkin et al., 1990). Later, it was shown that a new species resembling S. bovis is 
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important clinical implications (Boleij et al., 2009a; Kok et al., 2007). The majority of the 
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endocarditis and 17% association between S. bovis biotype II bacteraemia and colonic 
carcinoma (Murray & Baron, 2007). Following the description of S. gallolyticus, Devriese 
team used whole-cell protein analysis to show that all six bacterial isolates studied, which 
were derived from patients with endocarditis and identified by conventional techniques as 
S. bovis, were in fact S. gallolyticus. Therefore, they suggested that S. gallolyticus is more likely 
to be involved in human infections than is S. bovis (Devriese et al., 1998). 
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colonoscopy comparing between patients with S. bovis/gallolyticus endocarditis and sex- and 
age- matched unaffected patients. This study showed that colonic adenomatous polyps were 
present in twice as many cases as controls (15 of 32 vs 15 of 64), and colorectal cancer was 
present approximately 3 times as often (3 of 32 vs 2 of 64) (Hoen et al., 1994). However, 
surprisingly, another study (Devis et al., 1989) found that the association between S. 
bovis/gallolyticus and adenoma was more evident than that with colorectal cancer; they 
reported that 36% of positive blood cultures of S. bovis/gallolyticus were found in 
proliferative lesions (15% of cancers and 21% of adenomas). A recent study (Abdulamir et 
al., 2009) supported this concept showing that the level of S. bovis/gallolyticus IgG antibodies 
in adenoma patients is much higher than in both colorectal cancer patients and control 
subjects. However, other reports did not reveal the same thing. (Burns et al., 1985) stated 
that the incidence of S. bovis/gallolyticus carriage in all colons with polyps was intermediary 
between normal colons and colons with carcinoma although the difference did not achieve 
statistical significance. 
Regarding the fecal carriage of S. bovis/gallolyticus, (Burns et al., 1985) demonstrated that 
highly premalignant polyps were found to be more often associated with S. bovis/gallolyticus 
carriage than were benign polyps. A clue for the active role of intestinal bacteria in the 
development of CRC, S. bovis/gallolyticus endocarditis, rather than other members of group 
D Streptococcus, showed special predilection to colonic lesions. It was found that of 77 
infections with group D Streptococcus endocarditis, colonic polyps and colonic carcinoma 
were significantly more frequent in the S. bovis/gallolyticus group (67 and 18%) respectively 
than in the Enterococcus group (21 and 2%) respectively (Leport et al., 1987). This indicates 
that certain bacteria have role in the etiology of CRC development from premalignant poly 
lesions.  
The remarkable association between adenomatous polyps and S. bovis/gallolyticus seems to 
be of importance due to the compelling evidence that colon cancer progresses from normal 
tissue to adenoma and then to carcinoma through an accumulation of genetic alterations 
(Baron & Sandler, 2000). Although ulceration of the neoplastic lesion might form a pathway 
for the S. bovis/gallolyticus to enter the bloodstream (Gupta et al., 2009), the association of S. 
bovis/gallolyticus bacteremia with non-ulcerated colonic polyps indicates an 
etiological/promoter role of these bacteria in polyps progression (Cutait et al., 1988; Konda 
& Duffy, 2008). The possibility of S. bovis/gallolyticus to act as a promoter for the 
preneoplastic lesions is worthy to be considered. A remarkable study supported this 
hypothesis using rats treated with S. bovis wall extracted antigens (WEA), rats treated with a 
chemical carcinogen, rats treated with both WEA and chemical carcinogen, and untreated 
rats. All groups of rats did not develop hyperplastic colonic crypts except for the group 
treated with both WEA and the chemical carcinogen; about 50 % rats of this group 
developed neoplastic lesions (Ellmerich et al., 2000a). This indicated that S. bovis bacteria 
might exert their pathological activity in the colonic mucosa only when preneoplastic lesions 
are established. Another model supporting the promoter effect of S. bovis/gallolyticus, H. 
pylori infection and subsequent inflammation seem most likely to be promoters in the 
multistep development of carcinoma (from chronic gastritis to atrophy, intestinal 
metaplasia, dysplasia, and, ultimately, cancer) rather than the causative agents (Leung, 
2006). Therefore, the association of S. bovis/gallolyticus in etiology and/or acceleration of 
the transformation of aberrant crypts to adenoma and to cancer is now being 
reconsidered.  
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Accordingly, the knowledge of association of colorectal adenoma with S. bovis/gallolyticus 
has important clinical implications. If the lesion can be discovered at an early stage, curative 
resection may become possible (Waisberg et al., 2002). Thus, bacteremia due to S. 
bovis/gallolyticus should prompt rigorous investigation to exclude both endocarditis and 
tumors of the large bowel (Beeching et al., 1985; Konda & Duffy, 2008). Therefore, it was 
concluded that the discovery of a malignant or premalignant proliferative lesion in one third 
of the cases justifies the exploration of the colon by barium enema and/or colonoscopy in 
the case of S. bovis/gallolyticus septicemia (Beeching et al., 1985; Konda & Duffy, 2008). This 
would empirically aid for the early detection of adenoma in the gastrointestinal tract before 
its progression to cancer.  
4. The proposed mechanisms for the development of colorectal cancer by  
S. bovis/gallolyticus 
Chronic inflammation is associated with malignant changes. Host genetic polymorphisms of 
the adaptive and innate immune response play an important role in bacteria-induced cancer 
formation (El-Omar, 2006; Hou et al., 2007; Karin & Greten, 2005). Therefore, studying the 
immunological responses to chronic bacterial infections is likely to yield important clues 
on both the mechanisms of persistent infection and the relationship between 
inflammation and cancer formation (Ernst et al., 2006; Monack et al., 2004). Clinical 
studies have shown that the use of non-steroidal anti-inflammatory drugs is associated 
with a reduced risk of gastric cancer (Dai & Wang, 2006). However, bacteria implicated in 
carcinogenesis, like S. bovis/gallolyticus, might use several mechanisms for carcinogenesis 
such as the colonization of epithelial surfaces and the use of virulence factors to 
chronically affect host cell cycle control, apoptosis, cell junction integrity or cell polarity 
((Vogelmann & Amieva, 2007). 
4.1 Clues for etiological role 
The big question is whether bacteria play an etiological role in the carcinoma of colon or it is 
merely marker of the disease. There are many clues collectively provide evidence for the 
etiological role of bacteria in colon cancer development. The striking association between 
bacteremia caused by S. bovis biotype I and both colonic neoplasia (71%) and bacterial 
endocarditis (94%), rather than bacteremia caused by closely related organisms such as S. 
bovis variant and S. salivarius, suggests the possibility of specific bacterium-host interactions 
(Ruoff et al., 1989). Moreover, the appearance of new colonic lesions 2-4 after the incidence 
of S. bovis/gallolyticus bacteremia/endocarditis, provides more evidence that S. 
bovis/gallolyticus is not merely a consequence of the tumor lesion (Wentling et al., 2006). In 
terms of pathogenesis, as S. bovis/gallolyticus is a transient normal flora in the gut, 
researchers have postulated that the increased bacterial load of S. bovis/gallolyticus in colon 
might be responsible for its association with colon cancer. Several studies have shown that 
increased stool carriage of S. bovis/gallolyticus is particularly found in patients with 
inflammatory bowel diseases or malignant/premalignant lesions of the colon while S. 
bovis/gallolyticus bacteria were rarely isolated from normal subjects (Teitelbaum & 
Triantafyllopoulou, 2006). Another clue supporting the etiological role of S. bovis/gallolyticus, 
patients diagnosed with colon cancer have only 3–6% chance to develop S. bovis/gallolyticus 
endocarditis (zur Hausen, 2006), which is far lower than the percentage of the detection of 
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colonoscopy comparing between patients with S. bovis/gallolyticus endocarditis and sex- and 
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colorectal cancer in patients with S. bovis/gallolyticus bacteremia/endocarditis, which his 
more than 70%.  
4.2 Mechanisms of the proposed etiological role of S. bovis/gallolyticus in the 
development of colorectal cancer 
4.2.1 Selective adherence to intestinal tumor cells 
Some bacteria such as S. bovis/gallolyticus are frequent colonizers of the intestinal tract, 
which can also cause endocarditis. However, their ability to adhere to and colonize host 
tissues is largely unknown. It was found that S. bovis/gallolyticus bacteria possess collagen-
binding proteins and pili that are responsible for adhesion to colorectal mucosa as well as to 
endocardium (Sillanpaa et al., 2009). On the other hand, another study (Boleij et al., 2009b) 
found a histone-like protein A on the surface of S. bovis/gallolyticus able to bind heparan 
sulfate proteoglycans at the colon tumor cell surface during the first stages of infection; this 
cell surface protein in S. gallolyticus acts as one of the main heparin-binding proteins that is 
largely responsible for bacteria selective adhesive potential as well as entry to the blood 
circulation. Another study assessing 17 endocarditis-derived human isolates, identified 15 S. 
gallolyticus subspecies gallolyticus, one S. gallolyticus subspecies pasteurianus (biotype II/2) 
and one S. infantarius subspecies coli (biotype II/1) for their in vitro adherence to 
components of the extracellular matrix; this study provided evidence that S. gallolyticus 
subspecies gallolyticus bacteria possess very efficient adherence characteristics to the host 
extracellular matrix; this bacteria showed powerful adherence to collagen type I and type 
IV, fibrinogen, collagen type V, and fibronectin (Sillanpaa et al., 2008). These adherence 
merits render these bacteria successful colonizers in both intestinal and cardiac tissues 
which might explain the association between S. bovis/gallolyticus endocarditis and intestinal 
lesions.  
4.2.2 Changing the intestinal bacterial flora and alterations in the local vascular 
attributes  
Increased incidence of hepatic dysfunction has been reported in patients with bacterial 
infectious endocarditis (Fagundes et al., 2000). It has been speculated that S. bovis/gallolyticus 
affects portal circulation through bacterial translocation, thereby determining hepatic 
alterations. Modifications in the hepatic secretion of bile salts and the production of 
immunoglobulins contribute towards increasing the participation of S. bovis/gallolyticus in 
abnormal changes in the bacterial flora of the colonic lumen which might then promote 
carcinogenesis of the intestinal mucosa (Beeching et al., 1985; Gupta et al., 2009). 
It has been suggested that alterations in local conditions and disruption of capillary channels 
at the site of neoplasm allowed S. bovis/gallolyticus to proliferate and gain entry into blood 
stream (Biarc et al., 2004; Ellmerich et al., 2000a; Nguyen et al., 2006). The local action of 
cytokines or of chemical mediators able to promote vasodilatation and the enhancement of 
capillary permeability, may support the bacterial entry at tumor sites, and increase bacterial 
adherence to various cells (Biarc et al., 2004; Ellmerich et al., 2000b).  
4.2.3 Promoting/propagating effect on preneoplastic lesions and inflammation-driven 
carcinogenesis  
A series of interesting experiments was conducted for investigating the role of S. 
bovis/gallolyticus in the initiation and development of colorectal cancer. Chemical carcinomas 
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were induced by giving adult rats intraperitonial injections of azoxymethane (15 mg/kg 
body weight) once per week for 2 weeks. Fifteen days (week 4) after the last injection of the 
carcinogen, the rats received, by gavage twice per week during 5 weeks, either S. bovis (1010 
bacteria) or wall-extracted antigens (WEAs) (100 µg). One week after the last gavage (week 
10), it was found that administration of either S. bovis or its antigens promoted the 
progression of preneoplastic lesions into neoplastic lesions through the increased formation 
of hyperproliferative aberrant colonic crypts, which enhanced the expression of proliferation 
markers and increased the production of IL-8 in the colonic mucosa (Biarc et al., 2004; 
Ellmerich et al., 2000b). Therefore, this study suggests that S. bovis/gallolyticus bacteria act as 
potential promoters of early preneoplastic lesions in the colon of rats, and their cell wall 
proteins are more potent inducers of neoplastic transformation than the intact bacteria. This 
study also revealed that the development of colonic adenomas increased remarkably in 50% 
of the tested rats and the expression level of proliferation markers, the polyamine content 
and proliferating cell nuclear antigen was also increased (Biarc et al., 2004; Ellmerich et al., 
2000a; Nguyen et al., 2006). This provided extra evidence that S. bovis/gallolyticus acts more 
likely as promoter/propagator of colorectal carcinoma rather than just a consequence of the 
tumor lesion. These studies might suggest that bacteria, in general, are often not capable to 
induce cancer without the presence of other predisposing factors for carcinogenesis. In this 
regard, it was conceived that the transformation process of colorectal tumors associated 
with S. bovis/gallolyticus is more likely accompanied with long-lasting bacterial 
promoting/propagating effect along with chronic inflammation status in intestinal mucosa. 
This conclusion was supported by Balkwill et al. stating that tumor formation might require 
independent mutations in oncogenic signaling pathways in addition to chronic 
inflammatory conditions which are needed to promote transformation process (Balkwill et 
al., 2005). 
In vitro experiments showed that the binding of S. bovis wall extracted antigens to various 
cell lines including human colonic cancer cells (Caco-2) stimulated the production of 
inflammatory cytokines by those cells (Biarc et al., 2004; Nguyen et al., 2006). Earlier it was 
found that the production of inflammatory cytokines in response to S. bovis/gallolyticus, such 
as TNF-α, IL-1ß and IL-6, and the chemokine IL-8, were found to contribute to the normal 
defense mechanisms of the host (Ellmerich et al., 2000b; Travers & Rosen, 1997) leading to 
the formation of nitric oxide and free radicals such as superoxide, peroxynitrites, hydroxyl 
radicals as well as alkylperoxy radicals (Nguyen et al., 2006; Ohshima & Bartsch, 1994). 
Owing to their potent mutagenicity, all these molecular species can contribute to the 
neoplastic processes by modifying cellular DNA. On the other hand, in the colonic mucosa, 
the production of angiogenic factors, such as IL-8, triggered by S. bovis/gallolyticus antigens 
may also favor the progression of colon carcinogenesis (Eisma et al., 1999; Ellmerich et al., 
2000b; Norrby, 1996). This resembles H. pylori infection for the development of chronic 
inflammation in the gastric mucosa (Dixon et al., 1996); therefore, it seems that chronic 
infection and subsequent chronic inflammation are responsible for the maintenance and 
development of pre-existing neoplastic lesions (Shacter & Weitzman, 2002).  
Moreover, it was found that WEAs of S. bovis induced in vitro overexpression of 
cyclooxygenase-2 (COX-2) (Biarc et al., 2004; Nguyen et al., 2006). COX-2, via 
prostaglandins, promotes cellular proliferation and angiogenesis and inhibits apoptosis, 
thus acting as a promoter in the cancer pathway (Tafte & Ruoff, 2007). It is noteworthy to 
mention that non-steroidal anti-inflammatory drugs (NSAIDS) were found to decrease the 
relative risk of gastrointestinal carcinomas and their main target was found to be 
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colorectal cancer in patients with S. bovis/gallolyticus bacteremia/endocarditis, which his 
more than 70%.  
4.2 Mechanisms of the proposed etiological role of S. bovis/gallolyticus in the 
development of colorectal cancer 
4.2.1 Selective adherence to intestinal tumor cells 
Some bacteria such as S. bovis/gallolyticus are frequent colonizers of the intestinal tract, 
which can also cause endocarditis. However, their ability to adhere to and colonize host 
tissues is largely unknown. It was found that S. bovis/gallolyticus bacteria possess collagen-
binding proteins and pili that are responsible for adhesion to colorectal mucosa as well as to 
endocardium (Sillanpaa et al., 2009). On the other hand, another study (Boleij et al., 2009b) 
found a histone-like protein A on the surface of S. bovis/gallolyticus able to bind heparan 
sulfate proteoglycans at the colon tumor cell surface during the first stages of infection; this 
cell surface protein in S. gallolyticus acts as one of the main heparin-binding proteins that is 
largely responsible for bacteria selective adhesive potential as well as entry to the blood 
circulation. Another study assessing 17 endocarditis-derived human isolates, identified 15 S. 
gallolyticus subspecies gallolyticus, one S. gallolyticus subspecies pasteurianus (biotype II/2) 
and one S. infantarius subspecies coli (biotype II/1) for their in vitro adherence to 
components of the extracellular matrix; this study provided evidence that S. gallolyticus 
subspecies gallolyticus bacteria possess very efficient adherence characteristics to the host 
extracellular matrix; this bacteria showed powerful adherence to collagen type I and type 
IV, fibrinogen, collagen type V, and fibronectin (Sillanpaa et al., 2008). These adherence 
merits render these bacteria successful colonizers in both intestinal and cardiac tissues 
which might explain the association between S. bovis/gallolyticus endocarditis and intestinal 
lesions.  
4.2.2 Changing the intestinal bacterial flora and alterations in the local vascular 
attributes  
Increased incidence of hepatic dysfunction has been reported in patients with bacterial 
infectious endocarditis (Fagundes et al., 2000). It has been speculated that S. bovis/gallolyticus 
affects portal circulation through bacterial translocation, thereby determining hepatic 
alterations. Modifications in the hepatic secretion of bile salts and the production of 
immunoglobulins contribute towards increasing the participation of S. bovis/gallolyticus in 
abnormal changes in the bacterial flora of the colonic lumen which might then promote 
carcinogenesis of the intestinal mucosa (Beeching et al., 1985; Gupta et al., 2009). 
It has been suggested that alterations in local conditions and disruption of capillary channels 
at the site of neoplasm allowed S. bovis/gallolyticus to proliferate and gain entry into blood 
stream (Biarc et al., 2004; Ellmerich et al., 2000a; Nguyen et al., 2006). The local action of 
cytokines or of chemical mediators able to promote vasodilatation and the enhancement of 
capillary permeability, may support the bacterial entry at tumor sites, and increase bacterial 
adherence to various cells (Biarc et al., 2004; Ellmerich et al., 2000b).  
4.2.3 Promoting/propagating effect on preneoplastic lesions and inflammation-driven 
carcinogenesis  
A series of interesting experiments was conducted for investigating the role of S. 
bovis/gallolyticus in the initiation and development of colorectal cancer. Chemical carcinomas 
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were induced by giving adult rats intraperitonial injections of azoxymethane (15 mg/kg 
body weight) once per week for 2 weeks. Fifteen days (week 4) after the last injection of the 
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of hyperproliferative aberrant colonic crypts, which enhanced the expression of proliferation 
markers and increased the production of IL-8 in the colonic mucosa (Biarc et al., 2004; 
Ellmerich et al., 2000b). Therefore, this study suggests that S. bovis/gallolyticus bacteria act as 
potential promoters of early preneoplastic lesions in the colon of rats, and their cell wall 
proteins are more potent inducers of neoplastic transformation than the intact bacteria. This 
study also revealed that the development of colonic adenomas increased remarkably in 50% 
of the tested rats and the expression level of proliferation markers, the polyamine content 
and proliferating cell nuclear antigen was also increased (Biarc et al., 2004; Ellmerich et al., 
2000a; Nguyen et al., 2006). This provided extra evidence that S. bovis/gallolyticus acts more 
likely as promoter/propagator of colorectal carcinoma rather than just a consequence of the 
tumor lesion. These studies might suggest that bacteria, in general, are often not capable to 
induce cancer without the presence of other predisposing factors for carcinogenesis. In this 
regard, it was conceived that the transformation process of colorectal tumors associated 
with S. bovis/gallolyticus is more likely accompanied with long-lasting bacterial 
promoting/propagating effect along with chronic inflammation status in intestinal mucosa. 
This conclusion was supported by Balkwill et al. stating that tumor formation might require 
independent mutations in oncogenic signaling pathways in addition to chronic 
inflammatory conditions which are needed to promote transformation process (Balkwill et 
al., 2005). 
In vitro experiments showed that the binding of S. bovis wall extracted antigens to various 
cell lines including human colonic cancer cells (Caco-2) stimulated the production of 
inflammatory cytokines by those cells (Biarc et al., 2004; Nguyen et al., 2006). Earlier it was 
found that the production of inflammatory cytokines in response to S. bovis/gallolyticus, such 
as TNF-α, IL-1ß and IL-6, and the chemokine IL-8, were found to contribute to the normal 
defense mechanisms of the host (Ellmerich et al., 2000b; Travers & Rosen, 1997) leading to 
the formation of nitric oxide and free radicals such as superoxide, peroxynitrites, hydroxyl 
radicals as well as alkylperoxy radicals (Nguyen et al., 2006; Ohshima & Bartsch, 1994). 
Owing to their potent mutagenicity, all these molecular species can contribute to the 
neoplastic processes by modifying cellular DNA. On the other hand, in the colonic mucosa, 
the production of angiogenic factors, such as IL-8, triggered by S. bovis/gallolyticus antigens 
may also favor the progression of colon carcinogenesis (Eisma et al., 1999; Ellmerich et al., 
2000b; Norrby, 1996). This resembles H. pylori infection for the development of chronic 
inflammation in the gastric mucosa (Dixon et al., 1996); therefore, it seems that chronic 
infection and subsequent chronic inflammation are responsible for the maintenance and 
development of pre-existing neoplastic lesions (Shacter & Weitzman, 2002).  
Moreover, it was found that WEAs of S. bovis induced in vitro overexpression of 
cyclooxygenase-2 (COX-2) (Biarc et al., 2004; Nguyen et al., 2006). COX-2, via 
prostaglandins, promotes cellular proliferation and angiogenesis and inhibits apoptosis, 
thus acting as a promoter in the cancer pathway (Tafte & Ruoff, 2007). It is noteworthy to 
mention that non-steroidal anti-inflammatory drugs (NSAIDS) were found to decrease the 
relative risk of gastrointestinal carcinomas and their main target was found to be 
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cyclooxygenase 2 (COX-2) that is over-expressed in up to 85% of colorectal adenocarcinomas 
(Kargman et al., 1995). Moreover, (Haqqani et al., 2000) revealed that the activation of 
leukocytes by S. bovis/gallolyticus was found to release various other inflammatory 
mediators (NO, free radicals, peroxynitriles, etc.) which could interfere directly or indirectly 
with the cell proliferation process. A recent study conducted by our team, S. gallolyticus has 
shown a specific association with colorectal cancer and colorectal adenoma when compared 
with the more dominant intestinal bacteria, B. fragilis. This provided evidence for a possible 
important role of S. gallolyticus in the carcinogenesis of colorectal cancer from pre-malignant 
polyps. In addition, it was also found that NF-κB and IL-8 rather than other transformation 
factors p21, p27 and p53 act as important mediators for the S. gallolyticus-associated 
transformation of adenoma to carcinoma (Abdulamir et al., 2009). Moreover, it was 
concluded that NF-κB exerts most probably a promoting carcinogenic effect and IL-8 exerts 
mainly an angiogenic-based propagating effect on colorectal mucosal cells (Abdulamir et al., 
2009). In addition, a more recent study done by our team showed a direct and active role of 
S. bovis/gallolyticus in colorectal cancer development through inflammation-based sequel of 
tumor development or propagation via IL-1, COX-2, and IL-8 (Abdulamir et al., 2010). By 
these studies, a strong relationship was shown to be evident between the proinflammatory 
potential of S. bovis/gallolyticus bacteria and their carcinogenic properties confirming the 
linkage between inflammation and colon carcinogenesis.        
In the presence of WEAs proteins of S. bovis/gallolyticus, Caco-2 cells exhibited enhanced 
phosphorylation of 3 classes of mitogen activated protein kinases (MAPKs) (Biarc et al., 
2004). Several reports showed that MAPKs activation stimulates cells to undergo DNA 
synthesis and cellular uncontrolled proliferation (Hirata et al., 2001; Ihler, 1996; Smith & 
Lawson, 2001). Therefore S. bovis/gallolyticus proteins could promote cell proliferation by 
triggering MAPKs which might increase the incidence of cell transformation and the rate of 
genetic mutations. Furthermore MAPKs, particularly p38 MAPK, can induce COX-2 which 
is an important factor in tumorogenesis (Lasa et al., 2002; Wang & Dubois, 2010) and up-
regulate the expression of NFkB which is considered the central link between inflammation 
and carcinogenesis (Karin & Greten, 2005). Accordingly, the pro-inflammatory potential of 
S. bovis/gallolyticus proteins and their pro-carcinogenic properties as well as the chronic 
inflammation and the leucocytic recruitment driven by S. bovis/gallolyticus provide strong 
evidence on the possible causal link between S. bovis/gallolyticus inflammation and colonic 
carcinogenesis. Therefore, the above data support the hypothesis that colonic bacteria can 
contribute to cancer development particularly via chronic infection/inflammation where 
bacterial components may interfere with cell function for long time (Biarc et al., 2004; Wang 
& Dubois, 2010). 
5. Selective colonization of S. bovis/gallolyticus in colorectal mucosa 
The association of bacteria with colorectal cancer has always been described through the 
incidence of S. bovis/gallolyticus bacteremia and/or endocarditis (Leport et al., 1987; Murray 
& Roberts, 1978; Reynolds et al., 1983; Wilson et al., 1981; Zarkin et al., 1990). On the other 
hand, little bacteriological research has been done on elucidating the colonization of S. 
bovis/gallolyticus in tumor lesions of colorectal cancer in order to confirm or refute, on solid 
bases, the direct link between colorectal cancer and S. bovis/gallolyticus (Norfleet & Mitchell, 
1993; Potter et al., 1998). A recent study of by our team was conducted to assess the 
colonization of S. bovis/gallolyticus bacteria in colon by detecting S. bovis/gallolyticus DNA in 
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colorectal cancer tumors using advanced molecular assays (Abdulamir et al., 2010). In 
Abdulamir et al. study, S. bovis/gallolyticus-specific primers and probes were used in PCR 
and in situ hybridization (ISH) assays, respectively, to detect S. bovis/gallolyticus DNA from 
feces, tumor mucosal surfaces, and from the inside of tumor lesions. In addition, 
bacteriological isolation of S. bovis/gallolyticus was conducted to isolate S. bovis/gallolyticus 
cells from feces, tumor mucosal surfaces, and from the inside of tumor lesions. In this study, 
S. bovis/gallolyticus was successfully isolated, via bacteriological assays, from tumorous and 
non-tumorous tissues, of colorectal cancer patients with bacteremia, 20.5% and 17.3%, and of 
colorectal cancer patients without bacteremia, 12.8% and 11.5%, respectively while only 2% 
of control tissues revealed colonization of S. bovis/gallolyticus.  
On the other hand, the positive detection of S. bovis/gallolyticus DNA, via PCR, in tumorous 
and non-tumorous tissues of colorectal cancer patients with bacteremia, 48.7 and 35.9%, and 
without bacteremia, 32.7 and 23%, respectively, was remarkably higher than that in control 
tissues, 4%. And the positive detection of S. bovis/gallolyticus DNA, via ISH, in tumorous and 
non-tumorous tissues of colorectal cancer patients with bacteremia, 46.1 and 30.7%, and 
without bacteremia 28.8 and 17.3%, respectively was remarkably higher than that in control 
tissues, 2%. In addition, by using absolute quantitative PCR for S. bovis/gallolyticus DNA, the 
S. bovis/gallolyticus count, in terms of copy number (CN), in tumorous and non-tumorous 
tissues of colorectal cancer patients with bacteremia, 2.96-4.72 and 1.29-2.81 log10 CN/g, 
respectively, and colorectal cancer patients without bacteremia, 2.16-2.92 and 0.67-2.07 log10 
CN/g, respectively, showed significantly higher level of colonization in tumorous than in 
non-tumorous tissues and in colorectal cancer patients with bacteremia than in colorectal 
cancer patients without bacteremia. Accordingly, this study provided several new 
observations. First, S. bovis/gallolyticus colonizes selectively tumorous tissues of colorectal 
cancer  patients rather than normal mucosal tissues. Second, the colonization of S. 
bovis/gallolyticus is mainly found inside tumor lesions rather than on mucosal surfaces of 
tumors. Third, the titer of the colonizing S. bovis/gallolyticus bacteria in colorectal cancer 
patients with bacteremia/endocarditis was much higher than in patients without 
bacteremia/endocarditis; this explains why some colorectal cancer patients develop 
concomitant bacteremia of S. bovis/endocarditis while others do not. Actually, the newly 
discovered selective colonization of S. bovis/gallolyticus explains the conclusions of an earlier 
report (Tjalsma et al., 2006) stating that colonic lesions provide a suitable microenvironment 
for S. bovis/gallolyticus colonization resulting in silent tumor-associated infections that only 
become apparent when cancer patients become immunocompromised, as in bacteraemia, or 
have coincidental cardiac valve lesions and develop endocarditis.  
6. Using S. bovis/gallolyticus in the early detection of colorectal tumors 
For a long time, it has been conceived that there is a need to establish a good screening test 
for colonic cancer patients, particularly a test which could detect early lesions. It has been 
suggested that the presence of antibodies to certain bacterial antigens or the presence of 
certain bacterial antigens in the bloodstream may act as markers for carcinogenesis of the 
colon (Beeching et al., 1985; Potter et al., 1998). The serology-based detection of colorectal 
cancer has advantage on other tests such as fecal occult blood which is neither sensitive nor 
specific or carcinoembryonic antigen which is regularly detectable in only advanced 
diseases (Tafte & Ruoff, 2007). Darjee and Gibb stated that it might be possible to develop a 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
382 
cyclooxygenase 2 (COX-2) that is over-expressed in up to 85% of colorectal adenocarcinomas 
(Kargman et al., 1995). Moreover, (Haqqani et al., 2000) revealed that the activation of 
leukocytes by S. bovis/gallolyticus was found to release various other inflammatory 
mediators (NO, free radicals, peroxynitriles, etc.) which could interfere directly or indirectly 
with the cell proliferation process. A recent study conducted by our team, S. gallolyticus has 
shown a specific association with colorectal cancer and colorectal adenoma when compared 
with the more dominant intestinal bacteria, B. fragilis. This provided evidence for a possible 
important role of S. gallolyticus in the carcinogenesis of colorectal cancer from pre-malignant 
polyps. In addition, it was also found that NF-κB and IL-8 rather than other transformation 
factors p21, p27 and p53 act as important mediators for the S. gallolyticus-associated 
transformation of adenoma to carcinoma (Abdulamir et al., 2009). Moreover, it was 
concluded that NF-κB exerts most probably a promoting carcinogenic effect and IL-8 exerts 
mainly an angiogenic-based propagating effect on colorectal mucosal cells (Abdulamir et al., 
2009). In addition, a more recent study done by our team showed a direct and active role of 
S. bovis/gallolyticus in colorectal cancer development through inflammation-based sequel of 
tumor development or propagation via IL-1, COX-2, and IL-8 (Abdulamir et al., 2010). By 
these studies, a strong relationship was shown to be evident between the proinflammatory 
potential of S. bovis/gallolyticus bacteria and their carcinogenic properties confirming the 
linkage between inflammation and colon carcinogenesis.        
In the presence of WEAs proteins of S. bovis/gallolyticus, Caco-2 cells exhibited enhanced 
phosphorylation of 3 classes of mitogen activated protein kinases (MAPKs) (Biarc et al., 
2004). Several reports showed that MAPKs activation stimulates cells to undergo DNA 
synthesis and cellular uncontrolled proliferation (Hirata et al., 2001; Ihler, 1996; Smith & 
Lawson, 2001). Therefore S. bovis/gallolyticus proteins could promote cell proliferation by 
triggering MAPKs which might increase the incidence of cell transformation and the rate of 
genetic mutations. Furthermore MAPKs, particularly p38 MAPK, can induce COX-2 which 
is an important factor in tumorogenesis (Lasa et al., 2002; Wang & Dubois, 2010) and up-
regulate the expression of NFkB which is considered the central link between inflammation 
and carcinogenesis (Karin & Greten, 2005). Accordingly, the pro-inflammatory potential of 
S. bovis/gallolyticus proteins and their pro-carcinogenic properties as well as the chronic 
inflammation and the leucocytic recruitment driven by S. bovis/gallolyticus provide strong 
evidence on the possible causal link between S. bovis/gallolyticus inflammation and colonic 
carcinogenesis. Therefore, the above data support the hypothesis that colonic bacteria can 
contribute to cancer development particularly via chronic infection/inflammation where 
bacterial components may interfere with cell function for long time (Biarc et al., 2004; Wang 
& Dubois, 2010). 
5. Selective colonization of S. bovis/gallolyticus in colorectal mucosa 
The association of bacteria with colorectal cancer has always been described through the 
incidence of S. bovis/gallolyticus bacteremia and/or endocarditis (Leport et al., 1987; Murray 
& Roberts, 1978; Reynolds et al., 1983; Wilson et al., 1981; Zarkin et al., 1990). On the other 
hand, little bacteriological research has been done on elucidating the colonization of S. 
bovis/gallolyticus in tumor lesions of colorectal cancer in order to confirm or refute, on solid 
bases, the direct link between colorectal cancer and S. bovis/gallolyticus (Norfleet & Mitchell, 
1993; Potter et al., 1998). A recent study of by our team was conducted to assess the 
colonization of S. bovis/gallolyticus bacteria in colon by detecting S. bovis/gallolyticus DNA in 
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colorectal cancer tumors using advanced molecular assays (Abdulamir et al., 2010). In 
Abdulamir et al. study, S. bovis/gallolyticus-specific primers and probes were used in PCR 
and in situ hybridization (ISH) assays, respectively, to detect S. bovis/gallolyticus DNA from 
feces, tumor mucosal surfaces, and from the inside of tumor lesions. In addition, 
bacteriological isolation of S. bovis/gallolyticus was conducted to isolate S. bovis/gallolyticus 
cells from feces, tumor mucosal surfaces, and from the inside of tumor lesions. In this study, 
S. bovis/gallolyticus was successfully isolated, via bacteriological assays, from tumorous and 
non-tumorous tissues, of colorectal cancer patients with bacteremia, 20.5% and 17.3%, and of 
colorectal cancer patients without bacteremia, 12.8% and 11.5%, respectively while only 2% 
of control tissues revealed colonization of S. bovis/gallolyticus.  
On the other hand, the positive detection of S. bovis/gallolyticus DNA, via PCR, in tumorous 
and non-tumorous tissues of colorectal cancer patients with bacteremia, 48.7 and 35.9%, and 
without bacteremia, 32.7 and 23%, respectively, was remarkably higher than that in control 
tissues, 4%. And the positive detection of S. bovis/gallolyticus DNA, via ISH, in tumorous and 
non-tumorous tissues of colorectal cancer patients with bacteremia, 46.1 and 30.7%, and 
without bacteremia 28.8 and 17.3%, respectively was remarkably higher than that in control 
tissues, 2%. In addition, by using absolute quantitative PCR for S. bovis/gallolyticus DNA, the 
S. bovis/gallolyticus count, in terms of copy number (CN), in tumorous and non-tumorous 
tissues of colorectal cancer patients with bacteremia, 2.96-4.72 and 1.29-2.81 log10 CN/g, 
respectively, and colorectal cancer patients without bacteremia, 2.16-2.92 and 0.67-2.07 log10 
CN/g, respectively, showed significantly higher level of colonization in tumorous than in 
non-tumorous tissues and in colorectal cancer patients with bacteremia than in colorectal 
cancer patients without bacteremia. Accordingly, this study provided several new 
observations. First, S. bovis/gallolyticus colonizes selectively tumorous tissues of colorectal 
cancer  patients rather than normal mucosal tissues. Second, the colonization of S. 
bovis/gallolyticus is mainly found inside tumor lesions rather than on mucosal surfaces of 
tumors. Third, the titer of the colonizing S. bovis/gallolyticus bacteria in colorectal cancer 
patients with bacteremia/endocarditis was much higher than in patients without 
bacteremia/endocarditis; this explains why some colorectal cancer patients develop 
concomitant bacteremia of S. bovis/endocarditis while others do not. Actually, the newly 
discovered selective colonization of S. bovis/gallolyticus explains the conclusions of an earlier 
report (Tjalsma et al., 2006) stating that colonic lesions provide a suitable microenvironment 
for S. bovis/gallolyticus colonization resulting in silent tumor-associated infections that only 
become apparent when cancer patients become immunocompromised, as in bacteraemia, or 
have coincidental cardiac valve lesions and develop endocarditis.  
6. Using S. bovis/gallolyticus in the early detection of colorectal tumors 
For a long time, it has been conceived that there is a need to establish a good screening test 
for colonic cancer patients, particularly a test which could detect early lesions. It has been 
suggested that the presence of antibodies to certain bacterial antigens or the presence of 
certain bacterial antigens in the bloodstream may act as markers for carcinogenesis of the 
colon (Beeching et al., 1985; Potter et al., 1998). The serology-based detection of colorectal 
cancer has advantage on other tests such as fecal occult blood which is neither sensitive nor 
specific or carcinoembryonic antigen which is regularly detectable in only advanced 
diseases (Tafte & Ruoff, 2007). Darjee and Gibb stated that it might be possible to develop a 
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test to screen patients for the presence of colonic cancer by measuring IgG antibody titer of 
S. bovis/gallolyticus (Darjee & Gibb, 1993). Hence, since the association between slow 
evolving bacterial inflammation and colorectal cancer takes long time, it is prudent to seek 
specifically for IgG antibodies. Furthermore, IgG antibodies reflect an image of the past and 
the chronic presence of S. bovis/gallolyticus antigens in the circulation. 
Some studies showed the possibility of constructing a serology test for the successful 
detection of colonic cancer based on the detection of antibody to S. bovis/gallolyticus or 
Enterococcus faecalis (Abdulamir et al., 2009; Groves, 1997). Therefore, a simple ELISA test 
with no more than 2 ml of patient’s blood might be a good candidate for screening high risk 
individuals for the presence of premalignant neoplastic polyps, adenomas, and cancers. 
However, some other studies of antibody response to S. bovis/gallolyticus and other 
streptococci have found that antibody is detectable in endocarditis but not in either clinically 
insignificant bacteremias (Burnie et al., 1987), or colonic cancers ((Kaplan et al., 1983) by 
using immunoblotting, immunoflourescence and other techniques. In a recent study of our 
team (Abdulamir et al., 2009), the serum level of IgG antibodies against S. gallolyticus 
subspecies gallolyticus antigens adsorbed on solid phase of ELISA was found to be 
significantly higher in colorectal cancer patients than in control subjects. This is in full 
agreement with the study of (Darjee & Gibb, 1993) who showed that patients with colonic 
cancer had higher median IgG antibody titers to S. bovis and E. faecalis preparations than did 
the control samples. Accordingly, the applicability of using ELISA as a cheap and effective 
assay for the early detection of colorectal cancer using IgG antibodies against S. 
bovis/gallolyticus has been tested and proven (Abdulamir et al., 2009). Therefore, the early 
detection of colorectal cancer using simple means of testing opens doors to monitor high 
risk groups of colorectal cancer more efficiently.  
7. Conclusions 
Colorectal tumors, adenoma or carcinoma, are associated remarkably with bacterial 
infections of intestine. The manifestation of this association is usually observed as 
concurrent bacteremia or endocarditis of S. bovis/gallolyticus. The association of S. 
bovis/gallolyticus bacteria with colorectal cancer is more likely etiological in nature rather 
than a consequence of the disease. The proposed etiological role of S. bovis/gallolyticus in the 
development of colorectal cancer might be attributed to many factors including selective 
adhesion potential of S. bovis/gallolyticus to tumor tissues, the selective colonization of S. 
bovis/gallolyticus inside tumor tissues, the suitable microenvironment of tumors for S. 
bovis/gallolyticus proliferation, the local disruption of tumor tissues and capillaries which 
allow the entry of S. bovis/gallolyticus into blood circulation leading to bacteremia and 
endocarditis, and the bacterially-induced cytokines and transcriptional factors, such as IL-1, 
IFN-γ, IL-8, and NFkB, which induce and propagate the chronic inflammatory environment 
which promote/propagate premaligant intestinal lesions to malignant ones. This is a very 
important role of S. bovis/gallolyticus in the carcinogenesis of colorectal tissues since the 
majority of cases of colorectal cancer are sporadic cancers arising through the 
transformation of normal colorectal tissues to premalignant lesions, adenomas, and finally 
to malignant tissues. Besides, the early detection of colorectal adenomas or carcinomas via 
detection of S. bovis/gallolyticus DNA or their specific IgG antibodies might be of high value 
in screening the high risk groups for colorectal cancer. More in-depth research is needed to 
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exploit the association of bacteria with colorectal cancer in terms of early diagnosis of the 
disease as well as understanding the bacterial carcinogenic potential to determine the 
appropriate means to prevent and/or treat bacterially-associated cancers.  
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test to screen patients for the presence of colonic cancer by measuring IgG antibody titer of 
S. bovis/gallolyticus (Darjee & Gibb, 1993). Hence, since the association between slow 
evolving bacterial inflammation and colorectal cancer takes long time, it is prudent to seek 
specifically for IgG antibodies. Furthermore, IgG antibodies reflect an image of the past and 
the chronic presence of S. bovis/gallolyticus antigens in the circulation. 
Some studies showed the possibility of constructing a serology test for the successful 
detection of colonic cancer based on the detection of antibody to S. bovis/gallolyticus or 
Enterococcus faecalis (Abdulamir et al., 2009; Groves, 1997). Therefore, a simple ELISA test 
with no more than 2 ml of patient’s blood might be a good candidate for screening high risk 
individuals for the presence of premalignant neoplastic polyps, adenomas, and cancers. 
However, some other studies of antibody response to S. bovis/gallolyticus and other 
streptococci have found that antibody is detectable in endocarditis but not in either clinically 
insignificant bacteremias (Burnie et al., 1987), or colonic cancers ((Kaplan et al., 1983) by 
using immunoblotting, immunoflourescence and other techniques. In a recent study of our 
team (Abdulamir et al., 2009), the serum level of IgG antibodies against S. gallolyticus 
subspecies gallolyticus antigens adsorbed on solid phase of ELISA was found to be 
significantly higher in colorectal cancer patients than in control subjects. This is in full 
agreement with the study of (Darjee & Gibb, 1993) who showed that patients with colonic 
cancer had higher median IgG antibody titers to S. bovis and E. faecalis preparations than did 
the control samples. Accordingly, the applicability of using ELISA as a cheap and effective 
assay for the early detection of colorectal cancer using IgG antibodies against S. 
bovis/gallolyticus has been tested and proven (Abdulamir et al., 2009). Therefore, the early 
detection of colorectal cancer using simple means of testing opens doors to monitor high 
risk groups of colorectal cancer more efficiently.  
7. Conclusions 
Colorectal tumors, adenoma or carcinoma, are associated remarkably with bacterial 
infections of intestine. The manifestation of this association is usually observed as 
concurrent bacteremia or endocarditis of S. bovis/gallolyticus. The association of S. 
bovis/gallolyticus bacteria with colorectal cancer is more likely etiological in nature rather 
than a consequence of the disease. The proposed etiological role of S. bovis/gallolyticus in the 
development of colorectal cancer might be attributed to many factors including selective 
adhesion potential of S. bovis/gallolyticus to tumor tissues, the selective colonization of S. 
bovis/gallolyticus inside tumor tissues, the suitable microenvironment of tumors for S. 
bovis/gallolyticus proliferation, the local disruption of tumor tissues and capillaries which 
allow the entry of S. bovis/gallolyticus into blood circulation leading to bacteremia and 
endocarditis, and the bacterially-induced cytokines and transcriptional factors, such as IL-1, 
IFN-γ, IL-8, and NFkB, which induce and propagate the chronic inflammatory environment 
which promote/propagate premaligant intestinal lesions to malignant ones. This is a very 
important role of S. bovis/gallolyticus in the carcinogenesis of colorectal tissues since the 
majority of cases of colorectal cancer are sporadic cancers arising through the 
transformation of normal colorectal tissues to premalignant lesions, adenomas, and finally 
to malignant tissues. Besides, the early detection of colorectal adenomas or carcinomas via 
detection of S. bovis/gallolyticus DNA or their specific IgG antibodies might be of high value 
in screening the high risk groups for colorectal cancer. More in-depth research is needed to 
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exploit the association of bacteria with colorectal cancer in terms of early diagnosis of the 
disease as well as understanding the bacterial carcinogenic potential to determine the 
appropriate means to prevent and/or treat bacterially-associated cancers.  
8. References 
Abdulamir, A.S., Hafidh, R.R., Bakar, F.A., (2010). Molecular detection, quantification, and 
isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: 
inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8. Mol 
Cancer, Vol. 9, No. pp. 249, 1476-4598 (Electronic)1476-4598 (Linking) 
Abdulamir, A.S., Hafidh, R.R., Mahdi, L.K., Al-jeboori, T., Abubaker, F., (2009). 
Investigation into the controversial association of Streptococcus gallolyticus with 
colorectal cancer and adenoma. BMC Cancer, Vol. 9, No. pp. 403, 1471-2407 
(Electronic) 1471-2407 (Linking) 
Al-Jashamy, K., Murad, A., Zeehaida, M., Rohaini, M., Hasnan, J., (2010). Prevalence of 
colorectal cancer associated with Streptococcus bovis among inflammatory bowel 
and chronic gastrointestinal tract disease patients. Asian Pac J Cancer Prev, Vol. 11, 
No. 6, pp. 1765-1768, 1513-7368 (Print) 1513-7368 (Linking) 
Balkwill, F., Charles, K.A., Mantovani, A., (2005). Smoldering and polarized inflammation in 
the initiation and promotion of malignant disease. Cancer Cell, Vol. 7, No. 3, pp. 
211-217, 1535-6108 (Print) 1535-6108 (Linking) 
Baron, J.A., Sandler, R.S., (2000). Nonsteroidal anti-inflammatory drugs and cancer 
prevention. Annu Rev Med, Vol. 51, No. pp. 511-523, 0066-4219 (Print) 0066-4219 
(Linking) 
Beeching, N.J., Christmas, T.I., Ellis-Pegler, R.B., Nicholson, G.I., (1985). Streptococcus bovis 
bacteraemia requires rigorous exclusion of colonic neoplasia and endocarditis. Q J 
Med, Vol. 56, No. 220, pp. 439-450, 0033-5622 (Print) 0033-5622 (Linking) 
Biarc, J., Nguyen, I.S., Pini, A., Gosse, F., Richert, S., Thierse, D., Van Dorsselaer, A., Leize-
Wagner, E., Raul, F., Klein, J.P., Scholler-Guinard, M., (2004). Carcinogenic 
properties of proteins with pro-inflammatory activity from Streptococcus 
infantarius (formerly S.bovis). Carcinogenesis, Vol. 25, No. 8, pp. 1477-1484, 0143-
3334 (Print) 0143-3334 (Linking) 
Bisno, A., 12.ed. New York:, (1991). Streptococcal infection. In: Harrison's principles of internal 
medicine. Harrison, T., Stone, R.s (Eds.), pp. 563-569, McGraw-Hill, New York. 
Boleij, A., Schaeps, R.M., de Kleijn, S., Hermans, P.W., Glaser, P., Pancholi, V., Swinkels, 
D.W., Tjalsma, H., (2009b). Surface-exposed histone-like protein a modulates 
adherence of Streptococcus gallolyticus to colon adenocarcinoma cells. Infect 
Immun, Vol. 77, No. 12, pp. 5519-5527, 1098-5522 (Electronic) 0019-9567 (Linking) 
Boleij, A., Schaeps, R.M., Tjalsma, H., (2009a). Association between Streptococcus bovis and 
colon cancer. J Clin Microbiol, Vol. 47, No. 2, pp. 516, 1098-660X (Electronic) 0095-
1137 (Linking) 
Bond, J.H., (2005). Colon polyps and cancer. Endoscopy, Vol. 37, No. 3, pp. 208-212, 0013-
726X (Print) 0013-726X (Linking) 
Burnie, J.P., Holland, M., Matthews, R.C., Lees, W., (1987). Role of immunoblotting in the 
diagnosis of culture negative and enterococcal endocarditis. J Clin Pathol, Vol. 40, 
No. 10, pp. 1149-1158, 0021-9746 (Print) 0021-9746 (Linking) 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
386 
Burns, C.A., McCaughey, R., Lauter, C.B., (1985). The association of Streptococcus bovis 
fecal carriage and colon neoplasia: possible relationship with polyps and their 
premalignant potential. Am J Gastroenterol, Vol. 80, No. 1, pp. 42-46, 0002-9270 
(Print) 0002-9270 (Linking) 
Cutait, R., Mansur, A., Habr-Gama, A., (1988). Endocardite por Streptococcus bovis e 
pólipos de cólon. Rev Bras Coloproctol, Vol. 8, No. pp. 109-110,  
Dai, Y., Wang, W.H., (2006). Non-steroidal anti-inflammatory drugs in prevention of gastric 
cancer. World J Gastroenterol, Vol. 12, No. 18, pp. 2884-2889, 1007-9327 (Print) 1007-
9327 (Linking) 
Darjee, R., Gibb, A.P., (1993). Serological investigation into the association between 
Streptococcus bovis and colonic cancer. J Clin Pathol, Vol. 46, No. 12, pp. 1116-1119, 
0021-9746 (Print) 0021-9746 (Linking) 
Devis, A., Dony, A., De Boelpaepe, F., Verhulst, C., Serste, J.P., (1989). [Streptococcus bovis 
septicemia and colonic cancer]. Acta Chir Belg, Vol. 89, No. 1, pp. 58-60, 0001-5458 
(Print) 0001-5458 (Linking) 
Devriese, L.A., Vandamme, P., Pot, B., Vanrobaeys, M., Kersters, K., Haesebrouck, F., (1998). 
Differentiation between Streptococcus gallolyticus strains of human clinical and 
veterinary origins and Streptococcus bovis strains from the intestinal tracts of 
ruminants. J Clin Microbiol, Vol. 36, No. 12, pp. 3520-3523, 0095-1137 (Print) 0095-
1137 (Linking) 
Dixon, M.F., Genta, R.M., Yardley, J.H., Correa, P., (1996). Classification and grading of 
gastritis. The updated Sydney System. International Workshop on the 
Histopathology of Gastritis, Houston 1994. Am J Surg Pathol, Vol. 20, No. 10, pp. 
1161-1181, 0147-5185 (Print) 0147-5185 (Linking) 
Eisma, R.J., Spiro, J.D., Kreutzer, D.L., (1999). Role of angiogenic factors: coexpression of 
interleukin-8 and vascular endothelial growth factor in patients with head and neck 
squamous carcinoma. Laryngoscope, Vol. 109, No. 5, pp. 687-693, 0023-852X (Print) 
0023-852X (Linking) 
El-Omar, E.M., (2006). Role of host genes in sporadic gastric cancer. Best Pract Res Clin 
Gastroenterol, Vol. 20, No. 4, pp. 675-686, 1521-6918 (Print) 1521-6918 (Linking) 
Ellmerich, S., Djouder, N., Scholler, M., Klein, J.P., (2000b). Production of cytokines by 
monocytes, epithelial and endothelial cells activated by Streptococcus bovis. 
Cytokine, Vol. 12, No. 1, pp. 26-31, 1043-4666 (Print) 1043-4666 (Linking) 
Ellmerich, S., Scholler, M., Duranton, B., Gosse, F., Galluser, M., Klein, J.P., Raul, F., (2000a). 
Promotion of intestinal carcinogenesis by Streptococcus bovis. Carcinogenesis, Vol. 
21, No. 4, pp. 753-756, 0143-3334 (Print) 0143-3334 (Linking) 
Ernst, P.B., Peura, D.A., Crowe, S.E., (2006). The translation of Helicobacter pylori basic 
research to patient care. Gastroenterology, Vol. 130, No. 1, pp. 188-206; quiz 212-183, 
0016-5085 (Print) 0016-5085 (Linking) 
Fagundes, J., Noujain, H., Coy, C., Ayrizono, M., Góes, J., Martinuzzo, W., (2000). 
Associação entre endocardite bacteriana e neoplasias - relato de 4 casos. Rev Bras 
Coloproctol, Vol. 20, No. pp. 95-99,  
Grinberg, M., Mansur, A., Ferreira, D., Bellotti, G., Pileggi, F., (1990). Endocardite por 
Streptococcus bovis e neoplasias de cólon e reto. Arq Bras Cardiol, Vol. 67, No. pp. 
265-269,  
 
Streptococcus bovis/gallolyticus Induce the Development of Colorectal Cancer 
 
387 
Groves, C., (1997). Case presentation. The Jhon Hokins Microbiology Newsletter, Vol. 16, No. 
pp. 42-44,  
Gupta, A., Madani, R., Mukhtar, H., (2009). Streptococcus bovis endocarditis; a silent sign 
for colonic tumour. Colorectal Dis, Vol., No. pp., 1463-1318 (Electronic) 1462-8910 
(Linking) 
Haqqani, A.S., Sandhu, J.K., Birnboim, H.C., (2000). Expression of interleukin-8 promotes 
neutrophil infiltration and genetic instability in mutatect tumors. Neoplasia, Vol. 2, 
No. 6, pp. 561-568, 1522-8002 (Print) 1476-5586 (Linking) 
Hirata, Y., Maeda, S., Mitsuno, Y., Akanuma, M., Yamaji, Y., Ogura, K., Yoshida, H., 
Shiratori, Y., Omata, M., (2001). Helicobacter pylori activates the cyclin D1 gene 
through mitogen-activated protein kinase pathway in gastric cancer cells. Infect 
Immun, Vol. 69, No. 6, pp. 3965-3971, 0019-9567 (Print) 0019-9567 (Linking) 
Hoen, B., Briancon, S., Delahaye, F., Terhe, V., Etienne, J., Bigard, M.A., Canton, P., (1994). 
Tumors of the colon increase the risk of developing Streptococcus bovis 
endocarditis: case-control study. Clin Infect Dis, Vol. 19, No. 2, pp. 361-362, 1058-
4838 (Print) 1058-4838 (Linking) 
Hou, L., El-Omar, E.M., Chen, J., Grillo, P., Rabkin, C.S., Baccarelli, A., Yeager, M., Chanock, 
S.J., Zatonski, W., Sobin, L.H., Lissowska, J., Fraumeni, J.F., Jr., Chow, W.H., (2007). 
Polymorphisms in Th1-type cell-mediated response genes and risk of gastric 
cancer. Carcinogenesis, Vol. 28, No. 1, pp. 118-123, 0143-3334 (Print) 0143-3334 
(Linking) 
Ihler, G.M., (1996). Bartonella bacilliformis: dangerous pathogen slowly emerging from deep 
background. FEMS Microbiol Lett, Vol. 144, No. 1, pp. 1-11, 0378-1097 (Print) 0378-
1097 (Linking) 
Kahveci, A., Ari, E., Arikan, H., Koc, M., Tuglular, S., Ozener, C., (2010). Streptococcus bovis 
bacteremia related to colon adenoma in a chronic hemodialysis patient. Hemodial 
Int, Vol. 14, No. 1, pp. 91-93, 1542-4758 (Electronic) 1492-7535 (Linking) 
Kaplan, M.H., Chmel, H., Stephens, A., Hsieh, H.C., Tenenbaum, M.J., Rothenberg, I.R., 
Joachim, G.R., (1983). Humoral reactions in human endocarditis due to 
Streptococcus bovis: evidence for a common S bovis antigen. J Infect Dis, Vol. 148, 
No. 2, pp. 266-274, 0022-1899 (Print) 0022-1899 (Linking) 
Kargman, S.L., O'Neill, G.P., Vickers, P.J., Evans, J.F., Mancini, J.A., Jothy, S., (1995). 
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. 
Cancer Res, Vol. 55, No. 12, pp. 2556-2559, 0008-5472 (Print) 0008-5472 (Linking) 
Karin, M., Greten, F.R., (2005). NF-kappaB: linking inflammation and immunity to cancer 
development and progression. Nat Rev Immunol, Vol. 5, No. 10, pp. 749-759, 1474-
1733 (Print) 1474-1733 (Linking) 
Kelly, C., Evans, P., Bergmeier, L., Lee, S.F., Progulske-Fox, A., Harris, A.C., Aitken, A., 
Bleiweis, A.S., Lehner, T., (1989). Sequence analysis of the cloned streptococcal cell 
surface antigen I/II. FEBS Lett, Vol. 258, No. 1, pp. 127-132, 0014-5793 (Print) 0014-
5793 (Linking) 
Klein, R.S., Catalano, M.T., Edberg, S.C., Casey, J.I., Steigbigel, N.H., (1979). Streptococcus 
bovis septicemia and carcinoma of the colon. Ann Intern Med, Vol. 91, No. 4, pp. 
560-562, 0003-4819 (Print) 0003-4819 (Linking) 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
386 
Burns, C.A., McCaughey, R., Lauter, C.B., (1985). The association of Streptococcus bovis 
fecal carriage and colon neoplasia: possible relationship with polyps and their 
premalignant potential. Am J Gastroenterol, Vol. 80, No. 1, pp. 42-46, 0002-9270 
(Print) 0002-9270 (Linking) 
Cutait, R., Mansur, A., Habr-Gama, A., (1988). Endocardite por Streptococcus bovis e 
pólipos de cólon. Rev Bras Coloproctol, Vol. 8, No. pp. 109-110,  
Dai, Y., Wang, W.H., (2006). Non-steroidal anti-inflammatory drugs in prevention of gastric 
cancer. World J Gastroenterol, Vol. 12, No. 18, pp. 2884-2889, 1007-9327 (Print) 1007-
9327 (Linking) 
Darjee, R., Gibb, A.P., (1993). Serological investigation into the association between 
Streptococcus bovis and colonic cancer. J Clin Pathol, Vol. 46, No. 12, pp. 1116-1119, 
0021-9746 (Print) 0021-9746 (Linking) 
Devis, A., Dony, A., De Boelpaepe, F., Verhulst, C., Serste, J.P., (1989). [Streptococcus bovis 
septicemia and colonic cancer]. Acta Chir Belg, Vol. 89, No. 1, pp. 58-60, 0001-5458 
(Print) 0001-5458 (Linking) 
Devriese, L.A., Vandamme, P., Pot, B., Vanrobaeys, M., Kersters, K., Haesebrouck, F., (1998). 
Differentiation between Streptococcus gallolyticus strains of human clinical and 
veterinary origins and Streptococcus bovis strains from the intestinal tracts of 
ruminants. J Clin Microbiol, Vol. 36, No. 12, pp. 3520-3523, 0095-1137 (Print) 0095-
1137 (Linking) 
Dixon, M.F., Genta, R.M., Yardley, J.H., Correa, P., (1996). Classification and grading of 
gastritis. The updated Sydney System. International Workshop on the 
Histopathology of Gastritis, Houston 1994. Am J Surg Pathol, Vol. 20, No. 10, pp. 
1161-1181, 0147-5185 (Print) 0147-5185 (Linking) 
Eisma, R.J., Spiro, J.D., Kreutzer, D.L., (1999). Role of angiogenic factors: coexpression of 
interleukin-8 and vascular endothelial growth factor in patients with head and neck 
squamous carcinoma. Laryngoscope, Vol. 109, No. 5, pp. 687-693, 0023-852X (Print) 
0023-852X (Linking) 
El-Omar, E.M., (2006). Role of host genes in sporadic gastric cancer. Best Pract Res Clin 
Gastroenterol, Vol. 20, No. 4, pp. 675-686, 1521-6918 (Print) 1521-6918 (Linking) 
Ellmerich, S., Djouder, N., Scholler, M., Klein, J.P., (2000b). Production of cytokines by 
monocytes, epithelial and endothelial cells activated by Streptococcus bovis. 
Cytokine, Vol. 12, No. 1, pp. 26-31, 1043-4666 (Print) 1043-4666 (Linking) 
Ellmerich, S., Scholler, M., Duranton, B., Gosse, F., Galluser, M., Klein, J.P., Raul, F., (2000a). 
Promotion of intestinal carcinogenesis by Streptococcus bovis. Carcinogenesis, Vol. 
21, No. 4, pp. 753-756, 0143-3334 (Print) 0143-3334 (Linking) 
Ernst, P.B., Peura, D.A., Crowe, S.E., (2006). The translation of Helicobacter pylori basic 
research to patient care. Gastroenterology, Vol. 130, No. 1, pp. 188-206; quiz 212-183, 
0016-5085 (Print) 0016-5085 (Linking) 
Fagundes, J., Noujain, H., Coy, C., Ayrizono, M., Góes, J., Martinuzzo, W., (2000). 
Associação entre endocardite bacteriana e neoplasias - relato de 4 casos. Rev Bras 
Coloproctol, Vol. 20, No. pp. 95-99,  
Grinberg, M., Mansur, A., Ferreira, D., Bellotti, G., Pileggi, F., (1990). Endocardite por 
Streptococcus bovis e neoplasias de cólon e reto. Arq Bras Cardiol, Vol. 67, No. pp. 
265-269,  
 
Streptococcus bovis/gallolyticus Induce the Development of Colorectal Cancer 
 
387 
Groves, C., (1997). Case presentation. The Jhon Hokins Microbiology Newsletter, Vol. 16, No. 
pp. 42-44,  
Gupta, A., Madani, R., Mukhtar, H., (2009). Streptococcus bovis endocarditis; a silent sign 
for colonic tumour. Colorectal Dis, Vol., No. pp., 1463-1318 (Electronic) 1462-8910 
(Linking) 
Haqqani, A.S., Sandhu, J.K., Birnboim, H.C., (2000). Expression of interleukin-8 promotes 
neutrophil infiltration and genetic instability in mutatect tumors. Neoplasia, Vol. 2, 
No. 6, pp. 561-568, 1522-8002 (Print) 1476-5586 (Linking) 
Hirata, Y., Maeda, S., Mitsuno, Y., Akanuma, M., Yamaji, Y., Ogura, K., Yoshida, H., 
Shiratori, Y., Omata, M., (2001). Helicobacter pylori activates the cyclin D1 gene 
through mitogen-activated protein kinase pathway in gastric cancer cells. Infect 
Immun, Vol. 69, No. 6, pp. 3965-3971, 0019-9567 (Print) 0019-9567 (Linking) 
Hoen, B., Briancon, S., Delahaye, F., Terhe, V., Etienne, J., Bigard, M.A., Canton, P., (1994). 
Tumors of the colon increase the risk of developing Streptococcus bovis 
endocarditis: case-control study. Clin Infect Dis, Vol. 19, No. 2, pp. 361-362, 1058-
4838 (Print) 1058-4838 (Linking) 
Hou, L., El-Omar, E.M., Chen, J., Grillo, P., Rabkin, C.S., Baccarelli, A., Yeager, M., Chanock, 
S.J., Zatonski, W., Sobin, L.H., Lissowska, J., Fraumeni, J.F., Jr., Chow, W.H., (2007). 
Polymorphisms in Th1-type cell-mediated response genes and risk of gastric 
cancer. Carcinogenesis, Vol. 28, No. 1, pp. 118-123, 0143-3334 (Print) 0143-3334 
(Linking) 
Ihler, G.M., (1996). Bartonella bacilliformis: dangerous pathogen slowly emerging from deep 
background. FEMS Microbiol Lett, Vol. 144, No. 1, pp. 1-11, 0378-1097 (Print) 0378-
1097 (Linking) 
Kahveci, A., Ari, E., Arikan, H., Koc, M., Tuglular, S., Ozener, C., (2010). Streptococcus bovis 
bacteremia related to colon adenoma in a chronic hemodialysis patient. Hemodial 
Int, Vol. 14, No. 1, pp. 91-93, 1542-4758 (Electronic) 1492-7535 (Linking) 
Kaplan, M.H., Chmel, H., Stephens, A., Hsieh, H.C., Tenenbaum, M.J., Rothenberg, I.R., 
Joachim, G.R., (1983). Humoral reactions in human endocarditis due to 
Streptococcus bovis: evidence for a common S bovis antigen. J Infect Dis, Vol. 148, 
No. 2, pp. 266-274, 0022-1899 (Print) 0022-1899 (Linking) 
Kargman, S.L., O'Neill, G.P., Vickers, P.J., Evans, J.F., Mancini, J.A., Jothy, S., (1995). 
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. 
Cancer Res, Vol. 55, No. 12, pp. 2556-2559, 0008-5472 (Print) 0008-5472 (Linking) 
Karin, M., Greten, F.R., (2005). NF-kappaB: linking inflammation and immunity to cancer 
development and progression. Nat Rev Immunol, Vol. 5, No. 10, pp. 749-759, 1474-
1733 (Print) 1474-1733 (Linking) 
Kelly, C., Evans, P., Bergmeier, L., Lee, S.F., Progulske-Fox, A., Harris, A.C., Aitken, A., 
Bleiweis, A.S., Lehner, T., (1989). Sequence analysis of the cloned streptococcal cell 
surface antigen I/II. FEBS Lett, Vol. 258, No. 1, pp. 127-132, 0014-5793 (Print) 0014-
5793 (Linking) 
Klein, R.S., Catalano, M.T., Edberg, S.C., Casey, J.I., Steigbigel, N.H., (1979). Streptococcus 
bovis septicemia and carcinoma of the colon. Ann Intern Med, Vol. 91, No. 4, pp. 
560-562, 0003-4819 (Print) 0003-4819 (Linking) 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
388 
Kok, H., Jureen, R., Soon, C.Y., Tey, B.H., (2007). Colon cancer presenting as Streptococcus 
gallolyticus infective endocarditis. Singapore Med J, Vol. 48, No. 2, pp. e43-45, 0037-
5675 (Print) 0037-5675 (Linking) 
Konda, A., Duffy, M.C., (2008). Surveillance of patients at increased risk of colon cancer: 
inflammatory bowel disease and other conditions. Gastroenterol Clin North Am, Vol. 
37, No. 1, pp. 191-213, viii, 0889-8553 (Print) 0889-8553 (Linking) 
Lasa, M., Abraham, S.M., Boucheron, C., Saklatvala, J., Clark, A.R., (2002). Dexamethasone 
causes sustained expression of mitogen-activated protein kinase (MAPK) 
phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol, 
Vol. 22, No. 22, pp. 7802-7811, 0270-7306 (Print) 0270-7306 (Linking) 
Lee, R.A., Woo, P.C., To, A.P., Lau, S.K., Wong, S.S., Yuen, K.Y., (2003). Geographical 
difference of disease association in Streptococcus bovis bacteraemia. J Med 
Microbiol, Vol. 52, No. Pt 10, pp. 903-908, 0022-2615 (Print) 0022-2615 (Linking) 
Leport, C., Bure, A., Leport, J., Vilde, J.L., (1987). Incidence of colonic lesions in 
Streptococcus bovis and enterococcal endocarditis. Lancet, Vol. 1, No. 8535, pp. 748, 
0140-6736 (Print) 0140-6736 (Linking) 
Leung, W.K., (2006). Helicobacter pylori and gastric neoplasia. Contrib Microbiol, Vol. 13, No. 
pp. 66-80, 1420-9519 (Print) 1420-9519 (Linking) 
Malkin, J., Kimmitt, P.T., Ou, H.Y., Bhasker, P.S., Khare, M., Deng, Z., Stephenson, I., 
Sosnowski, A.W., Perera, N., Rajakumar, K., (2008). Identification of Streptococcus 
gallolyticus subsp. macedonicus as the etiological agent in a case of culture-
negative multivalve infective endocarditis by 16S rDNA PCR analysis of resected 
valvular tissue. J Heart Valve Dis, Vol. 17, No. 5, pp. 589-592, 0966-8519 (Print) 0966-
8519 (Linking) 
Monack, D.M., Mueller, A., Falkow, S., (2004). Persistent bacterial infections: the interface of 
the pathogen and the host immune system. Nat Rev Microbiol, Vol. 2, No. 9, pp. 747-
765, 1740-1526 (Print) 1740-1526 (Linking) 
Murinello, A., Mendonca, P., Ho, C., Traverse, P., Peres, H., RioTinto, R., Morbey, A., 
Campos, C., Lazoro, A., Milheiro, A., Arias, M., Oliveira, J., Braz, S., (2006). 
Streptococcus gallolyticus bacteremia assoaiced with colonic adenmatous polyps. 
GE-J-Port Gastrentrol Vol. 13, No. pp. 152-156,  
Murray, H.W., Roberts, R.B., (1978). Streptococcus bovis bacteremia and underlying 
gastrointestinal disease. Arch Intern Med, Vol. 138, No. 7, pp. 1097-1099, 0003-9926 
(Print) 0003-9926 (Linking) 
Murray, P.R., Baron, E.J., (2007). Manual of clinical microbiology (9th). ASM Press, 1555813712 
(set) 9781555813710 (set) Washington, D.C. 
Nguyen, I., Biarc, J., Pini, A., Gosse, F., Richert, S., Thierse, D., Van Dorsselaer, A., Leize-
Wagner, E., Raul, F., Klein, J., Scholler-Guinard, M., (2006). Streptococcus 
infantarius and colonic cancer: Identification and purification of cell wall proteins 
putatively involved in colorectal inflammation and carcinogenesis in rats. 
International Congress Series Vol., No. pp. 257– 261,  
Nielsen, S.D., Christensen, J.J., Laerkeborg, A., Haunso, S., Knudsen, J.D., (2007). [Molecular-
biological methods of diagnosing colon-related Streptococcus bovis endocarditis]. 
Ugeskr Laeger, Vol. 169, No. 7, pp. 610-611, 1603-6824 (Electronic) 0041-5782 
(Linking) 
 
Streptococcus bovis/gallolyticus Induce the Development of Colorectal Cancer 
 
389 
Norfleet, R.G., Mitchell, P.D., (1993). Streptococcus bovis does not selectively colonize 
colorectal cancer and polyps. J Clin Gastroenterol, Vol. 17, No. 1, pp. 25-28, 0192-0790 
(Print) 0192-0790 (Linking) 
Norrby, K., (1996). Interleukin-8 and de novo mammalian angiogenesis. Cell Prolif, Vol. 29, 
No. 6, pp. 315-323, 0960-7722 (Print) 0960-7722 (Linking) 
Ohshima, H., Bartsch, H., (1994). Chronic infections and inflammatory processes as cancer 
risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res, Vol. 305, No. 
2, pp. 253-264, 0027-5107 (Print) 0027-5107 (Linking) 
Osawa, R., Fujisawa, T., LI., S., (1995). Streptococcus gallolyticus sp. nov.: gallate degrading 
organisms formerly assigned to Streptococcus bovis. Syst. Appl. Microbiol., Vol. 18, 
No. pp. 74-78,  
Potter, M.A., Cunliffe, N.A., Smith, M., Miles, R.S., Flapan, A.D., Dunlop, M.G., (1998). A 
prospective controlled study of the association of Streptococcus bovis with 
colorectal carcinoma. J Clin Pathol, Vol. 51, No. 6, pp. 473-474, 0021-9746 (Print) 
0021-9746 (Linking) 
Reynolds, J.G., Silva, E., McCormack, W.M., (1983). Association of Streptococcus bovis 
bacteremia with bowel disease. J Clin Microbiol, Vol. 17, No. 4, pp. 696-697, 0095-
1137 (Print) 0095-1137 (Linking) 
Ruoff, K.L., Miller, S.I., Garner, C.V., Ferraro, M.J., Calderwood, S.B., (1989). Bacteremia 
with Streptococcus bovis and Streptococcus salivarius: clinical correlates of more 
accurate identification of isolates. J Clin Microbiol, Vol. 27, No. 2, pp. 305-308, 0095-
1137 (Print) 0095-1137 (Linking) 
Schlegel, L., Grimont, F., Ageron, E., Grimont, P.A., Bouvet, A., (2003). Reappraisal of the 
taxonomy of the Streptococcus bovis/Streptococcus equinus complex and related 
species: description of Streptococcus gallolyticus subsp. gallolyticus subsp. nov., S. 
gallolyticus subsp. macedonicus subsp. nov. and S. gallolyticus subsp. pasteurianus 
subsp. nov. Int J Syst Evol Microbiol, Vol. 53, No. Pt 3, pp. 631-645, 1466-5026 (Print) 
1466-5026 (Linking) 
Shacter, E., Weitzman, S.A., (2002). Chronic inflammation and cancer. Oncology (Williston 
Park), Vol. 16, No. 2, pp. 217-226, 229; discussion 230-212, 0890-9091 (Print) 0890-
9091 (Linking) 
Sillanpaa, J., Nallapareddy, S.R., Qin, X., Singh, K.V., Muzny, D.M., Kovar, C.L., Nazareth, 
L.V., Gibbs, R.A., Ferraro, M.J., Steckelberg, J.M., Weinstock, G.M., Murray, B.E., 
(2009). A collagen-binding adhesin, Acb, and ten other putative MSCRAMM and 
pilus family proteins of Streptococcus gallolyticus subsp. gallolyticus 
(Streptococcus bovis Group, biotype I). J Bacteriol, Vol. 191, No. 21, pp. 6643-6653, 
1098-5530 (Electronic) 0021-9193 (Linking) 
Sillanpaa, J., Nallapareddy, S.R., Singh, K.V., Ferraro, M.J., Murray, B.E., (2008). Adherence 
characteristics of endocarditis-derived Streptococcus gallolyticus ssp. gallolyticus 
(Streptococcus bovis biotype I) isolates to host extracellular matrix proteins. FEMS 
Microbiol Lett, Vol. 289, No. 1, pp. 104-109, 0378-1097 (Print) 0378-1097 (Linking) 
Smaali, I., Bachraoui, K., Joulek, A., Selmi, K., Boujnah, M.R., (2008). [Infectious endocarditis 
secondary to streptococcus bovis revealing adenomatous polyposis coli ]. Tunis 
Med, Vol. 86, No. 7, pp. 723-724, 0041-4131 (Print) 0041-4131 (Linking) 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
388 
Kok, H., Jureen, R., Soon, C.Y., Tey, B.H., (2007). Colon cancer presenting as Streptococcus 
gallolyticus infective endocarditis. Singapore Med J, Vol. 48, No. 2, pp. e43-45, 0037-
5675 (Print) 0037-5675 (Linking) 
Konda, A., Duffy, M.C., (2008). Surveillance of patients at increased risk of colon cancer: 
inflammatory bowel disease and other conditions. Gastroenterol Clin North Am, Vol. 
37, No. 1, pp. 191-213, viii, 0889-8553 (Print) 0889-8553 (Linking) 
Lasa, M., Abraham, S.M., Boucheron, C., Saklatvala, J., Clark, A.R., (2002). Dexamethasone 
causes sustained expression of mitogen-activated protein kinase (MAPK) 
phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol, 
Vol. 22, No. 22, pp. 7802-7811, 0270-7306 (Print) 0270-7306 (Linking) 
Lee, R.A., Woo, P.C., To, A.P., Lau, S.K., Wong, S.S., Yuen, K.Y., (2003). Geographical 
difference of disease association in Streptococcus bovis bacteraemia. J Med 
Microbiol, Vol. 52, No. Pt 10, pp. 903-908, 0022-2615 (Print) 0022-2615 (Linking) 
Leport, C., Bure, A., Leport, J., Vilde, J.L., (1987). Incidence of colonic lesions in 
Streptococcus bovis and enterococcal endocarditis. Lancet, Vol. 1, No. 8535, pp. 748, 
0140-6736 (Print) 0140-6736 (Linking) 
Leung, W.K., (2006). Helicobacter pylori and gastric neoplasia. Contrib Microbiol, Vol. 13, No. 
pp. 66-80, 1420-9519 (Print) 1420-9519 (Linking) 
Malkin, J., Kimmitt, P.T., Ou, H.Y., Bhasker, P.S., Khare, M., Deng, Z., Stephenson, I., 
Sosnowski, A.W., Perera, N., Rajakumar, K., (2008). Identification of Streptococcus 
gallolyticus subsp. macedonicus as the etiological agent in a case of culture-
negative multivalve infective endocarditis by 16S rDNA PCR analysis of resected 
valvular tissue. J Heart Valve Dis, Vol. 17, No. 5, pp. 589-592, 0966-8519 (Print) 0966-
8519 (Linking) 
Monack, D.M., Mueller, A., Falkow, S., (2004). Persistent bacterial infections: the interface of 
the pathogen and the host immune system. Nat Rev Microbiol, Vol. 2, No. 9, pp. 747-
765, 1740-1526 (Print) 1740-1526 (Linking) 
Murinello, A., Mendonca, P., Ho, C., Traverse, P., Peres, H., RioTinto, R., Morbey, A., 
Campos, C., Lazoro, A., Milheiro, A., Arias, M., Oliveira, J., Braz, S., (2006). 
Streptococcus gallolyticus bacteremia assoaiced with colonic adenmatous polyps. 
GE-J-Port Gastrentrol Vol. 13, No. pp. 152-156,  
Murray, H.W., Roberts, R.B., (1978). Streptococcus bovis bacteremia and underlying 
gastrointestinal disease. Arch Intern Med, Vol. 138, No. 7, pp. 1097-1099, 0003-9926 
(Print) 0003-9926 (Linking) 
Murray, P.R., Baron, E.J., (2007). Manual of clinical microbiology (9th). ASM Press, 1555813712 
(set) 9781555813710 (set) Washington, D.C. 
Nguyen, I., Biarc, J., Pini, A., Gosse, F., Richert, S., Thierse, D., Van Dorsselaer, A., Leize-
Wagner, E., Raul, F., Klein, J., Scholler-Guinard, M., (2006). Streptococcus 
infantarius and colonic cancer: Identification and purification of cell wall proteins 
putatively involved in colorectal inflammation and carcinogenesis in rats. 
International Congress Series Vol., No. pp. 257– 261,  
Nielsen, S.D., Christensen, J.J., Laerkeborg, A., Haunso, S., Knudsen, J.D., (2007). [Molecular-
biological methods of diagnosing colon-related Streptococcus bovis endocarditis]. 
Ugeskr Laeger, Vol. 169, No. 7, pp. 610-611, 1603-6824 (Electronic) 0041-5782 
(Linking) 
 
Streptococcus bovis/gallolyticus Induce the Development of Colorectal Cancer 
 
389 
Norfleet, R.G., Mitchell, P.D., (1993). Streptococcus bovis does not selectively colonize 
colorectal cancer and polyps. J Clin Gastroenterol, Vol. 17, No. 1, pp. 25-28, 0192-0790 
(Print) 0192-0790 (Linking) 
Norrby, K., (1996). Interleukin-8 and de novo mammalian angiogenesis. Cell Prolif, Vol. 29, 
No. 6, pp. 315-323, 0960-7722 (Print) 0960-7722 (Linking) 
Ohshima, H., Bartsch, H., (1994). Chronic infections and inflammatory processes as cancer 
risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res, Vol. 305, No. 
2, pp. 253-264, 0027-5107 (Print) 0027-5107 (Linking) 
Osawa, R., Fujisawa, T., LI., S., (1995). Streptococcus gallolyticus sp. nov.: gallate degrading 
organisms formerly assigned to Streptococcus bovis. Syst. Appl. Microbiol., Vol. 18, 
No. pp. 74-78,  
Potter, M.A., Cunliffe, N.A., Smith, M., Miles, R.S., Flapan, A.D., Dunlop, M.G., (1998). A 
prospective controlled study of the association of Streptococcus bovis with 
colorectal carcinoma. J Clin Pathol, Vol. 51, No. 6, pp. 473-474, 0021-9746 (Print) 
0021-9746 (Linking) 
Reynolds, J.G., Silva, E., McCormack, W.M., (1983). Association of Streptococcus bovis 
bacteremia with bowel disease. J Clin Microbiol, Vol. 17, No. 4, pp. 696-697, 0095-
1137 (Print) 0095-1137 (Linking) 
Ruoff, K.L., Miller, S.I., Garner, C.V., Ferraro, M.J., Calderwood, S.B., (1989). Bacteremia 
with Streptococcus bovis and Streptococcus salivarius: clinical correlates of more 
accurate identification of isolates. J Clin Microbiol, Vol. 27, No. 2, pp. 305-308, 0095-
1137 (Print) 0095-1137 (Linking) 
Schlegel, L., Grimont, F., Ageron, E., Grimont, P.A., Bouvet, A., (2003). Reappraisal of the 
taxonomy of the Streptococcus bovis/Streptococcus equinus complex and related 
species: description of Streptococcus gallolyticus subsp. gallolyticus subsp. nov., S. 
gallolyticus subsp. macedonicus subsp. nov. and S. gallolyticus subsp. pasteurianus 
subsp. nov. Int J Syst Evol Microbiol, Vol. 53, No. Pt 3, pp. 631-645, 1466-5026 (Print) 
1466-5026 (Linking) 
Shacter, E., Weitzman, S.A., (2002). Chronic inflammation and cancer. Oncology (Williston 
Park), Vol. 16, No. 2, pp. 217-226, 229; discussion 230-212, 0890-9091 (Print) 0890-
9091 (Linking) 
Sillanpaa, J., Nallapareddy, S.R., Qin, X., Singh, K.V., Muzny, D.M., Kovar, C.L., Nazareth, 
L.V., Gibbs, R.A., Ferraro, M.J., Steckelberg, J.M., Weinstock, G.M., Murray, B.E., 
(2009). A collagen-binding adhesin, Acb, and ten other putative MSCRAMM and 
pilus family proteins of Streptococcus gallolyticus subsp. gallolyticus 
(Streptococcus bovis Group, biotype I). J Bacteriol, Vol. 191, No. 21, pp. 6643-6653, 
1098-5530 (Electronic) 0021-9193 (Linking) 
Sillanpaa, J., Nallapareddy, S.R., Singh, K.V., Ferraro, M.J., Murray, B.E., (2008). Adherence 
characteristics of endocarditis-derived Streptococcus gallolyticus ssp. gallolyticus 
(Streptococcus bovis biotype I) isolates to host extracellular matrix proteins. FEMS 
Microbiol Lett, Vol. 289, No. 1, pp. 104-109, 0378-1097 (Print) 0378-1097 (Linking) 
Smaali, I., Bachraoui, K., Joulek, A., Selmi, K., Boujnah, M.R., (2008). [Infectious endocarditis 
secondary to streptococcus bovis revealing adenomatous polyposis coli ]. Tunis 
Med, Vol. 86, No. 7, pp. 723-724, 0041-4131 (Print) 0041-4131 (Linking) 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
390 
Smith, D.G., Lawson, G.H., (2001). Lawsonia intracellularis: getting inside the pathogenesis 
of proliferative enteropathy. Vet Microbiol, Vol. 82, No. 4, pp. 331-345, 0378-1135 
(Print) 0378-1135 (Linking) 
Srivastava, S., Verma, M., Henson, D.E., (2001). Biomarkers for early detection of colon 
cancer. Clin Cancer Res, Vol. 7, No. 5, pp. 1118-1126, 1078-0432 (Print) 1078-0432 
(Linking) 
Tafte, L., Ruoff, K., (2007). Streptococcus bovis: Answers and Questions. Clin microbial 
newslett, Vol. 29, No. pp. 49-55,  
Teitelbaum, J.E., Triantafyllopoulou, M., (2006). Inflammatory bowel disease and 
Streptococcus bovis. Dig Dis Sci, Vol. 51, No. 8, pp. 1439-1442, 0163-2116 (Print) 
0163-2116 (Linking) 
Tjalsma, H., Scholler-Guinard, M., Lasonder, E., Ruers, T.J., Willems, H.L., Swinkels, D.W., 
(2006). Profiling the humoral immune response in colon cancer patients: diagnostic 
antigens from Streptococcus bovis. Int J Cancer, Vol. 119, No. 9, pp. 2127-2135, 0020-
7136 (Print) 0020-7136 (Linking) 
Travers, P., Rosen, F.S., 1997. Immuno biology bookshelf the comprehensive resource on 
CD-ROM. Current Biology; Garland Pub., [London ; San Francisco] [New York], 
pp. 1 CD-ROM. 
Vogelmann, R., Amieva, M.R., (2007). The role of bacterial pathogens in cancer. Curr Opin 
Microbiol, Vol. 10, No. 1, pp. 76-81, 1369-5274 (Print) 1369-5274 (Linking) 
Waisberg, J., Matheus Cde, O., Pimenta, J., (2002). Infectious endocarditis from 
Streptococcus bovis associated with colonic carcinoma: case report and literature 
review. Arq Gastroenterol, Vol. 39, No. 3, pp. 177-180, 0004-2803 (Print) 0004-2803 
(Linking) 
Wang, D., Dubois, R.N., (2010). The role of COX-2 in intestinal inflammation and colorectal 
cancer. Oncogene, Vol. 29, No. 6, pp. 781-788, 1476-5594 (Electronic) 0950-9232 
(Linking) 
Wentling, G.K., Metzger, P.P., Dozois, E.J., Chua, H.K., Krishna, M., (2006). Unusual 
bacterial infections and colorectal carcinoma--Streptococcus bovis and Clostridium 
septicum: report of three cases. Dis Colon Rectum, Vol. 49, No. 8, pp. 1223-1227, 
0012-3706 (Print) 0012-3706 (Linking) 
Wilson, W.R., Thompson, R.L., Wilkowske, C.J., Washington, J.A., 2nd, Giuliani, E.R., 
Geraci, J.E., (1981). Short-term therapy for streptococcal infective endocarditis. 
Combined intramuscular administration of penicillin and streptomycin. JAMA, 
Vol. 245, No. 4, pp. 360-363, 0098-7484 (Print) 0098-7484 (Linking) 
Zarkin, B.A., Lillemoe, K.D., Cameron, J.L., Effron, P.N., Magnuson, T.H., Pitt, H.A., (1990). 
The triad of Streptococcus bovis bacteremia, colonic pathology, and liver disease. 
Ann Surg, Vol. 211, No. 6, pp. 786-791; discussion 791-782, 0003-4932 (Print) 0003-
4932 (Linking) 
zur Hausen, H., (2006). Streptococcus bovis: causal or incidental involvement in cancer of 
the colon? Int J Cancer, Vol. 119, No. 9, pp. xi-xii, 0020-7136 (Print) 0020-7136 
(Linking) 
18 
Intestinal Host-Microbiome Interactions  
Harold Tjalsma and Annemarie Boleij 
Department of Laboratory Medicine, Nijmegen Institute for Infection, 
 Inflammation and Immunity (N4i) & Radboud University Centre for Oncology (RUCO) 
 of the Radboud University Nijmegen Medical Centre, 
The Netherlands 
1. Introduction  
A human body contains at least tenfold more bacteria cells than human cells and the most 
abundant and diverse microbial community (also known as microbiota or microbiome) 
resides in the large intestine (colon). It is estimated that this colonic microbiome is composed 
of ∼1014 bacterial cells, comprising >103 species (Dethlefsen et al., 2006; Qin et al., 2010). 
Intestinal microbiomes differ from individual to individual but remain relatively stable 
during adult life (Green et al., 2006; Arumugam et al., 2011). The resident microbiome 
provides the host with core functions that are essential for digestion of food and control of 
intestinal epithelial homeostasis. Conversely, an increasing body of evidence supports a 
relationship between infective agents and human colorectal cancer (CRC) by production of 
DNA damaging metabolites or toxins, and the induction of cell proliferation and pro-
carcinogenesis pathways by a subpopulation of the intestinal microbiota. It could be 
speculated that the intrinsic intestinal microbiome of a certain individual may contain an 
unfavorable number of disease-inducing bacteria. On the long term, their activities may 
override the health-promoting activities of the commensal bacterial population. On the 
other hand, the dramatic physiological alterations that result from colon carcinogenesis itself 
(Hirayama et al., 2009) disturbs the local intestinal microenvironment and causes (local) 
shifts in the microbiota composition and provides a portal of infection for certain 
opportunistic pathogens. The latter phenomenon could explain why some uncommon 
bacterial infections are often associated with CRC. In this chapter we will discuss the 
mechanisms by which intestinal bacteria may drive the initiation and progression of 
sporadic CRC, but also the driving forces of intestinal carcinogenesis on local microbial 
dysbiosis and the consequences thereof will be reviewed.  
2. Intestinal microbiome 
The colonic epithelium is the first line of defense against enteric antigens and bacteria. In a 
healthy colon, the epithelial barrier regulates uptake of nutrients and limits uptake of 
potential toxic substances and infectious agents (Chichlowski & Hale, 2008). Goblet cells are 
specialized epithelial cells within the mucosa that produce a viscous mucus layer that covers 
the intestinal epithelium (Heazlewood et al., 2008). This mucus layer is thick and consists of 
an inner firmly attached layer, that excludes bacteria from direct contact with the 
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speculated that the intrinsic intestinal microbiome of a certain individual may contain an 
unfavorable number of disease-inducing bacteria. On the long term, their activities may 
override the health-promoting activities of the commensal bacterial population. On the 
other hand, the dramatic physiological alterations that result from colon carcinogenesis itself 
(Hirayama et al., 2009) disturbs the local intestinal microenvironment and causes (local) 
shifts in the microbiota composition and provides a portal of infection for certain 
opportunistic pathogens. The latter phenomenon could explain why some uncommon 
bacterial infections are often associated with CRC. In this chapter we will discuss the 
mechanisms by which intestinal bacteria may drive the initiation and progression of 
sporadic CRC, but also the driving forces of intestinal carcinogenesis on local microbial 
dysbiosis and the consequences thereof will be reviewed.  
2. Intestinal microbiome 
The colonic epithelium is the first line of defense against enteric antigens and bacteria. In a 
healthy colon, the epithelial barrier regulates uptake of nutrients and limits uptake of 
potential toxic substances and infectious agents (Chichlowski & Hale, 2008). Goblet cells are 
specialized epithelial cells within the mucosa that produce a viscous mucus layer that covers 
the intestinal epithelium (Heazlewood et al., 2008). This mucus layer is thick and consists of 
an inner firmly attached layer, that excludes bacteria from direct contact with the 
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underlying mucosa, and an outer loose mucus layer that mainly functions as lubricant 
(Atuma et al., 2001). Bacterial colonization of the gastrointestinal tract occurs during the first 
two years of life. After this period, the microbiota composition is rather stable throughout 
adulthood (Dethlefsen et al., 2006). Nevertheless, it is likely that the colonic microbiota 
transiently respond to dietary intake and host physiology (Thompson-Chagoyan et al., 2007). 
The inter-individual microbiomes differ consistently, however, it is thought that these 
different marked microbiota may perform similar functions, and genetically complement 
their host with crucial physiological functions that are not provided by the human genome 
itself (Candela et al. 2010; Gill et al., 2006; Neish, 2009; O'Hara & Shanahan, 2006; Xu et al., 
2007). Intestinal microbiome-specific metabolic functions increase energy yield and storage 
from diet, regulate fat storage and generate essential vitamins, which are primarily due to 
the fermentation of indigestible dietary polysaccharides (Neish, 2009). It has been shown 
that mucosa-associated bacteria differ from the community recovered from feces, but are 
rather uniformly distributed throughout the colon (Green et al., 2006; Macfarlane et al., 2004; 
Zoetendal et al., 2002). This mucosa-adherent population is less prone to physiological 
effects, such as dietary changes (Sonnenburg et al., 2004), and prohibits colonization of 
intruding pathogens (Stecher & Hardt, 2008). Malfunctioning of the host epithelial defense 
mechanisms, increases the risk for bacterial infection and intestinal inflammation, as seen in 
patients with inflammatory bowel disease (IBD). Intestinal disease can also be directly 
triggered by enteropathogenic pathogens, like Shigella, Citrobacter and Salmonella species, 
that avail of virulence mechanisms that allows them to outcompete the commensal mucosa-
associated bacterial population and to breach the mucosal barrier and intestinal innate 
immune system (Stecher et al., 2007). 
3. Bacterial promotion of CRC 
The genetic background of the host together with dietary intake, influences the microbial 
composition in the gut. However progression of CRC itself also influences the gut barrier 
and micro-environment in the intestine. This dynamic interplay between environment, 
genetic and microbial influences makes it hard to dissect the exact contribution of the 
microbiota in the development and progression of CRC. In the next paragraphs, the 
mechanisms by which the intestinal microbiota could contribute to CRC are further 
discussed. The significance of the intestinal microbiome on the development of CRC is 
probably best illustrated by the fact that patients with IBD, which originates from an altered 
host response to a normal intestinal bacterial population (Round & Mazmanian, 2009), have 
a high predisposition for CRC (Macfarlane et al., 2005).  
3.1 Promotion of tumorigenesis  
The effect of intestinal bacteria on CRC development has been studied in the intestinal 
neoplasia mouse model (Apcmin/+). This mutant mouse strain carries a heterozygous 
mutation in the APC locus (Moser et al., 1990), meaning that only a single hit in the wild-
type allele results in adenoma formation. Studies with germ-free Apcmin/+ mice revealed that 
the formation of adenomas was strongly reduced by as much as 50%, compared to mice 
bred under conventional conditions (Dove et al., 1997; Moser et al., 1990; Su et al., 1992). 
When such mice were exposed to enterotoxigenic Bacteroides fragilis (ETBF), tumors 
developed more rapidly, whereas mice colonized with non-toxigenic Bacteroides fragilis 
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(NTBF) showed no increased tumor formation compared to conventional mice (Housseau & 
Sears, 2010).  
These data clearly show that the intestinal microbial population has a strong promoting 
effect on tumor progression in mice that have a genetic predisposition for developing 
intestinal adenomas and that certain species within the intestinal microbiota contribute 
more than average to this process. 
3.2 Stimulation of TLR signaling 
A balanced immune stimulation to commensal and pathogenic bacteria is crucial for a 
healthy intestinal tract. Toll-like receptors (TLRs) are proteins that activate immune 
responses towards potentially harmful pathogens upon sensing of pathogenic substances, 
such as cell wall components. However, chronic overstimulation of these responses may be 
detrimental by leading to the initiation and progression of CRC (Fukata & Abreu, 2007).  
A direct impact of bacteria on the development of CRC through the TLR5/MyD88 pathway 
was demonstrated in germ-free and gnotobiotic mice. These animal experiments revealed 
that MyD88-/- knock-out mice that were treated with the carcinogen azoxymethane (AOM) 
failed to develop colorectal tumors when these mice were subjected to bacteria. In contrast, 
control mice rapidly developed CRC upon bacterial colonization of their intestinal tract. 
These results implicate that TLR/MyD88 signaling is a prerequisite for the development of 
CRC (Uronis et al., 2009). In addition, it was shown that tumors in Apcmin/+ MyD88-/- mice 
were significantly smaller than those found in Apcmin/+ mice (Rakoff-Nahoum & Medzhitov, 
2007). Another study showed that TLR4-/- mice were partly protected against the 
development of neoplasia by tumor-inducing chemical agents (Killeen et al., 2009). 
Additional evidence was presented that TLR4 signaling can promote colon carcinogenesis 
by stimulating tumor infiltration of Th17 cells (T-helper cell subset that produces IL-17) 
through the increased production of pro-inflammatory signals (Su et al., 2010). It can be 
envisaged that bacterial TLR4 ligands, such as LPS, play an important role in this increased 
chemotactic activity of tumor cells (Scanlan et al., 2008). Importantly, Th17 cells have directly 
been implicated in the pathogenesis of Enterotoxigenic Bacteroides fragilis-induced CRC 
(Housseau & Sears, 2010; Wu et al., 2009). Thus, although TLR signaling is important for the 
effective clearance of harmful pathogens and can mediate anti-tumor cell responses, chronic 
TLR activation may tip the delicate balance towards tumor-promoting activities (Rakoff-
Nahoum & Medzhitov, 2009).  
Altogether, the above mentioned studies indicate that chronic bacterial stimulation of 
inflammatory pathways at malignant sites promotes, and may even be a prerequisite for, 
intestinal tumor development.  
3.3 Upregulation of COX-2 
Cyclooxygenase-2 (COX-2) is one of the key players in the progression of CRC. The 
expression of COX-2 is highly elevated in colonic tumors and correlated with disease stage 
and stimulates cell proliferation and pro-inflammatory pathways by the production of 
prostaglandins (Menter et al., 2010). Human intervention studies have clearly shown that the 
usage of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) can reduce CRC risk by as 
much as 75% (Eaden et al., 2000; Labayle et al., 1991; Thun et al., 1991). Evidence for bacterial 
involvement in the upregulation of COX-2 during CRC development was gained through 
animal and in vitro studies. First, superoxide radicals produced by Enterococcus faecalis were 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
392 
underlying mucosa, and an outer loose mucus layer that mainly functions as lubricant 
(Atuma et al., 2001). Bacterial colonization of the gastrointestinal tract occurs during the first 
two years of life. After this period, the microbiota composition is rather stable throughout 
adulthood (Dethlefsen et al., 2006). Nevertheless, it is likely that the colonic microbiota 
transiently respond to dietary intake and host physiology (Thompson-Chagoyan et al., 2007). 
The inter-individual microbiomes differ consistently, however, it is thought that these 
different marked microbiota may perform similar functions, and genetically complement 
their host with crucial physiological functions that are not provided by the human genome 
itself (Candela et al. 2010; Gill et al., 2006; Neish, 2009; O'Hara & Shanahan, 2006; Xu et al., 
2007). Intestinal microbiome-specific metabolic functions increase energy yield and storage 
from diet, regulate fat storage and generate essential vitamins, which are primarily due to 
the fermentation of indigestible dietary polysaccharides (Neish, 2009). It has been shown 
that mucosa-associated bacteria differ from the community recovered from feces, but are 
rather uniformly distributed throughout the colon (Green et al., 2006; Macfarlane et al., 2004; 
Zoetendal et al., 2002). This mucosa-adherent population is less prone to physiological 
effects, such as dietary changes (Sonnenburg et al., 2004), and prohibits colonization of 
intruding pathogens (Stecher & Hardt, 2008). Malfunctioning of the host epithelial defense 
mechanisms, increases the risk for bacterial infection and intestinal inflammation, as seen in 
patients with inflammatory bowel disease (IBD). Intestinal disease can also be directly 
triggered by enteropathogenic pathogens, like Shigella, Citrobacter and Salmonella species, 
that avail of virulence mechanisms that allows them to outcompete the commensal mucosa-
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3. Bacterial promotion of CRC 
The genetic background of the host together with dietary intake, influences the microbial 
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microbiota in the development and progression of CRC. In the next paragraphs, the 
mechanisms by which the intestinal microbiota could contribute to CRC are further 
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probably best illustrated by the fact that patients with IBD, which originates from an altered 
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The effect of intestinal bacteria on CRC development has been studied in the intestinal 
neoplasia mouse model (Apcmin/+). This mutant mouse strain carries a heterozygous 
mutation in the APC locus (Moser et al., 1990), meaning that only a single hit in the wild-
type allele results in adenoma formation. Studies with germ-free Apcmin/+ mice revealed that 
the formation of adenomas was strongly reduced by as much as 50%, compared to mice 
bred under conventional conditions (Dove et al., 1997; Moser et al., 1990; Su et al., 1992). 
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(NTBF) showed no increased tumor formation compared to conventional mice (Housseau & 
Sears, 2010).  
These data clearly show that the intestinal microbial population has a strong promoting 
effect on tumor progression in mice that have a genetic predisposition for developing 
intestinal adenomas and that certain species within the intestinal microbiota contribute 
more than average to this process. 
3.2 Stimulation of TLR signaling 
A balanced immune stimulation to commensal and pathogenic bacteria is crucial for a 
healthy intestinal tract. Toll-like receptors (TLRs) are proteins that activate immune 
responses towards potentially harmful pathogens upon sensing of pathogenic substances, 
such as cell wall components. However, chronic overstimulation of these responses may be 
detrimental by leading to the initiation and progression of CRC (Fukata & Abreu, 2007).  
A direct impact of bacteria on the development of CRC through the TLR5/MyD88 pathway 
was demonstrated in germ-free and gnotobiotic mice. These animal experiments revealed 
that MyD88-/- knock-out mice that were treated with the carcinogen azoxymethane (AOM) 
failed to develop colorectal tumors when these mice were subjected to bacteria. In contrast, 
control mice rapidly developed CRC upon bacterial colonization of their intestinal tract. 
These results implicate that TLR/MyD88 signaling is a prerequisite for the development of 
CRC (Uronis et al., 2009). In addition, it was shown that tumors in Apcmin/+ MyD88-/- mice 
were significantly smaller than those found in Apcmin/+ mice (Rakoff-Nahoum & Medzhitov, 
2007). Another study showed that TLR4-/- mice were partly protected against the 
development of neoplasia by tumor-inducing chemical agents (Killeen et al., 2009). 
Additional evidence was presented that TLR4 signaling can promote colon carcinogenesis 
by stimulating tumor infiltration of Th17 cells (T-helper cell subset that produces IL-17) 
through the increased production of pro-inflammatory signals (Su et al., 2010). It can be 
envisaged that bacterial TLR4 ligands, such as LPS, play an important role in this increased 
chemotactic activity of tumor cells (Scanlan et al., 2008). Importantly, Th17 cells have directly 
been implicated in the pathogenesis of Enterotoxigenic Bacteroides fragilis-induced CRC 
(Housseau & Sears, 2010; Wu et al., 2009). Thus, although TLR signaling is important for the 
effective clearance of harmful pathogens and can mediate anti-tumor cell responses, chronic 
TLR activation may tip the delicate balance towards tumor-promoting activities (Rakoff-
Nahoum & Medzhitov, 2009).  
Altogether, the above mentioned studies indicate that chronic bacterial stimulation of 
inflammatory pathways at malignant sites promotes, and may even be a prerequisite for, 
intestinal tumor development.  
3.3 Upregulation of COX-2 
Cyclooxygenase-2 (COX-2) is one of the key players in the progression of CRC. The 
expression of COX-2 is highly elevated in colonic tumors and correlated with disease stage 
and stimulates cell proliferation and pro-inflammatory pathways by the production of 
prostaglandins (Menter et al., 2010). Human intervention studies have clearly shown that the 
usage of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) can reduce CRC risk by as 
much as 75% (Eaden et al., 2000; Labayle et al., 1991; Thun et al., 1991). Evidence for bacterial 
involvement in the upregulation of COX-2 during CRC development was gained through 
animal and in vitro studies. First, superoxide radicals produced by Enterococcus faecalis were 
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shown to upregulate the expression of COX-2 in hybrid hamster cells containing human 
chromosomes, as well as in macrophages (Wang & Huycke, 2007). Furthermore, 
macrophages that were pre-treated with a COX-2 inhibitor and subsequently exposed to E. 
faecalis totally inhibited the induction of chromosome instability (CIN) in these hybrid 
hamster cells. Second, an animal study published by Ellmerich et al. (2000b) indicated that 
Streptococcus bovis biotype II.1 (Streptococcus infantarius) could also play a role in the 
progression of CRC through induction of the COX-2 pathway. These investigators 
employed a rat model in which pre-treatment with azoxymethane (AOM) induced pre-
neoplastic aberrant crypt foci (ACF). When such rats were co-exposed to S. infantarius or cell 
wall antigens from this bacterium, the number of ACF increased drastically and also 
adenomas were found, whereas the latter were totally absent in the control mice treated 
with AOM alone. In addition, the production of the pro-inflammatory cytokine IL-8 in the 
mucosa of rats exposed to S. infantarius was increased. This finding is in accordance with in 
vitro studies on epithelial Caco-2 cells that release both IL-8 and PGE2 upon incubation with 
S. infantarius (Biarc et al., 2004). Moreover, Abdulamir et al. (2010) have recently shown that 
increased COX-2 and IL-8 expression was associated with the presence of Streptococcus 
gallolyticus (S. bovis biotype I) in human colon tumor tissue. However, IL-8 expression was 
not increased in non-malignant tissue that contained S. gallolyticus. Together these studies 
indicate that COX-2 induction is associated with both tumor development and exposure to 
bacterial stimulants. 
3.4 Toxin-induced promotion of cell proliferation  
Enterotoxigenic Bacteroides fragilis (ETBF) has been implicated in the promotion of CRC 
through inflammatory pathways. B. fragilis is a normal inhabitant of the gastrointestinal 
tract, but its enterotoxigenic form is only present in approximately 20% of the healthy 
population (Sears, 2009). ETBF produces the B. fragilis toxin that degrades E-cadherin in 
epithelial cells, which causes β-catenin to migrate towards the nucleus where it can activate 
cell proliferation pathways (Wu et al., 2003). Consequently, APCmin/+ mice colonized with 
ETBF were shown to suffer from increased tumor burden compared to control mice 
colonized with non-toxigenic B. fragilis (NTBF) strains (Housseau & Sears, 2010; Wu et al., 
2009). Importantly, Wu et al (2009). showed that this increased tumor burden was mediated 
through the increased expression of STAT3 that leads to a Th17 response. Importantly, 
increased tumor formation could be blocked by anti-IL17 therapy. These experiments clearly 
show that induction of a STAT3/Th17-dependent pathway for inflammation, leads to 
inflammation-induced cancer by ETBF in a mouse model. Since ETBF is a quite common 
bacterium in the gastro-intestinal tract, this finding could have major implications for the 
role of these bacteria in the development of CRC in the human population. This idea is 
further corroborated by the fact that patients with CRC have indeed increased carriage 
rates of ETBF compared to NTBF (Toprak et al., 2006). It should be realized that this 
mechanism of tumor induction could also be associated with other toxigenic intestinal 
bacterial strains. 
3.5 Toxin-induced DNA damage 
Certain E. coli strains can induce increased mutation rates in eukaryotic cells as 
demonstrated by Cuevas-Ramos and colleagues (2010). Their experiments showed that E. 
coli strains harboring the pks island caused DNA damage in human epithelial cells and in an 
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ex vivo mouse intestinal model by the induction of single strand breaks and activation of 
DNA damage signaling pathways. The pks gene cluster codes for nonribosomal peptide 
synthetases and polyketide synthetases (pks) that synthesize a genotoxin named Colibactin. 
The pks island is commonly present in about 34% of commensal E. coli isolates. Upon 
infection of epithelial cells with physiological concentrations of pks+ strains, initial DNA 
damage occurred. Furthermore, it was shown that cells continued to proliferate in the 
presence of DNA damage after E. coli infection, resulting in an increased mutation frequency 
(Cuevas-Ramos et al., 2010). These studies suggest that pks+ strains of E. coli could be 
involved in the initiation and progression of CRC. As, E. coli is generally regarded as a 
normal commensal inhabitant of the gastro-intestinal tract, Bronowski and co-workers 
investigated the differences between E. coli strains collected from healthy individuals and 
CRC patients (Bronowski et al., 2008). These experiments showed that a subset of E. coli 
strains recovered from CRC tissue shared pathogenicity islands, encoding an alfa 
haemolysin and a cytotoxic necrotizing factor, with uropathogenic E. coli strains. This 
suggests that besides Colibactin production, other virulence characteristics may also 
mediate the tumor promoting capacity of E. coli pks+ strains. 
3.6 Metabolite-induced DNA damage 
Sulfate reducing bacteria use sulfate as energy source by converting it to sulfide and 
hydrogen sulfide (H2S) in the human colon. The genotoxic potential of H2S is in part 
mediated by oxidative free radicals, which results in increased levels of DNA damage in 
cultured epithelial cells (Attene-Ramos et al., 2006; Attene-Ramos et al., 2007; Attene-Ramos 
et al., 2010). Furthermore, exposure to H2S may disrupt the balance between apoptosis, 
proliferation and differentiation (Cai et al., 2010; Deplancke & Gaskins, 2003). Interestingly, 
also COX-2 was shown to be upregulated in epithelial cells after H2S treatment at 
physiological concentrations, probably through generation of reactive oxygen species 
(Attene-Ramos et al., 2010). Increased fecal H2S concentration was implicated as a risk factor 
for the development of colonic neoplasia in a clinical study (Kanazawa et al., 1996). Whether 
these increased H2S levels originates from increased activity of sulfate reducing bacteria 
and/or reduced epithelial capacity to degrade H2S remains to be investigated.  
E. faecalis was also found to produce extracellular superoxide in colonic tissue of rats, which 
is the result of dysfunctional microbial respiration (Huycke et al., 2002). These rats produced 
up to 25-fold increased concentrations of hydroxylated aromatic metabolites in urine than 
rats colonized with a closely-related strain. Importantly, superoxide can be converted to 
hydrogen peroxide, which has the potential to diffuse into epithelial cells and cause DNA 
damage. In an in vitro setup, it was shown that the formation of DNA adducts by E. faecalis 
was mediated by activated COX-2 expression in macrophages that in turn promoted DNA 
damage in epithelial target cells (Wang & Huycke, 2007; Wang et al., 2008). Since COX-2 
induction has a clear clinical association with CRC, this might indicate that superoxide-
producing bacteria have a contributing role in disease development. This notion is further 
underscored by the finding that E. faecalis fecal carriage was increased in CRC patients, 
whereas the number of butyrate producing bacteria was decreased (Balamurugan et al., 
2008). However, no clinical evidence has been presented that associates superoxide 
producing enterococci with adenomas or CRC (Winters et al., 1998). This clearly indicates 
that, although the in vitro data and animal studies strongly suggest that oxygen radicals 
from bacterial origin could play an important role in CRC initiation or progression, the 
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shown to upregulate the expression of COX-2 in hybrid hamster cells containing human 
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ex vivo mouse intestinal model by the induction of single strand breaks and activation of 
DNA damage signaling pathways. The pks gene cluster codes for nonribosomal peptide 
synthetases and polyketide synthetases (pks) that synthesize a genotoxin named Colibactin. 
The pks island is commonly present in about 34% of commensal E. coli isolates. Upon 
infection of epithelial cells with physiological concentrations of pks+ strains, initial DNA 
damage occurred. Furthermore, it was shown that cells continued to proliferate in the 
presence of DNA damage after E. coli infection, resulting in an increased mutation frequency 
(Cuevas-Ramos et al., 2010). These studies suggest that pks+ strains of E. coli could be 
involved in the initiation and progression of CRC. As, E. coli is generally regarded as a 
normal commensal inhabitant of the gastro-intestinal tract, Bronowski and co-workers 
investigated the differences between E. coli strains collected from healthy individuals and 
CRC patients (Bronowski et al., 2008). These experiments showed that a subset of E. coli 
strains recovered from CRC tissue shared pathogenicity islands, encoding an alfa 
haemolysin and a cytotoxic necrotizing factor, with uropathogenic E. coli strains. This 
suggests that besides Colibactin production, other virulence characteristics may also 
mediate the tumor promoting capacity of E. coli pks+ strains. 
3.6 Metabolite-induced DNA damage 
Sulfate reducing bacteria use sulfate as energy source by converting it to sulfide and 
hydrogen sulfide (H2S) in the human colon. The genotoxic potential of H2S is in part 
mediated by oxidative free radicals, which results in increased levels of DNA damage in 
cultured epithelial cells (Attene-Ramos et al., 2006; Attene-Ramos et al., 2007; Attene-Ramos 
et al., 2010). Furthermore, exposure to H2S may disrupt the balance between apoptosis, 
proliferation and differentiation (Cai et al., 2010; Deplancke & Gaskins, 2003). Interestingly, 
also COX-2 was shown to be upregulated in epithelial cells after H2S treatment at 
physiological concentrations, probably through generation of reactive oxygen species 
(Attene-Ramos et al., 2010). Increased fecal H2S concentration was implicated as a risk factor 
for the development of colonic neoplasia in a clinical study (Kanazawa et al., 1996). Whether 
these increased H2S levels originates from increased activity of sulfate reducing bacteria 
and/or reduced epithelial capacity to degrade H2S remains to be investigated.  
E. faecalis was also found to produce extracellular superoxide in colonic tissue of rats, which 
is the result of dysfunctional microbial respiration (Huycke et al., 2002). These rats produced 
up to 25-fold increased concentrations of hydroxylated aromatic metabolites in urine than 
rats colonized with a closely-related strain. Importantly, superoxide can be converted to 
hydrogen peroxide, which has the potential to diffuse into epithelial cells and cause DNA 
damage. In an in vitro setup, it was shown that the formation of DNA adducts by E. faecalis 
was mediated by activated COX-2 expression in macrophages that in turn promoted DNA 
damage in epithelial target cells (Wang & Huycke, 2007; Wang et al., 2008). Since COX-2 
induction has a clear clinical association with CRC, this might indicate that superoxide-
producing bacteria have a contributing role in disease development. This notion is further 
underscored by the finding that E. faecalis fecal carriage was increased in CRC patients, 
whereas the number of butyrate producing bacteria was decreased (Balamurugan et al., 
2008). However, no clinical evidence has been presented that associates superoxide 
producing enterococci with adenomas or CRC (Winters et al., 1998). This clearly indicates 
that, although the in vitro data and animal studies strongly suggest that oxygen radicals 
from bacterial origin could play an important role in CRC initiation or progression, the 
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clinical impact of these findings remains to be properly examined in well-designed clinical 
studies (Huycke & Gaskins, 2004).  
Bacteroides species produce fecapentaenes that are potent mutagens that have been shown to 
alkylate DNA, which leads to mutagenic adducts. Some evidence points towards a 
mechanism in which oxygen radicals cause oxidative damage to DNA (Hinzman et al., 1987; 
Povey et al., 1991; Shioya et al., 1989). Fecapentaenes appear in relatively high concentrations 
in human feces, however, no significant differences in fecapentaene levels were found in 
feces from CRC patients and controls (Schiffman et al., 1989). In view of their mutagenic 
potential, however, fecapentaenes should be regarded as possible bacterial inducers of CRC 
(de Kok & van Maanen, 2000). For instance, their detrimental effects may locally contribute 
to the accumulation of mutations in epithelial cells, which is not directly reflected by the 
increased levels in fecal material.  
3.7 Induction of pro-carcinogenic pathways 
Some evidence exists that certain intestinal bacteria can also directly induce host epithelial 
pathways that make cells more susceptible to DNA damage by carcinogenic substances. 
Maddocks et al. (2009) have shown that enteropathogenic E. coli can down-regulate 
mismatch repair genes in colon epithelial cells. It may be envisaged that this impaired 
expression can lead to a net increased mutation rate upon co-exposure to genotoxic dietary 
compounds. This study accentuates that bacteria can directly interfere with gene expression 
in epithelial cells which, under certain conditions, may lead to increased carcinogenesis 
rates. 
4. CRC microbiome 
The preceding paragraphs describe the potential mechanisms by which bacteria can play a 
role in the initiation and progression of CRC. In the following paragraphs, the effects of 
colonic malignancies on the (local) microbial composition are discussed. It is evident that the 
dramatic physiological and metabolic alterations that result from colon carcinogenesis itself 
(Hirayama et al., 2009) will locally disturb the intestinal environment. Consequently, this 
will cause (local) shifts in microbiota composition as the altered tumor metabolites and 
intestinal physiology will recruit a bacterial population with a competitive advantage in this 
specific microenvironment. This is exemplified by the fact that infections with certain 
opportunistic intestinal pathogens have been associated with CRC for many years (see 
Section 5). Thus pre-malignant sites seem to constitute a preferred niche for a subset of 
intestinal bacteria and facilitate their outgrowth and eventually entry into the human body. 
Importantly, local outgrowth of harmful bacteria could also accelerate tumor progression 
after disease has been initiated by other factors.  
The effect of colonic tumors on the microbiome composition has been investigated by 
several studies. First, Scanlan et al. (2008) investigated the bacterial diversity in healthy, 
polypectomized patients with increased risk for CRC and CRC patients. These studies 
showed a significant increased diversity of the Clostridium leptum and coccoides subgroups 
in the CRC patients compared to a healthy control group. Importantly, metabonomic faecal 
water analysis was able to distinguish CRC and polypectomized patients from healthy 
individuals, which is indicative for an altered metabolic activity of the intestinal microbiota 
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in these patients. In another study by Maddocks et al. (2009) it was shown that the mucosa of 
adenomas and carcinomas contained increased numbers of E. coli compared to colonic 
mucosa from healthy controls. It was speculated that certain surface antigens on tumor cells, 
which display homology to surface antigens of fetal origin, may be responsible for the 
binding of E. coli and thus local recruitment of these bacterial strains (Martin et al., 2004; 
Maddocks et al., 2009; Swidsinski et al., 1998). A similar relation has been described for the 
opportunistic pathogen Streptococcus bovis. This bacterium is thought to selectively colonize 
malignant and pre-malignant colonic sites by which it can cause systemic infections in 
susceptible individuals (see Section 5). Some contradicting results on actual S. bovis 
colonization of tumor tissue have, however, been reported. Conventional culturing 
techniques to determine the carriage rate of S. bovis in adenoma, carcinoma and healthy 
biopsies did not provide clear evidence for the selective colonization of adenomas or 
carcinomas by this bacterium (Norfleet & Mitchell, 1993; Potter et al., 1998). More recently, 
Abdulamir and co-workers showed the presence of Streptococcus gallolyticus (S. bovis biotype 
I) DNA in carcinoma and adenoma tissue via polymerase chain reaction (PCR)-based 
techniques, which are more sensitive than conventional culturing techniques. DNA from S. 
gallolyticus was detected in about 50% of the tumor biopsies and in 35% of off- tumor tissue 
samples from the same patients. Strikingly, however, S. gallolyticus DNA was only found in 
<5% of the colonic tissue samples of healthy control subjects (Abdulamir et al., 2010). More 
recently, several studies have assessed the bacterial communities in healthy, adenoma and 
CRC tissue by deep 16S ribosomal DNA sequencing approaches. Shen and colleagues 
compared the bacterial composition in normal tissue samples from adenoma patients and 
from individuals without colon abnormalities. The data showed increased levels of 
proteobacteria and decreased bacteroidetes species in off- tumor tissue samples from 
adenoma patients (Shen et al., 2010). Interestingly, Sobhani et al. (2011) reported that the 
abundance of Bacteroides was significantly increased in tumor and normal tissue of cancer 
patients compared to healthy controls. More importantly, the abundance of Bacteroides was 
higher in tumor tissue of cancer patients than adjacent off-tumor tissue, which was 
paralleled by an increased IL-17/CD3 immune cell infiltration in the malignant tissues. 
Another recent study by Marchesi et al. (2011), compared differences in healthy and 
cancerous tissue within cancer patients and found that tumor tissue was overrepresented by 
species of the genera Coriobacteridae, Roseburia, Fusobacterium and Faecalibacterium that are 
generally regarded as gut commensals with probiotic features. On the contrary, this study 
found decreased colonization of Enterobacteriaceae, such as Citrobacter, Shigella, Cronobacter, 
and Salmonella in adjacent off- tumor mucosa from the same investigated patients.  
The development of colorectal tumors is schematically depicted from left to right. Initiation 
of carcinogenesis is a process in which many factors are involved. As discussed in this 
Chapter, certain bacterial pathogens, bacterial toxins, or bacterial toxic metabolites (1) may 
contribute to the initiation and progression of CRC by causing DNA damage, induction of 
COX-2/IL-8, TLR signalling and/or cell proliferation pathways (2). Consequently, the 
altered metabolic profile of colon tumor cells and/or differentially expression of bacterial 
receptor molecules on tumor cells (3) creates a new niche that recruits a different bacterial 
population (4) of which certain opportunistic pathogens can eventually breach the bowel 
wall and cause a systemic bacterial infection (5). The latter group of bacteria may play an 
important signalling function for the early detection of CRC by serological assays. 
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5. CRC-associated bacterial infections 
5.1 Streptococcus bovis 
The most extensively studied bacterium that has a well-appreciated association with CRC 
concerns Streptococcus bovis. McCoy and Mason first reported such a case in 1951 (McCoy & 
Mason, 1951). In the 1970’s this association was re-discovered by Hoppes and Lerner, who 
reported that 64% of the S. bovis endocarditis cases had gastrointestinal disease (Hoppes & 
Lerner, 1974). A few years later, Klein et al. (1977) reported an increased incidence of CRC in 
patients with S. bovis endocarditis. These investigators additionally discovered that fecal 
carriage of S. bovis in CRC patients was increased about 5-fold compared to healthy controls. 
At the time, these findings led to the recommendation to perform colonic evaluation in 
patients that were diagnosed with an S. bovis infection. Over the years, many studies have 
confirmed the association between S. bovis infection and CRC. In these studies, the 
prevalence of S. bovis infection with underlying CRC ranged from 10 – 100% (median 60%) 
for patients that underwent colonic evaluation (Boleij et al., 2011b).  
5.1.1 Streptococcus bovis biotypes 
Based on phenotypic diversity, S. bovis was previously divided into three biotypes I, II.1 and 
II.2. Of these biotypes, biotype I is most often associated with endocarditis, while biotype II 
is mostly found in cases of bacteremia or liver disease. Strikingly, the association between S. 
bovis biotype I infection and CRC (21- 71%) is much higher then that of S. bovis biotype II 
(11-30%) (Corredoira et al., 2008; Corredoira et al., 2005; Giannitsioti et al., 2007; Herrero et al., 
2002; Jean et al., 2004; Lee et al., 2003; Ruoff et al., 1989; Vaska & Faoagali, 2009)(Beck et al., 
2008; Tripodi et al., 2004). In fact, the reported incidences of carcinomas and adenomas in S. 
bovis biotype II infected patients are within the range for the normal asymptomatic 
population (0.3% for carcinomas / 10-25% for adenomas), whereas the rates for S. bovis 
biotype I were significantly increased (Lieberman & Smith, 1991; Lieberman et al., 2000; 
Spier et al., 2010). The distinct association of these different S. bovis biotypes with CRC may 
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have accounted for the wide range of association percentages that have been reported over 
the years in literature. More importantly, because most studies have not discriminated 
between S. bovis biotypes the association between S. bovis biotype I and CRC may have 
structurally been underestimated. It is important to note that Schlegel et al. (2003) suggested 
renaming S. bovis biotype I into S. gallolyticus subsp. gallolyticus, S. bovis biotype II/1 into S. 
infantarius subsp. coli or S. infantarius subsp. infantarius and to rename S. bovis biotype II/2 
into S. gallolyticus subsp. pasteurianus. This new nomenclature should be used to better 
discriminate between the different S. bovis subspecies of which S. gallolyticus is the only 
species with an unambiguous association with CRC (Boleij et al., 2011b).  
5.1.2 Streptococcus gallolyticus 
Recently, some striking differences between S. bovis biotypes were revealed that could 
explain their different association rates with CRC. First of all, S. gallolyticus seems to contain 
distinguished mechanisms to adherence to extracellular matrix (ECM) structures like 
collagen and fibrinogen (Ellmerich et al., 2000a; Sillanpaa et al., 2008; Sillanpaa et al., 2009). 
Interestingly, (pre-)malignant colonic sites are characterized by displaced collagen of the 
lamina propria (Galbavy et al., 2002; Yantiss et al., 2001), through which specifically S. 
gallolyticus may colonize these sites. Besides the ECM components, also other structures at 
the epithelial surface may play a role in the initial adhesion to enterocytes. For example, 
Henry-Stanley et al. (2003) reported binding of S. bovis strains to heparan sulfate 
proteoglycans, which may be mediated by surface-associated HlpA (Boleij et al., 2009). In an 
in vitro trans-well model containing a differentiated intestinal monolayer, the paracellular 
translocation efficiency of S. gallolyticus was shown to be significantly higher than that of 
other S. bovis biotypes. This could mean that this bacterium has an advantage over other S. 
bovis subspecies to cross an intestinal epithelium, which possibly only occurs at (pre-
)malignant sites with reduced barrier function (Boleij et al., 2011a). Recent data suggested 
that S. gallolyticus does not induce a strong pro-inflammatory IL-8 response in epithelial cells 
in contrast to other S. bovis strains, which may be a possibly mechanism by which S. 
gallolyticus stays rather invisible for macrophages in the lamina propria. Furthermore, 
Hirota et al. (1995) discovered that S. gallolyticus isolates from endocarditis patients, express 
human sialyl Lewisx antigens on their cell surface unlike other fecal isolates. Mimicking 
human sialyl antigens, which are naturally present on monocytes and granulocutes, could 
therefore be a second mechanism of S. gallolyticus to remain unnoticed by the human innate 
immune system. Moreover, sialyl Lewisx antigens could make these bacteria more efficient 
in binding to endothelial cells and invasion into the circulatory system (Hirota et al., 1996). 
Finally, S. gallolyticus was shown to have superior efficiency to form biofilms on collagen I 
and IV surfaces (Boleij et al., 2011a; Sillanpaa et al., 2008). The latter finding could explain the 
increased incidence of S. gallolyticus as causative agent in infective endocarditis. Based on 
the current state-of-the-literature (July 2011), the following events in CRC-associated S. 
gallolyticus endocarditis can be envisaged i) S. gallolyticus specifically adheres to (pre-
)malignant colonic sites for instance via binding to displaced collagen of the lamina propria 
or other tumor cell specific adherence factors; ii) S. gallolyticus may promote tumor 
progression by induction of the COX-2 pathway; iii) S. gallolyticus takes advantage of the 
distorted structure of the colonic epithelium at (pre-)malignant sites to pass the colonic wall; 
iv) S. gallolyticus stays relatively invisible for the innate immune system and can reach the 
blood stream; v) S. gallolyticus can cause a secondary infection at sites with high exposure of 
collagens, such as present at damaged heart values. It should be noted, however, that many 
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of these data were obtained by in vitro studies and that it remains to be determined how this 
relates to the in vivo situation.  
5.2 Clostridium septicum 
In addition to S. gallolyticus endocarditis, also Clostridium septicum infections have been 
clinically associated with sporadic CRC (Chew & Lubowski, 2001; Mirza et al., 2009). C. 
septicum is not considered to be part of the normal intestinal microbiota and is a rare cause 
of bacteremia (<1% of all cases). Hermsen et al. (2008) investigated 320 cases of C. septicum 
infections, 42% of which had a gastrointestinal origin. Malignant disease was present in 30-
50% of these cases. The underlying mechanism of this association is not known, but it has 
been speculated that the hypoxic and acidic environment of the tumor specifically favor 
germination of C. septicum spores that enter the gastrointestinal tract via contaminated food 
(Dylewski & Luterman). A direct involvement of C. septicum in the development of CRC has 
thus far not been investigated, but it is hypothesized that C. septicum infections are primarily 
a consequence of CRC itself. Also Clostridium perfringens and Clostridium butyricum have 
been described in relation with CRC (Cabrera et al., 1965; Rathbun, 1968). However, these 
strains are much less virulent than C. septicum and their association with CRC is less evident. 
Although infections with C. septicum are rare, underlying malignancy should be suspected 
and also in these cases full bowel examination could eventually save patients’ lives. 
5.3 Helicobacter pylori 
Helicobacter pylori has been classified as gastric cancer-causing infective agent by the 
International Agency for Research on Cancer (IARC) in 1994. Most H. pylori strains, 
however, are non-invasive organism and exist in a non-adherent extracellular mucous 
environment. A small number of strains adheres to gastric epithelial cells, which most likely 
involves a number of different surface receptors (Wilkinson et al., 1998). The presence of the 
pathogenicity island, expressing the cytotoxins VacA and CagA, is an important virulence 
determinant in these strains (Ekstrom et al., 2001; Huang et al., 2003; Crabtree et al., 1994; 
Kuipers et al., 1995). It is thought that long-term exposure to these toxins induces gastric 
inflammation that can eventually lead to gastric carcinomas (Higashi et al., 2002; Fox, 2002). 
A meta-analysis conducted in 2006 by Zumkeller et al. indicated also a slightly increased risk 
for CRC (factor 1.4) in individuals with a H. pylori infection (Zumkeller et al., 2006). Another 
study showed that CagA status was associated with a significantly increased risk (factor 
>10) for CRC among hospitalized patients that were H. pylori seropositive (Shmuely et al., 
2001). Notably, this study again underscores the importance of proper microbiological 
classification and characterization of cancer-associated infectious agents, since not all 
Helicobacter strains may be associated with CRC. Like has been the case for S. bovis, lack of 
proper distinction between H. pylori subspecies could have biased or even underestimated a 
possible association of this bacterium with this disease (Erdman et al., 2003a,b). 
6. CRC Microbiome-based Immunoassays  
The occurrence of specific CRC-associated bacterial infections, as discussed in the previous 
section, paves the way for the development of novel diagnostic tools. In this respect, it is 
important to realize that S. gallolyticus infections occur without clinical symptoms due to its 
mild virulence (Haimowitz et al., 2005). Clinical manifestation of S. gallolyticus infections in 
otherwise compromised patients (e.g. damaged heart valves), may very well only represent 
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the tip of the iceberg of all infections with this bacterium in individuals with (pre-)malignant 
colonic lesions. This notion has been the incentive to investigate whether a humoral immune 
response to sub-clinical S. gallolyticus infections could aid in the early detection of CRC. 
Notably, as infectious agents in general induce a more pronounced immune response 
compared to tumor “self” antigens, CRC-associated bacterial antigens could be instrumental 
in the immunodiagnosis of this disease (Tjalsma, 2011). Furthermore, several features of 
circulating antibodies make these attractive targets in diagnostic medicine: i) they reflect a 
molecular imprint of disease-related antigens from all around the human body, ii) although 
an antigen may be present only briefly, the corresponding antibody response is likely to be 
persistent, iii) the half-life of antibodies is about 15 days which minimizes daily fluctuations, 
iv) antibodies are highly stable compared to many other serum proteins making serum-
handling protocols less stringent, v) the amplification cascade governed by the humoral 
immune system causes a surplus of circulating antibodies after appearance of the cognate 
(low-abundance) antigen. Several studies have shown that serum antibody levels against S. 
bovis/S. gallolyticus antigens could discriminate CRC cases from healthy controls (Abdulamir 
et al., 2009; Darjee & Gibb, 1993; Tjalsma et al., 2006). Interestingly, the humoral immune 
response to ribosomal protein (Rp) L7/L12 from S. gallolyticus was found to be higher in 
early CRC compared to late CRC stages, whereas this was not paralleled by increased 
antibody production to endotoxin, an intrinsic cell wall component of the majority of 
intestinal bacteria (Boleij et al., 2010). This implies that the immune response to RpL7/L12 is 
not a general phenomenon induced by the loss of colonic barrier function. Furthermore, this 
observation could point to a temporal relationship between S. gallolyticus and CRC, 
suggesting that late stage tumors may change in such a way that bacterial survival in the 
tumor microenvironment is diminished. The possibility that disease progression may drive 
bacteria out of the cancerous tissue is similar to what has been reported for H. pylori during 
gastric cancer progression (Corfield et al., 2000; Kang et al., 2006). A relationship of S. bovis 
with early stages of CRC is underscored by a vast amount of case studies showing that its 
infection was associated with pre-malignant adenomas. These cases would have remained 
undiscovered if these patients did not present with an active S. bovis infection. Future 
research should be aimed at development of more specific S. gallolyticus-based serological 
assays to investigate the clinical utility of such tests for the early detection of CRC (Tjalsma 
et al., 2006, 2008; Tjalsma, 2010). Furthermore, as CRC is a highly heterogeneous disease that 
is probably accompanied by even more heterogeneous microbiome shifts, accurate diagnosis 
based on biomarkers from a single bacterial species on the population level is highly 
unlikely. Therefore, future research should also be aimed at the identification of additional 
tumor-associated intestinal bacteria that may never have been found to cause clinical 
infections but do induce a humoral immune response. Furthermore, as discussed in Section 
3 of this Chapter, certain mucosa-associated bacteria may be involved in CRC initiation or 
progression. Invasiveness of these pathogens or exposure to their antigens may elicit IgG 
responses that are valuable for CRC risk assessment. These individuals may not directly 
need bowel examination, but could be enrolled in a more strict monitoring program.  
7. Conclusions  
The development of CRC is a multistep process that may take over 20 years to progress 
from an adenoma into an advanced carcinoma. The fact that the intestinal microbiome plays 
an important role in this process is clearly shown by the inflammatory effects of intestinal 
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of these data were obtained by in vitro studies and that it remains to be determined how this 
relates to the in vivo situation.  
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clinically associated with sporadic CRC (Chew & Lubowski, 2001; Mirza et al., 2009). C. 
septicum is not considered to be part of the normal intestinal microbiota and is a rare cause 
of bacteremia (<1% of all cases). Hermsen et al. (2008) investigated 320 cases of C. septicum 
infections, 42% of which had a gastrointestinal origin. Malignant disease was present in 30-
50% of these cases. The underlying mechanism of this association is not known, but it has 
been speculated that the hypoxic and acidic environment of the tumor specifically favor 
germination of C. septicum spores that enter the gastrointestinal tract via contaminated food 
(Dylewski & Luterman). A direct involvement of C. septicum in the development of CRC has 
thus far not been investigated, but it is hypothesized that C. septicum infections are primarily 
a consequence of CRC itself. Also Clostridium perfringens and Clostridium butyricum have 
been described in relation with CRC (Cabrera et al., 1965; Rathbun, 1968). However, these 
strains are much less virulent than C. septicum and their association with CRC is less evident. 
Although infections with C. septicum are rare, underlying malignancy should be suspected 
and also in these cases full bowel examination could eventually save patients’ lives. 
5.3 Helicobacter pylori 
Helicobacter pylori has been classified as gastric cancer-causing infective agent by the 
International Agency for Research on Cancer (IARC) in 1994. Most H. pylori strains, 
however, are non-invasive organism and exist in a non-adherent extracellular mucous 
environment. A small number of strains adheres to gastric epithelial cells, which most likely 
involves a number of different surface receptors (Wilkinson et al., 1998). The presence of the 
pathogenicity island, expressing the cytotoxins VacA and CagA, is an important virulence 
determinant in these strains (Ekstrom et al., 2001; Huang et al., 2003; Crabtree et al., 1994; 
Kuipers et al., 1995). It is thought that long-term exposure to these toxins induces gastric 
inflammation that can eventually lead to gastric carcinomas (Higashi et al., 2002; Fox, 2002). 
A meta-analysis conducted in 2006 by Zumkeller et al. indicated also a slightly increased risk 
for CRC (factor 1.4) in individuals with a H. pylori infection (Zumkeller et al., 2006). Another 
study showed that CagA status was associated with a significantly increased risk (factor 
>10) for CRC among hospitalized patients that were H. pylori seropositive (Shmuely et al., 
2001). Notably, this study again underscores the importance of proper microbiological 
classification and characterization of cancer-associated infectious agents, since not all 
Helicobacter strains may be associated with CRC. Like has been the case for S. bovis, lack of 
proper distinction between H. pylori subspecies could have biased or even underestimated a 
possible association of this bacterium with this disease (Erdman et al., 2003a,b). 
6. CRC Microbiome-based Immunoassays  
The occurrence of specific CRC-associated bacterial infections, as discussed in the previous 
section, paves the way for the development of novel diagnostic tools. In this respect, it is 
important to realize that S. gallolyticus infections occur without clinical symptoms due to its 
mild virulence (Haimowitz et al., 2005). Clinical manifestation of S. gallolyticus infections in 
otherwise compromised patients (e.g. damaged heart valves), may very well only represent 
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the tip of the iceberg of all infections with this bacterium in individuals with (pre-)malignant 
colonic lesions. This notion has been the incentive to investigate whether a humoral immune 
response to sub-clinical S. gallolyticus infections could aid in the early detection of CRC. 
Notably, as infectious agents in general induce a more pronounced immune response 
compared to tumor “self” antigens, CRC-associated bacterial antigens could be instrumental 
in the immunodiagnosis of this disease (Tjalsma, 2011). Furthermore, several features of 
circulating antibodies make these attractive targets in diagnostic medicine: i) they reflect a 
molecular imprint of disease-related antigens from all around the human body, ii) although 
an antigen may be present only briefly, the corresponding antibody response is likely to be 
persistent, iii) the half-life of antibodies is about 15 days which minimizes daily fluctuations, 
iv) antibodies are highly stable compared to many other serum proteins making serum-
handling protocols less stringent, v) the amplification cascade governed by the humoral 
immune system causes a surplus of circulating antibodies after appearance of the cognate 
(low-abundance) antigen. Several studies have shown that serum antibody levels against S. 
bovis/S. gallolyticus antigens could discriminate CRC cases from healthy controls (Abdulamir 
et al., 2009; Darjee & Gibb, 1993; Tjalsma et al., 2006). Interestingly, the humoral immune 
response to ribosomal protein (Rp) L7/L12 from S. gallolyticus was found to be higher in 
early CRC compared to late CRC stages, whereas this was not paralleled by increased 
antibody production to endotoxin, an intrinsic cell wall component of the majority of 
intestinal bacteria (Boleij et al., 2010). This implies that the immune response to RpL7/L12 is 
not a general phenomenon induced by the loss of colonic barrier function. Furthermore, this 
observation could point to a temporal relationship between S. gallolyticus and CRC, 
suggesting that late stage tumors may change in such a way that bacterial survival in the 
tumor microenvironment is diminished. The possibility that disease progression may drive 
bacteria out of the cancerous tissue is similar to what has been reported for H. pylori during 
gastric cancer progression (Corfield et al., 2000; Kang et al., 2006). A relationship of S. bovis 
with early stages of CRC is underscored by a vast amount of case studies showing that its 
infection was associated with pre-malignant adenomas. These cases would have remained 
undiscovered if these patients did not present with an active S. bovis infection. Future 
research should be aimed at development of more specific S. gallolyticus-based serological 
assays to investigate the clinical utility of such tests for the early detection of CRC (Tjalsma 
et al., 2006, 2008; Tjalsma, 2010). Furthermore, as CRC is a highly heterogeneous disease that 
is probably accompanied by even more heterogeneous microbiome shifts, accurate diagnosis 
based on biomarkers from a single bacterial species on the population level is highly 
unlikely. Therefore, future research should also be aimed at the identification of additional 
tumor-associated intestinal bacteria that may never have been found to cause clinical 
infections but do induce a humoral immune response. Furthermore, as discussed in Section 
3 of this Chapter, certain mucosa-associated bacteria may be involved in CRC initiation or 
progression. Invasiveness of these pathogens or exposure to their antigens may elicit IgG 
responses that are valuable for CRC risk assessment. These individuals may not directly 
need bowel examination, but could be enrolled in a more strict monitoring program.  
7. Conclusions  
The development of CRC is a multistep process that may take over 20 years to progress 
from an adenoma into an advanced carcinoma. The fact that the intestinal microbiome plays 
an important role in this process is clearly shown by the inflammatory effects of intestinal 
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bacteria, which are essential to develop disease in animal models. Furthermore, 
accumulating evidence suggests that bacterial production of toxins, toxic metabolites and 
the direct influences on pro-carcinogenic pathways in host epithelial cells are contributing 
factors that promote the accumulation of mutations that may eventually lead to carcinomas. 
However, still many questions remain to be answered. For example, our knowledge on the 
on the impact of CRC on the local intestinal microbiota and vice versa, is still in its infancy. 
Future research should focus on the detailed mapping of the microbiota in close proximity 
of early adenomas and carcinomas. These local changes in microbiota may for instance 
provide clues in the understanding why only 10% of the adenomas progress into 
carcinomas. Such knowledge could give us new leads for cancer diagnosis, for example by 
using signaling bacteria, such as S. gallolyticus that benefit from the altered tumor 
environment, as diagnostic targets. Furthermore, this knowledge could provide leads for the 
selective removal of high-risk bacterial populations by health promoting species, as a new 
strategy in CRC prevention. Altogether, this Chapter points out that the colonic microbiota 
should be regarded as an important factor in intestinal carcinogenesis. Further research in 
this field is crucial to fully understand the etiology of CRC and has a high potential to lead 
to new diagnostic tools and therapeutic interventions.  
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bacteria, which are essential to develop disease in animal models. Furthermore, 
accumulating evidence suggests that bacterial production of toxins, toxic metabolites and 
the direct influences on pro-carcinogenic pathways in host epithelial cells are contributing 
factors that promote the accumulation of mutations that may eventually lead to carcinomas. 
However, still many questions remain to be answered. For example, our knowledge on the 
on the impact of CRC on the local intestinal microbiota and vice versa, is still in its infancy. 
Future research should focus on the detailed mapping of the microbiota in close proximity 
of early adenomas and carcinomas. These local changes in microbiota may for instance 
provide clues in the understanding why only 10% of the adenomas progress into 
carcinomas. Such knowledge could give us new leads for cancer diagnosis, for example by 
using signaling bacteria, such as S. gallolyticus that benefit from the altered tumor 
environment, as diagnostic targets. Furthermore, this knowledge could provide leads for the 
selective removal of high-risk bacterial populations by health promoting species, as a new 
strategy in CRC prevention. Altogether, this Chapter points out that the colonic microbiota 
should be regarded as an important factor in intestinal carcinogenesis. Further research in 
this field is crucial to fully understand the etiology of CRC and has a high potential to lead 
to new diagnostic tools and therapeutic interventions.  
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1. Introduction  
Sixty percent of patients with colorectal cancer (CRC) are afflicted with distant metastases 
(liver or lung metastatic process) or a local relapse of malignancy (Bird et al., 2006). The 
possibilities of surgical and oncological treatment of this disease offer us a large spectrum of 
treatments including the combination of surgical procedures and consecutive oncological 
treatments. In the case of radical surgical therapy we can consider the curative access. The 
main medical problem of CRC is the high rate of recurrences after radically performed 
surgical therapy. The operability of recurrence is only about 30% in the case of local relapse 
and 20% in the case of distant metastases (Coleman et al., 2008; Kobayashi et al., 2007). The 
second dominant problem is the early recurrence of CRC after radical surgical treatment, 
when the patients undergo a difficult and exhausting procedure with a high risk of 
perioperative complications without any significant differences in overall survival against 
modern palliative therapy (Van den Eynde & Hendlisz, 2009).  
Contemporary clinical and histopathological prognostic factors (staging, grading, etc.) used 
for the detection of patients with a high risk of relapse and a short overall survival rate and 
for the indication of adjuvant oncological treatment after radical surgery are not sufficient. 
Tumor infiltrating lymphocytes (TIL) were described as a good prognostic factor for patients 
with a high risk of relapse. They are critical indicators of efficient antitumor immunological 
response. Their number, type and morphology of TIL cells determine resulting tumor 
prognosis (Atreya & Neurath, 2008; Galon et al., 2006). They could be connected also with 
the suppression of micrometastatical disease after radical surgery (Gajewski et al., 2006; 
Pages et al., 2005). We can recognize either the type of immune cells or distinguish their 
morphological aspects (infiltration of any part of tumor or surrounding of tumor or 
tributary lymph nodes) (Talmadge et al., 2007).  
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We detail only short overview of their types and function. We recommend the readers with 
deeper interest in these problems to find comprehensive reviews in the cited papers 
(Jochems et al., 2011; Ohtani 2007). From this view we find CD8+ and CD4+ T lymphocytes 
(Fig. 1a & Fig. 1b), natural killer cells (Fig. 1c), dendritic cells (Fig. 1d), macrophages, etc. 
The exact function of these cells is under current discussion. We only know that they play 
main role in controlling tumor development and growth. CD8+ T lymphocytes within 
cancer cell nests of colorectal cancer have significant impact on the survival of patients. They 
contain the cytolytic enzyme granzyme-B. In case of increased proliferating activity of CD8+ 
T lymphocytes we observe their activated and cytotoxic phenotype that is significantly 
associated with the absence of early metastatic events (vascular emboli, lymphatic invasion 
or perineural invasion of tumor cells) and with a decreased rate of cancer recurrence (Atreya 
& Neurath, 2008, Pages et al., 2010). A high density of memory T lymphocytes within 
colorectal cancer tissue was more frequently observed in patients without early detectable 
signs of metastatic events and was associated with both improved disease free interval (DFI) 
and prolonged overall survival (OS) (Galon et al., 2006; Pages et al., 2005).  
Natural killer cells (NK cells) mediate an effective lysis of cancer cells but the mechanism of 
detection of cancer cells is different from CD8+ T lymphocytes (Cooper et al., 2009). NK cells 
are mainly involved in the innate immune response and do not recognize specific tumor 
associated antigen on the surface of cancer cells as CD8+ T lymphocytes. NK cells lyse the 
cancer cells that are opsonized by surface antibody. NK cells also respond to other signals as 
cytokines produced by antigen presenting cells, which allow them to mediate early host 
responses against pathogen (Moretta et al., 2006). Decreased preoperative number of NK 
cells was associated with increased frequency of postoperative recurrence of colorectal 
cancer (Atreya & Neurath, 2008; Cooper et al., 2001). Their crucial role in the elimination of 
haematological malignancies, primary and secondary tumors has been recognized (Lucas et 
al., 2007; Ljunggren & Malmberg, 2007, Stojanovic & Cerwenka, 2011).  In the last year there 
are some signs that NK-cells have the capacity for memory-like responses, a property that 
was previously thought to be limited to adaptive immunity, but in this view the discussion 
still continues (Cooper et al., 2009).  
Dendritic cells are considered to be most potent antigen presenting cells. They play key role 
in activation, stimulation and recruitment of T lymphocytes. They can also induce antigen-
specific unresponsiveness or immune tolerance. Immature dendritic cells enter tumor tissue, 
uptake and process its antigens. Then after they migrate to lymph nodes, undergo 
maturation and interact with T-lymphocytes that are able to recognize presented antigen 
and so T-lymphocytes play effector role of this tumor-specific immunity (Atreya & Neurath, 
2008; Pages et al., 2005; Sandel et al., 2005; Steinman et al., 2003).  
Macrophages are important producers of different factors that have function during tumor 
progression and also during tumor progression control. Their function is not fully 
understand, but it was described that the number of tumor infiltrating macrophages 
correlates with overall survival of colorectal cancer patients (Atreya & Neurath, 2008; 
Pollard, 2004; Forssell et al., 2007). It seems that several types of tumor infiltrating 
macrophages influence the balance between pro- and anti-tumor properties of immune 
system (Forssell et al., 2007).  
From the morphologic view we can observe TIL in the specific portions of tumor and so we 
detect lymphocytic infiltration intratumoral (ITL – intratumoral lymphocytes) (Fig. 
Tumor Infiltrating Lymphocytes as Prognostic Factor of Early  
Recurrence and Poor Prognosis of Colorectal Cancer After Radical Surgical Treatment 
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2a),intrastromal (ISL – intrastromal lymphocytes) (Fig. 2b), peritumoral (PTL – peritumoral 
lymphocytes) (Fig. 2c) and Crohn-like reaction (Crohn-like PTL)(Fig. 2d). We can also 
describe reactive histological changes in tributary lymph nodes (LN reactions). It means 
follicular hyperplasia (LN-FH) (Fig. 3a.), sinus histiocytosis (LN-SH) (Fig. 3b.) and the 
presence of granulomas (LN-GR) (Fig. 3c) (Ogino et al, 2009; Pages et al., 2005). 
The aim of this study was to analyze the relationship of contemporary clinical and 
histopathological factors and TIL to determine patients with a high risk of poor overall 
survival and tendency to early recurrence of malignancy with shortened disease free 















Fig. 1. Examples of tumor infiltration by immune cells: a) CD8+ T lymphocytes; b) CD4+ T 
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2a),intrastromal (ISL – intrastromal lymphocytes) (Fig. 2b), peritumoral (PTL – peritumoral 
lymphocytes) (Fig. 2c) and Crohn-like reaction (Crohn-like PTL)(Fig. 2d). We can also 
describe reactive histological changes in tributary lymph nodes (LN reactions). It means 
follicular hyperplasia (LN-FH) (Fig. 3a.), sinus histiocytosis (LN-SH) (Fig. 3b.) and the 
presence of granulomas (LN-GR) (Fig. 3c) (Ogino et al, 2009; Pages et al., 2005). 
The aim of this study was to analyze the relationship of contemporary clinical and 
histopathological factors and TIL to determine patients with a high risk of poor overall 
survival and tendency to early recurrence of malignancy with shortened disease free 















Fig. 1. Examples of tumor infiltration by immune cells: a) CD8+ T lymphocytes; b) CD4+ T 










Fig. 2. Different localisation of TIL within the tumor tissue: a) intratumoral lymphocytes;  
b) intrastromal lymphocytes; c) peritumoral lymphocytes and d) Crohn-like peritumoral 




Fig. 3. Reactive histological changes in tributary lymph nodes: a) follicular hyperplasia; b) sinus 
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We analyzed 150 patients who underwent radical surgical procedure for CRC between the 
years 2004-2007 at the Department of Surgery, Medical School and Teaching Hospital in 
Pilsen, Charles University in Prague. We selected only patients who were operated on 
electively – our aim was to decrease the risk of inflammation that is often connected with the 
acute operation of CRC and does not depend on the immune reaction against a tumor but 
could be evoked by the distension of the bowel. We also excluded patients who had risk of 
understaging (for example low number of analysed lymph nodes) and patients with a 
synchronous metastatic process. The inclusion standard was also the entire follow-up of 
patients during the whole postoperative period to increase the number of patients with a 
diagnosed early recurrence of CRC. 
The following clinical parameters were statistically analysed in relation to the disease free 
interval (DFI) and the overall survival (OS): staging, grading, preoperative leukocytosis, 
type of surgical procedure (radical vs. palliative), postoperative complications and 
postoperative oncological treatment.  
2.1 Histology 
We examined three different sections of each tumor and also sections of all found lymph 
nodes. Tissue for light microscopy was fixed in 4% formaldehyde and embedded in paraffin 
using routine procedures. Five micrometer-thick sections were cut from the tissue blocks 
and stained with hematoxylin-eosin. 
The type and grade of all tumors were determined according to WHO 2000 guidelines. The 
stage of tumors was established according to UICC 2002 guidelines. We evaluated 
endovascular (VI), endolymphatic (LI) and perineural infiltration (PI) by cancer cells (0 – 
none, 1 – yes). Lymphocytic infiltration was detected as intratumoral (ITL – intratumoral 
lymphocytes), intrastromal (ISL – intrastromal lymphocytes), peritumoral (PTL – 
peritumoral lymphocytes) and Crohn-like reaction (Crohn-like PTL), and scaled as none (0), 
mild (1), moderate (2) and severe (3). Reactive histological changes in lymph nodes (LN 
reactions) were detected as follicular hyperplasia (LN-FH), sinus histiocytosis (LN-SH) and 
the presence of granulomas (LN-GR), and all these parameters were quantified in the same 
manner as lymphocytic infiltration. 
2.2 Immunohistochemistry  
For immunohistochemical investigations the following primary antibodies were used: CD4 
(clone 4B12, 1:50, Vector Laboratories, Burlingame, CA, USA) and CD8 (clone C8/144B, 1:50, 
Dako, Glostrup, Denmark). Microwave pretreatment was used in both cases. The primary 
antibodies were visualized using the supersensitive streptavidin-biotin-peroxidase complex 
(Biogenex, San Ramon, CA). Appropriate positive and negative control slides were employed. 
The density of intratumoral infiltration by lymphocytes was evaluated in five High power 
microscopical fields (HPF) and expressed as the number of immunopositive cells per HPF. 
2.3 Statistical evaluation   
Statistical analysis was processed by the statistical software Statistica 9.0. The mean, median, 
standard deviation (SD), minimum, maximum, quartiles, frequencies and other basic 
statistical measurements were computed in given groups and subgroups of patients 
corresponding to studied clinical and histopathological parameters.  
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The relationships between the variables were described by Spearman rank correlation 
coefficients.  
The analyses of Overall survival (OS) and Disease free interval (DFI) were performed by 
Kaplan-Meier´s survival functions. The influence of given covariates (clinical and 
histopathological factors) was tested by the Log-Rank test and Wilcoxon test. The Cox 
regression hazard model, hazard ratio (HR) and 95% confidence interval (CI) for HR were 
computed for the evaluation of given clinical and histopathological factors to OS or DFI. 
Multivariate analysis was performed by the use of classification and regression trees 
(CART). The Cox regression hazard model (stepwise regression) was applied to find the 
predictors in CART. 
3. Results 
The statistical analysis of the studied cohort of patients after surgical treatment for colorectal 
cancer demonstrated an acceptable distribution of basic statistical description parameters 
(gender ratio 93:57 (male vs. female)). 1, 3 and 5 years overall survival was 92.2%, 76.5% and 
70.2% and 1, 3 and 5 year DFI was 85.3%, 64.3% and 49.4%.  
The Spearman rank correlation coefficient did not prove any stronger correlation than a 
moderate correlation at endolymphatic invasion (LI) and lymph node infiltration by 
metastatic process (Spearman rank correlation coefficient 0.56, p<0,05). All the other studied 
factors were independent factors or factors with a low correlation. 
Statistical analysis proved lymph node infiltration by metastatic process as statistically 
significant for the prognosis of overall survival (p<0.05) and N2 status of lymph nodes 
increased the risk of shorter overall survival 9.3x (Fig. 4.). 
 
 
Fig. 4. Statistical analysis proved the lymph node infiltration by a metastatic process as 
statistically significant for the prognosis of overall survival (p<0.05), and the N2 status of 
lymph nodes increased the risk of a shorter overall survival 9.3x. 
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Endovascular infiltration (VI) was proved as a negative prognostic factor of shorter overall 
survival (Fig.5.). Patients with positive histopathological findings of VI have 3.1x increased 
risk for shorter overall survival. The presence of peritumoral lymphocytes (PTL) (Fig.6.) and 
of Crohn-like PTL (Fig.7.) was proved as a positive prognostic factor of OS. Patients with a 
positive histopathological finding of PTL and Crohn-like PTL have a decreased risk for 
shorter overall survival (2.3x and 2.3x respectively). Lymph node follicular hyperplasia (LN-
FH) was verified as a positive prognostic factor for longer overall survival (Fig.8.). The 
statistical significance of LN-FH increased also with the raised density of infiltration.  LN-
FH positivity decreased the risk of shorter overall survival 3.3times. 
The severity of CD8+ lymphocytic infiltration was proved by the Cox regression hazard 
model as a positive prognostic factor enlarging overall survival (cut off 30 cells/HPF). The 
severity of CD4+ lymphocytic infiltration was proved as a significant factor for the 
prognosis of overall survival (cut off 4cells/HPF) with 2.5x increased hazard ratio in 
patients over the cut off (Fig.9.). Statistical analysis did not confirm the statistical 











Fig. 5. Endovascular infiltration by cancer cells (VI) was proved as a statistically significant 
factor for the prognosis of overall survival (p<0.05). The patients with a positive 
histopathological finding of VI have 3.1x higher risk ratio for shorter overall survival. 
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histopathological finding of VI have 3.1x higher risk ratio for shorter overall survival. 
 




Fig. 6. Presence of peritumoral lymphocytes (PTL) was proved as a statistically significant 
positive factor for the prognosis of overall survival (p<0.05). The patients with a positive 
histopathological finding of PTL have 2.3x lower risk ratio for a shorter overall survival. 
 
 
Fig. 7. Presence of Crohn-like PTL was proved as a statistically significant positive factor for 
the prognosis of overall survival (p<0.05). The patients with a positive histopathological 
finding of PTL have 2.3x lower risk ratio for a shorter overall survival. 
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Fig. 8. Lymph node follicular hyperplasia (LN-FH) was verified as a positive prognostic 
factor for a longer overall survival (p<0.05). The statistical significance of LN-FH increased 
also with the raised density of infiltration. LN-FH positivity decreased the risk of a shorter 
overall survival 3.3x. 
 
 
Fig. 9.  Severity of CD4+ lymphocytic intratumoral infiltration was proved as a significant 
factor for the prognosis of overall survival (cut off 4cells/HPF) with a 2.5x increased hazard 
ratio in patients over the cut off (p<0.05).  
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The Multivariate Cox Regression Hazard Model proved the combination of the severity of 
lymph node infiltration by metastatic process and LN-FH as the best prognostic factors for 
the prediction of the risk of shorter overall survival. This situation is demonstrated in the 
Classification and Regression Tree (CART)(p<0.05) (Fig.10.). All other studied parameters 





Fig. 10. Multivariate Cox Regression Hazard Model proved the combination of the severity 
of lymph node infiltration by a metastatic process and LN-FH as the best prognostic factors 
for the prediction of risk of a shorter overall survival (p<0.05). This situation is 
demonstrated in the Classification and Regression Tree (CART).  
Perineural infiltration (PI) was proved as a negative prognostic factor of an earlier 
recurrence (Fig.11.). Patients with a positive histopathological finding of PI have 3.8x 
increased risk for shorter DFI. 
The severity of CD8+ lymphocytic infiltration was proved by the Cox regression hazard 
model as a positive prognostic factor enlarging DFI (cut off 30cells/HPF) (Fig.12.). Patients 
over the cut off have 2.2x increased risk of an early recurrence. The severity of CD4+ 
lymphocytic infiltration was not proved as a significant factor for the prognosis of DFI. 
Statistical analysis did not confirm the statistical significance of the CD8/CD4 ratio. 
Tumor Infiltrating Lymphocytes as Prognostic Factor of Early  




Fig. 11. Perineural infiltration (PI) was proved as a negative prognostic factor of an earlier 
recurrence (p<0.05). Patients with a positive histopathological finding of PI have a 3.8x 
increased risk for shorter DFI. 
Statistical analysis proved lymph node infiltration by a metastatic process as statistically 
significant for the prognosis of DFI and N2 status of lymph nodes increased the risk of 
shorter DFI 5x (Fig. 13.). 
 
 
Fig. 12.  Severity of CD8+ lymphocytic intratumoral infiltration was proved as a positive 
prognostic factor enlarging DFI (cut off 30 cells/HPF) by the Cox regression hazard model 
(p<0.05). Patients over the cut off have a 2.2x increased risk of an early recurrence. 
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Fig. 13. Statistical analysis proved lymph node infiltration by a metastatic process as 
statistically significant for the prognosis of DFI, and a N2 status of lymph nodes 5x 
increased the risk of a shorter DFI (p<0.05).  
The Multivariate Cox Regression Hazard Model proved the combination of the severity of 
the lymph node infiltration by a metastatic process and the severity of CD8 positivity of 
infiltrating lymphocytes as the best prognostic factors for the prediction of risk of early 
recurrence (p<0.05). This situation is demonstrated in the Classification and Regression Tree 
(CART) (Fig. 14). All other studied parameters were not proved as statistically significant for 
the prognosis of DFI. 
4. Discussion 
The role of the adaptive immunological response in controlling the growth and relapse of 
CRC remains controversial and contemporary studies have not answered all the questions 
about the prognosis of patients after radical surgical treatment of CRC (Galon et al., 2006; 
Ohtani, 2007; Van den Eynde & Hendlisz, 2009). We analysed our large cohort of patients of 
CRC with consideration to detect the negative and also positive prognostic factors of early 
recurrence of the disease and the poor overall survival after radical surgery. It was 
stimulated by the unsatisfactory situation and some dilemmas in the indication of surgical 
and oncological treatment, when early recurrence depreciates our effort to radical surgery 
with a high risk of complications and the long time of the decreased quality of life of our 
patients. 
In the presented clinico-pathological study we demonstrated that lymph node infiltration by 
a metastatic process, N2 status of lymph nodes, VI, and extent of CD4+ lymphocytic 
intratumoral infiltration as negative prognostic factors of OS. In contrary PTL, Crohn-like 
PTL, LN-FH, and severity of CD8+ lymphocytic intratumoral infiltration were proved as 
positive prognostic factors of the overall survival.  
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Fig. 14. Multivariate Cox Regression Hazard Model proved the combination of the severity 
of lymph node infiltration by a metastatic process and the severity of CD8 positivity as the 
best prognostic factors for the prediction of risk of an early recurrence (p<0.05). This 
situation is demonstrated in the Classification and Regression Tree (CART). 
The combination of the severity of the lymph node infiltration by a metastatic process and 
LN-FH were proved as the best prognostic factors for the prediction of risk of a shorter 
overall survival by the Multivariate Cox Regression Hazard Model.  
We also demonstrated PI, lymph node metastatic infiltration and the N2 status of lymph 
nodes as negative prognostic factors of an earlier recurrence, and the severity of CD8+ 
lymphocytic intratumoral infiltration as a positive prognostic factor enlarging DFI. The 
combination of the severity of the lymph node infiltration by a metastatic process and the 
severity of CD8+ lymphocytic intratumoral infiltration were proved as the best prognostic 
factors for the prediction of the risk of an early recurrence by the Multivariate Cox 
Regression Hazard Model.  
Our results support the hypothesis that the adaptive immunological response in tumor 
tissue and its reaction in regional lymph nodes can influence the behavior of CRC and so 
affect the prognosis of patients (Atreya & Neurath, 2008; Galon et al., 2006). CD4 and CD8 
positivity of ITL was demonstrated as a key histopathological sign of tumor-specific 
immune response that could reflect the contemporary clinical situation and a tendency to 
relapse (CD4+) or the larger overall survival (CD8+) (Chiba et al. 2004; Koch et al., 2006, 
Pages et al., 2010).  
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We assessed several types of tumor infiltrating lymphocytes and clearly identified their 
relationships to relapse and the overall survival as positive or negative prognostic factors in 
contrary to previous publications that evaluated only the infiltration of the tumor but not 
the quality and type of infiltration (Ogino et al., 2009).  
Tumor infiltration by lymphocytes seems to be a promising prognostic factor reflecting the 
risk of patients to early recurrence or poor overall survival. Future work has to be focused 
on the molecular-biological background of tumor infiltration by lymphocytes to understand 
their pathophysiological functions (Pages et al., 2005, Zbar, 2004).   
5. Conclusion 
Tumor infiltrating lymphocytes seem to be promising prognostic factors that could find 
their use in colorectal surgery and consecutive oncological treatment as an indicator of the 
type or combinations of therapies reflecting the risk of patients to early recurrence or poor 
overall survival. The TIL status corresponds to immune control of cancer progression.  
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overall survival. The TIL status corresponds to immune control of cancer progression.  
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Patients with gastrointestinal cancer exhibit a poorly functioning immune system that is 
characterized, in part, by decreases in T-lymphocyte proliferation (Greenstein, et al., 1991; 
Milasiene et al., 2007) and reduced CD4+:CD8+ ratios (Arista et al., 1994; Franciosi et al., 2002). 
In different pathologies (including these and other types of cancers), membrane damage in 
immune cells (and other cell types) often evolves as a consequence of alterations that are 
induced in cell-associated lipids and proteins in the affected patients (Gryzunov and 
Dobretsov, 1994, 1998; Rolinsky et al., 2007). It is now widely accepted that the dynamics 
(actual rate of occurrence - not only incidence) of these changes, along with the types of 
alterations in structure(s) of the immune system cells’ lipids/proteins themselves, play a 
critical role in the maintenance of the immune status of any given organism (Lakowicz, 2000). 
As a result of the potential importance of changes in the structural integrity of cells of the 
immune system, it is important for clinicians to receive information on the biophysical 
status of these cells via quick, reliable, reproducible methods. In this regard, fluorescent 
probes have shown to be excellent tools for use in such protocols (Lakowicz, 2000, 2006). 
The work reported here, which built upon earlier findings reported by our laboratories, 
investigated the possibility of using the fluorescent probe ABM (an amine derivative of 
benzanthrone) for the detection of structural/functional alterations in blood plasma 
albumin and among immunocompetent cells in patients with select types of pathologies, i.e,. 
cancers. Such an analysis has a great potential for use not only for helping to comprehend 
mechanisms of immunomodulation associated with the induction/progression of 
malignancies, but might also have the potential to serve as a very important prognostic 
indicator of long-term survival among patients with such pathologies.  
In the work reported here, ABM fluorescence intensity in blood plasma and following 
combination with cell suspensions from colorectal cancer patients was examined in the 
context of the host’s immunological parameters and state of cancer progression. For study 
patients with colorectal cancer were examined: 1) 1 day before and 10 days after their 
surgical treatment (Stages II-III) (Kalnina et al., 2009); 2) as disease worsened (Stages IIa, 
IIIb, IV) (Kalnina et al., 2010b); 3) advanced cancer patients, they were divided into two 
groups in accordance of its survival rate (0-6 months and > 24 months) (Kalnina et al., 2011). 
Apart from the aforementioned potential benefits from these types of studies to clinicians in 
general, this type of research is very important in Latvia itself. This is because, in the context 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
428 
Pagès, F., Galon, J., Die-Nosjeanu, M. C., Tartour, E., & Sautes-Fridman, C. (2010). Immune 
infiltration in human tumors: a prognostic factor that should not be ignored. 
Oncogene, Vol.29, No.8, (February 2010), pp. 1093-1102, ISSN 0950-9232 
Pollard, J. W. (2004). Tumor-educated macrophages promote tumour progression and 
metastasis. Nature Reviews. Cancer, Vol.4, No.1, (January 2004),  pp. 71-78, ISSN 
1474-175X 
Sandel, M. H., Dadabayev, A. R., Menon, A. G., Morreau, H., Melief, C. J., Offringa, R., van 
der Burg, S. H., Janssen-van Rhijn, C. M., Ensink, N. G. , Tollenaar, R. A., van de 
Velde, C. J., & Kuppen, P. J. (2005). Prognostic value of tumor-infiltrating dendritic 
cells in colorectal cancer: role of maturation status and intratumoral localization. 
Clinical Cancer Research, Vol.11, No.7, (April 2005),  pp. 2576-2582, ISSN 1078-0432 
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003). Tolerogenic dendritic cells. 
Annual review of immunology, Vol.21, pp. 685-711, ISSN 0732-0582 
Stojanovic, A., & Cerwenka, A. (2011). Natural Killer cells and solid tumors. In: Journal of 
Innate Immunity, 10.6.2011, Available from: <http://content.karger.com/ 
produktedb/produkte.asp?doi=325465>.   
Talmadge, J. E., Donkor, M., & Scholar, E. (2007).  Inflammatory cell infiltration of tumors: 
Jekyll or Hyde. Cancer and Metastasis Reviews. Vol.26, No.3-4, (December 2007), pp. 
373-400, ISSN 0167-7659 
Van den Eynde, M., & Hendlisz, A. (2009) Treatment of colorectal liver metastases: a review. 
Reviews on Recent Clinical Trials,, Vol.4, No.1, (January 2009), pp. 56-62, ISSN 1574-
8871 
Zbar, A. P. (2004) The immunology of colorectal cancer. Surgical Oncology, Vol.13, No.2-3, 
(August-November 2004), pp. 45-53, ISSN 0960-7404 
20 
Fluorescent Biomarker  
in Colorectal Cancer 
E. Kirilova1, I. Kalnina1, G. Kirilov1 and G. Gorbenko2 
 1Daugavpils University, Daugavpils,  




Patients with gastrointestinal cancer exhibit a poorly functioning immune system that is 
characterized, in part, by decreases in T-lymphocyte proliferation (Greenstein, et al., 1991; 
Milasiene et al., 2007) and reduced CD4+:CD8+ ratios (Arista et al., 1994; Franciosi et al., 2002). 
In different pathologies (including these and other types of cancers), membrane damage in 
immune cells (and other cell types) often evolves as a consequence of alterations that are 
induced in cell-associated lipids and proteins in the affected patients (Gryzunov and 
Dobretsov, 1994, 1998; Rolinsky et al., 2007). It is now widely accepted that the dynamics 
(actual rate of occurrence - not only incidence) of these changes, along with the types of 
alterations in structure(s) of the immune system cells’ lipids/proteins themselves, play a 
critical role in the maintenance of the immune status of any given organism (Lakowicz, 2000). 
As a result of the potential importance of changes in the structural integrity of cells of the 
immune system, it is important for clinicians to receive information on the biophysical 
status of these cells via quick, reliable, reproducible methods. In this regard, fluorescent 
probes have shown to be excellent tools for use in such protocols (Lakowicz, 2000, 2006). 
The work reported here, which built upon earlier findings reported by our laboratories, 
investigated the possibility of using the fluorescent probe ABM (an amine derivative of 
benzanthrone) for the detection of structural/functional alterations in blood plasma 
albumin and among immunocompetent cells in patients with select types of pathologies, i.e,. 
cancers. Such an analysis has a great potential for use not only for helping to comprehend 
mechanisms of immunomodulation associated with the induction/progression of 
malignancies, but might also have the potential to serve as a very important prognostic 
indicator of long-term survival among patients with such pathologies.  
In the work reported here, ABM fluorescence intensity in blood plasma and following 
combination with cell suspensions from colorectal cancer patients was examined in the 
context of the host’s immunological parameters and state of cancer progression. For study 
patients with colorectal cancer were examined: 1) 1 day before and 10 days after their 
surgical treatment (Stages II-III) (Kalnina et al., 2009); 2) as disease worsened (Stages IIa, 
IIIb, IV) (Kalnina et al., 2010b); 3) advanced cancer patients, they were divided into two 
groups in accordance of its survival rate (0-6 months and > 24 months) (Kalnina et al., 2011). 
Apart from the aforementioned potential benefits from these types of studies to clinicians in 
general, this type of research is very important in Latvia itself. This is because, in the context 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
430 
of oncological diseases seen among the Latvian population (as recently as in 2006), colorectal 
cancers rank third in incidence, only surpassed by lung cancers and urogenital tumors. 
2. ABM: Distribution and spectral characteristics in cells and blood plasma 
A new fluorescent probe, a derivative of 3-aminobenzanthrone (ABM) at the Daugavpils 
University, Daugavpils, Latvia. 
 
 
Fig. 1.Chemical Structure of probe ABM  
Synthesis and properties of probe ABM were described in (Kalnina et al., 2004, 2007, 2009, 
2010a; Kirilova et al., 2008). 
3. ABM binding with blood plasma albumin 
3.1 ABM binding with blood plasma albumin before and after surgical treatment  
In the colorectal cancer patients, the ABM emission spectra maximum (i.e., at 650 nm)—after 
combination with the patients’ blood plasma—was not altered in comparison to that seen 
with the plasma from the healthy control volunteers. In contrast, with respect to 
fluorescence intensity, before their individual surgical treatments, the average ABM 
intensity in the patients’ blood plasma was decreased compared to that seen with the 
samples from the healthy donors. Specifically, the fluorescence associated with samples 
from the colorectal cancer group (Figure 2) were decreased by 23.0%. At 10 days after their 
operations, the average ABM fluorescence intensity in the samples from the colorectal 
cancer group were decreased further by 13.9%.  
The average intensity values of the plasma samples from the cancer patients were significantly 
(P < 0.05) different from the control volunteers’ average value. Whether these observations 
tracked actual changes in the levels of plasma albumin were also investigated. The results 
(data not shown) indicate that plasma albumin concentrations (μg/μL) pre-surgery in the 
patient group (71.73 ± 1.34 ) were below those in the plasma of the health controls (83.41 ± 
1.16). This meant that the pre-surgery values for albumin only indicated levels in colorectal 
group samples that were ≈ 14% below control, while the samples’ fluorescence intensity was 
correspondingly lower than the control value by 23.0% . The plasma albumin concentrations 
after surgery seemed to be insignificantly impacted. Specifically, these value was in colorectal 
cancer patients samples 68.48 ± 1.78 (in μg/μL, mean ± SD).  
 





Fig. 2. ABM fluorescence intensity in lymphocytes and in plasma from “Colorectal group” 
patients. Colorectal cancer patients only (Stage II–III) (n = 10). Group number in figure is 
used to reflect from whom/when samples were isolated [i.e., Group 1: pre-surgery; Group 
2: post-surgery; and Group 3: from healthy donors (control group; n = 14)]. Solid bar in each 
set: ABM fluorescence in lymphocytes; hatched bar in each set: ABM fluorescence in plasma. 
All intensity values are shown in AU (arbitrary units; mean ± SE). At P < 0.05, *value 
significantly different from pre-surgical value and/or #significantly different from control 
group value.  
It is of interest to note that while the post-surgery albumin values in these patients samples 
were ≈18% below control levels, their corresponding fluorescence intensity were now even 
more depressed relative to that of the controls by ≈ 34%. These results strongly suggest that 
the noted changes in ABM fluorescence post-surgery in the cancer patients were most likely 
attributable to some change in the protein(s) themselves rather than due to post-surgery 
complications (i.e., bleeding or other mechanisms affecting blood volume/composition). To 
ascertain whether these results (different ABM spectral characteristics) could be explained, 
in part, by altered structural characteristics of the plasma albumin in the cancer patients, the 
average binding constant (Ka) values were determined using the Klotz graphical method. 
These analyses revealed that the average Ka values for the pre-surgery samples from the 
colorectal patient group decreased strongly from the respective constant associated with the 
control group (i.e., 1.0 X 105 M−1, colorectal cancer group; 1.8 X 105 M−1, healthy control 
group). These values represent decrements of from 28% to 45% in the binding of ABM to 
albumin in the plasma of these patients; the reason for the decrement remains to be fully 
determined. Interestingly, even though the fluorescence intensity values decreased further 
for the patients following their surgical procedures, the average Ka values for the samples 
from the patients increased relative to corresponding preoperative values (i.e., 1.3 X 105 
M−1).  
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of oncological diseases seen among the Latvian population (as recently as in 2006), colorectal 
cancers rank third in incidence, only surpassed by lung cancers and urogenital tumors. 
2. ABM: Distribution and spectral characteristics in cells and blood plasma 
A new fluorescent probe, a derivative of 3-aminobenzanthrone (ABM) at the Daugavpils 
University, Daugavpils, Latvia. 
 
 
Fig. 1.Chemical Structure of probe ABM  
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Fig. 2. ABM fluorescence intensity in lymphocytes and in plasma from “Colorectal group” 
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albumin in the plasma of these patients; the reason for the decrement remains to be fully 
determined. Interestingly, even though the fluorescence intensity values decreased further 
for the patients following their surgical procedures, the average Ka values for the samples 
from the patients increased relative to corresponding preoperative values (i.e., 1.3 X 105 
M−1).  
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3.2 ABM binding with blood plasma albumin as a function of stage 
The average ABM fluorescence intensity in patient’s blood plasma was decreased compared 
to that seen with healthy donors. Specifically, the fluorescence intensity associated with 
samples from colorectal cancer patients (Table 1) was decreased by 23% (average value of 
1.44 fluorescence units for those at Stage IIA-IIIB) and 42% (average value of 1.09 units for 
those at Stage IV) relative for the healthy controls(an average value of 1.87 units). 
 
Group Stage F (PI)a 
1 IIA-IIIB #*1.44±0.12 
2 IV *1.09±0.11 
3 Controls 1.87±0.13 
aF (PI) = fluorescence intensity in blood plasma; Values shown are in mean (± SE). 
Value (p<0.05) significantly different from that of * control or # Group 2 patients. 
Table 1. Spectral characteristics of ABM in blood plasma of colorectal cancer patients 
3.3 ABM spectral characteristics in blood plasma of advanced cancer patients 
The average ABM fluorescence intensity in the patients (Group 1 and Group 2) blood 
plasma was decreased (i.e., by 37.4% and 24.1%, respectively) as compared to that seen in 
healthy donors (Table 2). In Group 2 average intensity significantly  (p<0.05) differs from 
Group 1 value and also control group value by 10.6 % and 31.7 %, respectively. Total 
albumin (TA) concentration in Group 1 and Group 2 patients was decreased (relative to 
control value) by 23.5% and 16.1%, respectively. Effective albumin (EA) concentration was 
decreased  by 40.0% and 27.7%, respectively. The lowest value EA/TA in these patients 




F (Pl) EA TA EA/TA 
(months) 
1 0-6 1.17 ± 0.14 39.0 + 1.1 63,80 + 1.02 0,61 
2 > 24 1.42 ± 0.09 47.0 + 1.2 70,80 + 1.14 0,66 




 1-2, 1-3, 2-3 1-2, 1-3, 2-3 1-2, 1-3, 2-3  
F (Pl) = fluorescence intensity in blood plasma;. Values shown are in mean (± SE). 
EA- "healthy" albumin equivalent in patients plasma, g/L 
TA- total albumin concentration, g/L  
EA/TA- reserve of albumin binding capacity 
Table 2. Spectral parameters and binding sites čaracteristics of ABM in blood plasma of 
advanced cancer patients 
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4. ABM binding with lymphocytes 
4.1 ABM binding with lymphocytes before and after surgical treatment  
In the colorectal cancer patients, the ABM emission spectra maximum (i.e., at 650 nm) after 
combination with the patients’ lymphocytes (as with their plasma) was not altered in 
comparison to that seen with the cells from the healthy control volunteers. Surprisingly, the 
average ABM fluorescence intensity value noted from colorectal patients group was actually 
12.0% greater than the control level (Figure 3); however, even with this increase, the value 
was not significantly different from the average control value. In contrast to what was 
observed with the plasma samples, the average ABM fluorescence intensity values noted 
with the cells from patients at 10 days after their operations were greater than the values 
seen with the control volunteers’ cells by 44%. In comparison to the pre-operative values, 
these average ABM fluorescence intensity values at 10 days after the patients’ operations 
had increased by 28.6%.  
 
COLORECTAL CANCER PATIENTS (Stage II-III) (n=10) 
 CD16+% aCD16+ CD4+:CD8+ CD38+% Lymphocytes (%) 
b1 ‡15.95±2.18 ‡314.18±39.27 ‡1.27±0.10 ‡3.40±1.20 28.00±1.30 
2 *‡7.93±1.43 *‡144.75±22.44 *‡1.50±0.13 *‡12.70±3.40 *‡23.50±2.20 
3(Controls) 12.50±1.10 389.00±24.11 1.88±0.16 24.60±1.60 28.00±1.30 
a Values shown are in terms of absolute numbers (mean ± SE). 
b Indicates when or from whom samples were isolated: (1) before surgical treatment; (2) after surgical 
treatment; and (3) healthy donors (control group; n=14). 
* Value significantly different from pre-surgical value (P<0.05); ‡significantly different from control 
group value (P<0.05). 
Table 3. Peripheral blood lymphocyte subpopulation counts in the distinct subsets of the 
study’s cancer patients. 
4.2 ABM binding with lymphocytes as a function of stage  
In general, among the gastrointestinal cancer patients examined here, the ABM emission 
spectra maximum (i.e., at 650 nm) after combination of the probe with the patients’ 
lymphocytes was not altered in comparison to that seen with the cells from the healthy 
control volunteers (spectral data not shown). The ABM fluorescence intensity in the samples 
from colorectal patient group in Stages IIA-IIIB was not significantly different from the 
average control value (0.28 vs. 0.25 fluorescence units, respectively; Fig.3). In contrast, there 
was a significant reduction in ths parameter among the cells from the cancer patients in 
Stage IV (a decrease of 44%; (0.14 vs. 0.25 units). 
4.3 ABM spectral characteristics in lymphocytes of advanced cancer patients    
The ABM fluorescence intensity in the samples from advanced cancer patients (Group 1) 
was not different from the average value (0.25 vs. 0.25) fluorescence units, respectively: 
(Table 4). In contrast, there was a significant increase in this parameter among the cells from 
the cancer patients Group 2 as compared with Group 1 (by 80.8%) and healthy donors (by 
112%) (0.25 vs. 0.52 units).  
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Fig. 3. ABM fluorescence intensity in lymphocytes from colorectal cancer patients  
as a function of stage. 1) Stage IIA-IIIB (black fill); 20 Stage IV (clear fill); 3) healthy  
donors (control group; stripped fill). All values are shown as mean (-+SE). At p< 0.05,  
values significantly different from that of “control patients, Group 2 patients.    
5. Lymphocyte count and subpopulations 
5.1 Lymphocytes count and subpopulations before and after surgical treatment  
The absolute number of CD3+ cells and CD16+ natural killer cells; the relative percentages 
of all lymphocytes, CD16+ and CD38+ cells; as well as the CD4+:CD8+ ratio in the blood 
samples of the healthy volunteers and of the cancer patients, before and after each 
underwent their operations, were determined. The results among the patients in the 
“colorectal” group (Table 3) indicate that, before surgery, the numbers of CD16+ cells, the 
relative percentage of CD38+ cells, and the CD4+:CD8+ ratio were each significantly 
decreased (i.e., by 19.2%, 86.2%, and 32.4%, respectively) as compared to corresponding 
control subject values. Somewhat unexpectedly, relative percentages of CD16+ cells in this 
group were actually significantly greater (by 27.6%)—and the relative percentage of 
lymphocytes no different—than in the blood of the control volunteers. Within this same 
group, after surgery, the number and percentages of CD16+ cells, as well as the percentages 
of all lymphocytes, were each significantly reduced (i.e., by 53.9%, 50.3%, and 16.1%, 
respectively) relative to corresponding pre-surgery levels. Again, the relative percentage of 
CD38+ cells and the CD4+:CD8+ ratio increased (by 27.4% and 18.1%, respectively) 
compared to pre-surgical values, but again did not reach control levels (i.e., still were 48.4 
and 20.2% lower, respectively). 
5.2 Lymphocytes count and subpopulations as a function of stage  
On the other hand, there were significant changes in the relative percentages of CD4+ cells at 
almost every stage in both cancer groups (Fig. 4). Among colorectal cancer patients, the 
percentages of CD4+ cells decreased 25.5 and 38.3% from control levels as the stages 
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progressed (actual values: 28.6%, Stage IIA-IIIB; 23.7%, Stage IV; and, 38.4%, controls). 
Patients with Stage IV colorectal cancer yielded any statistically significant shift from control 
subject levels of CD8+ cells (an increase of ≈38%, i.e., shift from 19.5% to 26.9%).  
The levels of lymphocytes (both total and the CD4+ and CD8+ sub-populations) in the blood 
samples of the cancer patients and healthy volunteers were also assessed here. The results 
show that among the patients in both cancer groups, the relative percentages of 
lymphocytes were moreover not significantly altered relative to the control levels 
irrespective of disease stage (Figures 4 and 5). Of all the patients, only those in Stage IV had 
lower blood lymphocyte levels that approached or reached statistical significance. Among 
the Stage IV colorectal cancer patients, levels were decreased 18.5% (a shift from 28.0% 







Fig. 4. Lymphocyte counts (as percentage %) and T-lymphocyte subpopulation  
Levels (as % of all lymphocytes present) in cancer patients as a function of stage.  
1) Stage IIA-IIIB (black fill); 2) Stage IV (clear fill); 3) healthy donors (control group;  
striped fill).   
Because shifts in CD4+:CD8+ ratios are often used as indices of altered host immune status, 
these values were also calculated from the patients’ blood samples. The results show that 
among the colorectal cancer patients (Fig 5.), the CD4+:CD8+ ratios were all significantly 
lower than those for the healthy control subjects and became significantly further lower as 
the stage worsened. Specifically, the ratios dropped to 1.27 and 0.88 (shifts of 32.4% and 
53.2%) at Stages IIA-IIIB and IV, respectively, from the 1.88 value for the controls.   
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Fig. 5. T-lymphocyte subpopulation ratios in cancer patients as a function of stage.  
1) Stage IIA- IIIB (black fill); 2) Stage IV (clear fill); 3) healthy donors (control group; striped 
fill). 
5.3 Lymphocytes count and subpopulations in advanced cancer patients 
Among the patients in both advanced cancer groups, the relative number of lymphocytes 
were significantly decreased (i.e.by 52.6% and 39.6%, respectively) as compared to 
corresponding control values. It is necessary to note that relative number of lymphocytes in 
Group 2 is significantly higher than in the Group 1 patients, but lower than the control value 
(see Table 4). In patients with advanced cancer and metastases there is reduction in both 
numbers of lymphocytes and proportions of CD4+/CD8+ T-lymphocytes which are thought 
to play an important role in cell-mediated immunity. The results indicate that in Group 1 
and Group 2 patients the ratio CD4+/CD8+ was significantly reduced (i.e. by 58.5% and 
47.9%, respectively) relative to corresponding control level. Actual values of Group 1 and 
Group 2 – 0.78, 0.98, respectively from the 1.88 control value. It is of interest to note that in 
Group 2 this parameter stay significantly higher as compared with results in Group 1, but 
did not reached control value.  
 







F(Ly), a.u. Ly (%) CD4+(%) CD8+(%) CD4+/CD8+ 
1 0-6 0,25±0,03 13,31±1,16 20,93±1,13 27,00±1,39 0,78±0,09 
2 >24 0,53±0,11 16,95±1,18 26,14±1,32 26,70±1,31 0,98±0,08 
3 




 1-2;2-3 1-2;1-3;2-3 1-2;1-3;2-3 1-3;2-3 1-2;1-3;2-3 
F(Ly) - fluorescence intensity in lymphocytes 
Values shown are in mean (±SE) 
Table 4. ABM fluorescence intensity in lymphocytes. Peripheral blood lymphocytes 
subpopulation counts in advanced cancer patients 
6. Examination of relationship between ABM fluorescence and blood 
lymphocyte profiles 
Pre-operation, in the colorectal patient group, the ABM fluorescence intensity was found to 
correlate with the relative number of CD38+ cells (r = +0.956). After the operations, both the 
CD4+:CD8+ ratio and relative number of CD38+ cells in patients blood was observed to be 
increased.  
In colorectal cancer group, the ABM fluorescence intensity in blood plasma and the 
lymphocytes was found to correlate with CD4+:CD8+ ratios (in all stages of cancer) and the 
percentage (%) of lymphocytes/ subtypes in their blood. The degree of any relationship 
between cancer progression/staging, lymphocyte levels, and fluorescence among the 
lymphocytes was less obvious. Specifically, in terms of disease progression, cell levels and 
fluorescence intensity weakly tracked together (i.e., r = +0.512) for the colorectal patients. . 
With respect to associations between the plasma albumin fluorescence measurements and 
each of the individual lymphocyte-associated endpoints measured (except for cell 
fluorescence itself), many of the same patterns as noted above were evident. Once again, in 
terms of disease progression, although cell levels and albumin fluorescence intensity weakly 
tracked together (i.e., r = +0.513) among the colorectal patients.  
In both groups of advanced cancer the ABM fluorescence intensity in blood plasma and 
lymphocytes was found to correlate to with CD4+/CD8+ ratios. In advanced cancer groups 
(in contrast to other groups) there is direct (not inverse) correlation between lymphocytes 
count and ABM fluorescence intensity. There seemed to be a good relationship between 
total lymphocyte (and subpopulation) levels and ABM fluorescence in both groups of 
patients. There is also good associations between the plasma albumin fluorescence 
measurements and each of the individual lymphocyte/albumin associated endpoints 
measured “effective” and total albumin concentration, reserve of albumin binding 
capacity.  
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1) Stage IIA- IIIB (black fill); 2) Stage IV (clear fill); 3) healthy donors (control group; striped 
fill). 
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The novel fluorescent probe ABM (an amino derivative of benzanthrone) localizes deep 
within the phospholipids bilayer of lymphocytes membrane. Thus, in studies with 
lymphocytes, it can be concluded that changes in the spectral parameters of ABM (i.e., shifts 
in magnitude of fluorescence or actual wavelength associated with normal maximal 
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inter-related) properties of the cells. These could include the lymphocytes’ (1) outer 
membrane physicochemical state, (2) membrane microviscosity, 
(3) proliferative activity, (4) lipid metabolism, and/or (5) phenotypical profile. As seen in 
the studies mentioned here, while the noted changes in the studied parameters (i.e., 
fluorescence behavior) could be useful in reflecting alterations in lymphocytes of the cancer 
patients in each subgroup (at both pre- and post-surgical stages), they may also ultimately 
be of use as potential indicators of alteration in cellular immunity in these individuals. 
Follow-up studies are underway to see whether this concept can be validated. We also 
sought to ascertain whether shifts in ABM binding with plasma albumin could potentially 
be utilized as a part of an overall preliminary immunodiagnostic screening test in cancer 
patients. The choice to examine albumin, among the myriad of constituents in plasma, is 
that this protein is practically the single source of ABM binding and subsequent 
fluorescence in plasma (Gryzunov and Dobretsov, 1994, 1998). Our earlier studies showed 
that within plasma, albumin is nearly alone in binding with ABM with a very high level of 
selectivity (Kalnina et al., 1996, 2004, 2007). The distribution of ABM fluorescence (intensity) 
within fractions of human plasma was seen to be albumin >>> globulins >> non-specific 
binding by other components (i.e., 90%, ≈ 5%, < 1%, respectively). These widely disparate 
binding results were confirmed in studies wherein exogenous globulin was added to plasma 
samples and there was no shift in fluorescence intensity or Fmax. Clearly, only significant 
shifts in albumin levels or alterations/ conformational changes in albumin itself seemed to 
have a major impact on these ABM fluorescence endpoints. In the present study, the 
differences in total albumin concentrations, pre- and post-surgery, among the cancer 
patients in each group did not seem to correlate well with the relative changes in ABM 
fluorescence (relative to values in control subjects’ plasma). This apparent “extra 
diminution” in fluorescence strongly suggested that there was either a novel competition for 
probe by other substances in the patients’ plasma or that the albumin in these patients had 
undergone modification(s) that affected its ability to bind ABM. The fact there were 
substantive changes in binding constant (Ka) values lends support to the latter viewpoint. 
However, this finding in and of itself does not outright preclude the possibility of the former 
event having occurred as well.These shifts in ABM binding constants in the plasma samples 
from the cancer patients, as noted earlier, could be due to a generic decreased binding 
by/conformational changes in their albumin molecules. Structural or functional alterations 
of albumin could be manifest as “shifts” away from normal “main” binding sites with high 
affinity for the probe to other binding sites with far lower affinities and specificities. Such 
shifts would be in agreement with the observations of Togashi and Ryder (2006) that 
albumin molecules are known to contain different binding sites (i.e., classes) for various 
probes. As Petitpas et al. (2001b, 2003) noted, albumin normally carries a variety of 
endogenous ligands like nonesterified fatty acids, bilirubin, and thyroxine; however, this 
protein can also bind an impressive array of drug molecules, including warfarin, ibuprofen, 
and indomethacin, as well as their metabolites (Petitpas et al., 2001a). It seems very likely 
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that patients in the groups in the present study had ingested painkillers (both prescribed 
and retail) during the course of their disease; thus, a presence of these drugs/ metabolites on 
their albumin could have contributed to the noted shifts in ABM fluorescence /Ka values. 
Our future studies will endeavor to recruit non-cancer patients with a “similar” history of 
painkiller intake in order to ascertain whether this was a main reason underlying our 
observations (regarding the albumin outcomes) or if there is something more inherently 
unique to the patient’s cancer-bearing status that influenced the measured endpoints. This 
second standpoint is not without foundation. In oncopathology, the blood plasma content of 
two important unsaturated fatty acids (i.e., oleic acid and arachidonic acid) is increased, and 
these natural constituents also increasingly occupy binding sites on albumin (Gryzunov and 
Dobretsov, 1994, 1998). Both are observed to occupy binding sites distributed across the 
protein that happen to also be bound by medium or long-chain saturated fatty acids. The 
resulting restrictions imparted on the binding configurations of the protein would then 
account for shifts in the binding affinities at the primary sites between polyunsaturated fatty 
acids and their saturated or mono-unsaturated counterparts (Petitpas et al., 2001). It remains 
to be determined whether these alterations in fatty acid composition/binding also result in 
conformational changes in the albumin that impact upon ABM binding to its major (high 
selectivity) binding sites. As noted earlier, changes in fluorescence parameters of the cancer 
patients’ lymphocytes could be reflective of changes in one/more inherent characteristics of 
their cells. In these studies, at least two, that is, proliferative activity and phenotypical 
character, could readily, albeit indirectly, be evaluated by examining changes in lymphocyte 
populations (i.e., their numbers) themselves. While the flow cytometry studies did indicate 
 significant changes in lymphocyte (and subpopulation) levels among the cancer patients, 
unfortunately, the studies failed to yield overall lymphocyte (or subtype) population 
patterns that paralleled the concurrent changes in ABM fluorescence (i.e., Table 1 vs. Figure 
2, example of this “lack of comparativeness”). Among all the subpopulation endpoints 
reported, only those of “CD38+%” and the “CD4+:CD8+ ratios” approached reflecting 
trends seen with the patients’ fluorescence measurements. Specifically, the pre-surgery 
levels of each of these cytometric values were “maximally” reduced relative to the control 
subjects’ values; post-surgery, these two values were increased, but in contrast to the 
fluorescence levels, these values did not reattain (or surpass) counterpart control levels. In 
light of the cancer patients’ post-surgical (1) persistent lower numbers of lymphocytes (both 
total and within subclasses) and (2) fluorescence values that were uniformly significantly 
greater than in control subjects’ cells, we surmise some factor(s) about these patients’ 
lymphocytes (i.e., some undefined phenotypical characteristics) can cause amplification of 
the ABM fluorescent response. The fact that this “disconnect” between these two parameters 
is most predominant during the post-operative period strongly suggests that these as yet-
undefined modifying factors in the cancer patients might be related to their general immune 
response to the surgical procedure. Our future studies will need to recruit non-cancer 
patients with a “similar” history of surgical intervention/protocols (such as among patients 
suffering enterocolitis, undergoing local biopsies for non-cancer disorders, etc.) to ascertain 
whether the surgical procedure itself was a main reason for our observations (regarding the 
“disconnect”) or whether, as with the albumin findings, there is something more inherently 
unique to a cancer-bearing status that influenced the measured endpoints. As expected, the 
CD4+:CD8+ ratios were seen to be increased in the cancer patients after they had undergone 
their respective operation. This would be expected as it is well accepted that CD4+ helper 
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cells stimulate and CD8+ (suppressor and cytotoxic) cells inhibit the immune response 
during the healing process. While that explanation for any potential changes in the 
phenotypic characteristics of these patients’ lymphocytes is somewhat straightforward, 
what is less clear is the basis for the post-surgical increase in CD38+% values and why, to 
begin with, they are lower than in the control groups. This is because, most often, increased 
levels of CD38+ cells are associated with patients suffering with lymphocytic leukemias 
than with the solid tumors (such as those associated with gastrointestinal cancers (Kalnina 
et al., 2009). In general, CD38 is expressed primarily on B-lymphocytes and T-lymphocytes, 
as well as stem/germ cells,  the CD38 ligand is an ADP-ribosyl cyclase enzyme that 
regulates the activation and growth of these lymphoid (as well as myeloid) cells . The data 
in the current study clearly show no evidence of any B-lymphocyte-based leukemia (Kalnina 
 et al., 2009) (i.e., CD16+ cell levels were lower in patients’ pre- and post-surgery blood 
samples than in controls) among the cancer patients. Thus, we conclude that the increase in 
CD38+ cell levels is more probably due to an increased presence of CD38+ T-lymphocytes. 
We conclude from our findings that the increase in CD38+ cell levels post-surgery was not 
likely due to absolute increases in T-lymphocytes, but in their activities. Such an outcome 
would be in keeping with the changes in the fluorescence values for these lymphocytes. For 
this premise to be valid, apart from showing that there are increases in relative levels of 
CD38-bearing T-lymphocytes due to activation during the post-surgery healing process, 
there still needs to be an explanation as to why these cells’ levels were initially lower in the 
patients than in the controls. One potential explanation is in the biology of the tumors 
themselves, that is, they are solid tumors of the gastrointestinal system that impact on a 
wide variety of local cell types, including the endothelium. This particular cell type in the 
gut is of interest here in that there appears to be a critical relationship among endothelial 
cells, CD38 expression, and activation of T-lymphocytes (i.e., CD4+CD45RA+ cells. It is 
plausible that normal interactions between T-lymphocytes and endothelium are likely 
“interrupted” simply as a result of changes in accessibility (secondary to alterations in gut 
architecture as tumor grew). A lack of lymphocyte– endothelium interactions could help 
explain why there was a diminution in CD38+ cell levels before surgery; during the post-
surgery recovery, angiogenic processes (i.e., during microvasculature repair/reformation at 
wound site) would allow for an increase in these particular cell–cell interactions—in 
particular, with a population of endothelial cells in very active states during the reparative 
processes. Future histopathology studies using biopsied samples from the gastrointestinal 
tracts of patients with cancers and those that underwent biopsies for non-cancer-based 
reasons (see earlier comments) should be useful in allowing us to verify the degree of these 
hypothesized cell–cell interactions. Apart from potential changes in lymphocyte–
endothelium interactions as contributing factors for the reductions (vs. controls) in CD38+ 
cell levels—and their “recoveries” after surgical removal of the tumor—in the cancer 
patients, there are other possible reasons for these two observations. Among these, 
specifically, is the fact that patients with colorectal/gastrointestinal cancers (especially those 
at more advanced stages) tend to have significant levels of circulating interleukin (IL)-4 . 
This is critical in that it has been shown, at least with B-lymphocytes, that exposure of these 
cells to IL-4 reduced the amount of CD38 antigen on and in these cells; no evidence was 
obtained for accelerated breakdown, shedding, or internalization of CD38 molecules, or for 
the accumulation of CD38 molecules in the cell interior, due to IL-4 (Kalnina et al., 2009). In 
our ongoing studies, we will analyze patients’ blood samples for IL-4 both pre- and post-
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surgery to see whether its levels reflect the observed changes in the CD38+ lymphocytes and 
their fluorescence responses (indicative of phenotypic changes likely related to activation) in 
the presence of ABM. The results of the ABM studies presented here show that, as might be 
expected, the presence of solid tumors and surgical interventions can affect the functional 
activity of lymphocytes. These results are in agreement with previously- performed 
investigations to characterize the outer cell membrane of lymphocytes of cancer patients, 
patients with autoimmune disease (i.e., rheumatoid arthritis), and workers who had been 
contaminated during the clean up at Chernobyl (Kalnina et al., 2004, 2010a, Zvagule, 2010). 
Likewise, the observed changes in the ABM spectral parameters in blood plasma are 
probably coupled with alterations in cellular mechanisms of immune regulation in the 
patients here. Ongoing studies are seeking to answer this very question. 
The studies here showed that spectral characteristics (fluorescence intensity) differed among 
the various patient sub-groups. These findings suggest likely physical (structural) and 
functional alterations in the patients’ cells were a function of cancer stage. It is known that 
ABM fluorescence intensity can change in accordance with environment polarity and, 
consequently, in relation to plasma membrane microviscosity (that in turn correlates with 
cell lipid metabolism). There are various pathological states (i.e., cancer) in which the lipid 
composition and specific fatty acid content in lymphocyte membranes and blood plasma are 
disturbed (Kalofoutis et al., 1996). For example, colorectal cancer patients have abnormal 
plasma and erythrocyte fatty acid levels, as well as of their polyunsaturated metabolites 
(Robinson et al., 2001). Ultimately, in lymphocytes, because membrane physicochemical 
status and cell lipid metabolism play pivotal roles in signal transduction pathway(s) 
activities important in maintaining cell function (Kim et al., 1999), it would not be 
unexpected that disturbances in these parameters could result in altered 
immunocompetence in hosts with these affected cells. Fluorescence intensity of ABM in 
lymphocytes suspension tended to decrease with progression of cancer. Shifts in magnitude 
of ABM fluorescence could reflect modifications in one/more interdependent properties of 
cells (Kalnina et al., 2007). As seen in the studies mentioned here, at least two parameters are 
responsible for this phenomenon. In this studies, at least two, that is proliferative activity 
and phenotypical character could readily, albeit indirectly, be evaluated by examining 
changes in lymphocytes populations (ie., their numbers) themselves. While the flow 
cytometry studirs did indicate significant changes in lymphocytes (and sunpopulations) 
levels among the cancer patients, unfortunately, the studies failed to yield overall 
lymphocyte (or subtipe) population patterns that paralleled the concurrent changes in ABM 
fluorescence example of this “lack of comparativeness”). The studie of Milasiene (Milasiene 
et al., 2007) also suggest that immunosuppression covers many aspects of the complex 
immune system, and therefore, we have many unexpected findings.   
The studies here also revealed significant changes in ABM fluorescence associated with the 
plasma (re: albumin) of the cancer patients. The choise to examine albumin, among the 
myriad of constituents in plasma, is that this protein is practically the single source of ABM 
binding and subsequent fluorescence in plasma. We know form earlier studies that plasma 
albumin binds ABM with a very high selectivity (Kalnina et al., 1996, 2004, 2007, 2009, 2010b, 
Zvagule et al., 2010) and that only very significant shifts in plasma albumin levels or 
structural changes in albumin itself seemed to impact on ABM fluorescence. In the previous 
study (Kalnina et al., 2009) the differences in total albumin concentrations in patients groups 
did not seem to correlate well with the relative changes in ABM fluorescence (relative to 
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values of control subjects plasma). The fluorescent method reveal the “effective” 
concentration of albumin (equivalent of “healthy'' albumin in blood plasma). The total 
concentration of albumin is conservative.  In general, serious alterations in plasma albumin 
levels are often reflective of poor outcomes in cancer patients (Seve et al., 2007). As noted 
above, the changes in patient plasma albumin levels (≈14-18% below control) were far less 
than the recorded shifts in ABM intensities and it seemed these measures were “picking up” 
changes beyond those that could solely be attributed to a change in total albumin status. The 
additional ‘binding shifts’ seen with the cancer patients’ plasma samples could be due, in 
part, to decreased binding by/conformational changes in their albumin. There are several 
ways in which tumor-and/or treatment-associated agents can bind to albumin and cause 
allosteric modifications that lead to structure and function changes: (1) tumor cells release a 
variety of bioactive proteins/peptide fragments - sequestration by carrier proteins (like 
albumin) protect these materials from clearance (and amplify their circulating levels; 
Kazmierczak et al., 2006); (2) plasma content of select key unsaturated fatty acids (i.e., oleic 
and arachidonic acids) is increased - these then increasingly occupy binding sites on 
albumin (Gryzunov and Dobretsov, 1994, 1998; Petitpas et al., 2001b); and, (3) an array of 
drugs, e.g., ibuprofen, indomethacin, etc. (and their metabolites) commonly ingested by 
cancer patients readily bind with albumin (Petitpas et al., 2001a, 2003). As was the case with 
lymphocytes, the shifts in cancer patient plasma ABM fluorescence intensity were related to 
disease stage. While moderate alterations in albumin-ABM signals were already noted at 
early (Stages II) phases of cancer, the effects were amplified as cancer evolved to Stages III-
IV. It is likely that as cancer progressed, the levels of pathological/pharmacological 
metabolites in the patient’s blood increased and their albumin could not ultimately bind 
them all. One consequent structural/functional alteration induced in the albumin could be a 
shift in ABM binding away from normal primary high affinity sites to others with lower 
affinities/specificities. Such shifts would be in agreement with the observations of Togashi 
and Ryder (2006) and Rolinski et al. (2007) who noted that albumin molecules contained 
different binding sites (i.e., classes) that differed in affinity, quantum yield, and degrees of 
polarization (i.e., higher mobility of bound probe and increased accessibility by water) for 
ABM and various other probes. The results of the current investigation also seemed to 
reflect what was predicted to occur based upon electron spin resonance (ESR) spectroscopy 
studies that measured structural and functional changes in serum albumin of patients with 
other cancers (Kazmierczak et al., 2006). Specifically, analyses of ESR spectra (using spin 
probes) revealed substantial differences in spectrum variables when samples from patients 
were compared with those from healthy hosts. For example, the increasing width of the 
spectral line in samples from the cancer patients indicated an alteration in albumin 
conformation that limited the movement of the spin probe at a binding site, as well as 
changes in the albumin capacity to bind spin probe, polarity of spin probe binding site, and 
probe mobility (Kazmierczak et al., 2006). While increased binding of tumor-/treatment-
associated agents (leading to the sequelea outlined above) could be a means by which 
changes in albumin-ABM fluorescence evolved here, there are other means by which the 
albumin ability to bind the probe may have been altered. While we demonstrated here there 
were changes in ABM fluorescence after inter-actions with lymphocytes (and plasma 
albumin) obtained from gastrointestinal cancer patients, another major question that needed 
addressing was whether there were actual biologic/immunologic modifications associated 
with these alterations. As noted earlier, changes in fluorescence parameters of patient 
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lymphocytes could reflect changes in one/more inherent characteristics of these cells, 
including their phenotypical character. While the flow cytometry studies identified 
significant alterations in lymphocyte (and sub-populations) levels among all the cancer 
patients, variations in total lymphocyte levels never clearly and consistently paralleled the 
corresponding changes in ABM fluorescence for the gastric cancer subjects. In contrast, there 
seemed to be a good relationship between these endpoints in the colorectal patients. For 
now, it remains unclear why there should be a divergence in these patterns based on the 
cancer type itself. 
The observed changes in ABM intensity in the lymphocytes might be useful to reflect 
current CD4+ and/or CD8+ status in the pacients. In this regard, the same (as above) disease-
related differences in the relationships were apparent between changes in ABM fluorescence 
and those in CD4+ levels in the patients. The noted shifts in CD4+ levels were expected; 
cancer- related CD4+ cell deficiency is a frequent finding in digestive system cancer patients 
(Franciosi et al, 2002). In our previous investigations, CD4+:CD8+ ratios tended to parallel 
ABM fluorescence levels (i.e., lowest among patients who manifested decreased 
fluorescence in their lymphocyte suspensions (Kalnina et al, 2007, 2009, 2010a,2010b). In 
those earlier studies, CD4+:CD8+ ratios gradually decreased as CD8+ levels increased with 
progression of cancer stage (Wang et al., 2004; Kalnina et al., 2007). In the studies here, the 
shifts seem to depend more on decreases in CD4+ levels as each disease became metastatic. 
These outcomes would be in keeping with the studies by Tancini et al. (1990) and (McMillan 
et al. (1997) that indicated that decreases in CD4+:CD8+ ratios in gastric cancer patients 
mainly depended on increases in CD8+ T-cytotoxic cells in patients with early stage disease 
whereas it was due to decreases in CD4+ T-helper cells in those with metastases (later stage 
disease). Thus, at least clearly for colorectal cancer patients, our results suggest that 
measures of ABM fluorescence intensity values for lymphocytes (and to a lesser extent, for 
plasma albumin) could potentially be used in clinical immunological screenings (instead of 
more expensive routine tests) to provide a snapshot of immune status in these cancer 
patients. Whether the utility of these measures could/would extend to human disease states 
remains to be determined.  
8. Conclusion 
Fluorescence behaviour of ABM could be useful to reflecting alterations in lymphocytes in 
each subgroup and they may ultimately be of use as potential indicators of alterations in 
cellular immunity in individuals. We also sought to ascertain whether shifts in ABM 
binding with plasma albumin could be potentially utilized as part of an overall preliminary 
immunodiagnostic screening test in cancer patients. Taken together it would appear that 
progression of cancer is associated with changes of immune function and more specifically a 
reduction in absolute number of CD4 + T-lymphocytes and either an increase or not change 
in the absolute count of CD8+ T-lynphocytes. Study suggests that higher number of absolute 
lymphocytes count and ratio CD4+: CD8+ have beneficial effect on overall survival of 
patients with advanced tumor. Overall survival depends also on quantitative parameters of 
cellular immunity of cancer patients. Thus, immune status of the immune system of  
patients with advanced tumor before treatment is important for its survival. The 
immunosuppression and metastatic spread are interconnected. The low plasma albumin 
level also were identified as bad independent marker of prognosis. Fluorescent based 
method is pertinent to pathway profiling, target validation, and clinical diagnosis, 
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them all. One consequent structural/functional alteration induced in the albumin could be a 
shift in ABM binding away from normal primary high affinity sites to others with lower 
affinities/specificities. Such shifts would be in agreement with the observations of Togashi 
and Ryder (2006) and Rolinski et al. (2007) who noted that albumin molecules contained 
different binding sites (i.e., classes) that differed in affinity, quantum yield, and degrees of 
polarization (i.e., higher mobility of bound probe and increased accessibility by water) for 
ABM and various other probes. The results of the current investigation also seemed to 
reflect what was predicted to occur based upon electron spin resonance (ESR) spectroscopy 
studies that measured structural and functional changes in serum albumin of patients with 
other cancers (Kazmierczak et al., 2006). Specifically, analyses of ESR spectra (using spin 
probes) revealed substantial differences in spectrum variables when samples from patients 
were compared with those from healthy hosts. For example, the increasing width of the 
spectral line in samples from the cancer patients indicated an alteration in albumin 
conformation that limited the movement of the spin probe at a binding site, as well as 
changes in the albumin capacity to bind spin probe, polarity of spin probe binding site, and 
probe mobility (Kazmierczak et al., 2006). While increased binding of tumor-/treatment-
associated agents (leading to the sequelea outlined above) could be a means by which 
changes in albumin-ABM fluorescence evolved here, there are other means by which the 
albumin ability to bind the probe may have been altered. While we demonstrated here there 
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patients, variations in total lymphocyte levels never clearly and consistently paralleled the 
corresponding changes in ABM fluorescence for the gastric cancer subjects. In contrast, there 
seemed to be a good relationship between these endpoints in the colorectal patients. For 
now, it remains unclear why there should be a divergence in these patterns based on the 
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related differences in the relationships were apparent between changes in ABM fluorescence 
and those in CD4+ levels in the patients. The noted shifts in CD4+ levels were expected; 
cancer- related CD4+ cell deficiency is a frequent finding in digestive system cancer patients 
(Franciosi et al, 2002). In our previous investigations, CD4+:CD8+ ratios tended to parallel 
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mainly depended on increases in CD8+ T-cytotoxic cells in patients with early stage disease 
whereas it was due to decreases in CD4+ T-helper cells in those with metastases (later stage 
disease). Thus, at least clearly for colorectal cancer patients, our results suggest that 
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more expensive routine tests) to provide a snapshot of immune status in these cancer 
patients. Whether the utility of these measures could/would extend to human disease states 
remains to be determined.  
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each subgroup and they may ultimately be of use as potential indicators of alterations in 
cellular immunity in individuals. We also sought to ascertain whether shifts in ABM 
binding with plasma albumin could be potentially utilized as part of an overall preliminary 
immunodiagnostic screening test in cancer patients. Taken together it would appear that 
progression of cancer is associated with changes of immune function and more specifically a 
reduction in absolute number of CD4 + T-lymphocytes and either an increase or not change 
in the absolute count of CD8+ T-lynphocytes. Study suggests that higher number of absolute 
lymphocytes count and ratio CD4+: CD8+ have beneficial effect on overall survival of 
patients with advanced tumor. Overall survival depends also on quantitative parameters of 
cellular immunity of cancer patients. Thus, immune status of the immune system of  
patients with advanced tumor before treatment is important for its survival. The 
immunosuppression and metastatic spread are interconnected. The low plasma albumin 
level also were identified as bad independent marker of prognosis. Fluorescent based 
method is pertinent to pathway profiling, target validation, and clinical diagnosis, 
 
Colorectal Cancer Biology – From Genes to Tumor 
 
444 
prediction of therapeutic effacy, and monitoring of treatment outcomes. ABM fluorescence 
intensity values for plasma albumin and lymphocytes (as reflection of their functional 
activity) might be useful tool in the evolution of the immune status of pacients. Taken 
together, all the results showed that measures of ABM spectral characteristics could 
potentially be a useful tool to estimate the immune status of gastrointestinal patients.  
Compared to many commonly used diagnostic protocols, this fluorescence based method is 
less expensive and not very time consumming, technically simple and 100 times more 
sensitive than standard absorbance based methods.  
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